<SEC-DOCUMENT>0001493152-25-021941.txt : 20251112
<SEC-HEADER>0001493152-25-021941.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112162601
ACCESSION NUMBER:		0001493152-25-021941
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		251473206

	BUSINESS ADDRESS:	
		STREET 1:		433 PLAZA REAL
		STREET 2:		SUITE 275
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		433 PLAZA REAL
		STREET 2:		SUITE 275
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:LIXT="http://lixte.com/20250930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_031_LIXT_lixte.com_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250101_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_CAD_0_iso4217%2D%2DCAD -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  <ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2025-09-30" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2024-12-31" id="xdx2ixbrl0057" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividendPayable" contextRef="AsOf2024-12-31" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-09-30" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividend" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividend" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0293" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0295" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0383" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0398" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0436" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0524" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0539" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0566" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0579" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0592" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0619" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0632" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:CommonStockIssuedForServices" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentForAcquisitionCryptoAsset" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0732" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0733" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ExerciseOfPlacementAgentWarrantsOnCashlessBasis" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ExerciseOfPrefundedWarrants" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:AccrualOfDeferredOfferingCosts" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0753" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0886" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0890" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0917" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0922" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_country_CN" id="xdx2ixbrl0980" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_country_CN" id="xdx2ixbrl0981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_country_CN" id="xdx2ixbrl0982" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_country_NL" id="xdx2ixbrl0985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_country_NL" id="xdx2ixbrl0987" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="xdx2ixbrl1251" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="xdx2ixbrl1253" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1825" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1826" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl1845" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl1847" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20250930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-02</xbrli:startDate>
        <xbrli:endDate>2023-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-19_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-022025-07-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-02</xbrli:startDate>
        <xbrli:endDate>2025-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-07-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantFiveMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_OneVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OneVendorAndConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_TwoVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:TwoVendorAndConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_CompoundMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_CompoundMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CompoundMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CompoundMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_BitcoinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:BitcoinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_BitcoinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:BitcoinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_EthereumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:EthereumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_EthereumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:EthereumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-03-16</xbrli:startDate>
        <xbrli:endDate>2015-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember624785171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-21_custom_SeriesAConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-242023-08-07_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-20</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-202023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-20</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-132025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-13</xbrli:startDate>
        <xbrli:endDate>2025-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-13</xbrli:startDate>
        <xbrli:endDate>2025-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-132025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-13</xbrli:startDate>
        <xbrli:endDate>2025-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-022025-07-02_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-02</xbrli:startDate>
        <xbrli:endDate>2025-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-182025-07-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-18</xbrli:startDate>
        <xbrli:endDate>2025-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_custom_PlacementAgentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PlacementAgentsWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-15_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-022025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-02</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-022025-08-05_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-02</xbrli:startDate>
        <xbrli:endDate>2025-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_custom_PlacementAgentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MarketAwarenessAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MarketAwarenessAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-022023-06-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-02</xbrli:startDate>
        <xbrli:endDate>2023-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-162025-06-16_custom_EmploymentAgreementMember_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-16</xbrli:startDate>
        <xbrli:endDate>2025-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_NewIndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_DirectorMember624786375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_srt_DirectorMember624786375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_DirectorMember624786375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_DirectorMember624786375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-06</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-26</xbrli:startDate>
        <xbrli:endDate>2023-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-062022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-06</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-07-01_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SchellensMember624786734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_SchellensMember624786734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SchellensMember624786734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SchellensMember624786734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-30</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-30</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-20</xbrli:startDate>
        <xbrli:endDate>2025-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-20</xbrli:startDate>
        <xbrli:endDate>2025-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-312025-03-31_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-31</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-31</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-30</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-03_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-032025-07-03_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-03</xbrli:startDate>
        <xbrli:endDate>2025-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-312025-12-31_custom_EmploymentAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-31</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_MrPursgloveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-152025-08-15_custom_JasonSawyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-15</xbrli:startDate>
        <xbrli:endDate>2025-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-15_custom_JasonSawyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-142025-08-15_custom_JasonSawyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-14</xbrli:startDate>
        <xbrli:endDate>2025-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_JasonSawyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_JasonSawyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-152025-08-15_custom_DrMichaelHollowayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-15</xbrli:startDate>
        <xbrli:endDate>2025-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-15_custom_DrMichaelHollowayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-142025-08-15_custom_DrMichaelHollowayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-14</xbrli:startDate>
        <xbrli:endDate>2025-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_DrMichaelHollowayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_DrMichaelHollowayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-01_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-15_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-312025-09-01_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-31</xbrli:startDate>
        <xbrli:endDate>2025-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-01_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_PeterStazzoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-01_custom_LourdesFelixAndGuyPrimusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-31</xbrli:startDate>
        <xbrli:endDate>2025-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-01_custom_LourdesFelixAndGuyPrimusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_LourdesFelixAndGuyPrimusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_LourdesFelixAndGuyPrimusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-09-302026-09-30_custom_LourdesFelixAndGuyPrimusMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-09-30</xbrli:startDate>
        <xbrli:endDate>2026-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-07</xbrli:startDate>
        <xbrli:endDate>2024-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-11_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MDAndersonCancerCenterClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-052021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-05</xbrli:startDate>
        <xbrli:endDate>2021-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-22</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-27</xbrli:startDate>
        <xbrli:endDate>2023-08-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-232024-02-23_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-23</xbrli:startDate>
        <xbrli:endDate>2024-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2030-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-23</xbrli:startDate>
        <xbrli:endDate>2013-12-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-12</xbrli:startDate>
        <xbrli:endDate>2015-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember624788609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialPhaseMD1b2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SGNMediaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_LMCCommunicationsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_LMCCommunicationsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>LIXT:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>LIXT:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="CAD">
      <xbrli:measure>iso4217:CAD</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact002015" toRefs="Footnote002040"/>
  <ix:relationship fromRefs="Fact002027" toRefs="Footnote002040"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20250101__20250930_zaTCyH7qC7Lj"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000016" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentQuarterlyReport_c20250101__20250930_zZgQLWPrTl98"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20250101__20250930_zFeTZAlxxLEc"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_903_edei--DocumentFiscalYearFocus_c20250101__20250930_z2LVnNUjqqCg"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000019" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--DocumentTransitionReport_c20250101__20250930_zUfoaFhzSPG2"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span id="xdx_90A_edei--EntityFileNumber_c20250101__20250930_zn0AwXOGWDtk"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000021" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20250101__20250930_zCq7CHQLkEhe"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000022" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250101__20250930_zqfMKAJEQFN4"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20250101__20250930_zPp1Jd9vW8S5"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000024" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20250101__20250930_zvDieko3zwCd"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000025" name="dei:EntityAddressAddressLine1">433
Plaza Real</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250101__20250930_zAavuHofeP6i"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite 275</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250101__20250930_z8xtEDTJOds5"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000027" name="dei:EntityAddressCityOrTown">Boca
Raton</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20250101__20250930_zJKYQfRjmpUj"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000028" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20250101__20250930_zObNSrDK8941"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000029" name="dei:EntityAddressPostalZipCode">33432</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--CityAreaCode_c20250101__20250930_z7ACc49uPSG9"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000030" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_906_edei--LocalPhoneNumber_c20250101__20250930_zH8LnxYUEam2"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000031" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zfwXu2vtoVEf"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember" id="Fact000032" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z7soWN4Uur5j"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember" id="Fact000033" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90E_edei--SecurityExchangeName_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z46DAopCxIB1"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_z7ce36XAjDC5"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000035" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zgMAcwY4aUr6"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000036" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_902_edei--SecurityExchangeName_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zaivPtjtOZod"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000037" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityCurrentReportingStatus_c20250101__20250930_zPDJ5531PgUl"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000038" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityInteractiveDataCurrent_c20250101__20250930_ztjY56G9iQI1"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000039" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFilerCategory_c20250101__20250930_zZkk4PYqGi32"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000040" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90D_edei--EntitySmallBusiness_c20250101__20250930_zG8njPB0twu6"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleantrue" id="Fact000041" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250101__20250930_zWtZ18c4ARC6"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No <span id="xdx_90B_edei--EntityShellCompany_dbF_c20250101__20250930_zfL8cml9QoLl"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 5, 2025, the Company had <span id="xdx_90E_edei--EntityCommonStockSharesOutstanding_iI_c20251105_z2OCjehawpK5" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-11-05" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,704,200</ix:nonFraction></span> shares of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Aa_001">PART I - FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_002">Item 1. Condensed Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_003">Condensed Consolidated Balance Sheets &#8211; September 30, 2025 (Unaudited) and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_004">Condensed Consolidated Statements of Operations (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_005">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_006">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; Nine Months Ended September 30, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_007">Notes to Condensed Consolidated Financial Statements (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_008">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">45</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_009">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_010">Item 4. Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Aa_011">PART II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_012">Item 1. Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_013">Item 1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_014">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_015">Item 3. Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_016">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_017">Item 5. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_018">Item 6. Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_019">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">72</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_001"></span>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_002"></span>ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_003"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_zkDxv8YSB9p5" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20250930_zDwx6H0yRq52" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zMi6kepyE602" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Cash_i02I_maACzjDa_z9Xa1jEENZ13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-09-30" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,874</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,952</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--AdvancesOnResearchAndDevelopmentContractServices_i02I_maACzjDa_zyu5zkCkOzic" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advances on research and development contract
    services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0056">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0057">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidInsurance_i02I_maACzjDa_z9UHW8mxhlu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2025-09-30" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,490</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,898</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maACzjDa_zvdnu5D1vz96" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-09-30" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,839</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,653</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_i02I_maACzjDa_zKXmUtJqzixe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Digital assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2025-09-30" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0066">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtACzjDa_maAzbhU_zomaNu9lHTLj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,676</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzbhU_zRrgFALrQXY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,676</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzZbt_zAauU6jMqJde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued expenses, including
    $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAxF2GRCjsO2" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30_us-gaap_RelatedPartyMember" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,033</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zc3c30EVetbj" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span> to related parties at September 30, 2025 and December 31, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,900</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,206</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentContractLiabilitiesCurrent_i02I_maLCzZbt_zfJ82O4nri5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development contract liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,155</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--SeriesBConvertiblePreferredStockCumulativeDividendPayable_i02_maLCzZbt_zgSmNR5afn11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred
    Stock 8% cumulative dividend payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividendPayable" contextRef="AsOf2025-09-30" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0091">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_maLASEzrjf_mtLCzZbt_zjOByD7vDf1d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,422</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,284</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzrjf_z3dov6IGLbg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments and contingencies</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; equity:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_zaFvQoi3Uckg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Preferred Stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930_zgPoixhB7p2f" title="Preferred stock, par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zzVCwpZy8vPj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930_z2Sm2aMErgCi" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zsqKmN11WII9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zK4ucS5OjnIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Convertible Preferred Stock, $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNkixku9wgM4"><span id="xdx_904_eus-gaap--PreferredStockLiquidationPreference_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znFrFE8HSvJl" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></ix:nonFraction></span></span>
    per share stated value issued and outstanding &#8211; <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLvFkYXXSQhe" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zPlvZtCiH628" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zHkKjwz71Dt9" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zV7QpZ8wY7Pe" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares, convertible into <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAhmdL8D5nKg" title="Preferred stock, issuable upon conversion"><span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zRWlttLBr7f3" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></ix:nonFraction></span></span> shares of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0113">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zH7tDktSJeS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock, $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreference_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z4Ovs612H6Dh" title="Preferred stock liquidation preference per share"><span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_ze1fgyvhihKg" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7146</ix:nonFraction></ix:nonFraction></span></span>
    per share stated value issued and outstanding &#8211; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z0NADQp7umTe" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zr7eVx7nq1Gd" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z9hBYjN0z5N" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQQWWQqqFlx2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares, convertible into <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z5wfNSVl2lWe" title="Preferred stock, issuable upon conversion"><span id="xdx_90D_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqzMpNDk296g" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></ix:nonFraction></span></span> shares of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEzEMi_zNUwNbhgeNw1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">Preferred stock, value</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--CommonStockValue_i02I_maSEzEMi_zvtYv8VI1Xy" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250930_zC3sj9J1RcZj" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zVlgVkwMFLpa" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20250930_zWiTy1oc6sud" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zYZVAouAeppa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares;
    issued and outstanding &#8211; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20250930_zHk48TViVN33" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20250930_zFZu3tF52h8i" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,704,200</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20241231_zaB9siRpuC8g" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zkIMv25mzzqi" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2025 and December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-09-30" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_maSEzEMi_zMCaFWBTvRW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-09-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,891,644</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,394,687</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzEMi_zsqCo8GVOmI6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,533,319</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,067,693</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_maLASEzrjf_mtSEzEMi_zpevsKbw8gGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total stockholders&#8217;
    equity</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,912,254</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,219</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzrjf_z5XmGbCl0ped" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total liabilities and
    stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,676</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_004"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zGnmT1j5IPCk" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250701__20250930_z7FV1s4wTfvh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240701__20240930_zznVbWmbiVYd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20250930_zp8by2lJEZf3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240930_z0JVRnlFgpgf" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzpTl_zYd7M95iLAu2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0185">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0187">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zMQRYB4xD9Bc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs and expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzKmU_zc2sm0pY2hEg" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development costs</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,696</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,630</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,801</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,402</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzKmU_zRLHCSEFD6Yl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,627</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,080,302</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,267,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_i01T_mtOEzKmU_msOILzpTl_zgBk5sxCsKJc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    costs and expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-07-012025-09-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,801,354</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012024-09-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">983,257</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-09-30" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,283,103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-09-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,959,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtOILzpTl_maNILzoUu_zkHzq0vxObNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,801,354</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">983,257</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,283,103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,959,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zboMnSPYDlre" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--InvestmentIncomeNonoperating_maNILzoUu_zevuNa1pTW7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2025-07-012025-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,430</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2024-07-012024-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,437</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2025-01-01to2025-09-30" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,236</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2024-01-012024-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,529</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_iN_di_msNILzoUu_z4aQNiaZwYHc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-07-012025-09-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-07-012024-09-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,402</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-09-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,389</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_maNILzoUu_zHhwqMtvuLr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss) on digital assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-07-012025-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-01to2025-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ForeignCurrencyTransactionGainLossRealized_maNILzoUu_zUC0z4jk8uu7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Realized gain (loss)
    on foreign currency transactions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-07-012025-09-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2024-07-012024-09-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,161</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-09-30" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2024-01-012024-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,119</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_maNILATz34k_mtNILzoUu_zu8MJEX7MJMg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,980,398</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">986,030</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,465,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,968,271</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_ecustom--SeriesBConvertiblePreferredStockCumulativeDividend_maNILATz34k_zerZvhbJ7hDf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible
    Preferred Stock 8% cumulative dividend</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividend" contextRef="From2025-07-012025-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="LIXT:SeriesBConvertiblePreferredStockCumulativeDividend" contextRef="From2025-01-01to2025-09-30" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz34k_z33LCJhnuj31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable
    to common stockholders</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-07-012025-09-30" id="Fact000249" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,030,765</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012024-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">986,030</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000251" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,515,993</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,968,271</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per common share &#8211; basic and
    diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20250701__20250930_zhm3K6HMLOdg" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20250701__20250930_zO1W4amq5Ih3" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-012025-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-012025-09-30" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20240701__20240930_zAuJ5uNsxwWc" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20240701__20240930_zLCyUK70K7f8" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250930_zZ8BUKCAYRVg" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250101__20250930_z433Htyzitql" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.92</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240930_zbWgfdvkIiUe" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240930_z6ShkRn3hnIe" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-09-30" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-09-30" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.32</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding &#8211; basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20250930_zJ1a9no3YHE6" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20250930_zLsaFf8mYuL3" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-012025-09-30" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-012025-09-30" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,171,195</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20240930_zaqr5vmP6qm6" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20240930_zlXKUewZ2hBi" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250930_zW3hDdfjfDXh" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250930_zeGIsyHD1irc" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-09-30" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,801,400</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240930_z3fZt1L8JwMk" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240930_zmtqmmov0VBf" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_005"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_zFlQlX48Nco8" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Shares</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_z0WsznSlS89b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Amount</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Shares</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zkAvsDOiwq0d" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Amount</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Shares</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zptaPOWDarSk" style="border-bottom: Black 1pt solid; display: none; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Par</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Value</b></span></p></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zEhpXjZ0FEg" style="border-bottom: Black 1pt solid; display: none; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Paid-in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Capital</b></span></p></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zY3MDAt1PQ0k" style="border-bottom: Black 1pt solid; display: none; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Deficit</b></span></p></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_zRR7kZLCYhe7" style="border-bottom: Black 1pt solid; display: none; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Stockholders&#8217;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Equity</b></span></p></td><td style="display: none; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Par</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three months ended September 30, 2025:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_438_c20250701__20250930_eus-gaap--StockholdersEquity_iS_z99wVQbXAspl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2025</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zA1bPTY7iVH" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zAfJcR2ZDJJf" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcgxgwKuQUyd" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,756,991</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,204,101</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,552,921</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,456</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_z8CoYRtQtOUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in July 2025
    registered private placement, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGCaiUx9y065" title="Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2s2Hai6ct0c" title="Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,552</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,624,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-07-012025-09-30" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,178,162</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z18RC7jVxcZa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in July 2025
    registered direct offering, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZKWDumGIPji" title="Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,791</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,812</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_z2Q8IAKAvOff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of placement agent warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuph6TRFeej" title="Exercise of placement agent warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,690</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueOther_zVvARlQzsOA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSv3afVokLWd" title="Exercise of pre-funded warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,426,111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zmKWOPB5VGu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of common warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHWuZuDl77xf" title="Exercise of common warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,798</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-07-012025-09-30" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zSQqlfO3ym07" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcfWE3VIjEr5" title="Shares issued for services, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-07-012025-09-30" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_zAf16UsSCpC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock 8% cumulative
    dividend</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-07-012025-09-30" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z2v1CJ7ZuaNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-07-012025-09-30" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zcBYtyqsTGVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,980,398</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,980,398</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43E_c20250701__20250930_eus-gaap--StockholdersEquity_iE_z1ejKpLRCvgd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zG9ZUwl0MGL5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKLU24UzZvdh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFN2AcorpTgl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,704,200</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,891,644</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,533,319</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,912,254</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Par</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine months ended September 30, 2025:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_435_c20250101__20250930_eus-gaap--StockholdersEquity_iS_zH2z7hSOUlB1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHGMPSH3OgBa" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFkLM1FkNdc1" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEgiam2wWmJ" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,394,687</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,067,693</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,219</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zfVWVHOXEVwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in February
    2025 registered direct offering, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp24rDT2NQQk" title="Proceeds from sale of securities in February 2025 registered direct offering, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,185</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-09-30" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,228</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z3bm2uCGGuH8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from sale of securities in registered direct equity offering, net of offering costs</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz0MUF9ixB3e" title="Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,185</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-09-30" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,228</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zW6CxPMVl2f5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options issued to settle accrued payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-09-30" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zlwJMgSUsTZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series A convertible stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKKAytPIvD4g" title="Conversion of Series A convertible stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzoYXO49WwOf" title="Conversion of Series A convertible stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGXgWX2UwaDe" title="Conversion of Series A convertible stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,499,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_zMRHQFTSIo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in July 2025
    registered private placement, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkpep2vsP3U5" title="Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000447" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb5guUxymQWd" title="Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,552</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,624,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,178,162</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_z0oDeYq4GpWi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in July 2025
    registered direct offering, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zelHGzBMPb79" title="Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,791</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,812</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_zTPTJi3HVqr6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of placement agent warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwEZ41e7prVh" title="Exercise of placement agent warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,690</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zaE4fnhA2HQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z77GJeqlSoJ" title="Exercise of pre-funded warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000476" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,426,111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z83rrydPL3y3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of common warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ9ddVq80g15" title="Exercise of common warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,798</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-01to2025-09-30" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zg89UtkcloVb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWvAAnIs6Az1" title="Shares issued for services, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-09-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_z4oyMhbmFBN" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock 8% cumulative
    dividend</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0498">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-01-01to2025-09-30" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zWsDThiTuyfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,059,815</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-09-30" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,059,815</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zOBPkBP5PVY9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000514" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,465,626</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000515" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,465,626</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_433_c20250101__20250930_eus-gaap--StockholdersEquity_iE_zMQ3h5XIqWy7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zAkijhFrssCk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7PoJgRkOtQk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,553,359</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCMOgsDXvF8h" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,704,200</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,891,644</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,533,319</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,912,254</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Par</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three months ended September 30, 2024:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_436_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zzqbtYwIuL8f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20240701__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCxbjt7ExGDd" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000537" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20240701__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPaUa1Q4gTzl" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaRfO1U1uJLa" title="Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,209,883</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000534" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,463,969</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,246,139</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zPtBnsDuIXf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0547">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zalvxrn2nDvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000554" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">986,030</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000555" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">986,030</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_433_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zucYB2INNOCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, September 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20240701__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zAPOSxSMs2r2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000564" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20240701__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd9sFoxwdXv2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjk8BK1wlyci" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,316,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000561" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,449,999</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,366,936</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine months ended September 30, 2024:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_430_c20240101__20240930_eus-gaap--StockholdersEquity_iS_zcQIJfFIloIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zewsQII9faNi" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLPcQnm4AWzi" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxsSPrEyw6ab" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,976,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,481,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,994,762</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43E_c20240101__20240930_eus-gaap--StockholdersEquity_iS_z0PVWyUEC7v9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">Balance</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2sMtKJL81G5" title="Balance, shares" style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2H5hy5Cdcba" title="Balance, shares" style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0592">&#8212;</span></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8212;</span></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo6VjfChCA8" title="Balance, shares" style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,976,265</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000587" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,481,728</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">)</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,994,762</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zDL8nxFeTOg1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-09-30" id="Fact000601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zgEwdYj2kpl8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,968,271</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000608" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,968,271</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_436_c20240101__20240930_eus-gaap--StockholdersEquity_iE_zwXjA5eB3rIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, September 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znKT0FkMvXrb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBcTxf2DxRT" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4Jzl3zpg8Xe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,316,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000614" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,449,999</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,366,936</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_437_c20240101__20240930_eus-gaap--StockholdersEquity_iE_zzswRJlnxpLg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Balance</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuprfWFeYRyd" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkoplDNhMqxa" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0632">&#8212;</span></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0624">&#8212;</span></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqyYtJOlUc75" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,316,710</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000627" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,449,999</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">)</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,366,936</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_006"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zF8EiU2KV0oi" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: justify">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250101__20250930_zu7IQ7vWYhIf" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zvYimawCFV21" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
                                                                               Months Ended September 30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zWKuIiivzzhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUzQ49_ziDYLLXRodF" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000639" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,465,626</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000640" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,968,271</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zSGDjKEek2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationAbstract_i02B_zDxtVXMvVFP9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense included in
    -</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--ShareBasedCompensationIncludedInResearchAndDevelopmentCost_i03_maNCPBUzQ49_zlriCC8fbVf2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and development
    costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_i03_maNCPBUzQ49_zeKxWKrunWK4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative
    costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2025-01-01to2025-09-30" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2024-01-012024-09-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CommonStockIssuedForServices_i03_maNCPBUzQ49_zfCT56cKE6Y1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9.75pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common
    stock issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:CommonStockIssuedForServices" contextRef="From2025-01-01to2025-09-30" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_i03N_di_msNCPBUzQ49_zFtmmBbAcbBg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9.75pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    gain (loss) on digital assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-01to2025-09-30" id="Fact000657" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i03B_zMWwMPGXIgQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zXdXMhqxI6X8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Increase) decrease in -</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_i05N_di_msNCPBUzQ49_zJED2aRkdx29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Advances on research and
    development contract services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2024-01-012024-09-30" id="Fact000667" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidInsurance_i05N_di_msNCPBUzQ49_zqrwJ6a5SRF" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2025-01-01to2025-09-30" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2024-01-012024-09-30" id="Fact000670" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i05N_di_msNCPBUzQ49_zAuHBmGKyxSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2025-01-01to2025-09-30" id="Fact000672" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,814</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-01-012024-09-30" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,256</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i04B_zVaH1w1NVM7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (decrease) in -</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i05_maNCPBUzQ49_z600gxesqGh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-09-30" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,661</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-09-30" id="Fact000679" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_i05_maNCPBUzQ49_zKXzLc2630Zj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development contract liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2025-01-01to2025-09-30" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2024-01-012024-09-30" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,997</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzQ49_maCCERCzi8R_z6FCsiJdgk1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000684" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,982,720</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-09-30" id="Fact000685" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,565,861</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z4Gt0NJfFuM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PaymentForAcquisitionCryptoAsset_i01N_di_msNCPBUzOwx_zPcTGAwpbLg4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Purchase of digital
    assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentForAcquisitionCryptoAsset" contextRef="From2025-01-01to2025-09-30" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637,360</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzOwx_maCCERCzi8R_zDfxEUojWEzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000693" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,637,360</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0694">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zJNUKM6cnvw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzwqs_zbdPaIrUv675" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in registered
    direct offerings, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-09-30" id="Fact000699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,245,040</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzwqs_z4wxDz1x7wY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of securities in registered
    private placement, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-01-01to2025-09-30" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,178,162</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzwqs_zo6RGCuJKEf3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-09-30" id="Fact000705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,800</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzwqs_maCCERCzi8R_zFASQGw5vq82" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,469,002</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_zXQnnblQgbie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_mtCCERCzi8R_z34Kx1fznpj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-09-30" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,848,922</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-09-30" id="Fact000715" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,565,861</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zv6YLfE9dRr3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Balance at beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,952</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,203,488</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zwPhy3q8m7Ha" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-09-30" id="Fact000720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,874</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-09-30" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,637,627</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z7iiBQcSlMI1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosures of cash flow information:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationRelatedText_i01_zAiEHIAhgAy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for -</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaidNet_i01_zp8WERSXLnag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-09-30" id="Fact000729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,402</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-09-30" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,389</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesPaidNet_i01_znPWWfwfqGw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zI4hL84jbYvi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash investing and financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_i01_z31AWsojP7a6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Settlement of accrued
    compensation to members of the Board of Directors by issuance of stock options</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="From2025-01-01to2025-09-30" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--ExerciseOfPlacementAgentWarrantsOnCashlessBasis_i01_z5hYJYJ96ku6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of placement
    agent warrants on a cashless basis</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ExerciseOfPlacementAgentWarrantsOnCashlessBasis" contextRef="From2025-01-01to2025-09-30" id="Fact000741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--ExerciseOfPrefundedWarrants_i01_zORLiBZwO2P4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of pre-funded warrants</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ExerciseOfPrefundedWarrants" contextRef="From2025-01-01to2025-09-30" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--ConversionOfSeriesConvertiblePreferredStockIntoCommonStock_i01_zrq8P8Ygc3gj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series
    A Convertible Preferred Stock into common stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" contextRef="From2025-01-01to2025-09-30" id="Fact000747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend_i01_zbvw8MKUtnn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrual of Series B
    Convertible Preferred Stock 8% cumulative dividend</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" contextRef="From2025-01-01to2025-09-30" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,367</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--AccrualOfDeferredOfferingCosts_i01_zUse33MKFtH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrual of deferred
    offering costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:AccrualOfDeferredOfferingCosts" contextRef="From2024-01-012024-09-30" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,928</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_007"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000756" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znyUKB72O1Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_826_zDM7GbQZtkp1">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at September 30, 2025, and for the three months
and nine months ended September 30, 2025 and 2024, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2025, and the results of its operations for the three months and nine months ended September 30, 2025 and 2024, and its cash flows
for the nine months ended September 30, 2025 and 2024. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The condensed consolidated balance sheet at December 31, 2024 has been derived
from the Company&#8217;s audited consolidated financial statements at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s corporate office is located in Boca Raton, Florida.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBcx3g5UD546" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact000758" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z8TcbyKaXek8" title="Bid price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> minimum closing bid price requirement of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its noncompliance
with the minimum $<span id="xdx_904_eus-gaap--StockholdersEquity_iI_pn5n6_c20240819__srt--RangeAxis__srt--MinimumMember_zZOhlN2yyeg" title="Stock holders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-08-19_srt_MinimumMember" id="Fact000762" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market under Rule 5550(b)(1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a compliance plan, outlining proposed equity financings. On October 21, 2024, Nasdaq granted the
Company an extension through February 18, 2025 to complete its plan and evidence compliance via Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not meet the terms of the extension and, on February 19, 2025, received a Staff determination letter. The Company timely
requested a hearing before the Nasdaq Hearings Panel, staying any suspension or delisting pending the Panel&#8217;s decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
an April 3, 2025 hearing, the Panel granted the Company a further extension through July 3, 2025 to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2025, the Company closed a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20250702__20250702_zOIdUOONQYl3" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-07-022025-07-02" id="Fact000764" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">5.05</ix:nonFraction></span> million private placement and, on July 8, 2025, completed a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250708__20250708_zqySmEykS3Gd" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-07-082025-07-08" id="Fact000766" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million registered direct offering
(see Note 5). On July 15, 2025, Nasdaq notified the Company that it had regained compliance with the stockholders&#8217; equity requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remains subject to a Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B) through July 15, 2026. During this period, any future
deficiency in stockholders&#8217; equity would require the Company to request a hearing before the Panel rather than submit a new compliance
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, the Company recorded a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20250930_zG3hNcLDOK6b" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000768" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,465,626</ix:nonFraction></span> and used cash in operations of $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20250930_zuJd32C95Iv5" title="Net cash used in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000770" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,982,720</ix:nonFraction></span>. As
of September 30, 2025, the Company had cash of $<span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20250930_z7OyWuX8I5ug" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-09-30" id="Fact000772" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,887,874</ix:nonFraction></span> available to fund its operations. As of September 30, 2025, the Company had
net working capital and total stockholders&#8217; equity of $<span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20250930_zpZnF4tQkyYk" title="Total stockholders equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,912,254</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $<span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zJlN5Aagtzh1" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" id="Fact000776" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">510,000</ix:nonFraction></span>, which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenues
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities. These factors raise substantial doubt about the Company&#8217;s ability to continue as a
going concern within one year after the date the consolidated financial statements are issued. In addition the Company&#8217;s independent
registered public accounting firm, in their report on the Company&#8217;s audited consolidated financial statements as of and for the
year ended December 31, 2024, expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated
financial statements also do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary
if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities, including its ongoing clinical trials. The amount and timing of future cash requirements depends in substantial
part on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the availability of operating
capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2025 will provide sufficient working
capital to fund the Company&#8217;s operations as currently configured, including its ongoing clinical trial program with respect to
the development of the Company&#8217;s lead anti-cancer clinical compound LB-100, for at least the next 12 months. However, existing
cash resources will not be sufficient to complete the development of and to obtain regulatory approval for the Company&#8217;s product
candidate, which would require significant additional operating capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the appointment of a new Chairman and Chief Executive Officer in June 2025, the completion of the July 2025
equity financings, and other recent changes in senior management and the Board of Directors, the Company&#8217;s operating strategies
that may include the addition of personnel and/or the incurrence of additional operating costs, which may require that the Company raise
additional capital to fund operations. However, as market conditions present uncertainty as to the Company&#8217;s ability to secure
additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and
when necessary, to continue to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#8217;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000778" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zYZ49YeLjDWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_827_z4H8rgXvLVlg">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000780" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_z7xYeO3pzcZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles
of Consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000782" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zHIYsZTUAGY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently operates in a single</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90C_eus-gaap--NumberOfReportableSegments_pid_uSegment_c20250101__20250930_zwQwzLwkbG31" title="Number of reportable segment"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-09-30" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Segment">1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable segment, which consists of the development of a
drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated financial results of the Company. The CODM
uses consolidated net income (loss) as the sole measure of segment profit or loss. The required segment information, including significant
segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000786" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zJMjeDDk30gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

</ix:nonNumeric><p id="xdx_852_zuoKiUyUKyC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000788" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm6OkHpKYoI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zf16ZFjTYomb" title="Cash FDIC insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-09-30" id="Fact000790" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_z2hF7GXIuVpk" title="Cash SIPC insurance"><ix:nonFraction name="LIXT:CashSIPCInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000794" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zuOzzkcHOUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000796" name="LIXT:PrepaidInsurancePolicyTextBlock"><p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zFrIvmtS2QU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepaid
Insurance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000798" name="srt:PlatformOperatorCryptoAssetPolicyTextBlock"><p id="xdx_842_esrt--PlatformOperatorCryptoAssetPolicyTextBlock_zgFfkKeBmpB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Digital
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance
with FASB ASC 820, Fair Value Measurement, based on quoted prices on the active exchange(s) that it has determined is the principal market
for Bitcoin and Ethereum (Level 1). Changes in fair value are included in unrealized gain (loss) on digital assets in other income (expense)
in the Company&#8217;s consolidated statements of operations. Realized gains and losses on the sale of digital assets are included in
other income (expense) in the Company&#8217;s consolidated statements of operations. The Company tracks its cost basis of digital assets
in accordance with the first-in-first-out method of accounting. The Company&#8217;s digital assets are reasonably expected to be realized
in cash or sold or consumed during the Company&#8217;s normal operating cycle and as such have been classified as current assets in the
Company&#8217;s consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#8217;s accounting policies, disclosures, or internal controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000800" name="LIXT:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_84A_ecustom--DeferredOfferingCostsPolicyTextBlock_zLY2PmxIQFF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offering
Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000802" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zm6orj6nTYN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and Licensing Legal and Filing Fees and Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20250701__20250930_zDX7YqtyF8kc" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-07-012025-09-30" id="Fact000804" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,853</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20240701__20240930_zIIcxXwgiT0j" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-07-012024-09-30" id="Fact000806" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,416</ix:nonFraction></span> for the three months ended September 30, 2025 and 2024, respectively, and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20250101__20250930_zu5GWZr8Gp62" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-01to2025-09-30" id="Fact000808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,239</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20240930_zAXrnWi1nCPg" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-09-30" id="Fact000810" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,239</ix:nonFraction></span>
for the nine months ended September 30, 2025 and 2024, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000812" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z1Zs8QjNsB9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration
of Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMX12huKF4D" title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKIOtUXScmqc" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% or more of general and administrative costs or research and development costs for the three months ended September 30,
2025 and 2024 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2025 include charges from three vendors and consultants representing <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7NBiD4b04ei" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.4</ix:nonFraction></span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5CRKZi6OJBc" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28.8</ix:nonFraction></span>%
and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBr33L05Ay01" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.2</ix:nonFraction></span>%,
respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2024
include charges from three vendors and consultants representing<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVTJCBQXYcYe" title="Concentration of risk, percentage">
<ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.7</ix:nonFraction></span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zz6neRjiqpA8" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.1</ix:nonFraction></span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVc7dzNJM3u3" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.1</ix:nonFraction></span>%.
respectively, of total research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zE8OTDqRVpfi" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember" id="Fact000830" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zRlCNOyI4px4" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.1</ix:nonFraction></span>%, respectively
of total general and administrative costs. General and administrative costs for the three months ended September 30, 2025 also includes
a charge from a vendor representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zk2AiHpJ4xa2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.6</ix:nonFraction></span>% of total general and administrative costs. General and administrative costs for the three months
ended September 30, 2024 includes a charge from a vendor representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zTictifVolYe" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.4</ix:nonFraction></span>% of total general and administrative costs. General and administrative
costs for the three months ended September 30, 2025 and 2024 also included charges for the fair value of stock options granted to directors
and corporate officers representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_zA80E4u5xhoh" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44.4</ix:nonFraction></span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_z4BX9IqCpQo9" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.8</ix:nonFraction></span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2025 include charges from five vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfkMnrcwWfM2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24.3</ix:nonFraction></span>%,
<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zojGHZTSZXlb" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.7</ix:nonFraction></span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI7j6W9omBDd" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.9</ix:nonFraction></span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn9Mq8v8esu1" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.0</ix:nonFraction></span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziRtXm4Gk1V5" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantFiveMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.7</ix:nonFraction></span>%, respectively, of total research and development costs. Research and development costs for the nine months
ended September 30, 2024 include charges from three vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zidzYfsRqY3c" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41.2</ix:nonFraction></span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYc3gj0Mv6K3" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.4</ix:nonFraction></span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zycIFkh6Rn35" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.6</ix:nonFraction></span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_ztyHSrbxcdRl" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.9</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zVYVeCuNf6qk" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>%. respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 did not include
any charges from a single vendor/consultant in excess of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zYdU9FIC77Wb" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of total general and administrative costs. General and administrative costs
for the nine months ended September 30, 2024 also include charges from two vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--OneVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zhjULGl4DD04" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_custom_OneVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.0</ix:nonFraction></span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zJwQvJpmmook" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_custom_TwoVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.5</ix:nonFraction></span>%, respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 and 2024 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_z7GmotHUJjRf" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35.4</ix:nonFraction></span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_zFY9yQs4oTJj" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.6</ix:nonFraction></span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000872" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zZ7orfn7Lc42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at September 30, 2025 and December 31, 2024. In the event the Company was to determine that it
would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets
would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations
in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company did not have any unrecognized tax benefits as of September 30,
2025 or December 31, 2024, and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2025 or December
31, 2024. Subsequent to September 30, 2025, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000874" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZwY8nxr2DGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000876" name="LIXT:WarrantsPolicyTextBlock"><p id="xdx_844_ecustom--WarrantsPolicyTextBlock_zGXvgbX9R71e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging
(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet
the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under
ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity
classification. The Company has determined that the warrants issued in the July 2023 equity financing, the February 2025 equity financing,
and the July 2025 equity financings (see Note 5) meet the requirements for equity classification. This assessment, which requires the
use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At September 30, 2025 and December 31, 2024, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000878" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zqt9gtDBhmo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
(Loss) Per Share</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
The weighted average number of common shares outstanding utilized for determining basic net loss per common share for the three months
and nine months ended September 30, 2025 includes all pre-funded warrants sold in the July 2, 2025 and July 8, 2025 equity financings,
aggregating <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zkIN6MSKL6rk" title="Pre funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,085,883</ix:nonFraction></span> pre-funded warrants, of which <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zdWqV5Y5fxfj" title="Unexercised pre funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-09-30" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">659,772</ix:nonFraction></span> pre-funded warrants were unexercised at September 30, 2025. Basic and diluted
loss per common share was the same for all periods presented because all preferred shares, warrants (excluding pre-funded warrants) and
stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025 and 2024, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000884" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlGwgDhu5fc3" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact000887" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants (excluding pre-funded
    warrants)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,610,972</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_CommonStockWarrantsMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_custom_CommonStockOptionsMember" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,123,059</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_CommonStockOptionsMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">623,232</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-09-30" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,307,161</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,504,514</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zqAKuOIrhEic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000901" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVuorOgqkAq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were
converted into United States dollars at the average rate of <span id="xdx_90D_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250701__20250930_zyoYCullawD8" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2025-07-012025-09-30" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.1692</ix:nonFraction></span> and <span id="xdx_902_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240701__20240930_zgqHU1MsJlii" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2024-07-012024-09-30" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.0991</ix:nonFraction></span> Euros per United States dollar, respectively. During the
nine months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_908_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250101__20250930_zP2AECW2WxC5" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2025-01-01to2025-09-30" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.1182</ix:nonFraction></span> and <span id="xdx_909_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20240930_znMdqm0tPkX6" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2024-01-012024-09-30" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.0873</ix:nonFraction></span> Euros per United States dollar, respectively. As of September 30,
2025 and December 31, 2024, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was
not a party to any foreign currency forward or exchange contracts. Accordingly, the Company did not have any unrealized foreign currency
(gain) loss at September 30, 2025 or 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000911" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwovQEHQLDlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000913" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of financial instruments measured on a recurring basis was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zEcIGOa3Fk24">Schedule
of Fair Value Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Description</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of September 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Digital
    assets</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValueCurrent" contextRef="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zqxTOKxMJq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative
of their respective fair values due to the short-term nature of those instruments. The carrying value of digital assets is based on quoted
prices in active markets (Level 1 inputs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000925" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zksEpkVJ2Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-08, Intangibles &#8211; Goodwill and Other &#8211;
Crypto Assets (Subtopic 350-60). ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet
with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of operations
each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis,
fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during
the fiscal quarter ended September 30, 2025, the Company adopted and applied ASU-2023-08 henceforth. As the Company did not have any
crypto assets prior to the fiscal quarter ended September 30, 2025, no cumulative-effect adjustment was required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). These ASUs require disclosure of disaggregated information of Income Statement expense
captions that include certain costs, such as employee compensation, depreciation, and intangible asset amortization. They also require
disclosure of the total amounts of selling expenses, along with an entity&#8217;s definition of selling expenses. The amendments are
effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning
after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of these ASUs, but does not expect
them to have a material impact on its consolidated financial statements presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000927" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVCh9Es3C8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, effective January
1, 2024, certain reclassifications have been made to the prior year statement of operations to conform it to the current year presentation.
In presenting general and administrative costs on the Company&#8217;s consolidated statement of operations for the three months ended
September 30, 2024, $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG7YsqF1tvd" title="General and administrative costs"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000929" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">283,053</ix:nonFraction></span> of compensation to related parties, $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4nshvne9er" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000931" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,416</ix:nonFraction></span> of patent and licensing legal and filing fees and costs, and
$<span id="xdx_904_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJThg06Ayjqc" title="Other costs and expenses"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">293,158</ix:nonFraction></span> of other costs and expenses were shown separately. In presenting the Company&#8217;s consolidated statement of operations for
the three months ended September 30, 2024, the Company has combined these categories into general and administrative costs in the accompanying
consolidated statement of operations for the three months ended September 30, 2024. In presenting general and administrative costs on
the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, $<span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXewFRr0sdHe" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000935" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">907,069</ix:nonFraction></span> of compensation to related
parties, $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjPAU3N9b6x9" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,239</ix:nonFraction></span> of patent and licensing legal and filing fees and costs, and $<span id="xdx_901_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztNhdQDEcnyk" title="Other costs and expenses"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,168,582</ix:nonFraction></span> of other costs and expenses were shown separately.
In presenting the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, the Company has
combined these categories into general and administrative costs in the accompanying consolidated statement of operations for the nine
months ended September 30, 2024. These reclassifications had no effect on the reported results of operations, including loss from operations
and net loss.</span></p>

</ix:nonNumeric><p id="xdx_858_znt9FjXF96Y8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000941" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zfBoHoNrwicd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_822_zfbu9n4i88gj">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Company&#8217;s Chief Executive Officer
(&#8220;CEO&#8221;). The Company&#8217;s CODM evaluates performance and makes operating decisions about allocating resources based on
financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company
has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000943" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z3IccXWlfrE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhEnJlVTR3Zi" style="display: none">Schedule of Information by Segment</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250701__20250930_zxEwQzc9BImd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240701__20240930_z9nNu0oEZG5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20250930_z1Rpaa6OTP4k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930_ztpy1Q0wNB3b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zjwvHZtW1TBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical and related oversight
    costs</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,424</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,342</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,894</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,319</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zQYe1AIkkvq6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preclinical research focused on development
    of additional novel anti-cancer compounds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_PreclinicalResearchMember" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_PreclinicalResearchMember" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,821</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_PreclinicalResearchMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,573</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_PreclinicalResearchMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--CompoundMaintenanceMember_zu5wGjISNlol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compound maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_CompoundMaintenanceMember" id="Fact000955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,480</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_CompoundMaintenanceMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,062</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_CompoundMaintenanceMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,563</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_CompoundMaintenanceMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_z4CTJDswmHX1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory service
    costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_RegulatoryServiceCostsMember" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,581</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_RegulatoryServiceCostsMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,405</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_RegulatoryServiceCostsMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,771</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_RegulatoryServiceCostsMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,021</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zC7Lgo1pyIj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,696</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,630</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,801</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,402</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and
2024 based on the respective geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250701__20250930_zMTYFay3jd4b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240701__20240930_zk0xMuipl2Kl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zfN1oXRYk7f8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_zH2Z3CpfXAKh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zeXvwFWu7jNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_country_US" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,305</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_country_US" id="Fact000971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,808</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_country_US" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,804</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_country_US" id="Fact000973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,736</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zZAC6oFHO2y6" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Spain</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_country_ES" id="Fact000975" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,391</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_country_ES" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,544</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_country_ES" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,997</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_country_ES" id="Fact000978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,022</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zHdQmjEUyMt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">China</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_country_CN" id="Fact000983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,282</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zVKu5GRBX8Dk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Netherlands</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_country_NL" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,278</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_country_NL" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,362</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zUweL85KQMT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,696</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,630</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,801</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30" id="Fact000993" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,402</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250701__20250930_zgeyf2S7GSn2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zciJovYJXG54" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20250930_zJ464v40b1N" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zOtdAVQN8Jo5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Compensation to related parties:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--CashBasedCompensationToRelatedParties_i02_maGAAEzrRU_z3XRf7ahkMX" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2025-07-012025-09-30" id="Fact000995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,416</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2024-07-012024-09-30" id="Fact000996" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,226</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2025-01-01to2025-09-30" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,432</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2024-01-012024-09-30" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,624</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockBasedCompensationToRelatedParties_i02_maGAAEzrRU_z9ROGtGZ8R74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2025-07-012025-09-30" id="Fact001000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2024-07-012024-09-30" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2025-01-01to2025-09-30" id="Fact001002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2024-01-012024-09-30" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maGAAEzrRU_z72gHGOzFwMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patent and licensing legal and filing fees
    and costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2025-07-012025-09-30" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,853</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2024-07-012024-09-30" id="Fact001006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,415</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2025-01-01to2025-09-30" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2024-01-012024-09-30" id="Fact001008" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,238</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--OtherConsultingAndProfessionalFees_i02_maGAAEzrRU_zfY6Ns0pame2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other consulting and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2025-07-012025-09-30" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,822</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2024-07-012024-09-30" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,893</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2025-01-01to2025-09-30" id="Fact001012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">920,689</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2024-01-012024-09-30" id="Fact001013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">481,865</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_z67lYoTnxFA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2025-07-012025-09-30" id="Fact001015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,277</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2024-07-012024-09-30" id="Fact001016" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,440</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2025-01-01to2025-09-30" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2024-01-012024-09-30" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i02_maGAAEzrRU_z1HfQbQrluS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other costs and expenses,
    net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2025-07-012025-09-30" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,679</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-07-012024-09-30" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,826</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2025-01-01to2025-09-30" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,764</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-01-012024-09-30" id="Fact001023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,551</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzrRU_zVv1vUc3YWl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total general and
    administrative costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30" id="Fact001025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750,658</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,627</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,080,302</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30" id="Fact001028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,267,890</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250930_zqxGQxmvlkmc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zo3jfZph8zQc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zmHMXhdF3BGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30_custom_ResearchAndDevelopmentMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,412</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_ResearchAndDevelopmentMember" id="Fact001031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,298</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zhoArsta6Ayh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Corporate assets (primarily
    cash and digital assets)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30_us-gaap_CorporateMember" id="Fact001033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,423,264</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_us-gaap_CorporateMember" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,106,205</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_z3oqNeZnZW8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30" id="Fact001036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,676</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_znbhRckyCGqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001039" name="us-gaap:CryptoAssetTextBlock"><p id="xdx_80E_eus-gaap--CryptoAssetTextBlock_zUyUgMXuChic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82A_zRUED9T6vt06">Digital Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001041" name="us-gaap:CryptoAssetHoldingTableTextBlock"><p id="xdx_89B_eus-gaap--CryptoAssetHoldingTableTextBlock_zd15zlx3TLX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the cost and fair value of digital assets that were initially purchased during August 2025 were as follows (there
were no digital assets at December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zz8kIdnQJfF6">Schedule
of Digital Assets</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Units</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
                                            (Loss)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on
                                            Change</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Fair Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Bitcoin</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zjLwTZVrBjR9" title="Digital assets held, Quantity"><ix:nonFraction name="LIXT:CryptoAssetsNumberOfUnits" contextRef="AsOf2025-09-30_custom_BitcoinMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10.59</ix:nonFraction></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zs89YFu6a0Xe" title="Digital assets held, Cost basis" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetCost" contextRef="AsOf2025-09-30_custom_BitcoinMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,205,540</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zlguGps7Kc7f" title="Unrealized gain (loss) in fair value of digital assets" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-012025-09-30_custom_BitcoinMember" id="Fact001047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,261</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zE8YvwRZmWfb" title="Digital assets fair value" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-09-30_custom_BitcoinMember" id="Fact001049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,801</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Ethereum</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zIVTZhF7pqRj" title="Digital assets held, Quantity"><ix:nonFraction name="LIXT:CryptoAssetsNumberOfUnits" contextRef="AsOf2025-09-30_custom_EthereumMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">300.70</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zWSFVBkk2Cs3" title="Digital assets held, Cost basis" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetCost" contextRef="AsOf2025-09-30_custom_EthereumMember" id="Fact001053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,431,820</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--EthereumMember_zDWjvnB0gu3g" title="Unrealized gain (loss) in fair value of digital assets" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-012025-09-30_custom_EthereumMember" id="Fact001055" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,148</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9LtdhjJ3Z1g" title="Digital assets fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-09-30_custom_EthereumMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,246,672</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20250930_z4cXF93NQjvg" title="Digital assets held, Cost basis" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetCost" contextRef="AsOf2025-09-30" id="Fact001059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637,360</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930_zy5ZBpKgezha" title="Unrealized gain (loss) in fair value of digital assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-01to2025-09-30" id="Fact001061" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,887</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20250930_zWBMyrgrRA3h" title="Digital assets fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-09-30" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,473</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zMomer7ZKDe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
currency prices are affected by various forces, including global supply and demand, interest rates, exchange rates, inflation or deflation,
and the global political and economic conditions. Digital assets have a limited history, and the fair value historically has been very
volatile. The Company may not be able to liquidate its inventory of digital assets currency at its desired price if required. The Company
has recorded an unrealized net loss resulting from a decrease in the fair value of digital assets of $<span id="xdx_902_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_iN_di_c20250101__20250930_zljt2LVN7ln" title="Unrealized gain (loss) in fair value of digital assets"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedGainLossNonoperating" contextRef="From2025-01-01to2025-09-30" id="Fact001065" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,887</ix:nonFraction></span> that is included in the
loss from operations in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">The Company&#8217;s digital asset holdings
in Bitcoin and Ethereum represent <span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zNi0BRkEMxT" title="Digital asset holdings percentage"><span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9cm7kyoEgle" title="Digital asset holdings percentage"><ix:nonFraction name="LIXT:DigitalAssetHoldingsPercentage" contextRef="AsOf2025-09-30_custom_BitcoinMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="LIXT:DigitalAssetHoldingsPercentage" contextRef="AsOf2025-09-30_custom_EthereumMember" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></ix:nonFraction>%</span></span> of the Company&#8217;s digital assets as of September 30, 2025. Bitcoin and Ethereum are digital
assets, a novel asset class subject to potential legal, regulatory, commercial, and technical uncertainties. These assets do not generate
cash flow and require the Company to incur custodial and safeguarding costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">The market prices of Bitcoin and Ethereum
have historically exhibited significant volatility, and a material decrease in their fair value could adversely impact the Company&#8217;s
financial condition and results of operations. The Company&#8217;s strategy of acquiring and holding Bitcoin and Ethereum also subjects
it to counterparty risks related to third-party custody arrangements, as well as cybersecurity risks and other operational risks inherent
in managing digital assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">In particular, the Company is exposed
to the risk that the private cryptographic keys necessary to access its digital assets may potentially be lost, destroyed, or otherwise
rendered inaccessible. Any such loss could result in a partial or total loss of the affected digital assets, which would materially and
adversely affect the Company&#8217;s financial condition and operating results.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001071" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLQvZJWqtpib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82C_zPMcscojsL9h">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zO6T4pAKRQp3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zsEBrVSVv3j" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total
of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoXTEiE3fw98" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent
of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations.
The holders of each tranche of <span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzkdNIvwINwj" title="Principal cash obligations and commitments"><ix:nonFraction name="LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend
equal to <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBQbInIMDdn3" title="Preferred stock dividend, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% of the annual net revenue of the Company divided by <span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGH2EqT9R8ek" title="Annual net revenue"><ix:nonFraction name="LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span>, until converted or redeemed. <span id="xdx_900_eus-gaap--PreferredStockConversionBasis_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z93BDJLK69Rl" title="Preferred stock, conversion description"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" id="Fact001085" name="us-gaap:PreferredStockConversionBasis">Each share of Series A Convertible
Preferred Stock was convertible, at the option of the holder, into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv8UBi77REL2" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.20833</ix:nonFraction></span> shares of common stock (subject to customary anti-dilution
provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a
merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zafabE8HDhC7" title="Gross proceeds from sale of transaction"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember624785171" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,875,000</ix:nonFraction></span>.</ix:nonNumeric> </span>The Series A Convertible Preferred Stock
had a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred Stock did
not have any cash liquidation preference rights or any registration rights. Based on the attributes of the Series A Convertible Preferred
Stock as previously described, the Company accounted for the Series A Convertible Preferred Stock as a permanent component of stockholders&#8217;
equity. The <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z7m0NXVp5WA" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> outstanding shares of Series A Convertible Preferred Stock were converted into a total of <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWPilQQMsrxf" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></span> shares of common
stock pursuant to a notice of conversion dated May 16, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2025, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series B Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total
of <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zYE3Z8m2HGk3" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQT4GcVBq0Fj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></ix:nonFraction></span></span> shares as Series B Convertible Preferred Stock with a stated value of $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOxmQGkzZpbe" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7146</ix:nonFraction></span> per share. Each Preferred Share is convertible
into one share of Common Stock, subject to standard adjustments such as stock splits and stock dividends. The Preferred Shares are non-voting,
except that certain actions of the Company may not be taken except upon approval of holders who own a majority in stated value of the
Preferred Shares. The Preferred Shares bear an 8% per annum cumulative dividend non-compounding and payable at conversion either in cash
or, at the holder&#8217;s election, in shares of Common Stock valued at the then effective conversion rate. The holders of the Preferred
Shares have the right to designate two members to the Company&#8217;s Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 and December 31, 2024, the Company had <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBClampbIq44" title="Undesignated preferred stock"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,076,870</ix:nonFraction></span> shares and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuYwtxA7eA0i" title="Undesignated preferred stock"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,650,000</ix:nonFraction></span> shares, respectively, of undesignated preferred
stock, which may be issued with such rights and powers as the Board of Directors may designate. On October 21, 2025, the Company filed
a Certificate of Elimination of Certificate of Designations of Series A Convertible Preferred Stock with the Delaware Secretary of State
to amend the Company&#8217;s certificate of incorporation to eliminate the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20251021__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmAbLRV6GRDi" title="Convertible preferred stock shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-10-21_custom_SeriesAConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares of Preferred Stock associated with the Series
A Convertible Preferred Stock classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zZbV7kgLVITj" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zhxHRTJzu6bk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_zAssprUWK9ma" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zsCj204RVMXl" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of September 30, 2025 and
December 31, 2024, the Company had <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20250930_zzPQPUjVggn8" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250930_ztT5FzpCcsqh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,704,200</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zqVPKEpGRoue" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zTO7SAQ0yP43" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
20, 2023 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company completed a registered direct offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkji6hwJgN69" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-192023-07-20_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_us-gaap_CommonStockMember" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares of common stock at $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zu5RM9pbjg9l" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share and pre-funded
warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zk1EvCJHtW9b" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> shares of common stock at $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zEMqyaHOrShf" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.9999</ix:nonFraction></span> per warrant. The pre-funded warrants had an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z1NGIH7YqFdc" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share, were immediately exercisable, and were fully exercised between July 24 and August 7, 2023 for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z3ndgAQcx6dc" title="Exercise of common stock options"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></span>.
The pre-funded warrants were deemed to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, the Company issued to the same institutional investor common stock purchase warrants to acquire <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zAEY7d9C3FFe" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></span>
shares at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzDPZ0QnxDy7" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share. These warrants became exercisable immediately and expire on July 20, 2028. The warrants
and underlying shares were issued pursuant to Section 4(a)(2) and Rule 506(b) of the Securities Act and were subsequently registered
for resale under a Form S-3 declared effective on May 2, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zr5nAn5FtIi" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001139" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,499,964</ix:nonFraction></span> from the combined transactions and net proceeds of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zPOwVLUSLc" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001141" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,137,039</ix:nonFraction></span> after deducting offering
expenses of $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zgi1V87tzJ02" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001143" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">362,925</ix:nonFraction></span>. As compensation, the placement agent received warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zxsSPvbgPdg7" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></span> shares of common stock at an exercise
price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zrChCvITZEo8" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></span>, expiring <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zwQR9bfAu0t5" title="Warrant expires date"><ix:nonNumeric contextRef="From2023-07-202023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" format="ixt:datemonthdayyearen" id="Fact001149" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 20, 2028</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investor warrants include standard anti-dilution adjustments and a fundamental transaction provision entitling the holder, upon a qualifying
transaction, to elect cash settlement based on a defined Black-Scholes valuation formula. If such a transaction is outside the Company&#8217;s
control (e.g., not board-approved), the holder is entitled to receive the same form of consideration received by common shareholders.
These warrants are classified in permanent equity. Any cash payments upon settlement will be recorded as equity distributions when and
if such obligations arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February
13, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 13, 2025, the Company completed a registered direct offering of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250213__20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXWgP9FJrPng" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-02-132025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span> shares of common stock at $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zhn6iXHWTfx3" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.415</ix:nonFraction></span> per share and, in a
concurrent private placement, issued warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zt2GZjPp2ZX1" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAvzIUI7E157" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></span> per share. The
warrants are immediately exercisable and expire <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYplFEvhQJ3" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" format="ixt-sec:durwordsen" id="Fact001159" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants and underlying shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act and
were subsequently registered for resale on a Form S-1 declared effective on April 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
proceeds from the offering were $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zBowH4qR6g57" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001161" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,050,003</ix:nonFraction></span>, with net proceeds of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zORULInTsB66" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">914,228</ix:nonFraction></span> after deducting $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zIbID5N297M1" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001165" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">135,775</ix:nonFraction></span> in placement agent fees and other
offering costs. The Company granted the placement agent warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zQlILjiwlNVj" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,609</ix:nonFraction></span> shares of common stock at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_z4aTsu0PM44c" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.0188</ix:nonFraction></span> per share, expiring
<span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXc3eAd7IAng" title="Warrant expires date"><ix:nonNumeric contextRef="From2025-02-132025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" format="ixt:datemonthdayyearen" id="Fact001171" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">February 11, 2030</ix:nonNumeric></span>. Net proceeds are being used for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
warrants include customary anti-dilution adjustments and a &#8220;fundamental transaction&#8221; provision. If a qualifying transaction
within the Company&#8217;s control is consummated, holders may elect cash settlement equal to the Black-Scholes value. For transactions
outside the Company&#8217;s control, holders are entitled to receive the same consideration as common shareholders. The warrants are
classified in permanent equity. Any future cash settlements will be accounted for as equity distributions upon occurrence of the related
fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
2, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement (the &#8220;Offering&#8221;)
<span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zpBmiU7kXqGi" title="Private placement shares"><ix:nonFraction name="LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" contextRef="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,573,130</ix:nonFraction></span> shares of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;); <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250630__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCntfi9fhM29"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-06-302025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,552</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Common Stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhs5jTcI941c"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Common Shares&#8221;, the &#8220;Common
Stock&#8221;); common stock warrants (the &#8220;Common Stock Warrants&#8221;) to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zvp0JgwBD5Z2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,355,214</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock; and Pre-Funded Warrants to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantsMember_zHaHCUSZmLQg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,322,532</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Shares, the Common Stock Warrants, Pre-Funded Warrants, the Preferred Shares,  and the shares of
Common Stock underlying the Common Stock Warrants, Pre-Funded Warrants and Preferred Shares have been registered under the
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were issued in reliance on an exemption from the
registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. The Company filed a registration statement on
Form S-1 (the &#8220;Resale Registration Statement&#8221;) to cover the resale of the Common Shares and any shares of Common Stock
underlying the Pre-Funded Warrants, the Common Stock Warrants, the Placement Agent Warrants and the Preferred Shares, which was
declared effective by the Securities and Exchange Commission on July 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DescriptionOfOfferingPrice_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCILqsApGJyf" title="Description of offering price"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_SecuritiesPurchaseAgreementMember" id="Fact001179" name="LIXT:DescriptionOfOfferingPrice">The
Offering was priced at-the-market under Nasdaq rules at $0.8396 per common stock unit, with each unit consisting of one share of common
stock at a price of $0.7146 and one common stock warrant at a price of $0.125 to acquire one share of common stock at an exercise price
of $1.00 per share.</ix:nonNumeric></span> The Offering resulted in gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250630__20250630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zH42JvBt92N7" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-06-302025-06-30_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001181" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,050,000</ix:nonFraction></span> before deducting the placement agent&#8217;s fees and related
offering expenses of $<span id="xdx_909_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNrVN03cDj3" title="Offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember" id="Fact001183" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">871,838</ix:nonFraction></span>. The initial Offering closed on July 2, 2025 with the Company receiving gross proceeds of approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250702__20250702__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4u2tzfI6sf7" title="Gross proceeds from initial offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-022025-07-02_custom_SecuritiesPurchaseAgreementMember" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">4,050,000</ix:nonFraction></span>. The remaining $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250718__20250718__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZl95ubOMRj8" title="Gross proceeds from initial offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-182025-07-18_custom_SecuritiesPurchaseAgreementMember" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,000,000</ix:nonFraction></span> of gross proceeds were paid on July 18, 2025 upon the Resale Registration Statement having been
declared effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Placement Agent Agreement dated as of June 30, 2025, the Company engaged Spartan Capital Securities, LLC (the &#8220;Placement Agent&#8221;)
to act as the Company&#8217;s exclusive placement agent in connection with the Offering. The Company paid the Placement Agent a cash
fee equal to 8% of the aggregate gross proceeds raised in the Offering, a non-accountable expense allowance of 1.0% of the aggregate
gross proceeds raised in the Offering, and $<span id="xdx_90C_eus-gaap--LegalFees_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zGcmhkDjtCZ3" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-06-302025-06-30_custom_PlacementAgentAgreementMember" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> for its expenses including legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent&#8217;s Warrants&#8221;) to purchase
up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7P2LhTkZ113" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_PlacementAgentsWarrantsMember_us-gaap_CommonStockMember" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315,626</ix:nonFraction></span> shares of Common Stock, which represented 5% of the Shares and Pre-Funded Warrants sold in the Offering. The Placement
Agent&#8217;s Warrants had an exercise price of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_dp_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJ7hhsLL8D9" title="Warrants exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-30_custom_PlacementAgentsMember_us-gaap_CommonStockMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="USDPShares">125</ix:nonFraction></span>% of the offering price and otherwise had the same terms as the Common Stock Warrants.
On July 15, 2025, the Placement Agent&#8217;s warrants were exercised on a cashless basis, resulting in the Placement Agent being issued
<span id="xdx_904_eus-gaap--SharesIssued_iI_c20250715__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsvOqJrKrFRi" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-07-15_custom_PlacementAgentsMember_us-gaap_CommonStockMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,690</ix:nonFraction></span> shares of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 2, 2025 through September 30, 2025, <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250702__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zylM2vUpxJk1" title="Warrants exercisable"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2025-07-022025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,662,760</ix:nonFraction></span> pre-funded warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zgfQK5mkLNE3" title="Warrants exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share that were sold
in the private placement were exercised, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250702__20250805__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zetthfjE6ZFa" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-022025-08-05_custom_PlacementAgentsMember_us-gaap_CommonStockMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,662,760</ix:nonFraction></span> shares of Common Stock. During the period from October
1, 2025 through October 31, 2025, an additional <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqCCtwHSeey7" title="Warrants exercisable"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,521</ix:nonFraction></span> pre-funded warrants exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zwDvDWhC0B2c" title="Warrants exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share and sold in the private
placement, were exercised, resulting in the issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn1TAV9Zzvf3" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,521</ix:nonFraction></span> shares of Common Stock. As of October 31, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwuMEizjpsAb" title="Pre-funded warrants remained unexercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-10-31_us-gaap_SubsequentEventMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,251</ix:nonFraction></span> pre-funded warrants
remained unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the purchasers and to the placement agent are subject to customary adjustments for stock splits,
stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#8217;s common stock.
In addition, the warrants issued contain a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction
(including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control,
the holders of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment of the warrants, cash
consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction is not within
the Company&#8217;s control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion)
as the holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#8217;s assets, as
defined in the July 2, 2025 warrants, to the extent that the warrants are outstanding at the effective date that such a transaction is
closed, this &#8220;fundamental transaction&#8221; provision would entitle the holders to substantial cash consideration, thus reducing
the amounts to be retained by the Company or potentially distributable to the Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
8, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2025, the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering
(the &#8220;Offering&#8221;) <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250703__20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmwSiWtLi4v7" title="Number of shares issued and sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-032025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,675</ix:nonFraction></span> shares (the &#8220;Common Shares&#8221;) of the Company&#8217;s Common Stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTH5zLAGYEZ5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share (the &#8220;Common Stock&#8221;) and Pre-Funded Warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4YWchxOvC06" title="Warrants to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">763,351</ix:nonFraction></span> shares of
Common Stock, at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTBAubL2yrp8" title="Offering price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.54</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering resulted in gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250703__20250703__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHjxFnHLOLm6" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-07-032025-07-03_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001219" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span> before deducting placement agent&#8217;s fees and related offering expenses of $<span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztViDmKtOWA9" title="Offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-07-032025-07-03_custom_SecuritiesPurchaseAgreementMember" id="Fact001221" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,188</ix:nonFraction></span>.
The Offering closed on July 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Placement Agent Agreement dated as of July 3, 2025 (the &#8220;Placement Agent Agreement&#8221;), the Company engaged Spartan Capital
Securities, LLC (the &#8220;Placement Agent&#8221;) to act as the Company&#8217;s exclusive placement agent in connection with the Offering.
The Company paid the Placement Agent a cash fee equal to 8.0% of the aggregate gross proceeds raised in the Offering, and agreed to reimburse
the Placement Agent $<span id="xdx_901_eus-gaap--LegalFees_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zj691v7dSM4d" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-07-032025-07-03_custom_PlacementAgentAgreementMember" id="Fact001223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> for its legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 8, 2025 through August 18, 2025, all <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcsincbDe1d1" title="Warrants exercisable"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">763,351</ix:nonFraction></span> pre-funded warrants exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKBSjahIc3Lf" title="Warrants exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share that were sold
in the direct registered offering were exercised, resulting in the issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAqOobpvy0Jk" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_us-gaap_CommonStockMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">763,351</ix:nonFraction></span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
Issued for Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Market Awareness Agreement with MicroCap Advisory, LLC entered into during August 2025 and terminated in September
2025, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z8BPou2phvA" title="Shares Issued for Services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,181</ix:nonFraction></span> shares of its common stock, valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z9LTtHb4hL9d" title="Shares Issued for Services, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">44,711</ix:nonFraction></span>, as settlement of the original <span id="xdx_909_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_zNxheEMOJtAe" title="Shares Issued for Services"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,000</ix:nonFraction></span> common share obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001237" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLMEP9B3SPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offerings, but excluding pre-funded warrants, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zOW3PTkJm0Dg" style="display: none">Schedule of Warrants Outstanding</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (in Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbLrUoVZwJCi" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6AHvW9y4V29" title="Weighted Average Exercise Price, Warrants Outstanding" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwSXgkLGdfZc" title="Number of Shares, Issued" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,138,233</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhrcAB0cqCY4" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,096</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFRGGrhhcBwa" title="Number of Shares, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">335,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS53Czvd9U4k" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zc1dVWXKf6h1" title="Number of Shares, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCWHJwgaB2k6" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYsGkWW2f4l" title="Number of Shares, Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,610,972</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za6s0mfAUDR4" title="Weighted Average Exercise Price, Warrants Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.715</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zx4qnnj4z9Ib" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" format="ixt-sec:duryear" id="Fact001259" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">4.47</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrOJu4pl9rDg" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbyPAFAbJ7D8" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlHcPudAHm13" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,610,972</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjJMkJFfSPBj" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.715</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LFkTAwSHD8" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703" format="ixt-sec:duryear" id="Fact001269" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">4.47</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zDAb2IMK5oQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001271" name="LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zmxEoO6hcpIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9EBrlQodZ3h" style="display: none">Schedule of Warrants Outstanding and Exercisable</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 47%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1UbhatmWlf6" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.0000</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z76d4jVXfEj1" title="Warrants Outstanding Shares" style="width: 47%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,355,214</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5Snwck6OJ5h" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.2900</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1wSZ4uWjhU7" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">414,784</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq5gllk1hyFi" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.0188</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq7PgTU81iM3" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,609</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKSbDz7Ho2Ka" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.0000</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zn4IqgdoLFq7" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zw9YH3Jl64z1" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember" id="Fact001289" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.6000</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEosBDDDu4j1" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z0O3OlRmBUZk" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.0000</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znQLZIPvm5F6" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDavLkZBj0Qk" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.0000</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zsCTHMezFidb" title="Warrants Outstanding Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,331</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zZQEKaBA5dza" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.0000</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPFVokWjGrVa" title="Warrants Outstanding Shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,700</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930_zNpbqZzBUuX2" title="Warrants Outstanding Shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,610,972</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zD8W2llb0zrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPzHUOB8wBWe" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.00</ix:nonFraction></span> per share at September 30, 2025 consist of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlmzaR36heel" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,497,000</ix:nonFraction></span> publicly-traded warrants, described herein on a pre-split
<span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwnjSAGEZxLi" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact001311" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> basis, that were issued as part of the Company&#8217;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU3g44BDqF72" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact001313" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of the Company&#8217;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVrqZR5YGy5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span> per share. Accordingly, the exercise of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv8WZMMcqmw1" title="Warrants exercise"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-06-022023-06-02_us-gaap_WarrantMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10</ix:nonFraction></span> warrants, each exercisable at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBZUTWAZyOI1" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span>, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp1J4T6g6Iog" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXJTNYkbhavl" title="Fair market value of stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.030</ix:nonFraction></span> per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock warrants at September 30, 2025 was approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250930_zZjqF7wG0O42" title="Exercisable unexercised, intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2025-09-30" id="Fact001325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,113,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001327" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBEZtVD1pfj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_823_z2zSY6rVfgef">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023, 2024 and 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zoGTLzys5Ghc" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember" id="Fact001329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_z42046w4T2Ie" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember" id="Fact001331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZQoAivaWNFg" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>.
Dr. Miser was required to devote at least 50% of his business time to the Company&#8217;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the three months and nine months ended September 30, 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPVLULzG7bX8" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,583</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwA6p7huRxIk" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,083</ix:nonFraction></span>, respectively, to Dr. Miser under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zoCCEt0QVW5g" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_90D_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z6uwVYWywUTg" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact001341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zwNF9nTympwe" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. The employment agreement with Mr. Forman terminated upon his resignation as an officer
of the Company effective December 31, 2024. During the three months and nine months ended September 30, 2024, the Company paid $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFqi8QWUkc3" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRIpCYOgH3o9" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>, respectively, to Mr. Forman under this employment agreement, which costs are included in general and administrative costs
in the Company&#8217;s consolidated statements of operations for such periods. Additionally, Mr. Forman was provided a monthly office
rent allowance, pursuant to which the Company paid $<span id="xdx_908_eus-gaap--PaymentsForRent_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zcHOoXqu5Hle" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact001349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,843</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zItwyct990aj" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,058</ix:nonFraction></span> during the three months and nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_90E_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zCvj0aP4stzl" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_904_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z046HC6O7rP8" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. The employment agreement with Mr. Weingarten terminated upon his resignation as an officer of the Company effective August
31, 2025. During the three months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRj3FxVjK6r3" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,167</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZZB5PP51xU7" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods. During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_907_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8V232BevDl4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,667</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWIR5r25H8k" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span>, respectively,
to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_900_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGPnKJIsAtNl" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember" id="Fact001365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Effective June
16, 2025, the employment agreement was amended to provide that Mr. van der Baan will serve as President and Chief Scientific Officer
of the Company. Effective September 1, 2025, Mr. van der Bann resigned as President, but remained as the Company&#8217;s Chief Scientific
Officer. The term of the employment agreement was for three years and is automatically renewable for additional one-year periods unless
terminated by either party, subject to early termination provisions as described in the employment agreement. During the three months
ended September 30, 2025 and 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20250701__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztf31SRGcUzg" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,403</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDtS7pppnzS5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,175</ix:nonFraction></span>, respectively, to Mr. van der Baan under this employment agreement,
which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTH15zSkOyl4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,604</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zUaXpBBdI13l" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,754</ix:nonFraction></span>, respectively, to Mr. van der Baan under
this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#8217;s Chief Medical
Officer. The term of the agreement was in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#8217;
notice, (ii) Dr. Schellens&#8217; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#8217;s Chief Executive Officer. The Company paid Dr. Schellens annual compensation
of <span id="xdx_901_eus-gaap--ShareBasedCompensation_uEUR_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zfGpqJAIqWhc" title="Annual compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_SchellensMember" id="Fact001375" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">104,000</ix:nonFraction></span> Euros, payable on a monthly basis. Effective as of July 31, 2025, the Company agreed to accept the resignation of Dr. Schellens
and to terminate his consulting agreement, to allow Dr. Schellens to pursue other employment opportunities. During the three months ended
September 30, 2025 and 2024, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuD0jvzU9mp7" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_custom_SchellensMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,179</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zDOY09cawpUf" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_custom_SchellensMember" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,717</ix:nonFraction></span>, respectively, to Dr. Schellens under this consulting agreement, which
costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_901_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zqxygFp2LVIf" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_custom_SchellensMember" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,494</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zdHtwVZwc4fj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_custom_SchellensMember" id="Fact001383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,717</ix:nonFraction></span>, respectively, to Dr. Schellens under
this consulting agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board of Directors only in
the form of cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#8217;s other non-officer directors.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zuwgrEbKcTM1" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30_srt_DirectorMember" id="Fact001385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--GeneralAndAdministrativeExpense_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zPKg1aB1ePo8" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30_srt_DirectorMember" id="Fact001387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, with respect to his annual cash board compensation. During the nine months ended
September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations
of $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zfCUcup197S4" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-09-30_srt_DirectorMember" id="Fact001389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4mbEbGodiDb" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30_srt_DirectorMember" id="Fact001391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, respectively, with respect to his annual cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash during 2024, effective with the quarter ended June 30, 2024, Dr. Bernards
agreed to receive equity-based compensation for his services on the Board of Directors, for the quarters ended June 30, 2024 through
December 31, 2024. In order to reconcile his Board of Directors compensation with that of the other non-officer directors, Dr. Bernards
agreed to receive the same Board of Directors compensation, both in form and amount, as the other non-officer directors for the year
ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, Dr. Bernards resigned from the Board of Directors of the Company and was appointed as Chairman of the Company&#8217;s
Scientific Advisory Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 16, 2025, the Company entered into an employment agreement with Geordan Pursglove pursuant to which Mr. Pursglove was appointed
as the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors for a term of three years, subject to automatic
termination if the Company did not complete a successful financing that would enable it to maintain its listing on the Nasdaq Capital
Market by July 3, 2025, which was accomplished on July 2, 2025. Under the employment agreement, Mr. Pursglove will receive an annual
salary of $<span id="xdx_906_eus-gaap--SalariesAndWages_c20250616__20250616__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zbkymLim3SH4" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-06-162025-06-16_custom_EmploymentAgreementMember_custom_MrPursgloveMember" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span>, which may be increased from time to time in the sole discretion of the Board of Directors. At his election, Mr. Pursglove&#8217;s
compensation will be payable in cash and/or restricted shares of common stock, or a combination thereof. He will also be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors in the form of cash or equity, or a combination
thereof. Mr. Pursglove will not receive any additional compensation for serving as Chairman of the Board of Directors. During the three
months and nine months ended September 30, 2025, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zryiS53kemY6" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember" id="Fact001395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zZ8fqca1tkic" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember" id="Fact001397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>, respectively, to Mr. Pursglove under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company appointed Geordan Pursglove as the Company&#8217;s President as the result of the resignation of Bas van
der Baan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company entered into an employment agreement with Peter Stazzone to act as the Company&#8217;s Chief Financial
Officer, for a term of one year, automatically renewable for additional one-year periods, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z1CursYvcg11" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_PeterStazzoneMember" id="Fact001399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. During the
three months and nine months ended September 30, 2025, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z7xuCs8ZW9rd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zc8u0GGdIG3f" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember" id="Fact001403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></span>, respectively, to Mr. Stazzone under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors, which was subsequently amended effective May 25, 2022, July 9, 2024, March 21, 2025 and September
30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z1dYKt3Mivj2" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_srt_DirectorMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> per year (except for Dr. Bernards, who was paid an additional annual cash fee of $<span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zfXW0cSM2Cp3" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-04-09" id="Fact001407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, in lieu of
the annual June <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zTziMSWvU0Z4" title="Stock option grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-082021-04-09_srt_DirectorMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30</ix:nonFraction></span> grant of stock option as described below, through March 31, 2024)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zRZjU4szoXS4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_902_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zmvcSN8FNW0e" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember" id="Fact001413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_909_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zhjYBbOQZzgd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zyNnII6oWYji" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, the Board of Directors approved amendments to this compensation program,
such that for the quarters ended June 30, 2024 through December 31, 2025, the non-officer directors (including Dr. Bernards) have received
or will receive, in lieu of cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase
common stock at an exercise price based on the closing market price upon issuance, with the amount of such stock options equal to the
cash payment such director would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined
pursuant to the Black-Scholes option-pricing model. On September 30, 2025, the Board of Directors approved an amendment to this compensation
program such that at each quarter end, each non-officer director will have the choice as to whether to receive their quarterly compensation
in cash or in stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise price
based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director would
otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zXLfrl7c2G74" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-09-30_custom_NewIndependentDirectorMember" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zQ8j2qUyDA1l" title="Options exercisable period"><ix:nonNumeric contextRef="From2025-01-012025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" format="ixt-sec:durwordsen" id="Fact001421" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">five years</ix:nonNumeric></span>,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zxUO3uVC65Rg" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-01-012025-09-30_custom_NewIndependentDirectorMember" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% vesting <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930_zU2mt2haJmQi" title="Award vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-01-01to2025-09-30" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_ztbcyGr1UfDh" title="Cash fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" id="Fact001427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zgcOXulAstH9" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zDbQiB6cXVUl" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_901_eus-gaap--CostOfRevenue_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhn3Z8tJvCH5" title="Annual cash fee"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zV0WTqAxBt3a" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_IndependentDirectorMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z62qjh60HZq9" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_IndependentDirectorMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, for the three months ended September 30, 2025 and 2024.
Total cash compensation paid to non-officer directors was $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zdRcVhww1iP1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_IndependentDirectorMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z5aDYWEpIu8d" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_IndependentDirectorMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,819</ix:nonFraction></span>, respectively, for the nine months ended September 30,
2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001443" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zLCJimdBLzL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2025 and 2024, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zL0cMS94ajb6" style="display: none">Schedule of Related Party Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250701__20250930_zcdIbsCGawab" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240701__20240930_zdJ1cRuFo3Xg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250930_zl9uGesWLT28" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z9jUNNbn58Jg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zlMog63KdAt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375" id="Fact001445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,416</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375" id="Fact001446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,226</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,432</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375" id="Fact001448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,624</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zXVc4B64A722" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375" id="Fact001450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,611</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375" id="Fact001451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375" id="Fact001452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,348</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z9JmKrOQ8dLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">994,027</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,053</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593,780</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375" id="Fact001458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,069</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zU5J12vF3Vkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001460" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zIohc8vwLk4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_824_zlZJurXRODn1">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zV8AYlRJ6SZf" title="Number of restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,333</ix:nonFraction></span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zgnF4tWqeVf8" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares, to a total of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUcCJlzBXpze" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,333</ix:nonFraction></span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zrRYyne3KBa5" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,667</ix:nonFraction></span> shares, to a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zeaVlwv1scc5" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, unexpired stock options for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z1rsQGIMaUDa" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">694,309</ix:nonFraction></span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvW2SKiDrlB5" title="Shares were available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,691</ix:nonFraction></span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001476" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsyplzXokm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2025, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxe1ze8AJ6P9" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250101__20250930_zfDeiQPPq802" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2025-01-01to2025-09-30" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.58</ix:nonFraction></span>%
    to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250101__20250930_z9yRnL5v31Y1" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2025-01-01to2025-09-30" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.82</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20250101__20250930_zlaO1TZhMRGh" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-01to2025-09-30" id="Fact001482" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: -3.9pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20250101__20250930_zRKfZI8CZmWa" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2025-01-01to2025-09-30" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">128.78</ix:nonFraction></span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20250101__20250930_zZqyHmpbs9J" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2025-01-01to2025-09-30" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">139.42</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_z0QAUqANASf3" title="Expected life"><ix:nonNumeric contextRef="From2025-01-012025-09-30_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001488" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.5</ix:nonNumeric></span>
    to <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zdU5gdc2VqWe" title="Expected life"><ix:nonNumeric contextRef="From2025-01-012025-09-30_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001490" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20240101__20240930_zPq2t6s3INs" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-012024-09-30" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.55</ix:nonFraction></span>%
    to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20240101__20240930_zIvW7UAUMiK1" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-012024-09-30" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.29</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20240930_ziZpmFFOyoY6" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-09-30" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20240101__20240930_zAF8Sf0L6wsg" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-012024-09-30" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125.59</ix:nonFraction></span>
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20240101__20240930_zatfMJ5aqwV5" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-012024-09-30" id="Fact001500" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">126.45</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zDXFVVxLNRKg" title="Expected life"><ix:nonNumeric contextRef="From2024-01-012024-09-30_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001502" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.5</ix:nonNumeric></span>
    to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zvGTAGTgpIQl" title="Expected life"><ix:nonNumeric contextRef="From2024-01-012024-09-30_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001504" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zMWdC4QeEwBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4b0U5Vy0DRa" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7aIqnkJn6L2" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt-sec:durwordsen" id="Fact001508" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zSco97drUuSe" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" id="Fact001510" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.40</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z39t4QRA3Kbf" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</ix:nonNumeric></span> The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zgYjjTMXDtId" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001514" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,525</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjZxvlxu9nf5" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" id="Fact001516" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.341</ix:nonFraction></span>
per share), of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZq2raHj9fr1" title="Stock options vested"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,263</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the three months and nine months ended September 30, 2024, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zoHgZkF1IZhb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember" id="Fact001520" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zHe9ja4TjsO5" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember" id="Fact001522" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,390</ix:nonFraction></span>, respectively, with respect to these stock
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zS01Nplba2ci" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_srt_DirectorMember" id="Fact001524" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoBcSzbo9LCk" title="Stock price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001526" format="ixt:numdotdecimal" decimals="5" unitRef="Shares">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zLCuiZFm9Nrh" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt-sec:durwordsen" id="Fact001528" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zd8p1iqOgsC8" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoRSI7t2WO42" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zkl3x9Be0PY1" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001534" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,700</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zW3NWw8MHnRd" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001536" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">6.334</ix:nonFraction></span> per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the three months and nine months ended September 30, 2024, the Company recorded a charge to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zQ7whBFLDPY8" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001538" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zaqQ5a0f6v0k" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001540" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,310</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zthvzf8XOHH8" title="Number of stock option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares
(a total of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zTChVV1c9XCc" title="Number of stock option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_custom_FourOfficersMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHoMdJpKB6hj" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt-sec:durwordsen" id="Fact001546" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zcyjGUlrfoIk" title="Exercise price of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-11-062022-11-06_custom_FourOfficersMember" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zp0hm39r0pMg" title="Stock options description"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</ix:nonNumeric></span> The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4F5UkcGDeza" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zPFsc9abnuak" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001554" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">262,560</ix:nonFraction></span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znPs2ImgA1q4" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FourOfficersMember" id="Fact001556" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.282</ix:nonFraction></span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjP1kvOyrZIe" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_FourOfficersMember" id="Fact001558" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,132</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdxA7goZOASh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_FourOfficersMember" id="Fact001560" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,641</ix:nonFraction></span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z2kLy9ITx8kj" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_FourOfficersMember" id="Fact001562" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,264</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zaHnJfWYMyAc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_FourOfficersMember" id="Fact001564" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,304</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zsImUudkcvfg" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_srt_DirectorMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zlAAC25EKIPk" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zR60LRzjWbO7" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001570" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRs63wYdiI7j" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.88</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJdl8WKpRn76" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zW2m3eT0xCBh" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001576" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,593</ix:nonFraction></span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zMkq6EvdRt5i" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001578" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">4.8131</ix:nonFraction></span> per share), which was charged to operations ratably from July 1, 2023 through June 30, 2025. During
the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zzJPAv7SwcUb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001580" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zGjGQs1S0Vhe" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001582" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,232</ix:nonFraction></span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zH0XbEu4aBrh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001584" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,672</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLuU7Z99A4Y5" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001586" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,300</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted a stock
option to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO6mtqDyhATb" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of five years at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z1dlH9abT7uj" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share, which was equal to the closing market price
of the Company&#8217;s common stock on the grant date. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbffV98p1Joc" title="Options vesting term"><ix:nonNumeric contextRef="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001592" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The stock option initially vested in equal increments quarterly over a three-year
period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</ix:nonNumeric></span> The fair value of
this stock option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrx1hclsIfwj" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,066</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zL6Vu6rYWL14" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001596" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.612</ix:nonFraction></span> per share),
which was being charged to operations ratably from September 26, 2023 through September 30, 2026. Effective June 16, 2025, in connection
with an amendment to Mr. van der Baan&#8217;s employment agreement (see Note 6), the stock option was deemed fully vested and the remaining
unamortized fair value was charged to operations on such date, and the time period for Mr. van der Baan to exercise this stock option
at any time in the future that he is no longer providing services to the Company as a consultant, employee or otherwise was increased
from ninety days to one year. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and
administrative costs in the consolidated statements of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpFgpWER9OK" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001598" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUkwhxrUMzf4" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001600" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,712</ix:nonFraction></span>, respectively, with respect to this stock option.
During the nine months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbFQg6WbkuB" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001602" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,784</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2aWlP7zstre" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001604" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,402</ix:nonFraction></span>, respectively, with respect to this stock option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_znb5TqF57Zo6" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zaK3CJ0lBOk5" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001608" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zayRDXmyv4Wg" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_srt_DirectorMember" format="ixt-sec:durwordsen" id="Fact001610" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYinoXbtOLya" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_srt_DirectorMember" id="Fact001612" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.37</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zlseYSg9iEQ" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001614" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zSUtQrOTXra" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001616" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,976</ix:nonFraction></span> ($<span id="xdx_900_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zFklPNCRQFKb" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_srt_DirectorMember" id="Fact001618" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.8494</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zxdWlzUf2fzf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_srt_DirectorMember" id="Fact001620" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,324</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zW6Fa1seX156" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_srt_DirectorMember" id="Fact001622" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,993</ix:nonFraction></span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzpN38u8Ngjd" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_srt_DirectorMember" id="Fact001624" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,324</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4CzReg2Xopg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_srt_DirectorMember" id="Fact001626" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,333</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zjkmaO9cMm48" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember" id="Fact001628" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,598</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6qL8K9L6an8" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zkzlMs49jUee" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorMember" id="Fact001632" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.37</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRcCoIDlSWdi" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001634" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6rY0uUnW44h" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001636" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zD3MixaJV6Vh" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001638" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.6570</ix:nonFraction></span> per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted a stock
option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zRUTp9yrQlD4" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001640" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">15,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zWCdwhWtLz2h" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-07-012024-07-01_custom_SchellensMember" format="ixt-sec:durwordsen" id="Fact001642" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise e price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zIDwurdgYNzk" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-07-01_custom_SchellensMember" id="Fact001644" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.39</ix:nonFraction></span> per share, which was equal to the closing market price
of the Company&#8217;s common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zifUDNZtU1J8" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The stock option vested quarterly over a three-year period commencing on the last
day of each calendar quarter commencing September 30, 2024.</ix:nonNumeric></span> The fair value of this stock option, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zrFPR0cGi7Lf" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001648" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,074</ix:nonFraction></span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z9y8JcNRx9e2" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-07-01_custom_SchellensMember" id="Fact001650" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.9382</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2024
through June 30, 2027. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative
costs in the consolidated statements of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zQdwrMjzCcyi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_SchellensMember624786734" id="Fact001652" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zUlIPxHHlE74" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_SchellensMember624786734" id="Fact001654" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,418</ix:nonFraction></span>, respectively, with respect to this stock option. During the nine
months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements
of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoRKBTIEWPR7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_SchellensMember624786734" id="Fact001656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,810</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zPvHloitGUif" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_SchellensMember624786734" id="Fact001658" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,418</ix:nonFraction></span>, respectively, with respect to this stock option. Effective as of July 31, 2025, the Company agreed
to accept the resignation of Dr. Schellens and to terminate his consulting agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z1z1abyToHR7" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember" id="Fact001660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,217</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1JM6cdEhytd" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001662" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zppS4l7Ft7ai" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z0GA56Acd5s4" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001666" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znQiisOLIWr3" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001668" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znCkNv67Eh4j" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001670" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.2961</ix:nonFraction></span> per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zOWCjt6CGWc3" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember" id="Fact001672" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,665</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zAbQ0OE88392" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001674" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWiRSwycgRW5" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember" id="Fact001676" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9l68rnYIpDa" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001678" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zdt9nSmjGmI8" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember" id="Fact001680" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zDCTij9p76El" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember" id="Fact001682" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">1.65002</ix:nonFraction></span> per share). The grant date value of the stock options of $<span id="xdx_900_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6TIua4GRm0a" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember" id="Fact001684" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> was accrued at December
31, 2024 and charged to operations at that date. During the nine months ended September 30, 2025, there was no expense charged to operations
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z10NaCBkSs86" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,181</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z793ToKRxqC6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001688" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3pZ40QMaSaf" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember" id="Fact001690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.21</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRD5t1pECkd1" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001692" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended March 31, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1jnBTuB7T7k" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember" id="Fact001694" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_907_eus-gaap--SharePrice_iI_pp5d_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZnv70A92yug" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember" id="Fact001696" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">0.8546</ix:nonFraction></span> per share), which was charged to operations on March 31, 2025, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zm5fcu29pkI4" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-06-302025-06-30_srt_DirectorMember" id="Fact001698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zt7BT2t4Ugi8" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-06-302025-06-30_srt_DirectorMember" id="Fact001700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zOebc78z2Gm6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-06-302025-06-30_srt_DirectorMember" format="ixt-sec:durwordsen" id="Fact001702" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zw1n3vq0XvLi" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_srt_DirectorMember" id="Fact001704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.905</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_z0h0dcDaB7Ij" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2025-06-302025-06-30_srt_DirectorMember" id="Fact001706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdKfed54C6qa" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-06-302025-06-30_srt_DirectorMember" id="Fact001708" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,700</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zH5w36MVIAwj" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-06-30_srt_DirectorMember" id="Fact001710" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.7175</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2025 through June 30, 2027.
During the three months and nine months ended September 30, 2025, the Company recorded a charge to operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrmso34NSu8h" title="Stock based compensation"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTAZJLxT5Mo9" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember" id="Fact001712" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember" id="Fact001714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,712</ix:nonFraction></ix:nonFraction></span></span> with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_ztfk4prcpwtk" title="Purchase of stock options shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorMember" id="Fact001716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,648</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJ6JgmbYx2ph" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001718" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkoY0BTQ7BM4" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001720" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.905</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zPtmgTvUi0ok" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001722" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3hEhZB4Lyb8" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001724" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_909_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJta4OabAeTb" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001726" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.6448</ix:nonFraction></span> per share), which was charged to operations on June 30, 2025, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the employment agreement entered into with Geordan Pursglove, effective as of July 3, 2025, the end of the first trading
day of the Company&#8217;s common stock immediately following the successful completion of the above referenced financing, as an inducement
to Mr. Pursglove to join the Company, as a signing bonus, Mr. Pursglove was granted a stock option to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zSm24KQWqeO1" title="Stock option, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember" id="Fact001728" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares of the
Company&#8217;s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z79A5JlE6oF6" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-07-03_custom_MrPursgloveMember" id="Fact001730" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.83</ix:nonFraction></span> per share (the closing market price on the grant date), for a term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zpeoMUzKjHue" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember" format="ixt-sec:durwordsen" id="Fact001732" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five
years</ix:nonNumeric></span>, exercisable on a cashless basis and vesting <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7HSXSMliD78" title="Stock option, vesting percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-07-032025-07-03_custom_EmploymentAgreementMember" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% on the grant date, <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250930__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4SGZa18TMx2" title="Stock option, vesting percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-09-302025-09-30_custom_EmploymentAgreementMember" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on September 30, 2025, and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20251231__20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziBFEU30GNof" title="Stock option, vesting percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-12-312025-12-31_custom_EmploymentAgreementMember_us-gaap_SubsequentEventMember" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on December 31, 2025, subject
to continued service. The stock option grant was not issued under the Company&#8217;s 2020 Stock Incentive Plan. The stock option agreement
provides for certain registration rights and for accelerated vesting upon the occurrence of certain events, including early termination
of the agreement that is not the result of his voluntary termination or termination for cause, a sale or change in control of the Company,
or a sale, licensing or other disposition of all or substantially all of the assets of the Company. The total fair value of the stock
option to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zcYuh4IGXGt2" title="Stock option, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares of common stock, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zQVPNTUCFzy9" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember" id="Fact001742" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">728,671</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4p0_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z1WZOqhK1sD3" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-07-03_custom_MrPursgloveMember" id="Fact001744" format="ixt:numdotdecimal" decimals="4" scale="0" unitRef="USDPShares">2.0819</ix:nonFraction></span> per share), which is being charged to operations from July 3, 2025 through December 31, 2025. During the three months
and nine months ended September 30, 2025, the Company recorded a charge to operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zXEYJ3rLRULh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_MrPursgloveMember" id="Fact001746" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">546,499</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zDhHjujKf8a2" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_MrPursgloveMember" id="Fact001748" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">546,499</ix:nonFraction></span>, respectively, with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2025, the Board of Directors appointed Jason Sawyer to the Board of Directors. In connection with his appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Sawyer was granted stock options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zudGNx9oUKVj" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziCC1M8wo89l" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember" format="ixt-sec:durwordsen" id="Fact001752" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five
years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziyvoUqcWjN9" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-08-15_custom_JasonSawyerMember" id="Fact001754" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.59</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zHb5B5r9fRI2" title="Stock options description"><ix:nonNumeric contextRef="From2025-08-142025-08-15_custom_JasonSawyerMember" id="Fact001756" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</ix:nonNumeric></span> The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_z8QiZmbYEf8f" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-08-142025-08-15_custom_JasonSawyerMember" id="Fact001758" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,360</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zXzOQV6y2wYc" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-08-15_custom_JasonSawyerMember" id="Fact001760" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">2.7344</ix:nonFraction></span> per share),
of which $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zCoSVwlqjstc" title="Stock options vested"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember" id="Fact001762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,180</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August
15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zrTgBGcUoJ22" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_JasonSawyerMember" id="Fact001764" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,500</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zsPONKrJlA7e" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_JasonSawyerMember" id="Fact001766" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,500</ix:nonFraction></span>, respectively, with respect to these
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2025, the Board of Directors appointed Dr. Michael Holloway to the Board of Directors. In connection with his appointment
to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of
Directors, Dr. Holloway was granted stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zpPCDZ7SLfYb" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z7FLV8Cp5rDf" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember" format="ixt-sec:durwordsen" id="Fact001770" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zwuwg4nyX6K2" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-08-15_custom_DrMichaelHollowayMember" id="Fact001772" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.59</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z3qP1i4npCl6" title="Stock options description"><ix:nonNumeric contextRef="From2025-08-142025-08-15_custom_DrMichaelHollowayMember" id="Fact001774" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and
the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</ix:nonNumeric></span>
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z2CNPKAuDWEh" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-08-142025-08-15_custom_DrMichaelHollowayMember" id="Fact001776" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,360</ix:nonFraction></span>
($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zDnl8swzO0Xf" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-08-15_custom_DrMichaelHollowayMember" id="Fact001778" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">2.7344</ix:nonFraction></span> per share), of which $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zVKS6lRTJiZ4" title="Stock options vested"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember" id="Fact001780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,180</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore
charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations
ratably from August 15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zt68EyVReBy7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_DrMichaelHollowayMember" id="Fact001782" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,500</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zjB0VCAFVy36" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_DrMichaelHollowayMember" id="Fact001784" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,500</ix:nonFraction></span>, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2025, in connection with the employment agreement with Peter Stazzone, Mr. Stazzone was granted stock options to purchase
<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zrvIjPiiOisk" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-09-012025-09-01_custom_PeterStazzoneMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options are exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zBuEwb1d4Rik" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-09-012025-09-01_custom_PeterStazzoneMember" format="ixt-sec:durwordsen" id="Fact001788" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zitMkEj9p3ac" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-08-15_custom_PeterStazzoneMember" id="Fact001790" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">4.45</ix:nonFraction></span>
per share, which was equal to the closing market price of the Company&#8217;s common stock on the grant date. The <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zi5KTToCuqq4" title="Stock options description"><ix:nonNumeric contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember" id="Fact001792" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">options vested 25%
on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject
to continued service.</ix:nonNumeric></span> The stock option grant was not issued under the Company&#8217;s 2020 Stock Incentive Plan. The fair value of these
stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zdYM11S1Blra" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember" id="Fact001794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,070</ix:nonFraction></span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zsBaCUAGApRa" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-09-01_custom_PeterStazzoneMember" id="Fact001796" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.4614</ix:nonFraction></span> per share), of
which $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zEtbHWLUD9Jg" title="Stock options vested"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember" id="Fact001798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,268</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on September 1, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from September
1, 2025 through June 30, 2026. The Company recorded a charge to general and administrative costs in the consolidated statement of operations
for the three months and nine months ended September 30, 2023 of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z41x10lHn7V5" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_PeterStazzoneMember" id="Fact001800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,732</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z3mgoKF5fswh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_PeterStazzoneMember" id="Fact001802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,732</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company appointed Lourdes Felix and Guy Primus to the Board of Directors. Although it was the Company&#8217;s
policy to issue stock options to each new director to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zwZNiYTYPzQe" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-09-012025-09-01_custom_LourdesFelixAndGuyPrimusMember" id="Fact001804" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock on the appointment date,
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zRd7SFq8MNhi" title="Stock options description"><ix:nonNumeric contextRef="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember" id="Fact001806" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service,</ix:nonNumeric></span> due to limitations with respect to the Company&#8217;s 2020 Stock Incentive Plan, the Company did not issue
these stock options on such date To account for this obligation, the Company determined the fair value of these stock options for each
new director effective September 1, 2025 to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zKXs8dZ7oXj2" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember" id="Fact001808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,533</ix:nonFraction></span> ($<span id="xdx_90D_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z3AlyB116lpe" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-09-01_custom_LourdesFelixAndGuyPrimusMember" id="Fact001810" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.38</ix:nonFraction></span> per share), as calculated pursuant to the Black-Scholes option-pricing
model, and recorded a charge to operations reflecting 50% of the fair value of such stock options on such date and a related accrued
liability. The remaining 50% of the fair value of such stock options is being charged to operations ratably through September 30, 2026.
Accordingly, a total of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zS4Pm9hxf1vc" title="Stock based compensation"><span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z5qsNMUaW7G9" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_LourdesFelixAndGuyPrimusMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_LourdesFelixAndGuyPrimusMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,533</ix:nonFraction></ix:nonFraction></span></span> was charged to operations for the three months and nine months ended September 30, 2025, respectively,
for this obligation, and an additional $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20260930__20260930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zmSMK17uZhSc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2026-09-302026-09-30_custom_LourdesFelixAndGuyPrimusMember_srt_ScenarioForecastMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,533</ix:nonFraction></span> will be charged to operations ratably through September 30, 2026. The Company anticipates
issuing the stock options prior to December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreement of the Company&#8217;s Chief Medical Officer, Dr. James S. Miser expired on July 31, 2024, the employment agreement
of the Company&#8217;s Vice President and Chief Operating Officer, Eric J. Forman, terminated upon his resignation from the Company on
December 31, 2024, the consulting agreement of the Company&#8217;s Chief Medical Officer, Dr. Jan Schellens, was terminated effective
with his resignation on July 31, 2025, and Regina Brown, a former director, resigned from the Board of Directors effective September
1, 2025. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
services to the Company terminated. Furthermore, the expiration date of all vested stock options owned by each such person contractually
expire one year from the respective dates that their services to the Company terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
Forman, Yun Yen and Rene Bernards all resigned as members of the Board of Directors during the quarter ended September 30, 2025, although
all three continue to be of service to the Company through their membership on the Company&#8217;s Scientific Advisory Board. Similarly,
Robert Weingarten resigned as the Company&#8217;s Chief Financial Officer effective August 31, 2025, although Mr. Weingarten continues
to be of service to the Company as a consultant. Accordingly, the unvested stock options for each such person continue to vest. Furthermore,
the expiration date of all vested stock options maintain their original expiration dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001818" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3OF1ceTSh3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zg8Wd7PHcgc" style="display: none">Schedule of Stock-based Compensation Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zd5TWrO9Qe35" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240701__20240930_zW4DETeV4Bzk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250930_z5k2EcPLznU7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zFaQ1sfLAFq1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKlhKclfQ9U4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember" id="Fact001820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,611</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember" id="Fact001822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,348</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember" id="Fact001823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqGEfVo0zuX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Non-related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1826">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1828">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_z2UfvB4EbuXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,611</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact001831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,827</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-09-30" id="Fact001832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,348</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30" id="Fact001833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,445</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zuGkdsyYnDvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001835" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkVKv9cNiIv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2025 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zb1KqmhwbR62" style="display: none">Schedule of Stock Option Activity Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
                                            Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding at December
    31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zESYR1cepThd" title="Number of shares, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,232</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zSZOieKqu8if" title="Weighted average exercise price, stock options outstanding" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001839" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.317</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_zhUq2BYnjQc" title="Number of shares, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-09-30" id="Fact001841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">581,494</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z3I4tcpx8Z34" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001843" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.657</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930_zCKeHhL8A8M2" title="Number of shares, exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z98nef8tKazk" title="Weighted average exercise price, exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zDEuVVlzkhH3" title="Number of shares, expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2025-01-01to2025-09-30" id="Fact001849" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,667</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zxVjRmhuXhCj" title="Weighted average exercise price, expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">44.272</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zEukKDGE3OUb" title="Number of shares, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30" id="Fact001853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,123,059</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zqI02DpqC29h" title="Weighted average exercise price, stock options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.276</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zDUGlsCDl4Xh" title="Weighted average remaining contractual life (in years), stock options outstanding"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:duryear" id="Fact001857" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.48</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zm3m9flUQbb9" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">409,897</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zR7pLp0soPfd" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.100</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zXw2ZfeHrKDd" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-09-30" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">930,559</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zlVczi7UTR55" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001865" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.664</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zgeLOS7PnT0h" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:duryear" id="Fact001867" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.28</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zjFVy9k6vGc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20250101__20250930_zr4WH9d5jvMg" title="Deferred compensation expense for unvested stock options"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2025-01-01to2025-09-30" id="Fact001869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></span> at September 30, 2025, which
will be recognized subsequent to September 30, 2025 over a weighted-average period of approximately <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20250101__20250930_zYqWTmpXhCOi" title="Weighted-average recognition period"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:durmonth" id="Fact001871" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">7</ix:nonNumeric></span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001873" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWIdtGFaJ3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zeTmtxuULFBj" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFy2vjnucImf" title="Exercise Prices" style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceOneMember" id="Fact001875" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.905</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zS3bhr7tc3l" title="Options Outstanding (Shares)" style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember" id="Fact001877" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,648</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNjrN27i6Rpg" title="Options Exercisable (Shares)" style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember" id="Fact001879" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,398</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zFtqQE4Ptoz6" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceTwoMember" id="Fact001881" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.210</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zINxPTH9BK0f" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember" id="Fact001883" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztB4khiAhLEf" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember" id="Fact001885" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVHwIeCnnc5c" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceThreeMember" id="Fact001887" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.870</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9w2Je49z8k1" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember" id="Fact001889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,217</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zf2InRE71Txf" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember" id="Fact001891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,217</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zJjsIFlC7SO4" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceFourMember" id="Fact001893" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.950</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zHg9hz1kBov4" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember" id="Fact001895" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPoNbTpuzlL4" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember" id="Fact001897" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7GF7Dtp5Eti" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceFiveMember" id="Fact001899" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.330</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z8AFWEiHP208" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember" id="Fact001901" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,665</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPM6f8H75fw4" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember" id="Fact001903" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,665</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbpJHQu8nmu4" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceSixMember" id="Fact001905" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztSoEHezMDtd" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember" id="Fact001907" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSnIsAyYreO6" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember" id="Fact001909" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zQ5tnBGzrZpf" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceSevenMember" id="Fact001911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.390</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zgpfWwnDv5Wf" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember" id="Fact001913" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zeW922GIljji" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember" id="Fact001915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zgcbd38988A5" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceEightMember" id="Fact001917" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zWdCZaRoaIq6" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember" id="Fact001919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zBD725rewxz4" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember" id="Fact001921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">262,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlUTjnnlill8" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceNineMember" id="Fact001923" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.590</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zatlxUGhymj5" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceNineMember" id="Fact001925" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztLPSILRyIV8" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceNineMember" id="Fact001927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zoFQgp5IaqLa" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceTenMember" id="Fact001929" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.450</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEQwpU871QL3" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTenMember" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbkKICqJsEU5" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTenMember" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zpA2W3IiqC8k" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceElevenMember" id="Fact001935" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRAC6ByBkjRi" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceElevenMember" id="Fact001937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z19J2sZGXYn" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceElevenMember" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zkcU8Y5P0ljd" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceTwelveMember" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqSAfehc7vh3" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTwelveMember" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zYeDACEqeQ9l" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceTwelveMember" id="Fact001945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z90CGJHOVWh6" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceThirteenMember" id="Fact001947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSzewf2FlBC" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceThirteenMember" id="Fact001949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zfkeV5n6vP25" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceThirteenMember" id="Fact001951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zhP56C3XEhI2" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceFourteenMember" id="Fact001953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zjy3uCki4yPf" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFourteenMember" id="Fact001955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zs0fdhKj4iO2" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFourteenMember" id="Fact001957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z5wW3crMConi" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceFifteenMember" id="Fact001959" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj9l8hvCEdVb" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFifteenMember" id="Fact001961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zfZ4i2I8Vz6l" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceFifteenMember" id="Fact001963" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zNL7TafYxhG7" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceSixteenMember" id="Fact001965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmOZK5lelfV2" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSixteenMember" id="Fact001967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z05z3EYUt7z" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSixteenMember" id="Fact001969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zLp5jGUcrlDl" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceSeventeenMember" id="Fact001971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zrZV3MafP269" title="Options Outstanding (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSeventeenMember" id="Fact001973" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zWLHAYIXxFDe" title="Options Exercisable (Shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceSeventeenMember" id="Fact001975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zdR2aTe07Sdc" title="Exercise Prices" style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_ExercisePriceEighteenMember" id="Fact001977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.100</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z9EiO6QI40Wb" title="Options Outstanding (Shares)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceEighteenMember" id="Fact001979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zqpET658WCt7" title="Options Exercisable (Shares)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30_custom_ExercisePriceEighteenMember" id="Fact001981" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zv02I4tSjuI7" title="Options Outstanding (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30" id="Fact001983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,123,059</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zr1ecDZzshK6" title="Options Exercisable (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-09-30" id="Fact001985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">930,559</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z3kGiobEYIC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zcvytBh0nsA7" title="Fair market value, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-01to2025-09-30" id="Fact001987" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.030</ix:nonFraction></span> per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock options was approximately $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250930_zjeIdTkTCThk" title="Intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-09-30" id="Fact001989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,037,000</ix:nonFraction></span> at September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20250930_zXK55xiF7lZ9" title="Outstanding stock options to acquire shares of common stock not vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2025-09-30" id="Fact001991" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,000</ix:nonFraction></span> shares of the Company&#8217;s common stock had not vested at September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001993" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z0U5FMaNOFQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_828_zq6duLOo5yEi">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2025 and 2024, the Company did not record any provision for income taxes, as the
Company incurred losses during such periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001995" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zUpAvV2GQKkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_822_zYH6rh78kVYf">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2025 and
December 31, 2024, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zuwbwNyfaOrd" title="Clinical trial contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" id="Fact001997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,000</ix:nonFraction></span>, including clinical trial agreements of $<span id="xdx_907_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zL85lCVoapA3" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsMember" id="Fact001999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span>
and clinical trial monitoring agreements of $<span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zQdZVGlsWnWj" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember" id="Fact002001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction></span>, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended
or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial
endpoint is reached. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing active contractual clinical trials described below as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_001.jpg" alt=""/></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact002003" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_z9C2hyv19g93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zBp84ylVe1U5" style="display: none">Schedule of Contractual Clinical Trials</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Start
    Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Projected
    End Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Planned
    Number of Patients in Trial</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Study
    Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Clinical
    Update</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expected
    Date of Preliminary Efficacy Signal</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NCT
    No.</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    Financial Contractual Commitment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaP5LAXEvAwb" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002005" name="LIXT:ClinicalTrialDescription">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">MD Anderson</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaO4D4TiKJTl" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002007" name="LIXT:ContractualClinicalTrialPeriodStartDate">January 2024</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zfoSrgpSA6P2" title="Estimated End Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002009" name="LIXT:ContractualClinicalTrialPeriodEndDate">December
    2027</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zhflNXUAlJol" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002011" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">21</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine the OS of patients with
    recurrent ovarian clear cell carcinoma</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">20 patients
    entered</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zrGZ76wbvle" title="Expected Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002013" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">December
    2026</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06065462</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zi38KavQp34c" title="Remaining financial contractual commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialPhaseMD1b2Member" id="Fact002015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>-
                                            (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztgXW15eMPf4" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002017" name="LIXT:ClinicalTrialDescription">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Netherlands Cancer Institute
    (NKI)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zsFaYt73DN6k" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002019" name="LIXT:ContractualClinicalTrialPeriodStartDate">August 2024</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zQei3Nmu7j56" title="Estimated End Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002021" name="LIXT:ContractualClinicalTrialPeriodEndDate">December 2026</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zRHl3roycfN1" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002023" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">37</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine RP2D with atezolizumab</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">First patient entered
    August 2024, in total two patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zpvcj4boBNxi" title="Expected Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002025" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">June 2026</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06012734</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zfujZMcBfZSa" title="Remaining financial contractual commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialPhase1bMember" id="Fact002027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>-
                                            (1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_fKDIp_z7dHCrOkjqTh" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember" id="Fact002029" name="LIXT:ClinicalTrialDescription">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">GEIS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zQXHehVX1Cqj" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember" id="Fact002031" name="LIXT:ContractualClinicalTrialPeriodStartDate">June 2023</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Recruitment completed
    September 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zVzDL1upQ8ma" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember" id="Fact002033" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">14</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine MTD and RP2D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fourteen patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zeStniKU2End" title="Expected Date"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember" id="Fact002035" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">December 2025</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT05809830</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zJcP1wJGGHX8" title="Remaining financial contractual commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialPhase1bTwoMember" id="Fact002037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OtherCommitment_iI_c20250930_zVS6GHXac1Ke" title="Remaining financial contractual commitment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30" id="Fact002039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_z1w4UppxP86b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zXa6OfihDjG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002040" xml:lang="en-US">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zjCIva5JTmN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) (see Note 6) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial. The Investigational Review Board (IRB) of NKI has requested additional
information with respect to these SAEs and the study has been paused for enrollment until the IRB&#8217;s questions have been satisfactorily
addressed (see &#8220;Specific Risks Associated with the Company&#8217;s Business Activities - Serious Adverse Events&#8221; below for
additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
determine the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate,
duration of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $<span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zHFzhcA2bxe4" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember" id="Fact002042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,004</ix:nonFraction></span> for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this Agreement. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_909_eus-gaap--LitigationSettlementExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zmOvoudxcCF4" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact002044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--LitigationSettlementExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8G65npMwseh" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact002046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,015</ix:nonFraction></span>, respectively, pursuant to this Agreement. As of September
30, 2025, total costs of $<span id="xdx_90F_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zxLg8FAyD6m9" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact002048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">732,532</ix:nonFraction></span> had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 has consistently enhanced
the anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90C_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTjHf8mL7Xq5" title="Inventory costs"><ix:nonFraction name="us-gaap:InventoryPartsAndComponentsNetOfReserves" contextRef="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact002050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250311__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z4pxuqITXCHj" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-11_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact002052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,095,000</ix:nonFraction></span>. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2025 and 2024, the Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zN9jgSvQTnvb" title="Research and development costs"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqIiBMLmbj8f" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact002054" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact002056" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t incur any costs pursuant to this agreement. During the
nine months ended September 30, 2025 and 2024, the Company did <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0fDxddKP06d" title="Research and development costs"><span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhT7CeyAIeNj" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact002058" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact002060" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t incur any costs pursuant to this agreement. Through September 30,
2025, the Company has incurred charges of $<span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zVznNs2Nxx21" title="Amount related to milestone payment"><ix:nonFraction name="LIXT:AmountRelatedToMilestonePayment" contextRef="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact002062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,107</ix:nonFraction></span> for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zJyGMKZGmd37" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact002064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span>
for the Phase 1b portion of this clinical trial as of September 30, 2025, which is currently scheduled to be incurred through December
31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $<span id="xdx_903_ecustom--WorkOrderAgreementCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zcM8qGU1rfih" title="Work order agreement costs"><ix:nonFraction name="LIXT:WorkOrderAgreementCosts" contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></span>. During the three months ended
September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zs6jQaCL6uEa" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,942</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z09aRJfvGa4b" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,610</ix:nonFraction></span> pursuant to this letter of intent and subsequent work order.
During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z1B8Eo5MuY32" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,834</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zODXHIfsH1sj" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,838</ix:nonFraction></span> pursuant to this letter of
intent and subsequent work order. As of September 30, 2025, total costs of $<span id="xdx_904_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_zRRnNZBiDxG5" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember" id="Fact002076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,597</ix:nonFraction></span> have been incurred pursuant to this letter of intent
and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_za29YhEnbicj" title="Remaining financial contractual commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember" id="Fact002078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span>
as of September 30, 2025, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210205__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zKGiQHw4wBSa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-02-052021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,000</ix:nonFraction></span>. During the three months ended September 30, 2025 and 2024, the Company
incurred costs of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_ztpntij1zum2" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zNgHKBB8ijKg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,603</ix:nonFraction></span>, respectively, pursuant to this work order. During the nine months ended September 30, 2025 and 2024,
the Company incurred costs of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zjKlYFwG7iC1" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z6tnUsinvgRj" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,603</ix:nonFraction></span>, respectively, pursuant to this work order. As of September 30, 2025, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zEWJsuXXpRwd" title="Total costs incurred"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact002090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,823</ix:nonFraction></span>
had been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_907_ecustom--EstimatedWorkCost_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zC14pE0IumWc" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90E_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zKuzrwZjebK6" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002094" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction></span>% to Theradex for services and approximately <span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zaYLL26JA2Ml" title="Percentage of payment through software"><ix:nonFraction name="LIXT:ExpectedPaymentThroughSoftware" contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002096" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>% for payments for pass-through software costs. During the three months ended September
30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zES88iLLmkPi" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,981</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zysn0G0IgXY1" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,475</ix:nonFraction></span>, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWz4OPRPrwZ3" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,603</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zfxTLvE649Vd" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,207</ix:nonFraction></span>, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $<span id="xdx_901_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgX5vRWIvdpf" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember" id="Fact002106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,058</ix:nonFraction></span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zmKHrmLZnSuk" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember" id="Fact002108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,000</ix:nonFraction></span> as of September 30, 2025, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight was expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement were estimated to be approximately $<span id="xdx_901_ecustom--EstimatedWorkCost_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z4TFovY39Yg7" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,380</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zRoGOHDcFUF2" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002112" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47</ix:nonFraction></span>% to Theradex for services and approximately 53% for payments for pass-through software costs. During three months ended September
30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zjP9MKS3Cxvj" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember" id="Fact002114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEky91wqd4Qf" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember" id="Fact002116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,900</ix:nonFraction></span>, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z5symzdAdXfc" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,500</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_ziZWzYE5kzCg" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,900</ix:nonFraction></span>, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $<span id="xdx_90D_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zN5mtPJPHmPb" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,691</ix:nonFraction></span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zosuoyYedlb" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember" id="Fact002124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,000</ix:nonFraction></span> as of September 30, 2025, which was expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUZFhPnTDk59" title="Non refundable license issue royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact002126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $<span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zqYF26Uep6F5" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact002128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,643</ix:nonFraction></span> was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zf2blBVESAHk" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact002130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z6TzHYFgOXi5" title="Non refundable license issue royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember" id="Fact002132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and the first
minimum annual royalty of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zZdTzWdzYokl" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact002134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,643</ix:nonFraction></span> were paid in April 2024. The second minimum annual royalty for 2025 of $<span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zbjnfG9l6aw3" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-12-31_custom_LicenseAgreementMember" id="Fact002136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> was paid in December
2024 and was included in other prepaid expenses in the consolidated balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, each with a different specified
benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of $<span id="xdx_908_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zC3DxGQg7rm6" title="Dosing of product"><ix:nonFraction name="us-gaap:HealthCareOrganizationHealthCareCostsGross" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact002138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> was defined
as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product in the licensed fields
of use. The Company had not commenced a Phase 2 clinical study as of June 30, 2025. The total of all such benchmark payments is $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zl70yE30aGN5" title="Payment for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact002140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,225,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_909_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zQuXp9xvX2D1" title="Royalty percentage"><ix:nonFraction name="LIXT:RoyatiesPercentage" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact002142" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250701__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zUqz7NusFPcc" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-07-012025-09-30_us-gaap_LicensingAgreementsMember" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,397</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240701__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zsjmmsOjUVfc" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-07-012024-09-30_us-gaap_LicensingAgreementsMember" id="Fact002146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,537</ix:nonFraction></span>, respectively, in connection with
its obligations under the License Agreement. During the nine months ended June 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z1MAqiGL28dh" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,191</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zrdCARGgP48a" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-09-30_us-gaap_LicensingAgreementsMember" id="Fact002150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,106</ix:nonFraction></span>, respectively, in connection with its obligations under the License Agreement. Such costs when incurred have been included
in general and administrative costs in the Company&#8217;s consolidated statement of operations. As of September 30, 2025, total costs
of $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_ztjIqJAUZhSh" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember" id="Fact002152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,835</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts
previously paid to date, totaled approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zwx7mKI1VFb7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_us-gaap_LicensingAgreementsMember" id="Fact002154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,765,000</ix:nonFraction></span> as of September 30, 2025, which is expected to be incurred over approximately
the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $<span id="xdx_903_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zfvsvOapXVs7" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember" id="Fact002156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $<span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zN3VJggqVXK" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2025-07-012025-09-30_custom_NDAConsultingCorpMember" id="Fact002158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--ConsultingAndAdvisoryCashFee_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_ze29iZyqKYRg" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2025-01-012025-09-30_custom_NDAConsultingCorpMember" id="Fact002160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> for the three months and nine months ended September 30, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPtW1gOmPXt8" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact002162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90A_ecustom--ReimbursementExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zrMpUQzZQC75" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2025-07-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact002164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,600</ix:nonFraction></span> and $<span id="xdx_906_ecustom--ReimbursementExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zMn7eNWWERy6" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2024-07-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact002166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span> during the three months ended September
30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.
The Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_901_ecustom--ReimbursementExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zfeNIKVma0yi" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2025-01-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact002168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,400</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--ReimbursementExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zyYBAG5Crkig" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2024-01-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact002170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,200</ix:nonFraction></span> during the nine months ended
September 30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of <span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_z3hQZ2IFj1Ji" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002172" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">391,000</ix:nonFraction></span> Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
<span id="xdx_90E_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVyEX8akeWi4" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002174" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction></span> Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the trial at a project cost of
<span id="xdx_906_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYFUtLXqgl42" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002176" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">100,000</ix:nonFraction></span> Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred charges of $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVDW0LE9hPh6" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2025-07-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_903_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZURS9Oldcye" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-07-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,278</ix:nonFraction></span>, respectively, with respect to this
agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
During the nine months ended September 30, 2025 and 2024, the Company incurred charges of $<span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zU4gFSDlZpg2" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvKcEvDrSFZd" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-01-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact002184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,362</ix:nonFraction></span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of September 30, 2025, total costs of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NetherlandsCancerInstituteMember_zm0j0CfQtTEd" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember624788609" id="Fact002186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,918</ix:nonFraction></span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the three months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zFRpcJG4rCad" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2025-07-012025-09-30_custom_MRIGlobalMember" id="Fact002188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,200</ix:nonFraction></span> and $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCJJAsNtH4z5" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-07-012024-09-30_custom_MRIGlobalMember" id="Fact002190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,062</ix:nonFraction></span>,
respectively, pursuant to this contract. During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zaSs25DAbfP" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2025-01-012025-09-30_custom_MRIGlobalMember" id="Fact002192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,057</ix:nonFraction></span>
and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zZod257iaxCd" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-01-012024-09-30_custom_MRIGlobalMember" id="Fact002194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,932</ix:nonFraction></span>, respectively, pursuant to this contract. As of September 30, 2025, total costs of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zIvhX9UiRQBk" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_MRIGlobalMember" id="Fact002196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,579</ix:nonFraction></span> have been incurred pursuant to
this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z2gtgYw6UMAj" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-09-30_custom_MRIGlobalMember" id="Fact002198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></span> as
of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in the Company&#8217;s clinical trial. It is also possible that the
clinical trial could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase
development costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE
is confirmed to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further
development of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish the Company&#8217;s ability to attract clinical trial participants, and damage the Company&#8217;s
ability to interest investors and obtain financing in the future. There can be no assurances that the Company will not experience such
SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#8220;IRB&#8221;) of the
Netherlands Cancer Institute (&#8220;NKI&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through September 30,2025, the Company has been informed that a total of 86 patients had received
or were receiving experimental treatment with LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&#8217;s Brochure
(the &#8220;IB&#8221;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#8217;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs, and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There have been some indications that the United States economy may be at risk of entering a recessionary period. Although
it does not appear likely at this time, an economic recession could impact the general business environment and the capital markets,
which could, in turn, affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact002200" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zkhik7tSdHfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82C_z4eKQULVr7V8">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below or elsewhere in the notes to the consolidated financial statements, there were no material subsequent events
which affected, or could affect, the amounts or disclosures in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercise
of Pre-Funded Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from October 1, 2025 through October 31, 2025, an additional <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpTiDTK6m0df" title="Pre-funded warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact002202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,521</ix:nonFraction></span> pre-funded warrants exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpwIKWT01vBa" title="Warrants exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember" id="Fact002204" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> per share
that were sold in the July 2, 2025 private placement were exercised, resulting in the issuance of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2r1Dj0AY0hj" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact002206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,521</ix:nonFraction></span> shares of common stock. As
of October 31, 2025, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zamFPjpO4K8b" title="Pre-funded warrants remained unexercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-10-31_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember" id="Fact002208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,251</ix:nonFraction></span> pre-funded warrants remained unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SGN
Media Inc.</b> On October 1, 2025, the Company entered into an agreement with SGN Media Inc (&#8220;SGN&#8221;) for marketing consulting
services for a term of one year. The agreement provides for a one-time payment of $<span id="xdx_900_eus-gaap--ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_z4ptg0u3PL8e" title="Proceeds from sale of interest in subsidiary"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember" id="Fact002210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> upon execution of the agreement and the reimbursement
of pre-approved expenses. <span id="xdx_90E_eus-gaap--ManagementFeeDescription_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_zaLMiCnzWFQ6" title="Management fee description"><ix:nonNumeric contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember" id="Fact002212" name="us-gaap:ManagementFeeDescription">Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LMC
Communications Inc.</b> On October 1, 2025, the Company entered into an agreement with LMC Communications Inc (&#8220;LMC&#8221;) for
corporate communications services. The agreement is for a term of one year. The agreement provides for the payment of <span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_uCAD_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zkBgxpfs3yO1" title="Payments for of common stock services"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_LMCCommunicationsIncMember" id="Fact002214" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">150,000</ix:nonFraction></span> Canadian
dollars (approximately $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zu6ykoOs976g" title="Payments for of common stock services"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-01-012025-09-30_custom_LMCCommunicationsIncMember" id="Fact002216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,000</ix:nonFraction></span> as of September 30, 2025) upon execution, which can be paid by the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z4CLME4I6yKi" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember" id="Fact002218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock. The Company has elected to pay <span id="xdx_901_eus-gaap--SharesIssued_iI_c20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z7NCwSyB7Ir1" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember" id="Fact002220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> shares of the Company&#8217;s common stock.</span></p>

</ix:nonNumeric><p id="xdx_81F_zC59CBSX4kpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_008"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the &#8220;Company&#8221;) contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might
include statements regarding the Company&#8217;s financial position, business strategy and other plans and objectives for future operations,
and assumptions and predictions about future clinical trials and their timing and costs, product demand, supply, manufacturing costs,
marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as &#8220;intend&#8221;,
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;potential(ly)&#8221;, &#8220;continue&#8221;, &#8220;forecast&#8221;,
&#8220;predict&#8221;, &#8220;plan&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;,
&#8220;expect&#8221; or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations
reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company
cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action
that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties.
Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available
cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion
should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly
Report on Form 10-Q and the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including the section
entitled &#8220;Item 1A. Risk Factors&#8221;. The Company does not intend to update or revise any forward-looking statements to reflect
new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, the Company recorded a net loss of $3,465,626 and used cash in operations of $1,982,720. At
September 30, 2025, the Company had cash of $2,887,874 available to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $510,000, which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenues
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities. These factors raise substantial doubt about the Company&#8217;s ability to continue as a
going concern within one year after the date the consolidated financial statements are issued. The consolidated financial statements
also do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is
unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities, including its ongoing clinical trials. The amount and timing of future cash requirements depends in substantial
part on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the availability of operating
capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2025 will provide sufficient working
capital to fund the Company&#8217;s operations as currently configured, including its ongoing clinical trial program with respect to
the development of the Company&#8217;s lead anti-cancer clinical compound LB-100, for at least the next 12 months. However, existing
cash resources will not be sufficient to complete the development of and to obtain regulatory approval for the Company&#8217;s product
candidate, which would require significant additional operating capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the appointment of a new Chairman and Chief Executive Officer in June 2025, the completion of the July 2025
equity financings, and other recent changes in senior management and the Board of Directors, the Company&#8217;s operating strategies
that may include the addition of personnel and/or the incurrence of additional operating costs, which may require that the Company raise
additional capital to fund operations. However, as market conditions present uncertainty as to the Company&#8217;s ability to secure
additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and
when necessary, to continue to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#8217;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s independent registered public accounting firm included an explanatory paragraph in their report with respect to this
uncertainty that accompanied the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31,
2024, in which they expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its noncompliance
with the minimum $2.5 million stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market under Rule 5550(b)(1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a compliance plan, outlining proposed equity financings. On October 21, 2024, Nasdaq granted the
Company an extension through February 18, 2025 to complete its plan and evidence compliance via Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not meet the terms of the extension and, on February 19, 2025, received a Staff determination letter. The Company timely
requested a hearing before the Nasdaq Hearings Panel, staying any suspension or delisting pending the Panel&#8217;s decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
an April 3, 2025 hearing, the Panel granted the Company a further extension through July 3, 2025 to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2025, the Company closed a $5.05 million private placement and, on July 8, 2025, completed a $1.5 million registered direct offering
(see Note 5). On July 15, 2025, Nasdaq notified the Company that it had regained compliance with the stockholders&#8217; equity requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remains subject to a Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B) through July 15, 2026. During this period, any future
deficiency in stockholders&#8217; equity would require the Company to request a hearing before the Panel rather than submit a new compliance
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to recent accounting pronouncements is provided at Note 2 to the condensed consolidated financial statements for the three
months and nine months ended September 30, 2025 and 2024 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to concentration of risk is provided at Note 2 to the condensed consolidated financial statements for the three months and
nine months ended September 30, 2025 and 2024 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company&#8217;s
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure. ASU 2023-07 amends the FASB Accounting Standards Codification
to require additional reportable segment disclosures of a public entity by requiring disclosure of significant segment expenses that
are regularly provided to the chief operating decision maker, requiring other new disclosures, and requiring enhanced interim disclosures.
ASU 2023-07 requires public entities with a single reportable segment to provide all the disclosures required by ASU 2023-07 and all
existing segment disclosures in Topic 280 on an interim and annual basis. The Company adopted ASU 2023-07 effective January 1, 2024 for
the 2024 annual period, including quarterly periods, on a retrospective basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and Licensing Legal and Filing Fees and Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company appointed a new President and Chief Executive Officer, who, with the assistance of the Company&#8217;s management,
Board of Directors and patent legal counsel, conducted a comprehensive review and analysis of the Company&#8217;s patent portfolio in
order to implement a program to balance patent prosecution costs with intellectual property protection benefits. As a result of such
review and analysis, the Company identified certain patent filings that it decided not to continue to support in 2024 and thereafter.
In addition, the Company changed patent legal counsel in mid-2024. The Company expects that patent and licensing legal and filing fees
and costs will continue to be a significant continuing cost in 2025 and thereafter as the Company continues to manage its patent portfolio
related to the clinical development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of such review and analysis, patent and licensing legal and filing fees and costs related to the development and protection
of the Company&#8217;s intellectual property, primarily related to LB-100, decreased to $16,853 for the three months ended September
30, 2025, as compared to $45,415 for the three months ended September 30, 2024, a decrease of $28,562, or 62.9%. Patent and licensing
legal and filing fees and costs related to the development and protection of the Company&#8217;s intellectual property, primarily related
to LB-100, decreased to $90,239 for the nine months ended September 30, 2025, as compared to $192,238 for the nine months ended September
30, 2024, a decrease of $101,999, or 53.1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
descriptive summary of the patent portfolio for the Company&#8217;s most important clinical programs involving the development of LB-100,
as well as a detailed listing of each domestic and international patent that has been issued, is presented at &#8220;ITEM 1. BUSINESS
&#8211; Intellectual Property&#8221; in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 2023 equity financing, the February 2025 equity financing, and the July 2025 equity financings meet the requirements
for equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required
to be liability-classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each balance
sheet date thereafter. Changes in the estimated fair value of the warrants that are liability-classified are recognized as a non-cash
gain or loss in the statement of operations at each balance sheet date. At September 30, 2025 and December 31, 2024, the Company did
not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Digital
Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and if the fair value of a digital asset is other than its carrying amount, an unrealized gain or loss is recognized equal to the difference
between the carrying amount and the fair value at the measurement date. Realized gains and losses on the sale of digital assets are included
in other income (expense) in the Company&#8217;s consolidated statements of operations. The Company&#8217;s digital assets are reasonably
expected to be realized in cash or sold or consumed during the Company&#8217;s normal operating cycle and as such have been classified
as current assets in the Company&#8217;s consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#8217;s accounting policies, disclosures, or internal controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Business Activities and Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A,
which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that
inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for
clinical use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced
Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma,
all cancers of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly used anti-cancer drugs in animal models
of melanoma, breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer drugs occurs at doses of LB-100
that do not significantly increase toxicity in animals. It is therefore hoped that, when combined with standard anti-cancer regimens
against many tumor types, LB-100 will improve therapeutic benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to manage its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead, moving compounds forward
as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached. The
Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies
with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in the Company&#8217;s clinical trial. It is also possible that the
clinical trial could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase
development costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE
is confirmed to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further
development of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish the Company&#8217;s ability to attract clinical trial participants, and damage the Company&#8217;s
ability to interest investors and obtain financing in the future. There can be no assurances that the Company will not experience such
SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#8220;IRB&#8221;) of the
Netherlands Cancer Institute (&#8220;NKI&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through early July 2025, the Company has been informed that a total of 82 patients had received
or were receiving experimental treatment with LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&#8217;s Brochure
(the &#8220;IB&#8221;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although Covid-19 outbreak has
subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs, and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There have been some indications that the United States economy may be at risk of entering a recessionary period. Although
it does not appear likely at this time, an economic recession could impact the general business environment and the capital markets,
which could, in turn, affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations,
and is dependent on its ability to raise equity capital to fund its operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s condensed consolidated statements of operations as discussed herein are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs and expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development costs</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,696</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">361,630</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,801</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691,402</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative
    costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,750,658</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621,627</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,080,302</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,267,890</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total costs and expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,801,354</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">983,257</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,283,103</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,959,292</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,801,354</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(983,257</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,283,103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,959,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,430</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,437</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,236</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,529</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(457</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,049</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,402</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,389</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss) in fair value of digital
    assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(182,887</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(182,887</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Realized gain (loss) on
    foreign currency transactions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(130</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,161</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">530</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,119</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,980,398</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(986,030</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,465,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,968,271</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred
    Stock 8% cumulative dividend</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,367</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,367</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable
    to common stockholders</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,030,765</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(986,030</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,515,993</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,968,271</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per common
    share &#8211; basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.92</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.32</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding &#8211; basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,171,195</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,249,290</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,801,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,249,290</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the three months ended September 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the three months ended September 30, 2025, research and development costs were $50,696 which consisted
of clinical and related oversight costs of $13,424, compound maintenance costs of $7,480, regulatory service costs of $7,581, and preclinical
research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $22,211.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2024, research and development costs were $361,630, which consisted of clinical and related oversight
costs of $250,342, compound maintenance costs of $9,062, regulatory service costs of $11,405, and preclinical research focused on development
of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $90,821.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in preclinical research costs for the three months ended September 30, 2025 and 2024 were $0 and $76,278, respectively, of costs paid
to the Netherlands Cancer Institute. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potential LB-100 analogues, to be used to
treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provided for additional research activities, extended the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and added 500,000 Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the clinical trial at a project
cost of 100,000 Euros (see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer
Institute&#8221; below). The Company was recently notified that the preparations for this clinical trial were suspended and the clinical
trial is not expected commence. Accordingly, the Company expects that this agreement will be terminated and the Company will have no
further financial commitment or cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $310,934, or 86.0%, in 2025 as compared to 2024, primarily as a result of a decrease in clinical and
related oversight costs of $236,918 and preclinical research focused on development of additional novel anti-cancer compounds to add
to the Company&#8217;s clinical pipeline of $68,610.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the three months ended September 30, 2025, general and administrative costs were $1,750,658, which
consisted of the fair value of vested stock options issued to directors and officers of $776,611 (including the vested portion of stock
options granted to Geordan Pursglove, the Company&#8217;s CEO, on July 3, 2025 of $546,499, the vested portion of stock options granted
to Peter Stazzone, the Company&#8217;s CFO, on September 1, 2025 of $55,732, and the vested portion of stock options granted to two new
directors on August 15, 2025 of $76,010), patent and licensing legal and filing fees and costs of $16,853, other consulting and professional
fees of $538,218 (including public relation fees of $184,711 paid to MicroCap Advisory LLC and $150,000 paid to IR Agency LLC), insurance
expense of $64,277, travel expense of $40,320, officer compensation and related costs of $207,377, director fees paid in cash of $27,500,
licensing and royalties of $7,397, shareholder reporting costs of $27,566, listing fees of $13,250, filing fees of $6,211, investor relations
of $13,397, taxes and licenses of $5,056, and other operating costs of $6,625.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2024, general and administrative costs were $621,627, which consisted of the fair value of vested
stock options issued to directors and officers of $106,827 (including quarterly director and board committee fees of $27,500), patent
and licensing legal and filing fees and costs of $45,415, other consulting and professional fees of $117,893, insurance expense of $116,440,
officer compensation and related costs of $190,445, licensing and royalties of $7,537, shareholder reporting costs of $2,941, listing
fees of $12,375, filing fees of $2,864, investor relations of $13,397, rent of $3,218, and other operating costs of $2,275.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs increased by $1,129,031 or 181.6%, in 2025 as compared to 2024, primarily as a result of increases in the fair
value of vested stock options issued to directors and officers of $669,784 (including the vested portion of stock options granted to
Geordan Pursglove, the Company&#8217;s CEO, on July 3, 2025 of $546,499, the vested portion of stock options granted to Peter Stazzone,
the Company&#8217;s CFO, on September 1, 2025 of $55,732, and the vested portion of stock options granted to two new directors on August
15, 2025 of $76,010), other consulting and professional fees of $420,325 (including public relation fees of $184,711 paid to MicroCap
Advisory LLC and $150,000 paid to IR Agency LLC), officer compensation and related costs of $16,932, travel expenses of $40,320, director
fees paid in cash of $27,500, shareholder reporting of $24,645, taxes and licenses of $5,056, offset by decreases in patent and licensing
legal and filing fees and costs of $28,562, and insurance expense of $52,163.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 4, 2025, the Company entered into a Market Awareness Agreement (the &#8220;Agreement&#8221;) with MicroCap Advisory, LLC for a
term of six months to develop a clear, impactful, and marketable corporate strategy to identify, reach and engage with potential investors.
Following the initial 30 day term of the Agreement, either party may terminate it without cause by providing the other party with at
least 15 days prior written notice. This corporate strategy was intended to serve as the foundation for a comprehensive investor communications
program for the Company. The Agreement provided for a one-time account set-up fee of $15,000 and a cash fee of $125,000 per month over
a period of six months, subject to increase, depending on news, events, or other opportunities to amplify public awareness, which will
be reviewed and approved by both parties. In addition, the Agreement provided for the issuance of 48,000 shares of the Company&#8217;s
common stock to MicroCap Advisory, LLC. upon its signing. The Company also agreed to reimburse MicroCap Advisory, LLC for any pre-approved
expenses incurred, including analyst reports and travel expenses. Effective September 5, 2025, the Company terminated this Agreement
and issued 9,181 shares of common stock, valued at $44,711, under the Agreement as settlement of the original 48,000 common share obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the three months ended September 30, 2025, the Company had interest income of $4,430, as compared to interest income
of $1,437 for the three months ended September 30, 2024, related to the investment of the Company&#8217;s cash resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the three months ended September 30, 2025, the Company had interest expense of $457, as compared to interest expense
of $1,049 for the three months ended September 30, 2024, related to the financing of the premium for the Company&#8217;s directors and
officers liability insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unrealized
Gain (Loss) in Fair Value of Digital Assets, Net</span>. For the three months ended September 30, 2025, the Company had aa unrealized net
loss from a decrease in the fair value of digital assets of $182,887.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Realized
Gain (Loss) on Foreign Currency Transactions</span>. For the three months ended September 30, 2025, the Company had a realized foreign currency
loss of $130, as compared to a foreign currency loss of $3,161 for the three months ended September 30, 2024, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the three months ended September 30, 2025, the Company incurred a net loss of $1,980,398, as compared to a net loss of
$986,030 for the three months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Convertible Preferred Stock 8% Cumulative Dividend</span>. For the three months ended September 30, 2025, the Company recorded a Series
B Convertible Preferred Stock dividend of $50,367.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss Attributable to Common Stockholders</span>. For the three months ended September 30, 2025, the Company incurred a net loss attributed
to common stockholders of $2,030,765, as compared to a net loss attributed to common stockholders of $986,030 for the three months ended
September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the nine months ended September 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the nine months ended September 30, 2025, research and development costs were $202,801 which consisted
of clinical and related oversight costs of $40,894, compound maintenance costs of $60,563, regulatory service costs of $8,771, and preclinical
research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $92,573.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2024, research and development costs were $691,402, which consisted of clinical and related oversight
costs of $358,319, compound maintenance costs of $18,932, regulatory service costs of $14,021, and preclinical research focused on development
of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of 300,130.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in preclinical research costs for the nine months ended September 30, 2025 and 2024 were $0 and $210,362, respectively, of costs paid
to the Netherlands Cancer Institute. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potential LB-100 analogues, to be used to
treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provided for additional research activities, extended the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and added 500,000 Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the clinical trial at a project
cost of 100,000 Euros (see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer
Institute&#8221; below). The Company was recently notified that the preparations for this clinical trial were suspended and the clinical
trial is not expected commence. Accordingly, the Company expects that this agreement will be terminated and the Company will have no
further financial commitment or cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $488,601, or 70.7%, in 2025 as compared to 2024, primarily as a result of a decrease in clinical and
related oversight costs of $317,425 and preclinical research focused on development of additional novel anti-cancer compounds to add
to the Company&#8217;s clinical pipeline of $207,557, offset by an increase in compound maintenance of $41,631.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the nine months ended September 30, 2025, general and administrative costs were $3,080,302, which consisted
of the fair value of vested stock options issued to directors and officers of $1,144,348 (including quarterly director and board committee
fees of $55,000, the acceleration of the vesting of stock options held by Bas van der Baan of $167,460 as a result of the amendment of
his employment contract on June 16, 2025, the vested portion of stock options granted to Geordan Pursglove, the Company&#8217;s CEO,
on July 3, 2025 of $546,499, the vested portion of stock options granted to Peter Stazzone, the Company&#8217;s CFO, on September 1,
2025 of $55,732, and the vested portion of stock options granted to two new directors on August 15, 2025 of $76,010), patent and licensing
legal and filing fees and costs of $90,239, other consulting and professional fees of $920,084 (including public relation fees of $184,711
paid to MicroCap Advisory LLC and $150,000 paid to IR Agency LLC), insurance expense of $192,830, travel expense of $40,754, officer
compensation and related costs of $460,403, director fees paid in cash of $27,500, licensing and royalties of $22,192, shareholder reporting
costs of $39,731, listing fees of $59,750, filing fees of $21,381, investor relations of $36,191, taxes and licenses of $15,169, and
other operating costs of $9,729.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2024, general and administrative costs were $2,267,890, which consisted of the fair value of vested
stock options issued to directors and officers of $340,445 (including quarterly director and board committee fees of $55,000), patent
and licensing legal and filing fees and costs of $192,238, other consulting and professional fees of $481,865, insurance expense of $370,167,
officer compensation and related costs of $578,034, director fees paid in cash of $38,819, licensing and royalties of $68,106, shareholder
reporting costs of $15,690, listing fees of $37,125, filing fees of $21,917, investor relations of $48,191, rent of $13,099, conference
fees of $14,475, travel of $9,725, taxes and licenses of $30,869, and other operating costs of $7,125.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs increased by $812,412 or 35.8%, in 2025 as compared to 2024, primarily as a result of increases in the fair
value of vested stock options issued to directors and officers of $803,903 ((including quarterly director and board committee fees of
$55,000, the acceleration of the vesting of stock options held by Bas van der Baan of $167,460 as a result of the amendment of his employment
contract on June 16, 2025, the vested portion of stock options granted to Geordan Pursglove, the Company&#8217;s CEO, on July 3, 2025
of $546,499, the vested portion of stock options granted to Peter Stazzone, the Company&#8217;s CFO, on September 1, 2025 of $55,732,
and the vested portion of stock options granted to two new directors on August 15, 2025 of $76,010), other consulting and professional
fees of $438,219 (including public relation fees of $184,711 paid to MicroCap Advisory LLC and $150,000 paid to IR Agency LLC), travel
expenses of $31,029, director fees paid in cash of $27,500, shareholder reporting of $24,041, listing fees of $22,625, , offset by decreases
in patent and licensing legal and filing fees and costs of $101,999, officer compensation and related costs of $117,631, licensing and
royalties of $45,914, taxes and licenses of $15,700, investor relations of $12,000, director fees paid in cash of $11,319, rent of $13,099,
conference fees of $14,475, and insurance expense of $177,337.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 4, 2025, the Company entered into a Market Awareness Agreement (the &#8220;Agreement&#8221;) with MicroCap Advisory, LLC for a
term of six months to develop a clear, impactful, and marketable corporate strategy to identify, reach and engage with potential investors.
Following the initial 30 day term of the Agreement, either party may terminate it without cause by providing the other party with at
least 15 days prior written notice. This corporate strategy was intended to serve as the foundation for a comprehensive investor communications
program for the Company. The Agreement provided for a one-time account set-up fee of $15,000 and a cash fee of $125,000 per month over
a period of six months, subject to increase, depending on news, events, or other opportunities to amplify public awareness, which will
be reviewed and approved by both parties. In addition, the Agreement provided for the issuance of 48,000 shares of the Company&#8217;s
common stock to MicroCap Advisory, LLC. upon its signing. The Company also agreed to reimburse MicroCap Advisory, LLC for any pre-approved
expenses incurred, including analyst reports and travel expenses. Effective September 5, 2025, the Company terminated this Agreement
and issued 9,181 shares of common stock, valued at $44,711, under the Agreement as settlement of the original 48,000 common share obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the nine months ended September 30, 2025, the Company had interest income of $5,236, as compared to interest income of
$6,529 for the nine months ended September 30, 2024, related to the investment of the Company&#8217;s cash resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the nine months ended September 30, 2025, the Company had interest expense of $5.402, as compared to interest expense
of $12,389 for the nine months ended September 30, 2024, related to the financing of the premium for the Company&#8217;s directors and
officers liability insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unrealized
Gain (Loss) in Fair Value of Digital Assets, Net</span>. For the nine months ended September 30, 2025, the Company had aa unrealized net
loss from a decrease in the fair value of digital assets of $182,887.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Realized
Gain (Loss) on Foreign Currency Transactions</span>. For the nine months ended September 30, 2025, the Company had a realized foreign currency
gain of $530, as compared to a foreign currency loss of $3,119 for the nine months ended September 30, 2024, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the nine months ended September 30, 2025, the Company incurred a net loss of $3,465,626, as compared to a net loss of $2,968,271
for the three months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Convertible Preferred Stock 8% Cumulative Dividend</span>. For the nine months ended September 30, 2025, the Company recorded a Series
B Convertible Preferred Stock dividend of $50,367.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss Attributable to Common Stockholders</span>. For the nine months ended September 30, 2025, the Company incurred a net loss attributed
to common stockholders of $3,515,993, as compared to a net loss attributed to common stockholders of $2,968,271 for the nine months ended
September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources &#8211; September 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s condensed consolidated statements of cash flows as discussed herein are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine
    Months Ended September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,982,720</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,565,861</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,637,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,469,002</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,848,922</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,565,861</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company had working capital of $4,912,254, as compared to working capital of $827,219 at December 31, 2024, reflecting
a net increase in working capital of $4,085,035 for the nine months ended September 30, 2025. The increase in working capital during
the nine months ended September 30, 2025 was primarily the result net proceeds of $4,178,162 from the sale of securities in a registered
private placement that closed on July 2, 2025, and the net proceeds from the sale of securities in registered direct offerings of $914,228,
that closed on February 13, 2025, and $1,330,812, that closed on July 8, 2025, offset by the level of continuing expenditures related
to the Company&#8217;s ongoing operations. At September 30, 2025, the Company had cash of $2,887,874 available to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenues
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities. These factors raise substantial doubt about the Company&#8217;s ability to continue as a
going concern within one year after the date the consolidated financial statements are issued. The consolidated financial statements
also do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is
unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities, including its ongoing clinical trials. The amount and timing of future cash requirements depends in substantial
part on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the availability of operating
capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2025 will provide sufficient working
capital to fund the Company&#8217;s operations as currently configured, including its ongoing clinical trial program with respect to
the development of the Company&#8217;s lead anti-cancer clinical compound LB-100, for at least the next 12 months. However, existing
cash resources will not be sufficient to complete the development of and to obtain regulatory approval for the Company&#8217;s product
candidate, which would require significant additional operating capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the appointment of a new Chairman and Chief Executive Officer in June 2025, the completion of the July 2025
equity financings, and other recent changes in senior management and the Board of Directors, the Company&#8217;s operating strategies
that may include the addition of personnel and/or the incurrence of additional operating costs, which may require that the Company raise
additional capital to fund operations. However, as market conditions present uncertainty as to the Company&#8217;s ability to secure
additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and
when necessary, to continue to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#8217;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred aggregated $510,000, which are currently scheduled to be incurred through approximately
December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet
arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Activities</span>. For the nine months ended September 30, 2025, operating activities utilized cash of $1,982,720, as compared to utilizing
cash of $2,565,861 for the nine months ended September 30, 2024, to fund the Company&#8217;s ongoing research and development activities
and other operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investing
Activities</span>. For the nine months ended September 30, 2025, investing activities utilized cash of $2,637,360 for the purchase of digital
assets, For the nine months ended September 30, 2024 the Company did not have any investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Activities</span>. For the nine months ended September 30, 2025, financing activities consisted of the gross proceeds from the sale of securities
in the Company&#8217;s registered direct offerings of $2,550,003, reduced by offering costs of $304,963, gross proceeds from the sale
of securities in the Company&#8217;s registered private placement of $5,050,000, reduced by offering costs of $871,838, and proceeds
from the sale of common stock warrant of $45,800. For the nine months ended September 30, 2024, the Company had no financing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $510,000, including clinical trial agreements of $292,000
and clinical trial monitoring agreements of $218,000, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended
or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial
endpoint is reached. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing active contractual clinical trials described below as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Start
    Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Projected
    End Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Planned
    Number of Patients in Trial</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Study
    Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Clinical
    Update</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expected
    Date of Preliminary Efficacy Signal</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NCT
    No.</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    Financial Contractual Commitment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">MD Anderson</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">January 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    2027</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine the
    OS of patients with recurrent ovarian clear cell carcinoma</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">20 patients
    entered</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;December
    2026</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06065462</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-0-
                                            (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Netherlands Cancer Institute
    (NKI)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine RP2D with atezolizumab</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">First patient entered
    August 2024, in total two patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06012734</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-0-
                                            (1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">GEIS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Recruitment completed
    September 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine MTD and RP2D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fourteen patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT05809830</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) (see Note 6) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial. The Investigational Review Board (IRB) of NKI has requested additional
information with respect to these SAEs and the study has been paused for enrollment until the IRB&#8217;s questions have been satisfactorily
addressed (see &#8220;Specific Risks Associated with the Company&#8217;s Business Activities - Serious Adverse Events&#8221; below for
additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
determine the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate,
duration of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $207,004 for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this Agreement. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $0 and $78,015, respectively, pursuant to this Agreement. As of September
30, 2025, total costs of $732,532 had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 has consistently enhanced
the anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $1,144,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this agreement. During the
nine months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this agreement. Through September 30,
2025, the Company has incurred charges of $685,107 for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $292,000
for the Phase 1b portion of this clinical trial as of September 30, 2025, which is currently scheduled to be incurred through December
31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $95,000. During the three months ended
September 30, 2025 and 2024, the Company incurred costs of $4,942 and $12,610 pursuant to this letter of intent and subsequent work order.
During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $16,834 and $20,838 pursuant to this letter of
intent and subsequent work order. As of September 30, 2025, total costs of $43,597 have been incurred pursuant to this letter of intent
and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $53,000
as of September 30, 2025, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $335,000. During the three months ended September 30, 2025 and 2024, the Company
incurred costs of $0 and $1,603, respectively, pursuant to this work order. During the nine months ended September 30, 2025 and 2024,
the Company incurred costs of $0 and $10,603, respectively, pursuant to this work order. As of September 30, 2025, total costs of $87,823
had been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately
72% to Theradex for services and approximately 28% for payments for pass-through software costs. During the three months ended September
30, 2025 and 2024, the Company incurred costs of $3,981 and $13,475, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $11,603 and $26,207, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $61,058 have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $91,000 as of September 30, 2025, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight was expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement were estimated to be approximately $106,380, with such payments expected to be allocated approximately
47% to Theradex for services and approximately 53% for payments for pass-through software costs. During three months ended September
30, 2025 and 2024, the Company incurred costs of $4,500 and $14,900, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $13,500 and $14,900, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $33,691 have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $74,000 as of September 30, 2025, which was expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $50,000 and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $25,643 was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $30,000 is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $50,000 and the first
minimum annual royalty of $25,643 were paid in April 2024. The second minimum annual royalty for 2025 of $30,000 was paid in December
2024 and was included in other prepaid expenses in the consolidated balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, each with a different specified
benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of $100,000 was defined
as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product in the licensed fields
of use. The Company had not commenced a Phase 2 clinical study as of June 30, 2025. The total of all such benchmark payments is $1,225,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of 5% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred costs of $7,397 and $7,537, respectively, in connection with
its obligations under the License Agreement. During the nine months ended June 30, 2025 and 2024, the Company incurred costs of $22,191
and $68,106, respectively, in connection with its obligations under the License Agreement. Such costs when incurred have been included
in general and administrative costs in the Company&#8217;s consolidated statement of operations. As of September 30, 2025, total costs
of $97,835 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts
previously paid to date, totaled approximately $1,765,000 as of September 30, 2025, which is expected to be incurred over approximately
the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $4,000. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $4,000 and $12,000 for the three months and nine months ended September 30, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $13,600 and $8,000 during the three months ended September
30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.
The Company recorded charges to operations pursuant to this Collaboration Agreement of $38,400 and $35,200 during the nine months ended
September 30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of 391,000 Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
500,000 Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the trial at a project cost of
100,000 Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred charges of $0 and $76,278, respectively, with respect to this
agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
During the nine months ended September 30, 2025 and 2024, the Company incurred charges of $0 and $210,362, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of September 30, 2025, total costs of $695,918 have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the three months ended September 30, 2025 and 2024, the Company incurred costs of $7,200 and $9,062,
respectively, pursuant to this contract. During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $42,057
and $18,932, respectively, pursuant to this contract. As of September 30, 2025, total costs of $382,579 have been incurred pursuant to
this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $84,000 as
of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in the Company&#8217;s clinical trial. It is also possible that the
clinical trial could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase
development costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE
is confirmed to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further
development of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish the Company&#8217;s ability to attract clinical trial participants, and damage the Company&#8217;s
ability to interest investors and obtain financing in the future. There can be no assurances that the Company will not experience such
SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#8220;IRB&#8221;) of the
Netherlands Cancer Institute (&#8220;NKI&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through September 30,2025, the Company has been informed that a total of 86 patients had received
or were receiving experimental treatment with LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&#8217;s Brochure
(the &#8220;IB&#8221;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#8217;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs, and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There have been some indications that the United States economy may be at risk of entering a recessionary period. Although
it does not appear likely at this time, an economic recession could impact the general business environment and the capital markets,
which could, in turn, affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consideration
of Strategic Alternatives</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#8217;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will continue to evaluate various alternatives to be able to obtain the capital required to fund its operations and business
development activities, and to maintain its listing on the Nasdaq Capital Market, including merger or acquisition opportunities (including
reverse mergers and acquisitions) and funding transactions which could result in a change in control of the Company. There can be no
assurances that the evaluation process will result in the identification of an appropriate transaction, the negotiation and execution
of a definitive agreement to effect such a transaction, or that any such transaction will ultimately be approved by the Company&#8217;s
stockholders and then be consummated. Even if such a strategic transaction is consummated, there can be no assurances that it would enhance
stockholder value, and it may result in substantial dilution to existing stockholders. Any potential transaction would be dependent on
a number of factors that may be outside of the control of the Company, including, among other things, market conditions, industry trends,
the interest of third parties in a potential transaction with the Company, and the availability of appropriate financing for such a transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends,
Events and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development of new pharmaceutical compounds by its nature is unpredictable. Although the Company undertakes research and development
efforts with commercially reasonable diligence, there can be no assurance that the Company&#8217;s cash position will be sufficient to
enable it to develop any pharmaceutical compound to the extent needed to create future sales to sustain operations as contemplated herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company&#8217;s pharmaceutical compound will obtain the regulatory approvals and market acceptance to achieve
sustainable revenues sufficient to support the Company&#8217;s operations. Even if the Company is able to generate revenues, there can
be no assurance that the Company will be able to achieve operating profitability or positive operating cash flows. There can be no assurance
that the Company will be able to secure additional financing, to the extent required, on acceptable terms or at all. If cash resources
are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to reduce or discontinue its
research and development programs, or attempt to obtain funds, if available, through strategic alliances, joint ventures or other transaction
structures that could require the Company to relinquish rights to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, the Company is not currently aware of any trends, events or uncertainties that are likely to have a material
effect on its financial condition in the near term, although it is possible that new trends or events may develop in the future that
could have a material effect on the Company&#8217;s financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_009"></span>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_010"></span>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), that is designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its
principal executive officer and principal financial officer, or persons performing similar functions, as appropriate, to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed under the supervision and with the participation of
the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design
and operation of the Company&#8217;s disclosure controls and procedures as of September 30, 2025, the end of the most recent fiscal period
covered by this report. Based on that evaluation, the Company&#8217;s management has concluded that the Company&#8217;s disclosure controls
and procedures were effective in providing reasonable assurance that information required to be disclosed in the Company&#8217;s reports
filed or submitted under the Exchange Act was recorded, processed, summarized, and reported within the time periods specified in the
rules and forms of the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Effectiveness of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition,
the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to
apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, has determined that no change in the Company&#8217;s
internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act
of 1934) occurred during the period ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect,
the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_011"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_012"></span>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not currently subject to any pending or threatened legal actions or claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_013"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition, results of operations and cash flows may be impacted by a number of factors, many of which
are beyond the Company&#8217;s control, including those set forth in the Company&#8217;s Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, as filed with the Securities and Exchange Commission on March 24, 2025 (the &#8220;2024 Form 10-K&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Risk Factors set forth in the 2024 Form 10-K should be read carefully in connection with evaluating the Company&#8217;s business and
in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the
2024 Form 10-K could materially adversely affect the Company&#8217;s business, financial condition or future results, and the actual
outcome of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks
and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely
affect the Company&#8217;s business, financial condition and/or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the filing of this document, except as disclosed elsewhere in this document, including Note 9. Subsequent Events, there
have been no material changes to the Risk Factors previously disclosed in the Company&#8217;s 2024 Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_014"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_015"></span>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_016"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_017"></span>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
<span id="xdx_90F_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20250930_z0NgKjvU2Yn7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90A_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20250930_zBtytkagYhWb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact002221" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact002222" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>
or <span id="xdx_90C_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20250930_zRulwkUCBzxb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_903_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20250930_zfI4XktgfFeh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact002223" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact002224" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221;, as such term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_018"></span>ITEM
6. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223020163/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 6, 2023 and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2022 and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000164117225018256/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant to Purchase Common Stock, dated as of July 3, 2025, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 8, 2025 and incorporated herein by reference.</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000164117225018256/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated as of July 3, 2025, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 8, 2025 and incorporated herein by reference.</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_019"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    GEORDAN PURSGLOVE</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    PETER STAZZONE</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Stazzone</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- [encoded data, 4096 characters]
     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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Geordan Pursglove, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    GEORDAN PURSGLOVE</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Peter Stazzone, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    PETER STAZZONE</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Stazzone</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Geordan Pursglove, the Chief Executive Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    GEORDAN PURSGLOVE</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Peter Stazzone, the Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    PETER STAZZONE</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Stazzone</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10-q_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $& R # 2(  A$! Q$!_\0
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MO_H>[O\ \)_0?_D:C^P?%?\ T/=W_P"$_H/_ ,C5V=% '&?V#XK_ .A[N_\
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MCC8^-+4%HT8@>$]* &Y0V #<$X&<#)/%>/?&G_DD7Q,_[$CQ'_Z;+BO28?\
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M -#I;?\ A*:5_P#'Z/\ A,_B7_T.EM_X2FE?_'ZR** -?_A,_B7_ -#I;?\
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M (2FE?\ Q^LBB@#7_P"$S^)?_0Z6W_A*:5_\?H_X3/XE_P#0Z6W_ (2FE?\
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M]@33/_0DKO: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M202[/+FC>-F4XI7:75M+7NVHZ^5WKY%WTOV3?W)OR['<49'3//I7\5_[-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDDDF6(9F.9&,DAR>#)(0"[D?,SD NS,Q&324@(/3_/?]<Y_GS2UYYTA1110
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MCMO@3_XASXA_^BLH ^R**^-_^%9_MS?]';? G_Q#GQ#_ /164?\ "L_VYO\
MH[;X$_\ B'/B'_Z*R@#[(HKXW_X5G^W-_P!';? G_P 0Y\0__164?\*S_;F_
MZ.V^!/\ XASXA_\ HK* /LBBOC?_ (5G^W-_T=M\"?\ Q#GQ#_\ 164?\*S_
M &YO^CMO@3_XASXA_P#HK* /LBBOC?\ X5G^W-_T=M\"?_$.?$/_ -%91_PK
M/]N;_H[;X$_^(<^(?_HK* /LBBOC?_A6?[<W_1VWP)_\0Y\0_P#T5E'_  K/
M]N;_ *.V^!/_ (ASXA_^BLH ^R**^-_^%9_MS?\ 1VWP)_\ $.?$/_T5E'_"
ML_VYO^CMO@3_ .(<^(?_ **R@#[(HKXW_P"%9_MS?]';? G_ ,0Y\0__ $5E
M'_"L_P!N;_H[;X$_^(<^(?\ Z*R@#[(HKXW_ .%9_MS?]';? G_Q#GQ#_P#1
M64?\*S_;F_Z.V^!/_B'/B'_Z*R@#[(HKXW_X5G^W-_T=M\"?_$.?$/\ ]%91
M_P *S_;F_P"CMO@3_P"(<^(?_HK* /LBBOC?_A6?[<W_ $=M\"?_ !#GQ#_]
M%91_PK/]N;_H[;X$_P#B'/B'_P"BLH ^R**^-_\ A6?[<W_1VWP)_P#$.?$/
M_P!%91_PK/\ ;F_Z.V^!/_B'/B'_ .BLH ^R**^-_P#A6?[<W_1VWP)_\0Y\
M0_\ T5E'_"L_VYO^CMO@3_XASXA_^BLH Z/]H_\ Y&7]GG_LI_BS_P!45\6O
M\_\ ZQ7.5X7\6OA%^VAJ_C3X#:;J7[5_P3>6?XA^*6T^XMOV0-:A6UND^#7Q
M+66:XBG_ &H+H7D3V+W5NL"/:E9YH;EIV%K]GFZW_AF;]LS_ */ ^"W_ (AM
MJ?\ ]%#0!Z/17G'_  S-^V9_T>!\%O\ Q#;4_P#Z*&C_ (9F_;,_Z/ ^"W_B
M&VI__10T >CT5YQ_PS-^V9_T>!\%O_$-M3_^BAH_X9F_;,_Z/ ^"W_B&VI__
M $4- 'H]%><?\,S?MF?]'@?!;_Q#;4__ **&C_AF;]LS_H\#X+?^(;:G_P#1
M0T >CT5YQ_PS-^V9_P!'@?!;_P 0VU/_ .BAH_X9F_;,_P"CP/@M_P"(;:G_
M /10T 0_&G_DD7Q,_P"Q(\1_^FRXKTF'_4P_]<8O_1:U\Y_&3]FW]L&V^$WQ
M(GOOVN?@W<VD7@KQ%)<6\'['NI6TT\2:9<,\45P?VG)A \@78)3#*(]V_P M
M\;3Z-%^S/^V5Y<>W]K_X+;?+3;G]C;4L[=HQG_C*$\XQGWH ]*HKSC_AF;]L
MS_H\#X+?^(;:G_\ 10T?\,S?MF?]'@?!;_Q#;4__ **&@#T>BO./^&9OVS/^
MCP/@M_XAMJ?_ -%#1_PS-^V9_P!'@?!;_P 0VU/_ .BAH ]'HKSC_AF;]LS_
M */ ^"W_ (AMJ?\ ]%#1_P ,S?MF?]'@?!;_ ,0VU/\ ^BAH ]'HKSC_ (9F
M_;,_Z/ ^"W_B&VI__10T?\,S?MF?]'@?!;_Q#;4__HH: +_AHX\6?$[/_0Q>
M&_\ U7OA*NXKP'PU^S=^V'-XH^)21?M<_!F.>'Q'H,=V[_L=ZE(D\@\">%C%
M)"@_:>3R%%NT43QEI<R1O*' E\N/M_\ AF;]LS_H\#X+?^(;:G_]%#0!Z/17
MG'_#,W[9G_1X'P6_\0VU/_Z*&C_AF;]LS_H\#X+?^(;:G_\ 10T >CT5YQ_P
MS-^V9_T>!\%O_$-M3_\ HH:/^&9OVS/^CP/@M_XAMJ?_ -%#0!Z/17G'_#,W
M[9G_ $>!\%O_ !#;4_\ Z*&C_AF;]LS_ */ ^"W_ (AMJ?\ ]%#0!P'[5'_)
M$]8'_4^? K_U?OPOKZ*F_P!;+_UT?_T(U\9?M1?LZ?M=V'P;U&;5?VL?@_J-
MD_C[X(6\EK:?LB:CIT_G7'QS^&\5E.MRW[2UZNRTOFMKN> V^;N"&6T6:U,_
MVF+Z$;]FC]LQF9C^U_\ !8%F+8_X8VU/C))Q_P G0T >BT5YQ_PS-^V9_P!'
M@?!;_P 0VU/_ .BAH_X9F_;,_P"CP/@M_P"(;:G_ /10T >CT5YQ_P ,S?MF
M?]'@?!;_ ,0VU/\ ^BAH_P"&9OVS/^CP/@M_XAMJ?_T4- 'H]%><?\,S?MF?
M]'@?!;_Q#;4__HH:/^&9OVS/^CP/@M_XAMJ?_P!%#0!B::<_M#^.O^R$?!CK
MP?\ DI/[0_\ 3_Z_->Q5\K:5^SI^U_+^T)X_L5_:U^#J:C:?!/X-237I_9 U
M%[:YL+GQ[\?#:6R67_#3*M!<6=Q#?/)<_:IENXKR"(06QLC)=^Q?\,S?MF?]
M'@?!;_Q#;4__ **&@#T>BO./^&9OVS/^CP/@M_XAMJ?_ -%#1_PS-^V9_P!'
M@?!;_P 0VU/_ .BAH ]'HKSC_AF;]LS_ */ ^"W_ (AMJ?\ ]%#1_P ,S?MF
M?]'@?!;_ ,0VU/\ ^BAH ]'HKSC_ (9F_;,_Z/ ^"W_B&VI__10T?\,S?MF?
M]'@?!;_Q#;4__HH: /1Z*\X_X9F_;,_Z/ ^"W_B&VI__ $4-'_#,W[9G_1X'
MP6_\0VU/_P"BAH ]'HKSC_AF;]LS_H\#X+?^(;:G_P#10T?\,S?MF?\ 1X'P
M6_\ $-M3_P#HH: /1Z*\X_X9F_;,_P"CP/@M_P"(;:G_ /10T?\ #,W[9G_1
MX'P6_P#$-M3_ /HH: /1Z*\X_P"&9OVS/^CP/@M_XAMJ?_T4-'_#,W[9G_1X
M'P6_\0VU/_Z*&@#T>BO./^&9OVS/^CP/@M_XAMJ?_P!%#1_PS-^V9_T>!\%O
M_$-M3_\ HH: /1Z*\X_X9F_;,_Z/ ^"W_B&VI_\ T4-'_#,W[9G_ $>!\%O_
M !#;4_\ Z*&@#T>BO./^&9OVS/\ H\#X+?\ B&VI_P#T4-'_  S-^V9_T>!\
M%O\ Q#;4_P#Z*&@#T>BO./\ AF;]LS_H\#X+?^(;:G_]%#1_PS-^V9_T>!\%
MO_$-M3_^BAH ]'HKSC_AF;]LS_H\#X+?^(;:G_\ 10T?\,S?MF?]'@?!;_Q#
M;4__ **&@#T>BO./^&9OVS/^CP/@M_XAMJ?_ -%#1_PS-^V9_P!'@?!;_P 0
MVU/_ .BAH ]'HKSC_AF;]LS_ */ ^"W_ (AMJ?\ ]%#1_P ,S?MF?]'@?!;_
M ,0VU/\ ^BAH ]'HKSC_ (9F_;,_Z/ ^"W_B&VI__10T?\,S?MF?]'@?!;_Q
M#;4__HH: /1Z*\X_X9F_;,_Z/ ^"W_B&VI__ $4-'_#,W[9G_1X'P6_\0VU/
M_P"BAH [?5_^03JG_8-O_P#TDFKZ/^'YRB$=#X,\ $?^"W4*^*]3_9L_;%@T
MW49[K]KGX,W-M%87DES;Q?L>:E;RSVZ6\C30Q7!_:<F%O++$&2.<PS"%V60P
MRA=C?:G@#:50J"%/@SP!M!.2%_LW4< G R0."<#)YP* +FG?\E#\0_\ 8$TS
M_P!"2N]K@M._Y*'XA_[ FF?^A)7>T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B7Q,_P"2E?LZ?]E%\8?^
MJ5^)M>VUXC\2\_\ "ROV=<D?\E&\8_@/^%*_$WK7"^,_VOOA;X%\2ZYX4UG3
MO&<VI>'[Z33[Z2PTC3)[1YXE1F:WEFURVDDCPZX9X8CSRHKKP>7X_,:DZ67X
M2MC*M.'M*D*$.>4*;DH*<ESPM%S:C>[U>W4PQ&*P^$C&>)K4Z$)2Y8RJ2Y5*
M5G+E3Y97=DWMLMSZHR/4?YS_ ('\C17PW<?\% O@A;?ZS2/B*> ?E\/Z,>I&
M.OB4=<Y^F<XK%G_X*0? .W ,FB_$X@C(V^&]$.1@GH?%0QPO?'45Z\>$.+)V
MY.'LSE?:U"+_ /=@XGG>41^+,L(O6H__ )6??U%?G-<?\%/OV=[;[^A_%4G_
M &/"^@M[?]#<O?CK_.JO_#TC]G3_ * /Q9_\)30?_FPK9<#\9O;AG-GZ8>%O
MQQ:,_P#6#)/^AI@NW\5K;?>DC](Z*_-W_AZ3^SEWT'XM>Y_X170<?^I?5N'_
M (*>?L\3?=T3XJ+D _/X7T%>I(Y_XJ\^AS[<\T/@?C-?\TQFW_@B'_S4'^L&
M2?\ 0UP7_@Y__*S]%Z*_/B/_ (*5?L_R#(T3XHCDC#>&M"!X&?\ H:SVQCZC
MMS6@G_!1?X$/C&C?$L[MV/\ BG-#'0D'/_%4GI@X]NO)%9O@WBZ._#F:+UH1
MT_\ +G7Y%_V[D[VS+"?^#'_\J1]0?';_ )(Q\4O^Q$\3?^FJZKU*#_40_P#7
M*/\ ] %?G-\1OVXO@[XU^'OC3PKI.E^/8M1\1>&-9TBPDOM#TB&T2[U"RFMK
M<W,L7B*>2.$2R*972*5T3++&Y 4^B6W[>/P7:.-5TGXA_*BIEM T< E5Z_\
M(R'CY3W[^G-8RX4XHA\60YBGYT4O_=@I9SE3VS#"O_N(_P#Y6?;5%?'$7[</
MP?E)"Z7X]R."#HFD#GICCQ"><D#TSQZUH1_MG_">0X73/''3/.C:4.@!_P"@
M^?45F^&N(X_%DN/3[.E'_P"7[EK-LM>V.P[_ .WW_P#*SZWHKY8C_:]^%TOW
M=.\9C(!YT?3!U) _YC9YS^'ZU>B_:M^&LNW9I_B_YB ,Z5IHZD#G_B=>_;-9
M2R'/([Y3C5_BI17Y5G\R_P"TL ]5C*%N_/\ _:'TS17SO%^TU\/9L%;'Q4,\
M#=IFGCN<]-7(_A/4]N.]:$7[0_@:8?)9^)02<#=IUCSR!D?\30\<_P#UNE9R
MR?-XVY\MQ<7YTXV_].W+6.P<ML31?I)]=OLGO%%>+Q?';P;-]RT\0?1K&S!Z
M9Y_XF)'ZXS5^+XR^%)L;+76^<8S9V@^]NQR+\C^$YYQ6;RW,(_%@L1'UA']*
MC*6*PS5U6IM=U+_[7S-3PA_R.'Q8_P"QI\/_ /JO_"5>BUX7X=\:Z19:_P".
M=2FBOVM_$>MZ7J%@L<$32I!9^%=!T69;I6N%6*4WFG7#(L;RJ8#$Y=7=HT]K
ML[N"^MH+RV??!<Q)-$V,$HXR P/W67E64\JP*G!%85</7H6]M2J4^9V3G&R;
MM=I6;U2UZ:=S6%6G4^"<96WY7?3\.I9HHHK$L**** "BBB@#YC_; _Y(7J/_
M &4KX ?^M ?#"OIROF/]L#_DA>H_]E*^ '_K0'PPKZ<H **** "BBB@ HHHH
M \&T3_DY[XG?]D&^!7_JPOVB:]YKP;1/^3GOB=_V0;X%?^K"_:)KXT_;"_X*
M7^&/V3?VR/V(OV3[_P %'Q0O[4VJZ\?B+XVCUB:RC^!?A.[\8_#SX-?"?Q5J
MVEQ:5>C5K+XG_M _%?P-\++&22]TZ'3+W4)+VYD:!&:( _42BOQF_;W_ ."Y
M/[$/[$-K^T3\/!\3_!_Q+_:W^ OPWU/QVO[,$.J>)/#>L^*-0T_PQ8>-E\)G
MQW#X+\2>%M(UD^#M1A\4WUDC:KJNFZ&DM[<Z2%BE6/VOX3?\%1_V7/BMX]LX
M-%^,WPHN_A'\3KO]G+PG^SGXQL=2\>0>*_B3\3/CZ/V@7TSPCK_A7Q%X"T*S
M\(1ZR/@+K\/PXNYM;O9O%MYIOB6QO;30KFST&+Q  ?I=17YZ?&+_ (*L_P#!
M/OX :AX<TSXP?M*^$? ]WXK^*'Q%^#FC_P!IZ-XSGMSX]^$GC#0OA[\2;+4[
MW3_#5Y9Z%HO@_P =>)M"\(:OXOUN?3_"*>(=1CTR#7)KB&Z6#U/X8?M6^%?%
MGQ=^,_P:\8:AX?\ "_C#P)\0OB;I?@72%FOS=>+?AI\(?AS^S+XL\?>-KNXN
M(CIUK+X;US]I;PCI6H6BW4+O8:AIU[9V]Q'!JTUH ?7%&1TSR>@]<=:_.C]K
M[]NJY^$G['/P_P#VI?V8O#/@S]H&3XU_$/\ 9<\!?!2T\3>+M;^'O@/Q?%^U
M-\6_ 'PP\$^*=1\4V?A+Q/KVD^'XT\?:?X@>XA\)ZA=R6$8,=B[/M/E7@W_@
MK%\*?AS\ _B)\3/V_P >$/V3/'WP9_:7\5_LG_$7PCX<\2^)/C9X=UWXJ:#X
M3\/_ !-TJ3X.ZCX;\#:;X[^(6A:[\)?%WA_QS=$_#K2-5\+6\7B:W\1:?:6O
MARZU*4 _6RBOS_\ B3_P5._X)]_"+XB? #X4?$']J'X>:#X^_:C\*>"/'7P)
M\/J-?U:3Q]X+^)=[+IGP[\56M]HNBZCIND:#XYU."?3?"FI>(+S2;;7+ZWN;
M?3WGDM;D0L^ '_!5'_@GW^U-XJTWP3^S[^T]X$^*7BC5XO%$MAI7ANT\4,\_
M_"$^$O#GCCQ? +J]\/V=BMWX:\->+-"O-:LVNA=:?=W<VCW,4>M6&HZ?: 'Z
M!T?Y_P _D:_#O]H3_@N+^S=^S5J,?C+QWXN^%FH?L^>*O%7["^E?#[Q_H/B?
MX@7/B\>#?VP?"?Q4^(-Y\2O'7@R/X674>A^'O#_P\^&MSXQ\$6&E:MK&J^-M
M/M]=L=4B\)ZM9:79ZOV)_P""VW[$7PO\(_$'X@_M0_M#?!/X6>"H/V@?B;\*
M/@SJOA74OBAXXN_'GA?X?>"O@MXTDN?$FCM\+](U3P[\3(-+^-/AG4_$?@C3
M+3Q#IVD:)J>DZC:>)=2;^W8=% /V3HK\_OBS_P %3O\ @G]\#_B'\"OA5\3/
MVG/ FA>._P!I;PMX(\<?!+1+.W\2>)E\<^#/B7K/_"._#GQ9:ZEX6T+6M)TS
MPYX\UY9-)\):SKE]IFGZ]>V]W'I]Q.+.[:'U3]K?]MW]F#]A7P-H'Q'_ &IO
MBA;?"WPAXI\3#PAX>U*;PYXO\57&K>(!I&I:_/96ND^"= \1ZPR66AZ/JNL7
M]V]BEG8Z=I]U<W-Q%''D@'U;1TZU^67PZ_X*W?LK_$+]OC6_V"K#QIX>/C+6
M/@Q\!/C!\!O$^EZCKFOV7QWL_C)X)^)7Q1UFQ\/#3O"C:!H^G^"OA=X4\#>-
M[?Q!J'BR:T\6:=\1;:WTZ*WO=$N8;O+^-W_!3ZR^ _[4?[3?[/?C'X67"Z)\
M&/V)M5_:N^&OQ 37EAL_BSXR\'W*V_C;X%16DUB%TKQD!XO^$3>#X[>?4;KQ
M._C+4+>VL1=:7%!=@'ZPT5_/_P##G_@JG^W3\?\ X9_ GXE_LP_L'?"KXSW/
MC']C/X4?M:?%;X7ZE^T_<?##X@6,GQ/^(/Q4\#P_#[X/WNN_"C6?!?C#5=/3
MX5ZMJ7VWQIX@\!VMS)=VMA$[S2H6_7;PO^U)\(?&?[*>D_MEZ#KDLWP.UKX%
M)^T1:ZY<PQ07UM\.V\#MX_N9=3LHY[A=/UG3-$2>#6-*DG>;3-5M;O3KAA/;
M2  'T517X\?LI?\ !8WX _$[_@GQX5_;N_:PO_#W['VF?\)5J7P^^*GA;QGJ
MVK:K;_#/X@K:R>)O#?A+4;Z/0;75GU?Q5\/;[PIXMTC3;G0[34KEO%&F:-!:
M3:G=6=O=,_:D_P""W?[!OP*_8BTC]L/PK^T#\/O%>E_&OX<?'+6?V1[*[T[Q
MU):?&_XD?!WP[KDEYX.?3=)\.2^)O#UC8^-[#2_"'B[5-<T_1;7P[>ZM:0W]
M[9R7=H\@!^Q5%?GQ\./^"E'[+VN>,_V:_@-\0_BOX2\%_M2?M$_!CX8_%31O
MA&+?Q&]K'??$?P-<^,M-\,1>+)=*D\*V&O:Q;:'XMN?!_A;7/$-GXL\3Z7X:
MU*]TG2KY+=G;PS4_^"]?_!(C2O".J^.)?VW_ (87OA[1=:T;P[J,NBZ5X]U[
M48=:UO0=4\3Q6,6AZ-X1OM:NVTK0=%U/4/%$UG83VOA 6OV3Q1/I-_/;6LP!
M^O5%?%NG?\%$?V+M6_:9\._L=Z=\??"%U^T=XM\#:;\1/#7PVC@UU;O6O#FL
M^$)_B%I4=CK<FDIX9E\1W_P^M;CQY;>#?[:'BZ7P9#+XG71/[&1KP9?[(W_!
M2K]AS]O#7_B!X7_9*_:&\(?&C7OA=IWAS5_&VG:!9>)--GTO2O%1O8M(U&W'
MB31-%76+(W>G7NFZC<Z,=0BT;581IFKM8WL]O!, ?<U%%% !1110 4444 %%
M%% !1110!C^(O^0!KGMH^I_^D4]<;\/ON1_]B7\/_P#TVZA79>(?^0!KG_8'
MU/\ ](IZXWX??<C_ .Q+^'__ *;=0H MZ>V/B#XA..?[#TSCC@[H\CKVSZ_C
M7.^"OBC/XL^(GQ:\#RZ1#8P_#2[\*6T&HK=O-)JP\2:?J%[(\MNT,:VGV0V0
MC0)+-YQD&XQD8/06()^(/B$ #/\ 8>F<=LAH>,\9Z'&2<_I7S+I$?Q;\ ?'W
MXK:IIGPBU?Q3X3^)7B#P,J>)H-;T6PM-*L-'T^>QO=1-M<3RW=VD7]I3220^
M3#)BS98PS2QNGYUQSQ!F?#V.X%Q&&CFD\JQG%%;+^(EE>2XW.YK+\1PYG*P$
ML30R[ 8_&87"K/WE+J8VG"C3H-)XFO#"_6$?4\-Y5ALVPO%-&<L%',,-D$,7
MDSQV8X;+8?7:.<Y8\4J-7&8K"8>O7>4?VBH86<ZDZNU"E.O[(L_"7]JW6OB%
MXY\/>%-8^'::'IOBX>*T\/ZYI^O1ZL9)O"3NNH/?:?\ 98+BSMAL$7FS&/,T
ML1A6:(NR>Y_&SXJ/\'_A[JOC=/#FI>)I;.2&VAL+!"L$$UPLQ2^UB[^9M/T>
M%H@MS>)#<.DDMO$L),Q>/X#^$GP"^*MIXV\'%OASK/PZ;2]=\9R>.OB1_P )
M1IPG\2^$]=,L-IH5EHMM?7GE7$4!:*VNUAE,<MREW*BK:+GZ!^(GP0UGP%\#
M/B#X)^'C_$OXL:OX_FT_36B\5>)]'U*^T: 0NLNH6L\]GH<"6$:VZ+<VBL\\
M]Q<12*1$DBU^&\&<:>-&)\-.,\7G679W5SG!8'BBOEO$^,RK#87,\OQU+ARE
MB\ER_*^#:W#. S'BA_ZP>TRJIB*6"A@\!6KTE1Q?$6"PD\?+]0XDX<\.:'&O
M#=#+<;ET<MQ.)R*EC<CPV.KU\%B\)4SFIA\TQF/XCIYUB\)D5LI4,?3HSQ$\
M3BJ=*HZE#)L3B(X1=?\ $[]HG6_!^E_#^'PIX(7Q;XO\:^%;KQO<:*=1-E::
M1X9TG18M8UB[>[,1,TD(D>"W3"%S"Y"23-#;R\=XP_:\O]/L?"5_X)^'%UXI
MCU3X8V_Q>\4QRZK':/X=\'OJL^C7(A*P,M[>6U]:7:NXV+Y423>08WF:VX7Q
M;X=^,TNG?"WX@Z1\)-7GUS1_AMXS^$'B#P3-J^BG5+"#4M,32](\3)<PWOV2
M:RNKB$WC6\;R3PP!+>YEA>83Q<?K_P '/C7X)T?PQ9>&? $GB^X\1_LV1?!G
M78[;5]+A'ACQ#<^)=2UN>[NI);U$FM;:UU4Q+) SV<EQ;NQO$11YWC\3<=^,
M$L5Q'6R:KQEALK^H<-5L(\%P%/$U,MPV(PF6SP&+RN&,R*IBL?F&?YE+,,)Q
M-A,11Q-7)J%/FG@LDBH8B?I9'POX>K#9+3S*'#M?'O$YS2KQQ/%<:$<;B*6(
MQD<7A\?/#9K"AA,)E&"CA<1DN(I5*$,QJS2CB<TEST8_I=H.M6?B+1='U_36
M:73M<TO3M8L)67:TECJEI%>VCLO56:":-F'\).#SUV!S[?6N1\!^'I?"7@CP
M=X6FE6>7PWX7\/:#+,N LTND:1:Z?+*@!("R/;M(HR<*0,GK76+GG( .<X!S
MQV/XXK^O\LJ8RKE^75<PA[''5,OP%7'45%1C2QU7 8*IC:22;Y52QE3%TU%.
M2BJ:BI2Y5)_SWBXT*>+QD,+-U,+3Q>*IX6I+XJF&ABL5##5&VHMNIAX8>;=E
M=SO97LG4445Z!@%%%&1ZT %%%&>WI_6@+A1_DT4?TZ4 ?CWJW_!2_P"+$7C3
M7_B=X=_9O\):]_P3_P#!/[5UG^QOXU_:,E^-AT7XJZ?X\B^+&D_L_P#C/XS:
M9\&]3^'L/A34?V=/AK\>M2N_AGXL\3/\7[;QK/;^'O$OQ$T7P7?^!M,M]1U+
M]!KW]J?]G;3_  5#\1;SXP>"8/!,_B#XN>%(?$;:JK6$GB7X"V/Q'U+XRZ&#
M'&\W]I?#>Q^$/Q,N/%=J81+IB>"];$JE[=5D_#'6/@%^TWIOP(^+'_!)FW_9
M6^+VO>!OBW^VCX]\76/[7FF:S\+[;X'Z+^QS\<_VN[C]J7X@^+M5UB_^(,7C
MN#XW> ?"WB[QA\)M*^'H\ B]\1>.M*T#QCIL\WA"]N[BURO''[#7[<WPO_:;
M_P""C'CK]GC2K@_"CPW\%/VJOC_^PK:RZWH5]K^M_MI_M]Z+X&O/CPOAF/7]
M2ET;2]9^&WB?X/\ C_7OAII_BW0M.\++XD_:8N+35M?N/#5UX@AM@#]<E_X*
M>_\ !/K_ (5'<?'>Z_:X^"ND_"2R\?P?"K4_&GB#Q7#X<L=(^)%WX<U#Q?I_
M@?6[/7HM.U;1/$VK>%]+O?$&C:3JVGV=WK6D1QWVE1WEO<VKS8MQ_P %)?V8
M?A]X1UOX@?'OXY_ OX>>!KSXO>+OA]\.?%.A>.->\6Z3K>@^'?#/A?Q;%J7C
M2Z?P9HL?@7Q/::#XFM=8\7:-<-J7ASPKI-UI-]<>,+I+^1;7\-/V2?V&OC_=
M_M"7WQ(\3? S]K/Q#\)/$O\ P4H_8[^/6G>+_P!O'Q+\,_'G[0GBCX>?"[_@
MG5\<O@YXI^+/Q7@TOQ+JMEIUYH?Q=U/PMX?T'P[;V%CJOAW3+OP@ND^&=%L-
M.DL="Z']K[]F?]M:]T+]I;X<Z-\+OVQ[KX-_';]H'_@HCXHL/"G['OCCX6^"
MO%OQ1\=_$;X??!;PW^S7:?&SQ'XI\3Z1<:+^RGXLT:W^,+>+%T;6]$OV\4Z'
MX9M/&5O_ &/-I^CZZ ?O=KO_  4&_8F\-?''PU^S7KG[3GPBT[XZ>,+_ ,'Z
M7X:^&TWBJU?7M6U#XB:/:Z_\/;:!H1+I\;^/=+O;2;P0;B]A3Q;-<PV/A]M1
MOW6U.%^UY^U3\1/@KXJ^ WP-^ GP=L/C7^TC^TQJWCVS^'&@>+O&-Y\./A)X
M,\+_  M\/:?XA^(OQ/\ C#\0-)\*>/?$'A_P7X977O"NBV]IX8\#>*?$/B+Q
M-XKT'1--L(GNY+N#\'?@U^P1^UMH?['OBSPAXA^ GB#3_BK?^*?^#=W4;6UN
M=0\&2Z[=6_['GAG]AZ#]H>9-6@\1W"A?@_J/@+XL0ZHL^H+]IN--UV7PS_:\
M>JQ3ZA^Q?[;]E\=OAI^T9^QS^UY\(O@5XL_:-\&_!C1OVD/A+\>?AW\--0\*
MQ_%K2?AK\?-.^$NN6?Q'^'7ASQ?XB\*Z9X[U#PAXU^!WAC3]9\&Z=K">)=1\
M/^)M1O-"M;ZXT^6W< X#X8?\%(OB'IOQR\8_##]M#X1^!OV0=&^%7[)FL_'W
MXIZWKWQ'7Q9H>FZUH/[1?B?X(PZWX1\=M8>&['Q%\)/B!H^BZ9XO^'5WJ7A'
MP[X[OGUZST+5O#UAKPDT=/HSQ=_P4V_8)\!?#+P'\9?&7[3_ ,-_#OPR^)E]
MXZTSP9XMU*XUB&QU+4/AAJ*Z3\1[2]MAI+:CX?E\!ZDRV?B\>([/21X=G94U
M4VNX&OPH_;F_9G_;P_;Y\?Z[\?+3]E+XV? "SLO@K^S-J>@^!-.^*GP8L/CE
MXB\,_LZ_\%'9/C:/#6AZZNN^*/A[X#_:+\4_!:PMOBGX.\*>*9/$/A#P;XT'
MASPMXJUZZUJTU*R@Y?QU^R_^TK%\)].\$_#SX4?\%CO$OP(^/6N?ME^,/B3X
M=U'XR_LO>"_VLOC9^T/XY\$_ #P7\)8_VE/&5EX@\(6GPG_90\9>'?#?Q;LK
M[2],U#2O$ \2>'/#NO?$19-%\3:5H.H ']+%G^V)^RSJ'QQTO]FC3OC]\+-1
M_: UJTEU+2_A!I_B[2[[Q[>Z3'X(TWXDKK,7AZTFEOO[$N/ FKV'B6PUIXUT
MK4=.ED:PN[F:VNXH/D#XN_MQ_M-ZG\:OV@/A7^Q-^RGX*_:2M/V/;+P=_P -
M#W_CSX[S_!G6?%'COQKX.B^)&G_ W]G2RM/AE\1-"\8?%33OA]?>'=>UVY^*
M/B/X3>!]-O\ QOX/T0>(KA[O6+[1;7_!,_\ 9O\ $_P<T3XL^)OBS\*-.\(?
M%#Q+<_LM:19^*]2TWPU<^+M8\+?#?_@GE^Q[\,M5TC_A(M,GU'5/["\*?%_P
MY\9- M](N[]+6VUQ/%.I:;;266NC4M4\*;4OVFOV"/VF?V]M9\"?L8_&S]KS
MPA^V;\2?!'[17P$UCX)ZQ\*+#3--^,$/P-\!_!/QM\'OCCK7Q%^(GA"X^%'A
MZ/4/A/X,\5:!\39-$\2>%&\.>+=?2:1-9\+MHM^ ?9'CG_@H5^S]HEC\6O W
MASXC^!KK]IOX8?!'QY\4M0^ >IZSY_B'2/$'@GX9-\2-2\"^(;C2]VF_\))H
M6GSZ=<^*?#>FZM)XBTK1KH:Q-86^GR179\X_X)U_MU^.?VS?$/[16C^,O!7A
M/PC!\&M+_8YO]%F\,W&L3RZL_P"TI^Q5\$/VGO$D6J#5;NY15\.^)_BEJGAS
M1&M%A,N@Z=I\E^)M0-S<2_C!\*_V /VB_"OQE_:LL?BE\-/V\=0\=>-_CG_P
M4?\ VGOA#9>#/BO\ =;_ ."?,T'[57PJ^-EAX)US7[26WT7XI#XVK;?%6Z^"
M>I^#GN#Y6O6EMXTM[H?#5[>2/]*_^"0O[-GQT_9^\6?M=7_QE^'&L> ;/X@Z
M%_P3OM_!T^JWFAW:ZY<_"/\ X)N_LT?!OXDV]L-'U74FC?PC\3?!7B?PC?M<
MB"&XO])GGTR2^T]X;R4 _4/XF?\ )2OV=/\ LHOC#_U2OQ-K\F_VCO\ DM/Q
M,XS_ ,5/>>G_ #QMOY\#\N@S7ZR?$S_DI7[.G_91?&'_ *I7XFU^2_[2;^7\
M9/B?(>0GB2_<@'!.V"V; Y')QQVSC(/2OT7PRUS?,%WRZ"^_&TT?+<6?[EAN
MWUB5_P#P1.Y\N:J.#_NJ?R\O_P"OQS7FNJ?ZL _W#C'/.Q__ -9]./7-?H-X
MM_8]\8:/XQ^%7A27Q/HL]O\ %9]5M;'7(K&_%OHM_H^A/X@>TU"V+>9*UW8P
MR"S>&3$CP7!=8Q"#)Y5\//V4M5^(>B>(/%GB+X@^$OAMX,T3Q+>^"]/\1>)9
M0L>N>([.Y:S:VM()+FSCAMGE9%6>6Z,TLAEBM[:7[/.\?[7A.)LAAAHXMYC1
M=%0IRYX4\34G+VN)Q&"IPITJ>'G6J5)8G"8FDJ-.E*K:C4FX*FE-_"U<KS"5
M;V/U:?M+S5I3IQ2Y*5&LW*<JBA",:5:D^>4U#]Y&-W.\%\":J?F '7( Z=,Y
M'OQQT[]?6LC#8')SGG!'0''7U^I]:_2#0O\ @G_JWBIO$%G-\<?A=I.O>%+K
MQ&GB'0&>[N[W2=+\.:M<:>WB"]59K>XM-)OK5+758KJZM(8H[74+82R,7#'D
M?"/[">I^*M8\7*GQF^&MIX+T+Q)H_@7P[X^6Z%[I'CCQWK6AZ1K</A[0[:*]
M\S_1%UJTL[FZ\V=I;V.ZM[*WN6L[T6_K1XTX82K)YK23PT:<ZU\+F.BQ$E[!
M0;RY>V=>,G.C&C[2=6G"K6IQE1H5IT^)Y%FS<&L'+][*?)^]PMWR7=3F2Q+]
MFJ>D9N?*H2E"$G&=2G&7P83@9RV>01[^@_/.1VZ8R*W[$],YQY8R>/\ :^HY
MSQSG/;&:^C/A]^R5XW\6^,?BCX>\3^(O"OPY\._!?49-)^)/CWQ%J$7]@:/>
M-+<Q:=!9"26SEU$ZM]F\ZUE)M8H[>6V-R\=U=6=I<=?\.OV3SX[\>_%'0-*^
M+/@E/A]\*HO#+ZO\6)26\.ZH/%]F)]"32HDO&CD>687=E=/)J"P6MQ9M&\AF
MN;:&3KQ'$N0T5B>?,*+6$PV&Q>(J4Z6)K4J='&/#_5%[6CA:M*>(Q,<7AIT<
M)"=3%SIUZ518=0DY1PIY5F%1T;8:I>M6J4:<93I0G*=#VGMGR3JPE&E2]C5C
M.M*,:,94Y1=1R33^<+7 11_M'.,_\\AT//0$=3C\*ZVWSMCQQAG_ "W/G'X5
M[MH_[)OQ%N/C1XF^#.H7^@Z//X-TJ3Q5X@\8ZA=-#X:@\$!;-H?%$$I EG@N
MHKR';9L89;>XBOH;V6V2PNIHNJ\*?LW6/C+XK>(?ASX5^+/@[5M%\.>!7\>2
M?$&**1_#T^G0RZ-'?6["WO9Q;2V$FKL;J:6Z\J**UE:98BV$\S$\19+%3G]?
MISIT\#2S2I4I4\16I4\#7C#V-:=2EAIPC*NJT)4J$I+$U(N4HX=JG4Y>V&6X
MYNFOJ\U*6(EA5&<J4)2Q%-R]I",9U(RDH.$E.HDZ<792J7E&_AEEV(]%Y[X+
MXQUST'&.?H>O5V7^J']3ZQGZ^IP/6NV\:?"-_"/C7PWX(\+^,O#'Q.O_ !/:
MZ:^FWOA"[CFT\:CJ>KW6F6^E33FYGBBN=]O'<RO)*J1VUS%*^U 6/JWB?]FC
MQMX4^)OA'X1V=_I?B+Q-XMT*#789+7S;'3M/@,NM1WXNKB[^;R=/AT.[NFN$
MCW7">7#;6[74D<+^1B,YRO\ V=O&4J?UK"XG&T%5A5HSGA<&F\37E"M1IU*-
M.BE+F=:%)M^[",I-)]E/ XM<Z]C.7L:U*A4<)0FE6KO]U3C*$YQG*HVN54W-
M=VEJO(+3AV.>=RY^F4_# Y]_7-=;:'GIGY2<'UVK_0@$8ZGN*]0UOX(Z;HOB
M[P5X1T?XH^#/%%WXHU35])U6^TR4"Q\)W>B_8'NFU:1+JX/ENEU,("X@+O8W
M"';\S1;'Q)^#-[\-M/T#7[;Q'HWC'POXB:XM+'7]$8?9QJ-NDC3VC*)KA) R
M6UR8)XIW4FVN(Y5BDC"-XTLWRZO5PM.GB+3QT9RPD*E'$T755-RB[>VP])0E
M)TZCIPJ.G*K&+G3C.'OG<L%B:<*LI4]*$HJJXU*4U!RY6KJ%6;E%*45*45*,
M)249N,M#A+3M](__ $,UU-B,"+WV_P#H<?\ GU_2N5L\_+D<X3IS@>83R1D=
M ,^X/3I75672'_@/_H<=<F(7O._:_EMO^1M#X4=98_\ +/Z@_F937760Y7W9
MO_0U%<C8_P#++_@/_M2NNLOO)_O-_P"C%KQL3O\ ]OM?BSMH[+_MS]#J]..2
M/]U#^<==9I_\'TC_ )25R6G?P_[J?^BC76Z?UC^D?\I*\+$;O_#(].&W]=D=
M;9_ZP#L70?@"AQ],_P">N?8O NO?89?[.NG"VEV0T3N<+;W&" ,DA5BG"A2,
M<2;"#RY/CMG_ *T?]=%_]DKK[+^#UV1X/I\X[]>N.GI7AXZE"M"5.:T<59K>
M,DURR7FG]Z;CL['?AIN$8R6ZE*_FKJZ?E:_SL^A]+CH._'7UHKE?#&L-?VOV
M:X8M=VR#YFZSP[MJONSAG4@(_3/ROD[SCJJ^1G"5.<H2WBVO)]FK[IK5,]F,
ME.*DMFON[I^:>C"BBBH*"BBB@#YC_; _Y(7J/_92O@!_ZT!\,*^G*^8_VP/^
M2%ZC_P!E*^ '_K0'PPKZ<H **** "BBB@ HHHH \&T3_ ).>^)W_ &0;X%_^
MK"_:)K\4OV^/V!OVC_VOOB?^WQ\8?!?C;XC_  DO/AY\(_@%X!_9]\!V/@'X
M4>)-(_:9\8?LR"7]LSX<:M:^)?&'A_6O&GA/PTW[3'BS0_A]J'_"$ZYX.O\
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M\8P:9?SQ:;XAGBUFUL8;27RVO[P^78I,70$ _'#X#Z#\:/V-OB/IWP]\*?\
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M-2TJ>5;G3;D+W:?$;X=S:7I.N1>//!DFBZ]8?VIH6L1^*-#?2]9TP7ECI_\
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M7_BKP]HWQ=MK+P/XKC\-VOB"_P!!L->OM(U"^98=%\0)9VNN>'=4BN9K'5M
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M:76;8,;C2(T\_<^IVXC?SM/4&ZB"L9(5"DB'3_%'AG5KXZ9I?B/0M2U,6/\
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MR]F.G^ZGZ,3_ $KJ++I#_P !_P#0XZZ,1\3]/T_(RA\*_KN=98_\LO\ @/\
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MG5-%#OJ>DZ:L5X\FHW^DAY'O["U$UQ8 NUQ%%DD@'\DOPK_8S_85_8[\??\
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M4=,O+'4].7XBZKI?B'6(M)UB_M[LVVD16=GX8U;^TKB[D7^SYTA@N8TDG04
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M?A_QY\*]?_9M^)_P5^'OQ$_9W^/GP!^"]A=7?B7X*>-_ACX5OO#-YI7P,L-
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MBO;&^L)X+S3]0L[V/SX;NUNK=Y+>[M;N*59HIX7DBG1Q*CNKY-Z@#^ KX?\
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M%/HHMZ^7EMMVU5_4+;^9\^_';]F?X8?M%:C\#=5^)-MKMS=_L\?''PC^T/\
M#<Z+K=QHR6_Q'\$6&MZ=H4^LI C#6-&2V\0:BMWI%P4@NG:%G<>4 :_QS_9>
M^%W[1?B?X"^)?BC'XCU5?V<OBS8?'#X?>'+'7I].\*W/Q-T72M0T?PSXD\5Z
M/!$1XDE\*VNKZO+X?M+N=+.TO-2NKN:"YE$!@^BJ*Z(8G$T_8>SQ%:'U:-:&
M'<9M.A'$<_MU2=FX>V]I/VCCK+F;3BVV9NC2E[3FIPE[5PE4O%/G=/E]FYZ^
M\X<L>6^UDK-)" #KSSV)Z9Z\?S]Z6BBL$K&H8&<X&0" >X!QD9]#@9]<#TI
M HPH &2<  #+$LQX[LQ+$]222>32T4 '7K1110 4444 %%%% !1110 4444
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M)/Y^-<O?V)!^S1X-N_BOX>G@^&7B']@G]K^P_P""/=NWACX@6?AC2?VN+O\
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M8&MX?)C,4!MF5K<PQ[=D1@*(82@4Q%5,>TJ, '\)7[4'C;X2ZS_P4^^(^K>
M-;^!'@'XUZKHO_!8GX2_'3X(?"[X*^.?#?Q[F^'/@S]B+X[OX&^('[5GQ_UO
MQ?J&E?%6'XP:E\-?!?Q@^%W@.U\(>'K#PKH6I:))IE[K6J>'_$=V.C^.OBCX
M,^)OV\?V"M(NKOX!?#[X_>$_VB/^"7_P8/@:Q^!7C#5_VI?VB/V=?BK^SE\)
MM,^)/Q"\7?M$#Q@GA+PW^S!K6A_&#Q?\ [SX0/X$O]&\6ZUX+U>+7O$A\1>(
M+70M'_N3CMK>*6>>."&.>Z9&N9DBC26X:)!%$9Y%4/,8H@(HS(6*1@(I"C%
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M4 %%%% !1110 4444 %%%% &/XA_Y &N?]@?4_\ TBGKC?A]]R/_ +$OX?\
M_IMU"NF\6R7*^']1M[/[.+W48XM(LVNS(+6.YUBXATN"6X\E6E,,4EX)9%C4
MNRH549;(\R\.ZGJ/AGXEVGP^U#[#<Q7GPO\ #^JVE_:F=)OM'A?4AX<U*"X@
MF!3R+LZO9W=D\3F1#%<QSK@1LP!S7C_XO>%?"OQ/TCPY\1/&WPX\ :#I2-XF
MT6Y\6>*].\/ZOX@N?[(ET>YBLX=6O;2WFL[!_$$K74ENLDB/]A5B@E;?TO\
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M_8^D_P#0+T[_ , K;_XU0!X__P -.?LX?]%\^#7_ (<SP;_\N:/^&G/V</\
MHOGP:_\ #F>#?_ES7L']CZ3_ - O3O\ P"MO_C5']CZ3_P! O3O_  "MO_C5
M 'C_ /PTY^SA_P!%\^#7_AS/!O\ \N:/^&G/V</^B^?!K_PYG@W_ .7->P?V
M/I/_ $"]._\  *V_^-4?V/I/_0+T[_P"MO\ XU0!X_\ \-.?LX?]%\^#7_AS
M/!O_ ,N:/^&G/V</^B^?!K_PYG@W_P"7->P?V/I/_0+T[_P"MO\ XU1_8^D_
M] O3O_ *V_\ C5 'C_\ PTY^SA_T7SX-?^',\&__ "YH_P"&G/V</^B^?!K_
M ,.9X-_^7->P?V/I/_0+T[_P"MO_ (U1_8^D_P#0+T[_ , K;_XU0!X__P -
M.?LX?]%\^#7_ (<SP;_\N:/^&G/V</\ HOGP:_\ #F>#?_ES7L']CZ3_ - O
M3O\ P"MO_C5']CZ3_P! O3O_  "MO_C5 'C_ /PTY^SA_P!%\^#7_AS/!O\
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MCKGP_K?]- /^>:[X\/Y]+X<ES:7^'+L8_P J#.9YEERWQ^#7KBJ"_.H>@_\
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M,\&_UUFO8/['TG_H%Z=_X!6W_P :H_L?2?\ H%Z=_P" 5M_\:H ^+]&_:/\
MV>H_VD_B1?/\=/@^MG<? OX(V\%RWQ(\'B":>V^('[0;7$,<O]L>6TMNMQ;O
M-$&,D:7$#NJI(C-[A_PTY^SA_P!%\^#7_AS/!O\ \N:R=%TS3#^TW\3(SIU@
M43X#? S8AL[8JF[XA_M$LP4&+Y0S?,P& 6^8@GFO=O['TG_H%Z=_X!6W_P :
MH \?_P"&G/V</^B^?!K_ ,.9X-_^7-'_  TY^SA_T7SX-?\ AS/!O_RYKV#^
MQ])_Z!>G?^ 5M_\ &J/['TG_ *!>G?\ @%;?_&J /'_^&G/V</\ HOGP:_\
M#F>#?_ES1_PTY^SA_P!%\^#7_AS/!O\ \N:]@_L?2?\ H%Z=_P" 5M_\:H_L
M?2?^@7IW_@%;?_&J /'_ /AIS]G#_HOGP:_\.9X-_P#ES1_PTY^SA_T7SX-?
M^',\&_\ RYKV#^Q])_Z!>G?^ 5M_\:H_L?2?^@7IW_@%;?\ QJ@#Q_\ X:<_
M9P_Z+Y\&O_#F>#?_ )<T?\-.?LX?]%\^#7_AS/!O_P N:]@_L?2?^@7IW_@%
M;?\ QJC^Q])_Z!>G?^ 5M_\ &J /'_\ AIS]G#_HOGP:_P##F>#?_ES1_P -
M.?LX?]%\^#7_ (<SP;_\N:]@_L?2?^@7IW_@%;?_ !JC^Q])_P"@7IW_ (!6
MW_QJ@#Q__AIS]G#_ *+Y\&O_  YG@W_Y<T?\-.?LX?\ 1?/@U_X<SP;_ /+F
MO8/['TG_ *!>G?\ @%;?_&J/['TG_H%Z=_X!6W_QJ@#Q_P#X:<_9P_Z+Y\&O
M_#F>#?\ Y<T?\-.?LX?]%\^#7_AS/!O_ ,N:]@_L?2?^@7IW_@%;?_&J/['T
MG_H%Z=_X!6W_ ,:H \?_ .&G/V</^B^?!K_PYG@W_P"7-'_#3G[.'_1?/@U_
MX<SP;_\ +FO8/['TG_H%Z=_X!6W_ ,:H_L?2?^@7IW_@%;?_ !J@#Q__ (:<
M_9P_Z+Y\&O\ PYG@W_Y<T?\ #3G[.'_1?/@U_P"',\&__+FO8/['TG_H%Z=_
MX!6W_P :H_L?2?\ H%Z=_P" 5M_\:H \?_X:<_9P_P"B^?!K_P .9X-_^7-'
M_#3G[.'_ $7SX-?^',\&_P#RYKV#^Q])_P"@7IW_ (!6W_QJC^Q])_Z!>G?^
M 5M_\:H \?\ ^&G/V</^B^?!K_PYG@W_ .7-'_#3G[.'_1?/@U_X<SP;_P#+
MFO8/['TG_H%Z=_X!6W_QJC^Q])_Z!>G?^ 5M_P#&J /'_P#AIS]G#_HOGP:_
M\.9X-_\ ES1_PTY^SA_T7SX-?^',\&__ "YKV#^Q])_Z!>G?^ 5M_P#&J/['
MTG_H%Z=_X!6W_P :H \?_P"&G/V</^B^?!K_ ,.9X-_^7-'_  TY^SA_T7SX
M-?\ AS/!O_RYKV#^Q])_Z!>G?^ 5M_\ &J/['TG_ *!>G?\ @%;?_&J /'_^
M&G/V</\ HOGP:_\ #F>#?_ES1_PTY^SA_P!%\^#7_AS/!O\ \N:]@_L?2?\
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M6<\+--H\$C74L\-G=+<1O<7MG+%<QO;K;X:*>7=^0<-_2#R//N$,]S^ID]7
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MWU7P]]D^( \5Z'?W]EX:0 _I@HK^5GQS_P %/_VLOV*?^";?[%WQ3\9_&/X
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M+F6( _O5SQ_D\].WH>OIWI:_F*U+1-$^"O\ P46\0>/_ /@H9X)_;+\*>/\
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MCX6F\+7MCJUWK^@^)_\ !0__ (*9_M#>(?@M_P %?/A5\.?C_P#!?X*_$_\
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M\0:2VG^(8M+L;>^-I;@'T!\3/^2E?LZ?]E%\8?\ JE?B;7Y'?M._\E>^*O\
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M-EOQKTJO.O"'_(X?%?\ [&GP_P#^J_\ "5>BU\SN[VU>KTM_6^GEL>J%%%%
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MI6?A[X4^+-+\$/;Z5X=\;^"K/QA:1IIOB@>)M'%W:R?3^F_\$MOASHMC\9_
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MJFN6-K* ?J=KG[!'P:U^3X\2W>N_$>W?]H;]I[]F7]K+QL;/7/#\7]F_$O\
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M_H]R<# _<2^O^[W'KTX'.*C\F?\ Y]KGW_T>3D>A^7I7]AO]DZ5_T#-/_P#
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M<'_R,$]_^89K=6?_ "_9_.78QR JQCE4!023&ZJ!R3EB@  /)).,9KK[**4
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MJNI)<L4DH0O=0776RNY/5NRV2M9'?1I*E!1OS/>4K6N_2[M9/:_?Y>=>$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\0_\@#7/^P/J?\
MZ13UQOP^^Y'_ -B7\/\ _P!-NH5V7B'_ ) &N?\ 8'U/_P!(IZXWX??<C_[$
MOX?_ /IMU"@#C/$\7Q5E^(FH?\*VOOAW9(NA6G]K_P#"<:3XFU.:27?;?8SI
MAT#6M)AB@"?:1=B[6>5Y/LY@:-%F#I]E_:E_Z#GP!_\ "5^(G_S95Z#IW_)0
M_$/_ &!-,_\ 0DKN@PR>01@'KP![^G0X]><].%?R?7\NOY >"?9?VI?^@Y\
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MV5>_44 > _9?VI?^@Y\ ?_"5^(G_ ,V5'V7]J7_H.? '_P )7XB?_-E7OU%
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MQL-4\1_:]!O]/OM.L?MFH:5+;W;7MI&+:5  >U?9?VI?^@Y\ ?\ PE?B)_\
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MMSM1T;=WM;4YL3C,-@X1GB:T*,)R<(RGS6<DG)I<L):\J;Z+3<])^R_M2_\
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M .L>_%82R+.(_%E]>/JZ/_R]FBS'!-76(IM?]O\ _P K1<^R_M2_]!SX _\
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M[4O_ $'/@#_X2OQ$_P#FRH^R_M2_]!SX _\ A*_$3_YLJ]^HH \!^R_M2_\
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M;O3;5VBFCNXT>&YCE?VK_/\ G]:* "B@'/J,''/^>0?_ *QP00"@#Q+XF?\
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M4?\ LI7P _\ 6@/AA7TY7S'^V!_R0O4?^RE? #_UH#X85].4 %%%% !1110
M4444 >#:)_R<]\3O^R#? K_U87[1-?,/[2?[>'C;X3_&>\^ ?P _8Z^./[8?
MQ'\$_#GPW\9OC-;_  R\0_"SP'X>^&'PP\5ZYXFT'P\L?B3XL>,?"FG^-OBM
MXJF\'>*;WP=\)_#>_4=:TW0K^]O];T*,V/VWZ>T3_DY[XG?]D&^!7_JPOVB:
M_/+XE_'W6_V(?VUOVEO%_CG]G7]ISXH_"S]I/X5?!3QC\,?B'\ _@UXU^.MM
M>?&/X8:9XE^'6L_L]:KHWPXTOQ!K7@77O$.E'PGXN\%>(O&EIX?^'FHS:MXM
MBO\ Q5I=UIS"Z /T,\+_ +3WP%\4^*=%^',7Q3\#:)\7M8^'ND?%";X(^)?%
MGAO1?C/X?\'ZOHMKKZ:CXG^&MQJS>*-$_L_3;R*75OM5@(K +(\LQ@43-S-K
M^VY^QK?&T%C^UA^SA?&_\>:'\+;'[#\;/AQ>"]^)/B:QM]3\/> [1K;Q'*+C
MQ;K=A=VUWI>@0E]3O89D>WMI.<?@_J'@?Q!XG^.=OX$E_8H^-OA_]J>\_P""
MAWQ _;$\0?&Z^^$6M77A2Q^ /C+]EOQ;:V&LR_M$Z?IUS\/M3U#3/!/B/PU^
MQI<?![2/&M[XMG\8^%[B]@\'R:%96^M-X;8?L$>(=!\1>(VT#]CW4-(MK#_@
MW/\ V3/A9X>DTKX(FRBM/VF=)^+GQ8UWQIX'TJ>#P_&D?QNL(QX8UCQ)I=O)
M_P )M %T;4=252;.9@#^G>__ &H/V?+?Q]JGP=L/C9\(M5^-VG:-XIUA/@S:
M?$CPC+\39XO!VFQZIKZ'P5#JLOB6'^R[2XM;C4F?2\V-I.MW.BVZLX\O^!'[
M;?P8^*?PF_9(\9>._'/PW^$7Q+_:^^$7@#XH?#CX,>)_B+X<A\8ZU<>,_"FE
M>)I] \(:?J4^D:MXQETE]3_L_P"U:5I&;N:#]W;1ROY(_"'X/:7H?CS]N;]I
MOP#X!^"?Q!O_ (V^%_\ @LQ\4/C9XL^/FE?!#Q--X(\'_!?PM^P?H?A;6="U
M3X]'0T\)7&I>.G\4W?P8L/AA:^*+CQ1!<?$N;Q&?#"Z6D^IR?,_P%_9,^.G@
MSXT_L\P_'>Y_:Z^$?AWXA? [_@BR/ GACX:_L:Z)\<-+\8^)?V4+#P)JNN_"
M?XE?%2_^'_B3Q?\ LD7WP4^+^BZCXS\:W_B'Q3\+]'?PAXJ\0>(;&?6K_1M5
MM: /Z9/AC_P48_8P^)WP/OOVAK7]H/X4>#OACHWC/6?A]XEUGQ]\2_AUH \)
M>,=(\4Z_X3M_#WBJ>#Q;J.EZ'K'B&;PW>ZUX:TF]U--3U;PW/9:PEE%%-(D-
M+]M']O?X+_L>?#CPWXFUCQG\-=>\?_$/Q)\+-&^$_P *M1^)GAKPUXI^*EA\
M1/BO\/\ X<7VM>!+*>6]U+Q-9^'-.\<?\)/*^B:9J$%W;Z>+?SX$N1<Q?@AX
M^\ _%>+X4_LG6N@Z1^TQ^S5IO[)O[8G[<GA7]I?5/AU^PC>?M ZYHVM?%6;X
MVQ?!/XRZ%\+/%/PH\<^'OC7\)_$'P]\0ZAX:'Q2^%7ASXB7'A"S^-.CV-]>Z
M!#+XM;2?F_2OV:/%_P "/ GB_P"!UG^S=^V7\7X_B[\%_P#@CMX*_8G\:>/?
MV6?%.J?$'P5\*?V8OVC'U_XW^%?B_=^%]'U[1_V<]7^'.HWNJ?%+7?#7C+5/
M"US)X=\6Z"NG1:MJVGW4%H ?V0?%3XR?"3X%^%CXX^-7Q/\  'PE\&?VE9:.
M/%7Q(\7Z#X*\/MJVI&0:?I::OXBO].L9-1O?)G:VLHYVN9HX)Y(XV2&5DYK6
M/VE_V<_#WBOP/X$U[X]_!G1?&WQ-ET6'X<>$-4^)W@NP\3>/9/$EG+?^'1X.
MT.YUJ+4_$HU^SB>XT5]'MKQ-539]A:<RQ!_RU_X+!?#OXD>(?%/['7Q#\/>)
M/C1X+^&GP_\ $GQWT7XD^.?@;^ROX8_;+\3^!;[XE?"Z'P[X4\0:U\#M?\#_
M !,U*\\*ZKIUIXT^'FI^+_"/@36M?\,W/CNQM[J?2_#&N>(=0A_+?XE?L&:[
M:_L6_M Z'\,_V>_C;\0?$/A7]DG_ ((J?#C]G/Q;\2_@7=Z#^T-J.@_ OX\7
MGB'Q#ID'ARUTN?6/!?BCP'H,>F:[\0_!&B26UWX)M4M;/Q/:6CZ?Y, !_4+K
M'[5/[,GAZ'X@3Z[^T/\ !#2(OA/9:CJ7Q1.H_%3P/9M\.=/TGQ)/X,U*\\<Q
MSZXDOA6WL_&%M<>%)I-;2R5?$D,FAC.IHUL/@3]J[_@JQX?_ &>?BIX>\"^#
M/ &C?&3PIXK_ &;/AK^T9X<^(GAWX@V2:#KNC_$C]M']G;]DO3[+1Y].TG6K
M'4M.6S^/<?Q"L]>L]1FMM1A\/IH\,"KJ:ZG:_G!JW[)-Y\+/!7@C]HK5?V7-
M>>T\(_\ !?#]KW]J+]K&/PS\(-:UGXM?$+]G*[^/'[8FD_"#XNZCX4\,^'M5
M^(OQG\!> M7\7? KXQ>'O#FA:/XI>Y\+>&M+\<>%-#O[C0K29OC_ ,0?LG?M
M-Z@/ 6KZ-^S7\:+7PYK?P+^)VN^$]%C^&OB:*X\'^#_B3_P<7? K]J7X4_#S
M6=)BT]I/"GBCP]^RV;?QQJ'P_P!1@T[7O!7@[PUK,.L:/I<?A?4XK, _J]\1
M?MH_L@>$-;\=>&O%?[4W[/'AOQ%\,=%O/$?Q'T+7/C+\/=+UCP'H.G:U'X:O
M]5\8Z;>^(8;SPY9VGB*:'0IY=6AM%CU>XMM.;%Y<P0R==KW[2?[/'A:[^%MA
MXE^.OP?\/WOQPBM)_@S:ZS\2/!^F3_%>WU"VLKO3[GX=17FL0OXRMK^VU+39
M;*X\/#4(+L:EIRV\DC7]HLWXL^%_V)]!UOXX_L6>)?&?[*FC:K#IW_!1_P#X
M*F?%[XFZWXD^#^GWT,-AXYC_ &H%^%OQ'\=W>I:'-'/:>)C)\.3X$\1Z\\L5
MY*G@J70KCSK717A_*WQ'^QI\2?\ A!?@7\+?C)8_MG_!SX2>.O\ @GU^S+\
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M_9X^'_PYT/P7\-/CEHNA:JGP3^('Q0A^)NK>*=*U"ZUW3UT6^ /Z0-)_;L^
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MNR\0_P#( US_ + ^I_\ I%/7&_#[[D?_ &)?P_\ _3;J% %W3N?B'XBS_P!
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M=/\ LHOC#_U2OQ-K\B/VGO\ DL'Q7[_\5%?9'K_HD/ ^M?KO\3/^2E?LZ?\
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M?BVGPA^)WCG0]%\*_$6;X=:AJ]E)XDCT"\FVZ.;OQ%I?]I>'=-U'5K3\X_\
M@C'H_P"R!H'[7O\ P4VTC]ASQ/X7\8_ 2U\+_L!36OB/PA\1->^*>D:EXUU3
MX7?%_6O%UQ-XS\0>)/%=Y?:W=3:C87WB.UCUJ9+/7+R_CO8+?67U6.N ^+7[
M2GPO_P""C'[6'[3'@CX2_'OP!:7O['W[./[;'[-'[/?P(D\0Z!IOQL^//[:/
MCOX3:KX;^+7Q5\,^"KO6K7QH/A=\!O ^G:C\*O"E_+X;%IXZ\:>,/BEK]G=6
M?A[P#H.J>*P#]%/AM_P6*_8A^+OPF^,OQ@^'_B/XLZYHWP6T+PIXSO\ P?\
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MOZLT>GZ!/J%M MT^GMJ]T\5E#?26\=S+;6LTJ2W2VEUY"N8'%=%_PM#X9_\
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MU"?5)=$T>74[BW:VN-1DTRR>_GMV0PM!->- UQ+"T>8FADD\MD/EE2O P?\
MA:'PS_Z*)X$_\*WP_P#_ "PH_P"%H?#/K_PL3P+GU_X2WP__ /+"A5*JO:K5
M3:<6U5K*\7RWB[5DW%N$&XMN+<(-Q;A#E'AL.[)T*#49*<4Z%!J,XJ:C**=!
MJ,TJE11G%1E%5*BC)*<U/H+C0=#N[6TLKG1])NK*Q>)[*SN--LIK6SDB#")[
M6VEA>&V>)6*H\"(R@D*1S7ENI? SP9JGQ6\-_%6YC(OO"O@O5/!-AX=^PZ6W
MALV6J:PFLRW[63V;.E_!= BWDA>-%5W9D+L7KLO^%H_#/_HHG@7_ ,*[0/\
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M_9.BZ)H5FEK=0PV/A?X=?#GPMX'^&O@_3D#O#X>\(V5U?3W6K7VI7ES]'_\
M"T?AG_T43P+_ .%=H'_RPH [JBN%_P"%H_#/_HHG@7_PKM _^6%'_"T?AG_T
M43P+_P"%=H'_ ,L* .ZHKA?^%H_#/_HHG@7_ ,*[0/\ Y84?\+1^&?\ T43P
M+_X5V@?_ "PH [JBN%_X6C\,_P#HHG@7_P *[0/_ )84?\+1^&?_ $43P+_X
M5V@?_+"@#C/B8,_$K]G4?]5%\8=\?\T5^)OXC\/K7YF?M _"KXG:U\7/B)J>
MC?#[QAJFFWWB.ZFL[ZPT#4;FUNHF@MPDUO/% \<T;,K#>A*D@\GI7W]\2/B3
M\.I?B/\ L\R1>/\ P3(D'Q"\823NGBO066*,_!CXEIYDA6_.Q-[HA=L*&=%)
MRR@^T?\ "T/AG_T43P+_ .%=X?\ _EA7O</9_7X=Q5?%8?#4,5*OAUAY0KSJ
MTXQBJT:W,G1O)RO%1M+2S;W/-S/+*>:4:=&I5G25.HZBE",)-MP<&FIZ6L^F
MO38_G_U3X%?&N4CR_A-\0G&_G9X4U<_*0G86O<@Y_'M7F^I_L]_'B02"/X-?
M$M]QR-O@[6CG)R,@6A'OQSC."17])'_"T?AG_P!%$\"_^%=H'_RPH_X6C\,_
M^BB>!?\ PKM _P#EA7WM'Q>S:A:V399*W\V)S#]$?.SX+PTV_P#;\2KK_GSA
MWY]7Y_F?S!/^S?\ M![W(^"7Q1.6)!'@O7,8]O\ 0S_+_"F_\,X?M"?]$0^*
M/_A%Z[_\A5_3_P#\+1^&?_11/ O_ (5V@?\ RPH_X6C\,_\ HHG@7_PKM _^
M6%=?_$:<W_Z$.4O_ +F\S_R.?_4/!_\ 0QQ?_@G#'\R-E^SG^T A4O\ !7XG
MICGYO!FN?WG;_GT'J.V<?KUMI^S[\=EV[_@W\2P <\^#]:''SG!_T7(X/09P
M!CZ_T@_\+0^&?_11/ OK_P C;X?Z^O\ R$*/^%H?#/\ Z*)X%_\ "N\/_P#R
MPJ*GC-F]16>1Y4O3%9E^J-(<#X2&V88I[_\ +K#];?Y'\]-I\!?C>I3=\(_B
M*N!+G/A'61C<6QR;4=<]!_\ JZRT^!WQE5<-\*OB N0N,^%M7!X9R,YMO<9S
MT]ST_>K_ (6C\,_^BB>!?_"NT#_Y84?\+1^&?_11/ O_ (5V@?\ RPKAJ>+&
M:5-\GRU:WTQ./?6_5'1#@["PVQN(_P#!5"^]S\.'^%'Q0TBQN=4U7X>^,M-T
MW3X'N[^^O/#VI6]K9VL$.Z:XN)I8$CBAB16:21V5$4%B<"NRL/A#\5E$1;X;
M^-0,;LGP[J8&& ((S;CL?IU(SG-?J%\<?B7\.)_@Y\4(H?B!X'EDD\"^)52-
M/%F@,[L=*N0%51J!+,QP H!))  )(%>GP_%#X:"*('XB>!<B*//_ !5WA_\
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M]C6&\N]1CCB1+VYNXD2.ZGN5DDG1$25F55 Y;_A:/PS_ .BB>!?_  KM _\
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MKA0. , 8=7"_\+1^&?\ T43P+_X5V@?_ "PH_P"%H_#/_HHG@7_PKM _^6%
M'=45PO\ PM'X9_\ 11/ O_A7:!_\L*/^%H_#/_HHG@7_ ,*[0/\ Y84 =U17
M"_\ "T?AG_T43P+_ .%=H'_RPH_X6C\,_P#HHG@7_P *[0/_ )84 =U17"_\
M+1^&?_11/ O_ (5V@?\ RPH_X6C\,_\ HHG@7_PKM _^6% '=45PO_"T?AG_
M -%$\"_^%=H'_P L*/\ A:/PS_Z*)X%_\*[0/_EA0!W5%<+_ ,+1^&?_ $43
MP+_X5V@?_+"C_A:/PS_Z*)X%_P#"NT#_ .6% '=45PO_  M'X9_]%$\"_P#A
M7:!_\L*/^%H_#/\ Z*)X%_\ "NT#_P"6% '=45PO_"T?AG_T43P+_P"%=H'_
M ,L*/^%H_#/_ **)X%_\*[0/_EA0!W5%<+_PM'X9_P#11/ O_A7:!_\ +"C_
M (6C\,_^BB>!?_"NT#_Y84 =U17"_P#"T?AG_P!%$\"_^%=H'_RPH_X6C\,_
M^BB>!?\ PKM _P#EA0!T7B'_ ) &N?\ 8'U/_P!(IZXWX??<C_[$OX?_ /IM
MU"J_B#XF_#Z?1-5MM/\ &?AG6-1O+"ZLM/TG1-<TO5]7U*^O8FM;2RT[3+"[
MGO+V[N;B:.**"WB=V9N@4$C,\#Z]:V/B9?!E_;ZC8>(/^%<^"-6CMKS3[J"V
MGM+(7FD:B+:_:/['<7.FZC/;P7]G',;FV%U:2O%Y5Q$[ '1?$C0/%/B#1]-M
M_"(\#-J5IK=M?3I\0=#U+Q!HC6,=CJ5O+Y%CI>IZ3<)J8GNK9[>Y>Y:".%;E
M'A=I49/*?^$#^-G_ #[_ +,W_ALO%O\ \V-%% !_P@?QM_Y]_P!F;_PV7BW_
M .;&C_A _C;_ ,^_[,W_ (;+Q;_\V-%% !_P@?QM_P"??]F;_P -EXM_^;&C
M_A _C;_S[_LS?^&R\6__ #8T44 '_"!_&W_GW_9F_P##9>+?_FQH_P"$#^-O
M_/O^S-_X;+Q;_P#-C110 ?\ "!_&W_GW_9F_\-EXM_\ FQH_X0/XV_\ /O\
MLS?^&R\6_P#S8T44 '_"!_&W_GW_ &9O_#9>+?\ YL:/^$#^-O\ S[_LS?\
MALO%O_S8T44 '_"!_&W_ )]_V9O_  V7BW_YL:/^$#^-O_/O^S-_X;+Q;_\
M-C110 ?\('\;?^??]F;_ ,-EXM_^;&C_ (0/XV_\^_[,W_ALO%O_ ,V-%% !
M_P ('\;?^??]F;_PV7BW_P";&C_A _C;_P ^_P"S-_X;+Q;_ /-C110 ?\('
M\;?^??\ 9F_\-EXM_P#FQH_X0/XV_P#/O^S-_P"&R\6__-C110 ?\('\;?\
MGW_9F_\ #9>+?_FQH_X0/XV_\^_[,W_ALO%O_P V-%% !_P@?QM_Y]_V9O\
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M_P#/O^S-_P"&R\6__-C1_P ('\;?^??]F;_PV7BW_P";&BB@ _X0/XV][?\
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MV7BW_P";&BB@ _X0/XV_\^_[,W_ALO%O_P V-'_"!_&W_GW_ &9O_#9>+?\
MYL:** #_ (0/XV_\^_[,W_ALO%O_ ,V-'_"!_&W_ )]_V9O_  V7BW_YL:**
M #_A _C;_P ^_P"S-_X;+Q;_ /-C1_P@?QM_Y]_V9O\ PV7BW_YL:** #_A
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=>>(=+UE+M)5(A$"1:>\#1L-YDD5@=JD444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-q_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $, R # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^ZOQ'XS;_
M (2&R\(>%RM[XGM[V"]UFSO(=9L=-L]$DTN[E$\^LQ:1=Z<[S74FFPPV45PU
MS)).SA EM<F/=^U>//\ H#>%?_"@U3_YG:S-.MX?^%C^(IC&AE.AZ8#)M&XX
M,0ZXR.% X/3@Y%>AT <?]J\>?] ;PK_X4.J?_,[1]J\>?] ;PK_X4.J?_,[7
M844 <?\ :O'G_0&\*_\ A0ZI_P#,[1]J\>?] ;PK_P"%#JG_ ,SM=A10!Q_V
MKQY_T!O"O_A0ZI_\SM'VKQY_T!O"O_A0ZI_\SM=A10!Q_P!J\>?] ;PK_P"%
M#JG_ ,SM'VKQY_T!O"O_ (4.J?\ S.UV%% ''_:O'G_0&\*_^%#JG_S.T?:O
M'G_0&\*_^%#JG_S.UV%% ''_ &KQY_T!O"O_ (4.J?\ S.T?:O'G_0&\*_\
MA0ZI_P#,[7844 <?]J\>?] ;PK_X4.J?_,[1]J\>?] ;PK_X4.J?_,[7844
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M>_\ S-T?\+B\7_\ 0FZ#_P"%3>__ #-UP-% '??\+B\7_P#0FZ#_ .%3>_\
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MYX>T26R>'_A&O,::XE\0Q3QRA@BI;2(REI%*]7_PN+Q?_P!";H/_ (5-[_\
M,W7S!?\ _)P?A7_LB7C[_P!6!\-:]AH [[_A<7B__H3=!_\ "IO?_F;H_P"%
MQ>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3
M=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_
M^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH
M[[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B_
M_H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\
M"IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H
M_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_
M /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\
M*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN
M!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A
M<7B__H3=!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=
M!_\ "IO?_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?
M_F;H_P"%Q>+_ /H3=!_\*F]_^9NN!HH [[_A<7B__H3=!_\ "IO?_F;H_P"%
MQ>+_ /H3=!_\*F]_^9NN!HH ['4?C/XN@M)IV\':0J0*9I6M?$E_/="&,%YC
M;6Z^'5:>X\H.(8%(::0K&O+"KEQ\0Y?&7Q&^%9\ ZOK%WX3N/#WBS7/%.S1]
M7TS3I[.];P_:^%I;^35M,LL7+W2:PMK8JR7T86ZEFMDB3>. <!E8$9!!!!Z$
M8Z&O6OA#:6Z:1X2*1(K'X;Z!E@JAB?[1OWR3CKN&<]?7M0!V>G?\E#\0_P#8
M$TS_ -"2N]K@M._Y*'XA_P"P)IG_ *$E=[0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,'[2/_ "%/@%_V
M5W6/_5(?&&N6KJ?VD?\ D*? +_LKNL?^J0^,-?,/[47Q<O\ X ?LS_M$?'C2
M]'L_$6I_!3X'?%;XLZ=H&HW$]II^N7WP[\#:YXMM-(OKNV5[FVL]2GTE+.YN
M+=6GAAF>2(%U4548N<HPCK*<HPBKI>].481U>B]Z4=7HKW>PFU%-O1)-M[Z)
M-MV6]DF[>1[KG%&1USQZU^!O[*O_  6;\3:_XC\::#^WG\%/"7[+NB:1^QQX
M"_;J\*?$SP=XUU3XA^$=6^!OCWQCX(\$Z7_;NE1Z0?$.C>(&U3X@Z&\<4,=W
M$@MM7@NHK8P6%QJ'V)XG_P""P7_!.#PCX2\&^.M1_:>\+7WA3Q]J'C&T\-ZO
MX<T'QAXDAGTOX?\ B63P=XS\9W\.B>'[RXT;P!X?\2Q'2KWQOJL5IX=^T%3;
MWTT;AZZ*F!QE.?LW0G-Z6E17MJ<N92DN6I3YJ;=H3=N9-<KNE;7*.(HSCS*I
M%;W4[PDK-1UC*TDKR23M9MJS?3]+<Y_^N"/YTM>2?'#XT>"?V?\ X$_$[]HS
MQO<7-W\-?A3\.->^*&NW_AXVVIR:GX;T+2)-9!T"?SX]/OI=8A6"'2)S>)8W
M+WEM.;A;9O.'X->*/^"J7_!2;PW^R7\5/VM?&_[#OP[^$'PJUOX,^#_C9^S7
MXRO_ !QJ7CJ2+1O%_P 5_A;X9\.^&?C3X9LY=*GL-=\8_#SXA2^,/#=QIEUI
M%J3:()('99;&-4,)7Q*;IJFDJD:*=6K"ES596?LX*;YJDXQ?/.,(N487;3:Y
M6YUH4W:7,WRN?N0E*T%]J36D4WHFWK+1=S^D#(]>G6DR/\_Y_#Z\=:_*7PO_
M ,%(?A]\-=?_ &L]8_:V^.OP!\(?"_X1_M"_"_X*>!KSP?I7Q)CUOP+?_$/X
M>IXMM/#'QPNM8T$Z0/$]U*EWJ-IJOA*XU+PS9:% W]HZE#=*4K5?_@HCX ^,
MNJ_L$^,OV5?C9\#];^"?[3GQ[^)WPI\7W/Q$TGXBZ;XV\5I\._"TFI:GX6^%
M5M::&MEX>\<Z+?0/J^KR_$9M$T.;PQ<V-]I]Y.UW"6/J>)N_W;Y$G^]Y9^QY
MO8NOR<_L[<_)%KEM?F5KVM-GMJ>W,N;^2\>=+GY.9PYK\O-]K:VJ['ZC49'K
MUZ5^75G_ ,%G?^":.J:7\7=9T;]J#P[K^F?!(Z'_ ,)W=^'_  UXVUJ%H/$O
MC/2/A[HE_P"$I-.\.W">-].U#QMKVC^';>^\+G4K=[[4K<J[6T@G'":__P %
M1_!OQ(^*G_!-B#]DGQ=X#^*GP2_;$_:&^+OP7^)?B.^T?7H/$WA:?X:?"V\\
M;2:-8Z;>W&C7_A/Q9;:E_9DNHV?B+2+IY=$U"SN;>U%O?VMVPL%BV[2H5*:M
M)\U6G.$4XT95W%R<;*3IQ;BFES/1.]TCVU+I4A+RA*,F_>4&TDWHI-*3Z;OI
M?]2/B=_R3/XC?]B#XS_]1O4ZW_#G_(N>'?\ L :+_P"FRUKG_B<<_#3XC>A\
M >,C_P"6WJ>?Z8Y[GKVZ#PY_R+GAW_L :+_Z;+6N9&ILTF1Z_P"?\?;J>:_,
MS_@HU^V9\=_V5-5_9&\!_LY_!OP-\:_BI^UE\;=;^#'ACPWX]\7:CX+T>UU;
M3_"7_"2Z?,-9L()TA:\E22UD>\"V\2*CEE+';^;W@[_@X \,-XV_98U[]H#0
M/"O[,WP;\9^&_P!LGPE^TO;^)DU?QKXD\'_'W]F?6O!WAK1_#OPXUOPR\G]M
M:!XDUGQ9;*ENWAZ^U&??- ;JWCT^:]F[*67XNM25:E34X251Q49Q=1JGS)_N
ME>I[TH2A3]VTYQY4U=-X3Q-&$W"<G%KENW%J'O6^VVHZ)J4K.ZC=M:-']*N1
M_G^?T]Z*_.3XD?\ !6G_ ()Z_":X^#Z>./VC_#NG:9\=/ 'AOXI_#WQ18Z'X
MLUOP=<?#KQ;K^K^%-!\7^(_%.D:'>Z/X1T>[\3^']=T"9_$=SIUS9:OH^HV.
MH6]O-:3(O?7/_!1K]BRV_:3T_P#9+'QU\/WGQSU&]321X=TS3=?U30;'Q!)X
M:O?&,7A;6/'5CI=QX-T?Q2_A33[[7QH-_K=O?QZ9:323PQ/&R5B\-B;)_5ZU
MG&<[^RG;EIMQG+;:,DU*]K-/1M%^UI_\_*>\5;GC>\E>*WU<DTU;=,^W:*^-
M/V<_^"@?[('[6OCCQ?\ #G]GWXTZ)\0_%G@[19O%-Q96NF:]I-MXF\&VVNKX
M7O?'/P^U'7-+TVQ^(7@?3?%#Q^&]2\4^$9M6TBQUJ6"QN;F.6> R>3?%;]N_
MQ=\/O^"B_P"R[^PQ:_L_^,$\(?'BQ^(&HZG^T3XE,=CX"U&7PE\(O$WQ'B\+
M?"\V4]Q<Z[XGT.\T&VL/'4>MP6%MI=MJMH=.2[E<ST+#5W.5-TY0J0I3K2A4
M7LY*G"#J.5IN+^!-Q24G)Z)73Y3VL.52YDXRE&$91]Y.4I*"5XW^TTFW9+KH
MTW^D>1_D'/Y=?_K<TM?BY^S1_P %=_A'XN_:Q_:2_9 _:,^)7PW^'?QB\._M
ME>._@'^S7X.LM+\0:;=>-O /AOPIX3O=$O\ Q1KEU+J6@P^)_$/BO4M?\/:-
M+<7>B1:[J5E!H^FZ<UZJM<?M'R"5(P0<8]"."",#!'&1VR*5:A6P\HPK0<7.
M$:D'9\LX2C"490DTE->^DVM%)2CNKMPJ0J)N$E))N+LU>+3::DKMIZ7L[.UG
MZ</HW_(^^._^P;X(_P#277*[BN'T;_D??'?_ &#?!'_I+KE==>SM:65]=!0[
M6EE>W:*QPKFUM9;A49N2H9HPA;J <^]9:W275I?-M)?>W8INWYEJDR/7_/\
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M,ROXLU:\$D!DT>%Y$FB.,^#_ /!,C]MWQY^VY\+?BWJOQ1^'?@OP1\1?@/\
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M=_R4/Q#_ -@33/\ T)*[V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>WT.GZCJ-S86_P"PV>H(YSZ=3T!/0$XP/H>" 3A<$\^N<9ZX/^.3D=Q@'O7
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MMTZ:?<DOT^_7J%%%% PHHHH **** "BBB@ HHHH **** $;H?H?Y5[#\(_\
MD#^$O^R;Z!_Z7ZA7CS=#]#_*O8?A'_R!_"7_ &3?0/\ TOU"@#J]._Y*'XA_
M[ FF?^A)7>U\L_$OQW\7?!GQ&D3X7? :[^,Z:AH$;ZU<VOQ,\%> %\/26TED
MME;O;>+2LVJG4TFN95N+!O*LA8M%<C?=0$<Q_P +R_:U_P"C&M5_\2+^#O\
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MUJO_ (D7\'?_ ([1_P +R_:U_P"C&M5_\2+^#O\ \=H ^S:*^,O^%Y?M:_\
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M .U__P!&2W__ (DI\(/_ )%H_M_]K_\ Z,EO_P#Q)3X0?_(M 'N-%>'?V_\
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M_P#$E/A!_P#(M']O_M?_ /1DM_\ ^)*?"#_Y%H ]QHKP[^W_ -K_ /Z,EO\
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MC);_ /\ $E/A!_\ (M']O_M?_P#1DM__ .)*?"#_ .1: /<:*\._M_\ :_\
M^C);_P#\24^$'_R+1_;_ .U__P!&2W__ (DI\(/_ )%H ]QHKP[^W_VO_P#H
MR6__ /$E/A!_\BT?V_\ M?\ _1DM_P#^)*?"#_Y%H ]QHKP[^W_VO_\ HR6_
M_P#$E/A!_P#(M']O_M?_ /1DM_\ ^)*?"#_Y%H ]QHKP[^W_ -K_ /Z,EO\
M_P 24^$'_P BT?V_^U__ -&2W_\ XDI\(/\ Y%H ]QHP/3KU]Z\._M_]K_\
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M$'_R+1_;_P"U_P#]&2W_ /XDI\(/_D6@#W!NA^A_E7L/PC_Y _A+_LF^@?\
MI?J%?%K:_P#M@8./V)+\G!P/^&E/@_R<=.;7%?9OP<-VWA_P4U_9G3K]OAAX
M::^T\W,-X;"\:ZO3=6)O+?\ T>[-I.9+<W4'[BX\OSHOW;K0!V&G?\E#\0_]
M@33/_0DKO:X+3O\ DH?B'_L":9_Z$E=[0 4444 %%%% !1110 4444 %%%%
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M(_ !_N?&;X:M_N^,-$/;.>+SICO1_9>;+?*LS7KE^/\ _F$/KN#_ .@O"_\
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MT;PZII/@3P?INHQ2AO,AOK+P_I]K=0R$\EXIXY(W)ZL#GG->@CZ$8]<_U_\
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M%_\ &+2O%VOZ3\4[G4M.U >*='N38ZJIMUD$G]$_[>OQ*^'O[/O[8'_!./\
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M_JU/3]/I7-6G+)CGY1_Z'&?Y<UT]CTC_ -\?^BEKS,2W?=]]_P#@G3#9^O\
MGY'76('R' Y8=N.C'_/T%=;9*!Y7 ZK^/SQCFN3L>D?^\/\ T%JZVS_Y9?4?
M^AQUXV)T?_;[ZON_,]"CLO\ MWMV7D=78 ;@2!U?' XP,?T_6NKT\#='Q_"N
M?Q#?X?K["N5T_JOUD_F:ZO3_ +T?^ZG\GKP:[?=_ ^K_ )?4]&GM_7\J.MM5
M!?ZN!T[!2>/?)Z_3.0,5[EX"UYE"Z+=R909_L]ST4GYY+4G!/.YGB+'"X:,$
M HM>'6GW_P#MH/\ T77763,C*RL4=9$8.C%&5@@(96!!4J0"I!!R."" :\+,
M*,:]/V<NR<9;N,TVE)==G9VW5UU5O0PLW32FNDI771KJGY=5V=GWO],45@^'
M]7&JV2M*56[APEPF0"W0+.BD[MDF1V 60,@X K>KY&4)4Y2A)6E%M/Y/==TU
MJGU3OW/:C)22DG=-77]>74****D84444 ?+_ .VU_P F>?M1?]D#^*__ *A6
MLU]05\O_ +;7_)GG[47_ &0/XK_^H5K-?4% !1110 4444 %%%% 'ANH?\G*
M^$?^R&_$3_U/OA=7\]G_  6*^ GQN_;L_:&^+OP_^ O@/X9?$>3]CG]B*%TU
MOQQ\4?$/PVU;X.?M ?M!?&#PK\=_"WC#P)!H'P\\72>,/&OACPQ^Q?\ #VYN
M=$O]9\)V<6C_ !-TB*UUM!J^N);_ -">H?\ )ROA'_LAOQ$_]3[X75UGB_XA
M?"3X:ZQX3LO'GC;X>> =?^,'BRP\ >![7Q9XB\.>%]7^)WCF32[^]TOP9X7A
MU>[LKSQEXJDT;3-2N=/\/:6NHZJ^GV-Y);VAM[>4J ?R"?M<6?\ P36_;(M_
M^"@_COXCZ=I?CS_@IM\=OV8?%GBC_@GMX+GU3XHWGQ1\6?"KXB?\$GK7QE\'
MM.^!W@_0+I/#GBCP1J'B;5OC?)J;6.F7^B7?Q0@N[3Q/(?%'_"*6;L^%WPD_
M9Q^)'[/7C6+]@&Y\%IX,^"O_  3%_8>_:]^%B_#6_P!4UK1/^&D_V9/VN_C_
M /M#^/-#M9;R^NKRS\6>+_B!X,\3?#_Q3')+YFE7OB74K*[LQ';36%?V20^$
MO"EOJ.EZO;^&?#T&K:'I?]B:+J<.BZ;%J.D:+L6/^R-+O4MEN=/TORT1/L%I
M+#:;$5?*VJ . 3Q/\%? _P 0_"7P3MIO!GACXB?$/P=X^\8>$/ NG:39Z;J'
MB/P5\/\ 7/"\'Q!U:SMK&QCM)-,T'7_BAX8.L)-(A?4?%L5P(9I+JZD4 _C!
M_:WTWX#_ +2WPO\ V=_CS^T;XG_9U^ ?P*_;UTO]O[]J/P?XW_;5\)?&77/A
M_:_$CXH^)/ASX'^!&M:?JGPL^)7PSLO#'Q_\._L5^!/AY<_"J3Q5?WT9CT'7
MH/ 6FOXEAGN+[[L_:#^(OQQ_9L^"?CS]MCX)7-[^T3X]_96_;&_9PB\67<5G
M?:3?_&SP#^TI_P $K/V+/V:]7\8C3-;BN-6M;F+XE_$+X7?&K^R]8M+EH)/"
M;0>)A;:=!J][;?T3^*/C!^R>'^*/PY\9_$K]G\R?LY^%="\??&7P)XE\5_#Y
MG^!_@J?1;C7/#7C+XC>&-3OB?AWX9D\/V=UJVB:_XAL=)TQM)MI[RQNOLL3R
M+!\??V=/A]^U%X*\#^%O$FNZ[I_@S1?C1\#_ (_7=OX'U'3K'3?B3?\ P1\;
M>&?B7X(\-^,G:PU"W\1^ =4\0>$O"=WK.G1F)]3L-$TVU@OX((EP ?B+_P %
M1O@#K7[,7_!MOXZ_9\U3Q"NM>.OAE\%/V6/"_C7QPR7.H#Q/\6F^/WP1N_B-
M\0IX;^\NKJ\?Q7\2;[Q#XPNK:ZOYGFDU.6"2[(8RU^:'[8I\9^$]9\8_LX_M
MF?%KX4>)?BPO_!2/X)_&']O/XP_&3X5>/?#7[(GQD_9!\0?LL?$3P-^Q5\4O
MB!\*OAIXG\,6WA[]FG2/BQX%\*?!+XF>']6^)>J:/X8_:<\(:7JOQ#\7:[X<
M\2>%KK5?[2O$6O> !JN@^ /%VL^#QKGCN/5Y/"_@GQ%J.B_VKXSB\*16FJZ[
M)H'AO4YA>>(D\-P3V.I:NVG65XNCQ36EY>&W1X96Y+X?^,/@O^T7\/=)^*/@
M&\\'_%'X=?$+0[RPTSQ3!IEMJFD^*?#MIJU]87NGNVI60DO-)BUBQOHI;"[A
M-L;N&5S"6.\@'\H7@CP9_P $Q$\>_L8^&_\ @H5\9/AS\9/A?X0_8N^%Y_X)
MX?$+3[SXV>!_@/XH\<VW[7OQ;MO%-M^SOI:^*=3\3:S\2O!VC6G[+W@S0;>_
MUWQ)XQUOX=:59:II<FK^%=0\2W Y3]FGX=?LN_L7>&O^"6/_  42\=QVGPFT
M_P <?M[_ +<MS^U]^T9XQ\3>+K[PQ8FX^$G_  41^$7P9M?%USJ>I:GX=\$^
M'E\2:SHO@OPM!ING:+I UG6+*UE:2]OXI)/[(IO!_A&X@T&UG\+>')[;PK/;
MW7ABVFT33)(/#=S:1>1:7&@PO:M'H\]M#^YMY=/6WDAB_=QLJ<5+>^%O#&I:
M-)X<U#PYH-_X>DFBN)=!O=(T^ZT9[B'4(]7AGDTN>WDL6FBU6.+5(I&@+QZ@
MD=ZC"Y590 ?P+WGA;X.?M ?!?QUKOQ.T6V^(7P6TO]B7]C/X\:E-KT'BF#2=
M+^%UE_P7I_;0U+XA?$+5;.(Z9KVD:+I7P$UGQS?>*[B]MK.\T7P<^L2:G!9F
MP<6WUKX6_9R_8H_:<_; G_9QT'PGX-^)_P"PGXA_X*:_LUV?PY\#^%_$WB"?
MX:>(/A9X4_X-^9?$?P[M-&UK1M<@U/5/",5UI&BZG;QKK,MEK26L*W[7]G<3
M13_V.V=K\.M2OO$OAO3[?P5J&I:9IUMH/C'0+.'0[J^T_2=?BO-7L]&\2Z5
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M#/A_5H1K%KXA$.IZ-IU_$-?L5B2RUP1W5M*@UBS2"!+74\?;;=88EBG01H
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MI4HKV/+1J6A!UZDJ2KRC1GB)QA!/][[*$92CK4?+PUIU3M\@Z]?]8GN<^_\
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MR!_%?_U"M9KZ@KY?_;:_Y,\_:B_[('\5_P#U"M9KZ@H **** "BBB@ HHHH
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MZ+_P4%_X)Y?!7X?_ +,VE?\ "!I\ ]4^"?[3GP/_ &7KSXG1>*+*;PA-XO\
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M)_LNZT%=*@D\W["MW'X<O[_PM%KYLSXBA\)W]]X5BU9/#UY<Z;* ?RZ?LX?
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M0O!H_AOPUH=G'8Z1HVFPN\CPV5A9PQ6\"/(Y6.-5+$\UW%%% !1110 4444
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MXFB/R?\ /1/^>:C^]ZU_6?\ \*I^%W_1-O /_A'>'?\ Y74]?A;\,E^[\.O
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MF#'_ )*TY?"7A0 8\,>'QCI_Q)=-!&..UMQ^%>?4X\HU'?\ LK$+_N;P[_\
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M3]6\+ZS<:'_8UJNG0W]Z^'Q?^W;<^'?A[\.?$?\ P4P^.EGK\?\ P2M\9?\
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MT]\1_A'XY\)>%H['X:3>#=.^'.@ZQX,\%_$[X?Z'?>'=2U/0/'/AS31JVO\
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M>$ _*S5_VN_VJ?!?QV\%_M4?'OQO^U?X"^''Q%^#OPTUW]E3P#\-$^!WBO\
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M(#Z"HKY]_P"&9/AC_P!!7XV?^)-?M)__ #V*/^&9/AC_ -!7XV?^)-_M)_\
MSV*+KNOZ^0'H/Q:Y^%7Q, Z_\*^\9_\ J.:E71>%./"_AO/_ $ -'_\ 3=;U
M\P?%3]FKX:6_PP^)$T>J?&DO%X!\8N@D_:6_:/FC++X<U(@20S?%:2*5#C#1
MRH\;C*NK*2IZ#PS^S/\ #23PUX==]5^-8=M"T@L!^TS^TB@!_L^WX")\5U1
M.@1%5% "JJJ  77=?U\@/IZBOGW_ (9D^&/_ $%?C9_XDW^TG_\ /9H_X9D^
M&/\ T%?C9_XDW^TG_P#/8HO'NOZ^0'T%17S[_P ,R?#'_H*_&S_Q)O\ :3_^
M>S1_PS)\,?\ H*_&S_Q)O]I/_P">S1==_P"ON ^@J*^??^&9/AC_ -!7XV?^
M)-_M)_\ SV:/^&9/AC_T%?C9_P")-_M)_P#SV:+KN!]!45\^_P##,GPQ_P"@
MK\;/_$FOVD__ )[%'_#,GPQ_Z"OQL_\ $F_VD^W_ '5BF!Z#H /_  L/XAG!
MP=/\$8/KBUUS./6O0:^0=#_9K^&C^/O'T+:I\:=L5AX*VD?M+?M'K(=UIK>=
M\J_%82R ;0$$KNL8R(P@9@>\_P"&9/AC_P!!7XV?^)-_M)__ #V: /H*BOGW
M_AF3X8_]!7XV?^)-_M)__/9H_P"&9/AC_P!!7XV?^)-_M)__ #V: /H*BOGW
M_AF3X8_]!7XV?^)-_M)__/9H_P"&9/AC_P!!7XV?^)-_M)__ #V: /H*BOGW
M_AF3X8_]!7XV?^)-_M)__/9H_P"&9/AC_P!!7XV?^)-_M)__ #V: ,']MH$_
ML>?M18&?^+!_%?I_V).LU]05^='[9G[./PXT[]DC]IF_MM4^,C3VGP*^*-Q$
MMW^T?^T1J%JTD'@[5Y8Q<6%_\4KFQO(2Z+YMM=VT]O,F8YHGC9E/TQ)^S/\
M#25WD?5OC8SR.SNW_#37[20RSDLQP/BP ,DDX Q0![_17S[_ ,,R?#'_ *"O
MQL_\2;_:3_\ GLT?\,R?#'_H*_&S_P 2;_:3_P#GLT ?05%?/O\ PS)\,?\
MH*_&S_Q)O]I/_P">S1_PS)\,?^@K\;/_ !)O]I/_ .>S0!]!45\^_P##,GPQ
M_P"@K\;/_$F_VD__ )[-'_#,GPQ_Z"OQL_\ $F_VD_\ Y[- &AJ /_#2OA$X
MX_X4;\1!GMG_ (3[X7<5[E7PG?\ [-_PW7]HGPI9#5/C/Y+_  3^(,Y/_#2G
M[19N-T7CSX:(BI=M\5/M4<1$SE[=)UMY'$<DD;R0PNGM7_#,GPQ_Z"OQL_\
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M'_#,GPQ_Z"OQL_\ $F_VD_\ Y[- 'T%17S[_ ,,R?#'_ *"OQL_\2;_:3_\
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M_'KXB>,M*TC]GWX(1^.OV9?B]^SSX^^/OPS^+'QRO?&7[1O@;X@?LE:O\ _
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MGHE]-I.KZC=7_P"D?[-/[8?[-'[8>C^./$'[-/Q>\+?%S1_AQXTN? 'C*_\
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M-OQ.4_=;6+92 ,GYM"TL<#V]1@^^,U^B^&#MG6-?18"+?HL;AV_P3/EN+/\
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M\2>%_'_@70='\1OJ/BSX6^%Y;/7?%<EK9SO<^(O%&FV(UJY%JUL+1&%A%:W
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M %%%% !1110!\O\ [;7_ "9Y^U%_V0/XK_\ J%:S7U!7R_\ MM?\F>?M1?\
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MOC9X6\&^+8--^(_B_0M8\8Q_#FQ\-6GA#P'87MEI^CS7E]?:W(/ _AU^Q_\
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M;].FGL9H(_V.?@/X(T_3O@0T$=G<W,MJT.L^._B;IQ@O6CNGL]/L;N2&/[4
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MWTU>F_\ #O+]E'_HGM[_ .%=XK_^6]>G_P 1EX8_Z <\Z_\ ,-@^O_<\<?\
MJ/FW_/[ ?^#:W_RA?\ _G#L<[U'3U ]-[9'OQD #GN.:[2QX49Z%8\ ^F$S^
M(Z]/?!YQ_09'_P $]_V58CE/A]>@CGGQ;XJ/?/?5C^73'%7H_P!@C]F"+[G@
M.] ]/^$K\3GT'?5?0"LJOC#PS.-HX/.UI;7"X/NW?3'>:Z>7II3X*S6#NZN
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MO39%Z?\ +]>'ICUF)[?Y%>95S_!5-J>)5]=806OHJOZG:LNKI)<U+9+XI?\
MR)X[X5TF?6=0@L83L#+YD\N"1# FXN[8[M\J1C&&=U!P"2/IFTM8+*WAM;>,
M1PP($1!G@=22222S-EF))+,2223FLW1M TO0DFCTVU%NL[*TK&225W**%0;Y
M69PJY8A<X#%FZL:VJ^>Q^+^MU4XJ4:4/@C*R;;2YI22;2?V4KNR3U]X].A1]
ME'WK.;5FUJDDW9)NS\WIOY)'GN@?\E#^(?\ V#_!'_I)KE>A5Y[H'_)0_B'_
M -@_P1_Z2:Y7H5<)N%%%% !1110 4444 ?+_ .VU_P F>?M1?]D#^*__ *A6
MLU]05\O_ +;7_)GG[47_ &0/XK_^H5K-?4% !1110 4444 %%%% 'ANH?\G*
M^$?^R&_$3_U/OA=7XX?\%0O^";WQ0_;7^-'QB\7>"8-:L-9\'?LD?LXWGP77
M7O&'BBS_ &?OC+\5_A#^U!\5/C+K_P"S_P#M _##0_%&E>'?BEX"\<Z)8>$=
M U!/'FA:W9>"E\6IXI\-;=2MM1M+S]C]0_Y.5\(_]D-^(G_J??"ZO<J /YJ?
M%?PW_:G_ &@_BSX5^%$?[&_QE^&>G_$?]O[X)_\ !0F__:2\<7'PWM_"OP.\
M!Z7^RGX'T?Q3X/GEM?$UUX@O/CIX8\?^'M7_ &9Y/"VG>&I+2_\ !.K7'CBU
MU;5O"33&\[C]G;P9^TAXI^$__!,[]G7QG^Q7\6_A/??L _&']EW0/BE\0?&T
MOPVN/!'C(_"S]G3]I7X5>(/%GPOGT/QAKNK^(O &B:RW@7Q)I?BJ\L].=YOB
M;IFGV>FQZOHVO_9?Z'J* /Y6?CU^R9\?/"MIX?OM6^ _[=7C+X8>.-,_X*2_
M"?QQX&_8<^(/P>\'>.K>P^-'[9/Q$^+_ (!3QUHWQ#N8[;6?AS\;O _BAHO[
M;T;5;:3P5=Q6EYXELA%JGG:=^AG[??P7U:[_ &2_V1=+\$?"/]M/3_'OP+\0
M^ M7^&/C+]CGQ/\ "CQ#^TG^RUXKT;X'^+OA];>(=0T?XCZA9^ /C/X7O= \
M0ZY\'OBKX<,=[9>)M \9:K>VRV$)BUK3/V:HH _C6\4>!?VX_P!IS3OC+^QI
M\5O@G\0_%'[7G[3G[/G_  1)_P"&E?CCX?L_A;I'PT^ /B7X6_%7QQ\4_C#X
MW^+EQIGBO2;#2_%FF>'_  KJWB#2?"OPNT'7_#VO^/Y;_0?!8M+)-/M[CJ/%
MO[$/[9FO_LY_$3]CN/\ 9V^*#>*OV7_A)_P7?UFQ^--_/X*?X??M27G[>FF?
M'YOV;? GPDU:U\6W.L:IXE\?CX^Z=XA\;Z=XDTC0+;P#XA^%CZ/XBU"*_P!4
MT>.7^M32_ G@S1/%WBSQ]I'AC1M-\:^.['PSIGC+Q1:6,$.M^)M/\%QZO#X3
ML]9OT43WUOX>BU[6DTF*=F6R35+T1!?/D!ZV@#^=K]K']FKXCKH>E^($^$/[
M8D&H>&?AY_P3L@^'_P 1?V'[OX6#X[_!3XJ_!KP7^VGH_B;QKH?A+XD7K>$?
M'_A[PS9?$3P[\+OB)X'N[*[75O"/Q:EN=+PFCW.HZ5\3V_[,7_!3GQGX(^+'
M@_\ :>^ 7BWQO^T+_P %+?V8O^"</@CQ9\9_!D/PH@^''[,_Q7_9F^-7Q.OO
MBOJOQBM_#/BFWL/!]_X9\">+="^/>AS?#[1=:\+^*/BI=:_X*\'6\6H0Q1P_
MU^T4 ?S%>,OV/?VF/"O[)_PAUK2_A%^T!)XJ^$O_  5X_;A_:9^(7A?]G#Q=
M\./ W[2>J_!7XU?&/]L;P[X7^+GPVU3Q<]]X<\0^((O!7Q<\!>,/^$4GF3Q'
MXG\#27GAJRDTK4/)ET_R3X[?"#]IGP7^RG^T)\/_ ((?\$__ -LOXK:G^W?_
M ,$^OC9\!O"\WQ'\;?!'7/C+\'/BGXK_ &C_ -LSXF^/M;_:0UX>,=#T;1D^
M,&F?M4Z?\6--TKPFNJE+CP9:?"S[(?$D5NUI_6A10!X%\'O'7Q&U[Q?\7/ '
MC#X-Z[\/O"OPFO?AIX?^'7Q&U/7-+U+2_C;IVO\ PI\)^*_%.O:!I5DHOO#]
MOX&\8ZMK/PYU&VU62674-4\.76IV;BRN857WVBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *\C^&G_'MH'_8AZ3_Z==3KURO(
M_AI_Q[:!_P!B'I/_ *==3H Y[Q1X^;P1\1-05? OQ$\8G4-"M6+^!O#D.N06
M'V9[5?+U*674[#[+-<^=NM(E27SHX+ERR>4 [?\ A?<O_1$/C_\ ^$!9_P#S
M15Z%IW_)0_$/_8$TS_T)*[V@#P#_ (7W+_T1#X__ /A 6?\ \T5'_"^Y?^B(
M?'__ ,("S_\ FBKW^B@#P#_A?<O_ $1#X_\ _A 6?_S14?\ "^Y?^B(?'_\
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M2%N7@614%Q 9);KXV?#.Q^.&@_LXW7B5(_C)XG^%7B[XVZ)X/^P:F\MW\,O
MOB[P3X$\4>)#JB6;:-!'IOBKXB>$=+%A<:A%J=VVJFXL[.XM+*^GM@#EO^%]
MR_\ 1$/C_P#^$!9__-%1_P +[E_Z(A\?_P#P@+/_ .:*O?Z* / /^%]R_P#1
M$/C_ /\ A 6?_P T5'_"^Y?^B(?'_P#\("S_ /FBKW^J6I:A9Z3IU_JNH3"W
ML-,LKK4+ZX9798+.R@DN;F8K&K.PBAC=RJ*SD+A5)(! /#?^%]R_]$0^/_\
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M65@""I[@@@@]QS0!X%_PON7_ *(A\?\ _P ("S_^:*C_ (7W+_T1#X__ /A
M6?\ \T5>_P!% 'Q+\1/CC)-XX^ 4W_"E_CU$;7XG>(I DG@&S!G+_!/XM0^5
M$?\ A(N90)3*$(PT44S;@4 ;UO\ X7W+_P!$0^/_ /X0%G_\T5;/Q+_Y'_\
M9X_[*EXE_P#5&?%ZM_6/B[\+_#NI7FD:[\0?"&D:G82"*]T[4=>T^TO+25HT
MF6.>":9)(W:*1)%5E!*.K#((-:4J-:NW&A0K5Y)<SC0I5*TE&]N9QI4ZLDKM
M*[25]+WT(G4ITTG4G"FF[)SG"";WLG.4$W;6R;=M=M3A_P#A?<O_ $1#X_\
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M7KEV/7YX)#6-P;VQ>%?IB<._RKF?_P +[E_Z(A\?_P#P@+/_ .:*C_A?<O\
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M>TI_\_(:_P!^'_R1Y)_PON7_ *(A\?\ _P ("S_^:*C_ (7W+_T1#X__ /A
M6?\ \T5>XV6HV.I1R2V%[;7D4;['DMIDF5'P'VL4)"_*00#U7D<5>^M9M--Q
MDG%IV:>C3M>S32:?R7?JBDT]4TT]K:W^X^1M%^.DL?CSQY-_PI3X^MY^G^#/
MD'@"TW)LMM:'/_%1'=G/8 A@5(Z$]U_PON7_ *(A\?\ _P ("S_^:*N]T#_D
MH?Q#_P"P?X(_])-<KT*@9X!_PON7_HB'Q_\ _" L_P#YHJ/^%]R_]$0^/_\
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MHH \ _X7W+_T1#X__P#A 6?_ ,T5'_"^Y?\ HB'Q_P#_  @+/_YHJ]_HH \
M_P"%]R_]$0^/_P#X0%G_ /-%1_PON7_HB'Q__P#" L__ )HJ]_HH \ _X7W+
M_P!$0^/_ /X0%G_\T5'_  ON7_HB'Q__ /" L_\ YHJ]_HH \ _X7W+_ -$0
M^/\ _P"$!9__ #14?\+[E_Z(A\?_ /P@+/\ ^:*O?Z* / /^%]R_]$0^/_\
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M2Z1X/U/P9J=OXCUJ*>?2=.6?3;C^T(;,"2[EMKVVOYM.*6Z /<;KM/)4@RA
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MJZM=*^(<WA+PIJ'Q'N?%=[#J\NK@']E->=?"?XL?#_XX> M$^)WPN\0Q>*O
MWB.76X-&UV"SU"QBO9?#OB#5/"^LJMKJEI8WT7V/7=%U.P8SVT8E:U:6$R0/
M%*_\\VH_$_XTZ_\ ME?M-_&.;]J[XV:+=?!?]NG_ ()7?!;X/?LPZ5X_TG2_
M@=XE\(?M2_!C]D:;X[^%M5^'=SIK7OBF[\2:)\7/B;XZTF^O]6D;P7K/@F/Q
M;HHM(+'Q8NJ?G9\*/C'^W'KFO?#KX#?LTZAXM_L'X*?LGZ?\??!6E:'^U7\*
M_P!FCPKH?C3X@_MY_M?:!XL^.'Q5\.^-]%N]8_:$^%^A6?PT\+_#O7?ATVHP
M>$=&MM2UA=02U\3>-_#>J:> ?VM:+X@T#Q'!>77A[7-(UZUT[5]8\/ZA<Z+J
M5EJD%CK_ (>U*YT?Q!H=Y-8SSQVVKZ'J]G=Z5K&FSLE[IFI6MS8WL$%U!+$O
M'?&+XN_#SX!?"OXA?&SXM>(H?"/PQ^%?A'7/'7CSQ1<6>HZA!H'A7PY83:EK
M.JRV.D6E_JEVEE902SM!865U=2!-L,$CD*?YCO$=W\7?A'\,/%FA_LX^(OCO
M\4=?_:I_X+0?M>_"#XE?#S3/VN-,^!]QX;T?PM\1_P!L?XI:?X0^%GQ0\76=
MW8_ [5OB1JVC^&#XC&D@>*_B+8VFF^'=(OX+W5;.>OBO]I3QU^UU\8/V)_VQ
M_@C^W%^T9XR\)>)OV4O^"4OQ.^*\7AKX8_'7P5?:/\;OB!XT_:H_:W^#FCGX
MS_$#X;6D'AWXU7GPZ^&'P8^$'PD\=>$O.729OBEXP\;7&NZ'9>.-2L!I0!_<
M;17Y(_\ !7+XE_'#P=X*_9,^'WP/TSQMJVH?'S]K/3_A=XNTGX=_M ^%/V7?
M&7BSPYIOP ^/WQ3T[P!X?^.7BO3M3A\#7WB_QE\./"\5S)H\-OXC\2Z'I^L^
M!O#VI:7K?BK3]0M_Q;^-'B[_ (* >&/V8?BOXU^*W[8OQZ^'OQS_ &,?^"5W
MB+]I2PT+X6_&#X;>*_"WBSXR^#?VH?VF]-\"ZS\:?%/@KPG+X5^+^K6/PQ^&
M?@GP3\1M-TR/1_"OB?5O^$B?7M"_M6"U730#^Q*OF7]H/]L7]G']EB>RMOCS
M\2;3P#-J'PL^,_QJLUNM#\3:L)OAI^SY!X(N?B[XEWZ!HVJI''X0@^(W@Z2:
MPE9-4U-=87^QK+4#9WXMOY[/C-\5OVI+:^_:&^+-M^UA^T/I'AWXD_\ !7+]
MF+_@G;+X;T/Q1X?T3X9_LR_LV?'"Z_96'Q+^(W@C=X6NM7T;XH7]]XVUSPCX
M9^(FO>(+K3? 1\>6UQH&CZ;K%N=:G^#/^"@/C+QMK7AOXK_#SQ=XV\5?$O2/
MV=OV;?\ @XS_ &?OAK\0_'>L3^)O&OB;X;^!K/\ X)_7^C6OBKQ7='[=XLUS
MP!JWB+7OA;=^(]4,FLZF? :3:Y=:AK(O]1NP#^YV.1)8TEC.Z.1%D1L$;D=0
MRG! (R"#@@'U&:?7\SWQ?\._'OQ]\?KSQ%I'[;W[7/POLO'?_!6V;]BFY\&?
M#OXA:'IW@3PQ^S=-^RW<^/=>\(^"/"^K>$]8L?#WB_7_ !9X=M-3B^*3"^\=
M^$OM-['X(U7PY]HFDD^6/BG\5O\ @H?XN^'WPD_9T^ WQ#^.'Q)\?^ O@O\
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MBRPS1L.&CEC971AU5@>]3U_-/\5/CQ\??"W[2>B_&W2/V@_BEI?B:7_@J_\
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MKOA&T>[N=.UBVT34[3\<?BU^W^O[,G["/@K5O^":/P^^,W[+7B'X<6W_  4
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M*<M=$E'K*5U:*OOW?:-WZ^C1@YN*CMNWT23NW_EW=D+X5,O_  G/CHW'$_\
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M+_P2EUSX!:Y^Q7X"3]G7]GW3/V4_"GAKQA\6O ?CC]G/2+R/5K'X/_'#X?\
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M9?\ VG_^$6_X:-_9[^#?QT/@B\N+WPD?BO\ #GPIX[;0)+TV[:C!IS>(]+U
MPZ=JS6=D=9TC)TK638V)U2SN_L5KY7T'10!\OZ#^Q)^QUX7\=_$OXG^'?V6?
MV?-&^(GQET?Q%X>^*_C.P^$/@.#Q!\1-!\92)-XVT7Q=J*:&)];TGQQ/%!<>
M-]/OFEM/&-U;6EUXEBU2XM+:2+S:[_X)A_\ !.C4/"7A#P%J/[#G[*^I^"/
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M,^.O[,WP!_8]_;#TKQ=^U3^P=\??B?\ L_Z;\6?V2O#?['7[<7P-^-/C6_\
M#/[%OPY\/VWP@^#GPI^"WQ8\!3?%OPAXF\+>#_ WQEL_$GC+QEX[BL/B79?$
MGP]\48(_%]KXDU2UGT*W_>7P+^PC\(OA_P# 7X*?L^Z7XH^*^L>'O@G\7/!_
MQUM?&_B_QE;>+/BC\2/BGX7^)-S\6]4\7_%;QCK>AW;>*-4^('CV_P!3USQU
M<V.GZ'->-J5U;:#)X=M8[.*T\0^)7_!*CX5?%?\ :)O_ (Y^*?VC_P!M+_A
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MM;N+S6/$GBSQ=XFU;5O$OB?7M3NI;K5-;U2]NW\M9%B3VZBB@ HHHH ****
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M  GWPM_Z+E^T#_X27C+_ .=)1_PGWPM_Z+E^T#_X27C+_P"=)7VC10!\7?\
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MJ>"8I_$4?V72-& TNW_X2GPCH5ZFD6L3QRVZ6UBUB;JZO9$N);E[K;]&T@Y
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M /B[_A/OA;_T7+]H'_PDO&7_ ,Z2C_A/OA;_ -%R_:!_\)+QE_\ .DK[1HH
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M )TE'_"??"W_ *+E^T#_ .$EXR_^=)7VC10!\7?\)]\+?^BY?M _^$EXR_\
MG24?\)]\+?\ HN7[0/\ X27C+_YTE?:-% 'Q=_PGWPM_Z+E^T#_X27C+_P"=
M)1_PGWPM_P"BY?M _P#A)>,O_G25]HT4 ?%,WC3X5WZKI[?&;XZZBFH216+Z
M?J/A'QC_ &??I=RI;O8WV[X3QI]CO%D-M="2:"+R))#)/"@:1?2O%VA6.A?&
M;X'3>'_#UEIUO#X;^).@SW&D:/!:16FC(/!ES8Z1)/96T:6NFBZC>XM-/:2.
;U^T0M-% TD1*_1E)USGL?Z#KZ]3U_H* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lixt-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGHmbP9z5Z8KekhvWB7bUmqnyQmsU6jfy2H3o8mYS0D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:LIXT="http://lixte.com/20250930" elementFormDefault="qualified" targetNamespace="http://lixte.com/20250930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
          <link:definition>999012 - Disclosure - Organization and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999013 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999014 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/DigitalAssets" id="DigitalAssets">
          <link:definition>999015 - Disclosure - Digital Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999016 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999017 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999018 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999019 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999020 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999021 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999024 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/DigitalAssetsTables" id="DigitalAssetsTables">
          <link:definition>999025 - Disclosure - Digital Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999026 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999027 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999028 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999029 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
          <link:definition>999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" id="ScheduleOfInformationBySegmentDetails">
          <link:definition>999034 - Disclosure - Schedule of Information by Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" id="ScheduleOfDigitalAssetsDetails">
          <link:definition>999035 - Disclosure - Schedule of Digital Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/DigitalAssetsDetailsNarrative" id="DigitalAssetsDetailsNarrative">
          <link:definition>999036 - Disclosure - Digital Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>999037 - Disclosure - Schedule of Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999039 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" id="ScheduleOfRelatedPartyCostsDetails">
          <link:definition>999040 - Disclosure - Schedule of Related Party Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999041 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" id="ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails">
          <link:definition>999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" id="ScheduleOfStock-basedCompensationCostsDetails">
          <link:definition>999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails">
          <link:definition>999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails">
          <link:definition>999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999046 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" id="ScheduleOfContractualClinicalTrialsDetails">
          <link:definition>999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999048 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999049 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantOneMember" name="VendorAndConsultantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantTwoMember" name="VendorAndConsultantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantThreeMember" name="VendorAndConsultantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OtherVendorAndConsultantMember" name="OtherVendorAndConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GeneralAndAdministrativeMember" name="GeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DirectorsAndCorporateOfficersMember" name="DirectorsAndCorporateOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantFourMember" name="VendorAndConsultantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantFiveMember" name="VendorAndConsultantFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OneVendorAndConsultantMember" name="OneVendorAndConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoVendorAndConsultantMember" name="TwoVendorAndConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalAndRelatedOversightCostsMember" name="ClinicalAndRelatedOversightCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PreclinicalResearchMember" name="PreclinicalResearchMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CompoundMaintenanceMember" name="CompoundMaintenanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RegulatoryServiceCostsMember" name="RegulatoryServiceCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BitcoinMember" name="BitcoinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EthereumMember" name="EthereumMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" name="JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" name="FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentAgreementMember" name="PlacementAgentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsWarrantsMember" name="PlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MarketAwarenessAgreementMember" name="MarketAwarenessAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrKovachMember" name="DrKovachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesSMiserMember" name="DrJamesSMiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EricJFormanMember" name="EricJFormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RobertNWeingartenMember" name="RobertNWeingartenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BasvanderBaanMember" name="BasvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SchellensMember" name="SchellensMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrPursgloveMember" name="MrPursgloveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PeterStazzoneMember" name="PeterStazzoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfAuditCommitteeMember" name="ChairmanOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfOtherCommitteesMember" name="ChairmanOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfAuditCommitteeMember" name="MemberOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfOtherCommitteesMember" name="MemberOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NewIndependentDirectorMember" name="NewIndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AppointmentGrantsOfOptionsMember" name="AppointmentGrantsOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualGrantOfOptionsMember" name="AnnualGrantOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IndependentDirectorMember" name="IndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsOneMember" name="FiveNonOfficerDirectorsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourOfficersMember" name="FourOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficerDirectorsMember" name="FourNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrvanderBaanMember" name="MrvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficerDirectorMember" name="FourNonOfficerDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_JasonSawyerMember" name="JasonSawyerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrMichaelHollowayMember" name="DrMichaelHollowayMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LourdesFelixAndGuyPrimusMember" name="LourdesFelixAndGuyPrimusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFifteenMember" name="ExercisePriceFifteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixteenMember" name="ExercisePriceSixteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSeventeenMember" name="ExercisePriceSeventeenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEighteenMember" name="ExercisePriceEighteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsMember" name="ClinicalTrialAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalResearchSupportAgreementMember" name="ClinicalResearchSupportAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CityOfHopeNationalMedicalCenterMember" name="CityOfHopeNationalMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" name="GrupoEspanolDeInvestigacionEnSarcomasMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DevelopmentCollaborationAgreementMember" name="DevelopmentCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchMonitoringMember" name="ClinicalTrialResearchMonitoringMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MDAndersonCancerCenterClinicalMember" name="MDAndersonCancerCenterClinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementMember" name="WorkOrderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TheradexSystemsIncMember" name="TheradexSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DueEachJanuaryOneMember" name="DueEachJanuaryOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NDAConsultingCorpMember" name="NDAConsultingCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BioPharmaWorksLLCMember" name="BioPharmaWorksLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NetherlandsCancerInstituteMember" name="NetherlandsCancerInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MRIGlobalMember" name="MRIGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhaseMD1b2Member" name="ClinicalTrialPhaseMD1b2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bMember" name="ClinicalTrialPhase1bMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bTwoMember" name="ClinicalTrialPhase1bTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SGNMediaIncMember" name="SGNMediaIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LMCCommunicationsIncMember" name="LMCCommunicationsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvancesOnResearchAndDevelopmentContractServices" name="AdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" name="ResearchAndDevelopmentContractLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" name="SeriesBConvertiblePreferredStockCumulativeDividendPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" name="SeriesBConvertiblePreferredStockCumulativeDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" name="StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" name="StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" name="StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" name="StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" name="StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" name="StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" name="ShareBasedCompensationIncludedInResearchAndDevelopmentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" name="ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockIssuedForServices" name="CommonStockIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" name="ExerciseOfPlacementAgentWarrantsOnCashlessBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExerciseOfPrefundedWarrants" name="ExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" name="ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" name="AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AccrualOfDeferredOfferingCosts" name="AccrualOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PrepaidInsurancePolicyTextBlock" name="PrepaidInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ForeignCurrencyExchangeRateTranslation" name="ForeignCurrencyExchangeRateTranslation" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashBasedCompensationToRelatedParties" name="CashBasedCompensationToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockBasedCompensationToRelatedParties" name="StockBasedCompensationToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LegalFeesRelatingToPatentsAndLicensing" name="LegalFeesRelatingToPatentsAndLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OtherConsultingAndProfessionalFees" name="OtherConsultingAndProfessionalFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CryptoAssetsNumberOfUnits" name="CryptoAssetsNumberOfUnits" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DigitalAssetHoldingsPercentage" name="DigitalAssetHoldingsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" name="NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" name="AnnualNetRevenueDividedByConvertedOrRedeemedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DescriptionOfOfferingPrice" name="DescriptionOfOfferingPrice" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FairValueOfStockOptions" name="FairValueOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialDescription" name="ClinicalTrialDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodStartDate" name="ContractualClinicalTrialPeriodStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodEndDate" name="ContractualClinicalTrialPeriodEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfPatientInTrial" name="NumberOfPatientInTrial" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedDateOfPreliminaryEfficacySignal" name="ExpectedDateOfPreliminaryEfficacySignal" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AmountRelatedToMilestonePayment" name="AmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementCosts" name="WorkOrderAgreementCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EstimatedWorkCost" name="EstimatedWorkCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentinServices" name="ExpectedPaymentinServices" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentThroughSoftware" name="ExpectedPaymentThroughSoftware" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyaltyPayable" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyatiesPercentage" name="RoyatiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultingAndAdvisoryCashFee" name="ConsultingAndAdvisoryCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ReimbursementExpense" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvanceAmountRelatedToMilestonePayment" name="AdvanceAmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WellingtonPeelLLCMember" name="WellingtonPeelLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>lixt-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Cover" roleURI="http://lixte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheets" roleURI="http://lixte.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://lixte.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfOperations" roleURI="http://lixte.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfStockholdersEquity" roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfCashFlows" roleURI="http://lixte.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentation" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformation" roleURI="http://lixte.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssets" roleURI="http://lixte.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquity" roleURI="http://lixte.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactions" roleURI="http://lixte.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensation" roleURI="http://lixte.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#IncomeTaxes" roleURI="http://lixte.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingencies" roleURI="http://lixte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEvents" roleURI="http://lixte.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformationTables" roleURI="http://lixte.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsTables" roleURI="http://lixte.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityTables" roleURI="http://lixte.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsTables" roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationTables" roleURI="http://lixte.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfInformationBySegmentDetails" roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfDigitalAssetsDetails" roleURI="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsDetailsNarrative" roleURI="http://lixte.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfRelatedPartyCostsDetails" roleURI="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStock-basedCompensationCostsDetails" roleURI="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfContractualClinicalTrialsDetails" roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="loc_us-gaapCryptoAssetFairValueCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCryptoAssetFairValueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividend" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividend" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockIssuedForServices" xlink:label="loc_LIXTCommonStockIssuedForServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTCommonStockIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="loc_us-gaapPaymentForAcquisitionCryptoAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentForAcquisitionCryptoAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999012 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999014 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssets" xlink:title="999015 - Disclosure - Digital Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999016 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999019 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsTables" xlink:title="999025 - Disclosure - Digital Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" xlink:title="999035 - Disclosure - Schedule of Digital Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsDetailsNarrative" xlink:title="999036 - Disclosure - Digital Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" xlink:title="999040 - Disclosure - Schedule of Related Party Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999041 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" xlink:title="999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999046 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999048 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>lixt-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Cover" roleURI="http://lixte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheets" roleURI="http://lixte.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://lixte.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfOperations" roleURI="http://lixte.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfStockholdersEquity" roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfCashFlows" roleURI="http://lixte.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentation" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformation" roleURI="http://lixte.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssets" roleURI="http://lixte.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquity" roleURI="http://lixte.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactions" roleURI="http://lixte.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensation" roleURI="http://lixte.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#IncomeTaxes" roleURI="http://lixte.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingencies" roleURI="http://lixte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEvents" roleURI="http://lixte.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformationTables" roleURI="http://lixte.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsTables" roleURI="http://lixte.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityTables" roleURI="http://lixte.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsTables" roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationTables" roleURI="http://lixte.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfInformationBySegmentDetails" roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfDigitalAssetsDetails" roleURI="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsDetailsNarrative" roleURI="http://lixte.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfRelatedPartyCostsDetails" roleURI="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStock-basedCompensationCostsDetails" roleURI="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfContractualClinicalTrialsDetails" roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidInsurance_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="loc_us-gaapCryptoAssetFairValueCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCryptoAssetFairValueCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_90" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:label="loc_LIXTStockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_70" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999012 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999014 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssets" xlink:title="999015 - Disclosure - Digital Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999016 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999019 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsTables" xlink:title="999025 - Disclosure - Digital Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="loc_us-gaapCryptoAssetFairValueCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCryptoAssetFairValueCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_80" xlink:type="arc" order="84" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="loc_LIXTGeneralAndAdministrativeMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTGeneralAndAdministrativeMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfSalesMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherVendorAndConsultantMember" xlink:label="loc_LIXTOtherVendorAndConsultantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTOtherVendorAndConsultantMember_140" xlink:type="arc" order="144" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorMember" xlink:label="loc_LIXTVendorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFiveMember" xlink:label="loc_LIXTVendorAndConsultantFiveMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFiveMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OneVendorAndConsultantMember" xlink:label="loc_LIXTOneVendorAndConsultantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTOneVendorAndConsultantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoVendorAndConsultantMember" xlink:label="loc_LIXTTwoVendorAndConsultantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTTwoVendorAndConsultantMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_380" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_380" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount_380" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees_380" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_380" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_380" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_380" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="loc_LIXTForeignCurrencyExchangeRateTranslation_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTForeignCurrencyExchangeRateTranslation_380" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_380" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_380" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="loc_LIXTClinicalAndRelatedOversightCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTClinicalAndRelatedOversightCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreclinicalResearchMember" xlink:label="loc_LIXTPreclinicalResearchMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTPreclinicalResearchMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CompoundMaintenanceMember" xlink:label="loc_LIXTCompoundMaintenanceMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTCompoundMaintenanceMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="loc_LIXTRegulatoryServiceCostsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTRegulatoryServiceCostsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_ES" xlink:label="loc_countryES_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN" xlink:label="loc_countryCN_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="loc_countryNL_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="loc_LIXTResearchAndDevelopmentMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_LIXTResearchAndDevelopmentMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_430" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties_430" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties_430" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing_430" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees_430" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense_430" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_430" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_430" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapAssets_430" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" xlink:title="999035 - Disclosure - Schedule of Digital Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetHoldingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BitcoinMember" xlink:label="loc_LIXTBitcoinMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTBitcoinMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EthereumMember" xlink:label="loc_LIXTEthereumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTEthereumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CryptoAssetsNumberOfUnits" xlink:label="loc_LIXTCryptoAssetsNumberOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_LIXTCryptoAssetsNumberOfUnits_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetCost" xlink:label="loc_us-gaapCryptoAssetCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetCost_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsDetailsNarrative" xlink:title="999036 - Disclosure - Digital Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetHoldingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BitcoinMember" xlink:label="loc_LIXTBitcoinMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTBitcoinMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EthereumMember" xlink:label="loc_LIXTEthereumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTEthereumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DigitalAssetHoldingsPercentage" xlink:label="loc_LIXTDigitalAssetHoldingsPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_LIXTDigitalAssetHoldingsPercentage_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_600" xlink:type="arc" order="601" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:label="loc_LIXTJulyTwentyTwoThousandTwentyThreeEquityOfferingMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LIXTJulyTwentyTwoThousandTwentyThreeEquityOfferingMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:label="loc_LIXTFebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LIXTFebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPreFundedWarrantsMember_280" xlink:type="arc" order="283" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsWarrantsMember" xlink:label="loc_LIXTPlacementAgentsWarrantsMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsWarrantsMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentAgreementMember" xlink:label="loc_LIXTPlacementAgentAgreementMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTPlacementAgentAgreementMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MarketAwarenessAgreementMember" xlink:label="loc_LIXTMarketAwarenessAgreementMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMarketAwarenessAgreementMember_530" xlink:type="arc" order="532" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_620" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_620" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_620" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_620" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_620" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis_620" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_620" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_620" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_620" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_620" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_620" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_620" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_620" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_620" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_620" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_620" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_620" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_620" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_620" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_620" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_620" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_620" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_620" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_620" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_620" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_620" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DescriptionOfOfferingPrice" xlink:label="loc_LIXTDescriptionOfOfferingPrice_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTDescriptionOfOfferingPrice_620" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_620" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_620" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees_620" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_620" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_620" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_620" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_620" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_620" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_620" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_620" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_620" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_620" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_620" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" xlink:title="999040 - Disclosure - Schedule of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999041 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrPursgloveMember" xlink:label="loc_LIXTMrPursgloveMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrPursgloveMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PeterStazzoneMember" xlink:label="loc_LIXTPeterStazzoneMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPeterStazzoneMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTSchellensMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_480" xlink:type="arc" order="482" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember_440" xlink:type="arc" order="442" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_540" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_540" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_540" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_540" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_540" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash_540" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_540" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_540" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable_540" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_540" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" xlink:title="999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixteenMember" xlink:label="loc_LIXTExercisePriceSixteenMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixteenMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSeventeenMember" xlink:label="loc_LIXTExercisePriceSeventeenMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSeventeenMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEighteenMember" xlink:label="loc_LIXTExercisePriceEighteenMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEighteenMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_380" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_380" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_380" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999046 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="loc_LIXTFourNonOfficerDirectorMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrPursgloveMember" xlink:label="loc_LIXTMrPursgloveMember_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrPursgloveMember_690" xlink:type="arc" order="691" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JasonSawyerMember" xlink:label="loc_LIXTJasonSawyerMember_760" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTJasonSawyerMember_760" xlink:type="arc" order="761" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrMichaelHollowayMember" xlink:label="loc_LIXTDrMichaelHollowayMember_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrMichaelHollowayMember_810" xlink:type="arc" order="811" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PeterStazzoneMember" xlink:label="loc_LIXTPeterStazzoneMember_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPeterStazzoneMember_860" xlink:type="arc" order="861" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LourdesFelixAndGuyPrimusMember" xlink:label="loc_LIXTLourdesFelixAndGuyPrimusMember_920" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTLourdesFelixAndGuyPrimusMember_920" xlink:type="arc" order="921" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrvanderBaanMember" xlink:label="loc_LIXTMrvanderBaanMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrvanderBaanMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_290" xlink:type="arc" order="292" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSchellensMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_640" xlink:type="arc" order="642" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_730" xlink:type="arc" order="732" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_970" xlink:type="arc" order="972" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_1010" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1010" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1010" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1010" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_1010" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1010" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1010" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1010" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions_1010" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_1010" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_1010" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_1010" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1010" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1010" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1010" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1010" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1010" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_1010" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1010" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1010" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1010" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="loc_LIXTClinicalTrialPhaseMD1b2Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseMD1b2Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="loc_LIXTExpectedDateOfPreliminaryEfficacySignal_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTExpectedDateOfPreliminaryEfficacySignal_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999048 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="loc_LIXTClinicalTrialResearchMonitoringMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchMonitoringMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLicensingAgreementsMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="loc_LIXTMDAndersonCancerCenterClinicalMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMDAndersonCancerCenterClinicalMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_520" xlink:type="arc" order="522" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_640" xlink:type="arc" order="642" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_410" xlink:type="arc" order="412" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation_710" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_710" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts_710" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_710" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment_710" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_710" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment_710" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="loc_LIXTWorkOrderAgreementCosts_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTWorkOrderAgreementCosts_710" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost_710" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices_710" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware_710" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_710" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyaltyPayable_710" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="loc_us-gaapHealthCareOrganizationHealthCareCostsGross_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapHealthCareOrganizationHealthCareCostsGross_710" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_710" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyatiesPercentage_710" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_710" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee_710" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense_710" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment_710" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SGNMediaIncMember" xlink:label="loc_LIXTSGNMediaIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSGNMediaIncMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LMCCommunicationsIncMember" xlink:label="loc_LIXTLMCCommunicationsIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLMCCommunicationsIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeeDescription" xlink:label="loc_us-gaapManagementFeeDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapManagementFeeDescription_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>lixt-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="LIXT_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockMember" xlink:to="LIXT_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="LIXT_VendorAndConsultantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantOneMember_lbl" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="LIXT_VendorAndConsultantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantTwoMember_lbl" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="LIXT_VendorAndConsultantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantThreeMember_lbl" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherVendorAndConsultantMember" xlink:label="LIXT_OtherVendorAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherVendorAndConsultantMember" xlink:to="LIXT_OtherVendorAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OtherVendorAndConsultantMember_lbl" xml:lang="en-US">Other Vendor and Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorMember" xlink:label="LIXT_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorMember" xlink:to="LIXT_VendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="LIXT_GeneralAndAdministrativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeMember" xlink:to="LIXT_GeneralAndAdministrativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GeneralAndAdministrativeMember_lbl" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="LIXT_DirectorsAndCorporateOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_lbl" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="LIXT_VendorAndConsultantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantFourMember_lbl" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFiveMember" xlink:label="LIXT_VendorAndConsultantFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFiveMember" xlink:to="LIXT_VendorAndConsultantFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantFiveMember_lbl" xml:lang="en-US">Vendor and Consultant Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OneVendorAndConsultantMember" xlink:label="LIXT_OneVendorAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OneVendorAndConsultantMember" xlink:to="LIXT_OneVendorAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OneVendorAndConsultantMember_lbl" xml:lang="en-US">One Vendor and Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoVendorAndConsultantMember" xlink:label="LIXT_TwoVendorAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoVendorAndConsultantMember" xlink:to="LIXT_TwoVendorAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoVendorAndConsultantMember_lbl" xml:lang="en-US">Two Vendor And Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="LIXT_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockOptionsMember" xlink:label="LIXT_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalAndRelatedOversightCostsMember" xlink:to="LIXT_ClinicalAndRelatedOversightCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember_lbl" xml:lang="en-US">Clinical and Related Oversight Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreclinicalResearchMember" xlink:label="LIXT_PreclinicalResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreclinicalResearchMember" xlink:to="LIXT_PreclinicalResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PreclinicalResearchMember_lbl" xml:lang="en-US">Preclinical Research [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CompoundMaintenanceMember" xlink:label="LIXT_CompoundMaintenanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CompoundMaintenanceMember" xlink:to="LIXT_CompoundMaintenanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CompoundMaintenanceMember_lbl" xml:lang="en-US">Compound Maintenance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="LIXT_RegulatoryServiceCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RegulatoryServiceCostsMember" xlink:to="LIXT_RegulatoryServiceCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RegulatoryServiceCostsMember_lbl" xml:lang="en-US">Regulatory Service Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_ES" xlink:label="country_ES" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US">SPAIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="LIXT_ResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentMember" xlink:to="LIXT_ResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateMember" xlink:label="us-gaap_CorporateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl" xml:lang="en-US">Corporate Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="srt_CryptoAssetAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CryptoAssetAxis" xlink:to="srt_CryptoAssetAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CryptoAssetAxis_lbl" xml:lang="en-US">Crypto Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BitcoinMember" xlink:label="LIXT_BitcoinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BitcoinMember" xlink:to="LIXT_BitcoinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BitcoinMember_lbl" xml:lang="en-US">Bitcoin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EthereumMember" xlink:label="LIXT_EthereumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EthereumMember" xlink:to="LIXT_EthereumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EthereumMember_lbl" xml:lang="en-US">Ethereum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:label="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:to="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_lbl" xml:lang="en-US">July 20, 2023 Equity Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsMember" xlink:label="LIXT_PlacementAgentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:label="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:to="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_lbl" xml:lang="en-US">February 13, 2025 Equity Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="LIXT_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SecuritiesPurchaseAgreementMember" xlink:to="LIXT_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="LIXT_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreFundedWarrantsMember" xlink:to="LIXT_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PreFundedWarrantsMember_lbl" xml:lang="en-US">PreFunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentAgreementMember" xlink:label="LIXT_PlacementAgentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentAgreementMember" xlink:to="LIXT_PlacementAgentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentAgreementMember_lbl" xml:lang="en-US">Placement Agent Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsWarrantsMember" xlink:label="LIXT_PlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsWarrantsMember" xlink:to="LIXT_PlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsWarrantsMember_lbl" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MarketAwarenessAgreementMember" xlink:label="LIXT_MarketAwarenessAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MarketAwarenessAgreementMember" xlink:to="LIXT_MarketAwarenessAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MarketAwarenessAgreementMember_lbl" xml:lang="en-US">Market Awareness Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceOneMember" xlink:label="LIXT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="LIXT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="LIXT_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourMember" xlink:label="LIXT_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="LIXT_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixMember" xlink:label="LIXT_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="LIXT_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEightMember" xlink:label="LIXT_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EmploymentAgreementMember" xlink:label="LIXT_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrKovachMember" xlink:label="LIXT_DrKovachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrKovachMember_lbl" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrJamesSMiserMember" xlink:label="LIXT_DrJamesSMiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesSMiserMember_lbl" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EricJFormanMember" xlink:label="LIXT_EricJFormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EricJFormanMember_lbl" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RobertNWeingartenMember" xlink:label="LIXT_RobertNWeingartenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RobertNWeingartenMember_lbl" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="LIXT_BasvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BasvanderBaanMember_lbl" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SchellensMember" xlink:label="LIXT_SchellensMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SchellensMember" xlink:to="LIXT_SchellensMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SchellensMember_lbl" xml:lang="en-US">Schellens [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrPursgloveMember" xlink:label="LIXT_MrPursgloveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrPursgloveMember" xlink:to="LIXT_MrPursgloveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrPursgloveMember_lbl" xml:lang="en-US">Mr Pursglove [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PeterStazzoneMember" xlink:label="LIXT_PeterStazzoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PeterStazzoneMember" xlink:to="LIXT_PeterStazzoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PeterStazzoneMember_lbl" xml:lang="en-US">Peter Stazzone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="LIXT_ChairmanOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_lbl" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="LIXT_ChairmanOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_lbl" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="LIXT_MemberOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfAuditCommitteeMember_lbl" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="LIXT_MemberOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfOtherCommitteesMember_lbl" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="LIXT_NewIndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NewIndependentDirectorMember_lbl" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="LIXT_AppointmentGrantsOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_lbl" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="LIXT_AnnualGrantOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualGrantOfOptionsMember_lbl" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IndependentDirectorMember" xlink:label="LIXT_IndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IndependentDirectorMember_lbl" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourOfficersMember" xlink:label="LIXT_FourOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourOfficersMember_lbl" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="LIXT_FourNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficerDirectorsMember_lbl" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrvanderBaanMember" xlink:label="LIXT_MrvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrvanderBaanMember" xlink:to="LIXT_MrvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrvanderBaanMember_lbl" xml:lang="en-US">Mr van der Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="LIXT_FourNonOfficerDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorMember" xlink:to="LIXT_FourNonOfficerDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficerDirectorMember_lbl" xml:lang="en-US">Four Non Officer Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JasonSawyerMember" xlink:label="LIXT_JasonSawyerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_JasonSawyerMember" xlink:to="LIXT_JasonSawyerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_JasonSawyerMember_lbl" xml:lang="en-US">Jason Sawyer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrMichaelHollowayMember" xlink:label="LIXT_DrMichaelHollowayMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrMichaelHollowayMember" xlink:to="LIXT_DrMichaelHollowayMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrMichaelHollowayMember_lbl" xml:lang="en-US">Dr. Michael Holloway [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LourdesFelixAndGuyPrimusMember" xlink:label="LIXT_LourdesFelixAndGuyPrimusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LourdesFelixAndGuyPrimusMember" xlink:to="LIXT_LourdesFelixAndGuyPrimusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LourdesFelixAndGuyPrimusMember_lbl" xml:lang="en-US">Lourdes Felix and Guy Primus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceNineMember" xlink:label="LIXT_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTenMember" xlink:label="LIXT_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="LIXT_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="LIXT_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="LIXT_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="LIXT_ExercisePriceFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="LIXT_ExercisePriceFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixteenMember" xlink:label="LIXT_ExercisePriceSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixteenMember" xlink:to="LIXT_ExercisePriceSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixteenMember_lbl" xml:lang="en-US">Exercise Price Sixteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSeventeenMember" xlink:label="LIXT_ExercisePriceSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSeventeenMember" xlink:to="LIXT_ExercisePriceSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSeventeenMember_lbl" xml:lang="en-US">Exercise Price Seventeen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEighteenMember" xlink:label="LIXT_ExercisePriceEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEighteenMember" xlink:to="LIXT_ExercisePriceEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEighteenMember_lbl" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="LIXT_ClinicalResearchSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_lbl" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CollaborationAgreementMember" xlink:label="LIXT_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xml:lang="en-US">GEIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="LIXT_DevelopmentCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_lbl" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchMonitoringMember" xlink:to="LIXT_ClinicalTrialResearchMonitoringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember_lbl" xml:lang="en-US">Clinical Trial Research Monitoring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MDAndersonCancerCenterClinicalMember" xlink:to="LIXT_MDAndersonCancerCenterClinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember_lbl" xml:lang="en-US">MD Anderson Cancer Center Clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="LIXT_WorkOrderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementMember_lbl" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="LIXT_TheradexSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TheradexSystemsIncMember_lbl" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LicenseAgreementMember" xlink:label="LIXT_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="LIXT_DueEachJanuaryOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DueEachJanuaryOneMember_lbl" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="LIXT_NDAConsultingCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NDAConsultingCorpMember_lbl" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="LIXT_BioPharmaWorksLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BioPharmaWorksLLCMember_lbl" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="LIXT_NetherlandsCancerInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NetherlandsCancerInstituteMember_lbl" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MRIGlobalMember" xlink:label="LIXT_MRIGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MRIGlobalMember_lbl" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseMD1b2Member" xlink:to="LIXT_ClinicalTrialPhaseMD1b2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member_lbl" xml:lang="en-US">Phase 1b 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="LIXT_ClinicalTrialPhase1bMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bMember_lbl" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xml:lang="en-US">Phase 1b Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SGNMediaIncMember" xlink:label="LIXT_SGNMediaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SGNMediaIncMember" xlink:to="LIXT_SGNMediaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SGNMediaIncMember_lbl" xml:lang="en-US">SGN Media Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LMCCommunicationsIncMember" xlink:label="LIXT_LMCCommunicationsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LMCCommunicationsIncMember" xlink:to="LIXT_LMCCommunicationsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LMCCommunicationsIncMember_lbl" xml:lang="en-US">LMC Communications Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="us-gaap_CryptoAssetFairValueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValueCurrent" xlink:to="us-gaap_CryptoAssetFairValueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetFairValueCurrent_lbl" xml:lang="en-US">Digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, including $112,033 and $27,500 to related parties at September 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:to="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable_lbl" xml:lang="en-US">Series B Convertible Preferred Stock 8% cumulative dividend payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 5,704,200 and 2,249,290 shares at September 30, 2025 and December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Related parties accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, issuable upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="us-gaap_CryptoAssetUnrealizedGainLossNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:to="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_lbl" xml:lang="en-US">Unrealized gain (loss) on digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US">Realized gain (loss) on foreign currency transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" xlink:to="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend_lbl" xml:lang="en-US">Series B Convertible Preferred Stock 8% cumulative dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct equity offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:label="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:to="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_lbl" xml:lang="en-US">Exercise of placement agent warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:label="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:to="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_lbl" xml:lang="en-US">Exercise of placement agent warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xml:lang="en-US">Series B Convertible Preferred Stock 8% cumulative dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock options issued to settle accrued payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series A convertible stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series A convertible stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation expense included in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockIssuedForServices" xlink:label="LIXT_CommonStockIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockIssuedForServices" xlink:to="LIXT_CommonStockIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:to="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_2_lbl" xml:lang="en-US">Unrealized gain (loss) on digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForAcquisitionCryptoAsset" xlink:to="us-gaap_PaymentForAcquisitionCryptoAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset_lbl" xml:lang="en-US">Purchase of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct offerings, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from sale of securities in registered private placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Settlement of accrued compensation to members of the Board of Directors by issuance of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" xlink:label="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" xlink:to="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis_lbl" xml:lang="en-US">Exercise of placement agent warrants on a cashless basis</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExerciseOfPrefundedWarrants" xlink:label="LIXT_ExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExerciseOfPrefundedWarrants" xlink:to="LIXT_ExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" xlink:label="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" xlink:to="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock_lbl" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" xlink:label="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" xlink:to="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend_lbl" xml:lang="en-US">Accrual of Series B Convertible Preferred Stock 8% cumulative dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AccrualOfDeferredOfferingCosts" xlink:label="LIXT_AccrualOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AccrualOfDeferredOfferingCosts" xlink:to="LIXT_AccrualOfDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AccrualOfDeferredOfferingCosts_lbl" xml:lang="en-US">Accrual of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="us-gaap_CryptoAssetTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetTextBlock" xlink:to="us-gaap_CryptoAssetTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetTextBlock_lbl" xml:lang="en-US">Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetPolicyTextBlock" xlink:label="srt_PlatformOperatorCryptoAssetPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetPolicyTextBlock" xlink:to="srt_PlatformOperatorCryptoAssetPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_PlatformOperatorCryptoAssetPolicyTextBlock_lbl" xml:lang="en-US">Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:to="LIXT_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="LIXT_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Liabilities Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Information by Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTableTextBlock" xlink:label="us-gaap_CryptoAssetHoldingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingTableTextBlock" xlink:to="us-gaap_CryptoAssetHoldingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingTableTextBlock_lbl" xml:lang="en-US">Schedule of Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Each Option Award Estimated Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Bid price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Total stockholders equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="LIXT_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash SIPC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Pre funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Unexercised pre funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ForeignCurrencyExchangeRateTranslation" xlink:to="LIXT_ForeignCurrencyExchangeRateTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Foreign currency average rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="LIXT_CashBasedCompensationToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedCompensationToRelatedParties" xlink:to="LIXT_CashBasedCompensationToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashBasedCompensationToRelatedParties_lbl" xml:lang="en-US">Cash-based</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="LIXT_StockBasedCompensationToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedCompensationToRelatedParties" xlink:to="LIXT_StockBasedCompensationToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockBasedCompensationToRelatedParties_lbl" xml:lang="en-US">Stock-based</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:to="LIXT_LegalFeesRelatingToPatentsAndLicensing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="LIXT_OtherConsultingAndProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherConsultingAndProfessionalFees" xlink:to="LIXT_OtherConsultingAndProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OtherConsultingAndProfessionalFees_lbl" xml:lang="en-US">Other consulting and professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_2_lbl" xml:lang="en-US">Other costs and expenses, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xml:lang="en-US">Total general and administrative costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="us-gaap_CryptoAssetHoldingTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingTable" xlink:to="us-gaap_CryptoAssetHoldingTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingTable_lbl" xml:lang="en-US">Crypto Asset, Holding [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="us-gaap_CryptoAssetHoldingLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingLineItems" xlink:to="us-gaap_CryptoAssetHoldingLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingLineItems_lbl" xml:lang="en-US">Crypto Asset, Holding [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CryptoAssetsNumberOfUnits" xlink:label="LIXT_CryptoAssetsNumberOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CryptoAssetsNumberOfUnits" xlink:to="LIXT_CryptoAssetsNumberOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CryptoAssetsNumberOfUnits_lbl" xml:lang="en-US">Digital assets held, Quantity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetCost" xlink:label="us-gaap_CryptoAssetCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetCost" xlink:to="us-gaap_CryptoAssetCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetCost_lbl" xml:lang="en-US">Digital assets held, Cost basis</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:to="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_3_lbl" xml:lang="en-US">Unrealized gain (loss) in fair value of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="us-gaap_CryptoAssetFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetFairValue_lbl" xml:lang="en-US">Digital assets fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:to="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_CryptoAssetUnrealizedGainLossNonoperating_4_lbl" xml:lang="en-US">Unrealized gain (loss) in fair value of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DigitalAssetHoldingsPercentage" xlink:label="LIXT_DigitalAssetHoldingsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DigitalAssetHoldingsPercentage" xlink:to="LIXT_DigitalAssetHoldingsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DigitalAssetHoldingsPercentage_lbl" xml:lang="en-US">Digital asset holdings percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Warrants Outstanding Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Undesignated preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xml:lang="en-US">Principal cash obligations and commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xml:lang="en-US">Annual net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock, conversion description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds from sale of transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xml:lang="en-US">Convertible preferred stock shares issued upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued and sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_2_lbl" xml:lang="en-US">Private placement shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DescriptionOfOfferingPrice" xlink:label="LIXT_DescriptionOfOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DescriptionOfOfferingPrice" xlink:to="LIXT_DescriptionOfOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DescriptionOfOfferingPrice_lbl" xml:lang="en-US">Description of offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds from initial offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares Issued for Services, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Shares Issued for Services, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Exercisable unexercised, intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Cash-based</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_4_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_2_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Paid office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Options exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based payment award, award vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Cash fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Annual cash fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares avaliable for issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares were available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average recognition period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options are exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FairValueOfStockOptions" xlink:label="LIXT_FairValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FairValueOfStockOptions_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xml:lang="en-US">Stock options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of stock option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xml:lang="en-US">Stock option, vesting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Deferred compensation expense for unvested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair market value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Outstanding stock options to acquire shares of common stock not vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialDescription" xlink:label="LIXT_ClinicalTrialDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialDescription_lbl" xml:lang="en-US">Clinical trial, description</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xml:lang="en-US">Estimated Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xml:lang="en-US">Estimated End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="LIXT_NumberOfPatientInTrial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfPatientInTrial_lbl" xml:lang="en-US">Number of Patients in Trial</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:to="LIXT_ExpectedDateOfPreliminaryEfficacySignal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal_lbl" xml:lang="en-US">Expected Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Remaining financial contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_2_lbl" xml:lang="en-US">Contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Total costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:to="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xml:lang="en-US">Inventory costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitment_2_lbl" xml:lang="en-US">Aggregate commitments expected</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="LIXT_AmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="LIXT_WorkOrderAgreementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementCosts" xlink:to="LIXT_WorkOrderAgreementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementCosts_lbl" xml:lang="en-US">Work order agreement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EstimatedWorkCost" xlink:label="LIXT_EstimatedWorkCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EstimatedWorkCost_lbl" xml:lang="en-US">Work cost</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="LIXT_ExpectedPaymentinServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentinServices_lbl" xml:lang="en-US">Percentage of payment through services</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="LIXT_ExpectedPaymentThroughSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentThroughSoftware_lbl" xml:lang="en-US">Percentage of payment through software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Non refundable license issue royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyaltyPayable" xlink:label="LIXT_RoyaltyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyaltyPayable_lbl" xml:lang="en-US">Minimum annual royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="us-gaap_HealthCareOrganizationHealthCareCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:to="us-gaap_HealthCareOrganizationHealthCareCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationHealthCareCostsGross_lbl" xml:lang="en-US">Dosing of product</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payment for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyatiesPercentage" xlink:label="LIXT_RoyatiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyatiesPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development process costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="LIXT_ConsultingAndAdvisoryCashFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_lbl" xml:lang="en-US">Consulting and advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ReimbursementExpense" xlink:label="LIXT_ReimbursementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ReimbursementExpense_lbl" xml:lang="en-US">Reimbursed expense</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Advance amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Pre-funded warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercisable price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Pre-funded warrants remained unexercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_lbl" xml:lang="en-US">Proceeds from sale of interest in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeeDescription" xlink:label="us-gaap_ManagementFeeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeDescription" xlink:to="us-gaap_ManagementFeeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeDescription_lbl" xml:lang="en-US">Management fee description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Payments for of common stock services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of shares issued, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Number of shares issued, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Common Stock, par value $0.0001 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xml:lang="en-US">Research and development contract liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:to="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable_doc" xml:lang="en-US">Series B Convertible Preferred Stock cumulative dividend payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockMember" xlink:to="LIXT_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" xlink:to="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesBConvertiblePreferredStockCumulativeDividend_doc" xml:lang="en-US">Series B convertible preferred stock cumulative dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:to="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares_doc" xml:lang="en-US">Stock issued during period shares exercise of placement agent warrants shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:to="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares_doc" xml:lang="en-US">Stock issued during period value exercise of placement agent warrants shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period value proceeds from sale of securities in july 2025 registered private placement net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares proceeds from sale of securities in july 2025 registered private placement net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period value proceeds from sale of securities in july 2025 registered direct offering net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares proceeds from sale of securities in july 2025 registered direct offering net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xml:lang="en-US">Stock based compensation expense included in general and administrative costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xml:lang="en-US">Stock based compensation expense included in research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockIssuedForServices" xlink:to="LIXT_CommonStockIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockIssuedForServices_doc" xml:lang="en-US">Common stock issued for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Increase decrease in advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Increase decrease in research and development contract liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" xlink:to="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock_doc" xml:lang="en-US">Conversion of series convertible preferred stock into common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AccrualOfDeferredOfferingCosts" xlink:to="LIXT_AccrualOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AccrualOfDeferredOfferingCosts_doc" xml:lang="en-US">Accrual of deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" xlink:to="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis_doc" xml:lang="en-US">Exercise of placement agent warrants on a cashless basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExerciseOfPrefundedWarrants" xlink:to="LIXT_ExerciseOfPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExerciseOfPrefundedWarrants_doc" xml:lang="en-US">Exercise of pre-funded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" xlink:to="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend_doc" xml:lang="en-US">Accrual of Series B Convertible Preferred Stock 8% cumulative dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_doc" xml:lang="en-US">Prepaid Insurance [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:to="LIXT_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantOneMember_doc" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantTwoMember_doc" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantThreeMember_doc" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherVendorAndConsultantMember" xlink:to="LIXT_OtherVendorAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OtherVendorAndConsultantMember_doc" xml:lang="en-US">Other Vendor and Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeMember" xlink:to="LIXT_GeneralAndAdministrativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GeneralAndAdministrativeMember_doc" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OneVendorAndConsultantMember" xlink:to="LIXT_OneVendorAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OneVendorAndConsultantMember_doc" xml:lang="en-US">One Vendor and Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_doc" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorMember" xlink:to="LIXT_VendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorMember_doc" xml:lang="en-US">Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantFourMember_doc" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFiveMember" xlink:to="LIXT_VendorAndConsultantFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantFiveMember_doc" xml:lang="en-US">Vendor and Consultant Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoVendorAndConsultantMember" xlink:to="LIXT_TwoVendorAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoVendorAndConsultantMember_doc" xml:lang="en-US">Two Vendor And Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ForeignCurrencyExchangeRateTranslation" xlink:to="LIXT_ForeignCurrencyExchangeRateTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation_doc" xml:lang="en-US">Foreign currency exchange rate translation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedCompensationToRelatedParties" xlink:to="LIXT_CashBasedCompensationToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashBasedCompensationToRelatedParties_doc" xml:lang="en-US">Cash based compensation to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedCompensationToRelatedParties" xlink:to="LIXT_StockBasedCompensationToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockBasedCompensationToRelatedParties_doc" xml:lang="en-US">Stock based compensation to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:to="LIXT_LegalFeesRelatingToPatentsAndLicensing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing_doc" xml:lang="en-US">Legal fees relating to patents and licensing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherConsultingAndProfessionalFees" xlink:to="LIXT_OtherConsultingAndProfessionalFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OtherConsultingAndProfessionalFees_doc" xml:lang="en-US">Other consulting and professional fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CryptoAssetsNumberOfUnits" xlink:to="LIXT_CryptoAssetsNumberOfUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CryptoAssetsNumberOfUnits_doc" xml:lang="en-US">Crypto assets number of units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BitcoinMember" xlink:to="LIXT_BitcoinMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BitcoinMember_doc" xml:lang="en-US">Bitcoin [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EthereumMember" xlink:to="LIXT_EthereumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EthereumMember_doc" xml:lang="en-US">Ethereum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xml:lang="en-US">Number of share tranche of the series a convertible preferred stock receive a per share dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xml:lang="en-US">Annual net revenue divided by converted or redeemed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:to="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_doc" xml:lang="en-US">July 20, 2023 Equity Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsMember_doc" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:to="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_doc" xml:lang="en-US">February 13, 2025 Equity Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrKovachMember_doc" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesSMiserMember_doc" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EricJFormanMember_doc" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RobertNWeingartenMember_doc" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BasvanderBaanMember_doc" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SchellensMember" xlink:to="LIXT_SchellensMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SchellensMember_doc" xml:lang="en-US">Schellens [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrPursgloveMember" xlink:to="LIXT_MrPursgloveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrPursgloveMember_doc" xml:lang="en-US">Mr Pursglove [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_doc" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_doc" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfAuditCommitteeMember_doc" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfOtherCommitteesMember_doc" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NewIndependentDirectorMember_doc" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_doc" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualGrantOfOptionsMember_doc" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IndependentDirectorMember_doc" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FairValueOfStockOptions_doc" xml:lang="en-US">Fair value of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_doc" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourOfficersMember_doc" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficerDirectorsMember_doc" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrvanderBaanMember" xlink:to="LIXT_MrvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrvanderBaanMember_doc" xml:lang="en-US">Mr van der Baan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorMember" xlink:to="LIXT_FourNonOfficerDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficerDirectorMember_doc" xml:lang="en-US">Four Non Officer Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourteenMember_doc" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFifteenMember_doc" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixteenMember" xlink:to="LIXT_ExercisePriceSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixteenMember_doc" xml:lang="en-US">Exercise Price Sixteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSeventeenMember" xlink:to="LIXT_ExercisePriceSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSeventeenMember_doc" xml:lang="en-US">Exercise Price Seventeen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEighteenMember" xlink:to="LIXT_ExercisePriceEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEighteenMember_doc" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SecuritiesPurchaseAgreementMember" xlink:to="LIXT_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreFundedWarrantsMember" xlink:to="LIXT_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PreFundedWarrantsMember_doc" xml:lang="en-US">PreFunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DescriptionOfOfferingPrice" xlink:to="LIXT_DescriptionOfOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DescriptionOfOfferingPrice_doc" xml:lang="en-US">Description of offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentAgreementMember" xlink:to="LIXT_PlacementAgentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentAgreementMember_doc" xml:lang="en-US">Placement Agent Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsWarrantsMember" xlink:to="LIXT_PlacementAgentsWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsWarrantsMember_doc" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MarketAwarenessAgreementMember" xlink:to="LIXT_MarketAwarenessAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MarketAwarenessAgreementMember_doc" xml:lang="en-US">Market Awareness Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PeterStazzoneMember" xlink:to="LIXT_PeterStazzoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PeterStazzoneMember_doc" xml:lang="en-US">Peter Stazzone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_JasonSawyerMember" xlink:to="LIXT_JasonSawyerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_JasonSawyerMember_doc" xml:lang="en-US">Jason Sawyer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrMichaelHollowayMember" xlink:to="LIXT_DrMichaelHollowayMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrMichaelHollowayMember_doc" xml:lang="en-US">Dr. Michael Holloway [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LourdesFelixAndGuyPrimusMember" xlink:to="LIXT_LourdesFelixAndGuyPrimusMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LourdesFelixAndGuyPrimusMember_doc" xml:lang="en-US">Lourdes Felix and Guy Primus [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialDescription_doc" xml:lang="en-US">Clinical trial description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseMD1b2Member" xlink:to="LIXT_ClinicalTrialPhaseMD1b2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member_doc" xml:lang="en-US">Clinical Trial Phase MD 1b 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xml:lang="en-US">Contractual clinical trial period start date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xml:lang="en-US">Contractual clinical trial period end date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfPatientInTrial_doc" xml:lang="en-US">Number of patient in trial.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:to="LIXT_ExpectedDateOfPreliminaryEfficacySignal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal_doc" xml:lang="en-US">Expected date of preliminary efficacy signal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bMember_doc" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_doc" xml:lang="en-US">Phase 1b&#9;Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_doc" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xml:lang="en-US">GEIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_doc" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AmountRelatedToMilestonePayment_doc" xml:lang="en-US">Amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementCosts" xlink:to="LIXT_WorkOrderAgreementCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementCosts_doc" xml:lang="en-US">Work order agreement costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchMonitoringMember" xlink:to="LIXT_ClinicalTrialResearchMonitoringMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember_doc" xml:lang="en-US">Clinical Trial Research Monitoring [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MDAndersonCancerCenterClinicalMember" xlink:to="LIXT_MDAndersonCancerCenterClinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember_doc" xml:lang="en-US">MD Anderson Cancer Center Clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementMember_doc" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EstimatedWorkCost_doc" xml:lang="en-US">Estimated work cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TheradexSystemsIncMember_doc" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentinServices_doc" xml:lang="en-US">Expected payment in services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentThroughSoftware_doc" xml:lang="en-US">Percentage of expected paymen through software.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyaltyPayable_doc" xml:lang="en-US">Royalty payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DueEachJanuaryOneMember_doc" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyatiesPercentage_doc" xml:lang="en-US">Royaties percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_doc" xml:lang="en-US">Consulting and advisory quarterly cash fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NDAConsultingCorpMember_doc" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BioPharmaWorksLLCMember_doc" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ReimbursementExpense_doc" xml:lang="en-US">Reimbursement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NetherlandsCancerInstituteMember_doc" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xml:lang="en-US">Advance amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MRIGlobalMember_doc" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WellingtonPeelLLCMember" xlink:label="LIXT_WellingtonPeelLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WellingtonPeelLLCMember" xlink:to="LIXT_WellingtonPeelLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WellingtonPeelLLCMember_doc" xml:lang="en-US">Wellington Peel LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LMCCommunicationsIncMember" xlink:to="LIXT_LMCCommunicationsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LMCCommunicationsIncMember_doc" xml:lang="en-US">LMC Communications Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SGNMediaIncMember" xlink:to="LIXT_SGNMediaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SGNMediaIncMember_doc" xml:lang="en-US">SGN Media Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockOptionsMember_doc" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalAndRelatedOversightCostsMember" xlink:to="LIXT_ClinicalAndRelatedOversightCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember_doc" xml:lang="en-US">Clinical and Related Oversight Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreclinicalResearchMember" xlink:to="LIXT_PreclinicalResearchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PreclinicalResearchMember_doc" xml:lang="en-US">Preclinical Research [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CompoundMaintenanceMember" xlink:to="LIXT_CompoundMaintenanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CompoundMaintenanceMember_doc" xml:lang="en-US">Compound Maintenance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RegulatoryServiceCostsMember" xlink:to="LIXT_RegulatoryServiceCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RegulatoryServiceCostsMember_doc" xml:lang="en-US">Regulatory Service Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentMember" xlink:to="LIXT_ResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentMember_doc" xml:lang="en-US">Research and Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash SIPC insurance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DigitalAssetHoldingsPercentage" xlink:to="LIXT_DigitalAssetHoldingsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DigitalAssetHoldingsPercentage_doc" xml:lang="en-US">Digital asset holdings percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xml:lang="en-US">ShareBasedCompensationIncludedInResearchAndDevelopmentCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_3_lbl" xml:lang="en-US">ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xml:lang="en-US">IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForAcquisitionCryptoAsset" xlink:to="us-gaap_PaymentForAcquisitionCryptoAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset_2_lbl" xml:lang="en-US">Payment for Acquisition, Crypto Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExerciseOfPrefundedWarrants" xlink:to="LIXT_ExerciseOfPrefundedWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExerciseOfPrefundedWarrants_3_lbl" xml:lang="en-US">ExerciseOfPrefundedWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetPolicyTextBlock" xlink:to="srt_PlatformOperatorCryptoAssetPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetPolicyTextBlock_2_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>lixt-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Cover" roleURI="http://lixte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheets" roleURI="http://lixte.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://lixte.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfOperations" roleURI="http://lixte.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfStockholdersEquity" roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StatementsOfCashFlows" roleURI="http://lixte.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentation" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformation" roleURI="http://lixte.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssets" roleURI="http://lixte.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquity" roleURI="http://lixte.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactions" roleURI="http://lixte.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensation" roleURI="http://lixte.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#IncomeTaxes" roleURI="http://lixte.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingencies" roleURI="http://lixte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEvents" roleURI="http://lixte.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SegmentInformationTables" roleURI="http://lixte.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsTables" roleURI="http://lixte.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityTables" roleURI="http://lixte.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsTables" roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationTables" roleURI="http://lixte.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfInformationBySegmentDetails" roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfDigitalAssetsDetails" roleURI="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#DigitalAssetsDetailsNarrative" roleURI="http://lixte.com/role/DigitalAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfRelatedPartyCostsDetails" roleURI="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStock-basedCompensationCostsDetails" roleURI="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#ScheduleOfContractualClinicalTrialsDetails" roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="loc_us-gaapCryptoAssetFairValueCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCryptoAssetFairValueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividendPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockCumulativeDividend" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividend" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockCumulativeDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:label="loc_LIXTStockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaapShareBasedCompensationAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockIssuedForServices" xlink:label="loc_LIXTCommonStockIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTCommonStockIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="loc_us-gaapPaymentForAcquisitionCryptoAsset" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentForAcquisitionCryptoAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis" xlink:label="loc_LIXTExerciseOfPlacementAgentWarrantsOnCashlessBasis" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LIXTExerciseOfPlacementAgentWarrantsOnCashlessBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExerciseOfPrefundedWarrants" xlink:label="loc_LIXTExerciseOfPrefundedWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LIXTExerciseOfPrefundedWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock" xlink:label="loc_LIXTConversionOfSeriesConvertiblePreferredStockIntoCommonStock" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LIXTConversionOfSeriesConvertiblePreferredStockIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" xlink:label="loc_LIXTAccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LIXTAccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AccrualOfDeferredOfferingCosts" xlink:label="loc_LIXTAccrualOfDeferredOfferingCosts" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LIXTAccrualOfDeferredOfferingCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999012 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999014 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssets" xlink:title="999015 - Disclosure - Digital Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="loc_us-gaapCryptoAssetTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999016 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999019 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="loc_LIXTPrepaidInsurancePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTPrepaidInsurancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetPolicyTextBlock" xlink:label="loc_srtPlatformOperatorCryptoAssetPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_LIXTDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="loc_LIXTWarrantsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsTables" xlink:title="999025 - Disclosure - Digital Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTableTextBlock" xlink:label="loc_us-gaapCryptoAssetHoldingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValueCurrent" xlink:label="loc_us-gaapCryptoAssetFairValueCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCryptoAssetFairValueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="loc_LIXTGeneralAndAdministrativeMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTGeneralAndAdministrativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfSalesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherVendorAndConsultantMember" xlink:label="loc_LIXTOtherVendorAndConsultantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTOtherVendorAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorMember" xlink:label="loc_LIXTVendorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_VendorAndConsultantFiveMember" xlink:label="loc_LIXTVendorAndConsultantFiveMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OneVendorAndConsultantMember" xlink:label="loc_LIXTOneVendorAndConsultantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTOneVendorAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoVendorAndConsultantMember" xlink:label="loc_LIXTTwoVendorAndConsultantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTTwoVendorAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="loc_LIXTForeignCurrencyExchangeRateTranslation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTForeignCurrencyExchangeRateTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="loc_LIXTClinicalAndRelatedOversightCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTClinicalAndRelatedOversightCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreclinicalResearchMember" xlink:label="loc_LIXTPreclinicalResearchMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTPreclinicalResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CompoundMaintenanceMember" xlink:label="loc_LIXTCompoundMaintenanceMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTCompoundMaintenanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="loc_LIXTRegulatoryServiceCostsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTRegulatoryServiceCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_ES" xlink:label="loc_countryES" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="loc_LIXTResearchAndDevelopmentMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_LIXTResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfDigitalAssetsDetails" xlink:title="999035 - Disclosure - Schedule of Digital Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_us-gaapCryptoAssetHoldingLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BitcoinMember" xlink:label="loc_LIXTBitcoinMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTBitcoinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EthereumMember" xlink:label="loc_LIXTEthereumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTEthereumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CryptoAssetsNumberOfUnits" xlink:label="loc_LIXTCryptoAssetsNumberOfUnits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_LIXTCryptoAssetsNumberOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetCost" xlink:label="loc_us-gaapCryptoAssetCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/DigitalAssetsDetailsNarrative" xlink:title="999036 - Disclosure - Digital Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_us-gaapCryptoAssetHoldingLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BitcoinMember" xlink:label="loc_LIXTBitcoinMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTBitcoinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EthereumMember" xlink:label="loc_LIXTEthereumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_LIXTEthereumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedGainLossNonoperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedGainLossNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DigitalAssetHoldingsPercentage" xlink:label="loc_LIXTDigitalAssetHoldingsPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_LIXTDigitalAssetHoldingsPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SeriesBConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:label="loc_LIXTJulyTwentyTwoThousandTwentyThreeEquityOfferingMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LIXTJulyTwentyTwoThousandTwentyThreeEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:label="loc_LIXTFebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LIXTFebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPreFundedWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsWarrantsMember" xlink:label="loc_LIXTPlacementAgentsWarrantsMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentAgreementMember" xlink:label="loc_LIXTPlacementAgentAgreementMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTPlacementAgentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MarketAwarenessAgreementMember" xlink:label="loc_LIXTMarketAwarenessAgreementMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMarketAwarenessAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:label="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTStockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DescriptionOfOfferingPrice" xlink:label="loc_LIXTDescriptionOfOfferingPrice" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTDescriptionOfOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails" xlink:title="999040 - Disclosure - Schedule of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999041 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrPursgloveMember" xlink:label="loc_LIXTMrPursgloveMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrPursgloveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PeterStazzoneMember" xlink:label="loc_LIXTPeterStazzoneMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPeterStazzoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTSchellensMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails" xlink:title="999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSixteenMember" xlink:label="loc_LIXTExercisePriceSixteenMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceSeventeenMember" xlink:label="loc_LIXTExercisePriceSeventeenMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExercisePriceEighteenMember" xlink:label="loc_LIXTExercisePriceEighteenMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999046 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="loc_LIXTFourNonOfficerDirectorMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrPursgloveMember" xlink:label="loc_LIXTMrPursgloveMember" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrPursgloveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_JasonSawyerMember" xlink:label="loc_LIXTJasonSawyerMember" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTJasonSawyerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DrMichaelHollowayMember" xlink:label="loc_LIXTDrMichaelHollowayMember" />
      <link:presentationArc order="820" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrMichaelHollowayMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PeterStazzoneMember" xlink:label="loc_LIXTPeterStazzoneMember" />
      <link:presentationArc order="870" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPeterStazzoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LourdesFelixAndGuyPrimusMember" xlink:label="loc_LIXTLourdesFelixAndGuyPrimusMember" />
      <link:presentationArc order="930" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTLourdesFelixAndGuyPrimusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MrvanderBaanMember" xlink:label="loc_LIXTMrvanderBaanMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSchellensMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="980" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="loc_LIXTClinicalTrialPhaseMD1b2Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseMD1b2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="loc_LIXTExpectedDateOfPreliminaryEfficacySignal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTExpectedDateOfPreliminaryEfficacySignal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999048 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="loc_LIXTClinicalTrialResearchMonitoringMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchMonitoringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="loc_LIXTMDAndersonCancerCenterClinicalMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMDAndersonCancerCenterClinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_2" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="loc_LIXTWorkOrderAgreementCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTWorkOrderAgreementCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyaltyPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="loc_us-gaapHealthCareOrganizationHealthCareCostsGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapHealthCareOrganizationHealthCareCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyatiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_SGNMediaIncMember" xlink:label="loc_LIXTSGNMediaIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSGNMediaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250930.xsd#LIXT_LMCCommunicationsIncMember" xlink:label="loc_LIXTLMCCommunicationsIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLMCCommunicationsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementFeeDescription" xlink:label="loc_us-gaapManagementFeeDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapManagementFeeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">433
Plaza Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca
Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,887,874<span></span>
</td>
<td class="nump">$ 1,038,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">29,490<span></span>
</td>
<td class="nump">20,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">61,839<span></span>
</td>
<td class="nump">85,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="nump">2,454,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,433,676<span></span>
</td>
<td class="nump">1,145,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,433,676<span></span>
</td>
<td class="nump">1,145,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, including $112,033 and $27,500 to related parties at September 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">235,900<span></span>
</td>
<td class="nump">83,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent', window );">Research and development contract liabilities</a></td>
<td class="nump">235,155<span></span>
</td>
<td class="nump">235,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable', window );">Series B Convertible Preferred Stock 8% cumulative dividend payable</a></td>
<td class="nump">50,367<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">521,422<span></span>
</td>
<td class="nump">318,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 5,704,200 and 2,249,290 shares at September 30, 2025 and December 31, 2024</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">57,891,644<span></span>
</td>
<td class="nump">49,394,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(55,533,319)<span></span>
</td>
<td class="num">(52,067,693)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,912,254<span></span>
</td>
<td class="nump">827,219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">5,433,676<span></span>
</td>
<td class="nump">1,145,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 2,553,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Series B Convertible Preferred Stock cumulative dividend payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset classified as current. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 235,900<span></span>
</td>
<td class="nump">$ 83,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,704,200<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,704,200<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="nump">$ 0.7146<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 112,033<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">50,696<span></span>
</td>
<td class="nump">361,630<span></span>
</td>
<td class="nump">202,801<span></span>
</td>
<td class="nump">691,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">1,750,658<span></span>
</td>
<td class="nump">621,627<span></span>
</td>
<td class="nump">3,080,302<span></span>
</td>
<td class="nump">2,267,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">1,801,354<span></span>
</td>
<td class="nump">983,257<span></span>
</td>
<td class="nump">3,283,103<span></span>
</td>
<td class="nump">2,959,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,801,354)<span></span>
</td>
<td class="num">(983,257)<span></span>
</td>
<td class="num">(3,283,103)<span></span>
</td>
<td class="num">(2,959,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">5,236<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="num">(5,402)<span></span>
</td>
<td class="num">(12,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) on digital assets</a></td>
<td class="num">(182,887)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(182,887)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Realized gain (loss) on foreign currency transactions</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(3,161)<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="num">(3,119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,980,398)<span></span>
</td>
<td class="num">(986,030)<span></span>
</td>
<td class="num">(3,465,626)<span></span>
</td>
<td class="num">(2,968,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SeriesBConvertiblePreferredStockCumulativeDividend', window );">Series B Convertible Preferred Stock 8% cumulative dividend</a></td>
<td class="num">(50,367)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,367)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,030,765)<span></span>
</td>
<td class="num">$ (986,030)<span></span>
</td>
<td class="num">$ (3,515,993)<span></span>
</td>
<td class="num">$ (2,968,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share basic</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">6,171,195<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">3,801,400<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">6,171,195<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">3,801,400<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SeriesBConvertiblePreferredStockCumulativeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Series B convertible preferred stock cumulative dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SeriesBConvertiblePreferredStockCumulativeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as nonoperating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedGainLossNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 48,976,265<span></span>
</td>
<td class="num">$ (48,481,728)<span></span>
</td>
<td class="nump">$ 3,994,762<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">340,445<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">340,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,968,271)<span></span>
</td>
<td class="num">(2,968,271)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">49,316,710<span></span>
</td>
<td class="num">(51,449,999)<span></span>
</td>
<td class="nump">1,366,936<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">49,209,883<span></span>
</td>
<td class="num">(50,463,969)<span></span>
</td>
<td class="nump">2,246,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,827<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(986,030)<span></span>
</td>
<td class="num">(986,030)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">49,316,710<span></span>
</td>
<td class="num">(51,449,999)<span></span>
</td>
<td class="nump">1,366,936<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">49,394,687<span></span>
</td>
<td class="num">(52,067,693)<span></span>
</td>
<td class="nump">827,219<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,553,359<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,624,797<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,178,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">59,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">914,185<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">914,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares', window );">Exercise of placement agent warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares', window );">Exercise of placement agent warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,426,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">45,798<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 45,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,710<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 44,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Series B Convertible Preferred Stock 8% cumulative dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,367)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,059,815<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,059,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,465,626)<span></span>
</td>
<td class="num">(3,465,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options issued to settle accrued payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Series A convertible stock</a></td>
<td class="num">$ (3,500,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">3,499,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Series A convertible stock, shares</a></td>
<td class="num">(350,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">1,330,791<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,330,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,553,359<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">57,891,644<span></span>
</td>
<td class="num">(55,533,319)<span></span>
</td>
<td class="nump">4,912,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">54,204,101<span></span>
</td>
<td class="num">(53,552,921)<span></span>
</td>
<td class="nump">651,456<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,756,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,553,359<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,624,797<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,178,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">59,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">1,330,791<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,330,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares', window );">Exercise of placement agent warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares', window );">Exercise of placement agent warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,426,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">45,798<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,710<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Series B Convertible Preferred Stock 8% cumulative dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,367)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">692,078<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">692,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,980,398)<span></span>
</td>
<td class="num">(1,980,398)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,553,359<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 57,891,644<span></span>
</td>
<td class="num">$ (55,533,319)<span></span>
</td>
<td class="nump">$ 4,912,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of placement agent warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares proceeds from sale of securities in july 2025 registered direct offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares proceeds from sale of securities in july 2025 registered private placement net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of placement agent warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value proceeds from sale of securities in july 2025 registered direct offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value proceeds from sale of securities in july 2025 registered private placement net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,465,626)<span></span>
</td>
<td class="num">$ (2,968,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense included in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost', window );">Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost', window );">General and administrative costs</a></td>
<td class="nump">1,144,348<span></span>
</td>
<td class="nump">340,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CommonStockIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">44,711<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) on digital assets</a></td>
<td class="nump">182,887<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="num">(8,592)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Other prepaid expenses</a></td>
<td class="nump">23,814<span></span>
</td>
<td class="num">(24,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">95,661<span></span>
</td>
<td class="num">(90,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">98,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,982,720)<span></span>
</td>
<td class="num">(2,565,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForAcquisitionCryptoAsset', window );">Purchase of digital assets</a></td>
<td class="num">(2,637,360)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,637,360)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of securities in registered direct offerings, net of offering costs</a></td>
<td class="nump">2,245,040<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of securities in registered private placement, net of offering costs</a></td>
<td class="nump">4,178,162<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of common stock warrants</a></td>
<td class="nump">45,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,469,002<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease)</a></td>
<td class="nump">1,848,922<span></span>
</td>
<td class="num">(2,565,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of period</a></td>
<td class="nump">1,038,952<span></span>
</td>
<td class="nump">4,203,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of period</a></td>
<td class="nump">2,887,874<span></span>
</td>
<td class="nump">1,637,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">5,402<span></span>
</td>
<td class="nump">12,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Settlement of accrued compensation to members of the Board of Directors by issuance of stock options</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis', window );">Exercise of placement agent warrants on a cashless basis</a></td>
<td class="nump">22<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">242<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock', window );">Conversion of Series A Convertible Preferred Stock into common stock</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend', window );">Accrual of Series B Convertible Preferred Stock 8% cumulative dividend</a></td>
<td class="nump">50,367<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AccrualOfDeferredOfferingCosts', window );">Accrual of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AccrualOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AccrualOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual of Series B Convertible Preferred Stock 8% cumulative dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CommonStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CommonStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of series convertible preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of placement agent warrants on a cashless basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as nonoperating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedGainLossNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForAcquisitionCryptoAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForAcquisitionCryptoAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,980,398)<span></span>
</td>
<td class="num">$ (986,030)<span></span>
</td>
<td class="num">$ (3,465,626)<span></span>
</td>
<td class="num">$ (2,968,271)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znyUKB72O1Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_826_zDM7GbQZtkp1">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at September 30, 2025, and for the three months
and nine months ended September 30, 2025 and 2024, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2025, and the results of its operations for the three months and nine months ended September 30, 2025 and 2024, and its cash flows
for the nine months ended September 30, 2025 and 2024. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The condensed consolidated balance sheet at December 31, 2024 has been derived
from the Company&#8217;s audited consolidated financial statements at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s corporate office is located in Boca Raton, Florida.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBcx3g5UD546" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z8TcbyKaXek8" title="Bid price">1.00</span> minimum closing bid price requirement of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its noncompliance
with the minimum $<span id="xdx_904_eus-gaap--StockholdersEquity_iI_pn5n6_c20240819__srt--RangeAxis__srt--MinimumMember_zZOhlN2yyeg" title="Stock holders' equity">2.5</span> million stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market under Rule 5550(b)(1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a compliance plan, outlining proposed equity financings. On October 21, 2024, Nasdaq granted the
Company an extension through February 18, 2025 to complete its plan and evidence compliance via Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not meet the terms of the extension and, on February 19, 2025, received a Staff determination letter. The Company timely
requested a hearing before the Nasdaq Hearings Panel, staying any suspension or delisting pending the Panel&#8217;s decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
an April 3, 2025 hearing, the Panel granted the Company a further extension through July 3, 2025 to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2025, the Company closed a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20250702__20250702_zOIdUOONQYl3" title="Proceeds from issuance of private placement">5.05</span> million private placement and, on July 8, 2025, completed a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250708__20250708_zqySmEykS3Gd" title="Gross proceeds">1.5</span> million registered direct offering
(see Note 5). On July 15, 2025, Nasdaq notified the Company that it had regained compliance with the stockholders&#8217; equity requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remains subject to a Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B) through July 15, 2026. During this period, any future
deficiency in stockholders&#8217; equity would require the Company to request a hearing before the Panel rather than submit a new compliance
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, the Company recorded a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20250930_zG3hNcLDOK6b" title="Net loss">3,465,626</span> and used cash in operations of $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20250930_zuJd32C95Iv5" title="Net cash used in operations">1,982,720</span>. As
of September 30, 2025, the Company had cash of $<span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20250930_z7OyWuX8I5ug" title="Cash">2,887,874</span> available to fund its operations. As of September 30, 2025, the Company had
net working capital and total stockholders&#8217; equity of $<span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20250930_zpZnF4tQkyYk" title="Total stockholders equity">4,912,254</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $<span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zJlN5Aagtzh1" title="Contractual obligation">510,000</span>, which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenues
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities. These factors raise substantial doubt about the Company&#8217;s ability to continue as a
going concern within one year after the date the consolidated financial statements are issued. In addition the Company&#8217;s independent
registered public accounting firm, in their report on the Company&#8217;s audited consolidated financial statements as of and for the
year ended December 31, 2024, expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated
financial statements also do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary
if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities, including its ongoing clinical trials. The amount and timing of future cash requirements depends in substantial
part on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the availability of operating
capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2025 will provide sufficient working
capital to fund the Company&#8217;s operations as currently configured, including its ongoing clinical trial program with respect to
the development of the Company&#8217;s lead anti-cancer clinical compound LB-100, for at least the next 12 months. However, existing
cash resources will not be sufficient to complete the development of and to obtain regulatory approval for the Company&#8217;s product
candidate, which would require significant additional operating capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the appointment of a new Chairman and Chief Executive Officer in June 2025, the completion of the July 2025
equity financings, and other recent changes in senior management and the Board of Directors, the Company&#8217;s operating strategies
that may include the addition of personnel and/or the incurrence of additional operating costs, which may require that the Company raise
additional capital to fund operations. However, as market conditions present uncertainty as to the Company&#8217;s ability to secure
additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and
when necessary, to continue to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#8217;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zYZ49YeLjDWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_827_z4H8rgXvLVlg">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_z7xYeO3pzcZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles
of Consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zHIYsZTUAGY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently operates in a single</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90C_eus-gaap--NumberOfReportableSegments_pid_uSegment_c20250101__20250930_zwQwzLwkbG31" title="Number of reportable segment">1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable segment, which consists of the development of a
drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated financial results of the Company. The CODM
uses consolidated net income (loss) as the sole measure of segment profit or loss. The required segment information, including significant
segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--UseOfEstimates_zJMjeDDk30gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p id="xdx_852_zuoKiUyUKyC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm6OkHpKYoI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zf16ZFjTYomb" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_904_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_z2hF7GXIuVpk" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zuOzzkcHOUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zFrIvmtS2QU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepaid
Insurance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_esrt--PlatformOperatorCryptoAssetPolicyTextBlock_zgFfkKeBmpB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Digital
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance
with FASB ASC 820, Fair Value Measurement, based on quoted prices on the active exchange(s) that it has determined is the principal market
for Bitcoin and Ethereum (Level 1). Changes in fair value are included in unrealized gain (loss) on digital assets in other income (expense)
in the Company&#8217;s consolidated statements of operations. Realized gains and losses on the sale of digital assets are included in
other income (expense) in the Company&#8217;s consolidated statements of operations. The Company tracks its cost basis of digital assets
in accordance with the first-in-first-out method of accounting. The Company&#8217;s digital assets are reasonably expected to be realized
in cash or sold or consumed during the Company&#8217;s normal operating cycle and as such have been classified as current assets in the
Company&#8217;s consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#8217;s accounting policies, disclosures, or internal controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--DeferredOfferingCostsPolicyTextBlock_zLY2PmxIQFF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offering
Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zm6orj6nTYN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and Licensing Legal and Filing Fees and Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20250701__20250930_zDX7YqtyF8kc" title="Legal and filing fees and costs">16,853</span> and $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20240701__20240930_zIIcxXwgiT0j" title="Legal and filing fees and costs">45,416</span> for the three months ended September 30, 2025 and 2024, respectively, and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20250101__20250930_zu5GWZr8Gp62" title="Legal and filing fees and costs">90,239</span> and $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20240930_zAXrnWi1nCPg" title="Legal and filing fees and costs">192,239</span>
for the nine months ended September 30, 2025 and 2024, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z1Zs8QjNsB9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration
of Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMX12huKF4D" title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKIOtUXScmqc" title="Concentration risk percentage">10</span></span>% or more of general and administrative costs or research and development costs for the three months ended September 30,
2025 and 2024 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2025 include charges from three vendors and consultants representing <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7NBiD4b04ei" title="Concentration of risk, percentage">21.4</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5CRKZi6OJBc" title="Concentration of risk, percentage">28.8</span>%
and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBr33L05Ay01" title="Concentration of risk, percentage">14.2</span>%,
respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2024
include charges from three vendors and consultants representing<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVTJCBQXYcYe" title="Concentration of risk, percentage">
52.7</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zz6neRjiqpA8" title="Concentration of risk, percentage">21.1</span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVc7dzNJM3u3" title="Concentration of risk, percentage">15.1</span>%.
respectively, of total research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zE8OTDqRVpfi" title="Concentration risk percentage">1.0</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zRlCNOyI4px4" title="Concentration risk percentage">7.1</span>%, respectively
of total general and administrative costs. General and administrative costs for the three months ended September 30, 2025 also includes
a charge from a vendor representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zk2AiHpJ4xa2" title="Concentration of risk, percentage">10.6</span>% of total general and administrative costs. General and administrative costs for the three months
ended September 30, 2024 includes a charge from a vendor representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zTictifVolYe" title="Concentration of risk, percentage">18.4</span>% of total general and administrative costs. General and administrative
costs for the three months ended September 30, 2025 and 2024 also included charges for the fair value of stock options granted to directors
and corporate officers representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_zA80E4u5xhoh" title="Concentration risk percentage">44.4</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_z4BX9IqCpQo9" title="Concentration risk percentage">12.8</span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2025 include charges from five vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfkMnrcwWfM2" title="Concentration of risk, percentage">24.3</span>%,
<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zojGHZTSZXlb" title="Concentration of risk, percentage">20.7</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI7j6W9omBDd" title="Concentration of risk, percentage">18.9</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn9Mq8v8esu1" title="Concentration of risk, percentage">12.0</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziRtXm4Gk1V5" title="Concentration of risk, percentage">11.7</span>%, respectively, of total research and development costs. Research and development costs for the nine months
ended September 30, 2024 include charges from three vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zidzYfsRqY3c" title="Concentration of risk, percentage">41.2</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYc3gj0Mv6K3" title="Concentration of risk, percentage">30.4</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zycIFkh6Rn35" title="Concentration of risk, percentage">12.6</span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_ztyHSrbxcdRl" title="Concentration risk percentage">2.9</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zVYVeCuNf6qk" title="Concentration risk percentage">8.5</span>%. respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 did not include
any charges from a single vendor/consultant in excess of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zYdU9FIC77Wb" title="Concentration of risk, percentage">10</span>% of total general and administrative costs. General and administrative costs
for the nine months ended September 30, 2024 also include charges from two vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--OneVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zhjULGl4DD04" title="Concentration of risk, percentage">16.0</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zJwQvJpmmook" title="Concentration of risk, percentage">11.5</span>%, respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 and 2024 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_z7GmotHUJjRf" title="Concentration risk percentage">35.4</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_zFY9yQs4oTJj" title="Concentration risk percentage">12.6</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zZ7orfn7Lc42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at September 30, 2025 and December 31, 2024. In the event the Company was to determine that it
would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets
would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations
in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company did not have any unrecognized tax benefits as of September 30,
2025 or December 31, 2024, and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2025 or December
31, 2024. Subsequent to September 30, 2025, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZwY8nxr2DGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--WarrantsPolicyTextBlock_zGXvgbX9R71e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging
(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet
the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under
ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity
classification. The Company has determined that the warrants issued in the July 2023 equity financing, the February 2025 equity financing,
and the July 2025 equity financings (see Note 5) meet the requirements for equity classification. This assessment, which requires the
use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At September 30, 2025 and December 31, 2024, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zqt9gtDBhmo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
(Loss) Per Share</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
The weighted average number of common shares outstanding utilized for determining basic net loss per common share for the three months
and nine months ended September 30, 2025 includes all pre-funded warrants sold in the July 2, 2025 and July 8, 2025 equity financings,
aggregating <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zkIN6MSKL6rk" title="Pre funded warrants">3,085,883</span> pre-funded warrants, of which <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zdWqV5Y5fxfj" title="Unexercised pre funded warrants">659,772</span> pre-funded warrants were unexercised at September 30, 2025. Basic and diluted
loss per common share was the same for all periods presented because all preferred shares, warrants (excluding pre-funded warrants) and
stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025 and 2024, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlGwgDhu5fc3" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,573,130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants (excluding pre-funded
    warrants)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">623,232</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,307,161</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,504,514</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zqAKuOIrhEic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVuorOgqkAq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were
converted into United States dollars at the average rate of <span id="xdx_90D_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250701__20250930_zyoYCullawD8" title="Foreign currency average rate">1.1692</span> and <span id="xdx_902_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240701__20240930_zgqHU1MsJlii" title="Foreign currency average rate">1.0991</span> Euros per United States dollar, respectively. During the
nine months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_908_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250101__20250930_zP2AECW2WxC5" title="Foreign currency average rate">1.1182</span> and <span id="xdx_909_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20240930_znMdqm0tPkX6" title="Foreign currency average rate">1.0873</span> Euros per United States dollar, respectively. As of September 30,
2025 and December 31, 2024, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was
not a party to any foreign currency forward or exchange contracts. Accordingly, the Company did not have any unrealized foreign currency
(gain) loss at September 30, 2025 or 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwovQEHQLDlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of financial instruments measured on a recurring basis was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zEcIGOa3Fk24">Schedule
of Fair Value Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Description</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of September 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Digital
    assets</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zqxTOKxMJq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative
of their respective fair values due to the short-term nature of those instruments. The carrying value of digital assets is based on quoted
prices in active markets (Level 1 inputs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zksEpkVJ2Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-08, Intangibles &#8211; Goodwill and Other &#8211;
Crypto Assets (Subtopic 350-60). ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet
with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of operations
each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis,
fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during
the fiscal quarter ended September 30, 2025, the Company adopted and applied ASU-2023-08 henceforth. As the Company did not have any
crypto assets prior to the fiscal quarter ended September 30, 2025, no cumulative-effect adjustment was required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). These ASUs require disclosure of disaggregated information of Income Statement expense
captions that include certain costs, such as employee compensation, depreciation, and intangible asset amortization. They also require
disclosure of the total amounts of selling expenses, along with an entity&#8217;s definition of selling expenses. The amendments are
effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning
after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of these ASUs, but does not expect
them to have a material impact on its consolidated financial statements presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVCh9Es3C8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, effective January
1, 2024, certain reclassifications have been made to the prior year statement of operations to conform it to the current year presentation.
In presenting general and administrative costs on the Company&#8217;s consolidated statement of operations for the three months ended
September 30, 2024, $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG7YsqF1tvd" title="General and administrative costs">283,053</span> of compensation to related parties, $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4nshvne9er" title="Legal and filing fees and costs">45,416</span> of patent and licensing legal and filing fees and costs, and
$<span id="xdx_904_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJThg06Ayjqc" title="Other costs and expenses">293,158</span> of other costs and expenses were shown separately. In presenting the Company&#8217;s consolidated statement of operations for
the three months ended September 30, 2024, the Company has combined these categories into general and administrative costs in the accompanying
consolidated statement of operations for the three months ended September 30, 2024. In presenting general and administrative costs on
the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, $<span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXewFRr0sdHe" title="Legal and filing fees and costs">907,069</span> of compensation to related
parties, $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjPAU3N9b6x9" title="Legal and filing fees and costs">192,239</span> of patent and licensing legal and filing fees and costs, and $<span id="xdx_901_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztNhdQDEcnyk" title="Other costs and expenses">1,168,582</span> of other costs and expenses were shown separately.
In presenting the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, the Company has
combined these categories into general and administrative costs in the accompanying consolidated statement of operations for the nine
months ended September 30, 2024. These reclassifications had no effect on the reported results of operations, including loss from operations
and net loss.</span></p>

<p id="xdx_858_znt9FjXF96Y8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zfBoHoNrwicd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_822_zfbu9n4i88gj">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Company&#8217;s Chief Executive Officer
(&#8220;CEO&#8221;). The Company&#8217;s CODM evaluates performance and makes operating decisions about allocating resources based on
financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company
has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z3IccXWlfrE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhEnJlVTR3Zi" style="display: none">Schedule of Information by Segment</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250701__20250930_zxEwQzc9BImd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240701__20240930_z9nNu0oEZG5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20250930_z1Rpaa6OTP4k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930_ztpy1Q0wNB3b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zjwvHZtW1TBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical and related oversight
    costs</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,424</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,342</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,894</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,319</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zQYe1AIkkvq6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preclinical research focused on development
    of additional novel anti-cancer compounds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,821</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,573</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--CompoundMaintenanceMember_zu5wGjISNlol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compound maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,480</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,062</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,563</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_z4CTJDswmHX1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory service
    costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,581</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,405</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,771</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,021</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zC7Lgo1pyIj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,696</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">361,630</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,801</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and
2024 based on the respective geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250701__20250930_zMTYFay3jd4b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240701__20240930_zk0xMuipl2Kl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zfN1oXRYk7f8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_zH2Z3CpfXAKh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zeXvwFWu7jNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,305</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">278,808</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">146,804</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zZAC6oFHO2y6" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Spain</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,391</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,544</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zHdQmjEUyMt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">China</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,282</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zVKu5GRBX8Dk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Netherlands</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,278</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">210,362</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zUweL85KQMT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,696</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">361,630</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,801</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250701__20250930_zgeyf2S7GSn2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zciJovYJXG54" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20250930_zJ464v40b1N" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zOtdAVQN8Jo5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Compensation to related parties:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--CashBasedCompensationToRelatedParties_i02_maGAAEzrRU_z3XRf7ahkMX" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217,416</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,226</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">566,624</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockBasedCompensationToRelatedParties_i02_maGAAEzrRU_z9ROGtGZ8R74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maGAAEzrRU_z72gHGOzFwMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patent and licensing legal and filing fees
    and costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,853</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,415</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,238</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--OtherConsultingAndProfessionalFees_i02_maGAAEzrRU_zfY6Ns0pame2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other consulting and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,822</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">920,689</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">481,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_z67lYoTnxFA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,277</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">116,440</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,830</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">370,167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i02_maGAAEzrRU_z1HfQbQrluS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other costs and expenses,
    net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,679</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,826</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,764</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,551</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzrRU_zVv1vUc3YWl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total general and
    administrative costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,750,658</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621,627</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,080,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,267,890</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250930_zqxGQxmvlkmc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zo3jfZph8zQc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zmHMXhdF3BGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,412</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,298</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zhoArsta6Ayh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Corporate assets (primarily
    cash and digital assets)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,423,264</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,106,205</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_z3oqNeZnZW8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,433,676</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,145,503</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_znbhRckyCGqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Digital Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetTextBlock', window );">Digital Assets</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CryptoAssetTextBlock_zUyUgMXuChic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82A_zRUED9T6vt06">Digital Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89B_eus-gaap--CryptoAssetHoldingTableTextBlock_zd15zlx3TLX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the cost and fair value of digital assets that were initially purchased during August 2025 were as follows (there
were no digital assets at December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zz8kIdnQJfF6">Schedule
of Digital Assets</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Units</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
                                            (Loss)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on
                                            Change</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Fair Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Bitcoin</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zjLwTZVrBjR9" title="Digital assets held, Quantity">10.59</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zs89YFu6a0Xe" style="width: 12%; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">1,205,540</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zlguGps7Kc7f" style="width: 12%; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">2,261</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zE8YvwRZmWfb" style="width: 12%; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">1,207,801</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Ethereum</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zIVTZhF7pqRj" title="Digital assets held, Quantity">300.70</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zWSFVBkk2Cs3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">1,431,820</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--EthereumMember_zDWjvnB0gu3g" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">(185,148</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9LtdhjJ3Z1g" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">1,246,672</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20250930_z4cXF93NQjvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">2,637,360</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930_zy5ZBpKgezha" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">(182,887</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20250930_zWBMyrgrRA3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zMomer7ZKDe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
currency prices are affected by various forces, including global supply and demand, interest rates, exchange rates, inflation or deflation,
and the global political and economic conditions. Digital assets have a limited history, and the fair value historically has been very
volatile. The Company may not be able to liquidate its inventory of digital assets currency at its desired price if required. The Company
has recorded an unrealized net loss resulting from a decrease in the fair value of digital assets of $<span id="xdx_902_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_iN_di_c20250101__20250930_zljt2LVN7ln" title="Unrealized gain (loss) in fair value of digital assets">182,887</span> that is included in the
loss from operations in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">The Company&#8217;s digital asset holdings
in Bitcoin and Ethereum represent <span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zNi0BRkEMxT" title="Digital asset holdings percentage"><span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9cm7kyoEgle" title="Digital asset holdings percentage">100%</span></span> of the Company&#8217;s digital assets as of September 30, 2025. Bitcoin and Ethereum are digital
assets, a novel asset class subject to potential legal, regulatory, commercial, and technical uncertainties. These assets do not generate
cash flow and require the Company to incur custodial and safeguarding costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">The market prices of Bitcoin and Ethereum
have historically exhibited significant volatility, and a material decrease in their fair value could adversely impact the Company&#8217;s
financial condition and results of operations. The Company&#8217;s strategy of acquiring and holding Bitcoin and Ethereum also subjects
it to counterparty risks related to third-party custody arrangements, as well as cybersecurity risks and other operational risks inherent
in managing digital assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt">In particular, the Company is exposed
to the risk that the private cryptographic keys necessary to access its digital assets may potentially be lost, destroyed, or otherwise
rendered inaccessible. Any such loss could result in a partial or total loss of the affected digital assets, which would materially and
adversely affect the Company&#8217;s financial condition and operating results.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLQvZJWqtpib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82C_zPMcscojsL9h">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zO6T4pAKRQp3" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zsEBrVSVv3j" title="Preferred stock, par value">0.0001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total
of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoXTEiE3fw98" title="Preferred stock, shares authorized">350,000</span> shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent
of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations.
The holders of each tranche of <span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzkdNIvwINwj" title="Principal cash obligations and commitments">175,000</span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend
equal to <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBQbInIMDdn3" title="Preferred stock dividend, percentage">1</span>% of the annual net revenue of the Company divided by <span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGH2EqT9R8ek" title="Annual net revenue">175,000</span>, until converted or redeemed. <span id="xdx_900_eus-gaap--PreferredStockConversionBasis_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z93BDJLK69Rl" title="Preferred stock, conversion description">Each share of Series A Convertible
Preferred Stock was convertible, at the option of the holder, into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv8UBi77REL2" title="Preferred stock convertible into common stock">0.20833</span> shares of common stock (subject to customary anti-dilution
provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a
merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zafabE8HDhC7" title="Gross proceeds from sale of transaction">21,875,000</span>. </span>The Series A Convertible Preferred Stock
had a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred Stock did
not have any cash liquidation preference rights or any registration rights. Based on the attributes of the Series A Convertible Preferred
Stock as previously described, the Company accounted for the Series A Convertible Preferred Stock as a permanent component of stockholders&#8217;
equity. The <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z7m0NXVp5WA" title="Preferred stock, shares outstanding">350,000</span> outstanding shares of Series A Convertible Preferred Stock were converted into a total of <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWPilQQMsrxf" title="Preferred stock convertible into common stock">72,917</span> shares of common
stock pursuant to a notice of conversion dated May 16, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2025, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series B Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total
of <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zYE3Z8m2HGk3" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQT4GcVBq0Fj" title="Preferred stock, shares outstanding">3,573,130</span></span> shares as Series B Convertible Preferred Stock with a stated value of $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOxmQGkzZpbe" title="Preferred stock liquidation preference per share">0.7146</span> per share. Each Preferred Share is convertible
into one share of Common Stock, subject to standard adjustments such as stock splits and stock dividends. The Preferred Shares are non-voting,
except that certain actions of the Company may not be taken except upon approval of holders who own a majority in stated value of the
Preferred Shares. The Preferred Shares bear an 8% per annum cumulative dividend non-compounding and payable at conversion either in cash
or, at the holder&#8217;s election, in shares of Common Stock valued at the then effective conversion rate. The holders of the Preferred
Shares have the right to designate two members to the Company&#8217;s Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 and December 31, 2024, the Company had <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBClampbIq44" title="Undesignated preferred stock">6,076,870</span> shares and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuYwtxA7eA0i" title="Undesignated preferred stock">9,650,000</span> shares, respectively, of undesignated preferred
stock, which may be issued with such rights and powers as the Board of Directors may designate. On October 21, 2025, the Company filed
a Certificate of Elimination of Certificate of Designations of Series A Convertible Preferred Stock with the Delaware Secretary of State
to amend the Company&#8217;s certificate of incorporation to eliminate the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20251021__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmAbLRV6GRDi" title="Convertible preferred stock shares issued upon conversion">350,000</span> shares of Preferred Stock associated with the Series
A Convertible Preferred Stock classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zZbV7kgLVITj" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zhxHRTJzu6bk" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_zAssprUWK9ma" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zsCj204RVMXl" title="Common stock, par value">0.0001</span></span> per share. As of September 30, 2025 and
December 31, 2024, the Company had <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20250930_zzPQPUjVggn8" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250930_ztT5FzpCcsqh" title="Common stock, shares outstanding">5,704,200</span></span> shares and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zqVPKEpGRoue" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zTO7SAQ0yP43" title="Common stock, shares outstanding">2,249,290</span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
20, 2023 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company completed a registered direct offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkji6hwJgN69" title="Number of common stock shares issued during period">180,000</span> shares of common stock at $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zu5RM9pbjg9l" title="Sale of stock price per share">6.00</span> per share and pre-funded
warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zk1EvCJHtW9b" title="Warrants to purchase shares">403,334</span> shares of common stock at $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zEMqyaHOrShf" title="Common Stock, Par or Stated Value Per Share">5.9999</span> per warrant. The pre-funded warrants had an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z1NGIH7YqFdc" title="Warrant exercise price">0.0001</span>
per share, were immediately exercisable, and were fully exercised between July 24 and August 7, 2023 for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z3ndgAQcx6dc" title="Exercise of common stock options">41</span>.
The pre-funded warrants were deemed to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, the Company issued to the same institutional investor common stock purchase warrants to acquire <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zAEY7d9C3FFe" title="Warrants to purchase shares">583,334</span>
shares at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzDPZ0QnxDy7" title="Warrant exercise price">6.00</span> per share. These warrants became exercisable immediately and expire on July 20, 2028. The warrants
and underlying shares were issued pursuant to Section 4(a)(2) and Rule 506(b) of the Securities Act and were subsequently registered
for resale under a Form S-3 declared effective on May 2, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zr5nAn5FtIi" title="Proceeds from issuance initial public offering">3,499,964</span> from the combined transactions and net proceeds of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zPOwVLUSLc" title="Net proceeds from issuance of stock">3,137,039</span> after deducting offering
expenses of $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zgi1V87tzJ02" title="Costs of public offering">362,925</span>. As compensation, the placement agent received warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zxsSPvbgPdg7" title="Warrants to purchase shares">35,000</span> shares of common stock at an exercise
price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zrChCvITZEo8" title="Warrant exercise price">6.60</span>, expiring <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zwQR9bfAu0t5" title="Warrant expires date">July 20, 2028</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investor warrants include standard anti-dilution adjustments and a fundamental transaction provision entitling the holder, upon a qualifying
transaction, to elect cash settlement based on a defined Black-Scholes valuation formula. If such a transaction is outside the Company&#8217;s
control (e.g., not board-approved), the holder is entitled to receive the same form of consideration received by common shareholders.
These warrants are classified in permanent equity. Any cash payments upon settlement will be recorded as equity distributions when and
if such obligations arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February
13, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 13, 2025, the Company completed a registered direct offering of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250213__20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXWgP9FJrPng" title="Number of common stock shares issued during period">434,784</span> shares of common stock at $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zhn6iXHWTfx3" title="Sale of stock, price per share">2.415</span> per share and, in a
concurrent private placement, issued warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zt2GZjPp2ZX1" title="Warrants to purchase shares">434,784</span> shares of common stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAvzIUI7E157" title="Warrant exercise price">2.29</span> per share. The
warrants are immediately exercisable and expire <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYplFEvhQJ3" title="Warrants term">five years</span> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants and underlying shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act and
were subsequently registered for resale on a Form S-1 declared effective on April 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
proceeds from the offering were $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zBowH4qR6g57" title="Proceeds from issuance initial public offering">1,050,003</span>, with net proceeds of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zORULInTsB66" title="Net proceeds from issuance of stock">914,228</span> after deducting $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zIbID5N297M1" title="Costs of public offering">135,775</span> in placement agent fees and other
offering costs. The Company granted the placement agent warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zQlILjiwlNVj" title="Warrants to purchase shares">32,609</span> shares of common stock at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_z4aTsu0PM44c" title="Warrant exercise price">3.0188</span> per share, expiring
<span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXc3eAd7IAng" title="Warrant expires date">February 11, 2030</span>. Net proceeds are being used for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
warrants include customary anti-dilution adjustments and a &#8220;fundamental transaction&#8221; provision. If a qualifying transaction
within the Company&#8217;s control is consummated, holders may elect cash settlement equal to the Black-Scholes value. For transactions
outside the Company&#8217;s control, holders are entitled to receive the same consideration as common shareholders. The warrants are
classified in permanent equity. Any future cash settlements will be accounted for as equity distributions upon occurrence of the related
fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
2, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement (the &#8220;Offering&#8221;)
<span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zpBmiU7kXqGi" title="Private placement shares">3,573,130</span> shares of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;); <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250630__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCntfi9fhM29">59,552</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Common Stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhs5jTcI941c">0.0001</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Common Shares&#8221;, the &#8220;Common
Stock&#8221;); common stock warrants (the &#8220;Common Stock Warrants&#8221;) to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zvp0JgwBD5Z2">6,355,214</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock; and Pre-Funded Warrants to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantsMember_zHaHCUSZmLQg">2,322,532</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Shares, the Common Stock Warrants, Pre-Funded Warrants, the Preferred Shares,  and the shares of
Common Stock underlying the Common Stock Warrants, Pre-Funded Warrants and Preferred Shares have been registered under the
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were issued in reliance on an exemption from the
registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. The Company filed a registration statement on
Form S-1 (the &#8220;Resale Registration Statement&#8221;) to cover the resale of the Common Shares and any shares of Common Stock
underlying the Pre-Funded Warrants, the Common Stock Warrants, the Placement Agent Warrants and the Preferred Shares, which was
declared effective by the Securities and Exchange Commission on July 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DescriptionOfOfferingPrice_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCILqsApGJyf" title="Description of offering price">The
Offering was priced at-the-market under Nasdaq rules at $0.8396 per common stock unit, with each unit consisting of one share of common
stock at a price of $0.7146 and one common stock warrant at a price of $0.125 to acquire one share of common stock at an exercise price
of $1.00 per share.</span> The Offering resulted in gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250630__20250630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zH42JvBt92N7" title="Gross proceeds">5,050,000</span> before deducting the placement agent&#8217;s fees and related
offering expenses of $<span id="xdx_909_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNrVN03cDj3" title="Offering expenses">871,838</span>. The initial Offering closed on July 2, 2025 with the Company receiving gross proceeds of approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250702__20250702__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4u2tzfI6sf7" title="Gross proceeds from initial offering">4,050,000</span>. The remaining $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250718__20250718__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZl95ubOMRj8" title="Gross proceeds from initial offering">1,000,000</span> of gross proceeds were paid on July 18, 2025 upon the Resale Registration Statement having been
declared effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Placement Agent Agreement dated as of June 30, 2025, the Company engaged Spartan Capital Securities, LLC (the &#8220;Placement Agent&#8221;)
to act as the Company&#8217;s exclusive placement agent in connection with the Offering. The Company paid the Placement Agent a cash
fee equal to 8% of the aggregate gross proceeds raised in the Offering, a non-accountable expense allowance of 1.0% of the aggregate
gross proceeds raised in the Offering, and $<span id="xdx_90C_eus-gaap--LegalFees_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zGcmhkDjtCZ3" title="Legal fees">125,000</span> for its expenses including legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent&#8217;s Warrants&#8221;) to purchase
up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7P2LhTkZ113" title="Warrants to purchase of common stock">315,626</span> shares of Common Stock, which represented 5% of the Shares and Pre-Funded Warrants sold in the Offering. The Placement
Agent&#8217;s Warrants had an exercise price of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_dp_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJ7hhsLL8D9" title="Warrants exercisable price per share">125</span>% of the offering price and otherwise had the same terms as the Common Stock Warrants.
On July 15, 2025, the Placement Agent&#8217;s warrants were exercised on a cashless basis, resulting in the Placement Agent being issued
<span id="xdx_904_eus-gaap--SharesIssued_iI_c20250715__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsvOqJrKrFRi" title="Number of shares issued">221,690</span> shares of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 2, 2025 through September 30, 2025, <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250702__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zylM2vUpxJk1" title="Warrants exercisable">1,662,760</span> pre-funded warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zgfQK5mkLNE3" title="Warrants exercisable price per share">0.00001</span> per share that were sold
in the private placement were exercised, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250702__20250805__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zetthfjE6ZFa" title="Number of shares issued">1,662,760</span> shares of Common Stock. During the period from October
1, 2025 through October 31, 2025, an additional <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqCCtwHSeey7" title="Warrants exercisable">475,521</span> pre-funded warrants exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zwDvDWhC0B2c" title="Warrants exercisable price per share">0.00001</span> per share and sold in the private
placement, were exercised, resulting in the issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn1TAV9Zzvf3" title="Number of shares issued">475,521</span> shares of Common Stock. As of October 31, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwuMEizjpsAb" title="Pre-funded warrants remained unexercised">184,251</span> pre-funded warrants
remained unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the purchasers and to the placement agent are subject to customary adjustments for stock splits,
stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#8217;s common stock.
In addition, the warrants issued contain a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction
(including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control,
the holders of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment of the warrants, cash
consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction is not within
the Company&#8217;s control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion)
as the holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#8217;s assets, as
defined in the July 2, 2025 warrants, to the extent that the warrants are outstanding at the effective date that such a transaction is
closed, this &#8220;fundamental transaction&#8221; provision would entitle the holders to substantial cash consideration, thus reducing
the amounts to be retained by the Company or potentially distributable to the Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July
8, 2025 equity offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2025, the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering
(the &#8220;Offering&#8221;) <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250703__20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmwSiWtLi4v7" title="Number of shares issued and sold">210,675</span> shares (the &#8220;Common Shares&#8221;) of the Company&#8217;s Common Stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTH5zLAGYEZ5" title="Common stock, par value">0.0001</span>
per share (the &#8220;Common Stock&#8221;) and Pre-Funded Warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4YWchxOvC06" title="Warrants to purchase of common stock">763,351</span> shares of
Common Stock, at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTBAubL2yrp8" title="Offering price per share">1.54</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering resulted in gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250703__20250703__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHjxFnHLOLm6" title="Gross proceeds">1,500,000</span> before deducting placement agent&#8217;s fees and related offering expenses of $<span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztViDmKtOWA9" title="Offering expenses">169,188</span>.
The Offering closed on July 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Placement Agent Agreement dated as of July 3, 2025 (the &#8220;Placement Agent Agreement&#8221;), the Company engaged Spartan Capital
Securities, LLC (the &#8220;Placement Agent&#8221;) to act as the Company&#8217;s exclusive placement agent in connection with the Offering.
The Company paid the Placement Agent a cash fee equal to 8.0% of the aggregate gross proceeds raised in the Offering, and agreed to reimburse
the Placement Agent $<span id="xdx_901_eus-gaap--LegalFees_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zj691v7dSM4d" title="Legal fees">40,000</span> for its legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 8, 2025 through August 18, 2025, all <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcsincbDe1d1" title="Warrants exercisable">763,351</span> pre-funded warrants exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKBSjahIc3Lf" title="Warrants exercisable price per share">0.00001</span> per share that were sold
in the direct registered offering were exercised, resulting in the issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAqOobpvy0Jk" title="Number of shares issued">763,351</span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
Issued for Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Market Awareness Agreement with MicroCap Advisory, LLC entered into during August 2025 and terminated in September
2025, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z8BPou2phvA" title="Shares Issued for Services, shares">9,181</span> shares of its common stock, valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z9LTtHb4hL9d" title="Shares Issued for Services, value">44,711</span>, as settlement of the original <span id="xdx_909_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_zNxheEMOJtAe" title="Shares Issued for Services">48,000</span> common share obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLMEP9B3SPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offerings, but excluding pre-funded warrants, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zOW3PTkJm0Dg" style="display: none">Schedule of Warrants Outstanding</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (in Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbLrUoVZwJCi" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6AHvW9y4V29" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">16.407</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwSXgkLGdfZc" style="text-align: right" title="Number of Shares, Issued"><span style="font-family: Times New Roman, Times, Serif">7,138,233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhrcAB0cqCY4" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif">1,096</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFRGGrhhcBwa" style="text-align: right" title="Number of Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif">(335,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS53Czvd9U4k" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">1.31</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zc1dVWXKf6h1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCWHJwgaB2k6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYsGkWW2f4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za6s0mfAUDR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">2.715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zx4qnnj4z9Ib" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">4.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrOJu4pl9rDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbyPAFAbJ7D8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">16.407</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlHcPudAHm13" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjJMkJFfSPBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">2.715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LFkTAwSHD8" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">4.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zDAb2IMK5oQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zmxEoO6hcpIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9EBrlQodZ3h" style="display: none">Schedule of Warrants Outstanding and Exercisable</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 47%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1UbhatmWlf6" title="Exercise Prices">1.0000</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z76d4jVXfEj1" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">6,355,214</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5Snwck6OJ5h" title="Exercise Prices">2.2900</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1wSZ4uWjhU7" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">414,784</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq5gllk1hyFi" title="Exercise Prices">3.0188</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq7PgTU81iM3" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">32,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKSbDz7Ho2Ka" title="Exercise Prices">6.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zn4IqgdoLFq7" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">583,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zw9YH3Jl64z1" title="Exercise Prices">6.6000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEosBDDDu4j1" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z0O3OlRmBUZk" title="Exercise Prices">20.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znQLZIPvm5F6" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">29,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDavLkZBj0Qk" title="Exercise Prices">37.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zsCTHMezFidb" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">11,331</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zZQEKaBA5dza" title="Exercise Prices">57.0000</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPFVokWjGrVa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">149,700</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930_zNpbqZzBUuX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zD8W2llb0zrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPzHUOB8wBWe" title="Warrants exercisable">57.00</span> per share at September 30, 2025 consist of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlmzaR36heel" title="Warrants outstanding">1,497,000</span> publicly-traded warrants, described herein on a pre-split
<span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwnjSAGEZxLi" title="Reverse stock split">1-for-10</span> basis, that were issued as part of the Company&#8217;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU3g44BDqF72" title="Reverse stock split">1-for-10</span> reverse split of the Company&#8217;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVrqZR5YGy5" title="Exercise price">5.70</span> per share. Accordingly, the exercise of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv8WZMMcqmw1" title="Warrants exercise">10</span> warrants, each exercisable at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBZUTWAZyOI1" title="Warrants exercisable">5.70</span>, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp1J4T6g6Iog" title="Warrants exercise price">57.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXJTNYkbhavl" title="Fair market value of stock">5.030</span> per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock warrants at September 30, 2025 was approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250930_zZjqF7wG0O42" title="Exercisable unexercised, intrinsic value">20,113,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBEZtVD1pfj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_823_z2zSY6rVfgef">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023, 2024 and 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zoGTLzys5Ghc" title="Annual salary">250,000</span>.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_z42046w4T2Ie" title="Annual salary">150,000</span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZQoAivaWNFg" title="Increase in annual salary">175,000</span>.
Dr. Miser was required to devote at least 50% of his business time to the Company&#8217;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the three months and nine months ended September 30, 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPVLULzG7bX8" title="Compensation">14,583</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwA6p7huRxIk" title="Compensation">102,083</span>, respectively, to Dr. Miser under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zoCCEt0QVW5g" title="Annual salary">120,000</span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_90D_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z6uwVYWywUTg" title="Increase in annual salary">175,000</span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zwNF9nTympwe" title="Compensation">200,000</span>. The employment agreement with Mr. Forman terminated upon his resignation as an officer
of the Company effective December 31, 2024. During the three months and nine months ended September 30, 2024, the Company paid $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFqi8QWUkc3" title="Compensation">50,000</span>
and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRIpCYOgH3o9" title="Compensation">150,000</span>, respectively, to Mr. Forman under this employment agreement, which costs are included in general and administrative costs
in the Company&#8217;s consolidated statements of operations for such periods. Additionally, Mr. Forman was provided a monthly office
rent allowance, pursuant to which the Company paid $<span id="xdx_908_eus-gaap--PaymentsForRent_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zcHOoXqu5Hle" title="Paid office rent">2,843</span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zItwyct990aj" title="Paid office rent">12,058</span> during the three months and nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_90E_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zCvj0aP4stzl" title="Annual salary">120,000</span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_904_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z046HC6O7rP8" title="Increase in annual salary">175,000</span>. The employment agreement with Mr. Weingarten terminated upon his resignation as an officer of the Company effective August
31, 2025. During the three months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRj3FxVjK6r3" title="Compensation">29,167</span> and $<span id="xdx_905_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZZB5PP51xU7" title="Compensation">43,750</span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods. During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_907_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8V232BevDl4" title="Compensation">116,667</span> and $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWIR5r25H8k" title="Compensation">131,250</span>, respectively,
to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_900_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGPnKJIsAtNl" title="Annual salary">150,000</span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Effective June
16, 2025, the employment agreement was amended to provide that Mr. van der Baan will serve as President and Chief Scientific Officer
of the Company. Effective September 1, 2025, Mr. van der Bann resigned as President, but remained as the Company&#8217;s Chief Scientific
Officer. The term of the employment agreement was for three years and is automatically renewable for additional one-year periods unless
terminated by either party, subject to early termination provisions as described in the employment agreement. During the three months
ended September 30, 2025 and 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20250701__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztf31SRGcUzg" title="Compensation">41,403</span> and $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDtS7pppnzS5" title="Compensation">39,175</span>, respectively, to Mr. van der Baan under this employment agreement,
which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTH15zSkOyl4" title="Compensation">118,604</span> and $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zUaXpBBdI13l" title="Compensation">115,754</span>, respectively, to Mr. van der Baan under
this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#8217;s Chief Medical
Officer. The term of the agreement was in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#8217;
notice, (ii) Dr. Schellens&#8217; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#8217;s Chief Executive Officer. The Company paid Dr. Schellens annual compensation
of <span id="xdx_901_eus-gaap--ShareBasedCompensation_uEUR_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zfGpqJAIqWhc" title="Annual compensation">104,000</span> Euros, payable on a monthly basis. Effective as of July 31, 2025, the Company agreed to accept the resignation of Dr. Schellens
and to terminate his consulting agreement, to allow Dr. Schellens to pursue other employment opportunities. During the three months ended
September 30, 2025 and 2024, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuD0jvzU9mp7" title="Compensation">10,179</span> and $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zDOY09cawpUf" title="Compensation">28,717</span>, respectively, to Dr. Schellens under this consulting agreement, which
costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $<span id="xdx_901_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zqxygFp2LVIf" title="Compensation">67,494</span> and $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zdHtwVZwc4fj" title="Compensation">28,717</span>, respectively, to Dr. Schellens under
this consulting agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board of Directors only in
the form of cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#8217;s other non-officer directors.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zuwgrEbKcTM1" title="General administrative expense">0</span> and $<span id="xdx_904_eus-gaap--GeneralAndAdministrativeExpense_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zPKg1aB1ePo8" title="General administrative expense">0</span>, respectively, with respect to his annual cash board compensation. During the nine months ended
September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations
of $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zfCUcup197S4" title="General administrative expense">0</span> and $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4mbEbGodiDb" title="General administrative expense">10,000</span>, respectively, with respect to his annual cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash during 2024, effective with the quarter ended June 30, 2024, Dr. Bernards
agreed to receive equity-based compensation for his services on the Board of Directors, for the quarters ended June 30, 2024 through
December 31, 2024. In order to reconcile his Board of Directors compensation with that of the other non-officer directors, Dr. Bernards
agreed to receive the same Board of Directors compensation, both in form and amount, as the other non-officer directors for the year
ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, Dr. Bernards resigned from the Board of Directors of the Company and was appointed as Chairman of the Company&#8217;s
Scientific Advisory Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 16, 2025, the Company entered into an employment agreement with Geordan Pursglove pursuant to which Mr. Pursglove was appointed
as the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors for a term of three years, subject to automatic
termination if the Company did not complete a successful financing that would enable it to maintain its listing on the Nasdaq Capital
Market by July 3, 2025, which was accomplished on July 2, 2025. Under the employment agreement, Mr. Pursglove will receive an annual
salary of $<span id="xdx_906_eus-gaap--SalariesAndWages_c20250616__20250616__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zbkymLim3SH4" title="Annual salary">240,000</span>, which may be increased from time to time in the sole discretion of the Board of Directors. At his election, Mr. Pursglove&#8217;s
compensation will be payable in cash and/or restricted shares of common stock, or a combination thereof. He will also be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors in the form of cash or equity, or a combination
thereof. Mr. Pursglove will not receive any additional compensation for serving as Chairman of the Board of Directors. During the three
months and nine months ended September 30, 2025, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zryiS53kemY6" title="Compensation">60,000</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zZ8fqca1tkic" title="Compensation">70,000</span>, respectively, to Mr. Pursglove under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company appointed Geordan Pursglove as the Company&#8217;s President as the result of the resignation of Bas van
der Baan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company entered into an employment agreement with Peter Stazzone to act as the Company&#8217;s Chief Financial
Officer, for a term of one year, automatically renewable for additional one-year periods, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z1CursYvcg11" title="Annual salary">150,000</span>. During the
three months and nine months ended September 30, 2025, the Company paid $<span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z7xuCs8ZW9rd" title="Compensation">12,500</span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zc8u0GGdIG3f" title="Compensation">12,500</span>, respectively, to Mr. Stazzone under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors, which was subsequently amended effective May 25, 2022, July 9, 2024, March 21, 2025 and September
30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z1dYKt3Mivj2" title="Compensation">20,000</span> per year (except for Dr. Bernards, who was paid an additional annual cash fee of $<span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zfXW0cSM2Cp3" title="Cash">40,000</span>, in lieu of
the annual June <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zTziMSWvU0Z4" title="Stock option grant">30</span> grant of stock option as described below, through March 31, 2024)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zRZjU4szoXS4" title="Compensation">10,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_902_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zmvcSN8FNW0e" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_909_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zhjYBbOQZzgd" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zyNnII6oWYji" title="Compensation">2,500</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, the Board of Directors approved amendments to this compensation program,
such that for the quarters ended June 30, 2024 through December 31, 2025, the non-officer directors (including Dr. Bernards) have received
or will receive, in lieu of cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase
common stock at an exercise price based on the closing market price upon issuance, with the amount of such stock options equal to the
cash payment such director would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined
pursuant to the Black-Scholes option-pricing model. On September 30, 2025, the Board of Directors approved an amendment to this compensation
program such that at each quarter end, each non-officer director will have the choice as to whether to receive their quarterly compensation
in cash or in stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise price
based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director would
otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zXLfrl7c2G74" title="Options, grants in period, gross">25,000</span> shares of common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zQ8j2qUyDA1l" title="Options exercisable period">five years</span>,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zxUO3uVC65Rg" title="Share-based payment award, award vesting period">50</span>% vesting <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930_zU2mt2haJmQi" title="Award vesting rights, percentage">12.5</span>% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_ztbcyGr1UfDh" title="Cash fee payable">100,000</span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zgcOXulAstH9" title="Options, grants in period, gross">10,000</span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zDbQiB6cXVUl" title="Share-based payment award, award vesting period">12.5</span>%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_901_eus-gaap--CostOfRevenue_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhn3Z8tJvCH5" title="Annual cash fee">40,000</span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zV0WTqAxBt3a" title="Stock based compensation">27,500</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z62qjh60HZq9" title="Stock based compensation">0</span>, respectively, for the three months ended September 30, 2025 and 2024.
Total cash compensation paid to non-officer directors was $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zdRcVhww1iP1" title="Stock based compensation">27,500</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z5aDYWEpIu8d" title="Stock based compensation">38,819</span>, respectively, for the nine months ended September 30,
2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zLCJimdBLzL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2025 and 2024, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zL0cMS94ajb6" style="display: none">Schedule of Related Party Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250701__20250930_zcdIbsCGawab" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240701__20240930_zdJ1cRuFo3Xg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250930_zl9uGesWLT28" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z9jUNNbn58Jg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zlMog63KdAt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217,416</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,226</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">566,624</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zXVc4B64A722" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z9JmKrOQ8dLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">994,027</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,053</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,593,780</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">907,069</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zU5J12vF3Vkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zIohc8vwLk4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_824_zlZJurXRODn1">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zV8AYlRJ6SZf" title="Number of restricted stock issued">233,333</span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zgnF4tWqeVf8" title="Common shares avaliable for issuable">180,000</span> shares, to a total of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUcCJlzBXpze" title="Shares total">413,333</span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zrRYyne3KBa5" title="Common shares avaliable for issuable">336,667</span> shares, to a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zeaVlwv1scc5" title="Shares total">750,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, unexpired stock options for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z1rsQGIMaUDa" title="Shares outstanding">694,309</span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvW2SKiDrlB5" title="Shares were available for issuance">55,691</span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsyplzXokm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2025, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxe1ze8AJ6P9" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250101__20250930_zfDeiQPPq802" title="Risk-free interest rate minimum">3.58</span>%
    to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250101__20250930_z9yRnL5v31Y1" title="Risk-free interest rate maximum">3.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20250101__20250930_zlaO1TZhMRGh" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: -3.9pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20250101__20250930_zRKfZI8CZmWa" title="Expected volatility minimum">128.78</span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20250101__20250930_zZqyHmpbs9J" title="Expected volatility maximum">139.42</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_z0QAUqANASf3" title="Expected life">2.5</span>
    to <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zdU5gdc2VqWe" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20240101__20240930_zPq2t6s3INs" title="Risk-free interest rate minimum">3.55</span>%
    to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20240101__20240930_zIvW7UAUMiK1" title="Risk-free interest rate maximum">4.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20240930_ziZpmFFOyoY6" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20240101__20240930_zAF8Sf0L6wsg" title="Expected volatility minimum">125.59</span>
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20240101__20240930_zatfMJ5aqwV5" title="Expected volatility maximum">126.45</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zDXFVVxLNRKg" title="Expected life">2.5</span>
    to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zvGTAGTgpIQl" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8A8_zMWdC4QeEwBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4b0U5Vy0DRa" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7aIqnkJn6L2" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zSco97drUuSe" title="Stock options are exercisable price per share">7.40</span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z39t4QRA3Kbf" title="Stock options description">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</span> The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zgYjjTMXDtId" title="Fair value of stock options">158,525</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjZxvlxu9nf5" title="Stock price per share">6.341</span>
per share), of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZq2raHj9fr1" title="Stock options vested">79,263</span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the three months and nine months ended September 30, 2024, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zoHgZkF1IZhb" title="Stock based compensation">0</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zHe9ja4TjsO5" title="Stock based compensation">19,390</span>, respectively, with respect to these stock
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zS01Nplba2ci" title="Fair value of stock options">10,000</span> shares (a total
of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoBcSzbo9LCk" title="Stock price per share">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zLCuiZFm9Nrh" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zd8p1iqOgsC8" title="Stock options are exercisable price per share">7.40</span> per share
(the closing market price on the grant date), <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoRSI7t2WO42" title="Stock options description">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zkl3x9Be0PY1" title="Fair value of stock options">316,700</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zW3NWw8MHnRd" title="Stock price per share">6.334</span> per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the three months and nine months ended September 30, 2024, the Company recorded a charge to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zQ7whBFLDPY8" title="Stock based compensation">0</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zaqQ5a0f6v0k" title="Stock based compensation">47,310</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zthvzf8XOHH8" title="Number of stock option granted">20,000</span> shares
(a total of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zTChVV1c9XCc" title="Number of stock option exercisable">80,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHoMdJpKB6hj" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zcyjGUlrfoIk" title="Exercise price of options">20.00</span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zp0hm39r0pMg" title="Stock options description">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</span> The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4F5UkcGDeza" title="Stock options granted to purchase common stock, issued">80,000</span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zPFsc9abnuak" title="Fair value of stock options">262,560</span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znPs2ImgA1q4" title="Stock price per share">3.282</span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjP1kvOyrZIe" title="Stock based compensation">4,132</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdxA7goZOASh" title="Stock based compensation">9,641</span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z2kLy9ITx8kj" title="Stock based compensation">12,264</span>
and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zaHnJfWYMyAc" title="Stock based compensation">34,304</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zsImUudkcvfg" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zlAAC25EKIPk" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zR60LRzjWbO7" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRs63wYdiI7j" title="Exercise price">5.88</span> per share
(the closing market price on the grant date), <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJdl8WKpRn76" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zW2m3eT0xCBh" title="Fair value of stock options">192,593</span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zMkq6EvdRt5i" title="Stock price per share">4.8131</span> per share), which was charged to operations ratably from July 1, 2023 through June 30, 2025. During
the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zzJPAv7SwcUb" title="Stock based compensation">0</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zGjGQs1S0Vhe" title="Stock based compensation">24,232</span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zH0XbEu4aBrh" title="Stock based compensation">47,672</span>
and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLuU7Z99A4Y5" title="Stock based compensation">72,300</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted a stock
option to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO6mtqDyhATb" title="Options, grants in period, gross">250,000</span> shares of the Company&#8217;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of five years at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z1dlH9abT7uj" title="Stock options are exercisable price per share">1.95</span> per share, which was equal to the closing market price
of the Company&#8217;s common stock on the grant date. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbffV98p1Joc" title="Options vesting term">The stock option initially vested in equal increments quarterly over a three-year
period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</span> The fair value of
this stock option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrx1hclsIfwj" title="Fair value of stock options">403,066</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zL6Vu6rYWL14" title="Stock price per share">1.612</span> per share),
which was being charged to operations ratably from September 26, 2023 through September 30, 2026. Effective June 16, 2025, in connection
with an amendment to Mr. van der Baan&#8217;s employment agreement (see Note 6), the stock option was deemed fully vested and the remaining
unamortized fair value was charged to operations on such date, and the time period for Mr. van der Baan to exercise this stock option
at any time in the future that he is no longer providing services to the Company as a consultant, employee or otherwise was increased
from ninety days to one year. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and
administrative costs in the consolidated statements of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpFgpWER9OK" title="Stock based compensation">0</span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUkwhxrUMzf4" title="Stock based compensation">33,712</span>, respectively, with respect to this stock option.
During the nine months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbFQg6WbkuB" title="Stock based compensation">233,784</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2aWlP7zstre" title="Stock based compensation">100,402</span>, respectively, with respect to this stock option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_znb5TqF57Zo6" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zaK3CJ0lBOk5" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zayRDXmyv4Wg" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYinoXbtOLya" title="Exercise price">2.37</span> per share
(the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zlseYSg9iEQ" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zSUtQrOTXra" title="Fair value of stock options">73,976</span> ($<span id="xdx_900_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zFklPNCRQFKb" title="Stock price per share">1.8494</span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zxdWlzUf2fzf" title="Stock based compensation">9,324</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zW6Fa1seX156" title="Stock based compensation">6,993</span>, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzpN38u8Ngjd" title="Stock based compensation">9,324</span>
and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4CzReg2Xopg" title="Stock based compensation">25,333</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zjkmaO9cMm48" title="Fair value of stock options">16,598</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6qL8K9L6an8" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zkzlMs49jUee" title="Exercise price">2.37</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRcCoIDlSWdi" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6rY0uUnW44h" title="Fair value of stock options">27,500</span> ($<span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zD3MixaJV6Vh" title="Stock price per share">1.6570</span> per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted a stock
option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zRUTp9yrQlD4" title="Fair value of stock options">15,000</span> shares of the Company&#8217;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zWCdwhWtLz2h" title="Stock option vested exercisable term">five years</span> at an exercise e price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zIDwurdgYNzk" title="Exercise price">2.39</span> per share, which was equal to the closing market price
of the Company&#8217;s common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zifUDNZtU1J8" title="Share based compensation vesting rights, percentage">The stock option vested quarterly over a three-year period commencing on the last
day of each calendar quarter commencing September 30, 2024.</span> The fair value of this stock option, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zrFPR0cGi7Lf" title="Fair value of stock options">29,074</span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z9y8JcNRx9e2" title="Stock price per share">1.9382</span> per share), which is being charged to operations ratably from July 1, 2024
through June 30, 2027. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative
costs in the consolidated statements of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zQdwrMjzCcyi" title="Stock based compensation">0</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zUlIPxHHlE74" title="Stock based compensation">2,418</span>, respectively, with respect to this stock option. During the nine
months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements
of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoRKBTIEWPR7" title="Stock based compensation">4,810</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zPvHloitGUif" title="Stock based compensation">2,418</span>, respectively, with respect to this stock option. Effective as of July 31, 2025, the Company agreed
to accept the resignation of Dr. Schellens and to terminate his consulting agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z1z1abyToHR7" title="Fair value of stock options">21,217</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1JM6cdEhytd" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zppS4l7Ft7ai" title="Exercise price">1.87</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z0GA56Acd5s4" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znQiisOLIWr3" title="Fair value of stock options">27,500</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znCkNv67Eh4j" title="Stock price per share">1.2961</span> per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zOWCjt6CGWc3" title="Fair value of stock options">16,665</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zAbQ0OE88392" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWiRSwycgRW5" title="Exercise price">2.33</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9l68rnYIpDa" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zdt9nSmjGmI8" title="Fair value of stock options">27,500</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zDCTij9p76El" title="Stock price per share">1.65002</span> per share). The grant date value of the stock options of $<span id="xdx_900_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6TIua4GRm0a" title="Fair value of stock options">27,500</span> was accrued at December
31, 2024 and charged to operations at that date. During the nine months ended September 30, 2025, there was no expense charged to operations
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z10NaCBkSs86" title="Fair value of stock options">32,181</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z793ToKRxqC6" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3pZ40QMaSaf" title="Exercise price">1.21</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRD5t1pECkd1" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended March 31, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1jnBTuB7T7k" title="Fair value of stock options">27,500</span> ($<span id="xdx_907_eus-gaap--SharePrice_iI_pp5d_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZnv70A92yug" title="Stock price per share">0.8546</span> per share), which was charged to operations on March 31, 2025, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zm5fcu29pkI4" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zt7BT2t4Ugi8" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zOebc78z2Gm6" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zw1n3vq0XvLi" title="Exercise price">0.905</span> per share
(the closing market price on the grant date), <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_z0h0dcDaB7Ij" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdKfed54C6qa" title="Fair value of stock options">28,700</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zH5w36MVIAwj" title="Stock price per share">0.7175</span> per share), which is being charged to operations ratably from July 1, 2025 through June 30, 2027.
During the three months and nine months ended September 30, 2025, the Company recorded a charge to operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrmso34NSu8h" title="Stock based compensation"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTAZJLxT5Mo9" title="Stock based compensation">2,712</span></span> with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_ztfk4prcpwtk" title="Purchase of stock options shares">42,648</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJ6JgmbYx2ph" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkoY0BTQ7BM4" title="Exercise price">0.905</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zPtmgTvUi0ok" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3hEhZB4Lyb8" title="Fair value of stock options">27,500</span> ($<span id="xdx_909_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJta4OabAeTb" title="Stock price per share">0.6448</span> per share), which was charged to operations on June 30, 2025, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the employment agreement entered into with Geordan Pursglove, effective as of July 3, 2025, the end of the first trading
day of the Company&#8217;s common stock immediately following the successful completion of the above referenced financing, as an inducement
to Mr. Pursglove to join the Company, as a signing bonus, Mr. Pursglove was granted a stock option to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zSm24KQWqeO1" title="Stock option, granted">350,000</span> shares of the
Company&#8217;s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z79A5JlE6oF6" title="Stock options are exercisable price per share">2.83</span> per share (the closing market price on the grant date), for a term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zpeoMUzKjHue" title="Stock option vested exercisable term">five
years</span>, exercisable on a cashless basis and vesting <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7HSXSMliD78" title="Stock option, vesting percentage">50</span>% on the grant date, <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250930__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4SGZa18TMx2" title="Stock option, vesting percentage">25</span>% on September 30, 2025, and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20251231__20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziBFEU30GNof" title="Stock option, vesting percentage">25</span>% on December 31, 2025, subject
to continued service. The stock option grant was not issued under the Company&#8217;s 2020 Stock Incentive Plan. The stock option agreement
provides for certain registration rights and for accelerated vesting upon the occurrence of certain events, including early termination
of the agreement that is not the result of his voluntary termination or termination for cause, a sale or change in control of the Company,
or a sale, licensing or other disposition of all or substantially all of the assets of the Company. The total fair value of the stock
option to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zcYuh4IGXGt2" title="Stock option, granted">350,000</span> shares of common stock, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zQVPNTUCFzy9" title="Fair value of stock options">728,671</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4p0_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z1WZOqhK1sD3" title="Stock price per share">2.0819</span> per share), which is being charged to operations from July 3, 2025 through December 31, 2025. During the three months
and nine months ended September 30, 2025, the Company recorded a charge to operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zXEYJ3rLRULh" title="Stock based compensation">546,499</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zDhHjujKf8a2" title="Stock based compensation">546,499</span>, respectively, with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2025, the Board of Directors appointed Jason Sawyer to the Board of Directors. In connection with his appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Sawyer was granted stock options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zudGNx9oUKVj" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziCC1M8wo89l" title="Stock option vested exercisable term">five
years</span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziyvoUqcWjN9" title="Stock options are exercisable price per share">3.59</span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zHb5B5r9fRI2" title="Stock options description">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</span> The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_z8QiZmbYEf8f" title="Fair value of stock options">68,360</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zXzOQV6y2wYc" title="Stock price per share">2.7344</span> per share),
of which $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zCoSVwlqjstc" title="Stock options vested">34,180</span> was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August
15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zrTgBGcUoJ22" title="Stock based compensation">38,500</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zsPONKrJlA7e" title="Stock based compensation">38,500</span>, respectively, with respect to these
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2025, the Board of Directors appointed Dr. Michael Holloway to the Board of Directors. In connection with his appointment
to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of
Directors, Dr. Holloway was granted stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zpPCDZ7SLfYb" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z7FLV8Cp5rDf" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zwuwg4nyX6K2" title="Stock options are exercisable price per share">3.59</span> per share (the closing market price on the grant date), <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z3qP1i4npCl6" title="Stock options description">vesting 50% on the grant date and
the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</span>
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z2CNPKAuDWEh" title="Fair value of stock options">68,360</span>
($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zDnl8swzO0Xf" title="Stock price per share">2.7344</span> per share), of which $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zVKS6lRTJiZ4" title="Stock options vested">34,180</span> was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore
charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations
ratably from August 15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zt68EyVReBy7" title="Stock based compensation">38,500</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zjB0VCAFVy36" title="Stock based compensation">38,500</span>, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2025, in connection with the employment agreement with Peter Stazzone, Mr. Stazzone was granted stock options to purchase
<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zrvIjPiiOisk" title="Number of fully vested option exercisable">50,000</span> shares of the Company&#8217;s common stock. The options are exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zBuEwb1d4Rik" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zitMkEj9p3ac" title="Stock options are exercisable price per share">4.45</span>
per share, which was equal to the closing market price of the Company&#8217;s common stock on the grant date. The <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zi5KTToCuqq4" title="Stock options description">options vested 25%
on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject
to continued service.</span> The stock option grant was not issued under the Company&#8217;s 2020 Stock Incentive Plan. The fair value of these
stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zdYM11S1Blra" title="Fair value of stock options">173,070</span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zsBaCUAGApRa" title="Stock price per share">3.4614</span> per share), of
which $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zEtbHWLUD9Jg" title="Stock options vested">43,268</span> was attributable to the portion of the stock options fully vested on September 1, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from September
1, 2025 through June 30, 2026. The Company recorded a charge to general and administrative costs in the consolidated statement of operations
for the three months and nine months ended September 30, 2023 of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z41x10lHn7V5" title="Stock based compensation">55,732</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z3mgoKF5fswh" title="Stock based compensation">55,732</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2025, the Company appointed Lourdes Felix and Guy Primus to the Board of Directors. Although it was the Company&#8217;s
policy to issue stock options to each new director to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zwZNiYTYPzQe" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock on the appointment date,
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zRd7SFq8MNhi" title="Stock options description">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service,</span> due to limitations with respect to the Company&#8217;s 2020 Stock Incentive Plan, the Company did not issue
these stock options on such date To account for this obligation, the Company determined the fair value of these stock options for each
new director effective September 1, 2025 to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zKXs8dZ7oXj2" title="Fair value of stock options">84,533</span> ($<span id="xdx_90D_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z3AlyB116lpe" title="Stock price per share">3.38</span> per share), as calculated pursuant to the Black-Scholes option-pricing
model, and recorded a charge to operations reflecting 50% of the fair value of such stock options on such date and a related accrued
liability. The remaining 50% of the fair value of such stock options is being charged to operations ratably through September 30, 2026.
Accordingly, a total of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zS4Pm9hxf1vc" title="Stock based compensation"><span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z5qsNMUaW7G9" title="Stock based compensation">84,533</span></span> was charged to operations for the three months and nine months ended September 30, 2025, respectively,
for this obligation, and an additional $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20260930__20260930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zmSMK17uZhSc" title="Stock based compensation">84,533</span> will be charged to operations ratably through September 30, 2026. The Company anticipates
issuing the stock options prior to December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreement of the Company&#8217;s Chief Medical Officer, Dr. James S. Miser expired on July 31, 2024, the employment agreement
of the Company&#8217;s Vice President and Chief Operating Officer, Eric J. Forman, terminated upon his resignation from the Company on
December 31, 2024, the consulting agreement of the Company&#8217;s Chief Medical Officer, Dr. Jan Schellens, was terminated effective
with his resignation on July 31, 2025, and Regina Brown, a former director, resigned from the Board of Directors effective September
1, 2025. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
services to the Company terminated. Furthermore, the expiration date of all vested stock options owned by each such person contractually
expire one year from the respective dates that their services to the Company terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
Forman, Yun Yen and Rene Bernards all resigned as members of the Board of Directors during the quarter ended September 30, 2025, although
all three continue to be of service to the Company through their membership on the Company&#8217;s Scientific Advisory Board. Similarly,
Robert Weingarten resigned as the Company&#8217;s Chief Financial Officer effective August 31, 2025, although Mr. Weingarten continues
to be of service to the Company as a consultant. Accordingly, the unvested stock options for each such person continue to vest. Furthermore,
the expiration date of all vested stock options maintain their original expiration dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3OF1ceTSh3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zg8Wd7PHcgc" style="display: none">Schedule of Stock-based Compensation Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zd5TWrO9Qe35" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240701__20240930_zW4DETeV4Bzk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250930_z5k2EcPLznU7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zFaQ1sfLAFq1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKlhKclfQ9U4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqGEfVo0zuX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Non-related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1826">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1828">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_z2UfvB4EbuXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zuGkdsyYnDvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkVKv9cNiIv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2025 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zb1KqmhwbR62" style="display: none">Schedule of Stock Option Activity Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
                                            Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding at December
    31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zESYR1cepThd" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"><span style="font-family: Times New Roman, Times, Serif">613,232</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zSZOieKqu8if" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding"><span style="font-family: Times New Roman, Times, Serif">12.317</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_zhUq2BYnjQc" style="text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">581,494</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z3I4tcpx8Z34" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.657</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930_zCKeHhL8A8M2" style="text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z98nef8tKazk" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zDEuVVlzkhH3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"><span style="font-family: Times New Roman, Times, Serif">(71,667</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zxVjRmhuXhCj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif">44.272</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zEukKDGE3OUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zqI02DpqC29h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding"><span style="font-family: Times New Roman, Times, Serif">5.276</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zDUGlsCDl4Xh" title="Weighted average remaining contractual life (in years), stock options outstanding">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zm3m9flUQbb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">409,897</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zR7pLp0soPfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">17.100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zXw2ZfeHrKDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">930,559</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zlVczi7UTR55" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">5.664</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zgeLOS7PnT0h" title="Weighted average remaining contractual life (in years), stock options exercisable">3.28</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zjFVy9k6vGc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20250101__20250930_zr4WH9d5jvMg" title="Deferred compensation expense for unvested stock options">401,000</span> at September 30, 2025, which
will be recognized subsequent to September 30, 2025 over a weighted-average period of approximately <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20250101__20250930_zYqWTmpXhCOi" title="Weighted-average recognition period">7</span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWIdtGFaJ3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zeTmtxuULFBj" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFy2vjnucImf" style="width: 30%; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">0.905</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zS3bhr7tc3l" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">72,648</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNjrN27i6Rpg" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">46,398</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zFtqQE4Ptoz6" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.210</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zINxPTH9BK0f" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">32,181</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztB4khiAhLEf" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">32,181</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVHwIeCnnc5c" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9w2Je49z8k1" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">21,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zf2InRE71Txf" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">21,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zJjsIFlC7SO4" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.950</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zHg9hz1kBov4" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPoNbTpuzlL4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7GF7Dtp5Eti" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.330</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z8AFWEiHP208" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">16,665</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPM6f8H75fw4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">16,665</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbpJHQu8nmu4" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztSoEHezMDtd" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">51,598</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSnIsAyYreO6" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zQ5tnBGzrZpf" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zgpfWwnDv5Wf" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zeW922GIljji" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zgcbd38988A5" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.830</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zWdCZaRoaIq6" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zBD725rewxz4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">262,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlUTjnnlill8" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">3.590</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zatlxUGhymj5" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztLPSILRyIV8" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zoFQgp5IaqLa" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">4.450</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEQwpU871QL3" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbkKICqJsEU5" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">12,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zpA2W3IiqC8k" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">5.025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRAC6ByBkjRi" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">8,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z19J2sZGXYn" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">8,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zkcU8Y5P0ljd" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">5.880</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqSAfehc7vh3" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zYeDACEqeQ9l" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z90CGJHOVWh6" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">7.400</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSzewf2FlBC" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zfkeV5n6vP25" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zhP56C3XEhI2" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">20.000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zjy3uCki4yPf" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zs0fdhKj4iO2" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z5wW3crMConi" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">20.600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj9l8hvCEdVb" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zfZ4i2I8Vz6l" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zNL7TafYxhG7" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">28.000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmOZK5lelfV2" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z05z3EYUt7z" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zLp5jGUcrlDl" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">30.300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zrZV3MafP269" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zWLHAYIXxFDe" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zdR2aTe07Sdc" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">32.100</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z9EiO6QI40Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zqpET658WCt7" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zv02I4tSjuI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zr1ecDZzshK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">930,559</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_z3kGiobEYIC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zcvytBh0nsA7" title="Fair market value, per share">5.030</span> per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock options was approximately $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250930_zjeIdTkTCThk" title="Intrinsic value">2,037,000</span> at September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20250930_zXK55xiF7lZ9" title="Outstanding stock options to acquire shares of common stock not vested">205,000</span> shares of the Company&#8217;s common stock had not vested at September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z0U5FMaNOFQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_828_zq6duLOo5yEi">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2025 and 2024, the Company did not record any provision for income taxes, as the
Company incurred losses during such periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zUpAvV2GQKkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_822_zYH6rh78kVYf">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2025 and
December 31, 2024, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zuwbwNyfaOrd" title="Clinical trial contractual commitment">510,000</span>, including clinical trial agreements of $<span id="xdx_907_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zL85lCVoapA3" title="Contractual commitment">292,000</span>
and clinical trial monitoring agreements of $<span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zQdZVGlsWnWj" title="Contractual commitment">218,000</span>, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended
or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial
endpoint is reached. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing active contractual clinical trials described below as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="form10-q_001.jpg"/></span></p>

<p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_z9C2hyv19g93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zBp84ylVe1U5" style="display: none">Schedule of Contractual Clinical Trials</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Start
    Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Projected
    End Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Planned
    Number of Patients in Trial</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Study
    Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Clinical
    Update</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expected
    Date of Preliminary Efficacy Signal</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NCT
    No.</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    Financial Contractual Commitment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaP5LAXEvAwb" title="Clinical trial, description">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">MD Anderson</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaO4D4TiKJTl" title="Estimated Start Date">January 2024</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zfoSrgpSA6P2" title="Estimated End Date">December
    2027</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zhflNXUAlJol" title="Number of Patients in Trial">21</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine the OS of patients with
    recurrent ovarian clear cell carcinoma</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">20 patients
    entered</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zrGZ76wbvle" title="Expected Date">December
    2026</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06065462</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zi38KavQp34c" title="Remaining financial contractual commitment">0</span>-
                                            (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztgXW15eMPf4" title="Clinical trial, description">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Netherlands Cancer Institute
    (NKI)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zsFaYt73DN6k" title="Estimated Start Date">August 2024</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zQei3Nmu7j56" title="Estimated End Date">December 2026</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zRHl3roycfN1" title="Number of Patients in Trial">37</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine RP2D with atezolizumab</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">First patient entered
    August 2024, in total two patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zpvcj4boBNxi" title="Expected Date">June 2026</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06012734</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zfujZMcBfZSa" title="Remaining financial contractual commitment">0</span>-
                                            (1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_fKDIp_z7dHCrOkjqTh" title="Clinical trial, description">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">GEIS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zQXHehVX1Cqj" title="Estimated Start Date">June 2023</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Recruitment completed
    September 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zVzDL1upQ8ma" title="Number of Patients in Trial">14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine MTD and RP2D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fourteen patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zeStniKU2End" title="Expected Date">December 2025</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT05809830</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zJcP1wJGGHX8" title="Remaining financial contractual commitment">292,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OtherCommitment_iI_c20250930_zVS6GHXac1Ke" style="text-align: right" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif">292,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_z1w4UppxP86b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zXa6OfihDjG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</span></td></tr>
  </table>
<p id="xdx_8A6_zjCIva5JTmN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) (see Note 6) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial. The Investigational Review Board (IRB) of NKI has requested additional
information with respect to these SAEs and the study has been paused for enrollment until the IRB&#8217;s questions have been satisfactorily
addressed (see &#8220;Specific Risks Associated with the Company&#8217;s Business Activities - Serious Adverse Events&#8221; below for
additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
determine the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate,
duration of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $<span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zHFzhcA2bxe4" title="Litigation settlement expense">207,004</span> for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this Agreement. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_909_eus-gaap--LitigationSettlementExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zmOvoudxcCF4" title="Litigation settlement expense">0</span> and $<span id="xdx_90A_eus-gaap--LitigationSettlementExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8G65npMwseh" title="Litigation settlement expense">78,015</span>, respectively, pursuant to this Agreement. As of September
30, 2025, total costs of $<span id="xdx_90F_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zxLg8FAyD6m9" title="Total costs">732,532</span> had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 has consistently enhanced
the anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90C_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTjHf8mL7Xq5" title="Inventory costs">1,144,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250311__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z4pxuqITXCHj" title="Aggregate commitments expected">3,095,000</span>. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2025 and 2024, the Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zN9jgSvQTnvb" title="Research and development costs"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqIiBMLmbj8f" title="Research and development costs">no</span></span>t incur any costs pursuant to this agreement. During the
nine months ended September 30, 2025 and 2024, the Company did <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0fDxddKP06d" title="Research and development costs"><span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhT7CeyAIeNj" title="Research and development costs">no</span></span>t incur any costs pursuant to this agreement. Through September 30,
2025, the Company has incurred charges of $<span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zVznNs2Nxx21" title="Amount related to milestone payment">685,107</span> for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zJyGMKZGmd37" title="Aggregate commitments expected">292,000</span>
for the Phase 1b portion of this clinical trial as of September 30, 2025, which is currently scheduled to be incurred through December
31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $<span id="xdx_903_ecustom--WorkOrderAgreementCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zcM8qGU1rfih" title="Work order agreement costs">95,000</span>. During the three months ended
September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zs6jQaCL6uEa" title="Research and development process costs">4,942</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z09aRJfvGa4b" title="Research and development process costs">12,610</span> pursuant to this letter of intent and subsequent work order.
During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z1B8Eo5MuY32" title="Research and development process costs">16,834</span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zODXHIfsH1sj" title="Research and development process costs">20,838</span> pursuant to this letter of
intent and subsequent work order. As of September 30, 2025, total costs of $<span id="xdx_904_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_zRRnNZBiDxG5" title="Research and development costs">43,597</span> have been incurred pursuant to this letter of intent
and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_za29YhEnbicj" title="Remaining financial contractual commitment">53,000</span>
as of September 30, 2025, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210205__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zKGiQHw4wBSa" title="Research and development expense">335,000</span>. During the three months ended September 30, 2025 and 2024, the Company
incurred costs of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_ztpntij1zum2" title="Research and development expense">0</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zNgHKBB8ijKg" title="Research and development expense">1,603</span>, respectively, pursuant to this work order. During the nine months ended September 30, 2025 and 2024,
the Company incurred costs of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zjKlYFwG7iC1" title="Research and development expense">0</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z6tnUsinvgRj" title="Research and development expense">10,603</span>, respectively, pursuant to this work order. As of September 30, 2025, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zEWJsuXXpRwd" title="Total costs incurred">87,823</span>
had been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_907_ecustom--EstimatedWorkCost_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zC14pE0IumWc" title="Work cost">153,000</span>, with such payments expected to be allocated approximately
<span id="xdx_90E_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zKuzrwZjebK6" title="Percentage of payment through services">72</span>% to Theradex for services and approximately <span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zaYLL26JA2Ml" title="Percentage of payment through software">28</span>% for payments for pass-through software costs. During the three months ended September
30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zES88iLLmkPi" title="Research and development costs">3,981</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zysn0G0IgXY1" title="Research and development costs">13,475</span>, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWz4OPRPrwZ3" title="Research and development costs">11,603</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zfxTLvE649Vd" title="Research and development costs">26,207</span>, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $<span id="xdx_901_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgX5vRWIvdpf" title="Total costs">61,058</span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zmKHrmLZnSuk" title="Aggregate commitments expected">91,000</span> as of September 30, 2025, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight was expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement were estimated to be approximately $<span id="xdx_901_ecustom--EstimatedWorkCost_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z4TFovY39Yg7" title="Work cost">106,380</span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zRoGOHDcFUF2" title="Percentage of payment through services">47</span>% to Theradex for services and approximately 53% for payments for pass-through software costs. During three months ended September
30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zjP9MKS3Cxvj" title="Research and development costs">4,500</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEky91wqd4Qf" title="Research and development costs">14,900</span>, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z5symzdAdXfc" title="Research and development costs">13,500</span> and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_ziZWzYE5kzCg" title="Research and development costs">14,900</span>, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $<span id="xdx_90D_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zN5mtPJPHmPb" title="Total costs">33,691</span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zosuoyYedlb" title="Aggregate commitments expected">74,000</span> as of September 30, 2025, which was expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUZFhPnTDk59" title="Non refundable license issue royalty">50,000</span> and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $<span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zqYF26Uep6F5" title="Minimum annual royalty payable">25,643</span> was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zf2blBVESAHk" title="Minimum annual royalty payable">30,000</span> is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z6TzHYFgOXi5" title="Non refundable license issue royalty">50,000</span> and the first
minimum annual royalty of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zZdTzWdzYokl" title="Minimum annual royalty payable">25,643</span> were paid in April 2024. The second minimum annual royalty for 2025 of $<span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zbjnfG9l6aw3" title="Minimum annual royalty payable">30,000</span> was paid in December
2024 and was included in other prepaid expenses in the consolidated balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, each with a different specified
benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of $<span id="xdx_908_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zC3DxGQg7rm6" title="Dosing of product">100,000</span> was defined
as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product in the licensed fields
of use. The Company had not commenced a Phase 2 clinical study as of June 30, 2025. The total of all such benchmark payments is $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zl70yE30aGN5" title="Payment for royalties">1,225,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_909_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zQuXp9xvX2D1" title="Royalty percentage">5</span>% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250701__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zUqz7NusFPcc" title="Research and development process costs">7,397</span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240701__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zsjmmsOjUVfc" title="Research and development process costs">7,537</span>, respectively, in connection with
its obligations under the License Agreement. During the nine months ended June 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z1MAqiGL28dh" title="Research and development process costs">22,191</span>
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zrdCARGgP48a" title="Research and development process costs">68,106</span>, respectively, in connection with its obligations under the License Agreement. Such costs when incurred have been included
in general and administrative costs in the Company&#8217;s consolidated statement of operations. As of September 30, 2025, total costs
of $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_ztjIqJAUZhSh" title="Research and development costs">97,835</span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts
previously paid to date, totaled approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zwx7mKI1VFb7" title="Aggregate commitments expected">1,765,000</span> as of September 30, 2025, which is expected to be incurred over approximately
the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $<span id="xdx_903_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zfvsvOapXVs7" title="Consulting and advisory fee">4,000</span>. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $<span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zN3VJggqVXK" title="Consulting and advisory fee">4,000</span> and $<span id="xdx_905_ecustom--ConsultingAndAdvisoryCashFee_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_ze29iZyqKYRg" title="Consulting and advisory fee">12,000</span> for the three months and nine months ended September 30, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPtW1gOmPXt8" title="Consulting and advisory fee">10,000</span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90A_ecustom--ReimbursementExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zrMpUQzZQC75" title="Reimbursed expense">13,600</span> and $<span id="xdx_906_ecustom--ReimbursementExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zMn7eNWWERy6" title="Reimbursed expense">8,000</span> during the three months ended September
30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.
The Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_901_ecustom--ReimbursementExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zfeNIKVma0yi" title="Reimbursed expense">38,400</span> and $<span id="xdx_90D_ecustom--ReimbursementExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zyYBAG5Crkig" title="Reimbursed expense">35,200</span> during the nine months ended
September 30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of <span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_z3hQZ2IFj1Ji" title="Aggregate commitments expected">391,000</span> Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
<span id="xdx_90E_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVyEX8akeWi4" title="Aggregate commitments expected">500,000</span> Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the trial at a project cost of
<span id="xdx_906_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYFUtLXqgl42" title="Aggregate commitments expected">100,000</span> Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred charges of $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVDW0LE9hPh6" title="Advance amount related to milestone payment">0</span> and $<span id="xdx_903_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZURS9Oldcye" title="Advance amount related to milestone payment">76,278</span>, respectively, with respect to this
agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
During the nine months ended September 30, 2025 and 2024, the Company incurred charges of $<span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zU4gFSDlZpg2" title="Advance amount related to milestone payment">0</span> and $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvKcEvDrSFZd" title="Advance amount related to milestone payment">210,362</span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of September 30, 2025, total costs of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NetherlandsCancerInstituteMember_zm0j0CfQtTEd" title="Research and development costs">695,918</span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the three months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zFRpcJG4rCad" title="Advance amount related to milestone payment">7,200</span> and $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCJJAsNtH4z5" title="Advance amount related to milestone payment">9,062</span>,
respectively, pursuant to this contract. During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $<span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zaSs25DAbfP" title="Advance amount related to milestone payment">42,057</span>
and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zZod257iaxCd" title="Advance amount related to milestone payment">18,932</span>, respectively, pursuant to this contract. As of September 30, 2025, total costs of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zIvhX9UiRQBk" title="Research and development costs">382,579</span> have been incurred pursuant to
this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z2gtgYw6UMAj" title="Aggregate commitments expected">84,000</span> as
of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in the Company&#8217;s clinical trial. It is also possible that the
clinical trial could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase
development costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE
is confirmed to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further
development of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish the Company&#8217;s ability to attract clinical trial participants, and damage the Company&#8217;s
ability to interest investors and obtain financing in the future. There can be no assurances that the Company will not experience such
SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#8220;IRB&#8221;) of the
Netherlands Cancer Institute (&#8220;NKI&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through September 30,2025, the Company has been informed that a total of 86 patients had received
or were receiving experimental treatment with LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&#8217;s Brochure
(the &#8220;IB&#8221;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#8217;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs, and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There have been some indications that the United States economy may be at risk of entering a recessionary period. Although
it does not appear likely at this time, an economic recession could impact the general business environment and the capital markets,
which could, in turn, affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zkhik7tSdHfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82C_z4eKQULVr7V8">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below or elsewhere in the notes to the consolidated financial statements, there were no material subsequent events
which affected, or could affect, the amounts or disclosures in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercise
of Pre-Funded Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from October 1, 2025 through October 31, 2025, an additional <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpTiDTK6m0df" title="Pre-funded warrants exercisable">475,521</span> pre-funded warrants exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpwIKWT01vBa" title="Warrants exercisable price per share">0.00001</span> per share
that were sold in the July 2, 2025 private placement were exercised, resulting in the issuance of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2r1Dj0AY0hj" title="Number of shares issued">475,521</span> shares of common stock. As
of October 31, 2025, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zamFPjpO4K8b" title="Pre-funded warrants remained unexercised">184,251</span> pre-funded warrants remained unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SGN
Media Inc.</b> On October 1, 2025, the Company entered into an agreement with SGN Media Inc (&#8220;SGN&#8221;) for marketing consulting
services for a term of one year. The agreement provides for a one-time payment of $<span id="xdx_900_eus-gaap--ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_z4ptg0u3PL8e" title="Proceeds from sale of interest in subsidiary">20,000</span> upon execution of the agreement and the reimbursement
of pre-approved expenses. <span id="xdx_90E_eus-gaap--ManagementFeeDescription_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_zaLMiCnzWFQ6" title="Management fee description">Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LMC
Communications Inc.</b> On October 1, 2025, the Company entered into an agreement with LMC Communications Inc (&#8220;LMC&#8221;) for
corporate communications services. The agreement is for a term of one year. The agreement provides for the payment of <span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_uCAD_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zkBgxpfs3yO1" title="Payments for of common stock services">150,000</span> Canadian
dollars (approximately $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zu6ykoOs976g" title="Payments for of common stock services">108,000</span> as of September 30, 2025) upon execution, which can be paid by the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z4CLME4I6yKi" title="Number of shares issued, shares">30,000</span> shares of the Company&#8217;s
common stock. The Company has elected to pay <span id="xdx_901_eus-gaap--SharesIssued_iI_c20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z7NCwSyB7Ir1" title="Number of shares issued, shares">30,000</span> shares of the Company&#8217;s common stock.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_z7xYeO3pzcZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles
of Consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zHIYsZTUAGY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently operates in a single</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90C_eus-gaap--NumberOfReportableSegments_pid_uSegment_c20250101__20250930_zwQwzLwkbG31" title="Number of reportable segment">1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable segment, which consists of the development of a
drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated financial results of the Company. The CODM
uses consolidated net income (loss) as the sole measure of segment profit or loss. The required segment information, including significant
segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_zJMjeDDk30gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm6OkHpKYoI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zf16ZFjTYomb" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_904_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_z2hF7GXIuVpk" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zuOzzkcHOUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PrepaidInsurancePolicyTextBlock', window );">Prepaid Insurance</a></td>
<td class="text"><p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zFrIvmtS2QU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepaid
Insurance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetPolicyTextBlock', window );">Digital Assets</a></td>
<td class="text"><p id="xdx_842_esrt--PlatformOperatorCryptoAssetPolicyTextBlock_zgFfkKeBmpB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Digital
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance
with FASB ASC 820, Fair Value Measurement, based on quoted prices on the active exchange(s) that it has determined is the principal market
for Bitcoin and Ethereum (Level 1). Changes in fair value are included in unrealized gain (loss) on digital assets in other income (expense)
in the Company&#8217;s consolidated statements of operations. Realized gains and losses on the sale of digital assets are included in
other income (expense) in the Company&#8217;s consolidated statements of operations. The Company tracks its cost basis of digital assets
in accordance with the first-in-first-out method of accounting. The Company&#8217;s digital assets are reasonably expected to be realized
in cash or sold or consumed during the Company&#8217;s normal operating cycle and as such have been classified as current assets in the
Company&#8217;s consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#8217;s accounting policies, disclosures, or internal controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_DeferredOfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><p id="xdx_84A_ecustom--DeferredOfferingCostsPolicyTextBlock_zLY2PmxIQFF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offering
Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zm6orj6nTYN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and Licensing Legal and Filing Fees and Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20250701__20250930_zDX7YqtyF8kc" title="Legal and filing fees and costs">16,853</span> and $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20240701__20240930_zIIcxXwgiT0j" title="Legal and filing fees and costs">45,416</span> for the three months ended September 30, 2025 and 2024, respectively, and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20250101__20250930_zu5GWZr8Gp62" title="Legal and filing fees and costs">90,239</span> and $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20240930_zAXrnWi1nCPg" title="Legal and filing fees and costs">192,239</span>
for the nine months ended September 30, 2025 and 2024, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z1Zs8QjNsB9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration
of Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMX12huKF4D" title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKIOtUXScmqc" title="Concentration risk percentage">10</span></span>% or more of general and administrative costs or research and development costs for the three months ended September 30,
2025 and 2024 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2025 include charges from three vendors and consultants representing <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7NBiD4b04ei" title="Concentration of risk, percentage">21.4</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5CRKZi6OJBc" title="Concentration of risk, percentage">28.8</span>%
and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBr33L05Ay01" title="Concentration of risk, percentage">14.2</span>%,
respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2024
include charges from three vendors and consultants representing<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVTJCBQXYcYe" title="Concentration of risk, percentage">
52.7</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zz6neRjiqpA8" title="Concentration of risk, percentage">21.1</span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVc7dzNJM3u3" title="Concentration of risk, percentage">15.1</span>%.
respectively, of total research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zE8OTDqRVpfi" title="Concentration risk percentage">1.0</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zRlCNOyI4px4" title="Concentration risk percentage">7.1</span>%, respectively
of total general and administrative costs. General and administrative costs for the three months ended September 30, 2025 also includes
a charge from a vendor representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zk2AiHpJ4xa2" title="Concentration of risk, percentage">10.6</span>% of total general and administrative costs. General and administrative costs for the three months
ended September 30, 2024 includes a charge from a vendor representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zTictifVolYe" title="Concentration of risk, percentage">18.4</span>% of total general and administrative costs. General and administrative
costs for the three months ended September 30, 2025 and 2024 also included charges for the fair value of stock options granted to directors
and corporate officers representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_zA80E4u5xhoh" title="Concentration risk percentage">44.4</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_z4BX9IqCpQo9" title="Concentration risk percentage">12.8</span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2025 include charges from five vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfkMnrcwWfM2" title="Concentration of risk, percentage">24.3</span>%,
<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zojGHZTSZXlb" title="Concentration of risk, percentage">20.7</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI7j6W9omBDd" title="Concentration of risk, percentage">18.9</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn9Mq8v8esu1" title="Concentration of risk, percentage">12.0</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziRtXm4Gk1V5" title="Concentration of risk, percentage">11.7</span>%, respectively, of total research and development costs. Research and development costs for the nine months
ended September 30, 2024 include charges from three vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zidzYfsRqY3c" title="Concentration of risk, percentage">41.2</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYc3gj0Mv6K3" title="Concentration of risk, percentage">30.4</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zycIFkh6Rn35" title="Concentration of risk, percentage">12.6</span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_ztyHSrbxcdRl" title="Concentration risk percentage">2.9</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zVYVeCuNf6qk" title="Concentration risk percentage">8.5</span>%. respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 did not include
any charges from a single vendor/consultant in excess of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zYdU9FIC77Wb" title="Concentration of risk, percentage">10</span>% of total general and administrative costs. General and administrative costs
for the nine months ended September 30, 2024 also include charges from two vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--OneVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zhjULGl4DD04" title="Concentration of risk, percentage">16.0</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zJwQvJpmmook" title="Concentration of risk, percentage">11.5</span>%, respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 and 2024 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_z7GmotHUJjRf" title="Concentration risk percentage">35.4</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_zFY9yQs4oTJj" title="Concentration risk percentage">12.6</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zZ7orfn7Lc42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at September 30, 2025 and December 31, 2024. In the event the Company was to determine that it
would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets
would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations
in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company did not have any unrecognized tax benefits as of September 30,
2025 or December 31, 2024, and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2025 or December
31, 2024. Subsequent to September 30, 2025, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZwY8nxr2DGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_844_ecustom--WarrantsPolicyTextBlock_zGXvgbX9R71e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging
(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet
the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under
ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity
classification. The Company has determined that the warrants issued in the July 2023 equity financing, the February 2025 equity financing,
and the July 2025 equity financings (see Note 5) meet the requirements for equity classification. This assessment, which requires the
use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At September 30, 2025 and December 31, 2024, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zqt9gtDBhmo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
(Loss) Per Share</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
The weighted average number of common shares outstanding utilized for determining basic net loss per common share for the three months
and nine months ended September 30, 2025 includes all pre-funded warrants sold in the July 2, 2025 and July 8, 2025 equity financings,
aggregating <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zkIN6MSKL6rk" title="Pre funded warrants">3,085,883</span> pre-funded warrants, of which <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zdWqV5Y5fxfj" title="Unexercised pre funded warrants">659,772</span> pre-funded warrants were unexercised at September 30, 2025. Basic and diluted
loss per common share was the same for all periods presented because all preferred shares, warrants (excluding pre-funded warrants) and
stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025 and 2024, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlGwgDhu5fc3" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,573,130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants (excluding pre-funded
    warrants)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">623,232</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,307,161</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,504,514</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zqAKuOIrhEic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVuorOgqkAq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were
converted into United States dollars at the average rate of <span id="xdx_90D_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250701__20250930_zyoYCullawD8" title="Foreign currency average rate">1.1692</span> and <span id="xdx_902_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240701__20240930_zgqHU1MsJlii" title="Foreign currency average rate">1.0991</span> Euros per United States dollar, respectively. During the
nine months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_908_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250101__20250930_zP2AECW2WxC5" title="Foreign currency average rate">1.1182</span> and <span id="xdx_909_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20240930_znMdqm0tPkX6" title="Foreign currency average rate">1.0873</span> Euros per United States dollar, respectively. As of September 30,
2025 and December 31, 2024, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was
not a party to any foreign currency forward or exchange contracts. Accordingly, the Company did not have any unrealized foreign currency
(gain) loss at September 30, 2025 or 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwovQEHQLDlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of financial instruments measured on a recurring basis was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zEcIGOa3Fk24">Schedule
of Fair Value Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Description</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of September 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Digital
    assets</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zqxTOKxMJq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative
of their respective fair values due to the short-term nature of those instruments. The carrying value of digital assets is based on quoted
prices in active markets (Level 1 inputs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zksEpkVJ2Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-08, Intangibles &#8211; Goodwill and Other &#8211;
Crypto Assets (Subtopic 350-60). ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet
with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of operations
each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis,
fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during
the fiscal quarter ended September 30, 2025, the Company adopted and applied ASU-2023-08 henceforth. As the Company did not have any
crypto assets prior to the fiscal quarter ended September 30, 2025, no cumulative-effect adjustment was required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). These ASUs require disclosure of disaggregated information of Income Statement expense
captions that include certain costs, such as employee compensation, depreciation, and intangible asset amortization. They also require
disclosure of the total amounts of selling expenses, along with an entity&#8217;s definition of selling expenses. The amendments are
effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning
after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of these ASUs, but does not expect
them to have a material impact on its consolidated financial statements presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVCh9Es3C8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, effective January
1, 2024, certain reclassifications have been made to the prior year statement of operations to conform it to the current year presentation.
In presenting general and administrative costs on the Company&#8217;s consolidated statement of operations for the three months ended
September 30, 2024, $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG7YsqF1tvd" title="General and administrative costs">283,053</span> of compensation to related parties, $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4nshvne9er" title="Legal and filing fees and costs">45,416</span> of patent and licensing legal and filing fees and costs, and
$<span id="xdx_904_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJThg06Ayjqc" title="Other costs and expenses">293,158</span> of other costs and expenses were shown separately. In presenting the Company&#8217;s consolidated statement of operations for
the three months ended September 30, 2024, the Company has combined these categories into general and administrative costs in the accompanying
consolidated statement of operations for the three months ended September 30, 2024. In presenting general and administrative costs on
the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, $<span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXewFRr0sdHe" title="Legal and filing fees and costs">907,069</span> of compensation to related
parties, $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjPAU3N9b6x9" title="Legal and filing fees and costs">192,239</span> of patent and licensing legal and filing fees and costs, and $<span id="xdx_901_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztNhdQDEcnyk" title="Other costs and expenses">1,168,582</span> of other costs and expenses were shown separately.
In presenting the Company&#8217;s consolidated statement of operations for the nine months ended September 30, 2024, the Company has
combined these categories into general and administrative costs in the accompanying consolidated statement of operations for the nine
months ended September 30, 2024. These reclassifications had no effect on the reported results of operations, including loss from operations
and net loss.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PrepaidInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Insurance [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PrepaidInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for safeguarding liability and corresponding asset for crypto-asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section FF<br> -Paragraph Question 2<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zlGwgDhu5fc3" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,573,130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants (excluding pre-funded
    warrants)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">623,232</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,307,161</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,504,514</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of financial instruments measured on a recurring basis was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zEcIGOa3Fk24">Schedule
of Fair Value Liabilities Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Description</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="display: none; font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of September 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Digital
    assets</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Information by Segment</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z3IccXWlfrE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhEnJlVTR3Zi" style="display: none">Schedule of Information by Segment</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250701__20250930_zxEwQzc9BImd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240701__20240930_z9nNu0oEZG5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20250930_z1Rpaa6OTP4k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930_ztpy1Q0wNB3b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zjwvHZtW1TBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical and related oversight
    costs</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,424</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,342</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,894</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,319</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zQYe1AIkkvq6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preclinical research focused on development
    of additional novel anti-cancer compounds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,821</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,573</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--CompoundMaintenanceMember_zu5wGjISNlol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compound maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,480</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,062</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,563</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_z4CTJDswmHX1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory service
    costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,581</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,405</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,771</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,021</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zC7Lgo1pyIj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,696</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">361,630</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,801</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and
2024 based on the respective geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250701__20250930_zMTYFay3jd4b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240701__20240930_zk0xMuipl2Kl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zfN1oXRYk7f8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_zH2Z3CpfXAKh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zeXvwFWu7jNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,305</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">278,808</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">146,804</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zZAC6oFHO2y6" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Spain</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,391</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,544</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zHdQmjEUyMt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">China</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,282</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zVKu5GRBX8Dk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Netherlands</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,278</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">210,362</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zUweL85KQMT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total research and
    development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,696</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">361,630</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,801</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250701__20250930_zgeyf2S7GSn2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zciJovYJXG54" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20250930_zJ464v40b1N" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zOtdAVQN8Jo5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Compensation to related parties:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--CashBasedCompensationToRelatedParties_i02_maGAAEzrRU_z3XRf7ahkMX" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217,416</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,226</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">566,624</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockBasedCompensationToRelatedParties_i02_maGAAEzrRU_z9ROGtGZ8R74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maGAAEzrRU_z72gHGOzFwMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patent and licensing legal and filing fees
    and costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,853</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,415</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,238</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--OtherConsultingAndProfessionalFees_i02_maGAAEzrRU_zfY6Ns0pame2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other consulting and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,822</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">920,689</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">481,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_z67lYoTnxFA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,277</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">116,440</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,830</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">370,167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i02_maGAAEzrRU_z1HfQbQrluS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other costs and expenses,
    net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,679</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,826</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,764</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,551</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzrRU_zVv1vUc3YWl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total general and
    administrative costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,750,658</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621,627</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,080,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,267,890</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250930_zqxGQxmvlkmc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zo3jfZph8zQc" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zmHMXhdF3BGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,412</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,298</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zhoArsta6Ayh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Corporate assets (primarily
    cash and digital assets)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,423,264</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,106,205</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_z3oqNeZnZW8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,433,676</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,145,503</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Digital Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingTableTextBlock', window );">Schedule of Digital Assets</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--CryptoAssetHoldingTableTextBlock_zd15zlx3TLX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the cost and fair value of digital assets that were initially purchased during August 2025 were as follows (there
were no digital assets at December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zz8kIdnQJfF6">Schedule
of Digital Assets</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Units</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
                                            (Loss)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on
                                            Change</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Fair Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Bitcoin</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zjLwTZVrBjR9" title="Digital assets held, Quantity">10.59</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zs89YFu6a0Xe" style="width: 12%; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">1,205,540</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zlguGps7Kc7f" style="width: 12%; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">2,261</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zE8YvwRZmWfb" style="width: 12%; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">1,207,801</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Ethereum</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zIVTZhF7pqRj" title="Digital assets held, Quantity">300.70</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zWSFVBkk2Cs3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">1,431,820</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--EthereumMember_zDWjvnB0gu3g" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">(185,148</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9LtdhjJ3Z1g" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">1,246,672</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20250930_z4cXF93NQjvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets held, Cost basis"><span style="font-family: Times New Roman, Times, Serif">2,637,360</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930_zy5ZBpKgezha" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"><span style="font-family: Times New Roman, Times, Serif">(182,887</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20250930_zWBMyrgrRA3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets fair value"><span style="font-family: Times New Roman, Times, Serif">2,454,473</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLMEP9B3SPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offerings, but excluding pre-funded warrants, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zOW3PTkJm0Dg" style="display: none">Schedule of Warrants Outstanding</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (in Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbLrUoVZwJCi" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6AHvW9y4V29" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">16.407</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwSXgkLGdfZc" style="text-align: right" title="Number of Shares, Issued"><span style="font-family: Times New Roman, Times, Serif">7,138,233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhrcAB0cqCY4" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif">1,096</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFRGGrhhcBwa" style="text-align: right" title="Number of Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif">(335,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS53Czvd9U4k" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">1.31</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zc1dVWXKf6h1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCWHJwgaB2k6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYsGkWW2f4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za6s0mfAUDR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">2.715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zx4qnnj4z9Ib" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">4.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrOJu4pl9rDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">808,365</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbyPAFAbJ7D8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">16.407</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at September 30,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlHcPudAHm13" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjJMkJFfSPBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif">2.715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LFkTAwSHD8" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">4.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zmxEoO6hcpIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9EBrlQodZ3h" style="display: none">Schedule of Warrants Outstanding and Exercisable</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 47%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1UbhatmWlf6" title="Exercise Prices">1.0000</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z76d4jVXfEj1" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">6,355,214</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5Snwck6OJ5h" title="Exercise Prices">2.2900</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1wSZ4uWjhU7" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">414,784</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq5gllk1hyFi" title="Exercise Prices">3.0188</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq7PgTU81iM3" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">32,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKSbDz7Ho2Ka" title="Exercise Prices">6.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zn4IqgdoLFq7" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">583,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zw9YH3Jl64z1" title="Exercise Prices">6.6000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEosBDDDu4j1" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z0O3OlRmBUZk" title="Exercise Prices">20.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znQLZIPvm5F6" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">29,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDavLkZBj0Qk" title="Exercise Prices">37.0000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zsCTHMezFidb" style="text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">11,331</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zZQEKaBA5dza" title="Exercise Prices">57.0000</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPFVokWjGrVa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">149,700</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930_zNpbqZzBUuX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"><span style="font-family: Times New Roman, Times, Serif">7,610,972</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Costs</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zLCJimdBLzL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2025 and 2024, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zL0cMS94ajb6" style="display: none">Schedule of Related Party Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250701__20250930_zcdIbsCGawab" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240701__20240930_zdJ1cRuFo3Xg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250930_zl9uGesWLT28" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z9jUNNbn58Jg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
                                            Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zlMog63KdAt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Cash-based</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217,416</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,226</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">566,624</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zXVc4B64A722" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z9JmKrOQ8dLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">994,027</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,053</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,593,780</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">907,069</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Award Estimated Assumption</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsyplzXokm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2025, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxe1ze8AJ6P9" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250101__20250930_zfDeiQPPq802" title="Risk-free interest rate minimum">3.58</span>%
    to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250101__20250930_z9yRnL5v31Y1" title="Risk-free interest rate maximum">3.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20250101__20250930_zlaO1TZhMRGh" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: -3.9pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20250101__20250930_zRKfZI8CZmWa" title="Expected volatility minimum">128.78</span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20250101__20250930_zZqyHmpbs9J" title="Expected volatility maximum">139.42</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_z0QAUqANASf3" title="Expected life">2.5</span>
    to <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zdU5gdc2VqWe" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20240101__20240930_zPq2t6s3INs" title="Risk-free interest rate minimum">3.55</span>%
    to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20240101__20240930_zIvW7UAUMiK1" title="Risk-free interest rate maximum">4.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20240930_ziZpmFFOyoY6" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20240101__20240930_zAF8Sf0L6wsg" title="Expected volatility minimum">125.59</span>
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20240101__20240930_zatfMJ5aqwV5" title="Expected volatility maximum">126.45</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zDXFVVxLNRKg" title="Expected life">2.5</span>
    to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zvGTAGTgpIQl" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock-based Compensation Costs</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3OF1ceTSh3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zg8Wd7PHcgc" style="display: none">Schedule of Stock-based Compensation Costs</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zd5TWrO9Qe35" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240701__20240930_zW4DETeV4Bzk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250930_z5k2EcPLznU7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zFaQ1sfLAFq1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKlhKclfQ9U4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqGEfVo0zuX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Non-related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1826">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1828">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_z2UfvB4EbuXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,611</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,827</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,144,348</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,445</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkVKv9cNiIv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2025 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zb1KqmhwbR62" style="display: none">Schedule of Stock Option Activity Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
                                            Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding at December
    31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zESYR1cepThd" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"><span style="font-family: Times New Roman, Times, Serif">613,232</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zSZOieKqu8if" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding"><span style="font-family: Times New Roman, Times, Serif">12.317</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_zhUq2BYnjQc" style="text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif">581,494</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z3I4tcpx8Z34" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.657</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930_zCKeHhL8A8M2" style="text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z98nef8tKazk" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zDEuVVlzkhH3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"><span style="font-family: Times New Roman, Times, Serif">(71,667</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zxVjRmhuXhCj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif">44.272</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zEukKDGE3OUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zqI02DpqC29h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding"><span style="font-family: Times New Roman, Times, Serif">5.276</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zDUGlsCDl4Xh" title="Weighted average remaining contractual life (in years), stock options outstanding">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zm3m9flUQbb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">409,897</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zR7pLp0soPfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">17.100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options exercisable
    at September 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zXw2ZfeHrKDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">930,559</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zlVczi7UTR55" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="font-family: Times New Roman, Times, Serif">5.664</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zgeLOS7PnT0h" title="Weighted average remaining contractual life (in years), stock options exercisable">3.28</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWIdtGFaJ3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2025, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zeTmtxuULFBj" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Prices</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                            (Shares)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFy2vjnucImf" style="width: 30%; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">0.905</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zS3bhr7tc3l" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">72,648</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNjrN27i6Rpg" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">46,398</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zFtqQE4Ptoz6" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.210</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zINxPTH9BK0f" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">32,181</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztB4khiAhLEf" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">32,181</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVHwIeCnnc5c" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9w2Je49z8k1" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">21,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zf2InRE71Txf" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">21,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zJjsIFlC7SO4" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">1.950</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zHg9hz1kBov4" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPoNbTpuzlL4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7GF7Dtp5Eti" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.330</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z8AFWEiHP208" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">16,665</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPM6f8H75fw4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">16,665</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbpJHQu8nmu4" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztSoEHezMDtd" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">51,598</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSnIsAyYreO6" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zQ5tnBGzrZpf" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zgpfWwnDv5Wf" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zeW922GIljji" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zgcbd38988A5" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">2.830</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zWdCZaRoaIq6" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zBD725rewxz4" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">262,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlUTjnnlill8" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">3.590</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zatlxUGhymj5" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztLPSILRyIV8" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zoFQgp5IaqLa" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">4.450</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEQwpU871QL3" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbkKICqJsEU5" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">12,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zpA2W3IiqC8k" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">5.025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRAC6ByBkjRi" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">8,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z19J2sZGXYn" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">8,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zkcU8Y5P0ljd" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">5.880</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqSAfehc7vh3" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zYeDACEqeQ9l" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z90CGJHOVWh6" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">7.400</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSzewf2FlBC" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zfkeV5n6vP25" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zhP56C3XEhI2" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">20.000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zjy3uCki4yPf" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zs0fdhKj4iO2" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z5wW3crMConi" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">20.600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj9l8hvCEdVb" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zfZ4i2I8Vz6l" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zNL7TafYxhG7" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">28.000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmOZK5lelfV2" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z05z3EYUt7z" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zLp5jGUcrlDl" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">30.300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zrZV3MafP269" style="text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zWLHAYIXxFDe" style="text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zdR2aTe07Sdc" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif">32.100</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z9EiO6QI40Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zqpET658WCt7" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zv02I4tSjuI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"><span style="font-family: Times New Roman, Times, Serif">1,123,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zr1ecDZzshK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"><span style="font-family: Times New Roman, Times, Serif">930,559</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Clinical Trials</a></td>
<td class="text"><p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_z9C2hyv19g93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zBp84ylVe1U5" style="display: none">Schedule of Contractual Clinical Trials</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Start
    Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Projected
    End Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Planned
    Number of Patients in Trial</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Study
    Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Clinical
    Update</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expected
    Date of Preliminary Efficacy Signal</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NCT
    No.</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    Financial Contractual Commitment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaP5LAXEvAwb" title="Clinical trial, description">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">MD Anderson</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaO4D4TiKJTl" title="Estimated Start Date">January 2024</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zfoSrgpSA6P2" title="Estimated End Date">December
    2027</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zhflNXUAlJol" title="Number of Patients in Trial">21</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine the OS of patients with
    recurrent ovarian clear cell carcinoma</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">20 patients
    entered</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zrGZ76wbvle" title="Expected Date">December
    2026</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06065462</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zi38KavQp34c" title="Remaining financial contractual commitment">0</span>-
                                            (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztgXW15eMPf4" title="Clinical trial, description">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Netherlands Cancer Institute
    (NKI)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zsFaYt73DN6k" title="Estimated Start Date">August 2024</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zQei3Nmu7j56" title="Estimated End Date">December 2026</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zRHl3roycfN1" title="Number of Patients in Trial">37</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine RP2D with atezolizumab</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">First patient entered
    August 2024, in total two patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zpvcj4boBNxi" title="Expected Date">June 2026</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT06012734</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zfujZMcBfZSa" title="Remaining financial contractual commitment">0</span>-
                                            (1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_fKDIp_z7dHCrOkjqTh" title="Clinical trial, description">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">GEIS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zQXHehVX1Cqj" title="Estimated Start Date">June 2023</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Recruitment completed
    September 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zVzDL1upQ8ma" title="Number of Patients in Trial">14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Determine MTD and RP2D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fourteen patients entered</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zeStniKU2End" title="Expected Date">December 2025</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;NCT05809830</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zJcP1wJGGHX8" title="Remaining financial contractual commitment">292,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OtherCommitment_iI_c20250930_zVS6GHXac1Ke" style="text-align: right" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif">292,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_z1w4UppxP86b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zXa6OfihDjG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2025</div></th>
<th class="th"><div>Jul. 02, 2025</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,912,254<span></span>
</td>
<td class="nump">$ 1,366,936<span></span>
</td>
<td class="nump">$ 4,912,254<span></span>
</td>
<td class="nump">$ 1,366,936<span></span>
</td>
<td class="nump">$ 651,456<span></span>
</td>
<td class="nump">$ 827,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,246,139<span></span>
</td>
<td class="nump">$ 3,994,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,178,162<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245,040<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,980,398<span></span>
</td>
<td class="nump">986,030<span></span>
</td>
<td class="nump">3,465,626<span></span>
</td>
<td class="nump">2,968,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,982,720<span></span>
</td>
<td class="nump">2,565,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">12,307,161<span></span>
</td>
<td class="nump">1,504,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,610,972<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,123,059<span></span>
</td>
<td class="nump">623,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="nump">$ 2,454,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="nump">2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="nump">2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValueCurrent', window );">Digital assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section FF<br> -Paragraph Question 2<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset classified as current. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashSIPCInsuredAmount', window );">Cash SIPC insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and filing fees and costs</a></td>
<td class="nump">$ 16,853<span></span>
</td>
<td class="nump">$ 45,416<span></span>
</td>
<td class="nump">$ 90,239<span></span>
</td>
<td class="nump">$ 192,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre funded warrants | shares</a></td>
<td class="nump">3,085,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,085,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Unexercised pre funded warrants | shares</a></td>
<td class="nump">659,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ForeignCurrencyExchangeRateTranslation', window );">Foreign currency average rate</a></td>
<td class="nump">1.1692<span></span>
</td>
<td class="nump">1.0991<span></span>
</td>
<td class="nump">1.1182<span></span>
</td>
<td class="nump">1.0873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Legal and filing fees and costs</a></td>
<td class="nump">$ 1,750,658<span></span>
</td>
<td class="nump">$ 621,627<span></span>
</td>
<td class="nump">$ 3,080,302<span></span>
</td>
<td class="nump">$ 2,267,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses</a></td>
<td class="nump">$ 136,679<span></span>
</td>
<td class="nump">58,826<span></span>
</td>
<td class="nump">$ 282,764<span></span>
</td>
<td class="nump">316,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and filing fees and costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Legal and filing fees and costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor And Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="nump">52.70%<span></span>
</td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">41.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor And Consultant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">28.80%<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor and Consultant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor and Consultant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor and Consultant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Other Vendor and Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor And Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Stock Options Granted to Directors and Corporate Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">44.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">35.40%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | One Vendor and Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Cost of Sales [Member] | Supplier Concentration Risk [Member] | Two Vendor And Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash SIPC insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency exchange rate translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_OtherVendorAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_OtherVendorAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_DirectorsAndCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_DirectorsAndCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_OneVendorAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_OneVendorAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_TwoVendorAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_TwoVendorAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Information by Segment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">$ 50,696<span></span>
</td>
<td class="nump">$ 361,630<span></span>
</td>
<td class="nump">$ 202,801<span></span>
</td>
<td class="nump">$ 691,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashBasedCompensationToRelatedParties', window );">Cash-based</a></td>
<td class="nump">217,416<span></span>
</td>
<td class="nump">176,226<span></span>
</td>
<td class="nump">449,432<span></span>
</td>
<td class="nump">566,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockBasedCompensationToRelatedParties', window );">Stock-based</a></td>
<td class="nump">776,611<span></span>
</td>
<td class="nump">106,827<span></span>
</td>
<td class="nump">1,144,348<span></span>
</td>
<td class="nump">340,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_LegalFeesRelatingToPatentsAndLicensing', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">16,853<span></span>
</td>
<td class="nump">45,415<span></span>
</td>
<td class="nump">90,239<span></span>
</td>
<td class="nump">192,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_OtherConsultingAndProfessionalFees', window );">Other consulting and professional fees</a></td>
<td class="nump">538,822<span></span>
</td>
<td class="nump">117,893<span></span>
</td>
<td class="nump">920,689<span></span>
</td>
<td class="nump">481,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">64,277<span></span>
</td>
<td class="nump">116,440<span></span>
</td>
<td class="nump">192,830<span></span>
</td>
<td class="nump">370,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses, net</a></td>
<td class="nump">136,679<span></span>
</td>
<td class="nump">58,826<span></span>
</td>
<td class="nump">282,764<span></span>
</td>
<td class="nump">316,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="nump">1,750,658<span></span>
</td>
<td class="nump">621,627<span></span>
</td>
<td class="nump">3,080,302<span></span>
</td>
<td class="nump">2,267,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,433,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,433,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,145,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,423,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,423,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,106,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">46,305<span></span>
</td>
<td class="nump">278,808<span></span>
</td>
<td class="nump">146,804<span></span>
</td>
<td class="nump">427,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">4,391<span></span>
</td>
<td class="nump">6,544<span></span>
</td>
<td class="nump">55,997<span></span>
</td>
<td class="nump">51,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">76,278<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember', window );">Clinical and Related Oversight Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">13,424<span></span>
</td>
<td class="nump">250,342<span></span>
</td>
<td class="nump">40,894<span></span>
</td>
<td class="nump">358,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember', window );">Preclinical Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">22,211<span></span>
</td>
<td class="nump">90,821<span></span>
</td>
<td class="nump">92,573<span></span>
</td>
<td class="nump">300,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_CompoundMaintenanceMember', window );">Compound Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">7,480<span></span>
</td>
<td class="nump">9,062<span></span>
</td>
<td class="nump">60,563<span></span>
</td>
<td class="nump">18,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember', window );">Regulatory Service Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">$ 7,581<span></span>
</td>
<td class="nump">$ 11,405<span></span>
</td>
<td class="nump">$ 8,771<span></span>
</td>
<td class="nump">$ 14,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashBasedCompensationToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash based compensation to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashBasedCompensationToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_LegalFeesRelatingToPatentsAndLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal fees relating to patents and licensing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_LegalFeesRelatingToPatentsAndLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_OtherConsultingAndProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other consulting and professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_OtherConsultingAndProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockBasedCompensationToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockBasedCompensationToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_CompoundMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_CompoundMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Digital Assets (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetCost', window );">Digital assets held, Cost basis</a></td>
<td class="nump">$ 2,637,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,637,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="num">(182,887)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(182,887)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Digital assets fair value</a></td>
<td class="nump">$ 2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,454,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CryptoAssetAxis=LIXT_BitcoinMember', window );">Bitcoin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CryptoAssetsNumberOfUnits', window );">Digital assets held, Quantity</a></td>
<td class="nump">10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetCost', window );">Digital assets held, Cost basis</a></td>
<td class="nump">$ 1,205,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,205,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Digital assets fair value</a></td>
<td class="nump">$ 1,207,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,207,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CryptoAssetAxis=LIXT_EthereumMember', window );">Ethereum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CryptoAssetsNumberOfUnits', window );">Digital assets held, Quantity</a></td>
<td class="nump">300.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetCost', window );">Digital assets held, Cost basis</a></td>
<td class="nump">$ 1,431,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,431,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Digital assets fair value</a></td>
<td class="nump">$ 1,246,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,246,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CryptoAssetsNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Crypto assets number of units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CryptoAssetsNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as nonoperating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedGainLossNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=LIXT_BitcoinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=LIXT_BitcoinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=LIXT_EthereumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=LIXT_EthereumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Digital Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="nump">$ 182,887<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 182,887<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CryptoAssetAxis=LIXT_BitcoinMember', window );">Bitcoin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_DigitalAssetHoldingsPercentage', window );">Digital asset holdings percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CryptoAssetAxis=LIXT_EthereumMember', window );">Ethereum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating', window );">Unrealized gain (loss) in fair value of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_DigitalAssetHoldingsPercentage', window );">Digital asset holdings percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_DigitalAssetHoldingsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Digital asset holdings percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_DigitalAssetHoldingsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedGainLossNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as nonoperating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedGainLossNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=LIXT_BitcoinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=LIXT_BitcoinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=LIXT_EthereumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=LIXT_EthereumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">7,610,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Issued</a></td>
<td class="nump">7,138,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(335,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">7,610,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding</a></td>
<td class="nump">$ 2.715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Outstanding</a></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants exercisable</a></td>
<td class="nump">7,610,972<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable', window );">Weighted Average Exercise Price, Warrants exercisable</a></td>
<td class="nump">$ 2.715<span></span>
</td>
<td class="nump">$ 16.407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Exercisable</a></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">7,610,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">6,355,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.2900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">414,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.0188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">32,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">583,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 37.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">11,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 57.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">149,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Jul. 08, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jul. 02, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Aug. 07, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
<th class="th"><div>Aug. 05, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 21, 2025</div></th>
<th class="th"><div>Jul. 15, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>May 16, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,245,040<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,239<span></span>
</td>
<td class="nump">$ 192,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued for Services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,085,883<span></span>
</td>
<td class="nump">3,085,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,085,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable unexercised, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,113,000<span></span>
</td>
<td class="nump">$ 20,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_DescriptionOfOfferingPrice', window );">Description of offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Offering was priced at-the-market under Nasdaq rules at $0.8396 per common stock unit, with each unit consisting of one share of common
stock at a price of $0.7146 and one common stock warrant at a price of $0.125 to acquire one share of common stock at an exercise price
of $1.00 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 871,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial offering</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_PlacementAgentAgreementMember', window );">Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,355,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,355,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Private placement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember', window );">July 20, 2023 Equity Offering [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember', window );">July 20, 2023 Equity Offering [Member] | Private Placement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember', window );">July 20, 2023 Equity Offering [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember', window );">February 13, 2025 Equity Offering [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember', window );">February 13, 2025 Equity Offering [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 11,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Private placement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares Issued for Services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued for Services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Market Awareness Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares Issued for Services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued for Services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,662,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | PreFunded Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Placement Agents Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | July 20, 2023 Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | February 13, 2025 Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,076,870<span></span>
</td>
<td class="nump">6,076,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,076,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,662,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Subsequent Event [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.030<span></span>
</td>
<td class="nump">$ 5.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(335,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend', window );">Principal cash obligations and commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares', window );">Annual net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A Convertible
Preferred Stock was convertible, at the option of the holder, into 0.20833 shares of common stock (subject to customary anti-dilution
provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a
merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued for Services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts', window );">Private placement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued for Services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net revenue divided by converted or redeemed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_DescriptionOfOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_DescriptionOfOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share tranche of the series a convertible preferred stock receive a per share dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares proceeds from sale of securities in july 2025 registered private placement net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_PlacementAgentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_PlacementAgentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MarketAwarenessAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MarketAwarenessAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Related Party Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">$ 776,611<span></span>
</td>
<td class="nump">$ 106,827<span></span>
</td>
<td class="nump">$ 1,144,348<span></span>
</td>
<td class="nump">$ 340,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">1,750,658<span></span>
</td>
<td class="nump">621,627<span></span>
</td>
<td class="nump">3,080,302<span></span>
</td>
<td class="nump">2,267,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Cash-based</a></td>
<td class="nump">217,416<span></span>
</td>
<td class="nump">176,226<span></span>
</td>
<td class="nump">449,432<span></span>
</td>
<td class="nump">566,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">776,611<span></span>
</td>
<td class="nump">106,827<span></span>
</td>
<td class="nump">1,144,348<span></span>
</td>
<td class="nump">340,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 994,027<span></span>
</td>
<td class="nump">$ 283,053<span></span>
</td>
<td class="nump">$ 1,593,780<span></span>
</td>
<td class="nump">$ 907,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 16, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 12, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,658<span></span>
</td>
<td class="nump">$ 621,627<span></span>
</td>
<td class="nump">$ 3,080,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,267,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,887,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,887,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,038,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember', window );">Schellens [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,179<span></span>
</td>
<td class="nump">28,717<span></span>
</td>
<td class="nump">$ 67,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember', window );">Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Appointment Grants of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash fee payable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember', window );">Mr Pursglove [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember', window );">Peter Stazzone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember', window );">Chairman of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember', window );">Chairman of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember', window );">Member of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember', window );">Member of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">116,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,403<span></span>
</td>
<td class="nump">$ 39,175<span></span>
</td>
<td class="nump">118,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Mr Pursglove [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Mr Pursglove [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Peter Stazzone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee payable for management of fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrKovachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrKovachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="nump">128.78%<span></span>
</td>
<td class="nump">125.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="nump">139.42%<span></span>
</td>
<td class="nump">126.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 776,611<span></span>
</td>
<td class="nump">$ 106,827<span></span>
</td>
<td class="nump">$ 1,144,348<span></span>
</td>
<td class="nump">$ 340,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">776,611<span></span>
</td>
<td class="nump">106,827<span></span>
</td>
<td class="nump">1,144,348<span></span>
</td>
<td class="nump">340,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the beginning | shares</a></td>
<td class="nump">613,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding | $ / shares</a></td>
<td class="nump">$ 12.317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">581,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 2.657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, expired | shares</a></td>
<td class="num">(71,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired | $ / shares</a></td>
<td class="nump">$ 44.272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end | shares</a></td>
<td class="nump">1,123,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding | $ / shares</a></td>
<td class="nump">$ 5.276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), stock options outstanding</a></td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, stock options exercisable | shares</a></td>
<td class="nump">930,559<span></span>
</td>
<td class="nump">409,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable | $ / shares</a></td>
<td class="nump">$ 5.664<span></span>
</td>
<td class="nump">$ 17.100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">1,123,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">930,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">72,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">46,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">32,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">32,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">21,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">21,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">16,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">16,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">51,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">40,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 4.450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember', window );">Exercise PriceThirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 7.400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember', window );">Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember', window );">Exercise Price Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixteenMember', window );">Exercise Price Sixteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 28.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSeventeenMember', window );">Exercise Price Seventeen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 30.300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEighteenMember', window );">Exercise Price Eighteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 32.100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 01, 2025</div></th>
<th class="th"><div>Sep. 01, 2025</div></th>
<th class="th"><div>Aug. 15, 2025</div></th>
<th class="th"><div>Aug. 15, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jan. 20, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Nov. 27, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred compensation expense for unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding stock options to acquire shares of common stock not vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember', window );">Schellens [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock option vested quarterly over a three-year period commencing on the last
day of each calendar quarter commencing September 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="nump">$ 4,810<span></span>
</td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,712<span></span>
</td>
<td class="nump">233,784<span></span>
</td>
<td class="nump">100,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember', window );">Mr van der Baan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock option initially vested in equal increments quarterly over a three-year
period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">25,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember', window );">Five Non-Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember', window );">Four Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132<span></span>
</td>
<td class="nump">$ 9,641<span></span>
</td>
<td class="nump">12,264<span></span>
</td>
<td class="nump">$ 34,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember', window );">Four Non-officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.905<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6448<span></span>
</td>
<td class="nump">$ 0.8546<span></span>
</td>
<td class="nump">$ 1.65002<span></span>
</td>
<td class="nump">$ 1.2961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,232<span></span>
</td>
<td class="nump">47,672<span></span>
</td>
<td class="nump">$ 72,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember', window );">Four Non Officer Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,648<span></span>
</td>
<td class="nump">32,181<span></span>
</td>
<td class="nump">16,665<span></span>
</td>
<td class="nump">21,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember', window );">Mr Pursglove [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_JasonSawyerMember', window );">Jason Sawyer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7344<span></span>
</td>
<td class="nump">$ 2.7344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_DrMichaelHollowayMember', window );">Dr. Michael Holloway [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and
the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7344<span></span>
</td>
<td class="nump">$ 2.7344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember', window );">Peter Stazzone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">options vested 25%
on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject
to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4614<span></span>
</td>
<td class="nump">$ 3.4614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_LourdesFelixAndGuyPrimusMember', window );">Lourdes Felix and Guy Primus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_LourdesFelixAndGuyPrimusMember', window );">Lourdes Felix and Guy Primus [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">$ 84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares avaliable for issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_FairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_FairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MrPursgloveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_JasonSawyerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_JasonSawyerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrMichaelHollowayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrMichaelHollowayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_PeterStazzoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_LourdesFelixAndGuyPrimusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_LourdesFelixAndGuyPrimusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Contractual Clinical Trials (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment</a></td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member', window );">Phase 1b 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">January 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December
    2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">December
    2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">August 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December 2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">June 2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">June 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">December 2025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment</a></td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClinicalTrialDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClinicalTrialDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period end date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected date of preliminary efficacy signal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedDateOfPreliminaryEfficacySignal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfPatientInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patient in trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfPatientInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2030 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,696<span></span>
</td>
<td class="nump">$ 361,630<span></span>
</td>
<td class="nump">202,801<span></span>
</td>
<td class="nump">$ 691,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember', window );">GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AmountRelatedToMilestonePayment', window );">Amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember', window );">NDA Consulting Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember', window );">Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 207,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">78,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPartsAndComponentsNetOfReserves', window );">Inventory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ReimbursementExpense', window );">Reimbursed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">38,400<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="nump">&#8364; 391,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">210,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,942<span></span>
</td>
<td class="nump">12,610<span></span>
</td>
<td class="nump">16,834<span></span>
</td>
<td class="nump">20,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WorkOrderAgreementCosts', window );">Work order agreement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member] | MD Anderson Cancer Center Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,981<span></span>
</td>
<td class="nump">13,475<span></span>
</td>
<td class="nump">11,603<span></span>
</td>
<td class="nump">26,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EstimatedWorkCost', window );">Work cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,380<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentinServices', window );">Percentage of payment through services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentThroughSoftware', window );">Percentage of payment through software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non refundable license issue royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationHealthCareCostsGross', window );">Dosing of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyatiesPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non refundable license issue royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member] | Due Each January 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development process costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,397<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">22,191<span></span>
</td>
<td class="nump">68,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember', window );">MRI Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 9,062<span></span>
</td>
<td class="nump">$ 42,057<span></span>
</td>
<td class="nump">$ 18,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvanceAmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvanceAmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConsultingAndAdvisoryCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory quarterly cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConsultingAndAdvisoryCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EstimatedWorkCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated work cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EstimatedWorkCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentThroughSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected paymen through software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentThroughSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentinServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected payment in services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentinServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyatiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royaties percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyatiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WorkOrderAgreementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work order agreement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WorkOrderAgreementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationHealthCareCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478201/954-450-30-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478201/954-450-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationHealthCareCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPartsAndComponentsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPartsAndComponentsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2025 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 15, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 02, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Pre-funded warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LMCCommunicationsIncMember', window );">LMC Communications Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for of common stock services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Pre-funded warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,675<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,662,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Pre-funded warrants remained unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | SGN Media Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from sale of interest in subsidiary | $</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeDescription', window );">Management fee description</a></td>
<td class="text">Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.<span></span>
</td>
<td class="text">Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | LMC Communications Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for of common stock services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PreFunded Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Pre-funded warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Pre-funded warrants remained unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PreFunded Warrants [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | LMC Communications Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature of payments to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP), including the fee rate, basis of calculation, relevant accounting period, whether the fee is paid to an entity other than the managing member or general partner, or whether the fee is waived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_LMCCommunicationsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_LMCCommunicationsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SGNMediaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SGNMediaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>496</ContextCount>
  <ElementCount>289</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>142</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Digital Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/DigitalAssets</Role>
      <ShortName>Digital Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SegmentInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Digital Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/DigitalAssetsTables</Role>
      <ShortName>Digital Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/DigitalAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfInformationBySegmentDetails</Role>
      <ShortName>Schedule of Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Digital Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfDigitalAssetsDetails</Role>
      <ShortName>Schedule of Digital Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Digital Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/DigitalAssetsDetailsNarrative</Role>
      <ShortName>Digital Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/DigitalAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Related Party Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails</Role>
      <ShortName>Schedule of Related Party Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails</Role>
      <ShortName>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Stock Option Activity Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails</Role>
      <ShortName>Schedule of Contractual Clinical Trials (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>lixt-20250930.xsd</File>
    <File>lixt-20250930_cal.xml</File>
    <File>lixt-20250930_def.xml</File>
    <File>lixt-20250930_lab.xml</File>
    <File>lixt-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
    <File>form10-q_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1047">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "lixt-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lixt-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 228,
   "keyCustom": 61,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 99,
   "hidden": {
    "total": 170,
    "http://fasb.org/us-gaap/2025": 136,
    "http://lixte.com/20250930": 30,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 496,
   "entityCount": 1,
   "segmentCount": 142,
   "elementCount": 649,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1047,
    "http://xbrl.sec.gov/dei/2025": 33,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/srt/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://lixte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lixte.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lixte.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_us-gaap_RelatedPartyMember",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lixte.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://lixte.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://lixte.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentation",
     "longName": "999012 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999013 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lixte.com/role/SegmentInformation",
     "longName": "999014 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lixte.com/role/DigitalAssets",
     "longName": "999015 - Disclosure - Digital Assets",
     "shortName": "Digital Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lixte.com/role/StockholdersEquity",
     "longName": "999016 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lixte.com/role/RelatedPartyTransactions",
     "longName": "999017 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lixte.com/role/Stock-basedCompensation",
     "longName": "999018 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lixte.com/role/IncomeTaxes",
     "longName": "999019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lixte.com/role/CommitmentsAndContingencies",
     "longName": "999020 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lixte.com/role/SubsequentEvents",
     "longName": "999021 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999022 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lixte.com/role/SegmentInformationTables",
     "longName": "999024 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lixte.com/role/DigitalAssetsTables",
     "longName": "999025 - Disclosure - Digital Assets (Tables)",
     "shortName": "Digital Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CryptoAssetHoldingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CryptoAssetHoldingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lixte.com/role/StockholdersEquityTables",
     "longName": "999026 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsTables",
     "longName": "999027 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lixte.com/role/Stock-basedCompensationTables",
     "longName": "999028 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesTables",
     "longName": "999029 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "longName": "999030 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-022025-07-02",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "999031 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "999032 - Disclosure - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CryptoAssetFairValueCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CryptoAssetFairValueCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
     "longName": "999034 - Disclosure - Schedule of Information by Segment (Details)",
     "shortName": "Schedule of Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "LIXT:CashBasedCompensationToRelatedParties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://lixte.com/role/ScheduleOfDigitalAssetsDetails",
     "longName": "999035 - Disclosure - Schedule of Digital Assets (Details)",
     "shortName": "Schedule of Digital Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CryptoAssetCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetHoldingTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://lixte.com/role/DigitalAssetsDetailsNarrative",
     "longName": "999036 - Disclosure - Digital Assets (Details Narrative)",
     "shortName": "Digital Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:CryptoAssetUnrealizedGainLossNonoperating",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "999037 - Disclosure - Schedule of Warrants Outstanding (Details)",
     "shortName": "Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999038 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_custom_ExercisePriceOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://lixte.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999039 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_custom_SecuritiesPurchaseAgreementMember",
      "name": "LIXT:DescriptionOfOfferingPrice",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
     "longName": "999040 - Disclosure - Schedule of Related Party Costs (Details)",
     "shortName": "Schedule of Related Party Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_srt_DirectorMember624786375",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999041 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_SchellensMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
     "longName": "999042 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "shortName": "Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails",
     "longName": "999043 - Disclosure - Schedule of Stock-based Compensation Costs (Details)",
     "shortName": "Schedule of Stock-based Compensation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_us-gaap_RelatedPartyMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
     "longName": "999044 - Disclosure - Schedule of Stock Option Activity Including Options Form of Warrants (Details)",
     "shortName": "Schedule of Stock Option Activity Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
     "longName": "999045 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "shortName": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999046 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
     "longName": "999047 - Disclosure - Schedule of Contractual Clinical Trials (Details)",
     "shortName": "Schedule of Contractual Clinical Trials (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member",
      "name": "LIXT:ClinicalTrialDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999048 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember",
      "name": "LIXT:AmountRelatedToMilestonePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://lixte.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999049 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-09-30_custom_LMCCommunicationsIncMember",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-09-30_custom_LMCCommunicationsIncMember",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses, including $112,033 and $27,500 to related parties at September 30, 2025 and December 31, 2024, respectively",
        "verboseLabel": "Related parties accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "LIXT_AccrualOfDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AccrualOfDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual of deferred offering costs",
        "documentation": "Accrual of deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual of Series B Convertible Preferred Stock 8% cumulative dividend",
        "documentation": "Accrual of Series B Convertible Preferred Stock 8% cumulative dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r529",
      "r530",
      "r531",
      "r532",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r529",
      "r530",
      "r531",
      "r532",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r910",
      "r1281"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1211",
      "r1287"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Series B Convertible Preferred Stock 8% cumulative dividend",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r70"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options issued to settle accrued payable",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1173"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvanceAmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AdvanceAmountRelatedToMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance amount related to milestone payment",
        "documentation": "Advance amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on research and development contract services",
        "documentation": "Advances on research and development contract services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1007"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r974",
      "r984",
      "r1010"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1003",
      "r1011",
      "r1015",
      "r1023"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based",
        "label": "Total stock-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r448",
      "r457"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AmountRelatedToMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount related to milestone payment",
        "documentation": "Amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AnnualGrantOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AnnualGrantOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Grant of Options [Member]",
        "documentation": "Annual Grant of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AnnualNetRevenueDividedByConvertedOrRedeemedShares",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual net revenue",
        "documentation": "Annual net revenue divided by converted or redeemed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "LIXT_AppointmentGrantsOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "AppointmentGrantsOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appointment Grants of Options [Member]",
        "documentation": "Appointment Grants of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r91",
      "r141",
      "r163",
      "r164",
      "r165",
      "r200",
      "r214",
      "r240",
      "r244",
      "r284",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r492",
      "r494",
      "r555",
      "r654",
      "r655",
      "r660",
      "r759",
      "r863",
      "r864",
      "r876",
      "r910",
      "r928",
      "r929",
      "r941",
      "r1167",
      "r1168",
      "r1239"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r163",
      "r164",
      "r165",
      "r284",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r492",
      "r494",
      "r555",
      "r910",
      "r1167",
      "r1168",
      "r1239"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r899"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "LIXT_BasvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "BasvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasvanderBaan [Member]",
        "documentation": "BasvanderBaan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BioPharmaWorksLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "BioPharmaWorksLLCMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Pharma Works LLC [Member]",
        "documentation": "Bio Pharma Works LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BitcoinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "BitcoinMember",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bitcoin [Member]",
        "documentation": "Bitcoin [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r663",
      "r730",
      "r754",
      "r910",
      "r928",
      "r929",
      "r941",
      "r1049"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "LIXT_CashBasedCompensationToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CashBasedCompensationToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash-based",
        "documentation": "Cash based compensation to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r60",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease)",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r60"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insurance",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CashSIPCInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CashSIPCInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash SIPC insurance",
        "documentation": "Cash SIPC insurance."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ChairmanOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Audit Committee [Member]",
        "documentation": "Chairman of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ChairmanOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Other Committees [Member]",
        "documentation": "Chairman of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "documentation": "Person with designation of chief operating officer."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1237"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CityOfHopeNationalMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CityOfHopeNationalMedicalCenterMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City of Hope [Member]",
        "documentation": "City of Hope [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r142",
      "r143",
      "r144",
      "r163",
      "r165",
      "r190",
      "r191",
      "r194",
      "r196",
      "r202",
      "r203",
      "r284",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r353",
      "r356",
      "r357",
      "r360",
      "r363",
      "r371",
      "r555",
      "r709",
      "r710",
      "r711",
      "r712",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r746",
      "r768",
      "r790",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r1032",
      "r1108",
      "r1109",
      "r1118"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r202",
      "r347",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r369",
      "r371",
      "r522",
      "r709",
      "r710",
      "r711",
      "r712",
      "r877",
      "r1032",
      "r1106",
      "r1108"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expires date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices",
        "verboseLabel": "Warrants exercise price",
        "terseLabel": "Warrants exercisable price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r167",
      "r372"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase of common stock",
        "verboseLabel": "Pre-funded warrants remained unexercised",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre funded warrants",
        "verboseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unexercised pre funded warrants",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalAndRelatedOversightCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalAndRelatedOversightCostsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and Related Oversight Costs [Member]",
        "documentation": "Clinical and Related Oversight Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalResearchSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalResearchSupportAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Research Support Agreement [Member]",
        "documentation": "Clinical Research Support Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]",
        "documentation": "Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements [Member]",
        "documentation": "Clinical Trial Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialDescription",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial, description",
        "documentation": "Clinical trial description."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Monitoring Agreements [Member]",
        "documentation": "Clinical Trial Monitoring Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialPhase1bMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b [Member]",
        "documentation": "Phase 1b [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialPhase1bTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b Two [Member]",
        "documentation": "Phase 1b\tTwo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhaseMD1b2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialPhaseMD1b2Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b 2 [Member]",
        "documentation": "Clinical Trial Phase MD 1b 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialResearchMonitoringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ClinicalTrialResearchMonitoringMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research Monitoring [Member]",
        "documentation": "Clinical Trial Research Monitoring [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "LIXT_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r84",
      "r662",
      "r745"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r323",
      "r324",
      "r827",
      "r1160",
      "r1162"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares were available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "LIXT_CommonStockIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CommonStockIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for services",
        "documentation": "Common stock issued for services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938",
      "r1114",
      "r1115",
      "r1117",
      "r1211",
      "r1279",
      "r1287"
     ]
    },
    "LIXT_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]",
        "documentation": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share",
        "documentation": "Common Stock, par value $0.0001 per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r746"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r48",
      "r746",
      "r765",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; authorized \u2013 100,000,000 shares; issued and outstanding \u2013 5,704,200 and 2,249,290 shares at September 30, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r345",
      "r352",
      "r665",
      "r910"
     ]
    },
    "LIXT_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "LIXT_CompoundMaintenanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CompoundMaintenanceMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compound Maintenance [Member]",
        "documentation": "Compound Maintenance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r252",
      "r703",
      "r704",
      "r826",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r252",
      "r703",
      "r704",
      "r826",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r252",
      "r703",
      "r704",
      "r826",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r553"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r252",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r252",
      "r703",
      "r704",
      "r826",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r852"
     ]
    },
    "LIXT_ConsultingAndAdvisoryCashFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ConsultingAndAdvisoryCashFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and advisory fee",
        "documentation": "Consulting and advisory quarterly cash fee."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodEndDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ContractualClinicalTrialPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated End Date",
        "documentation": "Contractual clinical trial period end date"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodStartDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ContractualClinicalTrialPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Start Date",
        "documentation": "Contractual clinical trial period start date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "verboseLabel": "Contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1113",
      "r1248"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contractual Clinical Trials",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1107",
      "r1113",
      "r1248"
     ]
    },
    "LIXT_ConversionOfSeriesConvertiblePreferredStockIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ConversionOfSeriesConvertiblePreferredStockIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A Convertible Preferred Stock into common stock",
        "documentation": "Conversion of series convertible preferred stock into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock convertible into common stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issuable upon conversion",
        "verboseLabel": "Convertible preferred stock shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r47",
      "r68",
      "r366"
     ]
    },
    "us-gaap_CorporateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Segment [Member]",
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual cash fee",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r163",
      "r164",
      "r165",
      "r284",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r555",
      "r863",
      "r1167"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CryptoAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CryptoAssetAxis",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset [Axis]",
        "documentation": "Information by crypto-asset."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r318",
      "r1149",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_CryptoAssetCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets held, Cost basis",
        "documentation": "Cost of crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308"
     ]
    },
    "srt_CryptoAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CryptoAssetDomain",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crypto-asset."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r318",
      "r1149",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_CryptoAssetFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetFairValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets fair value",
        "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r309",
      "r311"
     ]
    },
    "us-gaap_CryptoAssetFairValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetFairValueCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets",
        "documentation": "Fair value of crypto asset classified as current. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r309",
      "r311"
     ]
    },
    "us-gaap_CryptoAssetHoldingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingLineItems",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset, Holding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ]
    },
    "us-gaap_CryptoAssetHoldingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingTable",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset, Holding [Table]",
        "documentation": "Disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ]
    },
    "us-gaap_CryptoAssetHoldingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingTableTextBlock",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Digital Assets",
        "documentation": "Tabular disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_CryptoAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetTextBlock",
     "presentation": [
      "http://lixte.com/role/DigitalAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital Assets",
        "documentation": "The entire disclosure for crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314"
     ]
    },
    "us-gaap_CryptoAssetUnrealizedGainLossNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetUnrealizedGainLossNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain (loss) on digital assets",
        "negatedLabel": "Unrealized gain (loss) on digital assets",
        "verboseLabel": "Unrealized gain (loss) in fair value of digital assets",
        "negatedTerseLabel": "Unrealized gain (loss) in fair value of digital assets",
        "documentation": "Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as nonoperating. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "LIXT_CryptoAssetsNumberOfUnits": {
     "xbrltype": "pureItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "CryptoAssetsNumberOfUnits",
     "presentation": [
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets held, Quantity",
        "documentation": "Crypto assets number of units."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of accrued compensation to members of the Board of Directors by issuance of stock options",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation expense for unvested stock options",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r72"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1050"
     ]
    },
    "LIXT_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r735",
      "r737",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r778",
      "r779",
      "r780",
      "r781",
      "r784",
      "r785",
      "r786",
      "r787",
      "r808",
      "r809",
      "r810",
      "r811",
      "r844",
      "r845",
      "r846",
      "r896",
      "r897",
      "r931",
      "r933",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r735",
      "r737",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r778",
      "r779",
      "r780",
      "r781",
      "r784",
      "r785",
      "r786",
      "r787",
      "r808",
      "r809",
      "r810",
      "r811",
      "r844",
      "r845",
      "r846",
      "r896",
      "r897",
      "r931",
      "r933",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1225",
      "r1226"
     ]
    },
    "LIXT_DescriptionOfOfferingPrice": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DescriptionOfOfferingPrice",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of offering price",
        "documentation": "Description of offering price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DevelopmentCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DevelopmentCollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Collaboration Agreement [Member]",
        "documentation": "Development Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DigitalAssetHoldingsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DigitalAssetHoldingsPercentage",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset holdings percentage",
        "documentation": "Digital asset holdings percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1131",
      "r1280"
     ]
    },
    "LIXT_DirectorsAndCorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DirectorsAndCorporateOfficersMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Granted to Directors and Corporate Officers [Member]",
        "documentation": "Stock Options Granted to Directors and Corporate Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r413",
      "r444",
      "r445",
      "r446",
      "r888"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Costs",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r955",
      "r967"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "LIXT_DrJamesSMiserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DrJamesSMiserMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr.James S. Miser [Member]",
        "documentation": "Dr.James S. Miser [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrKovachMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DrKovachMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Kovach [Member]",
        "documentation": "Dr. Kovach [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrMichaelHollowayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DrMichaelHollowayMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Michael Holloway [Member]",
        "documentation": "Dr. Michael Holloway [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DueEachJanuaryOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "DueEachJanuaryOneMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Each January 1 [Member]",
        "documentation": "Due Each January 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_ES": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "ES",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r152",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r190",
      "r194",
      "r195",
      "r196",
      "r199",
      "r343",
      "r447",
      "r485",
      "r490",
      "r536",
      "r537",
      "r653",
      "r672",
      "r854"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r152",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r190",
      "r194",
      "r195",
      "r196",
      "r199",
      "r343",
      "r447",
      "r485",
      "r490",
      "r536",
      "r537",
      "r653",
      "r672",
      "r854"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r198"
     ]
    },
    "LIXT_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r129",
      "r130",
      "r131",
      "r149",
      "r150",
      "r151",
      "r170",
      "r171",
      "r172",
      "r174",
      "r181",
      "r183",
      "r185",
      "r201",
      "r285",
      "r286",
      "r315",
      "r342",
      "r373",
      "r447",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r486",
      "r489",
      "r490",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r670",
      "r696",
      "r697",
      "r698",
      "r718",
      "r790"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "LIXT_EricJFormanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "EricJFormanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric J. Forman [Member]",
        "documentation": "Eric J. Forman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1007"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1004"
     ]
    },
    "LIXT_EstimatedWorkCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "EstimatedWorkCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work cost",
        "documentation": "Estimated work cost."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_EthereumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "EthereumMember",
     "presentation": [
      "http://lixte.com/role/DigitalAssetsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ethereum [Member]",
        "documentation": "Ethereum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "LIXT_ExerciseOfPlacementAgentWarrantsOnCashlessBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExerciseOfPlacementAgentWarrantsOnCashlessBasis",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of placement agent warrants on a cashless basis",
        "documentation": "Exercise of placement agent warrants on a cashless basis."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExerciseOfPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of pre-funded warrants",
        "documentation": "Exercise of pre-funded warrants.",
        "label": "ExerciseOfPrefundedWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eight [Member]",
        "documentation": "Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceEighteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eighteen [Member]",
        "documentation": "Exercise Price Eighteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceElevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eleven [Member]",
        "documentation": "Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceFifteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fifteen [Member]",
        "documentation": "Exercise Price Fifteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceFourteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fourteen [Member]",
        "documentation": "Exercise Price Fourteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Nine [Member]",
        "documentation": "Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seven [Member]",
        "documentation": "Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceSeventeenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seventeen [Member]",
        "documentation": "Exercise Price Seventeen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "documentation": "Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceSixteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Sixteen [Member]",
        "documentation": "Exercise Price Sixteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Ten [Member]",
        "documentation": "Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceThirteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise PriceThirteen [Member]",
        "documentation": "Exercise PriceThirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceTwelveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Twelve [Member]",
        "documentation": "Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedDateOfPreliminaryEfficacySignal": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExpectedDateOfPreliminaryEfficacySignal",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Date",
        "documentation": "Expected date of preliminary efficacy signal."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentThroughSoftware": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExpectedPaymentThroughSoftware",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through software",
        "documentation": "Percentage of expected paymen through software."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentinServices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ExpectedPaymentinServices",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through services",
        "documentation": "Expected payment in services."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1213",
      "r1214"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r538",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r549",
      "r551",
      "r585",
      "r586",
      "r587",
      "r840",
      "r874",
      "r875",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r899",
      "r902",
      "r909"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r543",
      "r899",
      "r1216",
      "r1227"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r378",
      "r383",
      "r389",
      "r540",
      "r547",
      "r551",
      "r585",
      "r840",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r899",
      "r909"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r378",
      "r383",
      "r389",
      "r391",
      "r540",
      "r541",
      "r547",
      "r551",
      "r586",
      "r840",
      "r874",
      "r875",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r899",
      "r909"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r540",
      "r541",
      "r542",
      "r543",
      "r547",
      "r551",
      "r587",
      "r840",
      "r874",
      "r875",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r899",
      "r902",
      "r909"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r543",
      "r899",
      "r1216",
      "r1227"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r538",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r549",
      "r551",
      "r585",
      "r586",
      "r587",
      "r840",
      "r874",
      "r875",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r899",
      "r902",
      "r909"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1227"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "LIXT_FairValueOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FairValueOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock options",
        "documentation": "Fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 13, 2025 Equity Offering [Member]",
        "documentation": "February 13, 2025 Equity Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r341",
      "r369",
      "r522",
      "r533",
      "r550",
      "r554",
      "r557",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r659",
      "r671",
      "r870",
      "r899",
      "r900",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1212",
      "r1215",
      "r1216",
      "r1217",
      "r1224",
      "r1227",
      "r1229",
      "r1230"
     ]
    },
    "LIXT_FiveNonOfficerDirectorsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FiveNonOfficerDirectorsOneMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non-Officer Directors [Member]",
        "documentation": "Five Non-Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ForeignCurrencyExchangeRateTranslation": {
     "xbrltype": "pureItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ForeignCurrencyExchangeRateTranslation",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency average rate",
        "documentation": "Foreign currency exchange rate translation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized gain (loss) on foreign currency transactions",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r939",
      "r1232",
      "r1233",
      "r1286"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1011"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1011"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1011"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1011"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1011"
     ]
    },
    "LIXT_FourNonOfficerDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FourNonOfficerDirectorMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non Officer Director [Member]",
        "documentation": "Four Non Officer Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FourNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FourNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non-officer Directors [Member]",
        "documentation": "Four Non-officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FourOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "FourOfficersMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Officers [Member]",
        "documentation": "Four Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs",
        "verboseLabel": "Legal and filing fees and costs",
        "totalLabel": "Total general and administrative costs",
        "terseLabel": "Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r770"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "LIXT_GeneralAndAdministrativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "GeneralAndAdministrativeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative [Member]",
        "documentation": "General And Administrative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "GrupoEspanolDeInvestigacionEnSarcomasMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEIS [Member]",
        "documentation": "GEIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationHealthCareCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HealthCareOrganizationHealthCareCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dosing of product",
        "documentation": "Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r319",
      "r320",
      "r497",
      "r503",
      "r520",
      "r521",
      "r544",
      "r545",
      "r548",
      "r556",
      "r557",
      "r558",
      "r693",
      "r695",
      "r775",
      "r839",
      "r840",
      "r891",
      "r892",
      "r897",
      "r898",
      "r901",
      "r909",
      "r1204",
      "r1205",
      "r1250"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r497",
      "r503",
      "r520",
      "r521",
      "r544",
      "r545",
      "r548",
      "r556",
      "r557",
      "r558",
      "r693",
      "r695",
      "r775",
      "r839",
      "r840",
      "r891",
      "r892",
      "r897",
      "r898",
      "r901",
      "r909",
      "r1204",
      "r1205",
      "r1250"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r478",
      "r479",
      "r480",
      "r481",
      "r658",
      "r702",
      "r714",
      "r890"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r463",
      "r464",
      "r469",
      "r470",
      "r471",
      "r475",
      "r708"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r159",
      "r473",
      "r474"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances on research and development contract services",
        "documentation": "Increase decrease in advances on research and development contract services.",
        "label": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidInsurance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid insurance",
        "label": "Increase (Decrease) in Prepaid Insurance",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development contract liabilities",
        "documentation": "Increase decrease in research and development contract liabilities",
        "label": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_IndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "IndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Independent Director [Member]",
        "documentation": "Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1003",
      "r1011",
      "r1015",
      "r1023"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1027"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1027"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1027"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Licensing Legal and Filing Fees and Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r618",
      "r853",
      "r1138"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r214",
      "r218",
      "r224",
      "r244",
      "r567",
      "r863",
      "r864",
      "r1283"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r158"
     ]
    },
    "us-gaap_InventoryPartsAndComponentsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPartsAndComponentsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory costs",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r1051"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1236"
     ]
    },
    "LIXT_JasonSawyerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "JasonSawyerMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jason Sawyer [Member]",
        "documentation": "Jason Sawyer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "JulyTwentyTwoThousandTwentyThreeEquityOfferingMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 20, 2023 Equity Offering [Member]",
        "documentation": "July 20, 2023 Equity Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_LMCCommunicationsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "LMCCommunicationsIncMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LMC Communications Inc [Member]",
        "documentation": "LMC Communications Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and filing fees and costs",
        "verboseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1284",
      "r1285"
     ]
    },
    "LIXT_LegalFeesRelatingToPatentsAndLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "LegalFeesRelatingToPatentsAndLicensing",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and licensing legal and filing fees and costs",
        "documentation": "Legal fees relating to patents and licensing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r85",
      "r667",
      "r910",
      "r928",
      "r929",
      "r1106",
      "r1110",
      "r1136",
      "r1231"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r140",
      "r163",
      "r164",
      "r165",
      "r284",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r493",
      "r494",
      "r495",
      "r555",
      "r910",
      "r1167",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r895",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1203"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation settlement expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r325",
      "r326",
      "r327",
      "r330",
      "r458",
      "r873",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r325",
      "r326",
      "r327",
      "r330",
      "r458",
      "r873",
      "r1163",
      "r1164"
     ]
    },
    "LIXT_LourdesFelixAndGuyPrimusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "LourdesFelixAndGuyPrimusMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lourdes Felix and Guy Primus [Member]",
        "documentation": "Lourdes Felix and Guy Primus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MDAndersonCancerCenterClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MDAndersonCancerCenterClinicalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MD Anderson Cancer Center Clinical [Member]",
        "documentation": "MD Anderson Cancer Center Clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MRIGlobalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MRIGlobalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MRI Global [Member]",
        "documentation": "MRI Global [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r878",
      "r881",
      "r921",
      "r926",
      "r1249",
      "r1251",
      "r1252",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_ManagementFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManagementFeeDescription",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management fee description",
        "documentation": "Description of the nature of payments to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP), including the fee rate, basis of calculation, relevant accounting period, whether the fee is paid to an entity other than the managing member or general partner, or whether the fee is waived."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r1234"
     ]
    },
    "us-gaap_ManagementFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManagementFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee payable",
        "documentation": "Amount of fee payable for management of fund or trust."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "LIXT_MarketAwarenessAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MarketAwarenessAgreementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Awareness Agreement [Member]",
        "documentation": "Market Awareness Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r100",
      "r101",
      "r103",
      "r120",
      "r122",
      "r123",
      "r127",
      "r128",
      "r209",
      "r326",
      "r327",
      "r328",
      "r329",
      "r407",
      "r439",
      "r440",
      "r441",
      "r458",
      "r543",
      "r613",
      "r692",
      "r694",
      "r701",
      "r736",
      "r737",
      "r798",
      "r801",
      "r805",
      "r806",
      "r812",
      "r821",
      "r822",
      "r824",
      "r825",
      "r837",
      "r838",
      "r869",
      "r877",
      "r887",
      "r891",
      "r893",
      "r894",
      "r902",
      "r903",
      "r907",
      "r908",
      "r922",
      "r1169",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "LIXT_MemberOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MemberOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Audit Committee [Member]",
        "documentation": "Member of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MemberOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MemberOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Other Committees [Member]",
        "documentation": "Member of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r100",
      "r101",
      "r103",
      "r120",
      "r122",
      "r123",
      "r127",
      "r128",
      "r209",
      "r326",
      "r327",
      "r328",
      "r329",
      "r407",
      "r439",
      "r440",
      "r441",
      "r458",
      "r543",
      "r613",
      "r692",
      "r694",
      "r701",
      "r736",
      "r737",
      "r798",
      "r801",
      "r805",
      "r806",
      "r812",
      "r821",
      "r822",
      "r824",
      "r825",
      "r837",
      "r838",
      "r869",
      "r877",
      "r887",
      "r891",
      "r893",
      "r894",
      "r902",
      "r903",
      "r907",
      "r922",
      "r1169",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "LIXT_MrPursgloveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MrPursgloveMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Pursglove [Member]",
        "documentation": "Mr Pursglove [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MrvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "MrvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr van der Baan [Member]",
        "documentation": "Mr van der Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "LIXT_NDAConsultingCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "NDAConsultingCorpMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NDA Consulting Corp [Member]",
        "documentation": "NDA Consulting Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "NL",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r878",
      "r881",
      "r921",
      "r926",
      "r1249",
      "r1251",
      "r1252",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operations",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r62",
      "r87",
      "r131",
      "r138",
      "r146",
      "r147",
      "r151",
      "r163",
      "r164",
      "r165",
      "r169",
      "r173",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r192",
      "r284",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r343",
      "r346",
      "r349",
      "r354",
      "r447",
      "r485",
      "r490",
      "r537",
      "r555",
      "r669",
      "r767",
      "r788",
      "r789",
      "r848",
      "r850",
      "r851",
      "r939",
      "r1167"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r153",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r188",
      "r193",
      "r196",
      "r346",
      "r349",
      "r354",
      "r490"
     ]
    },
    "LIXT_NetherlandsCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "NetherlandsCancerInstituteMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands Cancer Institute [Member]",
        "documentation": "Netherlands Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_NewIndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "NewIndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Independent Director [Member]",
        "documentation": "New Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses",
        "documentation": "Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r1285"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1111",
      "r1112"
     ]
    },
    "LIXT_NumberOfPatientInTrial": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "NumberOfPatientInTrial",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Patients in Trial",
        "documentation": "Number of patient in trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r858",
      "r868",
      "r1126"
     ]
    },
    "LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal cash obligations and commitments",
        "documentation": "Number of share tranche of the series a convertible preferred stock receive a per share dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash-based",
        "label": "Compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "LIXT_OneVendorAndConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "OneVendorAndConsultantMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Vendor and Consultant [Member]",
        "documentation": "One Vendor and Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r848",
      "r851",
      "r857",
      "r1119",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r132",
      "r133",
      "r135",
      "r705",
      "r706"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining financial contractual commitment",
        "verboseLabel": "Aggregate commitments expected",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1113",
      "r1248"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_OtherConsultingAndProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "OtherConsultingAndProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other consulting and professional fees",
        "documentation": "Other consulting and professional fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other costs and expenses",
        "verboseLabel": "Other costs and expenses, net",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r673",
      "r863"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1137"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "LIXT_OtherVendorAndConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "OtherVendorAndConsultantMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Vendor and Consultant [Member]",
        "documentation": "Other Vendor and Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r973",
      "r983",
      "r1009"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1012"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1012"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_PaymentForAcquisitionCryptoAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentForAcquisitionCryptoAsset",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of digital assets",
        "label": "Payment for Acquisition, Crypto Asset",
        "documentation": "Amount of cash outflow to acquire crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid office rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for of common stock services",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs of public offering",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "LIXT_PeterStazzoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PeterStazzoneMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peter Stazzone [Member]",
        "documentation": "Peter Stazzone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PlacementAgentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PlacementAgentAgreementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Agreement [Member]",
        "documentation": "Placement Agent Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PlacementAgentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PlacementAgentsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents [Member]",
        "documentation": "Placement Agents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PlacementAgentsWarrantsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents Warrants [Member]",
        "documentation": "Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r318"
     ]
    },
    "srt_PlatformOperatorCryptoAssetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Digital Assets",
        "label": "Platform Operator, Crypto Asset [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for safeguarding liability and corresponding asset for crypto-asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r318"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]",
        "documentation": "Disclosure of information about crypto-asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r318"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "LIXT_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreFunded Warrants [Member]",
        "documentation": "PreFunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PreclinicalResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PreclinicalResearchMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical Research [Member]",
        "documentation": "Preclinical Research [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, conversion description",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r47"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r799",
      "r802",
      "r804",
      "r813"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r47",
      "r1106",
      "r1108",
      "r1170"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r935",
      "r936",
      "r937",
      "r938",
      "r1279",
      "r1287"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r356"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Undesignated preferred stock",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r746"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r356"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r746",
      "r765",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r345",
      "r351",
      "r664",
      "r910"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r871",
      "r1137"
     ]
    },
    "LIXT_PrepaidInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "PrepaidInsurancePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "documentation": "Prepaid Insurance [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of interest in subsidiary",
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from initial offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct offerings, net of offering costs",
        "verboseLabel": "Gross proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of transaction",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered private placement, net of offering costs",
        "verboseLabel": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r124",
      "r248",
      "r617",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r841",
      "r847",
      "r850",
      "r851",
      "r878",
      "r879",
      "r920",
      "r922",
      "r923",
      "r927",
      "r930",
      "r1035",
      "r1047",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1165",
      "r1166",
      "r1249",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r124",
      "r248",
      "r617",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r841",
      "r847",
      "r850",
      "r851",
      "r878",
      "r879",
      "r920",
      "r922",
      "r923",
      "r927",
      "r930",
      "r1035",
      "r1047",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1165",
      "r1166",
      "r1249",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r100",
      "r101",
      "r103",
      "r120",
      "r122",
      "r123",
      "r127",
      "r128",
      "r209",
      "r326",
      "r327",
      "r328",
      "r329",
      "r377",
      "r407",
      "r439",
      "r440",
      "r441",
      "r446",
      "r458",
      "r543",
      "r588",
      "r597",
      "r613",
      "r692",
      "r694",
      "r701",
      "r736",
      "r737",
      "r798",
      "r801",
      "r805",
      "r806",
      "r812",
      "r821",
      "r822",
      "r824",
      "r825",
      "r837",
      "r838",
      "r869",
      "r877",
      "r887",
      "r891",
      "r893",
      "r894",
      "r902",
      "r903",
      "r907",
      "r908",
      "r922",
      "r933",
      "r1161",
      "r1169",
      "r1216",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r100",
      "r101",
      "r103",
      "r120",
      "r122",
      "r123",
      "r127",
      "r128",
      "r209",
      "r326",
      "r327",
      "r328",
      "r329",
      "r377",
      "r407",
      "r439",
      "r440",
      "r441",
      "r446",
      "r458",
      "r543",
      "r588",
      "r597",
      "r613",
      "r692",
      "r694",
      "r701",
      "r736",
      "r737",
      "r798",
      "r801",
      "r805",
      "r806",
      "r812",
      "r821",
      "r822",
      "r824",
      "r825",
      "r837",
      "r838",
      "r869",
      "r877",
      "r887",
      "r891",
      "r893",
      "r894",
      "r902",
      "r903",
      "r907",
      "r908",
      "r922",
      "r933",
      "r1161",
      "r1169",
      "r1216",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1004"
     ]
    },
    "LIXT_RegulatoryServiceCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "RegulatoryServiceCostsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Service Costs [Member]",
        "documentation": "Regulatory Service Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ReimbursementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ReimbursementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursed expense",
        "documentation": "Reimbursement expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r253",
      "r384",
      "r403",
      "r574",
      "r575",
      "r661",
      "r668",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r764",
      "r797",
      "r1282"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r574",
      "r575",
      "r576",
      "r577",
      "r661",
      "r668",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r764",
      "r797"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r253",
      "r574",
      "r575",
      "r577",
      "r771",
      "r772",
      "r775"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails",
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r253",
      "r384",
      "r403",
      "r574",
      "r575",
      "r661",
      "r668",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r764",
      "r797",
      "r1238",
      "r1282"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r573",
      "r575",
      "r578",
      "r715",
      "r716",
      "r717",
      "r773",
      "r774",
      "r775",
      "r794",
      "r796"
     ]
    },
    "LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ResearchAndDevelopmentContractLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contract liabilities",
        "documentation": "Research and development contract liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "verboseLabel": "Total research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r839",
      "r848",
      "r849",
      "r863",
      "r1247"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development process costs",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "LIXT_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Research and Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1005"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1006"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r987",
      "r1013"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r70",
      "r666",
      "r699",
      "r700",
      "r713",
      "r747",
      "r910"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r170",
      "r171",
      "r172",
      "r174",
      "r181",
      "r183",
      "r185",
      "r285",
      "r286",
      "r315",
      "r342",
      "r447",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r486",
      "r489",
      "r490",
      "r523",
      "r525",
      "r526",
      "r528",
      "r535",
      "r568",
      "r569",
      "r696",
      "r698",
      "r718",
      "r1287"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r200",
      "r215",
      "r216",
      "r238",
      "r244",
      "r248",
      "r250",
      "r252",
      "r374",
      "r375",
      "r376",
      "r617",
      "r848",
      "r851"
     ]
    },
    "LIXT_RobertNWeingartenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "RobertNWeingartenMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert N. Weingarten [Member]",
        "documentation": "Robert N. Weingarten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable license issue royalty",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "LIXT_RoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "RoyaltyPayable",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum annual royalty payable",
        "documentation": "Royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_RoyatiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "RoyatiesPercentage",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royaties percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "LIXT_SGNMediaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SGNMediaIncMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SGN Media Inc [Member]",
        "documentation": "SGN Media Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued and sold",
        "verboseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r1121",
      "r1122"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1044"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r134",
      "r136",
      "r186",
      "r408",
      "r1033"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r34",
      "r35",
      "r385",
      "r386",
      "r387",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r574",
      "r575",
      "r577",
      "r771",
      "r772",
      "r775"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Costs",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1236"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://lixte.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r446"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity Including Options Form of Warrants",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Each Option Award Estimated Assumption",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r67",
      "r69",
      "r70",
      "r142",
      "r143",
      "r144",
      "r202",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r369",
      "r371",
      "r522",
      "r709",
      "r710",
      "r711",
      "r712",
      "r877",
      "r1032",
      "r1106",
      "r1108"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1172"
     ]
    },
    "LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule Of Warrants Outstanding And Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SchellensMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SchellensMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schellens [Member]",
        "documentation": "Schellens [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r200",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r252",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r321",
      "r322",
      "r487",
      "r488",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r860",
      "r863",
      "r864",
      "r872",
      "r925",
      "r1249",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r102",
      "r104",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r206",
      "r250",
      "r251",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r732",
      "r733",
      "r734",
      "r800",
      "r803",
      "r807",
      "r814",
      "r821",
      "r823",
      "r824",
      "r825",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r842",
      "r855",
      "r878",
      "r880",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r924",
      "r933",
      "r1249",
      "r1251",
      "r1252",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r200",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r227",
      "r229",
      "r230",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r858",
      "r861",
      "r862",
      "r863",
      "r865",
      "r867",
      "r868"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r247",
      "r250",
      "r859",
      "r860",
      "r866"
     ]
    },
    "LIXT_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SeriesBConvertiblePreferredStockCumulativeDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SeriesBConvertiblePreferredStockCumulativeDividend",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock 8% cumulative dividend",
        "documentation": "Series B convertible preferred stock cumulative dividend."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SeriesBConvertiblePreferredStockCumulativeDividendPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SeriesBConvertiblePreferredStockCumulativeDividendPayable",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock 8% cumulative dividend payable",
        "documentation": "Series B Convertible Preferred Stock cumulative dividend payable."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense included in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r446"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Exercised",
        "verboseLabel": "Warrants exercise",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Warrants Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "label": "Warrants Outstanding Shares",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.",
        "label": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares avaliable for issuable",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, stock options exercisable",
        "verboseLabel": "Number of stock option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, stock options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, grants in period, gross",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value, per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, stock options outstanding, at the beginning",
        "periodEndLabel": "Number of shares, stock options outstanding, at the end",
        "label": "Shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted to purchase common stock, issued",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vested",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, stock options outstanding",
        "periodEndLabel": "Weighted average exercise price, stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable unexercised, intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options are exercisable price per share",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "verboseLabel": "Exercise price of options",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative costs",
        "documentation": "Stock based compensation expense included in research and development costs.",
        "label": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development costs",
        "documentation": "Stock based compensation expense included in general and administrative costs.",
        "label": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r417",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value of stock",
        "verboseLabel": "Stock price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award, award vesting period",
        "verboseLabel": "Stock option, vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding stock options to acquire shares of common stock not vested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average recognition period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued for Services",
        "verboseLabel": "Number of shares issued, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bid price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r137",
      "r200",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r252",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r317",
      "r321",
      "r322",
      "r487",
      "r488",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r860",
      "r863",
      "r864",
      "r872",
      "r925",
      "r1249",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r142",
      "r143",
      "r144",
      "r163",
      "r165",
      "r190",
      "r191",
      "r194",
      "r196",
      "r202",
      "r203",
      "r284",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r353",
      "r356",
      "r357",
      "r360",
      "r363",
      "r371",
      "r555",
      "r709",
      "r710",
      "r711",
      "r712",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r746",
      "r768",
      "r790",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r1032",
      "r1108",
      "r1109",
      "r1118"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r48",
      "r51",
      "r52",
      "r129",
      "r130",
      "r131",
      "r149",
      "r150",
      "r151",
      "r170",
      "r171",
      "r172",
      "r174",
      "r181",
      "r183",
      "r185",
      "r201",
      "r285",
      "r286",
      "r315",
      "r342",
      "r373",
      "r447",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r486",
      "r489",
      "r490",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r670",
      "r696",
      "r697",
      "r698",
      "r718",
      "r790"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r102",
      "r104",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r206",
      "r250",
      "r251",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r732",
      "r733",
      "r734",
      "r800",
      "r803",
      "r807",
      "r814",
      "r821",
      "r823",
      "r824",
      "r825",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r842",
      "r855",
      "r878",
      "r880",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r924",
      "r933",
      "r1249",
      "r1251",
      "r1252",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r201",
      "r344",
      "r345",
      "r347",
      "r350",
      "r569",
      "r617",
      "r707",
      "r719",
      "r731",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r769",
      "r770",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r850",
      "r851",
      "r934",
      "r1282"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r134",
      "r136",
      "r186",
      "r408",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r201",
      "r253",
      "r344",
      "r345",
      "r347",
      "r350",
      "r569",
      "r617",
      "r707",
      "r719",
      "r731",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r769",
      "r770",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r850",
      "r851",
      "r934",
      "r1282"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r972",
      "r982",
      "r1008"
     ]
    },
    "LIXT_StockBasedCompensationToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockBasedCompensationToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based",
        "documentation": "Stock based compensation to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A convertible stock, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r47",
      "r48",
      "r70"
     ]
    },
    "LIXT_StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of placement agent warrants, shares",
        "documentation": "Stock issued during period shares exercise of placement agent warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services, shares",
        "verboseLabel": "Shares Issued for Services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares",
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Number of shares issued, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r47",
      "r48",
      "r70",
      "r709",
      "r790",
      "r816"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs, shares",
        "documentation": "Stock issued during period shares proceeds from sale of securities in july 2025 registered direct offering net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in July 2025 registered private placement, net of offering costs, shares",
        "verboseLabel": "Private placement shares",
        "documentation": "Stock issued during period shares proceeds from sale of securities in july 2025 registered private placement net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r70"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lixte.com/role/ScheduleOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common warrants, shares",
        "negatedLabel": "Number of shares, exercised",
        "verboseLabel": "Pre-funded warrants exercisable",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r47",
      "r48",
      "r70",
      "r423"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A convertible stock",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r48",
      "r51",
      "r52",
      "r70"
     ]
    },
    "LIXT_StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of placement agent warrants",
        "documentation": "Stock issued during period value exercise of placement agent warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services",
        "verboseLabel": "Shares Issued for Services, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct equity offering, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r47",
      "r48",
      "r70",
      "r718",
      "r790",
      "r816",
      "r940"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs",
        "documentation": "Stock issued during period value proceeds from sale of securities in july 2025 registered direct offering net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in July 2025 registered private placement, net of offering costs",
        "documentation": "Stock issued during period value proceeds from sale of securities in july 2025 registered private placement net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common warrants",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r48",
      "r51",
      "r52",
      "r70"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1206"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Total stockholders equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r63",
      "r748",
      "r765",
      "r791",
      "r792",
      "r910",
      "r941",
      "r1106",
      "r1109",
      "r1110",
      "r1136",
      "r1231",
      "r1287"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r355",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r370",
      "r373",
      "r522",
      "r534",
      "r793",
      "r795",
      "r820"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r580"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r580"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r580"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r580"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r580"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lixte.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r581"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for -",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "LIXT_TheradexSystemsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "TheradexSystemsIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theradex Systems, Inc. [Member]",
        "documentation": "Theradex Systems, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1237"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r341",
      "r369",
      "r522",
      "r533",
      "r550",
      "r554",
      "r557",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r659",
      "r671",
      "r899",
      "r900",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1212",
      "r1215",
      "r1216",
      "r1217",
      "r1224",
      "r1227",
      "r1229",
      "r1230"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "LIXT_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_TwoVendorAndConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "TwoVendorAndConsultantMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Vendor And Consultant [Member]",
        "documentation": "Two Vendor And Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r204",
      "r207",
      "r208",
      "r209",
      "r654",
      "r656",
      "r856"
     ]
    },
    "LIXT_VendorAndConsultantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorAndConsultantFiveMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Five [Member]",
        "documentation": "Vendor and Consultant Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorAndConsultantFourMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Four [Member]",
        "documentation": "Vendor and Consultant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorAndConsultantOneMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant One [Member]",
        "documentation": "Vendor And Consultant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorAndConsultantThreeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Three [Member]",
        "documentation": "Vendor and Consultant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorAndConsultantTwoMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant Two [Member]",
        "documentation": "Vendor And Consultant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "VendorMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [Member]",
        "documentation": "Vendor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "LIXT_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share",
        "documentation": "Warrants to Purchase Common Stock, par value $0.0001 per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r196"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r196"
     ]
    },
    "LIXT_WorkOrderAgreementCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "WorkOrderAgreementCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work order agreement costs",
        "documentation": "Work order agreement costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WorkOrderAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250930",
     "localname": "WorkOrderAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work Order Agreement [Member]",
        "documentation": "Work Order Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "450",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478201/954-450-30-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "450",
   "Section": "30",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478201/954-450-30-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "FF",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001493152-25-021941-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-021941-xbrl.zip
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M-]Y<@F]/PK<FV=<HX=N6_@M02P,$%     @ .X-L6_R/_-A."   N4D   H
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M ^(8AER-<1]'VXM F: ZP?<^5UXH50+[/FJ66(;6CB>Q])@/CQ4Y!+/U&?"
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M>)=QP.V@YGVUXE<PX5<OV>]BPJ]L^A=02P,$%     @ .X-L6_/SJ\ZS!
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M1XJ!)2R0"5(-JZ;XFM2B&K*)' MH&\=K)&KWJO44CU*"-.Q$.78W/7,\"VU
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MM!*S#\X+R@",+ ##;5WFD@MC7=;A1-V)LJ[P<7%&!P M(- B#:GU9XKY:/4
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M20*%G,<+4 D*E26W3A$L%]I4!ZP$Q,J262<)%?D1S$I@J"R8=8I0Z<O/@)2
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M0!%!$8]4$;.5[P!%!$4\4D6D,L_A.R/V,>@5!;,MNUHSA\4U4C#3I![F]VR
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MPH@<K,.1"-TKF4D^S<7?Q_)2%'0,)Z)N"R[7R,Q:,M!]3R*3 $ B/<UW"_>
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MW0G9[@-B#_[&^;)>$XOI42#G&+>Q'/4I&?NU;#S8+Y]?M<%D*"K97BX @ 7
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M(*//.@V>D )9]Q#KUDMV@74*[#4!R+( ,@JMTTC630036XAB!S?#P$(%ME
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M).AC@51A&)>7C>RC+)O'=_H((K7IUD%5J.G6P5\*TRU ':!^7'Z!_Z8&@#I
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M\?WQ7+V>P#2U9>KKS,Y66=,[CD++9XPJD%"5[/%WO__L XY!OEJS^?(=2\P
M?':-_??4P ']+,[!K^.&7</-UZF@8WXILVLTT733&T*_[K]>?N_I Z56C0RA
MH::/!?/?,_G9?'NG:0K"X:D^16O8JGAA:VV,1"*U2K'\S@=IK[[>U*\'K>O+
MG\QUJ]>]'C"]F^O^3;TS8 9=!MON 3;0#,LSW6N&+?TM_<-T+YC!IQ:S-.M+
MDUYO#,C/;(TO GH//79B_#3]E3E"S)\Y!A@[A\$@LM+/[#*+/>OBEIU ] ;W
M!1K\JBO/SY<M,19P2R1UA>\;2<)LAG"TKJYAO.J%\96!GGWHHXEI)Z;X0FZ#
M2GZ-R@O9$ 7E)W[9!?[&\*:3N_RF=FY^__G3N(]G'JAYT;$VE#,K-^4[)<!,
M0>],45CW,$@#$YG$_=NFBINA)ER,7OJ]CUR<4\504(RUN8(K>/HA:Z-T)HNB
M[V0QN*YW^FUK2H#9(NNSA;6/P"!I_%=#64&,.B4V].V& :T[V&Y9R?8+?&EG
M:B_L>&%:+=2??G0_?F^:#[%83HYU(W=]#&2IA\WSM0I; 0-)Q]CGD=@ZC+@5
M&%VC>]DP2>5A!PO7&TJ-/Y7&IZ^7#ZT1B@=*W":45L=A+UBU7IVWNX-6XU.G
M>]G]^)/YU+ULMCL?^SFFW6F\/CJ<_=UZQ@QZ13C#:$-&7W"$$0S&F""1+)M*
MC(R%:1J,.+)\RW^R2:N73IG"';9^(E(4_*THJ_?_GF'@D+\G@B3-_PY-GRL7
MO$CIBJ29VL3 PYE_LE8KWIMZ^.<_(MTD&[[FS+)SJ\[JQWM3BCSB8NVO \P^
MV\U#6Q4U?>)TG;,6N!O:%,? LX8F^5B+/\.K+_7/K:\7G6(<SE3>0"(IP##1
M1-<>B7*LQR8<OVE.MH[[[$,3*<*30);_=ML04]I?E%SBDEQ3J#@&G0[^2BOX
M&PC/;:=BQ*Y9V.;R]";L9ZGV^+W:+\4S3Q4W@>4S(!(RYCD<Y):X<D!0X7_I
M%!F=A.<V2P>MT6DZHY'MLS@<U&5#DJWNDGC"BP>[V=&RA!G>?GW]NO_:&EYK
M/%&T&>;XR<)/=D\'"Q3J]X(JOUC?_9,%F68'?:LFTAJE;2?_\83@&\OU^Y!M
M]S4K8_>8<ULK<VY=DG1D&,Y_+F45L=[S[6-31@\:__+4D.*9;TN;\ZW'8,X^
M%'G^54\17@3F&@F*SWR[F8&^V$$FYTUF77B<?M*&J%>6XR&S'(1,[NQ#?RJ;
MB.$J_JGHK(:Z'AAL> FG@3]V]8'VI'J+IOILMIJ#SUW)B,GCJ_B*9CF4LP_G
MFBB\NA9,30V,O9H7>993U-5[.+#!,Y1///7YR\^OP^O?X\E-/$OA7-67QK7Q
MG'VXN/0A,!A]/0T';LHO>>(?+7;O.GV]^:5:*[+Q4%?SI6YE-&<?>+[(<T>G
M67\[Q+[2ALQ$QU*4)X+"H&<D3DWYD226\*Q,'H!_4J8DJ\)@CC"$)4>42LK*
MV#WLX+S6@=B;NHX$?]6IU!MBL3;M]3_68E$=?F5MROU^#*LRS_[CMQJU3D+9
M(>$2FTFE-]+4K0L5GZJ7ZO//FY8PCK[XMD+&RD+%^AC./E3Y0KY2J!VAZB]S
MZ/_WOU6.K;PS7IE(01-"O;.JY-9[ 4L7<Q@4/XV%ZSXVR+ILRLAX92?ZD8XD
M9C+5C2G)^)L:OM/.C+#<WW?_D 4!4E%2%\VWQR.M(\GXF]ID,_6Q5CQ^MUH\
M;C,H%#E\.?%T[$ V%2=)-V20((X841$,X^A2X3'*9H1#M#Q!+WZ]JCWIPF1)
M:2%Y@>D"41.+OOYL?*<I?QLQI;).3ES%Y,5%EK97U L]BR.R49/!=AZ/#7^S
MG P22]9ZFJN@CTNR>&M>!^G,C3.6N[,LDJ??.-_HC"^?[[MM$&/E:O9TZVQY
MQL[T<L]M3]"_"<H4%5Z3<L >TJV]ELX6Z9?ATX\I]VAJWUK#$,ZH1^?38"]<
M\UQ7ZB+6N7#VP7ZHK>SDR3EF(NC,(WDX\Q_[\:30E+&V6_JZM_L;!UISVI[:
MG7  YQ.].8;9MLD'Q&_%T+YWBC=3O10F6107?E<6XE=88!?T "8/@<G!R)YD
M_++\<\/2<B8?W\*O9"!:+#?KVJ3QW#X/D_'; Z+KQ21DTO6J(^&+7N;7S24R
M@QN2\,<O*6H-AKD2] =D,I>7C=.;PJN)3>'S_H@#K3?51=)7.[A1%!%?_E'_
MW6R$62781%SD(:SAK+1]FI^_QI*OJ3'SES'VVV#NI\3.^J4]8Y[[]P#^_55=
M?/I9%&[T,A7 +^_P#[X#<--T$+A$'80]<"S(CSWSM]G]I84I-(@5QX&=B,I!
MG(B$*V822'AG.EO?5B52RX1>W<T8<82P?/ X'K#N6D=?6YEY5[G^W^P_# 87
M0W;S2(R@*/A'LJW+P/_],Y5)HA]/ZW?(N0 _<Y'KYTEAFKUCR\GX+Q<*F#F*
M7M5%D_Q,=FPQ$OY5O;<NG>A(1-;2#LLQUFY.@_D;/P]CES&FX@@[!QK9,S#?
MC6J.!'-][$_"ZBBM'4G6S0X-_^080968O[E_7A$:[[ &X-_O?F,*R/76I?@F
M,@KG.=8)*=8@K$$*ALG4"HPDS(S7Q[.4D96Q;Z^):DQU';_2WH5()F=LUOVV
MYO::GTLEGNW=WRCQK-MZU*5XC^?LPT_23<Q[,=K99L]T-&:QB3*+@CHA>TGL
M"#8A8]DTL=%!"C8ENF8=HJ3,&(1CWQE#6IWI&"BDA*4IF )#MAZNF]/E,]SK
MJ*2-TJMBH40LYC6ZG]IMP)A^?L#\39A<><?QW&OG G,D6UNK)F1K5<RV]=6Z
M;;7'NS"9R/@'#&+J!K&ZMO]I@3L".\<>>1M$\_?/4OEC3?[:CJ>4C?<H9?,>
M#QC$XS*(V 8)C(('BAA!%+%!U 5BU8B-T(G[Y?DM#A[5O.</QAA;4OP6?3Z-
MOA*U,:9LEB/>)GX<=M$(4^Z9>UU[,D>,\_-K3 ZRQB:AH:Q:#0H,8B5)>1%7
M>.<S0NM7]EUN?IGO!:^<"S;&-Q_ XDG$XW0N]AFK<RG9'4L,/K;2=WEN[D//
M'6=2/G-$)O:8RV="#[=8^BM.?E\2;%N#VH#OAAF-H\ZB%._PZ\M!6T/S'?AI
M+$LT-UIGZ W,FWM-G_DT#WMX*/9^_ODH\[%TA+%31M;++4F(SLO7LT?%@G>3
MC<5HSSYT5JW\4KI^^:1%WS&Z<JA]V^A;0]DP_!NIR54!6O>>3PU9189/=/JQ
MJO[NG1?,IVF8U'>$[F]%C[XH*^/;U?GM^+4QOG1YG*-J.8Z$-9959V(#?NP*
M_.9W?K1N:MCW>,/PN_F+K8K%^G4C5AAZ=)8J>C15\1SHKN92L$,S_6AA^,K?
M*R<E_'8PP:P&$_+0*[%BI5.PZZ)J5C9D:M@>/2; ;D9H+GJ/S5,7)*5!WJ7,
MB'8\R?C51"=4/'R-..F/LF&Y0JJ@BK*@$ >)]-8@(R7G-TB"+AD,:=8A2WXE
M[?S?PC^>SCF$J%D*48T1CC461O-OC#8K4+2;%&T/PR#5=?BQ_T3&*T>_2#;(
MK_S6\6&(;.=SFW1WX3V_#2^KXEBI?=4NHR\"!)S?/+K\N,<8V,W*E,@R;5'J
MUB[4CO9H-X4MY1@B]IQE"QRIX2EJLQ_N:CL"UQ*]?2Q.=VI:\PR><&[EMHU+
MEBV4;E^X;N,W&@E/DR_D0!!23?7OF?V0M=HI^T&,ZTD+]%Y8Z55\Z<9:U)9Q
MG*V O;XXKPN#O;0&X](JX-7I6-),"8DRCAG.&.>#\>]9NW-QQI S4*Q'S@\$
M*N4JA6*.*Q3F*)\/=Q'NV6?M$),KVB0;5CV!;!A3LABM2HRV'/=!C/"1%!.D
M=T3)VE:7G4>4+(XTB<SR@Q]1<I( (HQ[AQ]%3J4CU5^LQ44K--[$@\\I-+O/
M>"E;";%EKMB=&U[/':^^<C/INY8<WLR[+?,6'MF(5<8H:&C=L4@">)V#M*(E
M<Z'- ]-Y5.J<OK3!.!T)#_D[A,TM'N#$8K:;666_<Y7F[UD^U8UY@/O!>R0$
M:0:;U5W[F+QZI_FJ?W/>;S?;]>N?V24EXR@;U,\O6Z^Z%TRCVQFT.H-L'O=T
M7*N%^RP,[IR!DC>TB6YF]IHOO1LS+J14>%TIR2HF.)FSY&)62#+3KNN@Q<U,
MC-[N-[,V_GU7>8Y/'Z*/?X[M0[<GV&N1[@ZK^[VN356)6$E-?\OH]W=_<R2H
MYZLYKE3Z)ZXNJHXT?=8%X^UA)3 CG:0I_K<NW!8*[-F'7OUZP+09[#6W._5.
MHUV_Q&X:.1.N/K .&A0^Q-=C.PPN^"0D^)ULX<F:V$ SCU\S5]62._O0-M&8
M85\S#4V5D$J6\? GR_&PRILN%FMZB_U<AJVKH*>@IZ"GA]%3GG1Z\=3/<T'!
M^HF8_@@AT[ J8EF69!#=Y^Z1E0?F[QM5F$H8[M(_5LZ_B43G"M:ZH@AJ#6H-
M:GU(M2[ZJO5RLB7+=MT)LL\I,%:T>*[L _Q,Q%QIU@XDHMH=65W\W;)*>CSL
M ;DP/;4O@MJ#VI^HVI<"JKU56##2% GIAM.^EVG]F9+:A6,Q R4P V &3M0,
ME .:@89@C)@+17ORGOTSH.55T'+0\A/5\@K9GV7B)YA:F!S;T<SP-=!]T/T3
MU?VJDU[G7C-7@BK<6ZH]/XB#:<J&.+4.>;=4M*X*RLR0K2E_:1&(R;"WXI!K
MKI$Q5=9S BD%\."Z@V*?JF+7',7F7S-?R4XV&<_;I \1T5'\A3+_FZBXHAE3
M4GY?O].FYKR)W[5L/*2CMV68D$%O3U1OV8*CMT5KO=O4-<7VHWNZ)B*)J"DH
M)2@E*.6!R\/817D8J0_K#CZUKNFH#:L40"]!+T]&+U>5TE4<=HGN<2QJS9)6
MQ\N4IDE01U#'DU5'?JZ.]==6^,B0_>.:#JJ8MIQ %4]-%8O+O.Z-ZCJKMR\H
MR$K..E4:KD;]),J\,<AAZ_-I%!0W;:F"XIZ:XI:6>=LF&@K66LK-A#2!0:JL
MZ2Z%!>4$Y03E/*AREI?)V2M2U] 7A@A/HJXU%%!*4$I0RH,J9<51RM)KIFLU
M?6RK=J\R65-!'4$=01T/JH[SBJ+R:Z;U/)+OY+1VXU98T$+0PA/5PMK9AW[[
M8Z<^N+EN]5/2/R[N;NP[FE,>2Y^P$,T7N7=,=V*56+XEKW1:E;]CK#-A\<_0
MFW$5$.L=3%VLG3/U'3.83?#[Z[IP)XOO&'+ZK<WXCD;8R:WT59S?9753A1Z/
M%&M5(MWWEDV@YSV$'%)(K<BK+:V$CJE'7S;M^:;TN(7TVH/6U2O2<:;;:;8Z
M_5:3?.IW+]O-^@#_L91I?X"_N,IVVT7,B+E4,TS"FBSYA2RA#6LF2,GX1+"P
M%*]6+,5Y_1);BA;3_]1J9=E&;&_-NLT!G!^0P!>JMRS+WKX\-)\?JS_[Y[5)
M";N'TS&F9V9=\G:YMQ#/FX&:"47H_!K,$UWO_.H=]VS&B#%*P3/F7;[)X?EB
MQF3W: 6Z-4& ^4.^_?>,6PJS6&NXCE-I/CV7/Q5FUW]*W+K#[QMC>#(J*]J
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M #H2'O)W")MB_.B))3XWT\L>3%]!V_*I[K&0,5H"!_4YQ-C?W[D*S^K";:%
MFIC;I%RV?PQ:K\[;W4&K\:G3O>Q^_,E\ZEXVVYV/_1S3[C2PN;O[D%FZZYWF
MJ_[->;_=;->O?V:7E(S#K]'M-%N=?JOY"G_J=R_;S?J@U63Z _R?JU9GT&>Z
M%TRWU[JN#]KX@NS*"=/Z]XTJ3"49NP__9)<.+[P%FT?GR1B^4+EE6?[VY:,Z
M'K"_2^U>XP'/LM,QIF=F78)GLKE3Q>1)!S?' VNX/;#%)=9.]NX$Z0)QY@W&
MQ>:S\$P--LV?K9V%&FA+:JCMIG/)S?F]=:.6):4G1$(X\C)%\EG.<#UL,11,
M'Y'EOV?<4D3%6O76JF&O%-C;VV4U>^7B&VL4GP;#Q]&Z7^3KBNT>JA?9Y)T[
MB/9,+6X\/C4.M@C?B@L.%FT.OJC?[KZ/[^1O/Z7D.5C,-@=K-O+850Q.JG<S
M3OG<^C7D 8,[.%BWD<>N8K#P^=NUJES<3^Z'V<3@8JOHUDQ\HK6B6U..'L-/
M(MVXD'GYS/?-L;H#9Q\&(QTAY@K?,3*L<;3PW"REPH:3X'='5FEA=] #X$]1
M[799SZ1ALM@[9 V2+^1.5R-!%*"M?HX1)1"Q_<K34E"JN+^^AQ*X#]@_%>ZG
MA'UZYZ.D94_Q<(%ZH/Y$J=]9)'J-'I$Z11>Z-F[@5Y%2H>^R.6I8/?V0WGH6
ME2E)7-4- ^'_2P/A^78L=-N7+Y.!<OOR4ZI<U4KR97W*T;[MV:'4..!.U0,6
M<X<JCTNJCMM]XY:3S:K%$SC9#&3O+?L2R/YD95\&V9^L["M4R#YH?+;']I8L
M@36+K312[!X/P@!A@#! &)0+PS/H=S?W=*H(U?O6\X24'!KU.\,*_6_E\]N7
MJZ_7/\^+S\W:N4A[3-_0#-/:[,D@AY*W $M:80G" && ,$ 8E O#<_8LK:3,
M#23HXJBN2DWTB!1M0LKSG:F4-%4@"?+6RY?QS>V+R!GCPN0G-VK=Q]=0P2G0
MY\M_Q9I.F--ES:?2DC)&)+.LCRR<L7!_);K5?+XE(5Z"MX)L_DKNKY@3)CNZ
M<6W!UNKN<;)D8[<]J.0+K%\#A%KD%KVE0JY<"]S](#T) ?32@EYQ ;VB)_1"
M=#)<A1Y?9G-ESQ,_ 7N O;G98_'_3<W7\(7H1;C6F[S Y:J>AP\!^@!]<\O'
M;K-\E:C8*]?87+' 48<]3Z>XX7**/R(5Z8*"65B7QK(JDWR2*3\B;[?X^O)3
MH]^Z:)9_*HFDF.:[K0@C[/VPL3+((=9Z*W&6A162/?WE(UERS$C/P!UHC.1(
M1VXER.8JQ)<N5>GHL Y8I!^+VSUKKA#YV-PRASUKCI)>_X!$^I&XR\_F"I$[
M+/*Y0K60XX-[.X#&4T?C=K\;?QW].'&N3 [1H>0(,T]W^WS;"J[5S/=V;#H>
M]MA8E&C?GS^4C.>&\>5SE.5<GQ1TP@ZVU=#7>J>XL<(+2INBTF[@+H(KC4.W
MZ*YTM<#F^."]XV'*.#WT[7*>(Z>E:U4^QY7 >0;L;;-\.]SER&EIC#V,/S9X
M7V? W^GA;Y>#'#DQS>5J)7+T,R7!FJ>#S'LYR&U5U,;H4C.PBVPYR(Y?/!8Z
M^)-V,[U]>?CT\J?P^-R]ZSQD,1M-:&.&6/Z,MN@.">5%6U^TXTPT#_!$\G-#
MI(Q]CD-+T^%=/[0/0)0(B':XJVR(7*\/B-+S6P%"A[)#V[U.-D22U@=$:;J?
M *-#6:)MSB,;(KOJ Z(TO<@ YWBZ"QHZFJJM\LUQO%?VRMQI5VJ_][.IZ"BY
M ]/V(+IKCA"FT!H_\[>30OT'-LG$]**LA=4@#! &" .$D4S^I>6:/MOJ(S),
M4D=I3Y[NZ=2=>T&/TX[ 3@;?*R/:-YNV25="3)0SG0(X]\AF;H-'E%0+&[DZ
MKY@K!M]I !8NTR#:D6KA(I?5L1A$)[$N""#:G6SA]CASF.,#[[@#&&4:1CN2
M+5SD4K9RKL0%/K<^!2^QNN(EVB[58I=(YU:2;\?&PCTL"E\[LO#KZ>>G&(O7
MDO )G=0*Z- ^B<HU.$1Q!+G(M65%6"$Y3L3L\OHBUX.QN4(Q#4L+F#F$E=GA
MY$6NXRJ%V> )J,D2:G;Y=)&KKU@NQU?3-S4[MR4T]-G$U$BO>/-&U1$>PPN2
M/@JR2M8<_5* GT9/?Z[,Q^FESM*> EP2Q=QCJIB_%4S7/PP&BR3?RZ:@, *A
M'<JO]E*UP"B*Y"#&4)15Y7+5*GB+] %KY4;_;M0<!@4-W:A!@(>V#-N=.G[_
M,BFP#;1"*[!MX*BP#9Z^5MWE:UUH.L+O;DQU':GB;* +JF&#;:X0UXZ"N)VM
MFT;AI?C[H3J=5JA,J%U[^%?6Z[ M&-H4,Z)#,F,N:89MH<EN3MEAF(.#,8K/
MQH=(ZOG9Y506>0]IDP&5<:-R1^*0#Y$X]"VJ9LN!&\T!+C.#RZ2-Y0XW-GIN
M\C1*84X1DHF;RFV93SY$YM/?5+*49D +[FT#R%S;<4I\[_K@A2\^W([-A1\^
MK5Y];OVH7'V^BM(8_*!)3TP20_SPM!64>UW"JB%ITSL%I:RC_D-)6$U7X!7)
ME8YC3VJ-].VJI='/,'7'!4 8!(0[/.=B''M:R[G":<9T ,& =G"[EUR,8T]L
ML5S*E;DT:C8!AIF X0['N!C+GMHR]@(KZ><1_/;4BM9A\OD\N0D9YPU-M3Q=
M+*R>CH8(1QQ2W]3$A\9T/%4$T@.R*3_*$E*E%>_Y!>F_'D=WGRNCYI#*W+5-
M'W/.N"BT7K<@D['H9*I_,>*"5D9RB$U;H4\S +YL_QB\#8_,*+YW<?\T=@D[
MWN5C7UT\170&79TLELX^Y(^W9N$417\8P[3#&0Z1,@;3=%KX#&R:*BF;IMT]
M7=SN>OU1D!4!:]1 :VCCL:9:"C72%,Q8XUPP9-%N&.AR0'G^LO%YI$Y_\]17
MJLZ3MHQ@FKI\-S6%N3-J:MA"$'KQ8Y<$IZU#B463_\E>(+D;F9&\S_TSOQQ)
MN>4JY=(I6GE Z-X(W9$6+D%:&/"9L@7=[B:7XL@9E]A2KE8[]CZ*@-'$;.BV
MA'+I2!/*%*9[84,'W3W*0!@@#! &"(-R8>PSR:634IH@?9%"&@DZ8JSM4BP9
M(/9:R&%MUB@D69F:Z)#+F@=P*.-/K,Y3E;5"V96J; FZ*JOW1@_I?<)C.R$I
MDL"D4"FPM[?6IQI?N'T9C?DOY4]7EUWI_HPQ99,,PU]6=XYGJ0B&8;]X,E+-
MVQO^>B1]_&;^^EXJM!N%^Z]<;?KKX[>IR'U[:+<ZCW<J_N>C\O#SQ[7RJW$^
MD#Y>%'Y]9Y4[]?JE_;$V;K=J3[]^?,;/4/"U5_=?+KY-?_[X]B!8US_4-ZEM
M;:&V:4/'F]XN^[THC/^4VB,^ +T."M.@>$<TX"GB*)F]4M!UY7;GPL?K[UDC
M,';M7/"14Z1!!UUQ"C#HPFO>*YSVBUX.M$*1T0VY:5B^9B#+5UQ8@J)M">K3
MSZ5IQWA^^BYFR?(5 EJ^#7HO&[.;+Y7"E\JP>B*6;U?&N$JCY=LQZ'+0-'<@
MRU?T.AH*+%]6+-\V6^#V^=A5'^A7]?SF2Z/^\_I;IGR^8F"?;XW>(L]_,F<O
MLOE'.1'+MW,MHAPTTWMHKV_'L&-T5@NO/4\2 NN7%>O7".CWL:M^T-WW^Z'T
M^-"6;U"6K!\?V.];H[?<'SU<J_Q(;0>A]QBLWXY5KG*,P6.L?M_60<?HK+*O
M>>HM'ZS>05H<A '" && ,(Y6&)E9O?N.").1Q AX@,(]<GQ&ZXV6WV@PVM0T
M3$$E9]5O+NFEL)QWNMN.UR.'"U?D,!=DW99C9SJ^0WIW:'N&W:4(MZP8?F:%
MFJKQ/S^URHMXP@<?7MB@)J"J[V:+XZ]O<,>;,9>&<#&LCG].+_DHC$DQ\MH>
MQ83"3)35O$JHG/8BI D6@X44;:3QATJF;8R_G&,K;(ZM>6V,2#DFHV,+YTE:
M;78OJ[VQ^B?\T4N/XU[YSSC;5KNTI]7>8(SRX\L->OK%C<YEL-IA5B(KH7+Q
M*5CM7>,/E0;<&#^7XXJU'%?SVBX$5OM4K79E3U][;>7R.S]J2L/?P^:/4::M
M]OG>OO8:8]#'MC'[U&1E702K'6X-M1)J)2$=;WL[!=7]X@4^5RVPN6(!+#=8
M;N\JPBC^]MJJ*S_\9;*7U<]/5P^9MMS%O?WM-<:,S3^8Z,?"M_,A6.XP*\#5
M_;(,!_&WMXY_OW@A6_[V/+/_QFJ=\N'5J_<3]Y/?,FP!V[6MSWW'C 7]7E;S
MIC9YR^#+%U_,3:3UG9L.$9%S)B-3\HZQKC7D%V0/<(.TR5Z46"->_I/TV/L(
MO1)$;$KP V?$=JB:B1]@M;!1)7(.IT0^64V/!&)]AK(JJ*(L*/CU^ MR'KOQ
M.INT>\CMU?O_R>>9"QDITENFAY7\';[[SQ2I(KZK^([Y)BA3_(EC\GG'39#D
MQZV3LZMEU"ZHELF@WEO*@*E5E(D@$3MB[20G?^-QBO._5U\I:HHB3 P\LOFG
M=\R3+)DC0FKA+P_:MRRGX?%Y.C3>9L$6R\KK\+4N+L[Y]XX9S";X_75=N)/%
M=TP'VU:;QQV-L+/HONG-_"[RR]):S$W%^S>8[1X"T)'PD+]#Y!BKM\S$$I^;
MZ65O^[!$PO*I[K&0,5H"IQ3:V;9 [^]<_E1=N"T42F?S^8ATZ&N].F]W!ZW&
MIT[WLOOQ)_.I>]EL=S[V<TR[T\"6Y^Y#9NFN=YJO^C?G_7:S7;_^F5U2,@Z_
M1K?3;'7ZK>8K_*G?O6PWZX-6D^D/\'^N6IU!G^E>X+^ZC2\$>ZWKOK5T7WG'
MM+[>M <9EANF_>\;59A*,I[9_\DN'1G'WV"D8R_L"O\R,JQ"D(ZL(L;YNX6]
M, G?/<&^%@XW&+Z08TC.Q[J0A!'');9@WL\\].9QZ,VRQ=N7"^6K\J-8[8A:
M%?M&TS&F9V9=@OV/N9O*Y$G;<,>G;;A]VL4E.(P>,NXN0?]E6G^FLCEC7'IR
M%IZ]P=RTL[4Z)TDV)HJ &8OC-GRE=]G39DG3VFT[8KBUJV/+5'D]]\D*H,G(
M%>P..P)>>&+L)-&Q+=B$>4^^_?>,6W>C?3WWW<3LU)0]:+&C^V!\]F"JQW@!
M RX,+#K9GC=O%VF\A4FP];^! V3\?FPAZL^RL;QLM5?TE66B/1[2('FX[M"Z
MR'K ZH$-==_NT\X37PK?C1>UK_2KM;N,@+8^UJ:J": %PP482-QP%5,R7/YM
M\^>&ZZ'^:#2[\M.?@I01T(+A L-U+(:+!H$OK=1%:"OE:MLZ-R@34^AUOS<%
MO?\0%4R>R(D0-*\]-FH,'5D$GMD$SZ>>?>@)^EJB@#EVDJVUFC6BZ=(7:@:R
M0W&KH16WCH=/EID%I2?(4EMM"!/9%)2Y$K=&DQ^_?Q4N6O>@PV%T6);RLGIJ
M>NQ@!S0Y!DT^#ZW)U\@49!5)\S8-<Q7^R5\UZR;;^UJ >3@$F.NB<RXEV>=Y
M6GK<1$-9E$W0XQCTN';[<GU=>?AUV?@Y0A50P. H=*_N..NXIZ:(ML&G6P^M
MVL"=>_YW[^</,O+83$;2K]HT"N7 JA^7KJ>U2&XG'"T.!/U?/0[%3JTH99E9
MS3(9BZQP*,E91GJ'@0*]/E6]/L^R0H!>TZ/7D99(TE/U*(L@84;;6/8K<@05
MU!KN7O X+IDMU[&",2-F02VSJU2*B#)Y9)5, /W*$ >:217>@_:E.WR/54I1
MD_;TMG51'R8UBB2UM00')$61I$"GLB(IT*FL2(IBG:)9+%E/A,54H976\(-4
M6QU1<';:2(VM#BFU+&R@FB+ ZU'@->::F[3("%8_ Y@]"LPF5*:2%CF!2DX2
MAVYFCI*P.@(P8\WJ (!\.@"\/6 +1#BS).1[0!@@#! &" .$ <( 88 P0!@@
M#! &"".Q@':Q-XBO>IZ\AEP;_Y:I!3LNOY7[MR^UVM.WKW<_ZL9$66198C].
M>-'OC*O^M0<KS@5%4$648SY/5;0(B'U$,'_C/B_<C=QY'[>_#G 8P*+S?-5]
MTM-F;WDL5B\H!.GS$K9#5=!]I3LZT+S4V;O>X&=%_O9IT?A^(6R[T_W9&L>+
M:QR/Y\P#Y\:\@<2\_)P?R9*$\,,QUSGY^4Y7"ER-)^*I<BRWE,\V_!T$&4<
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MZH7#[RD<&Q*WP1"QXI#QA?)>63H<%U3X',M['84-1HF&624TR!/P3-/&>(@
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MH!%;&):$,$PE  4YI0D:L<E)..C3"4!!3FF"1FQR$@[Z= )P1<GEAFR,[?F
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M"-O2W&&&A[3W/T[A$]T<$>W/PSQ Q.5G_OF?HR/I7">&]K=TH_2 Q-ODYXB
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MI_>D[2[OY5K,QFT:&*V\YN5\L2;G:T(A>!_,<1OJZXINPK7$;0#S.%M*H)U
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MDZT 8"SFE=\Z\UH_H?;B>^_;]_S]B](@*>,R^]-[5V0M%MZ6)%O)R[5<[#:
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MHG=_'Z2[\1#>7[>5CJY^D*Z!,[([OK;P.LO!A_[RGL*_3/F#QQS^^0NN/0(
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MB1<PW$V3_ZWO92/,(#6-.L_?6YQQ-+2[W\[)P^U8VX1G(36-CE(1A2SL<X)
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MK-@+/$YZY]VGS^1D,#RI')CL:N@][!&6H><2)0)O$UQ%D%S3"K9-][S"]DW
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MWJ8,?/XQF;X:,UH!NLSD \ZM&#RAU5 X>BS:SHL.8J 3 K/B<"RW3'@M0B:
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M3'</JRMX_<JSHAMX3W*\2\!G8"%UQ"PFA7G8!KIV-+3 NO*"49D(?N(=Q6/
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MWQ0]&MH^/)J!9E7@@OP2)E]#G=G0'^2X=RSCFKR8@'TN3\707,K,G],X- M
M=["B"C@;NGVG228= AB&<)OJ]%Y5*C^RXQT%\U2XZN"GO8!.]O_9>]/F1I5D
M?_@]GX+;SYQ_=$=@#XO6<\YTA+S;[7WM]AL' B1A8Y !698^_9-5Q2Y "*'-
M9N+>&;<M0556[I7YRPZ%;I? >EXF+!Y;2,?$X!+KK2@YOJO;RC8R38;E-FCH
M$KH/\H[:IQ6L0%:</V+#Z?WI!W;9G#2M[([O4+P;,.]&Q6>S3R2AGT[E((M
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MU0W#X;W3582\BS=:@NVN7S5!3,\48;RGNYMP84$]=VM4I<8(V?M'2@#(+\6
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M[X[0/8[L[ ;O%*MA*D8-[\^DAB5$2U;@ZH$!+-Z@EEV4M;KHX"^'<ZB$/JT
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MVKE<,?JDO"WHAN&ZN$E+$T(%\9;D\ !A6T_(N,WBH_?&W8Y:KU_OG_*)UBE
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MF8I"<O@7SG*+[+5Z>59KO>%)]QP!M#IVANQQ0G>%TXGR %,.7$;5F!INSD+
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M ;R\RM:^MW_X&#:N[J);DNW[X)97>JJ- G<'5 =#^V%8);P66J0/@*STS9:
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M?'=<W^>JZU/\LW0E.W_6D-_FTQLM_"H?*A2,)M2U!PM\TCK07(*V=)E0-
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M!-/A+%!- UH!)@:"#]K)2>%<5\<[.O*-T%A#Y(YX*,[5'<+C* $R!"NQ<ZO
M6Y%S"3C]/PK2J;HJ#A&@!_/'D%4*'C"!J8XPGH$2%3FW,H++4P5E5,=/+"H'
M)X74I  DK0A?HBM8@/*![R0;5KVN*0\6F8RQS\ )2;GB,W"!ICL;7"OFK#6$
M.:'862QSYJY8#GC$R!N&<=XX]>K!)"\L62=:9@VY7B6K]$DKB-29>,M0;\+D
MD2U=5[U$54!Q)5?J>!&[5'!E&/=81"NO4M'84VOT/N0(_4T<EJZ)5R$TECH
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MV.W\+"ML#;\\@A$IJXCQ0S#K",7)1.!%%'VH62V>AV.(D[HKI'!8$BS;SQ;
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M2FW$7[PS $;X@J-#A%___9^]/?Q(%"3^7_R:>Q%^@L="C'<(EDDV?^+WG&3
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M$=.%<J3"\CERG= Y<GF\Z'FNS:;2_(_R-MGN(7/ ><"\KKP*0_ JDDXRE)9
M?"# &3"$R6,\BK+&&;)I@0:ZS:H.CPK<<!RBOC"89K 0Q$F4%3#']+'Y)F 0
M*I]H_8O;^W>'&-4_.*[S//\2B+G0ZIRRU^TX@^..X&7<VY=Q""_#I'P<L0)^
MZ%S!@@$V.5G.[0?X_83$%^EQ$R+="?]DN?C/CU^N]G^ZW</#HZ-@P5K<E^5)
M53>VG8<68]MZ.+3UEN5Y;V*IR1H7Q[^Y_%+!5W)MG,'Q,8!"R,B(CUV*"E[D
M$;C'GG6%-^ &+T099J0\\]-GX]I0A= QX_/1@2#^OKY^;S5(![ZZ"9C_B"3P
MB?G$PB#0A#M;5AKB-4X\YDBBL!BP:N")[)$N8 L>YH]?5)V)+%__"]$F,#3]
M!-!:*P&8*4DK"* ]NY'/F0^*>"16$X#YQ,T3@+6.5 302A366D8 K25-T\HE
M/?]:T2>]"$WW&5Z8G5AIMQKI^[Z%',6AY=^B=7F1ASQNS5EVAFYUR=1?:F.H
M] MD<^V-%T,_YY(@&";$;*([L.@-"K$5<EGBKHC^T_CBYGCLR.7#<,1LK?(X
M;"LI!7&B\&.T(%Y2D%E:=MF$0"Z5Z^$1PPM<M6R*,S^Q5LY5+49TJ>;@J3VJ
MWO97<A8N=]FBY>Z]0V#Q/:.;L]%3K]5]FCQP00'LBA=LPBM:NJ^4TCA1E#]:
M&A-DJ]Y,[ADUUTP"L7RCI_?9R60ZT-JGRRE@ V[1TFVEI(!$"=%+*(!JU^G*
M-2K.-2I,#\.07]GN9_<U\%I5;=<O9P>K!=(@B4#J"^J$>.;UQU"1&E$R:"HN
M.Z6N\;MS]]ZY[-R.J*#<A33Z(WX+!%^/&,^;/.)N3Q.&__*&.A,X7_Y;JQ4(
M8!9V<#]^D74FT._!)+,HU1FPGDIQI=XJ4/Z.>>&'Y/W[@Y#[E7HK+V-=:3O0
M\*+(*Z4BKQ2'2]/*+]P"K5>V.YJZ<YEBA4?TZ2JBOP8:K*+?FXH*%!P)KZ("
M6QP5R*4J-E/4GG9,+MH$)J[?29W5J-ZEMA-!^T#'.Y^UEE.@ -AAD3VY(X&I
MSL9#]H';[WT\-.\Z=Q?BV6Z$[%==?T[()%TGE_0W+*T,K0"J(N/UY=1VY5S5
MFO7NT>:B\0&1*SY-)T='5S/ED=W.:/PJ&9L3]E]H+'[;I6H5@*]DZH9E*EF"
M2'M N':.6K>CQCG[J;WL0*1]E:3-*?^8()DZ$VG/1GDSN30LRQAF#]P_IX\N
M3AGN_?.>V8$X^_+[9QHYI1\3)%M?-F*J7 *S<F*J*/LW4K/,>D.R?HD:*\I^
M\.?H_O[K_/+F+$3KQ@W)AL^J2!%E9V#]49FC[('.5J6X4F^4_>.XWSGNOTQ[
MOZ7<KS1YE)UIT%64/5N4?=E\D];S_.*![]*_A<//_?'6C,+8N=@[ZM0O"SCA
MZ7X=TJF?FZ(&&8 5@>6)?X#7P[96^YS9QS7\2W6\)T,FE073TD7Q\;'H/,S5
M%A8+?MOL<2_*.#<<*BJ/FFDY$?9 ZQ).&Z//F^WXO5,GIL"Z@OV!8%^N"9(!
M3EN7D-=B%VK=NT&8$F#U)_%U$02+GQKJ< PX?G5F4U'ME1LL8;57!C\U+>':
MAP+T:M23$;YG<)*W1QQX$=@BV"'<H"V!Z4'CCKF?-0YNN)!N]R,#]OZ'35%@
M>QDS9<+JQU)H$]K$G98;[![!.C\YC41#MNR3^-EZ*I-,C(ZA\3K=NX[5&K9@
M]:!11MA*ISB-AK+;B*#+[<B\HYT4^*O#Q7(>!&A]@L\ 3P:PU(TPX8"Y)+]T
M%:<ICF4*#',FSB;7>Y??3F7V?%'K?>M.W[$HTWUVL(=.'*LA&<V$F ^?0$!I
M@NRCI_Q2+W._GQ^_1G">BF5;A!L>G [3KYR62TZ7H?\M),J<=HO67X1KN#S4
M+7-*+@1C%HJ['2KM)J_>&;="*,4!/:8*'GHSCV@*A[+ /18M$K.=5<1X@V0R
MDX@+")'>F7W73J/E.ATM,YV3-'MLP=%K*-O.T_;*W^+JGUI %><2C$/_<V_V
M!+M!4WAREG!46Z=_WW2HL\$H@MYX01NJ(OI'_F+-<ZWA_FP^Q_;CE]U9C6G\
M%=+RSVJTAJE(>$$KS/X\ 3Q?YQL2I\$OS!;)G,ZX)]CB39!Y3L7?#4X%6F /
M!C@-61<ECQE3@]]YA8W^@"$'#U"48:-?:SI9/4HP!EL;@O5HWD9ST'SUM)H#
M=B+L".O,05B=3UI#AJ>K$YS9 3 @?IEGP:8KQ].\&KG;@P&9V)@V<B;7E\?7
MU_[%GP.]QSOD>N0Y%<]Y1 G#\]Z?_K\1Z\[9P"/BYN(T'.PZ.$B7:=48,A*Z
MQO\.7$_ #W!I*CH?3?7Z]/4A?1EM><3X)$<:C92C=HAK4=,1VH&M4W1D]V7,
MV=8_<,B9-?@MS#JQ#R_'_N:F&]*SYI<<".9_$0WGS&=/[Z3*G;RV1RH1H19,
M8;:4P=:S\[SY-?5 X&:[1K+1XVV@7.5T714'AIFU;LGDJ:*B@PMI'*KY_%\9
M]^ F2&G!QZ(9-;"Y,3X$Y_DB\!AXM@(HE3.?@I07Y^XDJ]HV.MB#]73?.@*Z
MQK<R^%[K;;CW;>"_8'\S? 2NP@OT@,>HBO$R-K=A%TK4\8-%907XA."45L#]
MQ2^UL"<!J0*$;L 'S>5!P 1[,:=*F_-!/7.E ?5H.APN:O=915VY.1-V ?^Q
M:T#<QYG*'7'I0[K1#(&JT_"I<O+R]'9$])[& Q^?FAUYW9!4.L\@*F+;]"+>
M<=F+C&N[+U&'T;8[O-[ U:PVQ#U7$Q9%2',U)T+[E:/[K]J57S\6?35$RJN)
MFS2^S%)IUZAVY/V@H:/0:P1\)\UJ)K)J_<H2AYJW47,U[:9LH+TE<R-!^UK!
MZ'DH:&\#Y7 &+?3*;!T&Y3N@PSUK&JUK%JUO>EQ\A+WP 89NKPD*H,5/RT01
M^IM](@Z8U" NI]* (X=B%F]I(V@ZU5C\A.*IWLWY1%<V)\NV_(DX\[?POZWI
M;5C(]+9<FK(LI0Z&3TX<CJ<.^.%2D:],;G#XYTH6''MB?W@['RCM\^Y;#D[=
M1FC%4G>K]NHCH+A.(Q,VKR<.V?R3.0H3(#:B[%&8(BCTO&N(3T>3]J4Z+B8D
MDXZ8XL9GR.\2G\DS$IT]/C/,FPSYUI00WZ]>M&[K>\5ITDI8*MULS.1A&RQ;
MV":7CN/189M"E/;-;:^IDP]7='B4.ET,)[M2I=83T,D]0(.E#= $0;," C18
MO #-4<( 31&$^2917^U]H7'MZI2^MFA-#O2;0^B&(MA:<XEQF"QTXS7^\[FD
M!^KRX;-U<2+?\,7'<5)?11K[W!?4H>C5R@,H!#.B$P_>QD\-\!,1!]W&\D:W
M.6M]<'EIX&TL";P=2,_/'=Y>3:B_FY_C_:/S@^M'O\FU&:P[(04GB"OE!'RO
M!B.R M^K+XU[_\UPC1'[T? #"IM!P9-=&IU#M()NUB@B#T@<KR#QTD'BE\J'
M*:S9%:GL40BU8L \9T2,&4#IU>(YI[1O@@#O>K9^8F,*";!'B]\T6RSHXX_Y
MJ/7GZN2D%9+U[>F09YU<>0!' D@6QOF)=21+8)L^69)M=CP9!V3$;&PZ#"[,
M,V/6!2.8U^8>&9^1-OK=\?T],6S_Z0Y7T<8:2P$".XXP<I/11+9!\:T- <^Y
M],_-'WB&],</777SN8FK$^6"/YV>[;/CUP) YP0")2[,3 ='R);FGG*%F?>3
M"#4M'H\+CAI8"BO[Q%UV*AO.7H_O)'6D]-Y<Q:C^(\@K6)OK82Q1E6P*L9BH
MXT>HOT\VZM&2<9'$&<1_<^GW$H7_YB6/IHWQA&JKC>G%2UZ(;TJKA@GO"YXW
MQDN:"*^H0;1T:*;K6[]#YC0GRT"FJ!JGSLQ\?I02R8V $,XW!=^TKH+)D2NG
M!A29!YN_?4X?,7=OP^,#8<Y%$)C+H7'<$J]% 2^K>+M]Y>'D:\4SV:SX51;;
M.HHYL( 2/4P4*\B+QJZ/M&&;&\@&][;FZ$#:N\\A'D"R9(UAD\0# @EG(:4<
MV2Y"OM;(WN2E0[S3!4< DAUWUD(.JDY&#YP-P?Q%#7 '9)X8P+\?^'' ?]\?
M&'=V.^;!_R/P?L94;G'2VC/B_EH,X'_U@$^7:& <X)])@"&'4.3K-?'V<353
MGWK^*MA"46/&@?H9'VJ\BE1S /?I&D%%4VLHP%]\T4'8Y?!?G>:+\G35N?5G
M8&TH#K/B<M@<0/QVC8VN"4N#X;MK7I8$ ;$U"04\D5!8G2/C$0IATX]2T!WY
M=CYK]_I?K3<_"%.T4"!2"04VCWH*LD:RD7%K+%0J)(S5I@G[A=P.=R*?CAX>
M+V:=83D"?:MN)X_D#KI&-2)OIPKM%;IX\RW@Z(6OH63PPJ___L_>'GX$&XK_
MBU]S+\)/\%B8^#4$RR1;/W'D'X ?\;T]JYT9H&Y[D=:0'[,WYK^F;X43X/U(
M1-I+V].5*5J>\PO["RQJ:K@81^0>/^0?3^1]97"ND&_^4+!WXJ(+J+^W)UB?
M][PD882^X31N<_]Q*,!Y$Y[7_? <HWV /_'^; K>WU&Y@3C\B5\"=C4/^5*!
MQTFVW-_ZC_TU^*=%GS:[2=M__P/./>0&@+?^MC= =:S_XE-T@>Y39T-.W4-\
MBZ>ZUP(7::[#12H5;Y6GDHS:BDHR&*?/N9(L3XAP6="><I([J91U9%IO<F?P
M;\./T<OV]FBCG*10*F95&9NM-UOV:K)$P:UU48C;" S)I+)I1NITNB1S>-:[
M?MLEFG%9EY&;]U%1NF"6345T55P6$N,OBFIOV,;YS?SU87#5S#W0GY:8XL;\
MF_F-Z"UWS#_/$NP<6O]YA6@>1*BQU.<C+_::KQ%Y %M8/)9>@#;3A=S<D0"F
MWFIM;>48$GGN<2!%"+Y37FH]G$UOY.9B7!=:80A\X[3&0U,!@-$,3A"ZDH .
MBI2#'IH(;Y1>E9:MH[1L/TFXN AB?2 GE-!O?'7WQVN-'.="N7&=BJ5==L@:
MTXYN-98JB)S?]5R\O;.''_R-SHB%QI,S7$)<FSPJM$S76P05&1#*I9Z,"JTG
M8Z+KR;8BGIPP=)0RGKR$..>GUYV/YNWG\&ZM'=.6AI9C4FUK_;W35F-4>428
MEUS7\>OQ;XVX;=R/UYH)L#38'/>Z<HC_ :8EH[,"OEW@>;7GET?@>0DYGC3^
M# X-FML/=)_97 PZ+CGF$/"DFS6V&4F.X>'HUEK"T4ON[-RX:SZUVQWZL1R-
M&)/<60[&8I.L4=$ 8LF#U$7'HG8QN+:P $G6CK")P9E(4!(+DZFD(%<8YUZ
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MW%N5ANY.0P]S%@*YZ(L8V?I3T1-V!\J?#^7?HJA=G?<>5&K=\:A4/.KAPSQ
MC*2IZ(%>GF'1J=QNI_MV^<$V#\>T?[I=[G&JE'?0S!ZU(MLLD5<J>A0ZX,E'
MQ_QS7*I\]%)#/J><#$3T#%RG&PO<'L"GZ)Q9*^A -JR@ _HI.^!S]=!]U=GN
M\<,PDVI8-^"#HA=D8_%3<L"GF:XZUM5U@&6CIV&N'_ )3"4JA:GJ=C%R)%]'
M>78&OQM7AZT6U?8G>61W,1(266(7H[GME:[;/?$X/R)\$&]N/V?#EYL'9G<
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MMD:WH^D,WGC8 ,>"JI&67,[!^.35>#T;M3B_VB[Z<HA4EY-#%>6*RZG9E33
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M"-KT_@/-&^(">]E38QGX:X/68L)IZY*"2=:168JXOP@;6N^)7WMCD><%\'!
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MZ710G-=";S4K"WW+4+926NAN]FY_DJ<"W9ZWWHC*1D^HO2.9/1NZ1A(U,OY
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MB8R+2L!L1L 4'DLLHW_B%S#OT\,^R[0>NGHSF7NRXP(F!_=EF8!I9<L,++V
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MCV" ?_2Q@ \E18,Z>L2)*ESCFZ#C'YQD"+@RPO_7?*DCJQJ'*V551U4A_TS
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M$+B;*C(&Q:5MS$+QJ1G#L5</U=PB%7QV*@QUI)R@#M%&,_1G59 X*$VM;P[
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MT%5JS7?DP5Q!XI$"0YK0T@<J JA-8S*!,=J(M$5%?E&05V!:!AZ]X=$\ 40
M61QA(/&_.W2@N5)(M-AK^(N0,A;H0,]H\H)KZA!^2YT0C;WW9^"AU%^G+S^
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M^"R(%"_3%GP+S&@7' *<0#P"UY<=7C_-W&5UN1X?;=T<GAVJ5=BVE+$.RF*
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M%AE$&-3"+#]#$4A)>"QHLG@)!=D+@O#.P9N"]*7'LH.GJ9#1TTD*58Z%0U>
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M)A(^OSOR8CK:I1/,\MUJ_T#"(L$[-O:=@-'U,!,/)^;X$[@T,//&R6^0<JP
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M7<>G#C7Q$*-Q<!L42^;:&[C(]^6PRJR&3!=L=2=;A<3%E&T Q[KY'_Q6 "+
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MC%O*, 8:I:31!63[6GF+DD!(#.J*A7I[C6*()?9%Z/OAO2J>$X&KS0JL5$;
M&$48:_8(23NDFVJG8Y?P*Q2?8WR85:P)DK T,G8,S .X&R,OCK%#.SS4"=(^
M=C\F(UL:#>22\'3@MQ+X17Z-!*IX=XCE..U3K!1>R0@SMI5H+00Q<GC@%9OK
MEQO=&!QGM.8)<>]NI>/01+'88:^71K6B052ZRV"EP[-X:V1@UP*5(V-ULUZO
MXGE3AEC.*=/>5QBX7L+KIN2(\7!X%Z2!MKXFM,W#T'=KEOX2P0)=<-DRU EI
M_V!"9AZLF+KC#*]M[FG\5X+[C!6DR842JT>[0H;N&,Y3Z,;J909PZ =2#O\L
M;6=X.N;!S8<H'@D\XL<R9@A%:O$LIL2OZ>?QP;>[S\TC@QA6Q1[U$!X-/^9'
M_ PFQ(IX)2I97BEFE-\P.-D!9E80%G<GL=&#"/'"J)W9U^RJ+ S?)99QE\ V
M&X@Z,BK+GK^)7ZS)J>:J>>LQ.O$5E,W/3>UP_$VB5CL]CCV<!E<<#=,D2 MS
M@^B_GRE)S&IR--;F[X>]BS0^N>K-41&OXG-/KWJ>/=TYZ3_DF_ZJG%Y!L2Q?
MVU9K'52RU)37PC=7N/$+,W[,L_'QE]$HOOSRZ;=YJ!!>=>.G23T6W?BETUM[
MM9W6W,R\;*H&HJ=+3RST=;) _LR(_2/-GW.1C.7UT=Q]G^?21PN2?,PCEHWS
MSM_>^[/FOCM<<[&<YO%85"R7!W8U:XWJ"GOK:21#<RFD!:D[YMGYR#WL7+\?
M7+7WG37?^6EVC@5W?F?I*-GN?JU1WUU>(]D+::0;3K[%7,)A$#;D.!PH?X]%
M7P,1B @<98*KNHC*B!-96JC:(9OZ2J<Z<YG]6*%H4'_)VD3X^YQ-I:T*%-!S
M<A?-(]S)E]._?^E\^G-X,X=:>S'BH47%=FE\U\%>;;]5Z9#-10F2\8"4ILOG
M(Z"HH)FP'J.9>(S ]'!E-!/S"-/]M[W1Q]/&;R?=O5<@EUA4:):VNANUO=V9
M&8&G4&TC%W&!A53#F<T2U(W/_FJ<$B24U@V\Q.M[/<>L0^<HZR%\#T5B0S"Q
M9O$5))@XZEBP/]B<&IV:PS :,Z_$988$M!G9T&C-))3H94\IL*'#.^SB.RAT
M)[]"EH/%U@C2QBK[0Y,-A 'RE0\F6:T_7<51.C#O8S(]$,&ENVR7C*A&HP%%
M%LK,"BH<NM<XWR5B#Q>[9ATA:R/6,/OVT;;]&ZCB#V&_7[//MX^V:T1P*Q2J
MJGC'W?0P^XZ'P>[ A&+,*K'23H2P7:-'GHA&.A)9-EIF95<?JYH3P0)P/;$!
M,6I#6^+G,/VC""3^3F%E1 2W8L^)AW9?B%+'LY6%O;,M ]M%3>00OGPBQ%_C
M<7U<QPNST6K(^#?]U#:NQFL$X"$+<I1,;N'^C/E:B-]-S+_D@^*P.]E[45)T
M%<==?'?IC#__%F>7J2%42GIHL6%R,\/CLV969I(U6HC5Q4"Y_*FM N45PRU<
MK0O$-62<O(2N=E;*G4RM4M% * 9:;):3PG@=*JTE)%0@[I5LN)R!PX1;(+9(
M@%#D8I4%=H+ PY8 6"_$YM8(+%\*I3/)Q)2J0 ::;LJ"F14=X=VMF2$0@SE*
MB?DD&VU6 C=E++2W[1G;#<[)$-0J'^?,&RFA-M//L I<^+.*FV8>A=DQWY4>
M@HO6;[\,!G__]OGCBY^!:EKG^<[ TD&41_C**GI"+K!S56[D2G=.- ^\/R=_
M?_SC>O J6U=.93O7UNTNCQ5JSMP[S;ACYG9P):;#JM/J(!]#V23G7YF.HEW?
MT%$\(QU%N[ZAH_@GGL%5NGKOO/"*:)J0>#A&)V_;.BXQN!KL[>W,]/8.\2AU
M0\E+ULD[?/DWY2FEIX'\(AB "+E6_EN$W!$17CP:8:;;BJB;0SX"[=\P%MG?
M5;2[AI%#1$=3Q1K"00;(MA;'7IPH)\R D^7HDBP)@&0<(V'\$C";!PE%V/%O
M3*:&Z,4^Z+#P)YM<1]A,?+2/YF@U+Y:$9H]#?(9'=%&XOG%2$7RW% Q[[(T%
MUA_\9$S#"[@:CQU+T1LRPAJ]643_L"D,=@&L8U"8MG9:U4Q_RGGE^&CVL[VX
MA[&X21%&^1,MC3ESZ7A*ND=J)B8$O=:)O^;+LC08W RK@UL*S@FM59@&[B:T
MMRXZ)'] +8XZI(&L"D65@4X=GE@X;%=]^"9<HQP+B55G.H);$B7F"*W.+90K
M;PQB@,YE5)5I*0OW4,@X\O :Y#!)I4J2T1'B!_7HL.F(RGW(X6,VP*==9/ZF
MP9LA(=,*)2IY#S.WUH(5<"@*-;'S!82[=0:AC>&;D<):3W,[&IQQ_))M^W0Z
M/9A4SY?4M@9#9D$NA$$65*S#1K8_J0P''<_O237 ?VHT*1"$/[47H.HV)S)5
ML_\D?RP_X;.S0^6/726_-P:7HZO/R?[+AY/("VLT]4\ZG#1S)>1G*J94\-F6
M[W<^LP(I!_Q&(:1"C!)D-DJ; WI\$!)SHVL/PQ2#C\AB \?0\CV1JJ\90KAM
M\!F?DRIHF%S&>"> ^F")5]5Q66I\E@: ;4!;GL\"R#B/QZ+QP,6>(L;_19&?
M&Q/V"1CO2/30N7-EV"]^+.Q7)1EE.L_H:G@MO%$7GB6FP0?+]G][!5T7G8\_
M_?KPYZ^'>SL&J$'.3!,XS :4ERS$@LW?5J;:ED]4MVJ[2_1\>U08EN_T]@K"
M<![LB8O??S^^GNP^NS!4MWE;F3 L#1G=GQF:-)-T"_:=S$.[9-<,3#"8%"J5
MEFX.@%4.N(H+B"O+++U]3L78F$LQ+MM1[A7.0E]<G'[\;>34)]Y+*,:*=G(K
M.PM+IUA:^[7VHHKQ:"[%N&SKN%<0ALD?[SKO=PZCK][@)11C1=^X50G#WO*$
M@3NUYGR:<2I-4](8[C45XTO8OASAW]CMCZ",! 9@?=C3V"IV=*% -,*-%&/)
M/DE.8V;XV>QZ,C,4386?V=ME/YFLG4[-[HQB>+3KC+(N,!]U:QG[30R7_T4(
M3N+.VQH!;*33>A]&OJNCI[YPIEL9V/E6!EPH?AGT0E=DTZ]9GQ*XM(=)#<,Q
MSA=JCN**L:#M4(_0QX*?59.@G@P9A#8* R$)"S+7^A3!&:/0)4(:C.)UL+*:
M/G81;ML-G'(DDG#C(*_QA-!!GF?C$6"-R8$"%0MF(,B\Q8X;,IXOXS,Q57*,
M/*J2I98\$J?+37Q4[Z"S=UO(8,/T;2JSX4_D[T'\'3\<I#@%_G8:\]NHY0Z2
MFJ$UD+7=H50-7!&^C_];')7D3^K!\'PP17PGLD=PCIS BT>R7L*?J/)1^4V/
M^194WZ$X3UN3Q4J1T95>,K5*-20Q= (3DDQ74T4)^2RT>7K\Z9K,I 8LSO[\
MQI&QQ;/MI-F-4 VMR$I1JR1E$;6&O_[9/#WYTOC%>T'\>@-D90O60]&:SCE;
MA6AY9%8%*VF9,"EL&UA)!XV9#N1Q&H6QB<.T'2M.^R"OQ,P4I^.Q3V1+\FQ0
M]C&@#%^IW&V28&NB9"\#2QDJ+05UK#14\K=H4P7-Y[9>P!)1EK(4H[@ V;0R
M@]F@L]&MT"1Z6/59,\DEYQD$\F3J%!D,/F^B[=9DG@1-_P4[NFKEUP+I7X T
MX\64WV^3X\_[SE?QN]=^0>77(N77>AGEMTP@E93?SB,T=:S\I+!+APP,AV[J
M#@0(%8$!^IPXSC.Q;LS+-9Z0H?G:CS88S6N^UE,T7YS&8S9,]4,M5J<E90Z(
M'&%S5OE&NBA"LA&B\!&;UF/LB3+6P$WKR#Z%=U'N4QI\4SIO=TZ=UP:=MT!^
M_,5TWA\GGY*SSW\/?.3V>3&=UR:=UWX9G;=,OH!TWF/4G*3S-OIKC2>T<C8A
MF6$I2Y48T?&.>X=RV:$29AF7O@W//5_ WP,A^3Z?EE5^.:OHZ/?ZV?'!\&J8
M90_E!!5I<<131(T_4I-4C*TSH^?S+=1B6>?G529+)UP6S+6TEI*FI=/2+R9-
M?WZZOCFX]-W>1*R3-%6FK9]5FO:7SMCL[=::>_OSDHV0>25_I=+ 62V<,KHD
MXX+M+)6?F8\Y9"J1/9-9:;4*NK&D@EXRN_UB1^I3>W!R<^3_.1XTU^E(56:_
MG_=(+8V"7%!!-Y=4T$NFQU],FNX^]H[OCJ*;DS_==9*FRO3Y\TK3\KVS&O5:
M:[>YC(:V2BAQ7E%#ST7N5(4D?TYRIX6/QM/*?!\].:/ZE_IA_]?D]MA=(R*I
MYSDFN\WVWO[^;OV@<%Z6QN;M'NS4#AJ5%LV"/%0_D O[P_GD_^O^?'Y]:KWW
MPZ[C;]N(!>G$3.N.U7NF63=D$#\Q":F$,WS7YN]RG4[B=#T?[CE*-4^H8Q%(
M<(05JG3FD.C.ZZ:JWD;FWHB*1F;;+ KW:37Y*:#>I]0R,LY1?SXS(?&[EPT@
MP$+R.BK]=7(][OWROAT=.FMU\U<Z^H4)%#31TH[ZWDPL7*DMN-S.+>VL3^W<
MX2^_=.*+Y$/[86>==J[2J9ZY<P=+.\4'M?H,B\O*6UQE-#&D:!YA^UWEB3]^
M68]T2FZ<F[BY<]3I]J_626PJ;9C98K.TX]=NUNH[E532Y92].R_K_4WMW)^A
MV]S9\YQOAVNEJRN]M-E;MWQYSW[MH#6WDS7CR"_OY#1>QLF9DH#3N^'G@T_>
M]:_OOJZ?MS%[NY=O:;S?K.WL'2SI)%CY/?^!3.IU\1$6HP]J;.B#GI,^J+&A
M#WJV,[@^1^XY2JT79.Y6&C5/W&T_E;C[$2CU L3=E7=H<Y ,_KC?_73>^?(*
M;-USW95+N['[CY H$A__M,&S 1V_&JGVC:QNL*X])$WJQ''88R(-@_\E?T#?
MI3'VI88/:R3PAG#[5?<1_P1*SP(G"DFP[.,[U!\OO"'_%'OS62\_K.]C!JH>
MN%,>WUVRW GKJ<C!(#)D*CP:A!@SNG-H^S.6,XXMUU1?54S<82E6!$<<.:(2
MKB^,[!&86(@O3:A!KHQ(]\+41RYG[&G:XQ[WV$(5$=1&]UHG389A1(>?&NK"
M11NS%"*?$4FA("FTW]QTCN.W9F2@3*G@G"T]9YN9JYR "?5Z)1_FHB[J:*/K
MK/"?1NGD5.XQOS[;]BG5J(W#./;07J>E05(K''&V#D["P7RRZ6<,/]LRV:\8
MOR\SIDQ3C41=7>Q0//)X*6JPC;HC10P+!OL14R]=8B>*:Q:5K.&MOJ46T(5?
M#&-J8^N'P6"+\,=#:CA/"X6L7JI%#N*.A3WP8"?D>"*!%%*X4'!!@T'MBXCF
M5=@TV?P=Z^'P$5LT9$(U@O'4P\S'FZ.SV[?;]N_(4HBU&_!/V2W8YE6T8S!2
MY+?1L^?E-?XM6;*1PH\6([2'WH##"&D0.WVQ;9^D$3,JJE6@IJN!/[$<[-:,
M TQL_"$R'ASSF\@O-^Q!<M&)1\ZFAV^JMM=""Y[V+7@2G#AJ0HV@>%@QRIK1
M*:0FN]0%P34I 4"845JQ<7/A6(-HWX7^717]9%&W4O)M^V;;.@E#EV3O"#_1
M,=I5@5YY<W+4>5LC[/58P'#/A0NG (P@NS, !Q=.P_$Y?@![(Y# 5FC*D8-M
M@V/0E\:PJ4$U-9_V-' XQW"6QJ00B1H36]#"U_OR8(@@"GV?3@:%W[C,H I[
MD5LHI?ZH1\6T#BRLJM:&&04AZ)=@(G4MC%#"&>0GN<,VC'H(BFFJGWN%@BYN
M#BA/;.8MK*FP(M]M ?I,%&>U/7B2K&F<<BAEKA;6$MGSI.OG](8>/#6W4[(?
M.$Q,U[U1VS1L#X[B:+'*ZGO12'<0PC$KW9S/Q>!F=X7<6/Z\*KTT6B%@$0G5
MTE%5O"PYIL(25\1P$$FHG"Y,%^10;KM5LI;%&\A/P@'A*12.A_<%9Q]QM?2,
M)>M*$[]FPS7@!#V6 -U!7=;#4)C[-6L16JWMO1VR@3?Z=9:52==R1)&X4,DR
MEU02DY,BH\QI)"DOI!V0!:943B(Q3B6!+[F+LJ0)J9B'DQA4I!/ SVR<6)Y$
M\Z"68!D"58WI'2S =SU2N.4>IW&"T1A#J2VH)R1"A=?!MY1N<)T11OS**(Z-
MQQELR'(H3";<)1YH*?R91NVGQ-Z(U?P1T6[@ 0]"I$A.(\Q?Q5J!:C5P[_D^
M67X9CRPUXF$K,_=@,GN'5/@_T09S?E?H:61#]A.V?QT;=!IJ-)"& (][2!88
M'/'-R5S[DSF&&Q_%UI<"B'TXT8A039A\\-!ZB:;.2 03<4M 4<'[8:[O1#R$
MOO>0CIRN_>8Z[,%SKHZVSAKPZ:'7]>#Q;_.>9/9FLC[ EB?)U&:7XD+*GSB2
M4Z1V\9TT@)?0YSKI -;.YC8Z2'EQFIUY^,XU&..P/.]")W+M-_A0R81S>OU.
M,^'PW*UI,IV,RZ:400=Q6Z"-B@LGB6UX_:0ORV-3+@^8&-)T80^%[U::$!=Q
MW8=:L3&1E#N)QX%P[#<Q6'8)Q<)@U)BX2(9OE3OLI\0]+MTE:6"120179]?I
M^I.B3VSN988:@Q6P<ILJG5Q5/HKZJB^H?2%J]#&L@^<\[7UV\7UDE BT "SY
M6EY"-8;[86BL6W[FKNBA#>>J=2EY,WUA)!(GAO_C0HKI'22ES@O/5(3ZY2CV
MTRO03YE=F^CDL6XW"OD2*[BZ]'7DR8"M)+YPM.UI:!O]N=;Z\SV&-8JL.X7-
M5;75YA$NU6=LNH,>(GL=]*$I,;.U-*D62][ZH)'@0YP]0>EF0J'[H> XQK3X
ML9F5@0AZ#@6V)%_!G$>4C2G]5K!P0JD)1T@"AD9?SR1_G^^Q\HR73YX;0>"*
M$^ EQ%;1\G3C*KIPFL'*DNXL!EQ %1@6D,'C).-3CH]:C6<R?:W)0""K F*&
MJMF$LV%?Q@V_A5':1:=<.<*)$_D>S>(H^Z-%@5"D>MKZ&H3W\**A&-&SG?&D
M5ORJ7?RT-QJE@?HXKES69:2PT'C#^F$LBEK7H8+^W"K_0$?RA],Q:*.!H(=$
MZ%ZN6ZIL#3K2'/$5V%*& $)DV;,L:WV4#-/8[CLRRIGG.).G(HRL^0X%'MDH
M3 ?#?)95HLH**'<)6J)&&JYT/"3T# 1Y?S<;(G9WQ#:,<%!="PX_64'\"S1'
M^5QC-(+4J8K5&O/8"/EK Y^:&^#3<P*?FAO@TS_Q#*XN#1)8Y\[$GE;4Z9AK
M)0TS"AT:<J3SIILK?(]='?RL^AY>67AA[&S7E?5W:MAQ&:HC"GO#-!)6SB_7
M;GD610XP-(9I U\]#PP<<8?@+(--L);9UQ0MYOYDV%W;ZR$DRRGA!U"!;\Y(
MJZGIYZA&77B-#L%R"IC?DQP 8T;D/M+H DZ/3Z5];\N^D;V>;EIUIUOR=GUS
M<7A;WZTWFGNM]ENDLZ4NVVC]LJ4KW#(SN";SORH;I3;E]%V>$307CW'N'4]W
MC0,['N8M++5UY*#@YF^<TW5"X! $S]+(* )3;0!1ZZ->88L.D;]MJW%@_>9%
M*;>EI#,XX+I..&AT 2M=$(2(4>B%41@X=_@-^XUZPEM4$<+!-E.@K^NVS\Z=
MZ\51.N9((GQ@( )P$WT;PV;A"+1>1IR)19UHI,,[2=,1QS>&"E3>37 :8H":
M/F PJ#<:^P0OQ>! %()!KJ.66&M#JDPP-G:<=GUXG\*$1%[L(1@$_D&> =\N
M/!4];6LH6;H]71!+Y)Z%7IKF>E"KN\R;@:V#67*.&YXX'B,7'KGSU7G&8A8G
M"@>1,XJI_*GGC#WT)R*'Z:!%'PRCI)@Q\9""6?7MY*\%$F8#MY'K(;)F R]=
MGU-X&O1]&:."S3I5Z;=K%%[4FER;;=Z-;@COX"WU*6-/CJJGGF,3D3WA!#A1
M)Y^(#==B=L+1>W5TYEMBJS 7X"6Q932MT6!QU<;5(5'S(B7"DLPQ?[(GV_:'
M\![#S[5RL%V9X&=DI01GL!2\ N]ZL_6=GB:VK>38F#$_ZKP:PS$HG K=]2*+
M+=*!EA/OFPM6EB MC([C8N8C,<^2PS!$E ,IAYV =OM*SU('6L1A&O7$IN'J
M&IW+&R(*MPZ'J$=/$:(4SSB*F;'*Z$46=$DVWJ-G$,PIYGPU2:!C(YP%L>;H
M*F0G"EL<JWO/))>V,M,9/U)ES?] V_ CRM65:L]@70LX\NB*:KF*A)'WB%'S
MP4@4>C73G3EN#*5T%;H*/D.:%I0:Q7*HJ2J%)NE=J#95>UME %E>DDFRM%-\
M[RN!PA*VH!!1@5HO,][T$Q6N-S-JU'6@A5@$8""%@4;ED>$DE1]LSE>!P%X#
ME%4C[9U&B*QB%6VHT8V27!]A?B_"<>A[%'"D@IEME&3V(HP_V81:@!T7F(:G
MRQF%/6!1E9+-8F2HQ#PBSS!+*,&O87BR5[W#8"X3+$H-G.F>OY.X0 >+\$'L
MX! @;!&<@J26U]*&SU++ST%;U<STCX,P#@.,HI?2>2"#WY*I$3Q"4Q)<!N-2
M0$A%(E93\($:85SH=3#'M.]0OUS=-;Z6Y]<ANV8D73A_@K@ 3Z54J90"33I$
MHL;<NYY;VQOHR1H;5*;?1H$@W3:C%\GU4.:C&H)^ZE35!1F!W8D%NRG<*AQR
M:4=Z+AL8C6!QX5'> QNX8Q"G6&/AL6:#_3-UA1(&6FXO7JC2H=4B8TF=(STS
MA?]7X%K7O@O1QI1\1JZQ\Q.=XRIH+S5'N=MJDG>.GSIFGKEH6+)GZD^VDLA!
M7I-XZ$1H:)Q*]!VC:UT,G=?DR^P8[P_>*TI0]WK4ZCS4@U) 1<+%F9!@6!**
MPH/NOTE!V9KR;?%11%([<(&IYH+]VR")0K\P?EU)@_9)JEV(2HMW)GR6GL7;
M0.60QDG'#7(]>';$V -I9MD8J1P1,]0/I$]_Q OB<-)%-0C[!H>)2RJGK6B,
MM BD$/.]&'%S*),]3^@N/CT. %&? ?P)W;2:[DFENL;#B)P!_D/[M60'L=SD
MAH$,8HY2G?AR5'F#2&458F&\E'HJD+E]AS:-?"B]BYLFQ),X$:/"6//![ @.
M%(@_W@4T?*I[X#'*4S<]2%L/,K/Z\5FZNQ=H)5E(\8 U:0:@F2( \CZA&7'^
MVZ-0D0'$P0MLY'B^FH)%UW!>)^H,?_Y\*ZV$ X'!UN0*TH^X2W?P6'6Y590V
MS!Z*#*69'X)!>>KVB(07Y-=8SC>6QBW>R;A1O. <,#3[F%6LM='US/BFY4V;
M$4K&L._90%05F&@+>$R5WQH.C8LL[0)SBDJ6&'D FO@N]0-9CY:$%H*DRT=.
M:X'(S>*<9;6=!H3U]&V$5QVX XB"Q/QJ+ 2]AF[_0":I,.!)_R II4O.(L?
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M.U>BU@Q/"JW*C>BN3_[AF@!^5B<#%%Q%(:-97H.Q^+O>FN='C&HJ/:N(WY!
M30,8,L[M([,S$=K;10 T76)-A4A<A!U1X3= &0EA238'HDR<@]V!/H@>:P99
M$7XL[@G*1!@5K X)>^E+7W'?M>"M6"<0IPJ6GY.D@7N(M)$OI0@X!?)=;\=K
MZH&>N7=4=HF4G\]S^.WL\%N;P_^C''XL>NTY?LXD4+3 N(''JO)H8QJLCTI
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M[?CQC2._QA,Z#:P+N-4IYYA5,)UH<3$R6F@]N [VU&76*J463CHW[[1:D!'
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MWMB'#G W&5%W[(]X[$.O/]Y67-0=_,L]^-&37?<NH>D [GQ_F['_N'?^L#T
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M+39T'S6VIU]OC>U+O6KWG#'X*UBL<YD"V#KID@ /A["V) %6J7\5AKZ5!,A
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MO1S/8(K/_ 8\[]D_D_O[*'W3SN^W.9,JKI^FRPG'MKDZ/$CSPL](C?8GN@%
MRE'VQ)W&@):#U]6=^MDT2NBC[JL/7$W0GWP_>-H^7:W!@(?9N-_?N!=(T\VW
MN@>??LEGW]VSVON_?L(PT3LZ;+[ 5>O\)IX$\IM>8"^ZG5XLW;+QGOO1#1ZW
M#]T^2SP@LKWC:M^$DF_$:4#B?OO$H$?:;ZK TDR:V@X&_[7LV:!GMH=GP8PC
M#)[-\N])I6ORN_'7M@'O+S_WQKWQZ&2\K=O.<V;U-[0=O6\N?]0[XG7M^W^O
M7DAWT@.V5)[1%)^YY?KB9O]\&I_N.=!#+.@KO:O/8(HO[T(^[]EW[.2)O8H/
M[4KTB_"_:1S]MUSZ$_@1E]$T2W/4C<6D+?%L<LGL7(:%C[82T=3EV8?3@@%S
M&>C3>!@?L^'WOJG%7SJ#]R% ?6(?./R7LDZ=="@[\^K]/]X=U(+OS&PNRGF9
M%VW^P^>]+E,"V6(N=[RT/M!PF__T.:IEC\4K*G?>QP^#-YN\]04M]9<H(Q:A
M''':!\>3L+B'M#))N<+W.JV\FNTNN^?-7#3R_F,REH=?E>UJZP].AX\I$)XC
MV[PW/UKG/.NLW><D6E_.[)\+J^F<9]T4OXH+^;QGW[&3%^X\"]*_TJR<1-,H
ML7N_B-<LG15NP:U:W=S/IK4\O,=T&C4WX0>WQ7:XP\[\^O;=IQ=E^&AS;OBB
M5O4QG&:EE+M4_8!X&A7,RB.[_9XCK^QORZM\CFK7XSO'?O_\AM&?X"1[00O\
M)2VS@IN[OV0_E^U$'[VHE56^KM%9[_QLV.NXX,Z!%-[ELU,9.R]69[B]^-D_
M%R;2>;&Z*7X5%_)YS[YC)T_DQ?KR*7Y&W+WC)B_S/C[OV7?<I)/\SWB*+^]"
M/N_9/U"IW4OSE2A<X^>.0=]880-V.+=@AILPQ+=>] YLX7T_LAF/O/7PO>/!
M/6_AJ_[K77=K_QD^<*^DSZHHOFJJEEM-U78T#_+S/*4'"AVC59UK&@T'_,+=
M["YPO//N='VFGJX;X\2NQ7":M1C'+IJ"O9W-5/\;#N#V6WOSJ;",&R5%ZOH-
MK.VJTY@A'7=G#<@K]+H8]'YX_X]W_*_^#Z_=5WE(;Z5%Z(Y?UUHIN3KXW^SX
MLZ5]QBJCCZ /S2+-5PN_P,M1LH@F:"?EN9*0X)F,!&<CY=S#F&^.?NO;KW%[
MX2Q=95%8 "EFF<;AM)2>B+\<NW]/9S,ZD:/??#J:*3W[6Q$<NWJ=_"N]4H_;
M%=?A*AK50WM4#AV[_P1*CW1TTMM?/S.T3\*<KZ* =H"&BD,_X!@V[.AJ)Q!7
MY,Z<W$UHY6= '#7?="9A<8T0'1V6A""Q&$\MLS9&K2:*6V 9KI.7JU6:%:93
M<_THZYVB%,M*)W17?&X,5*3<(8P'0Q\F,R ]G871<E)FN6EYV: 2[G!Y['ZP
M>J/5]DRW@F*Z26F?:0]XGG0LNF.6V5]G<^XRJXG=<VJRELTJ7$7@3)<YG2R^
M>+%$P\[ 7^*YE6ZFJ+M*TXIIB]Z'85S\.W0_%6$X7] -__V-1_?@#1^6@X_K
M4=&^"NV)0"]Z<S,K9<%"1I%=KA:N=C&OVF?CYDQU*R;YDFF.13>?J#,4P8&;
M$&;%VF$ECYO.H.E2XTIZ=9IYS#9%G5C8J2-$N;.-JS)AA5=^7((-Y/XL1.>M
M=%5$2_0,2_-0=8BMX(A##4=,QW]SL:2FMB(+?:919P.]QV)\=<[H*L[8P@[?
M+9<E\082.OYJ[98Y.B@MTR2=QFF"9EQ)$4W2 *W2XNC/!J^B;SAALL"7>&KT
M8"5/(GS87#1<(#\B2:8K.+$9BTAX<;FDM<VS]!IK1F\^VB6?Y(#:%#"V"5CI
M+.7>@"E]&Y=0!@VU'$["/'>X.1I<H3Q(D)5S1H3_DTZ'VRK*[UE]!Q]1DHK;
M1AD)B,YB= 0?/@PNN$$9L(_R,IOYTY"8P<]Q.OT3+_#?B0W17'/:GIP.)L^Y
M"QEI?-P,F=<E8X5_K?!GO(=)\[MJO$;#-2$!GI&]UWS :D.6/C0+M>^:'"IR
M J54I.!L'#IW.JSM!']\P2##(:BOOA9NN;9$![FK,DZ(4$!*? H6Z73-U YX
M0<RY<@#OLQZ312!87[A2F!.]B[ZP8M[&3?;4W_ZB&>3F3R()4PW;K\56^V>B
M'#02V+!CD+!D.DD'1&&D WG[%1*T7EN,\'I!][W.#;F==D&S\[, ;Z&-$:Z[
M=4MD@FU3%_X\*S.0JZ4TA(Y(\$VN[!DF7I#.FJFNHJK/]\+/EOXT)3X0TA7+
MOP_6"1W---=;HE;!6UGCF+PBWB:9:Z.C+*D'"9L+=FUCM?RJTZ8>:&871Q(G
M4360^*M=!KGPZ;B8A\HGI)4KV@D<Z\X9KC\E]8=F$N6JZ:@\5/C$]LL5_DE3
MD<[DGI)/1.)_1<MRB?&&IPUII-.36\KWI8VLF0KKBVCJ"@KM&,G]+^C&;G T
MRZX;W!9?]3UT@QOWOMYN< ]QU0[G9MVK W*+5:M8O<5&1907>(3T1"5LHL06
M+VUP*[G5T[L:@752$A:865KFSD5 MX8DYMLKYN7:&?/IXFUNO$[I) ^S*\VZ
MV_T2[ZH1V)3X&%Y%M!T_IY#?K]Y]_)GE/4Q=*/C<+CGGUM.!M/N%*$K0"M1:
MCS*LE3>")HE9&5>$;(LQ%U9^B1[#4(<MP5F2>1#SXS0%8ZWPX-P>N!*59#Y%
M.6G]:*>.YN)! *V8OL@^-[TM-!^T&G8_1OF?N7NQZ0[>\+3]#"L+^O6%=&B&
M<76DM]^M;[_:<=6GEI;B5-OC6MOSNA.;![P@7.Y;1A9: @M1WKQG+VB+7MR9
M_SCYZ9(,!G@D_DYJ_4;00$&G]\\X;M!OQ W^"J<E,\,J9O"1^)V?31?N)^44
MKL('K_"N8DCFMX99@WS8S,%\7#4?TE$4%_D]#/C[EZSMP,!QWU^^.PI"-O^+
M4'S?64@66<Z-M;7G0#\>U#^LO_<+O#7"NU]!=9.%QVO/43.UWZJ\_(AA^!G:
M?)<W1#&T([Z-Q[)=1(=[-(WI(K4%-QPK2M%PNR7N+V\NCOP5.YF"RNC,PCF=
M>2*N..-WH9F03,&/]"R1E&S3$;U%FE5 IC86D"]]LC_9E127E2-*"]>W;XX^
M7?YVJ7?AV-%F,#&+.7Q;K=*=]FF2KF!U$SF&I 6FN;CW@V9@9MN*X/>'=T>M
MC'>?COH*DHA$7K4N-<&&4US-D@UN3%79=>(*:+7;9]%?(5OOH;&5AT=PTYG-
MI6]D[!3W=[@+=(#HP^"-V3-CR-+_B'RL^< 5$&#9T!I\4)6QDOL#RVI-RSC@
M%]B-"U.%'L84&6.I2)VZ-T/\ PV3WSXD7[R5<9K^*<$K(D+2/GQ6/S)_%99P
MU?JB!:SAE2-:%15CLK;\+,:'BA"3YP1EYNMH QUG!LK2CW@@]3F[&M/D:$:L
M *[+JXA6)%=5OZ!_VT47#D1>0$=HQA1\.*])V^/+1 ?^._/_<RTQ^'II8"SE
MOMGTW?"M_RM:(ABP9DU_37(DEV"Q%.8>NS^'4VC+^FN._AJFD)/JR2%36JG^
MNE?YW=6LQCRK85V.;0@'TEY#4=8_^9F_0(P[H849V6:"W97=<?G11+L]Y[V?
M+ZXB$B:TGV$"+3H,/1V<3)-YRI[Y=IE1#Y=N3 UZ6)248.(SQ#%YA[1_O[G-
M#EU0<6%8]@K'*L4<F2#4'1#9:(^_"9/:'\4?$M/"MBKF),*K12;;UA'1,J8<
M!!)+:(]):X84A'I\(DF+#EBPT('K,!:;=WE)MA[\%04927Y&###O],X#7M#%
MC([(44<(ZFL20;'(TG*^D+2586O:RN:UA5+)M#.-4T6X3:)LI@I 5.:*/BM=
MM3Z0BJ4'2$^(IDR+M7&WY*H@J*X&8GF,D&MM%(L[^5 TG/\MB?>)JGUR[/YS
MA;@>K:3,POJ$Z.K 11)(.# 3]7=!A\MS^7;0._5ZO9/J8J9Y4;^Z#?<Z,>E%
M1'PMPJ2G<0E5!M =TREIQ_3\RE^+H@&=#0?$.N2*=,AP2]88/VI*HX=]M:87
M1,$O[DJ^*3.TAN5+L8!*)E$4ES7;;4>\>2N#B.^)T"@G\7"2CKNJ73RB-',-
MCET96@0-]%89V;GER.96R("X"1+<^O;TS.OU1YZ5\8(8]JX97?#[9FA'#^TI
MI;P:XG0X\$;#@;OP W'(F6GL^/X+(IL7=P]^G#!ZS['3S)\DWBR,K'^^.W\2
M$:!)JLR?BMN#'=,<WUE>\Z-W1G%N9%UJH]3Y1$-$^0*:*,,E_4IR<>6^^C4K
M5ZG[EE;]__[_!B?]'TAG"RQO]C3"KX<_()2J7R5ZS;3_!2NLO!F_^T$6D;9,
M8T5)T[FA0O*P"0O(#&W5TLU*E[1O@8I=O_O^W;NFV\-=Q65>0X2Z(J/<_MF/
MTX0SYR1&'./Z(UZNP[(68I2C$*/4O$7!I$NV@JQG&;SA>U3Q_712^(Q&M=-1
M7^6F<'J/L9L;64].&\I5"[ 5+?2-_5#.8\SC=,*Q$>UJ2#-E/<5U;TW;#IA/
M&[OCXM/G3Y4_YLW&QIHP \9><FZ3SXNRMKLV+#[(DX()[I[TQ Q35EP<%40"
M.K&)7V'=6XQT=Y:E2V5O.-,U,4HRZ*8F)U5.(F-5G:TGL'Q.S'';'L8<K$T^
M)MJF<^$\-;)9PCCW[,RK*=(D\T*B1BKK*&!9AD2K(TER,CX,6J=]?E@;D_IJ
MY6>R*)TOQ7C--#%ZJV/:![P@\#,'A."[25A<I]F?..0LG(59!G'-+)J/DWF<
MTF2S-,_=MR7R7<7GQF$UFA(H'-XI9.]E2"* DT\\D<PD(B$TE14,0HZ2)+WR
M(2F87T9".[A-#8/>V"@ZSQE3UYDJR*2.;:8COD&Z*S%S6AW(5.GS[4P/F7/.
M-9RXXES4 \WH7F&JN^SU>6J8)F]9PR_3'_&4^J=5ST&3%]-T?1/_<,@^0< P
MT*D^].XL);60F8J,J-P@+H(%5G*R")U)./<3O6IEV"N%U#8,A[=(XC)QZLH#
MVF 'H W9?M8#*T:L)' $*J/5X3#GFDR4"UT4 XE*Z*%X>&?0OD*?^/J2\]R6
M88!6EEL]HX;G?_C%$MT)'11.%XD:6(?RY%M? <\-B,,OF#\[K)'#B^;A^9/C
MD=;SU2[7=B);RDV!.*'=39C ]4QI'OC$Z<Y/L *@$\WH<WQ0]'A>P&PE N'\
MSYSS7XC L&\(5$-M-@X@^DP6QC)V%N5\M5L76+F[]/D1A66AG-@J]A-)6Z.5
M1%B8'Z]):,#P%M\743E2ZY)@E48H=T%V7YW^1[WO]/'U>P/:>;X!R J(,A7$
M1\@TKCX>Y1(H"(-.?CQ%REB_2QE[R)2Q?I<R]I5<M0=*,PFL2*X5%5IP3'-3
MJY#HIXAVHK.@<AQMUPYZJ."[)EZ=>?H%&/,._B3R6MO863@O8]CE)$=*L@DR
M#G@&5U&NPD%ZWA*@C6$VS!=N5/!"3.":I3OKB)QS!0D:TF*PBHDO$J<6;?$<
M^H(1(FKMU6"TJ242O$J29 EM,Y+B$IYDI2=*B9]NBZW7HS+ .8(+N\E\"'N@
M35#1PW(N3)1?N-<0FGZ0KG 65FA%V<DT;U9[*UVFZ?H._XH:67]JRET@]T!N
MX;O$83&$,[4)S&^0V(9%HJT'-EN:AD?=*S8G%HP8114\I*\&J8KJ:@\3*U_+
M,BZB%2IV?"0H)F0CB96TY. PW: YFVU\Q<3#)#,U,U!$J1PJ]:1.4;6U\:?H
M70UE AY\:]<)XI1T1>5"S5.R7>K79H4L.$2!7OWZ^X?7^@+XXB1L7#AZGFXT
MQ[5>77QX]]K3".G3$LX38WU8Y95T"\,59G65QE>28L$64!"N0J8%XDP!\H'$
M>J*O2@X)=%52J9,<%J]LG:^V6S@*L5EX-_*ZZ<=)+6KKR&Z,\U16[M#BV,R,
M)-]43_GF&;5^NIICKOA(-;F44X0E]:04C@OW&Y1TKF5Q3$'P2FJT$4>+_0F[
M@/("%5]L=-!PDCQ"-A"1XZ0LJC]HSF4FIQT"&+44$V/3),Y1JL(NP]BAP6/Z
M"Y^8W@R.JR-+A8\,:0R)2DW"3F_?:![5_*54:4G$9Y=1H7,B%O7U5I+)T9(I
M4L6]F60LLYVFKX=H4_0?3)'SBW%YGC QL^/%NX+A'(#>C'-YH@*QJ>LO;5?.
MAAJPF]9L':<>1V#.J,K%=-X7J48SY:=5<K_BS@(4 BZF;HQXSV@C_IG0U?!8
M$>)X<]UP_K;O]4]. /G34=V!4-T?B?/'M$A!</TA$]R@F5^1I"5[OHQ*JHGH
M8D[JM]3P<B(M*@68B/X>0BMV/PCQY23V\&3DUR)5/D)5DH +-IKFSEJ_D>9$
MH$E4^%F4VO&JB[>_?S!>+]&VA0W^ES4,G4OU?59%I;373X3_#9FX0,^H$MLJ
M&(UF_,J#XR]OQ+0XU.+=+KPCGN%+9$/R'4- &K>]F5VG39U@/UMGR*?0*(YD
M_ K5W$(5SI*(0G*V$E4LU.UL#=A&8PZY7)  BE7.G*A\YDM '9$PDD*_X% F
M!"093!&'AN3[\LMVMS/21WY!"G85L?S?:$G_'-(_P_\Z;_#/TQ_\_X+!8.^A
M(/P]S5<1PO"O)'+Y&LDREF-:E7<*B$8M.KO-[VVC:NB):J)R&HY;DR3'66A(
MI0Y,%K%=SLJH)AR;TCNV]0@W>/])/6H@IYD[M (.401^X;MI%9O:CMK ,3D1
M(_55-(ZA?6KX53.+9]0Y,@]X0;\B#Y]MF1EIJ3D3R6:X0R?N@V9K  FXM*1!
M9O#O3XDI"O8"C#5B=% ;0&B;I=*ZMLV_\J-8%:$[G+8O]Y3LCK3,IICXUL2)
M"T1K^ *^3X_=OM:"MV53-#-[^XHZ15CA*H17RJK3PYEJ=%W45$,A,C!&'#[:
ME".[[P_R<L/E*M8)J1M3=ZJIPWBM:T=#KW<^8NV((T[8+U*Y/'B6V!:E/>8,
M!@GH72\8?\MB4HW9M?C-%)33-'S<0$1W5_?SA!I%Q*^CK;'(-?FGD$RXG*C
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M-MR<B1]SIG"^ +^G/7G2IJ\=6[H[6U)ZLU)(CR;KHX9JO'%#B,X&W^&MA$A
MKHD&M5<T>32AEP0]G\6>(WBE2OVV8*#H1JK.$A/IMJ0:6R@]8AIETW()2P4>
M<SO_LIH-TZQ*2C?].MB/EP6<FAYADR9EX0"?B?5F;AK?_ZZ&FF*LQ#I()#9J
M8P-T>*&-LVD 7P/%:3-"X0:5FL"[)\T-MNP<K#>U<=)8A&V0QL<391IJ8Z7-
M1&EJ(@[PK!J6D?DZ=WFLK)3N2C^O*UWIWQ71JFM.!N,1]'=]N7>H"Z()",JD
M 3(U%JQCQMAFK@?AC''"N0,@DU-E%G@6Q5H+JIKBI.*4#RNX2^5BJ2X/V=OH
M%Y<FT)T<TCS2K,A-WGFNQC?P;RW^).G.$?I!S!.EY1F$=.W2@U.=__^Y"E1!
MS/$FJ!:.040J#W?A42B<85!MC0[EJ3"!::QN /6C3&\[F$ %Z%G;+=G@QM2L
M,^;@6*\2_&KACO3@0.$VMUYM UY2BV@R!T'8T%BSQF8ST.H\O[:7-KU7W.N@
MS,,Z1!4J4,".*[CSK<-)B,0&/1_)MR1LAWUCX"][QZH0*A'5MWUO,!@]6B\"
ME0/T97?^,7F6FNC-V5PG73;70V9SG7R]V5QWNBM?O<#7?9*4.<@M'G)M6D,-
M(*D9%;GIG4I_NH;#GX6"%<<0=WCENC+.;^.TDAY1=352VB[HYEIJ=(_-YQ:E
M@JYG>JWS0L(D,+H$7< 0<0@VKCUWB>PS99NZY2I@MVB:F+ #6Q*UR4NT@S4<
MRY7&W96X76SN-3IZ*4V![1!9#OU6Q1/8F-&=+:[@(GPW8S<!#2F!"U&0>"]"
M3BV+R!2V]Z\V.S2AA0HO;:"/RE5J.T?==#HM,Z^I!;6>,JGF]"TY&N73<-!.
M)5 V^O;AM2MB0_NJ66+&Y#)-P#Q#1Q)F@;PN$Z-RK?F8%VD<>(YYR9/FO+&_
MKO=N2]:LVZ'Q5[V%((/8[+N,[U7,R-I!7ERJ0D!\*JS=2AMJTWG1\D>_(.;P
M=7$[R[RQ+V[=+S%BOT3][^C:7#(<=!A=J0CO//.EGYNR9R;:H2>LR[%8%_>5
M-W$!UC/;OM_9R ="1))_Z-P1,Z M ?'4&YZ?2O[AJ3<:;E1A"?=,PJD)LCL0
MOY5#::?GZ 9H@9H!M/^<!P.O?]YGJ?GM^,Q#4NN-LW9O->M/XBC*):!E)4O6
M\B>EYR:--0\30#5+*". 2YM;PS/\&7_$-%.IN^7:T=OKX.U[0B' (OWV_-0[
M&X[V2O+TZQ&2>^T7X-P65J;OG8Y'=RV7XN8@]5QE$XZQ,PTZIO9DJ8-_(";C
M?*HZ"=B("[@\E_0>>M,^]SQ"6:X^L4=?RF-D%;ZY<-#Y#UTUB;]?IME*D@G_
MJ()SKC@;^\.=6833ZBN-HAL:PVV.(7UGY9?,(!UANJ@_T&S69)BE"<IBYNLJ
MP8LM+;06M51QYK (JAB,D989>3P;;BXL=H^K^]B)-1KF$3;;<]Z@7 ")*['[
MYMC]/Q(_?T]G,\_]_?C-L<>5$J$.=#29[J>JW_H%&K;#YKMD]EN$M3[QNOV1
MBF=LSE:*?^PN2>V[["L@)!+#X(VJ!9_5J<G7G?2(34_]?.'.PE#54S"8T>=M
MG]9P/&CU2S3%3BEV;B?AM?YV(/85S*DD/.()8,JYMO']1/"2$3T7^;%$5U9H
MKI*9MD%J2%N=E(7N16SZ4CI5.AG":LN2TR6KV599!&U=#"T:U,3&9T-[D:M.
M2DP.5L>5S>Q[\PVG4;+S[8D)K@/QL&?U)Z_I>GA@#W2FD[HNU-F&![P@XJ,_
M1^D'3GS[5TJ6/$/X.F];J+$OK'2TDY5NZS/(W+0^4KVP:#-PI3K?._6WV&@-
M,_03-\X54_REJ59] LPAS</J[UIC]J G(GA32 - 9,"A U%.6G,#ZWPC <U1
MOC]QX4F3=>(I\X*U=/Q-TE/AN)N1:IW^X#)?IL/$IV/<U>V9ABIR9+I(<W9U
M%N;%%@7>T5&B5;0*$6_[P5J&:1W+:PJG"PD 0530UQ6? /!3F.V">.>5_E 3
M>?BT"+$HGT+M73<]B#](*Q9KY8JKJP1Z+@@-N4U+X>=_UM,0JA[<EKN*>#Z0
M_33.?*=%'PH/J5]01T1ZF:@L*+ ,2#S<6+IL'V;T9N;FHFCDNKJ8/8U<9,!=
MTH] 5]$JEC:\==VIX6)OZE)LG641@CVB@VQE24KUX(H+U5M:JRO7J5AJ(FTW
M]0=YTTJQ4]$"[2!5F>25S'=H!WR!='3K"3/CGCC$5O1FIL,,F]GR5A:N#,)]
MI9LNAF+[>IEM&S]@I4'" ]A@L;X(^'AM=*U^3_"+\EIFKZ3@M[B>\4W@<,Y3
MA=>U2$OH;TAKI,UVXB@L]6O64,=6'9!J1VO7 .'F$Y'(NG3,OW*B[#IGVB?$
M)67%M.DR'X?G0^P;+>ZR1_4U=HK*'9S8I@6A[B%Z@^:[C3)4^?-8Z[YGK/H&
M7PZ$57<!JEI3:-AV6NA6;E9SU.W55E$SN/O?EN&9=Z*W93CR!O5]V3 "=N.M
M/_JV/ ;=2Z;"LTA),5.].2EEU"6E/&12RNCK34JYXWWY&F3<#6A"IKN.SED\
M:X-!;QCD=F7M3N.<H\#5Z*IFN2K9]MR+)7J(!?ZRJC3^ARE?%E#C]V2WNJ/7
M'OOSE()WG69Q8.S)./0WR^7<>KF<9(W\D4S3(*R6[SG_)$-[NB@ 6+3T_\T%
MN$&X"ODX]">,&)%O><J'6#DB(=$E"L.NP[WVI^G+6Z8!IZ3"KKE F@4_]CX]
M=OM8<A86::=,'O""H$SN<_ (,,)=TLB=Y486@1@3VL.A;!DD 6?I,N(<!B[[
MKC"N+/PM >7RI(!#^WK("#)M9?TXG9=8@KQ=YC*:-,WS@74\#ZO2;G9>D4H5
M<P/SYJQ4!O64IA>'TQ*-OI=TC_PDRI<J"AVO=7!?O1E)\I6N;<_K><:5]8@B
M.QYD8Y<\E#'YB1T/954.LQXJ:$IN:&Z[_%W?R<L9S973J-$I-UY;(&;LB^.>
MONUC=BZA [E@?R2.%E+#-FCPFI"J<]"!=B[L+;E("FFK0I%1WHCN.)5Q8>4U
M&J@%%:C2. YV:=$^DT"5E'$8T>3KXGGLJ9 -S*21JB<0PE<+588+,8Q)&<S#
M0G6OGHD+K5Z#U8F5 UZ01?4G-X+7U*E^>!>JS\M\)0+)?-21J]02384/7<28
MUHE,[%65C8#X.*7VIC(7TWH0OE.62S06^P<5HW?Z-KUWM'O "[KW_#[E@[)Z
M\)R.O<'IV88[*.*^FOPK[9IRK*0'(7$-".=_D==HOZRW#>?:?7?NV]R20;_G
M#<>#77OBM*2Z/>&>[-\5:7P^\L[[^^'>=V#WSV%!Z 3\\9WS:YQ.T+L5_HB+
M7.H,$%.WB7XA01=.I=-&#[WKRKL2/2O\210SHA:I:&NNF\T+DG;S4"@7*:S1
MI-11,&4#</95#>78D/0_$\:A^ 3BW;^CQ1>E+ ^T<_S<Z]']=6Y 3-5;<8=&
M9S?-Z63@]4:GDI+</_/.AQM<9<>L]K_5P[.!-SH]O^%6._7OOZ [\.(N]><O
MAW-5QWO'CIYG&K/5:27!SJ9_LNSA3\IQY'R,D*%SD>?I5.+Y39!%0SD_EWG$
M?<HOC*']S!.IG_LYXD]T&YV+@#.NW+= S<Q?6#KX5\&5$3J1=*<I2?E(F*KR
M),-57?5O9)_N/(6BH2'_&@B!!A45M@.\W!E=<8'CXM!-1HH)]V"$19B'&E=P
MJO'Y5K$_%0 1E*K"264#[I7%(LTB@_M%$B 7*D3F,E-AR%3HOOIT\39_;7K"
M*Q](<^%8LV/6[$J:E"\8J"IWLOZP^,L;\*Q Y*JB4AOF3WU_CMUW[/Y?I7D>
M(5BM,20=S+C:![\0'94#VCNF7QV9ADF- VVT2<(XLL(FJ 1?1K(5P",UE48Y
M;1B=1\XURYPDE7N. 7D]TAL8T"\6.9<+QVDR/V(7ST+@@;G+!BU1UW3!M1.Z
M<U(.$S4?U>>4-@H(>D4:D]F'=34.32/  !.%/G'$4V;G 4GU*13Z5V]^^_SZ
MV/T74F+A&J4?556VJY X<[(:U-LP4&5[K9]5OCKR17DS4G<1S<6B+9/<GX7'
M[B]E)NF[!NH6Q:U)O';0..): %[QC\SZL,+69.W54E18D>6D19<__@P22+X&
M+OAN1O:,2S>.B_WA=Z0=8V.0;R$7,W,]2V!G)Q$Q@UH9_VNC8_=5&E]MRW5N
M\E:V*8\_'3N_I&D@.-5XXL*JKR2^\NJ7-Q>O/79QKD*:[N]A@)ZBM-"+>9A,
MZ3:\_1T/H,J%"78+IP2<H@ ?6M-F(  %X*3]<[5$RS)GALAYV*B]!LRBNAAA
MDJ5Q7"7*BB=WF_NGME&:_7&UT28/;.RJX8869+)[D:P5KZ49^E.=;(XG!<F
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MB!7E:L;BDK-8A+(H2,W6PM47%)J(RX2J=J8@#[&-6)'WZU^U2SKY[QO<P,*
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M;+I6UW=;:XB[2=N-ZP[@/Z:PI[DXFTI.^E+A>$;J#E]/.G@T[L3F]J[V^![
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M)J#TS0KQ=C;XNR,)!'X$_Z>5[I=%]A\'QU8!@6<L_>/<E>H1SZZAP!J,%O6
M^;/AO#S784) _]HE2DMT+;+2#WP16.6E:7@? /I/ .E-Z>K;W/RW*=6/3J'^
MLHI2X5?_?^YZ\DK0U;]#UQO:_+<IU1VZ7@NZ^G?3ZU7QJ__W32\4&-[QZXY?
M=_SZ-ORZFUZO!EU_V_2Z0]<=NN[0]6WK! 'P(\TM[\;7?R8J'05N9#7B;7"1
M[=#G"1)7'F/G-S.VVD96VFY73R\^]^MI.OAK[:2@L99I'<H-ZG9 AI:G5M,
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M65BMGFN7Y^<+E 1]3 5]0B!YS.%W>#JT>I*G3W)M'&C7Y>F\&*GO?=0JQ58
MVWX4LZ0PVSZWC>1%3.P?F!,"SLVY2A/H2J38Z/HJTK]I*9/RYF+54IQ\ GRK
MIPH9-2-1Y%9MW.-#"58U=<G)?WD[O<+I<)7^E8+FKW>N96<4N13FI L>)PU^
MCM6BH0*-<[S+GTY,+&G[S$<>?)I+I)-@+?I"&M3"^<#/794=RY\:7=QWD7O<
M"QY^RD-#E[L:,3+6F>X]%"G*\Q]UB]$LMH?'O&!7._@U*7FIH#/$;=YZ..3K
MJ_[%9ZWF^HLF3LTI7/(GNRF)GM"QM"FU)-!]NJI'=@,N//]UV1F02=UCQYKI
M"%&?"DW"R8.UU$G$0 1:!E8RD I4::A5JS#.UTN<F)X?C<YXY%O#J.C/.\^(
MP7\P-R?05WA\TXJ>7SPAT,4_&F]_H]72_>1%4BW'=\2UKL+>A4.T-@CV<S[/
M;6CQ3LN]T3V[N#"]:%[51G]7B@^\L5P5T:0:QO0:0X7&3)"0_WH65E\23E+#
M;547-1]+H@PB!#QFW\[Z=D!2U!M8>H<:&KQB\KBR;QJQ&>[I/#QW=+S^LV=$
MNR8HJ"KM(>@]L1.?L+[R=TR^=!#_K&&E6' P;/\OB45'(:!AYR$JW3^GW 5D
M9N+JB@MSWD\(/",*@5*5[L6@QK/SPX:C['M1_<]FR6U>J^@#Z*M,^ !:Q,%8
M(V<3A%DH9IT6[/3"!<-I7"0L!*:BNRB,\-]@C%)2#;QV#LIH3*TQ9"I@B6<$
MC!9HTVI)4BAY%FR_*]"E+7&.*C8W^B=W+#,S13],*3D*67=24@5B@X1  VF/
M.36T*#X#!#3$<\M$&IWJXVF^>Y[R<G,%N.3> C6FL-)HT8TF^$UPN6!#ONU0
MZQZ_+<-UYL<\+JQWMW!,0PR$P(.G,M:BWJ[Z5YA-PKI:^S2"#)2\VJGQK7GZ
MKTO3IBZ<QF+;9W6?RW9-AN9._ SWE!KK/K3U8[KKPZR7'DAS?5<U.ZO#YU+3
MPNI<.5\;FAO[JML;FWACHMY_XQ&XO@K_ :&,E[*&@CE(2&^TF\#P/\U_@#LY
M19<3O"L8N0?*_C:X@-HVAY:Z .;?:MW'(B,LV9A-HL@:CMS2:C_%5,9>=NO_
M42 57*R*>=F<X#6L@3_A*@028G"N+ =9W';BE!#H88XM^4))M]'^T@:<*)CT
M6##(?(E/@"A4U'Y!%Q2=AK-G,5/1TCS3FOGF6R ZM?58%=R,V7H^8'#"=]:,
MG%07KS+HWG:$\=?\.N%U-QK18TJ?H5?\G:'H/Y>6Z$[A9$X[VG7Q\M)9Y^ Q
MY[JBV<[";Z.L<U4R+@6U=ZY^+K\G*WER_'.LI65<GV&9IM%@U%>="7/&2_NR
M:30C>FIM$<.FW";)M*IS504# B5^8;L^#SG,.Q"&SD#Z@&66<-H4417VIT[*
M#K6:/,+J^((^$VVT$F+YO%EB]_UG'9$58S[T,ONR\;$QKU\RIT *>!;Q*=N'
MGX27XYT%F9GMAQB\0+@-^LFY*7*OL[AK\*URV'90A ^'\5JXLPDG&T8'.WVE
M7^1YV8M3/])8\\XAP=?RSK5U-1ZUJ H<H>])I'PWUSR;0/XU(P3(XZ!$_KQ1
M?/KS^7O.1<,VRP.W'QN7SUF>?6A[XXZ_MNWAT#R]V8<OR+5$L\=+IE;ZAY:S
M4^VU&LKPK@>SSKJ%5)#=L()"(: I.TWF[D-L1J]>$?0K+AA-,T)Y1>A,RL(=
MG$BOP]G<W]V?CQR\]7]QV""&V2+X+ 1JA<"B,S3_&RA-7JCGVL#R4_IEK'GB
M3@;.$FRDD6\7R/80[_Q]1?$ N^V$97T"M>0H&)KL:7<<0VTL^)V127Q"O1P=
M%ZI?$;-[\R?;99.)H3OBH]#:"GVP40AX?YMUR55)?>JR^^&X;03+208*PWTD
MM1RXNAAWHZX@L/QMC@N;_2LK;ODM;:V_QW6]9A>/SY,4Q=IAG#L_+Q1](52)
M)\Y_C).LQ-GPLU%[>00(0S,/I1$V7FD5E3T?>4[>Z,ILN_HL:A/HDY]:0&7-
M#O(4+R%WL>("_8:>+FAP39(O%7R8^\SPAF<61"!]LP [.D5*J1=I3UDP0-J*
MLW@X@5/@OT1MZ7@D:GFD1Y/P6MCV<4YE;<OM7K8UC9*<[WLDF*2*'>P,]]U2
M-?#CFJIMFNWS!(>/Y(5*RE!HA>#^ZY[5M361&W]TK/,_OL[E(&ZNK*UHFH<:
M=;?'#6?,':Q"^]DQ;,RRG^2;9]O8EO]RLK>TR]7Q>(JJ/NGY,=#:I>EK+]Y2
MZM5D7[WB^Y60ZD;FKWX$:$T?3T5LQ7>GE N8F"V\(Y %QQQVAJHY%\'1C!7R
M6(H(6SKR_Q)HX]"@_\T(BDQCXBIEIT-H/"1N,\@[5F,N:N?J/>Y?(2B<-*]X
MW036UP:C_*8=8).?;&(F4H>KC3LR0@DTN*62?YO@+YM$VHR4K,*NAXZ->@R@
M Q ;&CN92CYP+688)<4[U8^,N0Y1H0US<T?X&1 *HW0>5ED?FIM4EC1?_:RY
M'CME<'QFGEX9)S /#/M H)\A.*^OOJ'ICJLJ5>P:2',J/'L\Z,C:$[-,!\LG
M_$5W1?T <J#1NZ&GLE)6-I65PP]J%OV#3UKJ!%?D7"HNN#Y>TW,B)LOFX/F[
M5TWOI6?M+MF6M5VJ"7',%&@Y=F278<[-A$'>&C^<--.G%S-SVM%2 ?B'(4:J
M%@)O-%V$P/,0(2#(LL=8\]#<QT+@DO]-],KXH]$/*A3>[4@'[F:F$)C5&%XA
M4(5 ,XES$"LN!.R;,P#O0<J74CA)\+K _R>19QE=O\SL(DKQHB'EKD"OJ1Z:
M$ !XNK<'?\M 6DADX+?.(92NC%3EV6T>O#IX_2E*#W=$0,WLU&A-_39Y.O+>
M(Z.AHT\;,)>/?/Y) )\*@>NAZR=";Z'A)-0^(?#]Z0/9EUKD#!&<]1!\9JY$
M,3<0(!F<*+7W>UCS=-#CA8+,\2D'P3YZ,F%=1TM\(55GF@"[$1I-^'L:7Y-X
M%B01_EQQ$U7/K73.-R%0U@#+"X'D<#9"D/H.X.Y/A9D"1=)BGQ"P#@$UA<#V
MF2XT7S&'T%G+;Z)\7VS?* 38N^$D(?#PY4W4FX?M(D2<Z,\-)_2/XT1QV&4*
MR0H!2S_$O_/]_S.^__4RHM^_'MF*<KR+.XW\4PC,*WYP3^1YPI;<@""!(2Q=
M.8>I)W28Y!&2\=HA*/8XY[>14B^O<M@(TO,K8&L+@2"ITACY3VW#S:^)06XQ
MI4V!GSSY)=<;!;L*.>]%TK^&]432AXA":^7<1XFR?M\P(;"MCWN5T#^%4Q+)
M8RP"C.M: 4+@[E5^+?H[B)(BL%6#"'P%0['O*^Y%!.HQ_!AI!8O81(&DZ]&"
M5!4TZS[E&GT=*7N;"=]ED$3*D 9BS15G$.![9H,_7TVB(Y1G$>(@TM]=(GPU
M=/R8@"@^U2C8UU ETH3%;VI$RY@>WC&3Q?LB ]P"O40&&'<6::^T[!\YWHC^
MOSDQ^DGJ=A ARXX&V![:'[?$F)F:Z"OWW0HIY"N!^)[FW+K!K@(_*M+1&\&X
M<5'\C?*%'*H6,4H(Z$%UZX:86O1B[M>>1@X%UFOLM6_B9]3K+C*.D.!W\A^.
MD&*!E2<Z'_Y!UG\0\Z:Y6NK/?Y#5^I_$?"!K_;!U^I]D[?]'PXCW?R<?_P?K
M_%O# !16&5$)=Y;.W^:K*D(7<:Q#/W1>XXRX)OA/X=@RMI,EUYNW*Q.+LW[0
M$[7$W3/GI+$LNP%[GJ:AA0[\LJS@5>>(]*MX?Z^U]'5^+['Q?U>/D!#CNA#>
MRH](\!U(&RBK>)X!^6&E$/ RX$<0^%M&NS'UR@NS7)]/.-6AJ\.$8$3">D8V
MS)U*;,UK(+T\6%;E,..-"X=#%7/F;S#KZN<6ZMJ#@YNFC'^UW-X5HA3LC&9<
M6I>C7"6.'[G_U]^7"C?=NJI'A"^'.*1GB2)'4\1NVG\;N_\OA=REP"ITW7^
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MR[JFEU[G"0%^Z4J?XL]63-TH=>RY6P_- BG-N%IRHFAE^(U ?H@SW19@R;6
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MO6C?@T[T9H"0H92$,A541<_ZU ^]>/)%0A0C98.U9"-VB[K"1MM)M(YWLOY
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MLS&#+&@W<FX49(LH8/ \D0KF\;MK)W4QR5;:$G4FKXT]TYBOQYW-PZQ77+N
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MZOSP.3?#_O7^$">)J5_-@1Q"T%*(V+'/QXVN\6:?RXO/]/VIF]-#/,I^?;&
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M)#Y'JK.!8I]1V]6K259RV(4A-&)F,0HUK74_BB#V+:&^ZR<K;MTK5<!8#O.
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MCZO8OVH>MNB+=&/7%UJ-"$3?US]>#:Z6;2@$>A7L<A]]@-(KTX(>B0^1+[$
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MH\2SDOIG;#9&Z]S(]+-QWK2EF[=?5,Y1AXS])'L4NZC:S&OOJ4(K#:%S^=4
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MG6GJ5N9!B<]+(#A1AO""<,+%.7? P$M:@?Z#\B_U54\&)ABN\#B;9$A_:EL
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MD6TX- 59FW'EYR:G!!:055SEO-)P,\=.TB-A=KAS-KGB0J'B)Z>ZR;>"F^R
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MB'C=ON?BT2-M!WIO5#1.9#W\5KE@;?%CX(5S2H&5I<%%V6HVYT)!"-%FLEA
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MXV/\(?7-E@UX/VA-:KY)1''Y9.85;8?^MUO>CVP2Q@/+OJ?G&7/.MF+-NH'
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M5:Y/JC<FA.H.)+'+P\S#M'3O2G%36+/I3?.Q;3O>%J\JYQ[+5HE#-$BI3;>
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M?\(O"FTY[:0T5[H>QDY:70$QXU5+P@'C299Y6/"ZKLHZ-0+V8%1VCT^- 47
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MW]*24* G+T%H)$[EYCDI'^/"[=@9?=1-RAR6[0BN,C:C#B3MA[,+*(>562Y
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MJ?4B?UEHX0GJ?RS]W)TC^I=X]M\>!Y;1(N3[ 8Z'PN/H-/,&2H #"UC:EMG
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M&;'VRUDWY98[H;&(*F76A_8#66'!1V6$H@\2>Z$\SSJ":_FY$K5Q41YT77Q
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M6X[;UYT1:9Q%$\PQUY$L7J5W!9KW&R-/H54'4+BBZJ(=%L2;)ERVA"*^0N[
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MLN7J1+:JD"Y2DG'K6X+DRR,$8I/1)A*'#-D'BOIC" L(!9_+TJT^.W9'2:P
M;GJ+DL!L,Q$;""2S3,+?8^='^?*%EEL?PZ FH_5FM!P:4D$E9R@ 3.^FK&W=
M3\2PR=MOS<E4Z&DX):N4JIC72@' 5,JEJ63*G>@G$+W3[^8M?S="1^$N@)MF
MF3HYR$@W2EZZ$=P6N![<^"&+R6-NG,OD7VVA=NK[ )/4<MJ6[F=A?<7<[B+M
M\4/O_\WE.+;>)S91QD:FW&-K'CC4;4]1!-L%]*09 2V)TA"[0!%B-"6QU-/#
MJS!>":Z6T(;AN';;P;OHZ7&XY-;MY#:YFU#$&Z%L4>/+ 9()GZHR1B3PN4DH
M)SY7C5BX+(2SJLQ<&D<MN>L*W%T8G^T=!ZN#[)B-5=1Y+S[E-E=]7DXLA'3K
ME=A;K0@R*] ()$A4FCT@$WD L6-'M9@+)>7DD558O:HD?' 5=B'"M7/"^E4K
M= <TZF!J_%Q,H,"-48=XY22W>+Y94EX/T:S3.V?BCY'J^0NR_SR/]'L,GGP1
M@'3UU_%_KU5U-TR4'E9>U?74C]3S;'S#;9LG$>@-QA<1!OOO#FROXAY@I[R4
M)X0M:%V./]']_6 ;>3.C#MBV&,/S=Z4H35\>)YK.'M-CW)WJN.Q\KH9XA;]0
M;6HR$:%SZ4NH?IY&\([JIVM_&8U@+L 3N=J4\ 5M%E.5*RB8; :794KQ8@]9
M#T4+PT="XV!VAU]()N8B08G<C50G6SJ)[6?]0A);PHK#KI#4AV0F)%. EDXZ
MS%>H=46JAA\(="YWM6I]/#(#*DJVK67Y81(QY_O60,@38./\ I K4)Q/%VN2
M/P3NA#:"=-&_4#GXAAFN3)282JO(]A(+Z"! %VG5 -PN[-J96*X6"A$,6'0T
MM%I#F8+]Y%WX/(W[0K.D:\MDS6:@]UM%+F;B[G2<X7_9IG=*C?O#/><.GFC0
MJ#2.Z^JM;_"QJ[^2DE!:%A6"$F5S*Y7*(TIS-NX+?1IC:\?LI"4W24>H-^A$
MM?:FS\O)1VM1F.N5$.ZOH>KZ70);#G)KIJ[@.SNLOIU^I%>CUKAP3<71=[D3
M<7<W*##7<0/""Y6!K+)X@[SE4P#[YHWK%O \?/YKPQ'!=>U2S<D[GU94CQZJ
M+LQ[]JSB645:A;K7GUY>,%A%,6P_3/Y9<]/]?^C!WB,J7(7=;0=Q3,EIGS%=
MYO2_ )JQL@A:R([[_-X(<P'!1JZ4D/5&OU 6#-= _>"?*O^2L+$_5V'44$6'
MN*DL^.#NW]-/OT]I)BSD>E*NV=WY_LE?)DSV88"JN%]'BE9\^%1D6",%:2:7
M37G^1D5X7M\:X@_^P,0O/;Q.'-?Q]8#$6?>^<<9Y!,+/Z9./@?(+#Q,?OW^_
M94V&0QZK,'X.4Y[=>[40_\@T Z?O$COYE&ZS%(3N'D!66=E>4L7.?SY7:/@J
MV>]?]8?4,=YHE?> 2Y#TY\'PR_XMV:P]E,28^)[!R[F42\V(4PU[FA ^R/!4
M:T.%+.$[<_:Z2V\2_]U_U'";P<[K&2N%926]T3&EX7Y)^='&5PY;L6GQT1=0
M']YVOTN[OE"2^C6UYV#HEXO>QBX[LG$E7U$;49MG!+7S(]L.WF/65IZ,>6':
MJKK]TQ_OR@5&6.6E9\=/@T/1VD-EF^[->K+ZO8;/B%W\O]8\E$0=O+_#7=5K
MO\NYF:&3+,.8@LV.G<<?[?$9<S'@3R76WBO>?_Q1 =KW>Z6T1FP&F<[QN[L(
MXXIM>4E597.YK=NDC]!Z88BXUMP];THG^C8"\]DN%W_(?E4)KKN]-$\\%Q0!
MLH]EQO6-^;1KT=C(L3I^=R))A_*$F4)&R$8XBBR"1IA-7%555E$$;_R&WMB7
M4=7A+S9JSOE"A<KM0O_&VJ&(A:=WXZT35V$F Y.S'']:74" _\,17U.M"4'H
M9N#8X1S-/(-MO=O*UA\K^:Q])\?;86_-4(R#J<O% 8:1U!2?LI?Q,M?]]:N:
MG/@S1W4Y/HR[>CF?N^%*V=K+'OC9NBT:7<'D9K]#5;;!49[\%9".>NU^+TK3
M^LS#KXPI?^7-?^TQ)$Y?A"IJRHX_U54]5:QN6).1#U[^]5I+MT.U_?UI V?S
MLOW.6X<^&U\SVIA66G1J(,+]]HO310;NYE[9^>'*3YEXD@(%;&1QM9AAO7B>
M6W('5@-"^D+"QS.ZY@EL']5/O0[,I*LFZ 'AR8'$EE786*X?/H'H?>EL@,N-
M\]3PDN!_D7\!)CGIQ:1CTA<AD,(3R)5MMS*+4YK?#7G$.!@=!]PK(TV"\[MB
M3_D_#C@8F=@[E3+_KE/#CERI/&319;RLYN<*N?(7<-[]#]]3*V;CL)S=!\Y2
M+H8CXBB<W::S0?GSV8Z3[,,7QO6.#GSZ^]]X':530U=3!Q9=ALSJFQ_3MS8-
M1GXS-OWKBB;J/XDX[-R_;.C7Z'7OMO?'Z'!$F^==%KLP.*GLJ.]FNL+Q7-$-
MHO'9*\OWWF#M"HQ[;UQQNT!FWP;N =LS'':X'>M6Z74WIY4D"3;(OGET>MT3
MIG2-/)+5*,X'[CN7G:6 W21-PR+Z;$>(:3'Z[B:#QSU<19VL..O[0KB.; 2S
M$67PO#U&R$UE*DD4Z9U!%,'I85X-J)=JDV*R1%<\7-%K3!L3-5T)#,7CBRN<
MU^?CR['&WB,YFVJ<K]W !<BE)Q[([VS=_@%M8)HKMH4('<AM)#,])KZX&R/R
MFFZ\D.#5XIRPT."(:[P_7Y:I%V'A=3>4HU1_&]ZM;"H2C7PS$N-[*N._WHV_
M>4/AW8<)I:38:_D+!__+U@QX$YM]_=HY5U47JT]A<=7E8=%ZQ?CR66_.[3$U
M[C@WX'#\@8<])_2:LKP*L5;]?G]^MU[VNJB_2?&.YZT+1\T3W@6EENW89N"1
MM$?)<B1XA\9:4^*KD4[!LY'3NY)ZIEWA1S*/>TV/EFWBGGET[Y'88.K.LZ'6
MBIE>P;Y#33%/%I.(&4?U/[+5][_?<J4R]5G%^ZA[AI[WBN:?Y#7.NY7(<E=A
M2K*^S@F5IL&(&'HRKH[5I)O*K[P1H?]A":[V*3 'NQ$7> +$5IZ9.6EZ_TK_
M&Y%KT?ZT;T&$K\<4UX*YO[??) JQ"781#;2B4)S*!4"WI +?NB'?QX5D_]2M
M"!?6"/CZ=4:.>N=T>N0LGLYD^:9]5U)P"<F=;[TNX0Y>+-3DOTJZSF_*BD+%
MGG+;ZV-PR&/R?,'VXW61YTX4M;R[&WL%SZ@=BM$D(#SBQ5-#9R3L(=UO?+K?
MG[ ?RN/'0DPR>V@''NW0W:@^V9D8_G?4MH.G+3;8/2"U^AYS;U#U+#<<*$HO
M]O#2ZCJJUC%4F5&56J!/.EY1M"%X#[8 6RD^9YOF6>()W[?IY?TS[()0MN&C
M<(]'ISV??L(?M=SE<MRZI.?:]*LS]"&3HPOUF)156-USF;F6QDT!79^M=;2*
M3X=SDP%VHLY2Q?B,Q<Q*](ES@WN'Y QA4O+2"1GYX#KZ$CCSX1<Y%C0Z_ I
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MNL*7LK4&)H)^S9\1#V#D86&N&%<PF;%,@S= 8[&2&"=0AU'IQ$@O2H%K8O3
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M=!T/R))'\#%._A_&_W*,L(VQ^:;#BO. 7PBEWK2!+SR [-6W^/5Z[K?P\Q.
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M9/559TU-)@;3GP=FJ%)Y(C+5L!$Z1'F&?D  O. TCVX8M#HO@KFV6#H-CXU
MPH20ZQ2: ><5_P]>$(.T/Q!G !"3PI'C_>WN @J3M)-W#OC&#&C\]'C7[V"H
M8_TO1G/=K\USM2'5Y66Z8[ 7R'?+/#D9CBVXQM5"\KS9=5UIVR:PYT%YKC%/
M"VSG>L\*Y("U),0[LL(\[M1@]2.>F52\_UADREB=3P'8[8#>Y>DV6^?^[?OS
MUV=JG]\]G'&1I![N6:=DK>U85"Q[^ERC8\J-8H>HBI6&=#M\8U ][34G*'2?
MI8R%?1;A*<UNV"YG#=E<;FQ<O.S^"5C+:L0U.R!S(_$\V4+!CM52WM91(23
M!DF3MX))Z,(?<>CBJPH_3$ZR--'[S-B.@O?SC?AV4 "S?0E5^ (2+@_+V9[O
MMHNQ>%QQ2Z0"4SZVZH^!O8*=HD*X90V /C"5P%JP79=D"N:F=H,B);:$[$)(
MKIYNUF%YG8]*VS:KHMD F#:PH#)S=U1@#2,\&4:*4I><Z]3^$3V2+"W@SN7
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MK"7NG>[.HP7W_K']1>N%$$.5@ICN]845TB<A!-1(6QH2L4#8>[@4SV8(JUR
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M0[P[[4XD!UCTG+/2T"_5L+-SS+F=7FA_\6?K;>X[.T=?QV)%.UMKQ]! 7E_
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M;P%\7" 80HHCI@D425,83YS_S$2-S15)7%-Y+!QT9M''2=U(.9,SQ7,T4GN
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M(/*^?:Y@5UAPW3AN'Y[F1"(R1CU@V[&W^:6]5.DRUP@,%8&ON,AA+SC8B]=
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M/?Q;>3;*"HYL/.\\K-/%*R)ZT@+5*;'E_QWAZCY"OY"]MJ+2@VI!\I18A+2
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M'8'B-]Q&H3WV\AA<WFHIV6 (:\&7[X3)BY!LJ#Q8>FFT'E]!5< -H)HU:+W
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M!@1H7FW8#B:>>/VF96SO4_8?%(O"48]1]/XTMIFIS4%('NXGT+9(!S1H#IJ
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MW>!WA:E^RXH,D1/?B(9(U3,!O)^R\:K@#+,K_IEVT6K>4EV-F]$".O'WPPD
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M2XL6L:.!0N6N!K$;?EZF:@7$!4D?+;FS4Y;E,#6Z/OZ*R!)R%P=0VQ!:A*W
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M+RTD'.&)R>D4#?H6PB&$CF)4$C24)&68EI7@\P\"OFG MTCS($3'BF\E+R]
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M0'+BNZYC.T@CCJ*W"H@[$=8W2A_1-2$VGTX1.^%KNBB;B :RO[CZ1"N\L"L
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M;?<W[NU]2S;,K*C8M?LZ?(/L;P4CV@$,IP0M8;/.C![N4UTE_E76MW.5C-W
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M2S./$U*4PE$&0,$7"N HP*2B3/#5EG4(+694/*\"OH$4XA9_K7RORI2%-H0
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M$[PJ\@\6/\%K@3^?3B!=[HT,1@*RFROW'\O&$!MLH]!>%!\%%Z"J3 <HE E
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M[GUS!"1OS)/EEG^XC^!^+;KJXZG1L0\?)K.N/1^1,#0N9?MWPDT*'37S>16
M+&KS])[.3XV5%\IT7?5>_IFI_ M;W16>&GOI]2,=I'9BYYE0#V_J$75?C4<'
M&HMFSNF/6YO(^K)ULK&I)?GGOKVS^D!XM\K5BCG83CNZ^?3IL*&*H]Y45^WD
M)ZE/@C4GBGRS#KCL^_R9".=A1LQ8(N,= %9BFL=F?G<RXI$UH/R.>A!_E>6=
MT^D@C/SFMOWK2E=%7.ED_F+9QSML6.%).UE4P_V=,7>1YW[$%%\X!V^G:!.<
MH.U/\>@V+XCSY2UBD]&)NIOG4+D;]A7W'19-EK_/NQO5D#WV]QIU]8(2J="%
MJ2L"H&40)\)*<XF[""3($: RN7JQC,1"Q !]RX\L?SO 1\0UU0U0.&_6_ 2(
M[$"J,RML2V8:KI-3)/;%X]C)%:.2VH:\P;<66:^^O]J)MI+8*U!.E2@#[!F6
MV)D0(6UPP@+S(C_H)KC,3YCHLH#S:V4F S3LYL)5-'!//5%CL#;(#]/+20B8
M\ >JBOC.5\7' G\>6&SN/ON_4?>F84VDW]M@NE40$2.R@Q W1'85$,&0J(@(
M"%$04!#22B.;2*,@$4*B['M:$% 0H@)&9(D* 45(("QI14!V 25;*[)$JA1"
M2;:)O[G>ZYV9_SO7_#_,?)@/E0])JNK4<\YSG_NN>NJ<'^XEHWF%L2;X,1>.
MXKI@L5U)\(2/6W;7T(#FA?SQ=Y2[K/V\U@,(1#[Q$@_0\0A&-CT.*^!4_5W-
M>?67NO'IZI1JGX-/7T[67306G2O.PF-R^YYI?[P><O3^]U=<JPT'#_XQIK:S
M+H-Y"1O8R?NQ<>V^Z/8O!Y]<NO^R"AG@6K@](\?PJ':HD2L!Y&%ORF!Z-'=%
M;D\=!4KG+E/D*@$7THV&VV@IUR,VSAFL'V]<&JJ=7F-1:C@WKWG]>>UP,2UK
MVJWHQ_;M?WRWV-OJ(C(5>S0,M1I2Q Y@5*KY)4P2BS.0>VG<?%EUZVIL__/8
MNNGP^/U3$Y]>%=;;Z$WA6G]$64>O/ZL_A)Y8#4!+-SB+E.=UB3V?_)TDCZ5:
M$268A=G*T,!MT)NG7_VF(ORBDJW16]PB(RO#5[0FSVA=GWQ<9B/X3"^+CGW4
M6^UTH?K5\.+D).BGVH>+D&ZHE@NZ19"4B3?G_"JO-<967":KX<9Y:75 ''/2
M@9SA]BD"A1K,?U,?,W\J<@R]4%-M8VX_?AP\246D+L_/ST?HJYUEO+Z>B@/)
MSH'JK%HFKE91S[LNFQF,N^QA*8H[E&:ZZ?N"PUJP,<*KE_/L7EK4S0[N; CN
MGR&OOK]PN 37LPD>-(]:VVR\8\K9$Z>Z@'^-N37\FM,/ON.;8DQJ@\-?G UO
MI&21FYE_[#N8-7KUG1798HVJWY4RU_'<@Y(.KB7\"!>M#$4QA5=US,2V#[ZN
MJM3F[?\^]74UD4[>F(<Y]&_>IW.O["X9M<4H?PQ21(IF&/P^/$M+<$^T=^#)
MK.XQHC9R[VI1F^@8KEB(&3)7%/Y=)!)F 'C?85P!]T_LU^W.&8T9C?/CKZ9[
M+V3'?5_<RC% <(W$ZD'"79  1)R&7 "R, >ZP4=GV#NGB)WXB;Z=35HK/C_"
MZ'I 4?.U![ARH73Q5&/CL\9B1SJMQ/TX,^'NHF"IO:5W*G?WL39T'?=J/'32
MT$3[/$,#HU3,#3V5$I3>Y5JNIYA2D=;Q/J=JX7.O1Z')V?!]]Z?%F6_>$E;:
M?7J8M/C"FHMA&-4LJD^=BVN=C<F'K&43GLD;PUWW*9YUX?FG?5<J1SS]$FO7
M.Z 'QH=RQN72H)L(F<4M1',')A*$I9)*^CJQ,T 4;)5K!HWR-#R&@U#&E? [
M?2?I#3S&%C^<+S,^MHCV%$<\=6P8[U8;H.=NU#5F?_SYH_,8Y6/%&\^K_OA2
M((.M^R"YRQ)8<1>5<;V\."9"D?!V>K_D-G(=V, D:EO&8E3/1]BR=5K=0 H+
MO0'O!+PZ>HX5$OL8YR7=G'N:IG_<0?.3("KFD^LWX9R*A77LLO&?.J.AWM4;
MF]4+$>$4G<'[)C\&J]*I]J<K]B2$><=$GPD?3JHL._NJY<J50B<#ER]G][BJ
M%NTNG'D[[)53T6LW\OCQEZI_'E!<_[IS7Z!T]8=AGYX4'+R=\V_0. V?":H)
M?TA(4G7Q!>@&H,>#LV2P=+HN5 T>'W:E [YIEC8^A;'*Z,T-+&YIMB!\2"]W
MS5%2M]?V;*:@?BX^3KQKO[5;I3+#WM*J;!S-J9#!GBVFUQ),V>'DQN+.)ZQV
M$5'[(][O>3.C=<2&_)LC!YW18LG$J-EF6.LIFY:%]RXP5,5.%3C7=S;9!YX_
M#7PRV"U6Q5CCW=:0[@0=Y#R_HK%=9RB_TS?ZOI'OAZ/1^92W?'OVJYS2K%C=
M)'R_B7^K^]I_R^*-N]_N#QS3\LQQJ'"_-@U2%M_LFB2U102RK\R(\T*IJ=OD
ML'N7P+3"*P,K A-V8W-G;U02RA!<("LW#B "/X9?C[^(/T8Z-H9TMDR.=7,K
MLW?P.C9>?/0]S=UWP;X[-2<W.$J?6>16XT.N ^ "4(00>SR#XI[B3/FLI.4$
M>#9B(Y(H9Q/+PWU$RA$>-AVQ@>:?"^=A,FHK1Q8N#VJU3U:5":B9C?/)FVJJ
M]$S?U%_VG!Z[X5E5_$4UI\I,8?^^5)>A^U6I]7?"AUV]P^2 :#R<[7G?LD]]
M.-_E<7=6YYO*FL$KIW-XA7Z1;ZU:<O)GQO:'#R;8QC2AZ)5&VO]N_%N!N!_U
M4M%@F8G?"Y7*>1T#WKH3].(69T3^IY<TJ\2&DM&ZDQ>QOO[ABW%K-V @I'K2
M<$&S&7NIY?"?J9^;2>\R:C,V7JE-Z)3!Y@:HX9_O!"NYJN4\/.AZZKZ1EA+S
MKX*<BCUOC(^?OA.LXU0Y[&Y=<FDP_\Z91\,Y^7?\PAZ7N%L/RS_#'LM_649O
MHN^2<U'#1?IVPEL9K E[:[&4ZSTN. 3>EL$X3P,1$K)T3[A6^1XY^8KB+G8N
M0GO(/7T87DDHW:@$O<GMJ7_X@:828I(9WCNN,E1W:=*L26H\+#9->#);OFT4
MX?.#K" _/.(;82OAHPRF0;>?E<%^_]6K*U.Z!1H5>40@:,:2AW1#J(&7@FAD
MM ?XLK J2]B-8G=YB//;XWV3KHC7\(2OP-&B&MYB*OW@6&L<-YI3I]P=N/.]
M#55Y?B6>D)OXA%!&&"#3I*F@(Q<AT *+>3&!NI SASHQ)<R0U$LW0Y2N>$;&
M$'I3F%114B@UPTVUZZ9WD53G[>_;)]:G1Q ?0/91ZO/1)_N"'AU?44UL"C47
M_[!DHJ$]O@LAX'A'BQ9)JHG' W%92&.>.9:GF+XD<?(Z-Q2<'0CY<[Y F?PZ
M-9_AV#Y+]U%K<W]'B)#.,O(86ZBU6(:O5P=W%VH(\V9QIP8ZL-E$P)DX1>+#
M%X@B&T(_496 D':@Y3-:A);V(-09%[%KY\F;I2;BOT:DNOA]+2\!HMS+Z_&'
M)/6M-ISG@$U=K R6W4))$QO7AA;_XAS;V,K+!5RB!LZ19]"@/KUKT'F0K$[D
MY).W2O>(X^66F9N>D) )ZYWYU(EBWLK"#_XBB;%1:H:_V@86"_0X41F(%SY4
M -Y>#H,^B^S"#32'Z&JH:H#%B_R6#=I)K<.F34?QWK505#M*$:C*NU75=Z!Z
M=ZDH$6@0YD$(L.6["IIKV47>"*W.S7 Q<CD#&*5;&JS:0MX@#8FQ9))U2E,S
M_W"WZ@%PMEW-NO;62=_=$G??^-R49=1\@W$(92"=9M!66.2<J[C7PCC)WW@]
M_N('RTY&(SH3?<E2"^\+(GIPK5JBP^&Z;/E89,:A-Z!,\$1 L5.9M"D<M7Z<
M\!L>">:5U4_J!7CQ%$B@47>+45KLP);90(-GWL-+$1QX/WNJ0*ID([HJ_8C:
M!#2B-Q/T"4R_].Z$@8DX#J6]!JN'H_#8/:3-N!"A)QC5P<[37<R3[L ?E9!C
M7.AKD'3#,6(86P'#R34]-;X<:=6!,H'.3O_>"$R,X2,?G7\3?4T8DH?FE+$;
MB21D; U.^4P+M)O10".)U4L&A/.#R$OEA\#/E&ZB*G2(!T]&7JL0^T'GGD(*
M\+1BE#XPD]%J7H][*\%K\%[#,^-II&SKL,M7:.:'.EIRR[IKI<-@@G1#';!C
MGL/N8B,(_\A@F^GZ>#R([6!,^@K=(&40X9P5211I.=,D%<3PJ%_]%20#&4L"
MUVD5%$(M]'O8)#LO"JG,ARM/SP=N +4R\/K$L+":\%-A)95*2V@QTE\H%T(I
MPW(J0)3!5%0Y&,B5\2=;0:[<% 6_!<V$'Q^6JZ]DL681&RB;OS:_T\/^P&O%
MSOF:>7TCWM9 G1&;&NIO\RMC@0;@G[JHYEB5Y)M_$0$,*071!%_X ; ZL T,
MUIB$O$A7DPX@%*1Z8E7H"!^=2M\!]C_G+V8-XI&T5\ RHRLJ@[ 51-P2[^0N
MIL&?X PZ.\:L('CGY'B7=WJW<-ILI ),*3'LR8S$RN-7GBA.3>//2NX00RW7
M^,M@S'J2D +=4A0D<]BI#$T;MT4-9^Z LMA(4HV.*,5.>OY@QB\(RQ&O1KJ8
MEG#(S\'3#;,IG/HXXOHDK3PS\4!!S9RMKPQ626S "-)%UH0/\>@\Y!&1M3@0
M:.[N0W!9N1;XW_BF<JK9ME)8B2N:9@YXI^VU43ZD8[E4YNO*:!P1HWGN-A;B
M0SP'>VS35[_'#Z_DGR!OA2R%[R0OI%;B^$1_#F:A F#W()X1TZ2'H&0A#L1V
M2Z[Q@WN205'@&%Z5[T9*9:C1+7#*W+U XD!*,(0!IG@!>8S*0+]Y*:H!9&2W
MVG(&-N.HG:MFQHD/9N/:#=1$)PF=[*9Q0208U#Z]!>K@+GY(XW-FF*0I?ZZE
MP!8H$%8,8GDJ5($W,,^%=["S)IV[(I4YC'3\AFE8P.^=O$L-56&>^$-C*$M_
M?!"ILP"']A^G?B/HLR.N34U2/K*?43O(),8Z:^RD22>_YS9 ='L)E8E\\']!
M DXTD,ZSS"5L=T2DHO;BGA(U.BIQ]40=L2%T>G<IS_SWL"E,J<A@RG_89L^=
M0,.^Y.30O_#FOWI7R-T7#S&89%UQ9(5TA A_"+ 6!-&/6&"!YWA!%TH3I3PL
M=N;](U:2A]Z6C^=PI4Y#L2J^'24#.0BI:IMMSZ3&XVJN6UN@72UO=/+LG]X3
M49 Q:V$KN2$&37LM'2K_'7,S+M!B1&KP >KN?]&25P$JGJ"_?LX -I5RKE7!
M$>&H@^D+6O$90&YQFA&XMF2C)>_$DO ]FA=\&($[C=4/(P*G$!_8_E #4, A
MW 9_=,23NAAY]'7OZ3OQ9N\C];R+IKI16J!/9BPO2FD_=#., >2%V<OA66Q+
MF0O<!A2GV/3YGP2C,F,"+#U'E@*V"/M[>&=7$1,%PG')'1GL<A^Z:Y*ZT RR
MVMEZC0,*CMQS>*\G.-W51-=>1Y3U\&(L9I,_.\"A<;.A8+F\E/#C["[2#8I[
MF,/CJG55'R-AL$6ZH0PF1P/1(1ELPA.TE#X9R![]N4]TYB;!6NPY$.FS,9'X
MS/H=X>7!Q2Q)"%0L@^V4"^Q%&2S8K8NQ6H&R]/UW7.#Z6GI [.&UXG^VR1/V
MYF>CN=E?#FW'X70K["/H#T%9$-;I9C8A6R\]"CCY\XJ9#/;70QGLPA:W4>Z<
M(?1!8I#&^E7E"W\:J.BL,Q+&Y: VAF'AJ-T3YUV1'Y:)<!SYZ*C8KB9L[&M>
M?9518Y(;)?CV]C+KHJ"FZWZ0/XN E*,M:8)X'B0Q/_E%J4"D'@;-MBL"K045
M]2CKU?3J^>O']10)=?%IJT/?E/]L3>Y<W>Z<O_?1H7N\DRY/@\69,E@X)L/>
MJ*MO#2^M-.CAU%P)(JD6N<XBOX80DQMQ^-FTI\-IPIA%2<BK[Y;-'='KL[Z,
M:69ZG^GYJ)7$B$#KB.VR>R:/2;< MGFMIGRL9CC*N@T@YRSUYCJ[#+<Z/NF_
M,O-Z6&M +\AR*ZSSFD;[ITCUP58OG4!,PUO<(3MFR]6RC;M#4BJ0-9K?[Q^W
M2*)D5+OM[=]WKDC!V_14=7I,P/E+6HCTU6[[E^=&O?>\--+'(R_%)M7U%[J^
M]!O*VU\\-COX9,;5ZF&2G$]6;/B[>N#-T7J#IY0]WJ>B2ZX7H-(E^>A0:A[J
M($0&DSU <D;]@N"!'#D1B"DH-N:0RNZQWFX7K714+T\Y(>RRIM2H->T2XZSA
MRP*/ D&=3=NSYOS-5E)-<33TC-UP#*'!X)J]?@V1^%&3_%\WTY!>O N46:7J
M\&D]VF#KOI"(!^>KZ&4:+\ZVU2J'[TB:UOI>_VT0\:[M91C=9A@=3C4(96NA
M=HD#=1&I5UH=05MF/#7%)M>ACJ9M'7G(?;1NZ?6%W85K_9(##+O+Z 6A?Y>6
MWN/=SLFU_O.@-Q50$U:"U'8'4S]@[!Z7O1YB,R=[J!=XP<!,[N5+;2^&\-Z/
M=ZE.0 6N"3<NYD^=/KNPH.G9/=*6>O^]WHV*L#]7ST<I^E:;$4SAM_]\7Q8*
M5/G=B+6_>\*S6D).[0N;T=;(*-+IL:8_SVX_DWO^F+Y9S(M5;Q,GCW+]X>^A
M(3&\9TOA7[0GCB.FY&+K=)UQY[S&LZL=%P/VC+XN;JC(R$ZU,[XPMOM4=N/<
M-4+UN8^0'C>DBS0USC.HJ(E ;4FSU,/O'(Q">G'U]P^< 8\G1_*PBE""[VCI
M"9)GTO>Q3S0'8I>OENVX>91)#\]N3,?"S%S#KL_9!;3M2)4TMT97X7Z< 3&D
M.K$&4'!:SO!)RZ9NZT"S0(.1F(<AEU8&.T(TR>;]Y+#'5:73=2G.I])=&]I:
M4P)^0F) KF!B07@GZ@!4Q>L+<03B\A:D5N&:)90\_$Y>GT4$0R6 '5:L]N9A
M[X7+S0K^QP;_*#2KVW'O6Y';H0C#5VKG)Z;.=W_"10F94&$P:"47C%N6([68
M!KL16QHC30^#6LFQV<JOD#NLRU3-'[X77#9+G7+;//R'VY,[GUQPQ49>(Y27
MN?4A66>1U< 5XE'OCP_3>ICG"$ZZ;^F6"MQ[M4^1UN5GV^J5>,]&?KZH[2_S
M*XRVZ@6MP[E1*<*\JP'/^K^O/G]<8=*XZ[GVBCLS-]C,=NQSB0Q&$Q7R71OK
MLIG]FU,-,ZH.^DA6+$U0;T%R#@VSGC"._:W5/Z+J*X KX%&8F-0QNBWIU+ M
M0H!0FX^[[E=?L7;3H$U:@TI]ZH7'4Q^W^38WT2+B<I,/HLQYBUOP1^6JT0OT
MEVK\V1S!=R=V2W<!_276HD/^\S_53K]J*N*9GOC&*Y]6*KP\^F]KT6XWT]"9
ME]<S@\(J?NC!)XD]!>)+#.A3_5<#-1"=8=%8-1A3IW7^>?E,IU3G>5+$H38K
MD<+'\\JE;G4F;BZ!8PO](6'+^L?G?,.^_1N_9(J8)'=U\OZ!NJ,X4;!)7&:K
MI67ZI<;&X<7MP]\,7XU81%G@CQPR_-!*W'S>^;I0C:V7T_M'YA7NW\\H;KOZ
M]B^[(&O6Y-PY>#HXMJW^T"8 RHE$)EXF(!3]ROP\[P.XL]Z46\+[SRE[+OQ\
M" \QB<Y$$K0VSUP.W)%UXW57Q]&44;\SAFEI!G6A'OM/>\^]=%-]4_MH[ERS
MH454 O0)5.O1C>JFINO:)HD#BXGJ,9;I4@,HC@_?/*LZ&U='Y*MX_MPYTCBQ
M3;.YZ/EY_9.U*YK/VPO\!JX+>]4M=8[/HM!X3] H54SD!"@Z@WIS*#/(GWOC
M\C);XTU$R*&/4':W;F3&6+U3C;_RL0L7-.K:'7]+&ZU/.;+V;_OQ6VSIX&01
M@T]2P GYW/'.7@?_CF9[(25"H8P2..$WM]KT6JB$IL4VJ P-)"96G3];^NE
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M$!SDU 6!- WCB@3^'+1@E&^99G!P&,VI9"B)HSE1'Z[QX!V+BKBYZ4Z^LZ
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M!%045) >(B+21$0%)$)('J4)?504'D&(2-_WH @)38!'45"Z2!!"$ANZR(I
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M'G&>365(L_V*)2A\P]"*WRHJQIFR!^ZW0(7;([P_B95!7?9SL1HHRXG&\&O
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M-1)PS<P@6VZ_<\]5#R>,@>/J3W?@,8TU_9%HT=M#G+'L[72(R\R2RXS[B=<
M]=#; IN'9MWQ\3B3@C6(WV?F%Q5,>9^'=H,R?T7EU%M^Z=Y4S:EC!MU=VV]B
MR%O%&N"CL ")2ED/VKF1NMZJ6VR-)!$;WKQ:BL(^V- P]!CC;V=G+&^5?/JD
M!U0//H'_:4G-R*0V$KBR/E/!^AUT]\H&\HY"";A'L#)*.; MPJ.MO+8/H\^
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M_Q7H3>F-A[N?]R9HGI!Y7;,&B?UK5C7^1]NUYKHL_=.%*8F&^<VO=;Z?=C^
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M)PG+'0,X+L2O#%+JTJ\<21/8#I;<_X-,4PB14M%)*:W% ;06&0-+,EI,!71
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MJ^EY_;68MV=KUC:],!G^_YV5<&'XPDV:AL100%M%:!(BYI7*"7Y=!8BA%J3
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M3OAY;<)V;EB")9N.=1O2S3D"XP" H^/6+E3D",P#$.V$J%WFRI$8!T*^IQI
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MDT\N6Q1> (7')@B;>=U.Y;&1Z_'QXJ3FG5Q"9":0XT43BA2%J1 *F^F;B$P
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M!.@.38%4\R1Z6?">Q+#H"(/TLQE%T]-!@%<19W3X;O_X:%^P^6E,>/\< ,&
MP[X65SR(!,PC\<TH?6K44J/G,! &NY\A%+'*Q@M/=R+$!%(41C,480\&]20J
MD+8EGA@Y:,XYL]OI[4(,=MZ=JHVE(^M"K/N(>'_-2.!S1W/Y/<;12RWQRLB[
M$',,V>PJ(,_UC)>C:DNH6_H$0_RWA.0L],\AP[RA"46,-RD_K930AD5K-HSG
M<TA?.%#X*<13WKW#Z,SS2!Q&/(!-2( ]C"R,:LFF-;'1DX!01"$ZM[-J&4E;
MXES@)QS!X(PQ&U]7>+J]X=!@I'8W.N]0P >:SSUG]/) 8<B@9^?=](2M6FHH
M JXO,BG$F[#K0CJZM@2[YHGC'#W E<60VWBV+0&X6G,<2>_(/<^8R.'+TUD;
M'V"D;<]?/3+T/>:-7"Y%2Q:>J4BP6]?9L@OMP)5:M?L 'X/6E,B8=1<-;,75
M$G82&2RE*J7I+DK8VDI+V'7$L!2PBKSCZ%''C'KJ'3AR2T$M..PN9[Y $<0!
M^P*IF.PL40LYM,JRM0[BS9 ?!^AV>L:--O1Q$(L&[I$74QQQ^UVNO"#VD7]%
MR5QT@CB1Z'9Z"6G(K<PFB-[/^)0SE;&Z4[7?8OO&N(*8RA+1#8:/.)!R_88@
MBRGR;\,[(2OEHDBHZBO>B/MN8VCM3MR4;?O8Y2+D^4L:->MC9.32OM ;<;2^
MM.7DG20&M7M&!77[MOQ#,!<UDSB2E6S>_^I;U,1D)R+S2'"Y0M3#3$2P5A30
ML.PN7:OO12Q8M&_]?#8V)JS) -2SZ#KCK&UC>T8=QE41S;W9[4+F/,^0^I<L
MPG,A%_<3\7R1RWJ:!-9:[-M74Y,X-^Q;5MPZ4B(U(>\A2SX8KT.1FG%/DGS,
MKGB(?/4T#35KU$3[ZJ:>$4TH]I"HM_,Y!0ES$NH]:=MFZ5Z4CN>7S?R^#9_V
M<1>S1<I=8 R#,2<1BV8/%,.@ 6[5K'8P9:YM^UJ\NJJ--IAO5#'8%)5CX<6!
M[%4W_/<-D1'G'/(99R:T:*!BY3DEQY%X,MU"< "&8K]!+$S)?RQ=HVY+C,(:
M=)DXAUR&]0*BE(<S#_D($S\Q/B'S13P$*2>0LDJES>0-B+<A8R#V$1"Z"6^V
M)T/N%IA"]BBW#,1L^ 3A8B1P'Z$@8MDGLB?(7I!^\"V9&XSYM)>+FO$.X",*
M9(O?TN<*CXUZD56LP^I%3+XM2I9#_8QZ@%">WYX.#C(VD'H;6*L[+](G1DS,
ML@6;(>:X9O132N8F0Z5&(262YNW%&QF 9X2?9I$4KI%]U:%^<_WGP[<S?REZ
M&1/E#89X2S/N:R[0$@5D(?IGYCKO$5V*H%=B8<&G/AL[* [[@:*92JUCMO68
MF%"T@-B_#EE,TYU'FO&A/FD'T%&O8T6GGTL8W$8S1%-!+U<BA4*5#M5$8X?+
MVUYQJ=;9)83&]&41$:G7>J):"9&1R ZC=_W&F6JM70(IV^EBSD%<"?$:FY?C
MXI"5<PL?E2.@[-F>^D:RGL$F\$7,M7F<YI_0&/EUU*G%I.]>IE>LV./JFZ;[
MI-.<4%F!)OC49]-WTED-6S.]=@4<SW5YL^=<%#Z%CC#O4#S(3Q&7PI>5HG$\
ME^9<H@N\Q'Q6ZZ?]3H/@%OSZ3D_MH-S:8"X%A[*=GCIO:MH5NO,Y4,[@,LTQ
M3H/4A_MV]GJ[J],AG:HN]:-<V;P"#O7)OCVX-18Z)5T"XLSWL5 9!A,YBQ[#
MA=@18,B1= 1]>V-K6"I4=@F=.U$Y#Y&?;:_BB5L2+1!/"Z;8PX9DUH:V[T*"
M-6;VAG )OER"P!.Y.K&SFK+OB&2K6P'(G:2NK80G[1D$4Z2J/+C@P+2C#EP6
MAK##K<?<O(Z^A@>-:GX>%;6\X;]WO[Q8.%!:MM9XU&2M$;S9X/QS5VNENB.H
M98J\M5/DE24@4_#*%+SY&L*8AW[D_]S/4FHJ2_B4UL,-OJ3DT;XRD+)"1"J5
M*?DPDO4=O+1(*&F'A?8N!:[D70^!J/'Y<QQB%B5;+BH!JR3L.X#90F9I 9=
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MA@X$CH8@;JNY*W#K2LY; &YFZ<!$ND/(;<S9/>BYO.>:L1CY?$I2<0+.3.+
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M**$F1^Z'3G%$:4HN_LA8I12IOZ$Z@O.^8"-&(""U)-#M"*2RJPCWL056&PQ
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M,1&\_*F@]K5A^HJN@!L06&O7;H4:NCNRP#A]A5;$#HBMM0C22?#O+"F>HGC
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MEJY<MEB%<#?,75U N&KN:@'+0/I8@OQ?)OCI35X<GRP*R,H?UHB5OQA]O>?
M4_[QZ_WHT,(=.KFF8RZ9\#30LK<TD^N%0*X7]U9N3S25ZY),4*ZM[=,=Y'IV
M \OU[&9T:,$R;2K7)9F@7%O;H3O(]>8:ENO-M95+#TWENB037%[MW6Y8[1VG
M61+&*$F6F9'B"PV2;B_;]E23 0BV-:C+\SE)(OU6,SL7'-1DBT6$&[(].P;
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M[PR*#PWR+PU6GQJLOV7[5:C6EEQ--S0:RM?NU*5N'P17KE6]\R><J5^M3YG
M"M>:\. O4%U7O9849[EC/,"E/"M_=B"Q0!<0F,>?F>"U"ARB0CD;#<R7WZS+
M"_-),W3:KE&<3IYEJXO<H8>;OE"1S;*92.X;36Q48>0I*Q:0!ZX.1I>'+]ZS
M5++5)B,+52$DDJV1!ZX4UDX-6YL4*XM_;6LG=V'R_9(@]B(M(M35OZ/&>*E>
M'5BQ#2DP7O"Q<Z/-I."<RT7HGOMB]MI4W(*"O>+N(CCG\C2T<K]\'?R<525"
M<<"X-Z2QO$_O5;65Q'J2O;(CV[]C5BTK"M.%>;M 2,->:W<3G7.9/2;X-VH=
M"&G8J^]NHG,NM:GU&:N(_P=$9@<='&Y+O_DRU;,[42DD?UDXX+M/L?_]=8UK
M=D*9",[SCD3G>94Q!]5!!_FHMD_NSID(47"*8OJ/E%VS6#.B<#BGV-WV^5N=
MS&1-9Z)\QJ8TC#/G:(V@!8_*&HC.SG%8 X7X">O9-8%/?QT[)XI"[>O8F3BW
M,P:.DZ=ZW0'H:)G7':NNV4]0:UISS<4@ZPV.20,<N,U'#B0+"K& J09=6GL%
M/J)\7!3PW3+IG2NU_J,#2Q5X=K$HF["F< QGRSDL<S[ILOX4IHNKV(^R@-6U
M*?Q<]J+@</PM?RQ:Z#&^DWJ,JZ3/\E.#U;?*OR0#]C76?OF]BB^YEE,WLKAX
MIK9HF*!;$OJL= ][Z ''%0DEPRQ-4B]F!)_$0=F>F9NM9?9>)+,E08."(O:K
M@J8-:2:#"ED#^G^#"F'-).Q0R#?_;7*2I5-,PC]1\)4]'5?!(K?Z-Q#+,SH4
MW/NNOF<['K #7Z>+.F<[)NGN^EUG(@[=JF?#;%X]:#H?T]#,O#CXT<G''(B2
M=*I!*L<^6O!RR#/1NA*TJX.UX\?L1("ZU YM>BA#R*584]\5T>5H5Z^5U6A1
MMPTBAI+'9?F-+87,NEPFL K/NK<V%80>?F!UA%:-C:?F6X1HDVEPV>\4)-JT
MP42J-+<5\K0"U!;;VF.F*E!=XDQ<;QQH/?KP\P"UQ36$TX=.<0HE3\T#K4>6
MWM"Q@M,FUQ!.G[K$Z3Y\5H=IU9A:/#\/3%M<P\&<3G%B-2T:(+5N/CKXB8R)
M&M\@6IT:%!>L7H\Z6I7FHX.?R**H\0VBU:E-<1,V<:/6K4<'/Y%1L<TV"%6G
M9L5#DT7P8;T4_$16Q1;7($Z=FA474;/]JMJ>^H$_#UIUQN' 9[=Q"A0UL=BK
M[4>'/Y&%46<<!*SCF$5(4M1H.=SH,3K\B0P-'NL@;)W'+YK!MMEC=/@3V1P\
MUD'8.@YGC!NB5NTP.OR)[ \.YR!F78<VFF&VT6%T]!-9(1S.X?.LSL,<#5';
M[#(Z^HF,$2[O('+=ASP: ;?98W3T$]DC/-9!V.SEH&L5S=?Y')$R'6\6"I[;
MZ?*KHZ.7L!-?MZH'H%."D+*^C.2<FXQA.1Q7,KS+-&Y#6@L3L%=@[<($(V0O
M2I<KMQ/LZ'*=@+TN:Q<FZ&G9N.[$KX!17GNY8?=@V*M9*Z(K]W,^U.[GY&.=
MUBM?+&_1#%;C.76?9E^W?E^W?E^WWN:E%NY+SYSKLIO-G+U(TKJ>/9_/GM@^
M?7KVW-9]#UM/FHM.+/=:M--#\8Y>UK"E:4;O63S\P ]3G"7487SX06E;Y";H
M5<Q>8*-6)J-,&.I4[N_4;0Q-2P%N*0<SV]'^U9L=7[W16V9Y_^J-J^)T<A/J
MYZLW3=]F<?MI%F,EV"5B?6 QH^'X*@Y8A?C,B^!E&VCZ(I=PH5BZ+CO>%+)O
M83K-*WBQ*.8TG#_@"VH9",KY\1B4#6)^6Q!C(,!*31ZVMQ$;,+JZ'74$M5%W
MAZXM3QX[@SCU)(X-IZ7QRY4[S!LLYP22>>L,PU8S[#PDR*=#B6R&S3;F;^7M
MC@/ !!Q<UIS#Q.Y@WN!X.!Z'/B)+4A)98059M]&!A6<+-4P)-;Y =%H_> BA
M@S-2TI*(\:@U'!V\[R<" ">@S-]W('.."DC%#_89'9JN,:H/"0E3H"UV9 24
M%I@LZS=8>/NS,TBJ/$&(O-.=_/J%W&8DF418<FNJUF[TX;B7L@<8 8VE8\T"
M_Z>7X/C>^[% 8KVOM1M][*=Y"C ""?RC[@LPY^1+Z$\]%/T#1Q'^X<%%P5ES
MH/7H4S\-(2$[$ 2?=-L_MRAE66'>GW]BB4'*:3GZU$^]!UD!Q:Y;\Z_I-A.@
MY!+1OY_$P>=L<4O"62:V@<2=1L?]W'%5N()P.;;W2O=/^#Q/-_E".I[NL?8N
MX/[IGOW3/1;R8WKS=$\GL>!#T^Z-\BLP0HK!":+;C_E"%(5;;S@Z,FU,-Y(M
M1#"HMZW-Y9T7'Y:^-!Q7-D>Q*0 T?[&[OE \=2#?VX*QRB>U3F]P[*U_4UUZ
MP8FV3&EL.I =TT","]Z-)?=,!%OPNFQ<=*@"9NN8S^81+E:C"4$Y1>+2 5![
M:P9'VPF&E9F";9*V658 &&P_B2(DF$BLV5:KT3M+I8@T")[+"NB_:C[X;[ "
MGB,2/N77&J_B)"49X_ N3+Z+S15QKQ=KM:@(BW-081_;,[H'$*JS;&V7N<+B
M7G;,$B7!0UC!S+MDBN@'RV4C0S.@CCX\7+EN+S,@:TU''RR5*U*:.%B%>'!!
M?*<WA[L)(MEC@O[(J+9=L,)6\FN[8(<7N\E)1,0Y%W8(3.E-2KB+I4?4)-*6
M8N/NCJ83'I?W,DT0NKJ';=(KW<=XS4<?+3T"+I\O0G"JU(.KWY'1"TGWJ9?F
M>GGO(^J5AAB^D 0T?7D;%\PK!-HGHY"5)'V-DSGRPW&( M&=%4%S\Y>,Q'+%
M*D0;VI@,@>#D1J0#*(?NLBYIO,0$^5X"[SD5?C;;CHX_FD^&DL^!.@P\LB$0
MCC_:<YORD@I)DE&6,A+&DUOJ).*@J#%WAZ@''_HI"O)F^3K]F>!$Y%6U&H^J
MJ*7CZ>[*9>TB"$A1W*V* XEI676P+%KXY(41V^CI[/A,^S8NY;O[%U^BJG4K
M*D@9W2WT!?%;UKO,F4NNXF)&RA8T_1_;JV #*8%&9E^UKU)+N)A_W>E>[5-[
MS5.6$6@PV]([RMX,Q[F]<.;-P]2+5K8$(D\HH*OV999F!#&CPXM]0=W3QD.]
M0+UI*P/PI-_J>E0KE5R7T",P 7ZGMB@*3N+@XIDZ-_2?#YC]JE(F^AO*WYP(
M3IX0\2;H#C'@Z'Q9GB)E7O2 R.Q LI Y0>,+U&3GA M-$6NYGKON$8TEM%%]
MO;O]?3>Z7NI4L"U0Y[*%6DLE_P\3 )WK=XSO+ORD^D?VBJD@'=UG]E#U""\D
MOWM1QLYVUKD@/#W(BRSP6[\D0.5LFCF::CK_5;:B%[TMJ"S1QYISH_7YID5@
MY"KV":*-SU'Q_[D20BG71C[^DK3%N-3 R*IC<?ZFN_Y+4@H51D$<>QLBKUB\
M70<I:Y_Z:;1G=QF!BN=N=!Q, -ID%:T. SIRK;72\3.J;!<"!/796M2]<WO
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M(0I0\]'A!_=D+B867/H_Z,XO1"R?*/+B(#EC[RT0]GYXF&8I$HI:UFWTWG3
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ML5:;C7H@6(AH4*K67.=_($KD](S.OB&9>''X9QYZ6?\VW_$_$\HYK/?J8_0
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M/*O^Y@W[&UX)Y5_\RL9&O,%)?A8'67:[>LC3Y6^+URBKOL.-_+=O+.1_Z!O
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M;6Z=C?31=RY2 :HBJSFL9"!:;*:,YJYSD,8#LM-VA3UE(94 5J0AC4$GJ)7
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M"C$XL]36\VQ\KJ-)6R@7=3DWU8%M3TME<MZ)8@&N3YCV*WCE3'36J)JX=9Q
M1[<,?SI_]_3>\L!'5/!ST*,"+C_@Z4M[IXDU1.%Q:":&WCVA]TX/"/EGWST-
M(4DC[9$A?<@:>E2B4+G1PZ<DA@=:/'Y)AS&CI>"5' )P+3]J:;@4Z4-4LH0*
MSLV4AX\W+ HPT!Z[2(2<,4()L&:!( &CY56PA#QS'V\0%V1'*K.?J'PZ8W.8
M'>,D?]A,V^XZ:7<G*T;(S>F*4A0&)8SXA"W03V>HJS$I22;(AUWF4WP,GF+<
M,UDEY#83M@Q@-PUV6\([3[2P!-=1":%?N!@@0EQ'";YB)\4F^UJ"7H@A )62
MHY:"1Y ^- U)F"CBLJ[O )VG2Y[(_Y&6V#-(_-G5[1\9J.KJ3_LW[VVN "0<
MP98B_'UDQPV\H!\.V<<OXV M@=_[W5432V%5;=SY$40CRQ )+]16,H@)^6KF
M<YPM2<1?7M#9T1%SWN@2D$+;MV1@44 $IF9"2]:38[_'ZRC+B_CX>L31N#&%
MO&O7KX7='PNDPB!(8X-0.5JTE5"MY8E'Q?O;]YA=7=88VA5SS1H9R#Y9VC*@
M."(!IJ1&^1IZ(>R)$?^Q"TB.2;PWDD*0=,T+!=0^-7IBH-@AQZ8D2"WNER./
M)$BRB#DP(TE$4>?+#0588>G1DP/%$P4X]9*DEO?+E(=G',=GZ68;)&:'(A-V
MS18UX#Y?1$E0C%'"4W*&:Z!2!0YM+EA.NG,Z3;(TMB7ODSP";!U_:F&P%.HC
MM&015T-,SQ.3[C")TI!.LXF)0X*D:_8HH/9YTQ,#Q1@Y-B57"G'$Y?V3Y"()
MK2A2R_DA2 ^FG!ZE$$!R=)&9J$&E?1+C,LJ605Q@N:1_)\NFI9%U31 EW#Y)
M!$%01%&A4Y*E4*@XPU6\$N:_<$#LZ-*2]$,6 :J<*K480*+TL9EHPN2]D.1L
M1T@'M7K$48NZHHD);,43E1P(HAC "9E!"O$.43R-0!<\E^!E%..;G21>2"[B
MBALJ<!4G^K^#X(("E)#FNDCBR.10(>BEY:M3@B2_"38R#R$7<\L .<@N"[HR
M@)@@!:9@0R.+F+ 71K $,B2(KY(0O_X[WBOM$N3<<D(!LTN*GA @5LB1*6A1
M"B,NC:BX%V*P][0#LG^(EH:A0A1T2PT5T"XW^E* R*& IF!'*8T>KLY\CB2/
MP>M52(D:K<J@5@-+E/)NR6* W>6,0A@0=?0(%0RB2JBKY9-(5\DR)=NT%>YP
MENZH ]R?I:%ZAF+0<DLJ*Q.ZU-*J "*8#4X%S3JJ)T5,"DK9]4M> &(E>&'<
M(@QI167EOZZC!+]3VB^5=<LN#=PNIR2"@)BD1J?@3REY4OT'8CKH-H%"FO<#
M3'WOGS3O;4GS'C1IWH\AS>.7% AI/@PP]8-_TGRP)<T'T*3Y,(HTM.&]^AK^
MU -Y3+_(@K.5DEXH(T*5$J81@T<7 9N)+,5K&@0Q%9\TX1.K6W)'TI<H6:JG
MS"IQ+X11@):RIB<+CSIR@";^U!/B2L^KKRDFY<9.4HGY\3)=D'(74\C (TD7
MF-&Y%-(^*7&79GD0_]]HJUV(RX6]T$,*6$J2CB0\JLC@F0A3Z""JY&-A7=*5
M'6A(KY+U?G=VVBR#51\QMW\$00(9(O%YIF+WI!!RW<R,HP0'"H_0_=E9(TM
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M\K:#6<45@VS!5SPRR8-@DR7(/J>X6G=QS17YNX@^LQFUD]NKIW@=(<<S8PG
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M,;*X&[ZH%\I6E2$J^6.@R@ U\_H:0!FG@&ED6K4M42L"8]QU1$?AD#\"4?R
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M(KC'P8?AEJ5\,(8U067M5?*"LRGB:K4% 6"QA:$6;-:4 F;&,1JZ*:XVJDH
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M$8B@D75*%!W<#DMD@G"<CP9=GQA4%%-9-MMNQ'TPY>*5+'F4OLJHEH!33@C
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MVZ0J(!AEC]-T_%;IHB )$2L A\4=P6MO)W&U<6';,/T&FX6.<]J9X ND4RG
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MNEKF(Z.R/):!(:M*/#A*X^ >\2E(@B('X"7&ZO139G&73#:!;K-4)0N&@0:
M0C1(+<[V@J?,1#7I83NNWCJY79WQ!(]\LF%Q9JQ2]'40KS=$=2POUP+#.6NH
MBB/[C)_9]Y-WVH2W^EJTW^ O_"?YEHJ5)K2UVD#4EM/WD_*//E^1*9<ATJ9J
M_0YO@BU%![OBBQLNY:S],;TKG4'+%=P%10K\M]^_??OV'249M_(3[K]2>5A)
MOX;ITEE3TF_MF!\+5)DV#S5#N1.2IZ@J$15%HH?B%;!M4+WH_(]%P<T>R?<^
M.#&6 4?9WH>U+NR&+,_\LMM$'MQ29=U0WM$96@"LIAV)7G%RFB$>>Z\(Z:D2
M7=53(2\-KK?S.@J>Z *6;_3L")$=AP\M %:#CT1O';=5-W+<%(6615E>VILR
MET(X/6-9^DD>/<7XCI3I+[A+.MMM=C&MKA=\SEZ_PDFHNB,QNB18##C4#.&(
MDI>'3E&K1%076?A]RH"J4!26I59W-#RR8J&L!,7P;:<&L;TM,2L:=Z%MW%^*
M(ER?1UNQ6=N0)C6(#6F)>50OA=R0HEN:P$$?5P,K\2L;>]EJ[&W=V)G*)?MQ
MQ;J=FNIT_79U%P=+OK.[6--_5$M&\=FBJ<H$1HW)#)*_;5OLLJ"0E\V69+3P
M:@>F.J'D5]>J#Z" ?:$YT2QD(1&(KU.GY<^ (H^"/L/M&<">8I5_S.1I'W^6
M02%U&,!5\M==O+_'ZRAC1Y?A'8E>@AS75<BSFMVNJ,>E9<K3^KC[]/&0<1:[
M!Y-V*SVDSFHD[)CZ;Q0+8J=\B-2(6/@6@]1B>H)SIIN6L(K[3)"87G1O/U2?
MX]M'P?49#1\^OO]W8OM@)W,>$;S,JXIVZ-5-'SX*GL]EM3N/'G) #:/!,WRX
M:YF*XM-_^2@X/IO9#CTY8)9+7[*_2MA=<Q:+K3K/D.11'%\4,!X>:H><6/Q]
M8Q:S5!=9W:REM"G*9ORA*S=,@KB\>+V)$LHA4FPCP67)QP(TOV#>ACR*)[K"
MCHLI%I8<Q!7-4; OIK1B&0I7?ID2Y=F^3AA62UL@5<1E9.U1A04N>CV=I]PD
MF)+K'!?_ODH.#M XO$A833V9/6*2_:) VE/+_Z!=.#B>R ZQ8JR#'2Q(8UT6
M=+8,-<2*)F9JM.)!_/A]=A*6T5IB,W-V/*8\9KM*\E01S7Y@4;"H<; =DK0\
M98'%LH,?0NJ.("-:;"=*WD\(X'))V!-<J^I9'/WJ5R\.JXFML K!?(42:\.P
M:B\ *T'3.=5MPI)&Q3C+Z(PWDB53'Z0/JR''@1<?I+4XC*-],4#+LC0VTX^\
MMW>1SAF'E;6ZMNW+@FU'!5!MFXE7B?UZ3%/$RA\MHG8.*0Q6XTY@B<876T5P
M_?&?P,3UG-&_B)9!S%]4KQ^'X6]_M7_YE"91GK*QI9%179XXM$18=)G*'&$:
M5FH7;]FC1@O1HE'OUZ;TMJ#/0$!*Z6T0A5=)MB-LZ7F7QM%R_XA?\]-8-ATW
MR,-J<SNPDA023 O5:NB70A$Q3<15O;25=%II:C ;)5BM-@"QD/6]\L^5+N+*
M4!KP)SHZI(2_Q\A3JK+,)XGJ\II.&%:#62#M-U2A4KC(6@E1+:_.4&+(XY?4
MOGUJ8?#MTT=JUSY4"US[/--A=$ +->+PVTC JFBEH-=*3,]K._%G3R46*=I)
M+PZKG:RP]MN)*R%Y:_EL)]6)I**=].*PVLD*:[^=2B7N]KIJ?KM3@@=T)HTP
MK":R0"IT)#I!@->-B@BCE!0O;9-M2CF#Z0PT6F*B6EU;Z,!J+7O \B"&,C<K
M^L@VTHH\WW6196.6A:*J5 !S#>W, F(S29 I9@W^*[?3[R]I7=C/XQIIB-6O
MAVHWBV-JX-I(/3?02L-O(]/,0-%&OF<&=$%F/S/0"<-J(0ND_09B2U/YHM5G
M^U2G3:9-.H4<K%;1@U2FF0*R]W:9$ARMDR+1RG)_\;I\IG#Q/9UP\ S3<<?N
MNF7LU& UU"#,_78KE<LL,K3=<*F.^-PL;PKP<\X59,]"C.UC6CX^<Q<0:8"9
ME1:L1AP"63B3HKJRJ&$ZYZZ>V=D6!?B[2S.\$>W48+7B(,S6T=] VO$:KX/X
M$N.,6Q,EZ\?TCH(J3E6O^4O@]"^%=K13@]6.@S#WVY$KLQ3)6=%L[%R*-N&V
M*(!/*N.J""\-R?<GS]HO ]Z1=(4S%EQ8F"W?L]6JP&I :[SRO=ME]PW$;4N7
M-ZR?L9#LMWFZR#*<9]73"9^32!*QI92$U4@FF,(XQ^51P!504B>SW3$=+TUR
M&N7+-$H4*[#.K["J7@:M7]VEC-<5U07KCGBW4=1P]V=852S%)@0@ED)>*[GS
M$ ];,BR?L3%J_1XO<?2"JRRUR@C$*0N'U< S6&9(V,V78_0K["\H<:I; ('V
M'@ IODBEZF3 ?F,7%TFR"^(;G-_C%YSLRCH(3_=EI>'PEMSCD(7+A8H44L.+
M@$6=T?B%$%9>$+]23HJBRK8-T=.^H@6[8D#H[T5Y/A-"L:OZCU]HS=!_IH_/
MZ2ZCTZOR+U@8P\7ONRC?5]%<"J<_IA!8S7^ !7T"_+7(.'#"L@Y\0(5B$P[G
M-=2T<Y="=3 JE8+56CJ(0C!I??&C$/;: I?XB>P"0CD542> $X%L[$##JLN-
M+@E62QYJAK!Y6I:'WGTX^?^[N[KFMFTL^E<PTYEM.^-DDG3WH;-/BNTDREJV
MQE8WT^E#!A8ABUN*4$'2MOKK%Q< *5( 2-!?N,E#D]0^%SS$N0#Q<7&ATWY@
M:H"M,X7UZOSPQ0E=)"[YAFCV78Y ]AL4,?/P.G-&3("9OEGK_6X/,3<>3>ZH
M2,YYKB,JM(--\Z(4JK+J_*20[%N/%NV%U!=X*"Y'><$WMA9QU?C:L8A+]T^'
MH9D9ARN<N?:>4#AWEI <COAN==X/W9VD>QZ="VWU$@BBI#!CJOBB*HM2]KRR
MF_S"X)9/EDSD:)7>L,ZMO\_@SH%/_MY\>MQK/\ZQKRW'[O@UWU,A=X8+H9K,
M/JNMNJ_Y&_5N%?=63'.=QNR%'3S\X=^;CX]^\V=U\QL]XDCS.I7<@*]'OJ[I
M"3Z;]7W+D1Q_U/._-]]_R,L_J_LWMV^'MX!OU.\_<+%BJ5JV.[W?IB): W@8
MD>^M)3RJ%IZU2:QJ9K BRS2W[[YU]%5Z:U[U#,TA\,G?F_^/>^UG=?BA$4]K
M.AO/NZ^'*_O:6]F%?UYUR38TS=69=IVHK:+9@HF-V]-?F@5"KX]4!58P\Z'3
MBMJ^2;D'NVZE+$%E]9047AE_5PV@:$]PCZ!__W&>_Y[/\I-%_DG^=?4CF&UH
M>:3,V3W=;#-V)%%O?__7[.TO)S_*)VXA[9^ZN'<-!+9<;>2MZ%)GC\X9V3$J
M9 FPN;N1M-;%D8I6*LWJ-DGH+F+&X,=IV>JF(C:J\2R^NT;UX"IP?E8"ORK]
M'Y7N(JCUA?$WUCB-8;EF205)ZYM\<OO.89(GK0I>J#^\QT8>7!(RIWSD:UB.
M9<HC%ZO]+D^K2'5"J%4H^4,5&_N$2F=4YL\+XX;A4K27HS?GGD)'3P+3X>Y/
M_^*&(99A*.7+@0RQ<[UTN?=D>?$!,4LQF-GE4(SH*5TZ_'O.:GMPB,48/)]]
MH$7T@]E=]OXCV1X<9BF&CF$?2A'[_'6'_55Z'Z)$ T,LQ"'' 1TD')$,$/8:
M),0>B%D*B^60&&" 1XY3F(R%R-$"(I;#9CD@AS*(*\=FFW$]DZ]SSOKT\"&1
M"3) TU*DP>^S[L9-&"7^PV_I<NW+#=7Y-:ZZ=W*STK"*UT3#(E?S9[IAQ=5,
MMD;?>-6!P5;A/H*.6E=0<O6:*'3<7D?V?I\_P**V]V-\B,!5\3YZ5N\B<>3S
M:Z*A4>O\DLLGE^=?6)K?4%%ZAT$>'*[Z[R=YJ()&D_/79&\058OWM+BE><+$
M>^IM 0X,+@W\!*VSP6UDW)#ZY9IE&<M]9QL.?H^KPMWD7 O<"A6UHF=B7HGB
M)N/>%0@+@:NR??0.JWLF2 .,>X!G35/XR%RL)E62EG"<)2U+[\IH/QR7%D%<
MK?,\Q@CVOY49:>R0Z&32CAA2WN-6_7BL2O61[9-*IU39&\;MQ9@^M!_4HOK
MN%0*8&IU<ZS.+8"I+=4O$M:2>M$X%1K3BO82H6I#Y^QN*L=^6R;_R,LZK;-'
MHCXP+H4"F%KY.=@=:=DT*:ZCRC/9;GF:E_"N^CB,=#H=-^.1:,@ ETR!;*U,
M&7LSG92\4.W*!!1%U4OE\%"<!I7R0I%I-,33D\=$66#1);R/^T8ZN+&]&[J>
MS<K78.Y/7LI_0U*ES+OT$FR)2[&QM \5?/?FW1N3_Z Q(F 5-R^)G!O\EV85
M9,L";J:Q6Z)Y<+@DZB=I90R1:'(+<)742REC@EJ_K<,]=LB]/F!57V!_8NZO
M5U5C+\J]R&-Q.<J+OO/3G^FI0Z_;1_?-J;74$"&)8:(]/(I#0XP0!*_K.V6:
M*V?\\;5#!KB<*)"MU>U OP^G5(QAZRZ>J!\"64$#%R?9$&2"^/C9B?8K@>.J
M(V#B\*$> ;QH?%H,477*HLYOH6H9,S&XFVA#<*GAY>?8;Y%(^?$0)/INHMN%
M1C4-C%H$,/4U#'+XR< 3:WB>AIV:V>-PJ=)/<B#0$/!XI%B$Q> N<,:>]'(<
M.JN!*OHV"XV&;B,1B^&@.12 F^$*B%[<L2SLS$8;B5@2!\W!LV5@@4@2<T ^
M2)0.%K,L+J+]PM0F>)2!04>H,ETL8F6<1 -.G2&3)ET%*].&8A;&P7/P"-H*
MERQ7Z7VH+!TH8EE</(=/I"&3!08AP<)TP9BE<3(-.:&&2QYU2BM0G2X6L3A.
MHB''U6)+<\66E4CA7L.YK*$U+=C0R;5!"UPRA=*U=FT:.U(;(CG2-A?L0Y4G
M+!FX6<"#PR5//TGKBH\:C>-*@1-6+$6J$WROZGLGW.E%_5!<>@SRM(["[0U4
M;K3Z]HUX23.[=\8,=6>]:%S:A% =N!0'2Q?6O=9GJ"/K0V.6R$UU\-XB%'W;
M\][C\711*4&/P^4D+_*N,2]'B=+MSZCXDZEZ8CDKBJ%^OQ^.RV&"N%I;N\J(
M-%98NGY6,G%5TK__YMX=1 <&ER!^@E;G#DA20Z/6_&=:\/R*WNV\&1HL!*Y:
M]]&S[F4$'-' R%DQ9JF<.;+L$\\R?D=WGGKWX'#5?C])5UX2@R>U050MSF2-
M)*SXP++T?I(G'ZN=G-5L*M^8LQ^.2YD@KH<"&2.BK%3N:FE'M&'<$[WR!^F2
M9@N1TJSY9GG/\_:A<<D40M4ZRVMLB#+:?\(1233C>5IRF/./$\MOAUBV0=(#
M N[M46K96LSI%Z\%1*R6S=(K3ZGD2?8&4>8P'?9S6'.>G;R]?A?2G [1B&7Q
M4!UH.LJ*S$[(VVOR+O+EODUJ^^Y[J2,9<JPORA-:VFL<@7;(E!M%VKX&>'\+
MP++;ULP!E@)*((DL(DZ+ZWV]TSQY@)+&ZEO2L4MYO(I,CA]!PR@I$=1-O!>K
MN7QW60/37+V7I9D;ADND7HY6 @0%ADV7K8;#93=*E2@MZ?1^RY8E4WXDWT#(
M><4FS:G8G4(0.UWNKM*;W*%+H!TNH<:1M@,!M+5J,DK ?0&$F1)(H8I ,@YY
M>QT\"*FAN!0;Y&FMW*GQAAQLH!F=&];^BS)ZT?CE&+HVHU;D'S_\^N_8=V;4
M_"]9P:3-^JK:PBUA0[L.868XI0KB[!W$U];$F"/9CCA.R]W%ZA/?LG-5 7**
MSQ(@? QQ<[Z%\B K9"J.H&R)"'M]\C,%UI%G7IG\%1=ZPW2HK?6 D6DSS-0>
MDK=,D+2ECZ+:\M-B2W.>G;!I?LN*,KVA2]BPSJ]D*7Q#?4N#(VQQ:3>>^*&4
M'T^G5Y'#V&Y9QK?PFJ,:6* =+KW&D;:CW1IK@K$)3C:\RLM+ELF)1;+@LS23
M[LAS9J)(+ D'\+BD"R-KI3=35D1H,U)RLJD-ZP"7*'.L+US\>2$2)AK/.>9%
M:6=B\N!P2=-/TKKC5Z()!SBA3;-9@D'\V6X]3MWOU(1,MGQ6N%0:0WE@-;X9
MSK=VM*(F[3B90,*+@N?'5"*%'M76I'TQ8 %&N!0<P=B*!SLAM2W1QD1;DT;:
MF +:/8A'-!\0EU #+)T]HL(C&4B<RE'L!CZ8P SZ<GO=]A"!2P ?/6LMML:1
M.]  OD)1/D*+-1,T8?=7NZ)DFV*:+SW^[P/BJOX!EH<JU'!B\$>0,_-UY$.+
M>I'>C"[3_(J)VW3)[!&:%XE+DB&:WEV*.@P\S4EA3*+N,)D76*P%KV[65WQ5
M0HSSD"P'<-3:N+G:L<4"\LK2&[6'Q+IRD5*700I32!3)SJ2SY,-G2MTP7!+U
M<K2B*S48R<?\DN]H5NZD<SG/WG1_C:O6G=SL&\D4"#P_VO&3DXJ=TN7Z,\TK
M*G;^G*<>'*Y:[R=I+8I5C "<&#QY&]W;U7GOIGMT>GP7@JO^O?Q<GJ_.J&\;
M9*0HJJ+*2@B+S9-)<IL67.R.:;'^P)S!4UXP+AD"F#I"I8R)BJFGQHC\5<$]
MB2+;D:6T)RL6IY<Z/YGL&1YSL?7T4AX<+GGZ25KA4B<3TE('\'%OK4SY?$W%
MAL($M3@[._9(X<'ADJ*?I'6#9<J)AA.%)](@[B>#I9OK2A1JJ 9C<3EVLS\:
M#A N%7H86A^.-E3-'20V3I?$X'XM22XI]+(D'&M.RZKTC:"&#'!I$LC6OMVJ
M,:M7:QO#N#N,R2W0&;W1&&2&2[I1G*UM1VU,*-+MQ]GE]&/&K_U[(]W?XU+&
M3<[:\;B<$@T+:C%\V2$N_Y^6O*F8M6 K^</TOGSU[LV[?[WY]9<WK^^+Y >]
MVL\R";J1HLX9RZQO>6=CP =U5N6S[+3TD]UOM+AQN#RAGZ2US=*@"<"CCSO.
M9L=PKV0%VV_JBA?_LK\?BDN009[64MGLF'0M8.T_;NZ;C^<0'$G]:E@(7"+X
MZ%E)83Z>$P6,7N7@ 3QOW^+EC>IT W$),,#27C4 N+DM#L/]BW5(P"1/S,#G
MXI:) C)6JL">@9B8?C-D4HWA[(V*@<4>8TX:>Z(*B)TLLCZQUP3\>)+N^)"X
MY!JBZ4@9V1Q9;(*6(O=T6SDE2&8TS4N6PR3!W]6YD;@4&:+IZ.P4GK0,(J_^
MW%09C/5W9D>\KXOK ^/2)8"IO2I4FQ!C@Z +JUNM[*!;X==>>?Q@;/(,,K7E
M,?T7?&W:H>A1^S-:K*^F\^-I7E2")7JUQ.[+7"A<@O11M/HPV,0!,*1 K 1T
M87%VG=.;M)1CEZ)@Y2>>P<V@??N>_7!<<@1QM;:BM1&A8$76QBS>[FA5O+JA
M=/M5O45Q7 EQL#CJ!'Q]]S6[SEY,B@YO(T$_+VNQ4Z&.B,%%JN2SE%ZGF<K9
MWE/3-@I1=?>0LT.,&BBBBI=?,S6+A:8G9T$Z4>V #$X;G*+T4^V12'VR-3R2
M2!>R$Z2P]6TV!@N7*A8(D0Q^;H?UWB!)#8U=Y]-\R3?LC!?]M;Z'8:QW!SM_
MS6LP^0G@/T>J_BD<;V&%:T?? T%4[3YFAU5>XVI?/R)[$:#3.><YKW\028=S
M5NY]9W)+TPS"-!>\M4IJ.M3WM$B7+IU&%H%(QX<R=T0$=!L5:0J#7>7V$K(I
M[XBH$B.)KA+.%Q=56932#:7SN62U0%]_02.<GYLSM[ZL[A8VUCPC^5]5E"JK
MZ()/DB35J3[F-$VF^3'=PN3H)+U-$Y8GQ30_O5^RHKA87;*2ICE+3JG(8<+D
MG*$\3=&(6N93OY$= M*4#RUT_P0"CX#C-.8A1Z1Y#/Q4/PC.=-2/(O6S\-P$
M(KNBK$J8K"GW0I;SS.##BT+0+SS5&SA[CP<5B=$;/K)<#C8R%3"]2?.T*&'H
M<<L>Y ]]A7TK'A'T#F-]HJ_0&%XAF0DFZ9XP_?<T-_%OQ877?W5.4>^IRL<7
MB<5#GO!-[,'_8XN.-C4[)#X7;*N^O&8]W3U;&[)"-+P80=8G*_FI-OX9!@;&
MGC0%8!.O7FZY@.#E40)V++\%$=V$1PI9%R*G#E ,CIZ[O]]HK6D&=-G!9>'M
MJ\>_PG G'5QFO 4;V.&<"P[3DN3][K<"1AW-PM)D*0<;E@^,MT:@^B-(.S>%
MZP+@+KV?H S9WG]N+<F9<G8JPX4<S<'/3M)"BB)_74'TF(;R/)+VYEC#!RXF
MR[^JM%!SUF.QVY9<;?.Y%!^R0=2A!U.U LE,%HP5%Z1E>D2T,5'6N-JKR4;Y
MP/;JL$:DXP-(CVBO33'XVZNG(CZD$%CW4.T=UOBU[R,]0ONF&/S:PUO ?["Q
M?$LS6&F40XM2I) (!GZA@IK;/V@A]<T?]N#$O.GI_7(-%\->TI*=KE9LZ>SY
M7Y8!(A^,].(N/Y:?(/#F??E'9/]DHA$Z/KWSPXZ!9D0<\Y6V\]?$"# CFIH.
M1OQN6D7SLO*5MKR@V4?!JRT,U%NOV+RALT]]R><C&D%'>>WG:@_(.GR3)$S=
ML*TOG%E5N?QRU5?%6U/Q'BP"EPFF:.>D\]J\L")LF7R5DX@;GK-+MN2W3.RF
M>7).-YV%2S\*P:<L@-QA_1LXJ?'04!+8NX2KP< R@@JM7?<!)?Q()&H$$+0B
MKO8FJ%2!>^>3XCCC!5OP6;Y-H1_UZ-*'1:),$$4K $ 9$64%R[Z+=*-B=6;G
M\ZGZKLA?5"IR)+Y>"Y%,A/ (U/DE$D7<G*S$LH*JIC&!C\2-RG83N[:;^")V
M W0N&5R')#G.>98N=_K/!;LOWV=\^:<S:"K$$(%*#^-K;85K:]*8R\F*,B5_
MF+^A#*(*>>D#4.VAKQRK'L[RAJ4,,D0DY3B^SD47&'D?#+<+1)(6HOPZSVBY
MXF*C1_M<M):'>S0=9XE U <2MA;&31&D+J.[)(Y T]9F+M^P!;T/:)D^+ +=
M@BDZ-B(A?%A:(&IPG7!;*^1))\.078[D#DG+;YETM]ST.,Z/X_AB$$GZ&/;.
M&+)7JC!2;UZUAD$(I.^)GVL1?;_;0\Q[J('U>5TQK2G0%P9Y-U@RD=,@>L/J
MY8*Y2+L!12_[Y*__C.Y@D5[8Z9/D6OGDLL6!T)9C7N](T<+5UP]08$)R">:*
M"^&MJ>^=84.HID.8X4.V0 A5GQ90X28'T ,\^X4?C6 Q,=8;]_6W;0:=3E?Z
MMK-?!AY'=>JGSDF2(U*S(88.J?F0^3?LVZ?WVU34*>+T]M-S^+'C,>B_]T_S
M=L_IGZWGJGA&]614CJC/9$VJ<LU%^C=+?H.[SUH)V=0(JM.P+Z$2?MO*28SZ
MUUFZ29U;WL_Y//2N^<2O.7+,6GO@T4$72%311T0]1O\/40]RN&3[1V?R7_+'
M]8_D'S#DD#_Y/U!+ P04    "  [@VQ;?,BT05==  !I, 8 %0   &QI>'0M
M,C R-3 Y,S!?<')E+GAM;.V];9/;.)(N^OU&G/^@TQNQ,?O!W6WWRXSGY9Y0
MO7EJMES2K2JW=\^7#A:)DK!-D6J0E$O]ZR] 4A)%$D""))A0N3;.F;8M $3F
MDT@D$IF)O_^?YU4XV1"6T#CZQS=OO_W^FPF)_#B@T>(?WWRZ?S.]/[^^_F:2
MI%X4>&$<D7]\$\7?_)__]W_]/Q/^?W__WV_>3*XH"8._3BYB_\UU]!3_;7+K
MK<A?)Q](1)B7QNQODU^\,!/_$E_1D+#)>;Q:AR0E_(?BPW^=_/SMN\?)FS>
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MVP?F18GGP[2;O..@G'HC-MQ 6%*$?P(F0K)^0TWLFAN.*_+@/0.6W%';H2;
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M%94MOEOG<2MO_"4-]S+PQ.*5C'WE!V/EK&/&)?,?W[S]_GMT?G.!)]?\CPF
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M7@22^[;V0/[_V0G^RPEV ('\PNB"4P,'H=(%B,-?G,.A0382%/RL1N. D\$
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M-*C *%ASIYN@T$IAA>_KW7'CIJ!:.L-\>FF<>F'>$A<Q'51@C*S%LAD8NR\
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M=OX>&-(>K'( YGT0D+DE">J,?1HT@!',"I=@@QN0RD[8.8!=8'+6=&S,46>
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M=T1<L_%_/X^C/'HD\\('PE8J(1Y_+F#'O?/RC(6CLR:MS(TA(B"D1L! 9UG
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M074;"CWWOUV0JE95'QY9LFZOR"/+/,:_3UE*2-28F(C(-,"NQWA0 *V=0/0
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MV%HU6)LR?Z26@1Q$5\[W7N@Q2L3V]-E;* O_-EJ>9C4$&<7H4(Q8H,*U2@7
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M9T3=IWPCJ[TC?[*R^IF(I!P23#>$>0MR^4R83Q,R9]2W<:]K.@%L@]-UP8;
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M>JY,^UM*9?[(K4@H2>GF$.M9273YN9'HDH^5\^[X#:5=.LID/]YK8LH))*9
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MTT/S JN>P?E2J815K%)[ MOR*3??+G- 7*6PH.O(REOGY]Z:IEZXMS$(VY"
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MJ9,7QMLXVN01!L<1V?8D4?I!<*#R5R>&&HQ:9'#<ESWW^7N5J*MSWHWZ7OC
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M/2;D]TQ(C+AS 95[?=]XLVL_R*08Q9T2KW7Z]-5<Y3UP[(/:?#1E6]M;NQ%
MI<.B_FY>*RGXU5EK\VHH RTH-ZY59E6)F!J4&Y>JLM;)X)]2)]]).YPZ+ =*
MT"NSMLQ,EUNGZ.(F,#5!TV,S4'3ST.#HBL](FF-'9VE%3 V(8]&0^Z#Y2WY:
M3;>'T!>-+E-W<W/AJ#2:FIY!RZ9T@:DV+9U.DS1W!!:(R-7PD1!D)U]CSLA5
M)HXTG_/:1II:M-+6V(I**3/5,Z2&7G0=)>*_XN@^C?W?='M&2U/L>$00#/+I
M.X*!T*4TH![;WGOB]>U\CGI[5]+%$45D9O%*:$$O)%&9T:VWXG^LU&'0&K^
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M+FAT;5!+ 0(4 Q0    ( #N#;%OZ'?$/K00  $D=   *              "
M =(5  !E>#,R+3(N:'1M4$L! A0#%     @ .X-L6RNZH+6;KP( &\0?  P
M             ( !IQH  &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    ( #N#;%MK
M"@$UY5\! ,:1 0 0              "  6S* @!F;W)M,3 M<5\P,#$N:G!G
M4$L! A0#%     @ .X-L6X;P6M.F: $ X),! !               ( !?RH$
M &9O<FTQ,"UQ7S P,BYJ<&=02P$"% ,4    "  [@VQ;;RV#Y^(3  "JY@
M$0              @ %3DP4 ;&EX="TR,#(U,#DS,"YX<V102P$"% ,4
M"  [@VQ;JWI+O]H-  #7H   %0              @ %DIP4 ;&EX="TR,#(U
M,#DS,%]C86PN>&UL4$L! A0#%     @ .X-L6\5Q>'0(2P  E/<$ !4
M         ( !<;4% &QI>'0M,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    (
M #N#;%N'ISC38(<  *C.!P 5              "  :P !@!L:7AT+3(P,C4P
M.3,P7VQA8BYX;6Q02P$"% ,4    "  [@VQ;?,BT05==  !I, 8 %0
M        @ $_B 8 ;&EX="TR,#(U,#DS,%]P<F4N>&UL4$L%!@     ,  P
*X0(  ,GE!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20250930"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lixt-20250930.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2025-11-05</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2024-08-19_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-19</instant>
        </period>
    </context>
    <context id="From2025-07-022025-07-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-07-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantFiveMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OtherVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_OneVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:OneVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_TwoVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:TwoVendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CompoundMaintenanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_CompoundMaintenanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CompoundMaintenanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CompoundMaintenanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:CompoundMaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BitcoinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:BitcoinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BitcoinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:BitcoinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_EthereumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:EthereumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EthereumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">LIXT:EthereumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-17</instant>
        </period>
    </context>
    <context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-16</startDate>
            <endDate>2015-03-17</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember624785171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-16</instant>
        </period>
    </context>
    <context id="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-21_custom_SeriesAConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-21</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-242023-08-07_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-202023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:JulyTwentyTwoThousandTwentyThreeEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="From2025-02-132025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-13</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="AsOf2025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-13</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="From2025-02-132025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LIXT:FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-13</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-022025-07-02_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="From2025-07-182025-07-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_custom_PlacementAgentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PlacementAgentsWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-15_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="From2025-07-022025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-022025-08-05_custom_PlacementAgentsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-08-05</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_custom_PlacementAgentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-18</instant>
        </period>
    </context>
    <context id="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MarketAwarenessAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MarketAwarenessAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="From2023-06-022023-06-02_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-06-162025-06-16_custom_EmploymentAgreementMember_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-16</startDate>
            <endDate>2025-06-16</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_NewIndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_DirectorMember624786375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_DirectorMember624786375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_DirectorMember624786375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_DirectorMember624786375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-27</instant>
        </period>
    </context>
    <context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-26</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2022-11-062022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-07-01_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SchellensMember624786734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SchellensMember624786734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SchellensMember624786734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SchellensMember624786734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-20</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-312025-03-31_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-03_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="From2025-07-032025-07-03_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-12-312025-12-31_custom_EmploymentAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_MrPursgloveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrPursgloveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-08-152025-08-15_custom_JasonSawyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-15</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-15_custom_JasonSawyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="From2025-08-142025-08-15_custom_JasonSawyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-14</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_JasonSawyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_JasonSawyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:JasonSawyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-08-152025-08-15_custom_DrMichaelHollowayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-15</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-15_custom_DrMichaelHollowayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="From2025-08-142025-08-15_custom_DrMichaelHollowayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-14</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_DrMichaelHollowayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_DrMichaelHollowayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrMichaelHollowayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-01_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-15_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="From2025-08-312025-09-01_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-31</startDate>
            <endDate>2025-09-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-01_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-01</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PeterStazzoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PeterStazzoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-01_custom_LourdesFelixAndGuyPrimusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-01</endDate>
        </period>
    </context>
    <context id="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-31</startDate>
            <endDate>2025-09-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-01_custom_LourdesFelixAndGuyPrimusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-01</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LourdesFelixAndGuyPrimusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_LourdesFelixAndGuyPrimusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-09-302026-09-30_custom_LourdesFelixAndGuyPrimusMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:LourdesFelixAndGuyPrimusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-30</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-07</startDate>
            <endDate>2024-07-08</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-11_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-11</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MDAndersonCancerCenterClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2021-02-052021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-27</startDate>
            <endDate>2023-08-27</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-02-232024-02-23_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2030-01-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-23</startDate>
            <endDate>2013-12-24</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-12</startDate>
            <endDate>2015-09-14</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember624788609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialPhaseMD1b2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SGNMediaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_LMCCommunicationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_LMCCommunicationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LMCCommunicationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-01</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>LIXT:Segment</measure>
    </unit>
    <unit id="Integer">
        <measure>LIXT:Integer</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-09-30" id="Fact000005">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-09-30" id="Fact000006">0001335105</dei:EntityCentralIndexKey>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0056"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0066"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividendPayable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividend
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividend
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0295"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0398"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0524"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0539"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0566"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0579"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0592"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0619"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0632"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:CommonStockIssuedForServices
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentForAcquisitionCryptoAsset
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0732"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ExerciseOfPlacementAgentWarrantsOnCashlessBasis
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ExerciseOfPrefundedWarrants
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ConversionOfSeriesConvertiblePreferredStockIntoCommonStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:AccrualOfDeferredOfferingCosts
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0886"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0890"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0917"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_country_CN"
      id="xdx2ixbrl0980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_country_CN"
      id="xdx2ixbrl0981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_country_CN"
      id="xdx2ixbrl0982"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_country_NL"
      id="xdx2ixbrl0985"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_country_NL"
      id="xdx2ixbrl0987"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      id="xdx2ixbrl1251"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      id="xdx2ixbrl1253"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1825"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1826"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl1845"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl1847"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-09-30" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-09-30" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000018">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-09-30" id="Fact000019">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-09-30" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-09-30" id="Fact000021">001-39717</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-09-30" id="Fact000022">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-09-30" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-09-30" id="Fact000024">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-09-30" id="Fact000025">433 Plaza Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-09-30" id="Fact000026">Suite 275</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-09-30" id="Fact000027">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-09-30" id="Fact000028">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-09-30" id="Fact000029">33432</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-09-30" id="Fact000030">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-09-30" id="Fact000031">830-7092</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000032">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000033">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-09-30_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000035">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000036">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000037">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-09-30" id="Fact000038">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-09-30" id="Fact000039">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-09-30" id="Fact000040">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-09-30" id="Fact000041">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-09-30" id="Fact000042">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-09-30" id="Fact000043">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-11-05"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">5704200</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">2887874</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">1038952</us-gaap:Cash>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">29490</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">20898</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">61839</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">85653</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">2454473</us-gaap:CryptoAssetFairValueCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">5433676</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">1145503</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">5433676</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">1145503</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000083"
      unitRef="USD">112033</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000085"
      unitRef="USD">27500</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">235900</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">83206</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">235155</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">235078</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividendPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">50367</LIXT:SeriesBConvertiblePreferredStockCumulativeDividendPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000093"
      unitRef="USD">521422</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">318284</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000105"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000107"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000111"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000115"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000114"
      unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000134"
      unitRef="USDPShares">0.7146</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000136"
      unitRef="USDPShares">0.7146</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">3573130</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">3573130</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000131"
      unitRef="USD">2553359</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000150"
      unitRef="USD">2553359</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">5704200</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">5704200</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000153"
      unitRef="USD">570</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">225</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">57891644</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">49394687</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">-55533319</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">-52067693</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">4912254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">827219</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">5433676</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">1145503</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">50696</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">361630</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">202801</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000197"
      unitRef="USD">691402</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">1750658</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">621627</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">3080302</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">2267890</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">1801354</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">983257</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000206"
      unitRef="USD">3283103</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">2959292</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-1801354</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-983257</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-3283103</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-2959292</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">4430</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">1437</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">5236</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">6529</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">457</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">1049</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">5402</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">12389</us-gaap:InterestExpense>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-182887</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-182887</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-130</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-3161</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000236"
      unitRef="USD">530</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-3119</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-1980398</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-986030</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-3465626</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-2968271</us-gaap:NetIncomeLoss>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividend
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-50367</LIXT:SeriesBConvertiblePreferredStockCumulativeDividend>
    <LIXT:SeriesBConvertiblePreferredStockCumulativeDividend
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-50367</LIXT:SeriesBConvertiblePreferredStockCumulativeDividend>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-2030765</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-986030</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-3515993</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-2968271</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000254"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000262"
      unitRef="USDPShares">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000266"
      unitRef="USDPShares">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000268"
      unitRef="USDPShares">-1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">6171195</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">6171195</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">3801400</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">3801400</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">2756991</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">54204101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000290"
      unitRef="USD">-53552921</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000291"
      unitRef="USD">651456</us-gaap:StockholdersEquity>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">3573130</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">2553359</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">59552</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">6</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">1624797</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000304"
      unitRef="USD">4178162</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000317"
      unitRef="Shares">210675</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">21</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">1330791</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000315"
      unitRef="USD">1330812</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000326"
      unitRef="Shares">221690</LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">22</LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-22</LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000335"
      unitRef="Shares">2426111</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">242</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-242</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000344"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">45798</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000342"
      unitRef="USD">45800</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000353"
      unitRef="Shares">9181</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000349"
      unitRef="USD">44710</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000351"
      unitRef="USD">44711</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">50367</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000360"
      unitRef="USD">50367</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">692078</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000367"
      unitRef="USD">692078</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-1980398</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-1980398</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000385"
      unitRef="Shares">3573130</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">2553359</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000387"
      unitRef="Shares">5704200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">57891644</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-55533319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000381"
      unitRef="USD">4912254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000389"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">49394687</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-52067693</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000394"
      unitRef="USD">827219</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">434784</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">43</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">914185</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000407"
      unitRef="USD">914228</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">434784</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">43</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">914185</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000416"
      unitRef="USD">914228</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">27500</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">27500</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000434"
      unitRef="Shares">-350000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-3500000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Shares">72917</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">8</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">3499992</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000447"
      unitRef="Shares">3573130</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">2553359</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000449"
      unitRef="Shares">59552</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">6</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000443"
      unitRef="USD">1624797</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000445"
      unitRef="USD">4178162</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000458"
      unitRef="Shares">210675</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000453"
      unitRef="USD">21</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">1330791</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000456"
      unitRef="USD">1330812</LIXT:StockIssuedDuringPeriodValueProceedsFromSaleOfSecuritiesInJulyRegisteredDirectOfferingNetOfOfferingCosts>
    <LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000467"
      unitRef="Shares">221690</LIXT:StockIssuedDuringPeriodSharesExerciseOfPlacementAgentWarrantsShares>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">22</LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares>
    <LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">-22</LIXT:StockIssuedDuringPeriodValueExerciseOfPlacementAgentWarrantsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000476"
      unitRef="Shares">2426111</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">242</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-242</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000485"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">45798</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000483"
      unitRef="USD">45800</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">9181</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000489"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000490"
      unitRef="USD">44710</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">44711</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000499"
      unitRef="USD">50367</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000501"
      unitRef="USD">50367</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">1059815</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000508"
      unitRef="USD">1059815</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">-3465626</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000515"
      unitRef="USD">-3465626</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000526"
      unitRef="Shares">3573130</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000518"
      unitRef="USD">2553359</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">5704200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">57891644</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-55533319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000522"
      unitRef="USD">4912254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000537"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">49209883</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">-50463969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000535"
      unitRef="USD">2246139</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">106827</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000548"
      unitRef="USD">106827</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000554"
      unitRef="USD">-986030</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000555"
      unitRef="USD">-986030</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000564"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000568"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000559"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">49316710</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000561"
      unitRef="USD">-51449999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000562"
      unitRef="USD">1366936</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000570"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000581"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000573"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000590"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000583"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000585"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000587"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000599"
      unitRef="USD">340445</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">340445</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">-2968271</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000608"
      unitRef="USD">-2968271</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">49316710</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000614"
      unitRef="USD">-51449999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000615"
      unitRef="USD">1366936</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000623"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000625"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000626"
      unitRef="USD">49316710</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">-51449999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000628"
      unitRef="USD">1366936</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000639"
      unitRef="USD">-3465626</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">-2968271</us-gaap:NetIncomeLoss>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000651"
      unitRef="USD">1144348</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">340445</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:CommonStockIssuedForServices
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000654"
      unitRef="USD">44711</LIXT:CommonStockIssuedForServices>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000657"
      unitRef="USD">-182887</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">-78016</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000669"
      unitRef="USD">8592</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">-35</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">-23814</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000673"
      unitRef="USD">24256</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">95661</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000679"
      unitRef="USD">-90827</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000681"
      unitRef="USD">77</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">98997</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-1982720</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-2565861</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentForAcquisitionCryptoAsset
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">2637360</us-gaap:PaymentForAcquisitionCryptoAsset>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">-2637360</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">2245040</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">4178162</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">45800</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000708"
      unitRef="USD">6469002</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000714"
      unitRef="USD">1848922</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000715"
      unitRef="USD">-2565861</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000717"
      unitRef="USD">1038952</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">4203488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000720"
      unitRef="USD">2887874</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000721"
      unitRef="USD">1637627</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000729"
      unitRef="USD">5402</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000730"
      unitRef="USD">12389</us-gaap:InterestPaidNet>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000738"
      unitRef="USD">27500</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <LIXT:ExerciseOfPlacementAgentWarrantsOnCashlessBasis
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">22</LIXT:ExerciseOfPlacementAgentWarrantsOnCashlessBasis>
    <LIXT:ExerciseOfPrefundedWarrants
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000744"
      unitRef="USD">242</LIXT:ExerciseOfPrefundedWarrants>
    <LIXT:ConversionOfSeriesConvertiblePreferredStockIntoCommonStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000747"
      unitRef="USD">3500000</LIXT:ConversionOfSeriesConvertiblePreferredStockIntoCommonStock>
    <LIXT:AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000750"
      unitRef="USD">50367</LIXT:AccrualOfSeriesBConvertiblePreferredStock8CumulativeDividend>
    <LIXT:AccrualOfDeferredOfferingCosts
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000754"
      unitRef="USD">6928</LIXT:AccrualOfDeferredOfferingCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000756">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znyUKB72O1Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_826_zDM7GbQZtkp1"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#x201c;Company&#x201d;), at September 30, 2025, and for the three months
and nine months ended September 30, 2025 and 2024, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2025, and the results of its operations for the three months and nine months ended September 30, 2025 and 2024, and its cash flows
for the nine months ended September 30, 2025 and 2024. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The condensed consolidated balance sheet at December 31, 2024 has been derived
from the Company&#x2019;s audited consolidated financial statements at such date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#x2019;s corporate office is located in Boca Raton, Florida.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Compliance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &#x201c;LIXT&#x201d; and &#x201c;LIXTW&#x201d;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBcx3g5UD546" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock in order to remain in compliance
with the $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z8TcbyKaXek8" title="Bid price"&gt;1.00&lt;/span&gt; minimum closing bid price requirement of the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 19, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its noncompliance
with the minimum $&lt;span id="xdx_904_eus-gaap--StockholdersEquity_iI_pn5n6_c20240819__srt--RangeAxis__srt--MinimumMember_zZOhlN2yyeg" title="Stock holders' equity"&gt;2.5&lt;/span&gt; million stockholders&#x2019; equity requirement for continued listing on the Nasdaq Capital Market under Rule 5550(b)(1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2024, the Company submitted a compliance plan, outlining proposed equity financings. On October 21, 2024, Nasdaq granted the
Company an extension through February 18, 2025 to complete its plan and evidence compliance via Form 8-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not meet the terms of the extension and, on February 19, 2025, received a Staff determination letter. The Company timely
requested a hearing before the Nasdaq Hearings Panel, staying any suspension or delisting pending the Panel&#x2019;s decision.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
an April 3, 2025 hearing, the Panel granted the Company a further extension through July 3, 2025 to regain compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 2, 2025, the Company closed a $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20250702__20250702_zOIdUOONQYl3" title="Proceeds from issuance of private placement"&gt;5.05&lt;/span&gt; million private placement and, on July 8, 2025, completed a $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250708__20250708_zqySmEykS3Gd" title="Gross proceeds"&gt;1.5&lt;/span&gt; million registered direct offering
(see Note 5). On July 15, 2025, Nasdaq notified the Company that it had regained compliance with the stockholders&#x2019; equity requirement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company remains subject to a Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B) through July 15, 2026. During this period, any future
deficiency in stockholders&#x2019; equity would require the Company to request a hearing before the Panel rather than submit a new compliance
plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2025, the Company recorded a net loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20250930_zG3hNcLDOK6b" title="Net loss"&gt;3,465,626&lt;/span&gt; and used cash in operations of $&lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20250930_zuJd32C95Iv5" title="Net cash used in operations"&gt;1,982,720&lt;/span&gt;. As
of September 30, 2025, the Company had cash of $&lt;span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20250930_z7OyWuX8I5ug" title="Cash"&gt;2,887,874&lt;/span&gt; available to fund its operations. As of September 30, 2025, the Company had
net working capital and total stockholders&#x2019; equity of $&lt;span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20250930_zpZnF4tQkyYk" title="Total stockholders equity"&gt;4,912,254&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#x2019;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2025, the Company&#x2019;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $&lt;span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zJlN5Aagtzh1" title="Contractual obligation"&gt;510,000&lt;/span&gt;, which are currently scheduled to be incurred through approximately December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenues
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a
going concern within one year after the date the consolidated financial statements are issued. In addition the Company&#x2019;s independent
registered public accounting firm, in their report on the Company&#x2019;s audited consolidated financial statements as of and for the
year ended December 31, 2024, expressed substantial doubt about the Company&#x2019;s ability to continue as a going concern. The consolidated
financial statements also do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary
if the Company is unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities, including its ongoing clinical trials. The amount and timing of future cash requirements depends in substantial
part on the pace, design and results of the Company&#x2019;s clinical trial program, which, in turn, depends on the availability of operating
capital to fund such activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2025 will provide sufficient working
capital to fund the Company&#x2019;s operations as currently configured, including its ongoing clinical trial program with respect to
the development of the Company&#x2019;s lead anti-cancer clinical compound LB-100, for at least the next 12 months. However, existing
cash resources will not be sufficient to complete the development of and to obtain regulatory approval for the Company&#x2019;s product
candidate, which would require significant additional operating capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, as a result of the appointment of a new Chairman and Chief Executive Officer in June 2025, the completion of the July 2025
equity financings, and other recent changes in senior management and the Board of Directors, the Company&#x2019;s operating strategies
that may include the addition of personnel and/or the incurrence of additional operating costs, which may require that the Company raise
additional capital to fund operations. However, as market conditions present uncertainty as to the Company&#x2019;s ability to secure
additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and
when necessary, to continue to fund its operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is focusing on a disciplined approach to strategic expansion and is focused on advancing LB-100 in high-need cancer indications,
while pursuing acquisitions of complementary oncology assets that could enhance the Company&#x2019;s pipeline, accelerate development
and create durable value for patients and shareholders. The Company has announced that it is in advanced negotiations regarding potential
transactions consistent with its strategy, although there can be no assurance that any transaction will be completed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
cash resources are insufficient to satisfy the Company&#x2019;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact000758">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000760"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-08-19_srt_MinimumMember"
      decimals="-5"
      id="Fact000762"
      unitRef="USD">2500000</us-gaap:StockholdersEquity>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-07-022025-07-02"
      decimals="-4"
      id="Fact000764"
      unitRef="USD">5050000.00</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-082025-07-08"
      decimals="-5"
      id="Fact000766"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000768"
      unitRef="USD">-3465626</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000770"
      unitRef="USD">-1982720</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000772"
      unitRef="USD">2887874</us-gaap:Cash>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000774"
      unitRef="USD">4912254</us-gaap:StockholdersEquity>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact000776"
      unitRef="USD">510000</us-gaap:ContractualObligation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000778">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zYZ49YeLjDWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_827_z4H8rgXvLVlg"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_z7xYeO3pzcZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zHIYsZTUAGY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
Information&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer is the Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently operates in a single&lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90C_eus-gaap--NumberOfReportableSegments_pid_uSegment_c20250101__20250930_zwQwzLwkbG31" title="Number of reportable segment"&gt;1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reportable segment, which consists of the development of a
drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated financial results of the Company. The CODM
uses consolidated net income (loss) as the sole measure of segment profit or loss. The required segment information, including significant
segment expenses, is presented at Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zJMjeDDk30gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zuoKiUyUKyC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm6OkHpKYoI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zf16ZFjTYomb" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_z2hF7GXIuVpk" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zuOzzkcHOUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zFrIvmtS2QU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Prepaid
Insurance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_esrt--PlatformOperatorCryptoAssetPolicyTextBlock_zgFfkKeBmpB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Digital
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance
with FASB ASC 820, Fair Value Measurement, based on quoted prices on the active exchange(s) that it has determined is the principal market
for Bitcoin and Ethereum (Level 1). Changes in fair value are included in unrealized gain (loss) on digital assets in other income (expense)
in the Company&#x2019;s consolidated statements of operations. Realized gains and losses on the sale of digital assets are included in
other income (expense) in the Company&#x2019;s consolidated statements of operations. The Company tracks its cost basis of digital assets
in accordance with the first-in-first-out method of accounting. The Company&#x2019;s digital assets are reasonably expected to be realized
in cash or sold or consumed during the Company&#x2019;s normal operating cycle and as such have been classified as current assets in the
Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#x2019;s accounting policies, disclosures, or internal controls.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--DeferredOfferingCostsPolicyTextBlock_zLY2PmxIQFF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Offering
Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zm6orj6nTYN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20250701__20250930_zDX7YqtyF8kc" title="Legal and filing fees and costs"&gt;16,853&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20240701__20240930_zIIcxXwgiT0j" title="Legal and filing fees and costs"&gt;45,416&lt;/span&gt; for the three months ended September 30, 2025 and 2024, respectively, and $&lt;span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20250101__20250930_zu5GWZr8Gp62" title="Legal and filing fees and costs"&gt;90,239&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20240930_zAXrnWi1nCPg" title="Legal and filing fees and costs"&gt;192,239&lt;/span&gt;
for the nine months ended September 30, 2025 and 2024, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z1Zs8QjNsB9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Concentration
of Risk&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMX12huKF4D" title="Concentration risk percentage"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKIOtUXScmqc" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months ended September 30,
2025 and 2024 are described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended September 30, 2025 include charges from three vendors and consultants representing &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7NBiD4b04ei" title="Concentration of risk, percentage"&gt;21.4&lt;/span&gt;%, &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5CRKZi6OJBc" title="Concentration of risk, percentage"&gt;28.8&lt;/span&gt;%
and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBr33L05Ay01" title="Concentration of risk, percentage"&gt;14.2&lt;/span&gt;%,
respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2024
include charges from three vendors and consultants representing&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVTJCBQXYcYe" title="Concentration of risk, percentage"&gt;
52.7&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zz6neRjiqpA8" title="Concentration of risk, percentage"&gt;21.1&lt;/span&gt;%
and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVc7dzNJM3u3" title="Concentration of risk, percentage"&gt;15.1&lt;/span&gt;%.
respectively, of total research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zE8OTDqRVpfi" title="Concentration risk percentage"&gt;1.0&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zRlCNOyI4px4" title="Concentration risk percentage"&gt;7.1&lt;/span&gt;%, respectively
of total general and administrative costs. General and administrative costs for the three months ended September 30, 2025 also includes
a charge from a vendor representing &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zk2AiHpJ4xa2" title="Concentration of risk, percentage"&gt;10.6&lt;/span&gt;% of total general and administrative costs. General and administrative costs for the three months
ended September 30, 2024 includes a charge from a vendor representing &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zTictifVolYe" title="Concentration of risk, percentage"&gt;18.4&lt;/span&gt;% of total general and administrative costs. General and administrative
costs for the three months ended September 30, 2025 and 2024 also included charges for the fair value of stock options granted to directors
and corporate officers representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_zA80E4u5xhoh" title="Concentration risk percentage"&gt;44.4&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_z4BX9IqCpQo9" title="Concentration risk percentage"&gt;12.8&lt;/span&gt;%, respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the nine months ended September 30, 2025 include charges from five vendors and consultants representing &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfkMnrcwWfM2" title="Concentration of risk, percentage"&gt;24.3&lt;/span&gt;%,
&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zojGHZTSZXlb" title="Concentration of risk, percentage"&gt;20.7&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI7j6W9omBDd" title="Concentration of risk, percentage"&gt;18.9&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn9Mq8v8esu1" title="Concentration of risk, percentage"&gt;12.0&lt;/span&gt;% and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziRtXm4Gk1V5" title="Concentration of risk, percentage"&gt;11.7&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the nine months
ended September 30, 2024 include charges from three vendors and consultants representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zidzYfsRqY3c" title="Concentration of risk, percentage"&gt;41.2&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYc3gj0Mv6K3" title="Concentration of risk, percentage"&gt;30.4&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zycIFkh6Rn35" title="Concentration of risk, percentage"&gt;12.6&lt;/span&gt;%, respectively, of total
research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the nine months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_ztyHSrbxcdRl" title="Concentration risk percentage"&gt;2.9&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zVYVeCuNf6qk" title="Concentration risk percentage"&gt;8.5&lt;/span&gt;%. respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 did not include
any charges from a single vendor/consultant in excess of &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zYdU9FIC77Wb" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;% of total general and administrative costs. General and administrative costs
for the nine months ended September 30, 2024 also include charges from two vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--OneVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zhjULGl4DD04" title="Concentration of risk, percentage"&gt;16.0&lt;/span&gt;% and &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zJwQvJpmmook" title="Concentration of risk, percentage"&gt;11.5&lt;/span&gt;%, respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 and 2024 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_z7GmotHUJjRf" title="Concentration risk percentage"&gt;35.4&lt;/span&gt;% and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_zFY9yQs4oTJj" title="Concentration risk percentage"&gt;12.6&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zZ7orfn7Lc42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#x2019;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at September 30, 2025 and December 31, 2024. In the event the Company was to determine that it
would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets
would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations
in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company did not have any unrecognized tax benefits as of September 30,
2025 or December 31, 2024, and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2025 or December
31, 2024. Subsequent to September 30, 2025, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZwY8nxr2DGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#x2019;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--WarrantsPolicyTextBlock_zGXvgbX9R71e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards
Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging
(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet
the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under
ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity
classification. The Company has determined that the warrants issued in the July 2023 equity financing, the February 2025 equity financing,
and the July 2025 equity financings (see Note 5) meet the requirements for equity classification. This assessment, which requires the
use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At September 30, 2025 and December 31, 2024, the Company did not have any liability-classified warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zqt9gtDBhmo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
The weighted average number of common shares outstanding utilized for determining basic net loss per common share for the three months
and nine months ended September 30, 2025 includes all pre-funded warrants sold in the July 2, 2025 and July 8, 2025 equity financings,
aggregating &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zkIN6MSKL6rk" title="Pre funded warrants"&gt;3,085,883&lt;/span&gt; pre-funded warrants, of which &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zdWqV5Y5fxfj" title="Unexercised pre funded warrants"&gt;659,772&lt;/span&gt; pre-funded warrants were unexercised at September 30, 2025. Basic and diluted
loss per common share was the same for all periods presented because all preferred shares, warrants (excluding pre-funded warrants) and
stock options outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025 and 2024, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zlGwgDhu5fc3" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series A Convertible Preferred
    Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,573,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock warrants (excluding pre-funded
    warrants)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;623,232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,307,161&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,504,514&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqAKuOIrhEic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVuorOgqkAq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were
converted into United States dollars at the average rate of &lt;span id="xdx_90D_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250701__20250930_zyoYCullawD8" title="Foreign currency average rate"&gt;1.1692&lt;/span&gt; and &lt;span id="xdx_902_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240701__20240930_zgqHU1MsJlii" title="Foreign currency average rate"&gt;1.0991&lt;/span&gt; Euros per United States dollar, respectively. During the
nine months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of &lt;span id="xdx_908_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250101__20250930_zP2AECW2WxC5" title="Foreign currency average rate"&gt;1.1182&lt;/span&gt; and &lt;span id="xdx_909_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20240930_znMdqm0tPkX6" title="Foreign currency average rate"&gt;1.0873&lt;/span&gt; Euros per United States dollar, respectively. As of September 30,
2025 and December 31, 2024, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was
not a party to any foreign currency forward or exchange contracts. Accordingly, the Company did not have any unrealized foreign currency
(gain) loss at September 30, 2025 or 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwovQEHQLDlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of financial instruments measured on a recurring basis was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zEcIGOa3Fk24"&gt;Schedule
of Fair Value Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Digital
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zqxTOKxMJq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative
of their respective fair values due to the short-term nature of those instruments. The carrying value of digital assets is based on quoted
prices in active markets (Level 1 inputs).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zksEpkVJ2Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-08, Intangibles &#x2013; Goodwill and Other &#x2013;
Crypto Assets (Subtopic 350-60). ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet
with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of operations
each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis,
fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during
the fiscal quarter ended September 30, 2025, the Company adopted and applied ASU-2023-08 henceforth. As the Company did not have any
crypto assets prior to the fiscal quarter ended September 30, 2025, no cumulative-effect adjustment was required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40). These ASUs require disclosure of disaggregated information of Income Statement expense
captions that include certain costs, such as employee compensation, depreciation, and intangible asset amortization. They also require
disclosure of the total amounts of selling expenses, along with an entity&#x2019;s definition of selling expenses. The amendments are
effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning
after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of these ASUs, but does not expect
them to have a material impact on its consolidated financial statements presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVCh9Es3C8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the adoption of ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, effective January
1, 2024, certain reclassifications have been made to the prior year statement of operations to conform it to the current year presentation.
In presenting general and administrative costs on the Company&#x2019;s consolidated statement of operations for the three months ended
September 30, 2024, $&lt;span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG7YsqF1tvd" title="General and administrative costs"&gt;283,053&lt;/span&gt; of compensation to related parties, $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4nshvne9er" title="Legal and filing fees and costs"&gt;45,416&lt;/span&gt; of patent and licensing legal and filing fees and costs, and
$&lt;span id="xdx_904_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJThg06Ayjqc" title="Other costs and expenses"&gt;293,158&lt;/span&gt; of other costs and expenses were shown separately. In presenting the Company&#x2019;s consolidated statement of operations for
the three months ended September 30, 2024, the Company has combined these categories into general and administrative costs in the accompanying
consolidated statement of operations for the three months ended September 30, 2024. In presenting general and administrative costs on
the Company&#x2019;s consolidated statement of operations for the nine months ended September 30, 2024, $&lt;span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXewFRr0sdHe" title="Legal and filing fees and costs"&gt;907,069&lt;/span&gt; of compensation to related
parties, $&lt;span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjPAU3N9b6x9" title="Legal and filing fees and costs"&gt;192,239&lt;/span&gt; of patent and licensing legal and filing fees and costs, and $&lt;span id="xdx_901_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztNhdQDEcnyk" title="Other costs and expenses"&gt;1,168,582&lt;/span&gt; of other costs and expenses were shown separately.
In presenting the Company&#x2019;s consolidated statement of operations for the nine months ended September 30, 2024, the Company has
combined these categories into general and administrative costs in the accompanying consolidated statement of operations for the nine
months ended September 30, 2024. These reclassifications had no effect on the reported results of operations, including loss from operations
and net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_znt9FjXF96Y8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000780">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_z7xYeO3pzcZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000782">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zHIYsZTUAGY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
Information&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer is the Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and evaluates performance
and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis. Because
the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently operates in a single&lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90C_eus-gaap--NumberOfReportableSegments_pid_uSegment_c20250101__20250930_zwQwzLwkbG31" title="Number of reportable segment"&gt;1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reportable segment, which consists of the development of a
drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated financial results of the Company. The CODM
uses consolidated net income (loss) as the sole measure of segment profit or loss. The required segment information, including significant
segment expenses, is presented at Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000784"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-09-30" id="Fact000786">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zJMjeDDk30gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000788">&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm6OkHpKYoI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20250930_zf16ZFjTYomb" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_z2hF7GXIuVpk" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000790"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <LIXT:CashSIPCInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">500000</LIXT:CashSIPCInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-09-30" id="Fact000794">&lt;p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zuOzzkcHOUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <LIXT:PrepaidInsurancePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000796">&lt;p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zFrIvmtS2QU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Prepaid
Insurance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:PrepaidInsurancePolicyTextBlock>
    <srt:PlatformOperatorCryptoAssetPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000798">&lt;p id="xdx_842_esrt--PlatformOperatorCryptoAssetPolicyTextBlock_zgFfkKeBmpB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Digital
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds certain digital assets, consisting of Bitcoin and Ethereum cryptocurrencies. Digital assets are initially recorded at cost
and subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance
with FASB ASC 820, Fair Value Measurement, based on quoted prices on the active exchange(s) that it has determined is the principal market
for Bitcoin and Ethereum (Level 1). Changes in fair value are included in unrealized gain (loss) on digital assets in other income (expense)
in the Company&#x2019;s consolidated statements of operations. Realized gains and losses on the sale of digital assets are included in
other income (expense) in the Company&#x2019;s consolidated statements of operations. The Company tracks its cost basis of digital assets
in accordance with the first-in-first-out method of accounting. The Company&#x2019;s digital assets are reasonably expected to be realized
in cash or sold or consumed during the Company&#x2019;s normal operating cycle and as such have been classified as current assets in the
Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a combination of third-party custodial arrangements and cold storage solutions to secure its digital assets. While management
believes these arrangements provide appropriate safeguards, digital assets are subject to unique risks, including technological failures,
cybersecurity threats, loss of private keys, market volatility, and evolving legal and regulatory environments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
monitors developments in accounting and regulatory guidance related to digital assets. Any future updates may require changes in the
Company&#x2019;s accounting policies, disclosures, or internal controls.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</srt:PlatformOperatorCryptoAssetPolicyTextBlock>
    <LIXT:DeferredOfferingCostsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000800">&lt;p id="xdx_84A_ecustom--DeferredOfferingCostsPolicyTextBlock_zLY2PmxIQFF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Offering
Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000802">&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zm6orj6nTYN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20250701__20250930_zDX7YqtyF8kc" title="Legal and filing fees and costs"&gt;16,853&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20240701__20240930_zIIcxXwgiT0j" title="Legal and filing fees and costs"&gt;45,416&lt;/span&gt; for the three months ended September 30, 2025 and 2024, respectively, and $&lt;span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20250101__20250930_zu5GWZr8Gp62" title="Legal and filing fees and costs"&gt;90,239&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20240930_zAXrnWi1nCPg" title="Legal and filing fees and costs"&gt;192,239&lt;/span&gt;
for the nine months ended September 30, 2025 and 2024, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LegalFees
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000804"
      unitRef="USD">16853</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000806"
      unitRef="USD">45416</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000808"
      unitRef="USD">90239</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000810"
      unitRef="USD">192239</us-gaap:LegalFees>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-09-30" id="Fact000812">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z1Zs8QjNsB9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Concentration
of Risk&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zMX12huKF4D" title="Concentration risk percentage"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKIOtUXScmqc" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months ended September 30,
2025 and 2024 are described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended September 30, 2025 include charges from three vendors and consultants representing &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7NBiD4b04ei" title="Concentration of risk, percentage"&gt;21.4&lt;/span&gt;%, &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5CRKZi6OJBc" title="Concentration of risk, percentage"&gt;28.8&lt;/span&gt;%
and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBr33L05Ay01" title="Concentration of risk, percentage"&gt;14.2&lt;/span&gt;%,
respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2024
include charges from three vendors and consultants representing&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVTJCBQXYcYe" title="Concentration of risk, percentage"&gt;
52.7&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zz6neRjiqpA8" title="Concentration of risk, percentage"&gt;21.1&lt;/span&gt;%
and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVc7dzNJM3u3" title="Concentration of risk, percentage"&gt;15.1&lt;/span&gt;%.
respectively, of total research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zE8OTDqRVpfi" title="Concentration risk percentage"&gt;1.0&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zRlCNOyI4px4" title="Concentration risk percentage"&gt;7.1&lt;/span&gt;%, respectively
of total general and administrative costs. General and administrative costs for the three months ended September 30, 2025 also includes
a charge from a vendor representing &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zk2AiHpJ4xa2" title="Concentration of risk, percentage"&gt;10.6&lt;/span&gt;% of total general and administrative costs. General and administrative costs for the three months
ended September 30, 2024 includes a charge from a vendor representing &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zTictifVolYe" title="Concentration of risk, percentage"&gt;18.4&lt;/span&gt;% of total general and administrative costs. General and administrative
costs for the three months ended September 30, 2025 and 2024 also included charges for the fair value of stock options granted to directors
and corporate officers representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_zA80E4u5xhoh" title="Concentration risk percentage"&gt;44.4&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_z4BX9IqCpQo9" title="Concentration risk percentage"&gt;12.8&lt;/span&gt;%, respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the nine months ended September 30, 2025 include charges from five vendors and consultants representing &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfkMnrcwWfM2" title="Concentration of risk, percentage"&gt;24.3&lt;/span&gt;%,
&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zojGHZTSZXlb" title="Concentration of risk, percentage"&gt;20.7&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI7j6W9omBDd" title="Concentration of risk, percentage"&gt;18.9&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn9Mq8v8esu1" title="Concentration of risk, percentage"&gt;12.0&lt;/span&gt;% and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziRtXm4Gk1V5" title="Concentration of risk, percentage"&gt;11.7&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the nine months
ended September 30, 2024 include charges from three vendors and consultants representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zidzYfsRqY3c" title="Concentration of risk, percentage"&gt;41.2&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYc3gj0Mv6K3" title="Concentration of risk, percentage"&gt;30.4&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zycIFkh6Rn35" title="Concentration of risk, percentage"&gt;12.6&lt;/span&gt;%, respectively, of total
research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the nine months ended September 30, 2025 and 2024 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_ztyHSrbxcdRl" title="Concentration risk percentage"&gt;2.9&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--OtherVendorAndConsultantMember_zVYVeCuNf6qk" title="Concentration risk percentage"&gt;8.5&lt;/span&gt;%. respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 did not include
any charges from a single vendor/consultant in excess of &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zYdU9FIC77Wb" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;% of total general and administrative costs. General and administrative costs
for the nine months ended September 30, 2024 also include charges from two vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--OneVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zhjULGl4DD04" title="Concentration of risk, percentage"&gt;16.0&lt;/span&gt;% and &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoVendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember_zJwQvJpmmook" title="Concentration of risk, percentage"&gt;11.5&lt;/span&gt;%, respectively,
of total general and administrative costs. General and administrative costs for the nine months ended September 30, 2025 and 2024 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember_z7GmotHUJjRf" title="Concentration risk percentage"&gt;35.4&lt;/span&gt;% and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember_zFY9yQs4oTJj" title="Concentration risk percentage"&gt;12.6&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Pure">0.214</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Pure">0.288</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Pure">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Pure">0.527</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.211</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Pure">0.151</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember"
      decimals="INF"
      id="Fact000830"
      unitRef="Pure">0.010</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Pure">0.071</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Pure">0.106</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_custom_VendorMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember"
      decimals="INF"
      id="Fact000836"
      unitRef="Pure">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Pure">0.444</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Pure">0.128</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Pure">0.243</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Pure">0.207</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Pure">0.189</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000848"
      unitRef="Pure">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantFiveMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Pure">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Pure">0.412</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Pure">0.304</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfSalesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Pure">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Pure">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_OtherVendorAndConsultantMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Pure">0.085</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_custom_OneVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Pure">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_custom_TwoVendorAndConsultantMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_CostOfSalesMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Pure">0.115</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember_custom_GeneralAndAdministrativeMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Pure">0.354</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_us-gaap_CostOfSalesMember_us-gaap_SupplierConcentrationRiskMember_custom_GeneralAndAdministrativeMember_custom_DirectorsAndCorporateOfficersMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Pure">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000872">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zZ7orfn7Lc42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#x2019;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at September 30, 2025 and December 31, 2024. In the event the Company was to determine that it
would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets
would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations
in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company did not have any unrecognized tax benefits as of September 30,
2025 or December 31, 2024, and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2025 or December
31, 2024. Subsequent to September 30, 2025, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000874">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZwY8nxr2DGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#x2019;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <LIXT:WarrantsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000876">&lt;p id="xdx_844_ecustom--WarrantsPolicyTextBlock_zGXvgbX9R71e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards
Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging
(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet
the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under
ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity
classification. The Company has determined that the warrants issued in the July 2023 equity financing, the February 2025 equity financing,
and the July 2025 equity financings (see Note 5) meet the requirements for equity classification. This assessment, which requires the
use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At September 30, 2025 and December 31, 2024, the Company did not have any liability-classified warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:WarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000878">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zqt9gtDBhmo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
The weighted average number of common shares outstanding utilized for determining basic net loss per common share for the three months
and nine months ended September 30, 2025 includes all pre-funded warrants sold in the July 2, 2025 and July 8, 2025 equity financings,
aggregating &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930_zkIN6MSKL6rk" title="Pre funded warrants"&gt;3,085,883&lt;/span&gt; pre-funded warrants, of which &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250930_zdWqV5Y5fxfj" title="Unexercised pre funded warrants"&gt;659,772&lt;/span&gt; pre-funded warrants were unexercised at September 30, 2025. Basic and diluted
loss per common share was the same for all periods presented because all preferred shares, warrants (excluding pre-funded warrants) and
stock options outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025 and 2024, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zlGwgDhu5fc3" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series A Convertible Preferred
    Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,573,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock warrants (excluding pre-funded
    warrants)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;623,232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,307,161&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,504,514&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqAKuOIrhEic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">3085883</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">659772</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000884">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyCXh6L0AXq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zlGwgDhu5fc3" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930_zluRJzvb12Le" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zh4abhocixQ4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zLuA1UM9TLS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series A Convertible Preferred
    Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zzt5gJeaIQh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,573,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zMPYwQTJuy43" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock warrants (excluding pre-funded
    warrants)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zpPdUBjzXzg2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;623,232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z0TdmvnKF5m6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,307,161&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,504,514&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">3573130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">7610972</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Shares">808365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact000895"
      unitRef="Shares">1123059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Shares">623232</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">12307161</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">1504514</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000901">&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVuorOgqkAq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as realized foreign currency gain (loss) in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were
converted into United States dollars at the average rate of &lt;span id="xdx_90D_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250701__20250930_zyoYCullawD8" title="Foreign currency average rate"&gt;1.1692&lt;/span&gt; and &lt;span id="xdx_902_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240701__20240930_zgqHU1MsJlii" title="Foreign currency average rate"&gt;1.0991&lt;/span&gt; Euros per United States dollar, respectively. During the
nine months ended September 30, 2025 and 2024, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of &lt;span id="xdx_908_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20250101__20250930_zP2AECW2WxC5" title="Foreign currency average rate"&gt;1.1182&lt;/span&gt; and &lt;span id="xdx_909_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20240930_znMdqm0tPkX6" title="Foreign currency average rate"&gt;1.0873&lt;/span&gt; Euros per United States dollar, respectively. As of September 30,
2025 and December 31, 2024, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was
not a party to any foreign currency forward or exchange contracts. Accordingly, the Company did not have any unrealized foreign currency
(gain) loss at September 30, 2025 or 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000903"
      unitRef="Pure">1.1692</LIXT:ForeignCurrencyExchangeRateTranslation>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000905"
      unitRef="Pure">1.0991</LIXT:ForeignCurrencyExchangeRateTranslation>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000907"
      unitRef="Pure">1.1182</LIXT:ForeignCurrencyExchangeRateTranslation>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000909"
      unitRef="Pure">1.0873</LIXT:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000911">&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwovQEHQLDlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of financial instruments measured on a recurring basis was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zEcIGOa3Fk24"&gt;Schedule
of Fair Value Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Digital
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zqxTOKxMJq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments, which consists of accounts payable and accrued expenses, is considered to be representative
of their respective fair values due to the short-term nature of those instruments. The carrying value of digital assets is based on quoted
prices in active markets (Level 1 inputs).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000913">&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zELUl9woL1bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of financial instruments measured on a recurring basis was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zEcIGOa3Fk24"&gt;Schedule
of Fair Value Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znG7tRfge6kg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXxcZFQXGBFk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNUr5BmKkCPa" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zs5WHrqgMk0j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CryptoAssetFairValueCurrent_iI_zTQZvFBW8aI7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Digital
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_zi5LyU4Vp7Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">2454473</us-gaap:CryptoAssetFairValueCurrent>
    <us-gaap:CryptoAssetFairValueCurrent
      contextRef="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">2454473</us-gaap:CryptoAssetFairValueCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">2454473</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000923"
      unitRef="USD">2454473</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000925">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zksEpkVJ2Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-08, Intangibles &#x2013; Goodwill and Other &#x2013;
Crypto Assets (Subtopic 350-60). ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet
with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of operations
each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis,
fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during
the fiscal quarter ended September 30, 2025, the Company adopted and applied ASU-2023-08 henceforth. As the Company did not have any
crypto assets prior to the fiscal quarter ended September 30, 2025, no cumulative-effect adjustment was required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40). These ASUs require disclosure of disaggregated information of Income Statement expense
captions that include certain costs, such as employee compensation, depreciation, and intangible asset amortization. They also require
disclosure of the total amounts of selling expenses, along with an entity&#x2019;s definition of selling expenses. The amendments are
effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning
after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of these ASUs, but does not expect
them to have a material impact on its consolidated financial statements presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2025-01-01to2025-09-30" id="Fact000927">&lt;p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVCh9Es3C8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the adoption of ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, effective January
1, 2024, certain reclassifications have been made to the prior year statement of operations to conform it to the current year presentation.
In presenting general and administrative costs on the Company&#x2019;s consolidated statement of operations for the three months ended
September 30, 2024, $&lt;span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG7YsqF1tvd" title="General and administrative costs"&gt;283,053&lt;/span&gt; of compensation to related parties, $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4nshvne9er" title="Legal and filing fees and costs"&gt;45,416&lt;/span&gt; of patent and licensing legal and filing fees and costs, and
$&lt;span id="xdx_904_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJThg06Ayjqc" title="Other costs and expenses"&gt;293,158&lt;/span&gt; of other costs and expenses were shown separately. In presenting the Company&#x2019;s consolidated statement of operations for
the three months ended September 30, 2024, the Company has combined these categories into general and administrative costs in the accompanying
consolidated statement of operations for the three months ended September 30, 2024. In presenting general and administrative costs on
the Company&#x2019;s consolidated statement of operations for the nine months ended September 30, 2024, $&lt;span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXewFRr0sdHe" title="Legal and filing fees and costs"&gt;907,069&lt;/span&gt; of compensation to related
parties, $&lt;span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjPAU3N9b6x9" title="Legal and filing fees and costs"&gt;192,239&lt;/span&gt; of patent and licensing legal and filing fees and costs, and $&lt;span id="xdx_901_eus-gaap--OtherCostAndExpenseOperating_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztNhdQDEcnyk" title="Other costs and expenses"&gt;1,168,582&lt;/span&gt; of other costs and expenses were shown separately.
In presenting the Company&#x2019;s consolidated statement of operations for the nine months ended September 30, 2024, the Company has
combined these categories into general and administrative costs in the accompanying consolidated statement of operations for the nine
months ended September 30, 2024. These reclassifications had no effect on the reported results of operations, including loss from operations
and net loss.&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">283053</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">45416</us-gaap:LegalFees>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">293158</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000935"
      unitRef="USD">907069</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">192239</us-gaap:LegalFees>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">1168582</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000941">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zfBoHoNrwicd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_822_zfbu9n4i88gj"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Company&#x2019;s Chief Executive Officer
(&#x201c;CEO&#x201d;). The Company&#x2019;s CODM evaluates performance and makes operating decisions about allocating resources based on
financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company
has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z3IccXWlfrE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zhEnJlVTR3Zi" style="display: none"&gt;Schedule of Information by Segment&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250701__20250930_zxEwQzc9BImd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240701__20240930_z9nNu0oEZG5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_z1Rpaa6OTP4k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240930_ztpy1Q0wNB3b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zjwvHZtW1TBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical and related oversight
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,424&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,342&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,894&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,319&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zQYe1AIkkvq6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preclinical research focused on development
    of additional novel anti-cancer compounds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--CompoundMaintenanceMember_zu5wGjISNlol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compound maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,480&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60,563&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,932&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_z4CTJDswmHX1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory service
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,581&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,771&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zC7Lgo1pyIj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,801&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;691,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and
2024 based on the respective geographical regions where such costs were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250701__20250930_zMTYFay3jd4b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930_zk0xMuipl2Kl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zfN1oXRYk7f8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240930_zH2Z3CpfXAKh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zeXvwFWu7jNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,305&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;278,808&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146,804&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zZAC6oFHO2y6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,391&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,544&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zHdQmjEUyMt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,282&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zVKu5GRBX8Dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,278&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;210,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zUweL85KQMT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,801&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;691,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250701__20250930_zgeyf2S7GSn2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zciJovYJXG54" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250930_zJ464v40b1N" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240930_zOtdAVQN8Jo5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation to related parties:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--CashBasedCompensationToRelatedParties_i02_maGAAEzrRU_z3XRf7ahkMX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash-based&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176,226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;566,624&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--StockBasedCompensationToRelatedParties_i02_maGAAEzrRU_z9ROGtGZ8R74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maGAAEzrRU_z72gHGOzFwMg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patent and licensing legal and filing fees
    and costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,853&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,415&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,238&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--OtherConsultingAndProfessionalFees_i02_maGAAEzrRU_zfY6Ns0pame2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,822&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;920,689&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;481,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_z67lYoTnxFA4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;64,277&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,830&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;370,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i02_maGAAEzrRU_z1HfQbQrluS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other costs and expenses,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;58,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,764&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316,551&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzrRU_zVv1vUc3YWl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total general and
    administrative costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,750,658&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;621,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,080,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,267,890&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s total assets by segment at September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250930_zqxGQxmvlkmc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zo3jfZph8zQc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zmHMXhdF3BGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,412&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,298&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zhoArsta6Ayh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate assets (primarily
    cash and digital assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,423,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,106,205&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_iI_z3oqNeZnZW8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,433,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,145,503&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_znbhRckyCGqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000943">&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z3IccXWlfrE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zhEnJlVTR3Zi" style="display: none"&gt;Schedule of Information by Segment&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250701__20250930_zxEwQzc9BImd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240701__20240930_z9nNu0oEZG5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_z1Rpaa6OTP4k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240930_ztpy1Q0wNB3b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zjwvHZtW1TBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical and related oversight
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,424&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,342&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,894&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,319&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zQYe1AIkkvq6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preclinical research focused on development
    of additional novel anti-cancer compounds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--CompoundMaintenanceMember_zu5wGjISNlol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compound maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,480&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60,563&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,932&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_z4CTJDswmHX1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory service
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,581&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,771&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zC7Lgo1pyIj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,801&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;691,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and
2024 based on the respective geographical regions where such costs were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250701__20250930_zMTYFay3jd4b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930_zk0xMuipl2Kl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zfN1oXRYk7f8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240930_zH2Z3CpfXAKh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zeXvwFWu7jNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,305&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;278,808&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146,804&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zZAC6oFHO2y6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,391&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,544&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zHdQmjEUyMt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,282&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zVKu5GRBX8Dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,278&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;210,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zUweL85KQMT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and
    development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,801&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;691,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250701__20250930_zgeyf2S7GSn2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zciJovYJXG54" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250930_zJ464v40b1N" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240930_zOtdAVQN8Jo5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation to related parties:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--CashBasedCompensationToRelatedParties_i02_maGAAEzrRU_z3XRf7ahkMX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash-based&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176,226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;566,624&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--StockBasedCompensationToRelatedParties_i02_maGAAEzrRU_z9ROGtGZ8R74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maGAAEzrRU_z72gHGOzFwMg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patent and licensing legal and filing fees
    and costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,853&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,415&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,238&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--OtherConsultingAndProfessionalFees_i02_maGAAEzrRU_zfY6Ns0pame2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,822&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;920,689&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;481,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_z67lYoTnxFA4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;64,277&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,830&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;370,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i02_maGAAEzrRU_z1HfQbQrluS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other costs and expenses,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;58,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,764&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316,551&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzrRU_zVv1vUc3YWl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total general and
    administrative costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,750,658&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;621,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,080,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,267,890&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s total assets by segment at September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250930_zqxGQxmvlkmc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zo3jfZph8zQc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zmHMXhdF3BGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,412&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,298&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zhoArsta6Ayh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate assets (primarily
    cash and digital assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,423,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,106,205&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_iI_z3oqNeZnZW8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,433,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,145,503&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">13424</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">250342</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000947"
      unitRef="USD">40894</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">358319</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000950"
      unitRef="USD">22211</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">90821</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">92573</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000953"
      unitRef="USD">300130</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_CompoundMaintenanceMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">7480</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_CompoundMaintenanceMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">9062</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_CompoundMaintenanceMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">60563</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_CompoundMaintenanceMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">18932</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">7581</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">11405</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">8771</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">14021</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000965"
      unitRef="USD">50696</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000966"
      unitRef="USD">361630</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000967"
      unitRef="USD">202801</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000968"
      unitRef="USD">691402</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_country_US"
      decimals="0"
      id="Fact000970"
      unitRef="USD">46305</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_country_US"
      decimals="0"
      id="Fact000971"
      unitRef="USD">278808</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_country_US"
      decimals="0"
      id="Fact000972"
      unitRef="USD">146804</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_country_US"
      decimals="0"
      id="Fact000973"
      unitRef="USD">427736</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_country_ES"
      decimals="0"
      id="Fact000975"
      unitRef="USD">4391</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_country_ES"
      decimals="0"
      id="Fact000976"
      unitRef="USD">6544</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_country_ES"
      decimals="0"
      id="Fact000977"
      unitRef="USD">55997</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_country_ES"
      decimals="0"
      id="Fact000978"
      unitRef="USD">51022</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_country_CN"
      decimals="0"
      id="Fact000983"
      unitRef="USD">2282</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_country_NL"
      decimals="0"
      id="Fact000986"
      unitRef="USD">76278</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_country_NL"
      decimals="0"
      id="Fact000988"
      unitRef="USD">210362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000990"
      unitRef="USD">50696</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000991"
      unitRef="USD">361630</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000992"
      unitRef="USD">202801</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000993"
      unitRef="USD">691402</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000995"
      unitRef="USD">217416</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000996"
      unitRef="USD">176226</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000997"
      unitRef="USD">449432</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000998"
      unitRef="USD">566624</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001000"
      unitRef="USD">776611</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001001"
      unitRef="USD">106827</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001002"
      unitRef="USD">1144348</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001003"
      unitRef="USD">340445</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001005"
      unitRef="USD">16853</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001006"
      unitRef="USD">45415</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001007"
      unitRef="USD">90239</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001008"
      unitRef="USD">192238</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001010"
      unitRef="USD">538822</LIXT:OtherConsultingAndProfessionalFees>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001011"
      unitRef="USD">117893</LIXT:OtherConsultingAndProfessionalFees>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001012"
      unitRef="USD">920689</LIXT:OtherConsultingAndProfessionalFees>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001013"
      unitRef="USD">481865</LIXT:OtherConsultingAndProfessionalFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001015"
      unitRef="USD">64277</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001016"
      unitRef="USD">116440</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001017"
      unitRef="USD">192830</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001018"
      unitRef="USD">370167</us-gaap:GeneralInsuranceExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001020"
      unitRef="USD">136679</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001021"
      unitRef="USD">58826</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001022"
      unitRef="USD">282764</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001023"
      unitRef="USD">316551</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001025"
      unitRef="USD">1750658</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001026"
      unitRef="USD">621627</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001027"
      unitRef="USD">3080302</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001028"
      unitRef="USD">2267890</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_custom_ResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">10412</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_ResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001031"
      unitRef="USD">39298</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001033"
      unitRef="USD">5423264</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001034"
      unitRef="USD">1106205</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001036"
      unitRef="USD">5433676</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001037"
      unitRef="USD">1145503</us-gaap:Assets>
    <us-gaap:CryptoAssetTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001039">&lt;p id="xdx_80E_eus-gaap--CryptoAssetTextBlock_zUyUgMXuChic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82A_zRUED9T6vt06"&gt;Digital Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--CryptoAssetHoldingTableTextBlock_zd15zlx3TLX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the cost and fair value of digital assets that were initially purchased during August 2025 were as follows (there
were no digital assets at December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zz8kIdnQJfF6"&gt;Schedule
of Digital Assets&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gain
                                            (Loss)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;on
                                            Change&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;in
                                            Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bitcoin&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zjLwTZVrBjR9" title="Digital assets held, Quantity"&gt;10.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zs89YFu6a0Xe" style="width: 12%; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,205,540&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zlguGps7Kc7f" style="width: 12%; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zE8YvwRZmWfb" style="width: 12%; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,207,801&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ethereum&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zIVTZhF7pqRj" title="Digital assets held, Quantity"&gt;300.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zWSFVBkk2Cs3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,431,820&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--EthereumMember_zDWjvnB0gu3g" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(185,148&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9LtdhjJ3Z1g" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,246,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20250930_z4cXF93NQjvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,637,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930_zy5ZBpKgezha" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(182,887&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20250930_zWBMyrgrRA3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zMomer7ZKDe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Digital
currency prices are affected by various forces, including global supply and demand, interest rates, exchange rates, inflation or deflation,
and the global political and economic conditions. Digital assets have a limited history, and the fair value historically has been very
volatile. The Company may not be able to liquidate its inventory of digital assets currency at its desired price if required. The Company
has recorded an unrealized net loss resulting from a decrease in the fair value of digital assets of $&lt;span id="xdx_902_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_iN_di_c20250101__20250930_zljt2LVN7ln" title="Unrealized gain (loss) in fair value of digital assets"&gt;182,887&lt;/span&gt; that is included in the
loss from operations in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;The Company&#x2019;s digital asset holdings
in Bitcoin and Ethereum represent &lt;span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zNi0BRkEMxT" title="Digital asset holdings percentage"&gt;&lt;span id="xdx_900_ecustom--DigitalAssetHoldingsPercentage_iI_pid_dp_uPure_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9cm7kyoEgle" title="Digital asset holdings percentage"&gt;100%&lt;/span&gt;&lt;/span&gt; of the Company&#x2019;s digital assets as of September 30, 2025. Bitcoin and Ethereum are digital
assets, a novel asset class subject to potential legal, regulatory, commercial, and technical uncertainties. These assets do not generate
cash flow and require the Company to incur custodial and safeguarding costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;The market prices of Bitcoin and Ethereum
have historically exhibited significant volatility, and a material decrease in their fair value could adversely impact the Company&#x2019;s
financial condition and results of operations. The Company&#x2019;s strategy of acquiring and holding Bitcoin and Ethereum also subjects
it to counterparty risks related to third-party custody arrangements, as well as cybersecurity risks and other operational risks inherent
in managing digital assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;In particular, the Company is exposed
to the risk that the private cryptographic keys necessary to access its digital assets may potentially be lost, destroyed, or otherwise
rendered inaccessible. Any such loss could result in a partial or total loss of the affected digital assets, which would materially and
adversely affect the Company&#x2019;s financial condition and operating results.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CryptoAssetTextBlock>
    <us-gaap:CryptoAssetHoldingTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001041">&lt;p id="xdx_89B_eus-gaap--CryptoAssetHoldingTableTextBlock_zd15zlx3TLX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the cost and fair value of digital assets that were initially purchased during August 2025 were as follows (there
were no digital assets at December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zz8kIdnQJfF6"&gt;Schedule
of Digital Assets&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gain
                                            (Loss)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;on
                                            Change&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;in
                                            Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bitcoin&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zjLwTZVrBjR9" title="Digital assets held, Quantity"&gt;10.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zs89YFu6a0Xe" style="width: 12%; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,205,540&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zlguGps7Kc7f" style="width: 12%; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--BitcoinMember_zE8YvwRZmWfb" style="width: 12%; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,207,801&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ethereum&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--CryptoAssetsNumberOfUnits_iI_pid_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zIVTZhF7pqRj" title="Digital assets held, Quantity"&gt;300.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_zWSFVBkk2Cs3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,431,820&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930__srt--CryptoAssetAxis__custom--EthereumMember_zDWjvnB0gu3g" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(185,148&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20250930__srt--CryptoAssetAxis__custom--EthereumMember_z9LtdhjJ3Z1g" style="border-bottom: Black 1pt solid; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,246,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20250930_z4cXF93NQjvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets held, Cost basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,637,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_c20250101__20250930_zy5ZBpKgezha" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gain (loss) in fair value of digital assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(182,887&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20250930_zWBMyrgrRA3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Digital assets fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,454,473&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CryptoAssetHoldingTableTextBlock>
    <LIXT:CryptoAssetsNumberOfUnits
      contextRef="AsOf2025-09-30_custom_BitcoinMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Pure">10.59</LIXT:CryptoAssetsNumberOfUnits>
    <us-gaap:CryptoAssetCost
      contextRef="AsOf2025-09-30_custom_BitcoinMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">1205540</us-gaap:CryptoAssetCost>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-012025-09-30_custom_BitcoinMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">2261</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-09-30_custom_BitcoinMember"
      decimals="0"
      id="Fact001049"
      unitRef="USD">1207801</us-gaap:CryptoAssetFairValue>
    <LIXT:CryptoAssetsNumberOfUnits
      contextRef="AsOf2025-09-30_custom_EthereumMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Pure">300.70</LIXT:CryptoAssetsNumberOfUnits>
    <us-gaap:CryptoAssetCost
      contextRef="AsOf2025-09-30_custom_EthereumMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">1431820</us-gaap:CryptoAssetCost>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-012025-09-30_custom_EthereumMember"
      decimals="0"
      id="Fact001055"
      unitRef="USD">-185148</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-09-30_custom_EthereumMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">1246672</us-gaap:CryptoAssetFairValue>
    <us-gaap:CryptoAssetCost
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001059"
      unitRef="USD">2637360</us-gaap:CryptoAssetCost>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001061"
      unitRef="USD">-182887</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001063"
      unitRef="USD">2454473</us-gaap:CryptoAssetFairValue>
    <us-gaap:CryptoAssetUnrealizedGainLossNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001065"
      unitRef="USD">-182887</us-gaap:CryptoAssetUnrealizedGainLossNonoperating>
    <LIXT:DigitalAssetHoldingsPercentage
      contextRef="AsOf2025-09-30_custom_BitcoinMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Pure">1</LIXT:DigitalAssetHoldingsPercentage>
    <LIXT:DigitalAssetHoldingsPercentage
      contextRef="AsOf2025-09-30_custom_EthereumMember"
      decimals="INF"
      id="Fact001069"
      unitRef="Pure">1</LIXT:DigitalAssetHoldingsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001071">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLQvZJWqtpib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82C_zPMcscojsL9h"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zO6T4pAKRQp3" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zsEBrVSVv3j" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total
of &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoXTEiE3fw98" title="Preferred stock, shares authorized"&gt;350,000&lt;/span&gt; shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent
of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations.
The holders of each tranche of &lt;span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzkdNIvwINwj" title="Principal cash obligations and commitments"&gt;175,000&lt;/span&gt; shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend
equal to &lt;span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBQbInIMDdn3" title="Preferred stock dividend, percentage"&gt;1&lt;/span&gt;% of the annual net revenue of the Company divided by &lt;span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGH2EqT9R8ek" title="Annual net revenue"&gt;175,000&lt;/span&gt;, until converted or redeemed. &lt;span id="xdx_900_eus-gaap--PreferredStockConversionBasis_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z93BDJLK69Rl" title="Preferred stock, conversion description"&gt;Each share of Series A Convertible
Preferred Stock was convertible, at the option of the holder, into &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv8UBi77REL2" title="Preferred stock convertible into common stock"&gt;0.20833&lt;/span&gt; shares of common stock (subject to customary anti-dilution
provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a
merger or sale transaction resulting in gross proceeds to the Company of at least $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zafabE8HDhC7" title="Gross proceeds from sale of transaction"&gt;21,875,000&lt;/span&gt;. &lt;/span&gt;The Series A Convertible Preferred Stock
had a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred Stock did
not have any cash liquidation preference rights or any registration rights. Based on the attributes of the Series A Convertible Preferred
Stock as previously described, the Company accounted for the Series A Convertible Preferred Stock as a permanent component of stockholders&#x2019;
equity. The &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z7m0NXVp5WA" title="Preferred stock, shares outstanding"&gt;350,000&lt;/span&gt; outstanding shares of Series A Convertible Preferred Stock were converted into a total of &lt;span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250516__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWPilQQMsrxf" title="Preferred stock convertible into common stock"&gt;72,917&lt;/span&gt; shares of common
stock pursuant to a notice of conversion dated May 16, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 1, 2025, the Company filed a Certificate of Designations, Preferences, Rights and Limitations of its Series B Convertible Preferred
Stock with the Delaware Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total
of &lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zYE3Z8m2HGk3" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQT4GcVBq0Fj" title="Preferred stock, shares outstanding"&gt;3,573,130&lt;/span&gt;&lt;/span&gt; shares as Series B Convertible Preferred Stock with a stated value of $&lt;span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_c20250701__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOxmQGkzZpbe" title="Preferred stock liquidation preference per share"&gt;0.7146&lt;/span&gt; per share. Each Preferred Share is convertible
into one share of Common Stock, subject to standard adjustments such as stock splits and stock dividends. The Preferred Shares are non-voting,
except that certain actions of the Company may not be taken except upon approval of holders who own a majority in stated value of the
Preferred Shares. The Preferred Shares bear an 8% per annum cumulative dividend non-compounding and payable at conversion either in cash
or, at the holder&#x2019;s election, in shares of Common Stock valued at the then effective conversion rate. The holders of the Preferred
Shares have the right to designate two members to the Company&#x2019;s Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025 and December 31, 2024, the Company had &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBClampbIq44" title="Undesignated preferred stock"&gt;6,076,870&lt;/span&gt; shares and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuYwtxA7eA0i" title="Undesignated preferred stock"&gt;9,650,000&lt;/span&gt; shares, respectively, of undesignated preferred
stock, which may be issued with such rights and powers as the Board of Directors may designate. On October 21, 2025, the Company filed
a Certificate of Elimination of Certificate of Designations of Series A Convertible Preferred Stock with the Delaware Secretary of State
to amend the Company&#x2019;s certificate of incorporation to eliminate the &lt;span id="xdx_90A_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20251021__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmAbLRV6GRDi" title="Convertible preferred stock shares issued upon conversion"&gt;350,000&lt;/span&gt; shares of Preferred Stock associated with the Series
A Convertible Preferred Stock classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zZbV7kgLVITj" title="Common stock, shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zhxHRTJzu6bk" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_zAssprUWK9ma" title="Common stock, par value"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zsCj204RVMXl" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of September 30, 2025 and
December 31, 2024, the Company had &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20250930_zzPQPUjVggn8" title="Common stock, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250930_ztT5FzpCcsqh" title="Common stock, shares outstanding"&gt;5,704,200&lt;/span&gt;&lt;/span&gt; shares and &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zqVPKEpGRoue" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zTO7SAQ0yP43" title="Common stock, shares outstanding"&gt;2,249,290&lt;/span&gt;&lt;/span&gt; shares, respectively, of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;July
20, 2023 equity offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 20, 2023, the Company completed a registered direct offering of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkji6hwJgN69" title="Number of common stock shares issued during period"&gt;180,000&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zu5RM9pbjg9l" title="Sale of stock price per share"&gt;6.00&lt;/span&gt; per share and pre-funded
warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zk1EvCJHtW9b" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zEMqyaHOrShf" title="Common Stock, Par or Stated Value Per Share"&gt;5.9999&lt;/span&gt; per warrant. The pre-funded warrants had an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z1NGIH7YqFdc" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;
per share, were immediately exercisable, and were fully exercised between July 24 and August 7, 2023 for total cash proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_z3ndgAQcx6dc" title="Exercise of common stock options"&gt;41&lt;/span&gt;.
The pre-funded warrants were deemed to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a concurrent private placement, the Company issued to the same institutional investor common stock purchase warrants to acquire &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zAEY7d9C3FFe" title="Warrants to purchase shares"&gt;583,334&lt;/span&gt;
shares at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzDPZ0QnxDy7" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share. These warrants became exercisable immediately and expire on July 20, 2028. The warrants
and underlying shares were issued pursuant to Section 4(a)(2) and Rule 506(b) of the Securities Act and were subsequently registered
for resale under a Form S-3 declared effective on May 2, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zr5nAn5FtIi" title="Proceeds from issuance initial public offering"&gt;3,499,964&lt;/span&gt; from the combined transactions and net proceeds of $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zPOwVLUSLc" title="Net proceeds from issuance of stock"&gt;3,137,039&lt;/span&gt; after deducting offering
expenses of $&lt;span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zgi1V87tzJ02" title="Costs of public offering"&gt;362,925&lt;/span&gt;. As compensation, the placement agent received warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zxsSPvbgPdg7" title="Warrants to purchase shares"&gt;35,000&lt;/span&gt; shares of common stock at an exercise
price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zrChCvITZEo8" title="Warrant exercise price"&gt;6.60&lt;/span&gt;, expiring &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230720__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_zwQR9bfAu0t5" title="Warrant expires date"&gt;July 20, 2028&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investor warrants include standard anti-dilution adjustments and a fundamental transaction provision entitling the holder, upon a qualifying
transaction, to elect cash settlement based on a defined Black-Scholes valuation formula. If such a transaction is outside the Company&#x2019;s
control (e.g., not board-approved), the holder is entitled to receive the same form of consideration received by common shareholders.
These warrants are classified in permanent equity. Any cash payments upon settlement will be recorded as equity distributions when and
if such obligations arise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;February
13, 2025 equity offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
February 13, 2025, the Company completed a registered direct offering of &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250213__20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXWgP9FJrPng" title="Number of common stock shares issued during period"&gt;434,784&lt;/span&gt; shares of common stock at $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250213__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zhn6iXHWTfx3" title="Sale of stock, price per share"&gt;2.415&lt;/span&gt; per share and, in a
concurrent private placement, issued warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zt2GZjPp2ZX1" title="Warrants to purchase shares"&gt;434,784&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAvzIUI7E157" title="Warrant exercise price"&gt;2.29&lt;/span&gt; per share. The
warrants are immediately exercisable and expire &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250213__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYplFEvhQJ3" title="Warrants term"&gt;five years&lt;/span&gt; from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants and underlying shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act and
were subsequently registered for resale on a Form S-1 declared effective on April 10, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
proceeds from the offering were $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zBowH4qR6g57" title="Proceeds from issuance initial public offering"&gt;1,050,003&lt;/span&gt;, with net proceeds of $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zORULInTsB66" title="Net proceeds from issuance of stock"&gt;914,228&lt;/span&gt; after deducting $&lt;span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zIbID5N297M1" title="Costs of public offering"&gt;135,775&lt;/span&gt; in placement agent fees and other
offering costs. The Company granted the placement agent warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zQlILjiwlNVj" title="Warrants to purchase shares"&gt;32,609&lt;/span&gt; shares of common stock at $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_z4aTsu0PM44c" title="Warrant exercise price"&gt;3.0188&lt;/span&gt; per share, expiring
&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250213__20250213__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--PlanNameAxis__custom--FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember_zXc3eAd7IAng" title="Warrant expires date"&gt;February 11, 2030&lt;/span&gt;. Net proceeds are being used for general working capital purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
warrants include customary anti-dilution adjustments and a &#x201c;fundamental transaction&#x201d; provision. If a qualifying transaction
within the Company&#x2019;s control is consummated, holders may elect cash settlement equal to the Black-Scholes value. For transactions
outside the Company&#x2019;s control, holders are entitled to receive the same consideration as common shareholders. The warrants are
classified in permanent equity. Any future cash settlements will be accounted for as equity distributions upon occurrence of the related
fundamental transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;July
2, 2025 equity offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2025, the Company, entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers
named therein (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell, in a private placement (the &#x201c;Offering&#x201d;)
&lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zpBmiU7kXqGi" title="Private placement shares"&gt;3,573,130&lt;/span&gt; shares of the Company&#x2019;s Series B Convertible Preferred Stock (the &#x201c;Preferred Shares&#x201d;); &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250630__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCntfi9fhM29"&gt;59,552&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s Common Stock, par value $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhs5jTcI941c"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (the &#x201c;Common Shares&#x201d;, the &#x201c;Common
Stock&#x201d;); common stock warrants (the &#x201c;Common Stock Warrants&#x201d;) to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockWarrantsMember_zvp0JgwBD5Z2"&gt;6,355,214&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock; and Pre-Funded Warrants to purchase
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantsMember_zHaHCUSZmLQg"&gt;2,322,532&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Shares, the Common Stock Warrants, Pre-Funded Warrants, the Preferred Shares,  and the shares of
Common Stock underlying the Common Stock Warrants, Pre-Funded Warrants and Preferred Shares have been registered under the
Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) and were issued in reliance on an exemption from the
registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. The Company filed a registration statement on
Form S-1 (the &#x201c;Resale Registration Statement&#x201d;) to cover the resale of the Common Shares and any shares of Common Stock
underlying the Pre-Funded Warrants, the Common Stock Warrants, the Placement Agent Warrants and the Preferred Shares, which was
declared effective by the Securities and Exchange Commission on July 15, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DescriptionOfOfferingPrice_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCILqsApGJyf" title="Description of offering price"&gt;The
Offering was priced at-the-market under Nasdaq rules at $0.8396 per common stock unit, with each unit consisting of one share of common
stock at a price of $0.7146 and one common stock warrant at a price of $0.125 to acquire one share of common stock at an exercise price
of $1.00 per share.&lt;/span&gt; The Offering resulted in gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250630__20250630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zH42JvBt92N7" title="Gross proceeds"&gt;5,050,000&lt;/span&gt; before deducting the placement agent&#x2019;s fees and related
offering expenses of $&lt;span id="xdx_909_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNrVN03cDj3" title="Offering expenses"&gt;871,838&lt;/span&gt;. The initial Offering closed on July 2, 2025 with the Company receiving gross proceeds of approximately
$&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250702__20250702__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4u2tzfI6sf7" title="Gross proceeds from initial offering"&gt;4,050,000&lt;/span&gt;. The remaining $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20250718__20250718__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZl95ubOMRj8" title="Gross proceeds from initial offering"&gt;1,000,000&lt;/span&gt; of gross proceeds were paid on July 18, 2025 upon the Resale Registration Statement having been
declared effective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to a Placement Agent Agreement dated as of June 30, 2025, the Company engaged Spartan Capital Securities, LLC (the &#x201c;Placement Agent&#x201d;)
to act as the Company&#x2019;s exclusive placement agent in connection with the Offering. The Company paid the Placement Agent a cash
fee equal to 8% of the aggregate gross proceeds raised in the Offering, a non-accountable expense allowance of 1.0% of the aggregate
gross proceeds raised in the Offering, and $&lt;span id="xdx_90C_eus-gaap--LegalFees_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zGcmhkDjtCZ3" title="Legal fees"&gt;125,000&lt;/span&gt; for its expenses including legal fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company issued to the Placement Agent warrants (the &#x201c;Placement Agent&#x2019;s Warrants&#x201d;) to purchase
up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7P2LhTkZ113" title="Warrants to purchase of common stock"&gt;315,626&lt;/span&gt; shares of Common Stock, which represented 5% of the Shares and Pre-Funded Warrants sold in the Offering. The Placement
Agent&#x2019;s Warrants had an exercise price of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_dp_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJ7hhsLL8D9" title="Warrants exercisable price per share"&gt;125&lt;/span&gt;% of the offering price and otherwise had the same terms as the Common Stock Warrants.
On July 15, 2025, the Placement Agent&#x2019;s warrants were exercised on a cashless basis, resulting in the Placement Agent being issued
&lt;span id="xdx_904_eus-gaap--SharesIssued_iI_c20250715__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsvOqJrKrFRi" title="Number of shares issued"&gt;221,690&lt;/span&gt; shares of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from July 2, 2025 through September 30, 2025, &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250702__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zylM2vUpxJk1" title="Warrants exercisable"&gt;1,662,760&lt;/span&gt; pre-funded warrants exercisable at $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zgfQK5mkLNE3" title="Warrants exercisable price per share"&gt;0.00001&lt;/span&gt; per share that were sold
in the private placement were exercised, resulting in the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250702__20250805__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zetthfjE6ZFa" title="Number of shares issued"&gt;1,662,760&lt;/span&gt; shares of Common Stock. During the period from October
1, 2025 through October 31, 2025, an additional &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqCCtwHSeey7" title="Warrants exercisable"&gt;475,521&lt;/span&gt; pre-funded warrants exercisable at $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zwDvDWhC0B2c" title="Warrants exercisable price per share"&gt;0.00001&lt;/span&gt; per share and sold in the private
placement, were exercised, resulting in the issuance of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn1TAV9Zzvf3" title="Number of shares issued"&gt;475,521&lt;/span&gt; shares of Common Stock. As of October 31, 2025, &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwuMEizjpsAb" title="Pre-funded warrants remained unexercised"&gt;184,251&lt;/span&gt; pre-funded warrants
remained unexercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of the warrants issued to the purchasers and to the placement agent are subject to customary adjustments for stock splits,
stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#x2019;s common stock.
In addition, the warrants issued contain a &#x201c;fundamental transaction&#x201d; provision whereby in the event of a fundamental transaction
(including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#x2019;s control,
the holders of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment of the warrants, cash
consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction is not within
the Company&#x2019;s control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion)
as the holders of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#x2019;s assets, as
defined in the July 2, 2025 warrants, to the extent that the warrants are outstanding at the effective date that such a transaction is
closed, this &#x201c;fundamental transaction&#x201d; provision would entitle the holders to substantial cash consideration, thus reducing
the amounts to be retained by the Company or potentially distributable to the Company&#x2019;s stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;July
8, 2025 equity offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 3, 2025, the Company, entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers
named therein (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering
(the &#x201c;Offering&#x201d;) &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250703__20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmwSiWtLi4v7" title="Number of shares issued and sold"&gt;210,675&lt;/span&gt; shares (the &#x201c;Common Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTH5zLAGYEZ5" title="Common stock, par value"&gt;0.0001&lt;/span&gt;
per share (the &#x201c;Common Stock&#x201d;) and Pre-Funded Warrants (&#x201c;Pre-Funded Warrants&#x201d;) to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250703__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4YWchxOvC06" title="Warrants to purchase of common stock"&gt;763,351&lt;/span&gt; shares of
Common Stock, at an offering price of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTBAubL2yrp8" title="Offering price per share"&gt;1.54&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Offering resulted in gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250703__20250703__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHjxFnHLOLm6" title="Gross proceeds"&gt;1,500,000&lt;/span&gt; before deducting placement agent&#x2019;s fees and related offering expenses of $&lt;span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pp0p0_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztViDmKtOWA9" title="Offering expenses"&gt;169,188&lt;/span&gt;.
The Offering closed on July 8, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to a Placement Agent Agreement dated as of July 3, 2025 (the &#x201c;Placement Agent Agreement&#x201d;), the Company engaged Spartan Capital
Securities, LLC (the &#x201c;Placement Agent&#x201d;) to act as the Company&#x2019;s exclusive placement agent in connection with the Offering.
The Company paid the Placement Agent a cash fee equal to 8.0% of the aggregate gross proceeds raised in the Offering, and agreed to reimburse
the Placement Agent $&lt;span id="xdx_901_eus-gaap--LegalFees_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zj691v7dSM4d" title="Legal fees"&gt;40,000&lt;/span&gt; for its legal fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from July 8, 2025 through August 18, 2025, all &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcsincbDe1d1" title="Warrants exercisable"&gt;763,351&lt;/span&gt; pre-funded warrants exercisable at $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKBSjahIc3Lf" title="Warrants exercisable price per share"&gt;0.00001&lt;/span&gt; per share that were sold
in the direct registered offering were exercised, resulting in the issuance of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250708__20250818__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAqOobpvy0Jk" title="Number of shares issued"&gt;763,351&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares
Issued for Services&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Market Awareness Agreement with MicroCap Advisory, LLC entered into during August 2025 and terminated in September
2025, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z8BPou2phvA" title="Shares Issued for Services, shares"&gt;9,181&lt;/span&gt; shares of its common stock, valued at $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_z9LTtHb4hL9d" title="Shares Issued for Services, value"&gt;44,711&lt;/span&gt;, as settlement of the original &lt;span id="xdx_909_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MarketAwarenessAgreementMember_zNxheEMOJtAe" title="Shares Issued for Services"&gt;48,000&lt;/span&gt; common share obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLMEP9B3SPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offerings, but excluding pre-funded warrants, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zOW3PTkJm0Dg" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbLrUoVZwJCi" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6AHvW9y4V29" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16.407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwSXgkLGdfZc" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,138,233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhrcAB0cqCY4" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFRGGrhhcBwa" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(335,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS53Czvd9U4k" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zc1dVWXKf6h1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCWHJwgaB2k6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at September 30,
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYsGkWW2f4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za6s0mfAUDR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zx4qnnj4z9Ib" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;4.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrOJu4pl9rDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbyPAFAbJ7D8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16.407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at September 30,
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlHcPudAHm13" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjJMkJFfSPBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LFkTAwSHD8" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;4.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zDAb2IMK5oQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zmxEoO6hcpIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z9EBrlQodZ3h" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1UbhatmWlf6" title="Exercise Prices"&gt;1.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z76d4jVXfEj1" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,355,214&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5Snwck6OJ5h" title="Exercise Prices"&gt;2.2900&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1wSZ4uWjhU7" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,784&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq5gllk1hyFi" title="Exercise Prices"&gt;3.0188&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq7PgTU81iM3" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,609&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKSbDz7Ho2Ka" title="Exercise Prices"&gt;6.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zn4IqgdoLFq7" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zw9YH3Jl64z1" title="Exercise Prices"&gt;6.6000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEosBDDDu4j1" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z0O3OlRmBUZk" title="Exercise Prices"&gt;20.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znQLZIPvm5F6" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDavLkZBj0Qk" title="Exercise Prices"&gt;37.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zsCTHMezFidb" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,331&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zZQEKaBA5dza" title="Exercise Prices"&gt;57.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPFVokWjGrVa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,700&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930_zNpbqZzBUuX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zD8W2llb0zrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants exercisable at $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPzHUOB8wBWe" title="Warrants exercisable"&gt;57.00&lt;/span&gt; per share at September 30, 2025 consist of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlmzaR36heel" title="Warrants outstanding"&gt;1,497,000&lt;/span&gt; publicly-traded warrants, described herein on a pre-split
&lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwnjSAGEZxLi" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; basis, that were issued as part of the Company&#x2019;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU3g44BDqF72" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of the Company&#x2019;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVrqZR5YGy5" title="Exercise price"&gt;5.70&lt;/span&gt; per share. Accordingly, the exercise of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv8WZMMcqmw1" title="Warrants exercise"&gt;10&lt;/span&gt; warrants, each exercisable at $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBZUTWAZyOI1" title="Warrants exercisable"&gt;5.70&lt;/span&gt;, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp1J4T6g6Iog" title="Warrants exercise price"&gt;57.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the closing fair market value of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXJTNYkbhavl" title="Fair market value of stock"&gt;5.030&lt;/span&gt; per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock warrants at September 30, 2025 was approximately $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250930_zZjqF7wG0O42" title="Exercisable unexercised, intrinsic value"&gt;20,113,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001073"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001075"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesAuthorized>
    <LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">175000</LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001081"
      unitRef="Pure">0.01</us-gaap:PreferredStockDividendRatePercentage>
    <LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">175000</LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares>
    <us-gaap:PreferredStockConversionBasis
      contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      id="Fact001085">Each share of Series A Convertible
Preferred Stock was convertible, at the option of the holder, into 0.20833 shares of common stock (subject to customary anti-dilution
provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a
merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">0.20833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-01-012025-09-30_custom_SeriesAConvertiblePreferredStockMember624785171"
      decimals="0"
      id="Fact001089"
      unitRef="USD">21875000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-05-16_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">3573130</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-07-01_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001099"
      unitRef="USDPShares">0.7146</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">6076870</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001103"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-10-21_custom_SeriesAConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">350000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001109"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001111"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001113"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001115"
      unitRef="Shares">5704200</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">5704200</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001119"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001121"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-192023-07-20_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001123"
      unitRef="Shares">180000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001125"
      unitRef="USDPShares">6.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001127"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001129"
      unitRef="USDPShares">5.9999</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001131"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="0"
      id="Fact001133"
      unitRef="USD">41</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001135"
      unitRef="Shares">583334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="0"
      id="Fact001139"
      unitRef="USD">3499964</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="0"
      id="Fact001141"
      unitRef="USD">3137039</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-07-202023-07-20_us-gaap_PrivatePlacementMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">362925</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">35000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      decimals="INF"
      id="Fact001147"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-07-202023-07-20_custom_PlacementAgentsMember_custom_JulyTwentyTwoThousandTwentyThreeEquityOfferingMember"
      id="Fact001149">2028-07-20</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-02-132025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Shares">434784</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001153"
      unitRef="USDPShares">2.415</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">434784</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001157"
      unitRef="USDPShares">2.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-13_us-gaap_CommonStockMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      id="Fact001159">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="0"
      id="Fact001161"
      unitRef="USD">1050003</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="0"
      id="Fact001163"
      unitRef="USD">914228</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-02-132025-02-13_us-gaap_PrivatePlacementMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">135775</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001167"
      unitRef="Shares">32609</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact001169"
      unitRef="USDPShares">3.0188</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2025-02-132025-02-13_custom_PlacementAgentsMember_custom_FebruaryThirteenTwoThousandTwentyFiveEquityOfferingMember"
      id="Fact001171">2030-02-11</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts
      contextRef="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Shares">3573130</LIXT:StockIssuedDuringPeriodSharesProceedsFromSaleOfSecuritiesInJulyRegisteredPrivatePlacementNetOfOfferingCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-06-302025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">59552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001175"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001176"
      unitRef="Shares">6355214</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001177"
      unitRef="Shares">2322532</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <LIXT:DescriptionOfOfferingPrice
      contextRef="From2025-01-012025-06-30_custom_SecuritiesPurchaseAgreementMember"
      id="Fact001179">The
Offering was priced at-the-market under Nasdaq rules at $0.8396 per common stock unit, with each unit consisting of one share of common
stock at a price of $0.7146 and one common stock warrant at a price of $0.125 to acquire one share of common stock at an exercise price
of $1.00 per share.</LIXT:DescriptionOfOfferingPrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-06-302025-06-30_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">5050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-06-302025-06-30_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">871838</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-022025-07-02_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001185"
      unitRef="USD">4050000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-182025-07-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001187"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:LegalFees
      contextRef="From2025-06-302025-06-30_custom_PlacementAgentAgreementMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">125000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_PlacementAgentsWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001191"
      unitRef="Shares">315626</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-30_custom_PlacementAgentsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-07-15_custom_PlacementAgentsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">221690</us-gaap:SharesIssued>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2025-07-022025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">1662760</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_PlacementAgentsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-022025-08-05_custom_PlacementAgentsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001201"
      unitRef="Shares">1662760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">475521</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-012025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">475521</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-10-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001209"
      unitRef="Shares">184251</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-032025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">210675</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001213"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001215"
      unitRef="Shares">763351</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-07-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001217"
      unitRef="USDPShares">1.54</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-032025-07-03_us-gaap_PrivatePlacementMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-07-032025-07-03_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001221"
      unitRef="USD">169188</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:LegalFees
      contextRef="From2025-07-032025-07-03_custom_PlacementAgentAgreementMember"
      decimals="0"
      id="Fact001223"
      unitRef="USD">40000</us-gaap:LegalFees>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001225"
      unitRef="Shares">763351</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-08-18_custom_PlacementAgentAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001227"
      unitRef="USDPShares">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-082025-08-18_custom_PlacementAgentAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">763351</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">9181</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember"
      decimals="INF"
      id="Fact001233"
      unitRef="USD">44711</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember_custom_MarketAwarenessAgreementMember"
      decimals="INF"
      id="Fact001235"
      unitRef="Shares">48000</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001237">&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLMEP9B3SPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offerings, but excluding pre-funded warrants, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zOW3PTkJm0Dg" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbLrUoVZwJCi" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6AHvW9y4V29" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16.407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwSXgkLGdfZc" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,138,233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhrcAB0cqCY4" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFRGGrhhcBwa" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(335,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS53Czvd9U4k" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zc1dVWXKf6h1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCWHJwgaB2k6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at September 30,
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYsGkWW2f4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za6s0mfAUDR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zx4qnnj4z9Ib" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;4.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrOJu4pl9rDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbyPAFAbJ7D8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16.407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at September 30,
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlHcPudAHm13" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjJMkJFfSPBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LFkTAwSHD8" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;4.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">7138233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      decimals="INF"
      id="Fact001245"
      unitRef="USDPShares">1096</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      decimals="INF"
      id="Fact001247"
      unitRef="Shares">-335626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      decimals="INF"
      id="Fact001249"
      unitRef="USDPShares">1.31</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">7610972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">2.715</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      id="Fact001259">P4Y5M19D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001261"
      unitRef="Shares">808365</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001263"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">7610972</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001267"
      unitRef="USDPShares">2.715</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember624785703"
      id="Fact001269">P4Y5M19D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001271">&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zmxEoO6hcpIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z9EBrlQodZ3h" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1UbhatmWlf6" title="Exercise Prices"&gt;1.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z76d4jVXfEj1" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,355,214&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5Snwck6OJ5h" title="Exercise Prices"&gt;2.2900&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1wSZ4uWjhU7" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,784&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq5gllk1hyFi" title="Exercise Prices"&gt;3.0188&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zq7PgTU81iM3" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,609&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKSbDz7Ho2Ka" title="Exercise Prices"&gt;6.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zn4IqgdoLFq7" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zw9YH3Jl64z1" title="Exercise Prices"&gt;6.6000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zEosBDDDu4j1" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z0O3OlRmBUZk" title="Exercise Prices"&gt;20.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znQLZIPvm5F6" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDavLkZBj0Qk" title="Exercise Prices"&gt;37.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zsCTHMezFidb" style="text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,331&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zZQEKaBA5dza" title="Exercise Prices"&gt;57.0000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPFVokWjGrVa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,700&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930_zNpbqZzBUuX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,610,972&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001273"
      unitRef="USDPShares">1.0000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001275"
      unitRef="Shares">6355214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001277"
      unitRef="USDPShares">2.2900</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001279"
      unitRef="Shares">414784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001281"
      unitRef="USDPShares">3.0188</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001283"
      unitRef="Shares">32609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001285"
      unitRef="USDPShares">6.0000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Shares">583334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001289"
      unitRef="USDPShares">6.6000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001293"
      unitRef="USDPShares">20.0000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001297"
      unitRef="USDPShares">37.0000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">11331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001301"
      unitRef="USDPShares">57.0000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001303"
      unitRef="Shares">149700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001305"
      unitRef="Shares">7610972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001307"
      unitRef="USDPShares">57.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">1497000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact001311">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact001313">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001315"
      unitRef="USDPShares">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-06-022023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">5.70</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001321"
      unitRef="USDPShares">57.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001323"
      unitRef="USDPShares">5.030</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001325"
      unitRef="USD">20113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001327">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBEZtVD1pfj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_823_z2zSY6rVfgef"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
party transactions include transactions with the Company&#x2019;s officers, directors and affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023, 2024 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#x2019;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zoGTLzys5Ghc" title="Annual salary"&gt;250,000&lt;/span&gt;.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#x2019;s Chief
Medical Officer, with an annual salary of $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_z42046w4T2Ie" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective May 1, 2021, Dr. Miser&#x2019;s annual salary was increased to $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZQoAivaWNFg" title="Increase in annual salary"&gt;175,000&lt;/span&gt;.
Dr. Miser was required to devote at least 50% of his business time to the Company&#x2019;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the three months and nine months ended September 30, 2024, the Company paid $&lt;span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPVLULzG7bX8" title="Compensation"&gt;14,583&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwA6p7huRxIk" title="Compensation"&gt;102,083&lt;/span&gt;, respectively, to Dr. Miser under this
employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of
operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#x2019;s Chief Administrative Officer, with an annual salary of $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zoCCEt0QVW5g" title="Annual salary"&gt;120,000&lt;/span&gt;. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#x2019;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#x2019;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#x2019;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#x2019;s
annual salary was increased to $&lt;span id="xdx_90D_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z6uwVYWywUTg" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zwNF9nTympwe" title="Compensation"&gt;200,000&lt;/span&gt;. The employment agreement with Mr. Forman terminated upon his resignation as an officer
of the Company effective December 31, 2024. During the three months and nine months ended September 30, 2024, the Company paid $&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFqi8QWUkc3" title="Compensation"&gt;50,000&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRIpCYOgH3o9" title="Compensation"&gt;150,000&lt;/span&gt;, respectively, to Mr. Forman under this employment agreement, which costs are included in general and administrative costs
in the Company&#x2019;s consolidated statements of operations for such periods. Additionally, Mr. Forman was provided a monthly office
rent allowance, pursuant to which the Company paid $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zcHOoXqu5Hle" title="Paid office rent"&gt;2,843&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zItwyct990aj" title="Paid office rent"&gt;12,058&lt;/span&gt; during the three months and nine months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#x2019;s Vice President
and Chief Financial Officer, with an annual salary of $&lt;span id="xdx_90E_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zCvj0aP4stzl" title="Annual salary"&gt;120,000&lt;/span&gt;. Effective May 1, 2021, Mr. Weingarten&#x2019;s annual salary was increased
to $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z046HC6O7rP8" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. The employment agreement with Mr. Weingarten terminated upon his resignation as an officer of the Company effective August
31, 2025. During the three months ended September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRj3FxVjK6r3" title="Compensation"&gt;29,167&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZZB5PP51xU7" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods. During the nine months ended September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8V232BevDl4" title="Compensation"&gt;116,667&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWIR5r25H8k" title="Compensation"&gt;131,250&lt;/span&gt;, respectively,
to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s
consolidated statements of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $&lt;span id="xdx_900_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGPnKJIsAtNl" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Effective June
16, 2025, the employment agreement was amended to provide that Mr. van der Baan will serve as President and Chief Scientific Officer
of the Company. Effective September 1, 2025, Mr. van der Bann resigned as President, but remained as the Company&#x2019;s Chief Scientific
Officer. The term of the employment agreement was for three years and is automatically renewable for additional one-year periods unless
terminated by either party, subject to early termination provisions as described in the employment agreement. During the three months
ended September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_908_eus-gaap--OfficersCompensation_c20250701__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztf31SRGcUzg" title="Compensation"&gt;41,403&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OfficersCompensation_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDtS7pppnzS5" title="Compensation"&gt;39,175&lt;/span&gt;, respectively, to Mr. van der Baan under this employment agreement,
which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTH15zSkOyl4" title="Compensation"&gt;118,604&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zUaXpBBdI13l" title="Compensation"&gt;115,754&lt;/span&gt;, respectively, to Mr. van der Baan under
this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#x2019;s Chief Medical
Officer. The term of the agreement was in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#x2019;
notice, (ii) Dr. Schellens&#x2019; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#x2019;s Chief Executive Officer. The Company paid Dr. Schellens annual compensation
of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_uEUR_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zfGpqJAIqWhc" title="Annual compensation"&gt;104,000&lt;/span&gt; Euros, payable on a monthly basis. Effective as of July 31, 2025, the Company agreed to accept the resignation of Dr. Schellens
and to terminate his consulting agreement, to allow Dr. Schellens to pursue other employment opportunities. During the three months ended
September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuD0jvzU9mp7" title="Compensation"&gt;10,179&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OfficersCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zDOY09cawpUf" title="Compensation"&gt;28,717&lt;/span&gt;, respectively, to Dr. Schellens under this consulting agreement, which
costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations for such periods.
During the nine months ended September 30, 2025 and 2024, the Company paid $&lt;span id="xdx_901_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zqxygFp2LVIf" title="Compensation"&gt;67,494&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zdHtwVZwc4fj" title="Compensation"&gt;28,717&lt;/span&gt;, respectively, to Dr. Schellens under
this consulting agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
as of June 15, 2022, Dr. Ren&#xe9; Bernards was appointed to the Company&#x2019;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board of Directors only in
the form of cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#x2019;s other non-officer directors.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zuwgrEbKcTM1" title="General administrative expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--GeneralAndAdministrativeExpense_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zPKg1aB1ePo8" title="General administrative expense"&gt;0&lt;/span&gt;, respectively, with respect to his annual cash board compensation. During the nine months ended
September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations
of $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zfCUcup197S4" title="General administrative expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4mbEbGodiDb" title="General administrative expense"&gt;10,000&lt;/span&gt;, respectively, with respect to his annual cash board compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the Company&#x2019;s efforts to preserve cash during 2024, effective with the quarter ended June 30, 2024, Dr. Bernards
agreed to receive equity-based compensation for his services on the Board of Directors, for the quarters ended June 30, 2024 through
December 31, 2024. In order to reconcile his Board of Directors compensation with that of the other non-officer directors, Dr. Bernards
agreed to receive the same Board of Directors compensation, both in form and amount, as the other non-officer directors for the year
ending December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 1, 2025, Dr. Bernards resigned from the Board of Directors of the Company and was appointed as Chairman of the Company&#x2019;s
Scientific Advisory Committee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
June 16, 2025, the Company entered into an employment agreement with Geordan Pursglove pursuant to which Mr. Pursglove was appointed
as the Company&#x2019;s Chief Executive Officer and Chairman of the Board of Directors for a term of three years, subject to automatic
termination if the Company did not complete a successful financing that would enable it to maintain its listing on the Nasdaq Capital
Market by July 3, 2025, which was accomplished on July 2, 2025. Under the employment agreement, Mr. Pursglove will receive an annual
salary of $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_c20250616__20250616__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zbkymLim3SH4" title="Annual salary"&gt;240,000&lt;/span&gt;, which may be increased from time to time in the sole discretion of the Board of Directors. At his election, Mr. Pursglove&#x2019;s
compensation will be payable in cash and/or restricted shares of common stock, or a combination thereof. He will also be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors in the form of cash or equity, or a combination
thereof. Mr. Pursglove will not receive any additional compensation for serving as Chairman of the Board of Directors. During the three
months and nine months ended September 30, 2025, the Company paid $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zryiS53kemY6" title="Compensation"&gt;60,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zZ8fqca1tkic" title="Compensation"&gt;70,000&lt;/span&gt;, respectively, to Mr. Pursglove under this employment
agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations
for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 1, 2025, the Company appointed Geordan Pursglove as the Company&#x2019;s President as the result of the resignation of Bas van
der Baan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 1, 2025, the Company entered into an employment agreement with Peter Stazzone to act as the Company&#x2019;s Chief Financial
Officer, for a term of one year, automatically renewable for additional one-year periods, with an annual salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z1CursYvcg11" title="Annual salary"&gt;150,000&lt;/span&gt;. During the
three months and nine months ended September 30, 2025, the Company paid $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z7xuCs8ZW9rd" title="Compensation"&gt;12,500&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zc8u0GGdIG3f" title="Compensation"&gt;12,500&lt;/span&gt;, respectively, to Mr. Stazzone under this
employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of
operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensatory
Arrangements for Members of the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors, which was subsequently amended effective May 25, 2022, July 9, 2024, March 21, 2025 and September
30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
compensation for directors, payable quarterly, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Base
director compensation - $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z1dYKt3Mivj2" title="Compensation"&gt;20,000&lt;/span&gt; per year (except for Dr. Bernards, who was paid an additional annual cash fee of $&lt;span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zfXW0cSM2Cp3" title="Cash"&gt;40,000&lt;/span&gt;, in lieu of
the annual June &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zTziMSWvU0Z4" title="Stock option grant"&gt;30&lt;/span&gt; grant of stock option as described below, through March 31, 2024)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of audit committee &#x2013; additional $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zRZjU4szoXS4" title="Compensation"&gt;10,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of any other committees &#x2013; additional $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zmvcSN8FNW0e" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of audit committee &#x2013; additional $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zhjYBbOQZzgd" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of any other committees &#x2013; additional $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zyNnII6oWYji" title="Compensation"&gt;2,500&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the Company&#x2019;s efforts to preserve cash, the Board of Directors approved amendments to this compensation program,
such that for the quarters ended June 30, 2024 through December 31, 2025, the non-officer directors (including Dr. Bernards) have received
or will receive, in lieu of cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase
common stock at an exercise price based on the closing market price upon issuance, with the amount of such stock options equal to the
cash payment such director would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined
pursuant to the Black-Scholes option-pricing model. On September 30, 2025, the Board of Directors approved an amendment to this compensation
program such that at each quarter end, each non-officer director will have the choice as to whether to receive their quarterly compensation
in cash or in stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise price
based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director would
otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
compensation for directors is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Appointment
of new directors &#x2013; The Company grants options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zXLfrl7c2G74" title="Options, grants in period, gross"&gt;25,000&lt;/span&gt; shares of common stock, exercisable for a period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zQ8j2qUyDA1l" title="Options exercisable period"&gt;five years&lt;/span&gt;,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zxUO3uVC65Rg" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% vesting &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930_zU2mt2haJmQi" title="Award vesting rights, percentage"&gt;12.5&lt;/span&gt;% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $&lt;span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_ztbcyGr1UfDh" title="Cash fee payable"&gt;100,000&lt;/span&gt; to such director, payable upfront.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
grant of options to directors &#x2013; Effective on the last business day of the month of June, the Company grants options to purchase
&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zgcOXulAstH9" title="Options, grants in period, gross"&gt;10,000&lt;/span&gt; shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zDbQiB6cXVUl" title="Share-based payment award, award vesting period"&gt;12.5&lt;/span&gt;%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $&lt;span id="xdx_901_eus-gaap--CostOfRevenue_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhn3Z8tJvCH5" title="Annual cash fee"&gt;40,000&lt;/span&gt; to such director, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash compensation paid to non-officer directors was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zV0WTqAxBt3a" title="Stock based compensation"&gt;27,500&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z62qjh60HZq9" title="Stock based compensation"&gt;0&lt;/span&gt;, respectively, for the three months ended September 30, 2025 and 2024.
Total cash compensation paid to non-officer directors was $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zdRcVhww1iP1" title="Stock based compensation"&gt;27,500&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z5aDYWEpIu8d" title="Stock based compensation"&gt;38,819&lt;/span&gt;, respectively, for the nine months ended September 30,
2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation granted to members of the Company&#x2019;s Board of Directors, officers and affiliates is described at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zLCJimdBLzL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2025 and 2024, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zL0cMS94ajb6" style="display: none"&gt;Schedule of Related Party Costs&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930_zcdIbsCGawab" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240701__20240930_zdJ1cRuFo3Xg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930_zl9uGesWLT28" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_z9jUNNbn58Jg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three
                                            Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine
                                            Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related party costs:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zlMog63KdAt6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash-based&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176,226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;566,624&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zXVc4B64A722" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z9JmKrOQ8dLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;994,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;283,053&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;907,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zU5J12vF3Vkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      id="Fact001329"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember"
      decimals="0"
      id="Fact001331"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">14583</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001337"
      unitRef="USD">102083</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact001339"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">50000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">150000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact001349"
      unitRef="USD">2843</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">12058</us-gaap:PaymentsForRent>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="Fact001355"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">29167</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001359"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">116667</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001365"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">41403</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">39175</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001371"
      unitRef="USD">118604</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001373"
      unitRef="USD">115754</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_SchellensMember"
      decimals="0"
      id="Fact001375"
      unitRef="EUR">104000</us-gaap:ShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_custom_SchellensMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">10179</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_custom_SchellensMember"
      decimals="0"
      id="Fact001379"
      unitRef="USD">28717</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_custom_SchellensMember"
      decimals="0"
      id="Fact001381"
      unitRef="USD">67494</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_custom_SchellensMember"
      decimals="0"
      id="Fact001383"
      unitRef="USD">28717</us-gaap:OfficersCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001385"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001387"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001389"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001391"
      unitRef="USD">10000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-06-162025-06-16_custom_EmploymentAgreementMember_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001393"
      unitRef="USD">240000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001395"
      unitRef="USD">60000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001397"
      unitRef="USD">70000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">12500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_custom_EmploymentAgreementMember_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">12500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">20000</us-gaap:OfficersCompensation>
    <us-gaap:Cash
      contextRef="AsOf2021-04-09"
      decimals="0"
      id="Fact001407"
      unitRef="USD">40000</us-gaap:Cash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Shares">30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">10000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">2500</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-09-30_custom_NewIndependentDirectorMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2025-01-012025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      id="Fact001421">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-01-012025-09-30_custom_NewIndependentDirectorMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001425"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2025-09-30_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      decimals="0"
      id="Fact001427"
      unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">40000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">27500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">27500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">38819</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001443">&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zLCJimdBLzL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2025 and 2024, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zL0cMS94ajb6" style="display: none"&gt;Schedule of Related Party Costs&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930_zcdIbsCGawab" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240701__20240930_zdJ1cRuFo3Xg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930_zl9uGesWLT28" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_z9jUNNbn58Jg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three
                                            Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine
                                            Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related party costs:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zlMog63KdAt6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash-based&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176,226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;566,624&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zXVc4B64A722" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z9JmKrOQ8dLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;994,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;283,053&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;907,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001445"
      unitRef="USD">217416</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001446"
      unitRef="USD">176226</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001447"
      unitRef="USD">449432</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001448"
      unitRef="USD">566624</us-gaap:OfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001450"
      unitRef="USD">776611</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001451"
      unitRef="USD">106827</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001452"
      unitRef="USD">1144348</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001453"
      unitRef="USD">340445</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001455"
      unitRef="USD">994027</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001456"
      unitRef="USD">283053</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001457"
      unitRef="USD">1593780</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_srt_DirectorMember624786375"
      decimals="0"
      id="Fact001458"
      unitRef="USD">907069</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001460">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zIohc8vwLk4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_824_zlZJurXRODn1"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zV8AYlRJ6SZf" title="Number of restricted stock issued"&gt;233,333&lt;/span&gt; shares of the Company&#x2019;s common stock, under terms
and conditions as determined by the Company&#x2019;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zgnF4tWqeVf8" title="Common shares avaliable for issuable"&gt;180,000&lt;/span&gt; shares, to a total of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUcCJlzBXpze" title="Shares total"&gt;413,333&lt;/span&gt; shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zrRYyne3KBa5" title="Common shares avaliable for issuable"&gt;336,667&lt;/span&gt; shares, to a total of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zeaVlwv1scc5" title="Shares total"&gt;750,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, unexpired stock options for &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z1rsQGIMaUDa" title="Shares outstanding"&gt;694,309&lt;/span&gt; shares were issued and outstanding under the 2020 Plan and &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvW2SKiDrlB5" title="Shares were available for issuance"&gt;55,691&lt;/span&gt; shares were
available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#x2019;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsyplzXokm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2025, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zxe1ze8AJ6P9" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250101__20250930_zfDeiQPPq802" title="Risk-free interest rate minimum"&gt;3.58&lt;/span&gt;%
    to &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250101__20250930_z9yRnL5v31Y1" title="Risk-free interest rate maximum"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20250101__20250930_zlaO1TZhMRGh" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: -3.9pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20250101__20250930_zRKfZI8CZmWa" title="Expected volatility minimum"&gt;128.78&lt;/span&gt;%
    to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20250101__20250930_zZqyHmpbs9J" title="Expected volatility maximum"&gt;139.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_z0QAUqANASf3" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zdU5gdc2VqWe" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20240101__20240930_zPq2t6s3INs" title="Risk-free interest rate minimum"&gt;3.55&lt;/span&gt;%
    to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20240101__20240930_zIvW7UAUMiK1" title="Risk-free interest rate maximum"&gt;4.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20240930_ziZpmFFOyoY6" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20240101__20240930_zAF8Sf0L6wsg" title="Expected volatility minimum"&gt;125.59&lt;/span&gt;
    to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20240101__20240930_zatfMJ5aqwV5" title="Expected volatility maximum"&gt;126.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zDXFVVxLNRKg" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zvGTAGTgpIQl" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zMWdC4QeEwBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4b0U5Vy0DRa" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of
&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7aIqnkJn6L2" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zSco97drUuSe" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z39t4QRA3Kbf" title="Stock options description"&gt;vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.&lt;/span&gt; The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zgYjjTMXDtId" title="Fair value of stock options"&gt;158,525&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjZxvlxu9nf5" title="Stock price per share"&gt;6.341&lt;/span&gt;
per share), of which $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZq2raHj9fr1" title="Stock options vested"&gt;79,263&lt;/span&gt; was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the three months and nine months ended September 30, 2024, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zoHgZkF1IZhb" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zHe9ja4TjsO5" title="Stock based compensation"&gt;19,390&lt;/span&gt;, respectively, with respect to these stock
options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2022, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zS01Nplba2ci" title="Fair value of stock options"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoBcSzbo9LCk" title="Stock price per share"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zLCuiZFm9Nrh" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zd8p1iqOgsC8" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zoRSI7t2WO42" title="Stock options description"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zkl3x9Be0PY1" title="Fair value of stock options"&gt;316,700&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zW3NWw8MHnRd" title="Stock price per share"&gt;6.334&lt;/span&gt; per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the three months and nine months ended September 30, 2024, the Company recorded a charge to general and administrative costs in the consolidated
statement of operations of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zQ7whBFLDPY8" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zaqQ5a0f6v0k" title="Stock based compensation"&gt;47,310&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zthvzf8XOHH8" title="Number of stock option granted"&gt;20,000&lt;/span&gt; shares
(a total of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zTChVV1c9XCc" title="Number of stock option exercisable"&gt;80,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHoMdJpKB6hj" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zcyjGUlrfoIk" title="Exercise price of options"&gt;20.00&lt;/span&gt;
per share, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zp0hm39r0pMg" title="Stock options description"&gt;vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.&lt;/span&gt; The
total fair value of the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4F5UkcGDeza" title="Stock options granted to purchase common stock, issued"&gt;80,000&lt;/span&gt; stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zPFsc9abnuak" title="Fair value of stock options"&gt;262,560&lt;/span&gt; ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znPs2ImgA1q4" title="Stock price per share"&gt;3.282&lt;/span&gt; per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjP1kvOyrZIe" title="Stock based compensation"&gt;4,132&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdxA7goZOASh" title="Stock based compensation"&gt;9,641&lt;/span&gt;, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z2kLy9ITx8kj" title="Stock based compensation"&gt;12,264&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zaHnJfWYMyAc" title="Stock based compensation"&gt;34,304&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2023, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zsImUudkcvfg" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zlAAC25EKIPk" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zR60LRzjWbO7" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRs63wYdiI7j" title="Exercise price"&gt;5.88&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJdl8WKpRn76" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zW2m3eT0xCBh" title="Fair value of stock options"&gt;192,593&lt;/span&gt; ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zMkq6EvdRt5i" title="Stock price per share"&gt;4.8131&lt;/span&gt; per share), which was charged to operations ratably from July 1, 2023 through June 30, 2025. During
the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zzJPAv7SwcUb" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zGjGQs1S0Vhe" title="Stock based compensation"&gt;24,232&lt;/span&gt;, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zH0XbEu4aBrh" title="Stock based compensation"&gt;47,672&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLuU7Z99A4Y5" title="Stock based compensation"&gt;72,300&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted a stock
option to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO6mtqDyhATb" title="Options, grants in period, gross"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z1dlH9abT7uj" title="Stock options are exercisable price per share"&gt;1.95&lt;/span&gt; per share, which was equal to the closing market price
of the Company&#x2019;s common stock on the grant date. &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbffV98p1Joc" title="Options vesting term"&gt;The stock option initially vested in equal increments quarterly over a three-year
period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service.&lt;/span&gt; The fair value of
this stock option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrx1hclsIfwj" title="Fair value of stock options"&gt;403,066&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zL6Vu6rYWL14" title="Stock price per share"&gt;1.612&lt;/span&gt; per share),
which was being charged to operations ratably from September 26, 2023 through September 30, 2026. Effective June 16, 2025, in connection
with an amendment to Mr. van der Baan&#x2019;s employment agreement (see Note 6), the stock option was deemed fully vested and the remaining
unamortized fair value was charged to operations on such date, and the time period for Mr. van der Baan to exercise this stock option
at any time in the future that he is no longer providing services to the Company as a consultant, employee or otherwise was increased
from ninety days to one year. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and
administrative costs in the consolidated statements of operations of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpFgpWER9OK" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUkwhxrUMzf4" title="Stock based compensation"&gt;33,712&lt;/span&gt;, respectively, with respect to this stock option.
During the nine months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbFQg6WbkuB" title="Stock based compensation"&gt;233,784&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2aWlP7zstre" title="Stock based compensation"&gt;100,402&lt;/span&gt;, respectively, with respect to this stock option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_znb5TqF57Zo6" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zaK3CJ0lBOk5" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zayRDXmyv4Wg" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYinoXbtOLya" title="Exercise price"&gt;2.37&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zlseYSg9iEQ" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zSUtQrOTXra" title="Fair value of stock options"&gt;73,976&lt;/span&gt; ($&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zFklPNCRQFKb" title="Stock price per share"&gt;1.8494&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated
statements of operations of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zxdWlzUf2fzf" title="Stock based compensation"&gt;9,324&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_zW6Fa1seX156" title="Stock based compensation"&gt;6,993&lt;/span&gt;, respectively, with respect to these stock options. During the nine months ended September
30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements of operations of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzpN38u8Ngjd" title="Stock based compensation"&gt;9,324&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__srt--TitleOfIndividualAxis__srt--DirectorMember_z4CzReg2Xopg" title="Stock based compensation"&gt;25,333&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zjkmaO9cMm48" title="Fair value of stock options"&gt;16,598&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6qL8K9L6an8" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zkzlMs49jUee" title="Exercise price"&gt;2.37&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRcCoIDlSWdi" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6rY0uUnW44h" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zD3MixaJV6Vh" title="Stock price per share"&gt;1.6570&lt;/span&gt; per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted a stock
option to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zRUTp9yrQlD4" title="Fair value of stock options"&gt;15,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The stock option can be exercised on a cashless basis. The stock
option is exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zWCdwhWtLz2h" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise e price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zIDwurdgYNzk" title="Exercise price"&gt;2.39&lt;/span&gt; per share, which was equal to the closing market price
of the Company&#x2019;s common stock on the grant date. &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zifUDNZtU1J8" title="Share based compensation vesting rights, percentage"&gt;The stock option vested quarterly over a three-year period commencing on the last
day of each calendar quarter commencing September 30, 2024.&lt;/span&gt; The fair value of this stock option, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zrFPR0cGi7Lf" title="Fair value of stock options"&gt;29,074&lt;/span&gt; ($&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z9y8JcNRx9e2" title="Stock price per share"&gt;1.9382&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2024
through June 30, 2027. During the three months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative
costs in the consolidated statements of operations of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zQdwrMjzCcyi" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zUlIPxHHlE74" title="Stock based compensation"&gt;2,418&lt;/span&gt;, respectively, with respect to this stock option. During the nine
months ended September 30, 2025 and 2024, the Company recorded charges to general and administrative costs in the consolidated statements
of operations of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoRKBTIEWPR7" title="Stock based compensation"&gt;4,810&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zPvHloitGUif" title="Stock based compensation"&gt;2,418&lt;/span&gt;, respectively, with respect to this stock option. Effective as of July 31, 2025, the Company agreed
to accept the resignation of Dr. Schellens and to terminate his consulting agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z1z1abyToHR7" title="Fair value of stock options"&gt;21,217&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1JM6cdEhytd" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zppS4l7Ft7ai" title="Exercise price"&gt;1.87&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z0GA56Acd5s4" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znQiisOLIWr3" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_znCkNv67Eh4j" title="Stock price per share"&gt;1.2961&lt;/span&gt; per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2025, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zOWCjt6CGWc3" title="Fair value of stock options"&gt;16,665&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zAbQ0OE88392" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWiRSwycgRW5" title="Exercise price"&gt;2.33&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9l68rnYIpDa" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zdt9nSmjGmI8" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zDCTij9p76El" title="Stock price per share"&gt;1.65002&lt;/span&gt; per share). The grant date value of the stock options of $&lt;span id="xdx_900_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z6TIua4GRm0a" title="Fair value of stock options"&gt;27,500&lt;/span&gt; was accrued at December
31, 2024 and charged to operations at that date. During the nine months ended September 30, 2025, there was no expense charged to operations
with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 31, 2025, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z10NaCBkSs86" title="Fair value of stock options"&gt;32,181&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z793ToKRxqC6" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3pZ40QMaSaf" title="Exercise price"&gt;1.21&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zRD5t1pECkd1" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended March 31, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250331__20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z1jnBTuB7T7k" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp5d_c20250331__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZnv70A92yug" title="Stock price per share"&gt;0.8546&lt;/span&gt; per share), which was charged to operations on March 31, 2025, the date on which the
stock options were fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2025, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zm5fcu29pkI4" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zt7BT2t4Ugi8" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zOebc78z2Gm6" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zw1n3vq0XvLi" title="Exercise price"&gt;0.905&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_z0h0dcDaB7Ij" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdKfed54C6qa" title="Fair value of stock options"&gt;28,700&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__srt--DirectorMember_zH5w36MVIAwj" title="Stock price per share"&gt;0.7175&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2025 through June 30, 2027.
During the three months and nine months ended September 30, 2025, the Company recorded a charge to operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrmso34NSu8h" title="Stock based compensation"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTAZJLxT5Mo9" title="Stock based compensation"&gt;2,712&lt;/span&gt;&lt;/span&gt; with respect
to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2025, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_ztfk4prcpwtk" title="Purchase of stock options shares"&gt;42,648&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJ6JgmbYx2ph" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkoY0BTQ7BM4" title="Exercise price"&gt;0.905&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zPtmgTvUi0ok" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2025, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_90F_ecustom--FairValueOfStockOptions_pp0p0_c20250630__20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z3hEhZB4Lyb8" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp4d_c20250630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zJta4OabAeTb" title="Stock price per share"&gt;0.6448&lt;/span&gt; per share), which was charged to operations on June 30, 2025, the date on which the
stock options were fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the employment agreement entered into with Geordan Pursglove, effective as of July 3, 2025, the end of the first trading
day of the Company&#x2019;s common stock immediately following the successful completion of the above referenced financing, as an inducement
to Mr. Pursglove to join the Company, as a signing bonus, Mr. Pursglove was granted a stock option to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zSm24KQWqeO1" title="Stock option, granted"&gt;350,000&lt;/span&gt; shares of the
Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z79A5JlE6oF6" title="Stock options are exercisable price per share"&gt;2.83&lt;/span&gt; per share (the closing market price on the grant date), for a term of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zpeoMUzKjHue" title="Stock option vested exercisable term"&gt;five
years&lt;/span&gt;, exercisable on a cashless basis and vesting &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250703__20250703__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7HSXSMliD78" title="Stock option, vesting percentage"&gt;50&lt;/span&gt;% on the grant date, &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250930__20250930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4SGZa18TMx2" title="Stock option, vesting percentage"&gt;25&lt;/span&gt;% on September 30, 2025, and &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20251231__20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziBFEU30GNof" title="Stock option, vesting percentage"&gt;25&lt;/span&gt;% on December 31, 2025, subject
to continued service. The stock option grant was not issued under the Company&#x2019;s 2020 Stock Incentive Plan. The stock option agreement
provides for certain registration rights and for accelerated vesting upon the occurrence of certain events, including early termination
of the agreement that is not the result of his voluntary termination or termination for cause, a sale or change in control of the Company,
or a sale, licensing or other disposition of all or substantially all of the assets of the Company. The total fair value of the stock
option to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zcYuh4IGXGt2" title="Stock option, granted"&gt;350,000&lt;/span&gt; shares of common stock, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $&lt;span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20250703__20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zQVPNTUCFzy9" title="Fair value of stock options"&gt;728,671&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4p0_c20250703__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_z1WZOqhK1sD3" title="Stock price per share"&gt;2.0819&lt;/span&gt; per share), which is being charged to operations from July 3, 2025 through December 31, 2025. During the three months
and nine months ended September 30, 2025, the Company recorded a charge to operations of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zXEYJ3rLRULh" title="Stock based compensation"&gt;546,499&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MrPursgloveMember_zDhHjujKf8a2" title="Stock based compensation"&gt;546,499&lt;/span&gt;, respectively, with respect
to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2025, the Board of Directors appointed Jason Sawyer to the Board of Directors. In connection with his appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Sawyer was granted stock options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zudGNx9oUKVj" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziCC1M8wo89l" title="Stock option vested exercisable term"&gt;five
years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_ziyvoUqcWjN9" title="Stock options are exercisable price per share"&gt;3.59&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zHb5B5r9fRI2" title="Stock options description"&gt;vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.&lt;/span&gt; The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_z8QiZmbYEf8f" title="Fair value of stock options"&gt;68,360&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zXzOQV6y2wYc" title="Stock price per share"&gt;2.7344&lt;/span&gt; per share),
of which $&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zCoSVwlqjstc" title="Stock options vested"&gt;34,180&lt;/span&gt; was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August
15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company recorded charges to
general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zrTgBGcUoJ22" title="Stock based compensation"&gt;38,500&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--JasonSawyerMember_zsPONKrJlA7e" title="Stock based compensation"&gt;38,500&lt;/span&gt;, respectively, with respect to these
stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2025, the Board of Directors appointed Dr. Michael Holloway to the Board of Directors. In connection with his appointment
to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of
Directors, Dr. Holloway was granted stock options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zpPCDZ7SLfYb" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z7FLV8Cp5rDf" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zwuwg4nyX6K2" title="Stock options are exercisable price per share"&gt;3.59&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z3qP1i4npCl6" title="Stock options description"&gt;vesting 50% on the grant date and
the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.&lt;/span&gt;
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20250814__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_z2CNPKAuDWEh" title="Fair value of stock options"&gt;68,360&lt;/span&gt;
($&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zDnl8swzO0Xf" title="Stock price per share"&gt;2.7344&lt;/span&gt; per share), of which $&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250815__20250815__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zVKS6lRTJiZ4" title="Stock options vested"&gt;34,180&lt;/span&gt; was attributable to the portion of the stock options fully vested on August 15, 2025 and was therefore
charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations
ratably from August 15, 2025 through September 30, 2026. During the three months and nine months ended September 30, 2025, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zt68EyVReBy7" title="Stock based compensation"&gt;38,500&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--DrMichaelHollowayMember_zjB0VCAFVy36" title="Stock based compensation"&gt;38,500&lt;/span&gt;, respectively,
with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2025, in connection with the employment agreement with Peter Stazzone, Mr. Stazzone was granted stock options to purchase
&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zrvIjPiiOisk" title="Number of fully vested option exercisable"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The options are exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20250901__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zBuEwb1d4Rik" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20250815__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zitMkEj9p3ac" title="Stock options are exercisable price per share"&gt;4.45&lt;/span&gt;
per share, which was equal to the closing market price of the Company&#x2019;s common stock on the grant date. The &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zi5KTToCuqq4" title="Stock options description"&gt;options vested 25%
on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject
to continued service.&lt;/span&gt; The stock option grant was not issued under the Company&#x2019;s 2020 Stock Incentive Plan. The fair value of these
stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zdYM11S1Blra" title="Fair value of stock options"&gt;173,070&lt;/span&gt; ($&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zsBaCUAGApRa" title="Stock price per share"&gt;3.4614&lt;/span&gt; per share), of
which $&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20250831__20250901__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_zEtbHWLUD9Jg" title="Stock options vested"&gt;43,268&lt;/span&gt; was attributable to the portion of the stock options fully vested on September 1, 2025 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from September
1, 2025 through June 30, 2026. The Company recorded a charge to general and administrative costs in the consolidated statement of operations
for the three months and nine months ended September 30, 2023 of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z41x10lHn7V5" title="Stock based compensation"&gt;55,732&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--PeterStazzoneMember_z3mgoKF5fswh" title="Stock based compensation"&gt;55,732&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 1, 2025, the Company appointed Lourdes Felix and Guy Primus to the Board of Directors. Although it was the Company&#x2019;s
policy to issue stock options to each new director to purchase &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250901__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zwZNiYTYPzQe" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock on the appointment date,
&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zRd7SFq8MNhi" title="Stock options description"&gt;vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service,&lt;/span&gt; due to limitations with respect to the Company&#x2019;s 2020 Stock Incentive Plan, the Company did not issue
these stock options on such date To account for this obligation, the Company determined the fair value of these stock options for each
new director effective September 1, 2025 to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20250831__20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zKXs8dZ7oXj2" title="Fair value of stock options"&gt;84,533&lt;/span&gt; ($&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pp4d_c20250901__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z3AlyB116lpe" title="Stock price per share"&gt;3.38&lt;/span&gt; per share), as calculated pursuant to the Black-Scholes option-pricing
model, and recorded a charge to operations reflecting 50% of the fair value of such stock options on such date and a related accrued
liability. The remaining 50% of the fair value of such stock options is being charged to operations ratably through September 30, 2026.
Accordingly, a total of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250701__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_zS4Pm9hxf1vc" title="Stock based compensation"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember_z5qsNMUaW7G9" title="Stock based compensation"&gt;84,533&lt;/span&gt;&lt;/span&gt; was charged to operations for the three months and nine months ended September 30, 2025, respectively,
for this obligation, and an additional $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20260930__20260930__srt--TitleOfIndividualAxis__custom--LourdesFelixAndGuyPrimusMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zmSMK17uZhSc" title="Stock based compensation"&gt;84,533&lt;/span&gt; will be charged to operations ratably through September 30, 2026. The Company anticipates
issuing the stock options prior to December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
employment agreement of the Company&#x2019;s Chief Medical Officer, Dr. James S. Miser expired on July 31, 2024, the employment agreement
of the Company&#x2019;s Vice President and Chief Operating Officer, Eric J. Forman, terminated upon his resignation from the Company on
December 31, 2024, the consulting agreement of the Company&#x2019;s Chief Medical Officer, Dr. Jan Schellens, was terminated effective
with his resignation on July 31, 2025, and Regina Brown, a former director, resigned from the Board of Directors effective September
1, 2025. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
services to the Company terminated. Furthermore, the expiration date of all vested stock options owned by each such person contractually
expire one year from the respective dates that their services to the Company terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stephen
Forman, Yun Yen and Rene Bernards all resigned as members of the Board of Directors during the quarter ended September 30, 2025, although
all three continue to be of service to the Company through their membership on the Company&#x2019;s Scientific Advisory Board. Similarly,
Robert Weingarten resigned as the Company&#x2019;s Chief Financial Officer effective August 31, 2025, although Mr. Weingarten continues
to be of service to the Company as a consultant. Accordingly, the unvested stock options for each such person continue to vest. Furthermore,
the expiration date of all vested stock options maintain their original expiration dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3OF1ceTSh3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zg8Wd7PHcgc" style="display: none"&gt;Schedule of Stock-based Compensation Costs&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zd5TWrO9Qe35" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240701__20240930_zW4DETeV4Bzk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250930_z5k2EcPLznU7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240930_zFaQ1sfLAFq1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKlhKclfQ9U4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqGEfVo0zuX6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1827"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_z2UfvB4EbuXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total stock-based compensation
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zuGkdsyYnDvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkVKv9cNiIv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2025 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zb1KqmhwbR62" style="display: none"&gt;Schedule of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
                                            Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options outstanding at December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zESYR1cepThd" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;613,232&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zSZOieKqu8if" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.317&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_zhUq2BYnjQc" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;581,494&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z3I4tcpx8Z34" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.657&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930_zCKeHhL8A8M2" style="text-align: right" title="Number of shares, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z98nef8tKazk" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zDEuVVlzkhH3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zxVjRmhuXhCj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44.272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options outstanding
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zEukKDGE3OUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zqI02DpqC29h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zDUGlsCDl4Xh" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options exercisable
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zm3m9flUQbb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;409,897&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zR7pLp0soPfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17.100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options exercisable
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zXw2ZfeHrKDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zlVczi7UTR55" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.664&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zgeLOS7PnT0h" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;3.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zjFVy9k6vGc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $&lt;span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20250101__20250930_zr4WH9d5jvMg" title="Deferred compensation expense for unvested stock options"&gt;401,000&lt;/span&gt; at September 30, 2025, which
will be recognized subsequent to September 30, 2025 over a weighted-average period of approximately &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20250101__20250930_zYqWTmpXhCOi" title="Weighted-average recognition period"&gt;7&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWIdtGFaJ3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zeTmtxuULFBj" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFy2vjnucImf" style="width: 30%; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.905&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zS3bhr7tc3l" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,648&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNjrN27i6Rpg" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,398&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zFtqQE4Ptoz6" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.210&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zINxPTH9BK0f" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztB4khiAhLEf" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVHwIeCnnc5c" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9w2Je49z8k1" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zf2InRE71Txf" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zJjsIFlC7SO4" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.950&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zHg9hz1kBov4" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPoNbTpuzlL4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7GF7Dtp5Eti" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z8AFWEiHP208" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,665&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPM6f8H75fw4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,665&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbpJHQu8nmu4" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztSoEHezMDtd" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSnIsAyYreO6" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zQ5tnBGzrZpf" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zgpfWwnDv5Wf" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zeW922GIljji" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zgcbd38988A5" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.830&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zWdCZaRoaIq6" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zBD725rewxz4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;262,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlUTjnnlill8" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.590&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zatlxUGhymj5" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztLPSILRyIV8" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zoFQgp5IaqLa" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.450&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEQwpU871QL3" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbkKICqJsEU5" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zpA2W3IiqC8k" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRAC6ByBkjRi" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z19J2sZGXYn" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zkcU8Y5P0ljd" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.880&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqSAfehc7vh3" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zYeDACEqeQ9l" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z90CGJHOVWh6" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSzewf2FlBC" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zfkeV5n6vP25" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zhP56C3XEhI2" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zjy3uCki4yPf" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zs0fdhKj4iO2" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z5wW3crMConi" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj9l8hvCEdVb" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zfZ4i2I8Vz6l" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zNL7TafYxhG7" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmOZK5lelfV2" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z05z3EYUt7z" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zLp5jGUcrlDl" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30.300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zrZV3MafP269" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zWLHAYIXxFDe" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zdR2aTe07Sdc" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z9EiO6QI40Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zqpET658WCt7" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zv02I4tSjuI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zr1ecDZzshK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z3kGiobEYIC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the closing fair market value of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zcvytBh0nsA7" title="Fair market value, per share"&gt;5.030&lt;/span&gt; per common share on September 30, 2025, the intrinsic value attributed to exercisable but
unexercised common stock options was approximately $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250930_zjeIdTkTCThk" title="Intrinsic value"&gt;2,037,000&lt;/span&gt; at September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
stock options to acquire &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20250930_zXK55xiF7lZ9" title="Outstanding stock options to acquire shares of common stock not vested"&gt;205,000&lt;/span&gt; shares of the Company&#x2019;s common stock had not vested at September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001462"
      unitRef="Shares">233333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001464"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001466"
      unitRef="Shares">413333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001468"
      unitRef="Shares">336667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001470"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001472"
      unitRef="Shares">694309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-09-30_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001474"
      unitRef="Shares">55691</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001476">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsyplzXokm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2025, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zxe1ze8AJ6P9" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250101__20250930_zfDeiQPPq802" title="Risk-free interest rate minimum"&gt;3.58&lt;/span&gt;%
    to &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250101__20250930_z9yRnL5v31Y1" title="Risk-free interest rate maximum"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20250101__20250930_zlaO1TZhMRGh" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: -3.9pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20250101__20250930_zRKfZI8CZmWa" title="Expected volatility minimum"&gt;128.78&lt;/span&gt;%
    to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20250101__20250930_zZqyHmpbs9J" title="Expected volatility maximum"&gt;139.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_z0QAUqANASf3" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zdU5gdc2VqWe" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20240101__20240930_zPq2t6s3INs" title="Risk-free interest rate minimum"&gt;3.55&lt;/span&gt;%
    to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20240101__20240930_zIvW7UAUMiK1" title="Risk-free interest rate maximum"&gt;4.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20240930_ziZpmFFOyoY6" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20240101__20240930_zAF8Sf0L6wsg" title="Expected volatility minimum"&gt;125.59&lt;/span&gt;
    to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20240101__20240930_zatfMJ5aqwV5" title="Expected volatility maximum"&gt;126.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zDXFVVxLNRKg" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zvGTAGTgpIQl" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001478"
      unitRef="Pure">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001480"
      unitRef="Pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001482"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001484"
      unitRef="Pure">1.2878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001486"
      unitRef="Pure">1.3942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-09-30_srt_MinimumMember"
      id="Fact001488">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-09-30_srt_MaximumMember"
      id="Fact001490">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001492"
      unitRef="Pure">0.0355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001494"
      unitRef="Pure">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001496"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001498"
      unitRef="Pure">1.2559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001500"
      unitRef="Pure">1.2645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-09-30_srt_MinimumMember"
      id="Fact001502">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-09-30_srt_MaximumMember"
      id="Fact001504">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      id="Fact001508">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="2"
      id="Fact001510"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      id="Fact001512">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001514"
      unitRef="USD">158525</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="4"
      id="Fact001516"
      unitRef="USDPShares">6.341</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001518"
      unitRef="USD">79263</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001520"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">19390</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_srt_DirectorMember"
      decimals="0"
      id="Fact001524"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="Fact001526"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="Fact001528">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="INF"
      id="Fact001530"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="Fact001532">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001534"
      unitRef="USD">316700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="Fact001536"
      unitRef="USDPShares">6.334</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001538"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001540"
      unitRef="USD">47310</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001542"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="Fact001546">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-11-062022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001548"
      unitRef="USDPShares">20.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="Fact001550">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001552"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="0"
      id="Fact001554"
      unitRef="USD">262560</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="4"
      id="Fact001556"
      unitRef="USDPShares">3.282</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_FourOfficersMember"
      decimals="0"
      id="Fact001558"
      unitRef="USD">4132</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_FourOfficersMember"
      decimals="0"
      id="Fact001560"
      unitRef="USD">9641</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_FourOfficersMember"
      decimals="0"
      id="Fact001562"
      unitRef="USD">12264</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_FourOfficersMember"
      decimals="0"
      id="Fact001564"
      unitRef="USD">34304</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001568"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001570">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001572"
      unitRef="USDPShares">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001574">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">192593</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001578"
      unitRef="USDPShares">4.8131</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001580"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001582"
      unitRef="USD">24232</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001584"
      unitRef="USD">47672</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">72300</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001588"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001590"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember"
      id="Fact001592">The stock option initially vested in equal increments quarterly over a three-year
period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001594"
      unitRef="USD">403066</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="Fact001596"
      unitRef="USDPShares">1.612</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001598"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001600"
      unitRef="USD">33712</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001602"
      unitRef="USD">233784</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001604"
      unitRef="USD">100402</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001606"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001608"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      id="Fact001610">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001612"
      unitRef="USDPShares">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      id="Fact001614">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="0"
      id="Fact001616"
      unitRef="USD">73976</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_srt_DirectorMember"
      decimals="4"
      id="Fact001618"
      unitRef="USDPShares">1.8494</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001620"
      unitRef="USD">9324</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001622"
      unitRef="USD">6993</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001624"
      unitRef="USD">9324</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_srt_DirectorMember"
      decimals="0"
      id="Fact001626"
      unitRef="USD">25333</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001628"
      unitRef="Shares">16598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001630">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001632"
      unitRef="USDPShares">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001634">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001636"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001638"
      unitRef="USDPShares">1.6570</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      decimals="0"
      id="Fact001640"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      id="Fact001642">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-07-01_custom_SchellensMember"
      decimals="INF"
      id="Fact001644"
      unitRef="USDPShares">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      id="Fact001646">The stock option vested quarterly over a three-year period commencing on the last
day of each calendar quarter commencing September 30, 2024.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      decimals="0"
      id="Fact001648"
      unitRef="USD">29074</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-07-01_custom_SchellensMember"
      decimals="4"
      id="Fact001650"
      unitRef="USDPShares">1.9382</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_SchellensMember624786734"
      decimals="0"
      id="Fact001652"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_SchellensMember624786734"
      decimals="0"
      id="Fact001654"
      unitRef="USD">2418</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_SchellensMember624786734"
      decimals="0"
      id="Fact001656"
      unitRef="USD">4810</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_SchellensMember624786734"
      decimals="0"
      id="Fact001658"
      unitRef="USD">2418</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001660"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001662">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001664"
      unitRef="USDPShares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001666">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001668"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001670"
      unitRef="USDPShares">1.2961</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001672"
      unitRef="Shares">16665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember"
      id="Fact001674">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001676"
      unitRef="USDPShares">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember"
      id="Fact001678">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001680"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember"
      decimals="5"
      id="Fact001682"
      unitRef="USDPShares">1.65002</us-gaap:SharePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001684"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001686"
      unitRef="Shares">32181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember"
      id="Fact001688">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001690"
      unitRef="USDPShares">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember"
      id="Fact001692">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-03-312025-03-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001694"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_custom_FourNonOfficerDirectorsMember"
      decimals="5"
      id="Fact001696"
      unitRef="USDPShares">0.8546</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-06-302025-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001698"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-06-302025-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001700"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-06-302025-06-30_srt_DirectorMember"
      id="Fact001702">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001704"
      unitRef="USDPShares">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-06-302025-06-30_srt_DirectorMember"
      id="Fact001706">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-06-302025-06-30_srt_DirectorMember"
      decimals="0"
      id="Fact001708"
      unitRef="USD">28700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-06-30_srt_DirectorMember"
      decimals="4"
      id="Fact001710"
      unitRef="USDPShares">0.7175</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001712"
      unitRef="USD">2712</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_srt_DirectorMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001714"
      unitRef="USD">2712</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorMember"
      decimals="INF"
      id="Fact001716"
      unitRef="Shares">42648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001718">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001720"
      unitRef="USDPShares">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001722">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-06-302025-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001724"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001726"
      unitRef="USDPShares">0.6448</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember"
      decimals="INF"
      id="Fact001728"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-07-03_custom_MrPursgloveMember"
      decimals="INF"
      id="Fact001730"
      unitRef="USDPShares">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember"
      id="Fact001732">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-07-032025-07-03_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001734"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-09-302025-09-30_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001736"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-12-312025-12-31_custom_EmploymentAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember"
      decimals="INF"
      id="Fact001740"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-07-032025-07-03_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001742"
      unitRef="USD">728671</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-07-03_custom_MrPursgloveMember"
      decimals="4"
      id="Fact001744"
      unitRef="USDPShares">2.0819</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">546499</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_MrPursgloveMember"
      decimals="0"
      id="Fact001748"
      unitRef="USD">546499</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember"
      decimals="INF"
      id="Fact001750"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember"
      id="Fact001752">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-08-15_custom_JasonSawyerMember"
      decimals="2"
      id="Fact001754"
      unitRef="USDPShares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-08-142025-08-15_custom_JasonSawyerMember"
      id="Fact001756">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-08-142025-08-15_custom_JasonSawyerMember"
      decimals="0"
      id="Fact001758"
      unitRef="USD">68360</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-15_custom_JasonSawyerMember"
      decimals="4"
      id="Fact001760"
      unitRef="USDPShares">2.7344</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2025-08-152025-08-15_custom_JasonSawyerMember"
      decimals="0"
      id="Fact001762"
      unitRef="USD">34180</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_JasonSawyerMember"
      decimals="0"
      id="Fact001764"
      unitRef="USD">38500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_JasonSawyerMember"
      decimals="0"
      id="Fact001766"
      unitRef="USD">38500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember"
      decimals="INF"
      id="Fact001768"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember"
      id="Fact001770">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-08-15_custom_DrMichaelHollowayMember"
      decimals="2"
      id="Fact001772"
      unitRef="USDPShares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-08-142025-08-15_custom_DrMichaelHollowayMember"
      id="Fact001774">vesting 50% on the grant date and
the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-08-142025-08-15_custom_DrMichaelHollowayMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">68360</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-15_custom_DrMichaelHollowayMember"
      decimals="4"
      id="Fact001778"
      unitRef="USDPShares">2.7344</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2025-08-152025-08-15_custom_DrMichaelHollowayMember"
      decimals="0"
      id="Fact001780"
      unitRef="USD">34180</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_DrMichaelHollowayMember"
      decimals="0"
      id="Fact001782"
      unitRef="USD">38500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_DrMichaelHollowayMember"
      decimals="0"
      id="Fact001784"
      unitRef="USD">38500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-09-012025-09-01_custom_PeterStazzoneMember"
      decimals="INF"
      id="Fact001786"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-09-012025-09-01_custom_PeterStazzoneMember"
      id="Fact001788">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-08-15_custom_PeterStazzoneMember"
      decimals="2"
      id="Fact001790"
      unitRef="USDPShares">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember"
      id="Fact001792">options vested 25%
on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject
to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001794"
      unitRef="USD">173070</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-09-01_custom_PeterStazzoneMember"
      decimals="4"
      id="Fact001796"
      unitRef="USDPShares">3.4614</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2025-08-312025-09-01_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001798"
      unitRef="USD">43268</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001800"
      unitRef="USD">55732</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_PeterStazzoneMember"
      decimals="0"
      id="Fact001802"
      unitRef="USD">55732</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-09-012025-09-01_custom_LourdesFelixAndGuyPrimusMember"
      decimals="INF"
      id="Fact001804"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember"
      id="Fact001806">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service,</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-08-312025-09-01_custom_LourdesFelixAndGuyPrimusMember"
      decimals="0"
      id="Fact001808"
      unitRef="USD">84533</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-09-01_custom_LourdesFelixAndGuyPrimusMember"
      decimals="4"
      id="Fact001810"
      unitRef="USDPShares">3.38</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_LourdesFelixAndGuyPrimusMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">84533</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_LourdesFelixAndGuyPrimusMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">84533</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-09-302026-09-30_custom_LourdesFelixAndGuyPrimusMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">84533</us-gaap:ShareBasedCompensation>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001818">&lt;p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3OF1ceTSh3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zg8Wd7PHcgc" style="display: none"&gt;Schedule of Stock-based Compensation Costs&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zd5TWrO9Qe35" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240701__20240930_zW4DETeV4Bzk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250930_z5k2EcPLznU7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240930_zFaQ1sfLAFq1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKlhKclfQ9U4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqGEfVo0zuX6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1827"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_z2UfvB4EbuXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total stock-based compensation
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340,445&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001820"
      unitRef="USD">776611</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">106827</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">1144348</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001823"
      unitRef="USD">340445</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001830"
      unitRef="USD">776611</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001831"
      unitRef="USD">106827</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001832"
      unitRef="USD">1144348</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001833"
      unitRef="USD">340445</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001835">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkVKv9cNiIv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2025 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zb1KqmhwbR62" style="display: none"&gt;Schedule of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
                                            Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options outstanding at December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zESYR1cepThd" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;613,232&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zSZOieKqu8if" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.317&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_zhUq2BYnjQc" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;581,494&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z3I4tcpx8Z34" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.657&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930_zCKeHhL8A8M2" style="text-align: right" title="Number of shares, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_z98nef8tKazk" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zDEuVVlzkhH3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zxVjRmhuXhCj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44.272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options outstanding
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zEukKDGE3OUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zqI02DpqC29h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zDUGlsCDl4Xh" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options exercisable
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zm3m9flUQbb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;409,897&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zR7pLp0soPfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17.100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options exercisable
    at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zXw2ZfeHrKDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zlVczi7UTR55" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.664&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zgeLOS7PnT0h" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;3.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001837"
      unitRef="Shares">613232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001839"
      unitRef="USDPShares">12.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001841"
      unitRef="Shares">581494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001843"
      unitRef="USDPShares">2.657</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001849"
      unitRef="Shares">71667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001851"
      unitRef="USDPShares">44.272</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001853"
      unitRef="Shares">1123059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001855"
      unitRef="USDPShares">5.276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2025-01-01to2025-09-30" id="Fact001857">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001859"
      unitRef="Shares">409897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001861"
      unitRef="USDPShares">17.100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001863"
      unitRef="Shares">930559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001865"
      unitRef="USDPShares">5.664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-09-30" id="Fact001867">P3Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001869"
      unitRef="USD">401000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-09-30" id="Fact001871">P7M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001873">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWIdtGFaJ3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zeTmtxuULFBj" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable
                                            (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFy2vjnucImf" style="width: 30%; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.905&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zS3bhr7tc3l" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,648&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNjrN27i6Rpg" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,398&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zFtqQE4Ptoz6" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.210&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zINxPTH9BK0f" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztB4khiAhLEf" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVHwIeCnnc5c" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9w2Je49z8k1" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zf2InRE71Txf" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zJjsIFlC7SO4" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.950&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zHg9hz1kBov4" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPoNbTpuzlL4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7GF7Dtp5Eti" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z8AFWEiHP208" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,665&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zPM6f8H75fw4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,665&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbpJHQu8nmu4" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztSoEHezMDtd" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSnIsAyYreO6" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zQ5tnBGzrZpf" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zgpfWwnDv5Wf" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zeW922GIljji" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zgcbd38988A5" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.830&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zWdCZaRoaIq6" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zBD725rewxz4" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;262,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlUTjnnlill8" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.590&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zatlxUGhymj5" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztLPSILRyIV8" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zoFQgp5IaqLa" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.450&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEQwpU871QL3" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbkKICqJsEU5" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zpA2W3IiqC8k" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRAC6ByBkjRi" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z19J2sZGXYn" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zkcU8Y5P0ljd" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.880&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqSAfehc7vh3" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zYeDACEqeQ9l" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z90CGJHOVWh6" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSzewf2FlBC" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zfkeV5n6vP25" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zhP56C3XEhI2" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zjy3uCki4yPf" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zs0fdhKj4iO2" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z5wW3crMConi" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj9l8hvCEdVb" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zfZ4i2I8Vz6l" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zNL7TafYxhG7" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmOZK5lelfV2" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z05z3EYUt7z" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zLp5jGUcrlDl" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30.300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zrZV3MafP269" style="text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zWLHAYIXxFDe" style="text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zdR2aTe07Sdc" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z9EiO6QI40Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zqpET658WCt7" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zv02I4tSjuI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,123,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zr1ecDZzshK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001875"
      unitRef="USDPShares">0.905</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001877"
      unitRef="Shares">72648</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001879"
      unitRef="Shares">46398</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001881"
      unitRef="USDPShares">1.210</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001883"
      unitRef="Shares">32181</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001885"
      unitRef="Shares">32181</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001887"
      unitRef="USDPShares">1.870</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001889"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001891"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001893"
      unitRef="USDPShares">1.950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001895"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001897"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001899"
      unitRef="USDPShares">2.330</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001901"
      unitRef="Shares">16665</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001903"
      unitRef="Shares">16665</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001905"
      unitRef="USDPShares">2.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001907"
      unitRef="Shares">51598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001909"
      unitRef="Shares">40348</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001911"
      unitRef="USDPShares">2.390</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001913"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001917"
      unitRef="USDPShares">2.830</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001919"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001921"
      unitRef="Shares">262500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001923"
      unitRef="USDPShares">3.590</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001925"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001927"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001929"
      unitRef="USDPShares">4.450</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001931"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001933"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001935"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001937"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001939"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001941"
      unitRef="USDPShares">5.880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001943"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001945"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001947"
      unitRef="USDPShares">7.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001949"
      unitRef="Shares">55000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001951"
      unitRef="Shares">55000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001953"
      unitRef="USDPShares">20.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001955"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001957"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001959"
      unitRef="USDPShares">20.600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001961"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001963"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceSixteenMember"
      decimals="INF"
      id="Fact001965"
      unitRef="USDPShares">28.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixteenMember"
      decimals="INF"
      id="Fact001967"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSixteenMember"
      decimals="INF"
      id="Fact001969"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      id="Fact001971"
      unitRef="USDPShares">30.300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      id="Fact001973"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      id="Fact001975"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_ExercisePriceEighteenMember"
      decimals="INF"
      id="Fact001977"
      unitRef="USDPShares">32.100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceEighteenMember"
      decimals="INF"
      id="Fact001979"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30_custom_ExercisePriceEighteenMember"
      decimals="INF"
      id="Fact001981"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001983"
      unitRef="Shares">1123059</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001985"
      unitRef="Shares">930559</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001987"
      unitRef="USDPShares">5.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001989"
      unitRef="USD">2037000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001991"
      unitRef="Shares">205000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001993">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z0U5FMaNOFQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_828_zq6duLOo5yEi"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months and nine months ended September 30, 2025 and 2024, the Company did not record any provision for income taxes, as the
Company incurred losses during such periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001995">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zUpAvV2GQKkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_822_zYH6rh78kVYf"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2025 and
December 31, 2024, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2025, the Company&#x2019;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $&lt;span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zuwbwNyfaOrd" title="Clinical trial contractual commitment"&gt;510,000&lt;/span&gt;, including clinical trial agreements of $&lt;span id="xdx_907_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zL85lCVoapA3" title="Contractual commitment"&gt;292,000&lt;/span&gt;
and clinical trial monitoring agreements of $&lt;span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zQdZVGlsWnWj" title="Contractual commitment"&gt;218,000&lt;/span&gt;, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#x2019;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#x2019;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended
or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial
endpoint is reached. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions and are typically subject to significant modifications and revisions over time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s ongoing active contractual clinical trials described below as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;img alt="" src="form10-q_001.jpg"/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_z9C2hyv19g93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zBp84ylVe1U5" style="display: none"&gt;Schedule of Contractual Clinical Trials&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description
    of Clinical Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Institution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Start
    Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Projected
    End Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Planned
    Number of Patients in Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Study
    Objective&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    Update&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    Date of Preliminary Efficacy Signal&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NCT
    No.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining
    Financial Contractual Commitment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaP5LAXEvAwb" title="Clinical trial, description"&gt;LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;MD Anderson&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaO4D4TiKJTl" title="Estimated Start Date"&gt;January 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zfoSrgpSA6P2" title="Estimated End Date"&gt;December
    2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zhflNXUAlJol" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine the OS of patients with
    recurrent ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20 patients
    entered&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zrGZ76wbvle" title="Expected Date"&gt;December
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT06065462&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zi38KavQp34c" title="Remaining financial contractual commitment"&gt;0&lt;/span&gt;-
                                            (1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztgXW15eMPf4" title="Clinical trial, description"&gt;LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Netherlands Cancer Institute
    (NKI)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zsFaYt73DN6k" title="Estimated Start Date"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zQei3Nmu7j56" title="Estimated End Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zRHl3roycfN1" title="Number of Patients in Trial"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine RP2D with atezolizumab&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;First patient entered
    August 2024, in total two patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zpvcj4boBNxi" title="Expected Date"&gt;June 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT06012734&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zfujZMcBfZSa" title="Remaining financial contractual commitment"&gt;0&lt;/span&gt;-
                                            (1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_fKDIp_z7dHCrOkjqTh" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zQXHehVX1Cqj" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Recruitment completed
    September 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zVzDL1upQ8ma" title="Number of Patients in Trial"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine MTD and RP2D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fourteen patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zeStniKU2End" title="Expected Date"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zJcP1wJGGHX8" title="Remaining financial contractual commitment"&gt;292,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherCommitment_iI_c20250930_zVS6GHXac1Ke" style="text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;292,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0C_z1w4UppxP86b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zXa6OfihDjG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zjCIva5JTmN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute. &lt;/b&gt;Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#x201c;NKI&#x201d;) (see Note 6) to conduct a Phase 1b clinical trial of the Company&#x2019;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#x201c;Roche&#x201d;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#x2019;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#x2019;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#x201c;SAEs&#x201d;) observed in the clinical trial. The Investigational Review Board (IRB) of NKI has requested additional
information with respect to these SAEs and the study has been paused for enrollment until the IRB&#x2019;s questions have been satisfactorily
addressed (see &#x201c;Specific Risks Associated with the Company&#x2019;s Business Activities - Serious Adverse Events&#x201d; below for
additional information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has no financial contractual commitment associated with this clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#x201c;Agreement&#x201d;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#x201c;City of Hope&#x201d;), to carry out a Phase 1b clinical trial of LB-100, the Company&#x2019;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#x201c;ED-SCLC&#x201d;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#x201c;RP2D&#x201d;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
determine the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate,
duration of overall response, progression-free survival, and overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#x201c;SCRI&#x201d;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#x2019;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $&lt;span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zHFzhcA2bxe4" title="Litigation settlement expense"&gt;207,004&lt;/span&gt; for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025 and 2024, the Company did not incur any costs pursuant to this Agreement. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_909_eus-gaap--LitigationSettlementExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zmOvoudxcCF4" title="Litigation settlement expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--LitigationSettlementExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8G65npMwseh" title="Litigation settlement expense"&gt;78,015&lt;/span&gt;, respectively, pursuant to this Agreement. As of September
30, 2025, total costs of $&lt;span id="xdx_90F_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zxLg8FAyD6m9" title="Total costs"&gt;732,532&lt;/span&gt; had been incurred pursuant to this Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas or &#x201c;GEIS&#x201d;), Madrid, Spain, to carry out a
study entitled &#x201c;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#x201d;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#x201c;ASTS&#x201d;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 has consistently enhanced
the anti-tumor activity of doxorubicin without apparent increases in toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#x201c;PFS&#x201d;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#x2019;s existing LB-100 inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $&lt;span id="xdx_90C_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTjHf8mL7Xq5" title="Inventory costs"&gt;1,144,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#xf1;ola de Medicamentos
y Productos Sanitarios or &#x201c;AEMPS&#x201d;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#x2019;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#xf3;n Jim&#xe9;nez
D&#xed;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250311__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z4pxuqITXCHj" title="Aggregate commitments expected"&gt;3,095,000&lt;/span&gt;. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2025 and 2024, the Company did &lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zN9jgSvQTnvb" title="Research and development costs"&gt;&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqIiBMLmbj8f" title="Research and development costs"&gt;no&lt;/span&gt;&lt;/span&gt;t incur any costs pursuant to this agreement. During the
nine months ended September 30, 2025 and 2024, the Company did &lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0fDxddKP06d" title="Research and development costs"&gt;&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhT7CeyAIeNj" title="Research and development costs"&gt;no&lt;/span&gt;&lt;/span&gt;t incur any costs pursuant to this agreement. Through September 30,
2025, the Company has incurred charges of $&lt;span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zVznNs2Nxx21" title="Amount related to milestone payment"&gt;685,107&lt;/span&gt; for work done under this agreement through the fourth milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zJyGMKZGmd37" title="Aggregate commitments expected"&gt;292,000&lt;/span&gt;
for the Phase 1b portion of this clinical trial as of September 30, 2025, which is currently scheduled to be incurred through December
31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate, and have not been significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Clinical Trial&lt;/b&gt;. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#x201c;PD-1&#x201d;) blocking antibody of GSK plc
(&#x201c;GSK&#x201d;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#x201c;OCCC&#x201d;). The study objective is to determine the overall survival (&#x201c;OS&#x201d;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#x2019;s proprietary compound LB-100 with GSK&#x2019;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Monitoring Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Clinical Trial&lt;/b&gt;. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#x201c;PD-1&#x201d;) blocking antibody of GSK plc (&#x201c;GSK&#x201d;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#x201c;OCCC&#x201d;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this letter of intent and related work order agreement are estimated to be approximately $&lt;span id="xdx_903_ecustom--WorkOrderAgreementCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zcM8qGU1rfih" title="Work order agreement costs"&gt;95,000&lt;/span&gt;. During the three months ended
September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zs6jQaCL6uEa" title="Research and development process costs"&gt;4,942&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z09aRJfvGa4b" title="Research and development process costs"&gt;12,610&lt;/span&gt; pursuant to this letter of intent and subsequent work order.
During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z1B8Eo5MuY32" title="Research and development process costs"&gt;16,834&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zODXHIfsH1sj" title="Research and development process costs"&gt;20,838&lt;/span&gt; pursuant to this letter of
intent and subsequent work order. As of September 30, 2025, total costs of $&lt;span id="xdx_904_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_zRRnNZBiDxG5" title="Research and development costs"&gt;43,597&lt;/span&gt; have been incurred pursuant to this letter of intent
and subsequent work order.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_za29YhEnbicj" title="Remaining financial contractual commitment"&gt;53,000&lt;/span&gt;
as of September 30, 2025, which is expected to be incurred through December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210205__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zKGiQHw4wBSa" title="Research and development expense"&gt;335,000&lt;/span&gt;. During the three months ended September 30, 2025 and 2024, the Company
incurred costs of $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_ztpntij1zum2" title="Research and development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zNgHKBB8ijKg" title="Research and development expense"&gt;1,603&lt;/span&gt;, respectively, pursuant to this work order. During the nine months ended September 30, 2025 and 2024,
the Company incurred costs of $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zjKlYFwG7iC1" title="Research and development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z6tnUsinvgRj" title="Research and development expense"&gt;10,603&lt;/span&gt;, respectively, pursuant to this work order. As of September 30, 2025, total costs of $&lt;span id="xdx_908_eus-gaap--DeferredCosts_iI_c20250930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zEWJsuXXpRwd" title="Total costs incurred"&gt;87,823&lt;/span&gt;
had been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#x201c;Clinical Trial Agreements &#x2013; City
of Hope&#x201d; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_907_ecustom--EstimatedWorkCost_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zC14pE0IumWc" title="Work cost"&gt;153,000&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90E_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zKuzrwZjebK6" title="Percentage of payment through services"&gt;72&lt;/span&gt;% to Theradex for services and approximately &lt;span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230622__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zaYLL26JA2Ml" title="Percentage of payment through software"&gt;28&lt;/span&gt;% for payments for pass-through software costs. During the three months ended September
30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zES88iLLmkPi" title="Research and development costs"&gt;3,981&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zysn0G0IgXY1" title="Research and development costs"&gt;13,475&lt;/span&gt;, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWz4OPRPrwZ3" title="Research and development costs"&gt;11,603&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zfxTLvE649Vd" title="Research and development costs"&gt;26,207&lt;/span&gt;, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $&lt;span id="xdx_901_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgX5vRWIvdpf" title="Total costs"&gt;61,058&lt;/span&gt; have been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_905_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zmKHrmLZnSuk" title="Aggregate commitments expected"&gt;91,000&lt;/span&gt; as of September 30, 2025, which is expected to be incurred through December 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute. &lt;/b&gt;On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight was expected to be completed by May 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement were estimated to be approximately $&lt;span id="xdx_901_ecustom--EstimatedWorkCost_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z4TFovY39Yg7" title="Work cost"&gt;106,380&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230827__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zRoGOHDcFUF2" title="Percentage of payment through services"&gt;47&lt;/span&gt;% to Theradex for services and approximately 53% for payments for pass-through software costs. During three months ended September
30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zjP9MKS3Cxvj" title="Research and development costs"&gt;4,500&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEky91wqd4Qf" title="Research and development costs"&gt;14,900&lt;/span&gt;, respectively, pursuant to this work order. During the nine months
ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z5symzdAdXfc" title="Research and development costs"&gt;13,500&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_ziZWzYE5kzCg" title="Research and development costs"&gt;14,900&lt;/span&gt;, respectively, pursuant to this work order. As of
September 30, 2025, total costs of $&lt;span id="xdx_90D_eus-gaap--DeferredCosts_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zN5mtPJPHmPb" title="Total costs"&gt;33,691&lt;/span&gt; have been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zosuoyYedlb" title="Aggregate commitments expected"&gt;74,000&lt;/span&gt; as of September 30, 2025, which was expected to be incurred through May 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Institute of Health.&lt;/b&gt; Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#x201c;License Agreement&#x201d;)
with the National Institute of Neurological Disorders and Stroke (&#x201c;NINDS&#x201d;) and the National Cancer Institute (&#x201c;NCI&#x201d;),
each an institute or center of the National Institute of Health (&#x201c;NIH&#x201d;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#x2019;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#x201c;CRADA&#x201d;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $&lt;span id="xdx_90F_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUZFhPnTDk59" title="Non refundable license issue royalty"&gt;50,000&lt;/span&gt; and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $&lt;span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zqYF26Uep6F5" title="Minimum annual royalty payable"&gt;25,643&lt;/span&gt; was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $&lt;span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zf2blBVESAHk" title="Minimum annual royalty payable"&gt;30,000&lt;/span&gt; is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z6TzHYFgOXi5" title="Non refundable license issue royalty"&gt;50,000&lt;/span&gt; and the first
minimum annual royalty of $&lt;span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zZdTzWdzYokl" title="Minimum annual royalty payable"&gt;25,643&lt;/span&gt; were paid in April 2024. The second minimum annual royalty for 2025 of $&lt;span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zbjnfG9l6aw3" title="Minimum annual royalty payable"&gt;30,000&lt;/span&gt; was paid in December
2024 and was included in other prepaid expenses in the consolidated balance sheet at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#x2019;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#x201c;commercially reasonable
efforts&#x201d; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, each with a different specified
benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of $&lt;span id="xdx_908_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zC3DxGQg7rm6" title="Dosing of product"&gt;100,000&lt;/span&gt; was defined
as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product in the licensed fields
of use. The Company had not commenced a Phase 2 clinical study as of June 30, 2025. The total of all such benchmark payments is $&lt;span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zl70yE30aGN5" title="Payment for royalties"&gt;1,225,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH sublicensing royalties of &lt;span id="xdx_909_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zQuXp9xvX2D1" title="Royalty percentage"&gt;5&lt;/span&gt;% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250701__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zUqz7NusFPcc" title="Research and development process costs"&gt;7,397&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240701__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zsjmmsOjUVfc" title="Research and development process costs"&gt;7,537&lt;/span&gt;, respectively, in connection with
its obligations under the License Agreement. During the nine months ended June 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z1MAqiGL28dh" title="Research and development process costs"&gt;22,191&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20240930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zrdCARGgP48a" title="Research and development process costs"&gt;68,106&lt;/span&gt;, respectively, in connection with its obligations under the License Agreement. Such costs when incurred have been included
in general and administrative costs in the Company&#x2019;s consolidated statement of operations. As of September 30, 2025, total costs
of $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_ztjIqJAUZhSh" title="Research and development costs"&gt;97,835&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts
previously paid to date, totaled approximately $&lt;span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zwx7mKI1VFb7" title="Aggregate commitments expected"&gt;1,765,000&lt;/span&gt; as of September 30, 2025, which is expected to be incurred over approximately
the next twenty years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NDA
Consulting Corp.&lt;/b&gt; On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#x2019;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $&lt;span id="xdx_903_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zfvsvOapXVs7" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt;. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $&lt;span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zN3VJggqVXK" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ConsultingAndAdvisoryCashFee_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_ze29iZyqKYRg" title="Consulting and advisory fee"&gt;12,000&lt;/span&gt; for the three months and nine months ended September 30, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioPharmaWorks&lt;/b&gt;.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#x2019;s
product pipeline; assisting in preparing technical presentations concerning the Company&#x2019;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $&lt;span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPtW1gOmPXt8" title="Consulting and advisory fee"&gt;10,000&lt;/span&gt;, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded charges to operations pursuant to this Collaboration Agreement of $&lt;span id="xdx_90A_ecustom--ReimbursementExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zrMpUQzZQC75" title="Reimbursed expense"&gt;13,600&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--ReimbursementExpense_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zMn7eNWWERy6" title="Reimbursed expense"&gt;8,000&lt;/span&gt; during the three months ended September
30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.
The Company recorded charges to operations pursuant to this Collaboration Agreement of $&lt;span id="xdx_901_ecustom--ReimbursementExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zfeNIKVma0yi" title="Reimbursed expense"&gt;38,400&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--ReimbursementExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zyYBAG5Crkig" title="Reimbursed expense"&gt;35,200&lt;/span&gt; during the nine months ended
September 30, 2025 and 2024, respectively, which were included in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute&lt;/b&gt;. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#x201c;NKI&#x201d;) (see Note 5), one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of &lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_z3hQZ2IFj1Ji" title="Aggregate commitments expected"&gt;391,000&lt;/span&gt; Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVyEX8akeWi4" title="Aggregate commitments expected"&gt;500,000&lt;/span&gt; Euros to the operating budget being funded by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the trial at a project cost of
&lt;span id="xdx_906_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYFUtLXqgl42" title="Aggregate commitments expected"&gt;100,000&lt;/span&gt; Euros.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025 and 2024, the Company incurred charges of $&lt;span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zVDW0LE9hPh6" title="Advance amount related to milestone payment"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZURS9Oldcye" title="Advance amount related to milestone payment"&gt;76,278&lt;/span&gt;, respectively, with respect to this
agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated statements of operations.
During the nine months ended September 30, 2025 and 2024, the Company incurred charges of $&lt;span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zU4gFSDlZpg2" title="Advance amount related to milestone payment"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvKcEvDrSFZd" title="Advance amount related to milestone payment"&gt;210,362&lt;/span&gt;, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated statements of operations.
As of September 30, 2025, total costs of $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NetherlandsCancerInstituteMember_zm0j0CfQtTEd" title="Research and development costs"&gt;695,918&lt;/span&gt; have been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MRI
Global. &lt;/b&gt;As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the three months ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zFRpcJG4rCad" title="Advance amount related to milestone payment"&gt;7,200&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCJJAsNtH4z5" title="Advance amount related to milestone payment"&gt;9,062&lt;/span&gt;,
respectively, pursuant to this contract. During the nine months ended September 30, 2025 and 2024, the Company incurred costs of $&lt;span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zaSs25DAbfP" title="Advance amount related to milestone payment"&gt;42,057&lt;/span&gt;
and $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zZod257iaxCd" title="Advance amount related to milestone payment"&gt;18,932&lt;/span&gt;, respectively, pursuant to this contract. As of September 30, 2025, total costs of $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zIvhX9UiRQBk" title="Research and development costs"&gt;382,579&lt;/span&gt; have been incurred pursuant to
this contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z2gtgYw6UMAj" title="Aggregate commitments expected"&gt;84,000&lt;/span&gt; as
of September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Specific
Risks Associated with the Company&#x2019;s Business Activities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Serious
Adverse Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#x2019;s drug
candidate or to another company&#x2019;s drug used in combination in one of the Company&#x2019;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#x2019;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#x2019;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in the Company&#x2019;s clinical trial. It is also possible that the
clinical trial could be terminated. Any of these actions could delay or halt the development of the Company&#x2019;s drug candidate, increase
development costs, and negatively impact the Company&#x2019;s ability to ultimately achieve regulatory approval. Additionally, if an SAE
is confirmed to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further
development of the drug candidate altogether, which could materially impact the Company&#x2019;s business, financial condition, and prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#x2019;s reputation with patients, physicians, health
institutions, and investors, diminish the Company&#x2019;s ability to attract clinical trial participants, and damage the Company&#x2019;s
ability to interest investors and obtain financing in the future. There can be no assurances that the Company will not experience such
SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#x201c;IRB&#x201d;) of the
Netherlands Cancer Institute (&#x201c;NKI&#x201d;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through September 30,2025, the Company has been informed that a total of 86 patients had received
or were receiving experimental treatment with LB-100.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&#x2019;s Brochure
(the &#x201c;IB&#x201d;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
Business Risks&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Covid-19
Virus&lt;/b&gt;. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#x2019;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflation
and Interest Rate Risk. &lt;/b&gt;The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#x2019;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#x2019;s
operating costs, and which would put additional stress on the Company&#x2019;s working capital resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supply
Chain Issues. &lt;/b&gt;The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Potential
Recession. &lt;/b&gt;There have been some indications that the United States economy may be at risk of entering a recessionary period. Although
it does not appear likely at this time, an economic recession could impact the general business environment and the capital markets,
which could, in turn, affect the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Geopolitical
Risk.&lt;/b&gt; The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#x2019;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#x2019;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#x2019;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#x2019;s business, financial condition and results
of operations may differ from current estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risks. &lt;/b&gt;The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#x2019;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#x2019;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact001997"
      unitRef="USD">510000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-09-30_custom_ClinicalTrialAgreementsMember"
      decimals="0"
      id="Fact001999"
      unitRef="USD">292000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact002001"
      unitRef="USD">218000</us-gaap:ContractualObligation>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact002003">&lt;p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_z9C2hyv19g93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zBp84ylVe1U5" style="display: none"&gt;Schedule of Contractual Clinical Trials&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description
    of Clinical Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Institution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Start
    Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Projected
    End Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Planned
    Number of Patients in Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Study
    Objective&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    Update&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    Date of Preliminary Efficacy Signal&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NCT
    No.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining
    Financial Contractual Commitment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaP5LAXEvAwb" title="Clinical trial, description"&gt;LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;MD Anderson&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zaO4D4TiKJTl" title="Estimated Start Date"&gt;January 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zfoSrgpSA6P2" title="Estimated End Date"&gt;December
    2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zhflNXUAlJol" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine the OS of patients with
    recurrent ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20 patients
    entered&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zrGZ76wbvle" title="Expected Date"&gt;December
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT06065462&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zi38KavQp34c" title="Remaining financial contractual commitment"&gt;0&lt;/span&gt;-
                                            (1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztgXW15eMPf4" title="Clinical trial, description"&gt;LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Netherlands Cancer Institute
    (NKI)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zsFaYt73DN6k" title="Estimated Start Date"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodEndDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zQei3Nmu7j56" title="Estimated End Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zRHl3roycfN1" title="Number of Patients in Trial"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine RP2D with atezolizumab&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;First patient entered
    August 2024, in total two patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zpvcj4boBNxi" title="Expected Date"&gt;June 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT06012734&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zfujZMcBfZSa" title="Remaining financial contractual commitment"&gt;0&lt;/span&gt;-
                                            (1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ClinicalTrialDescription_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_fKDIp_z7dHCrOkjqTh" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zQXHehVX1Cqj" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Recruitment completed
    September 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zVzDL1upQ8ma" title="Number of Patients in Trial"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Determine MTD and RP2D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fourteen patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250101__20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zeStniKU2End" title="Expected Date"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zJcP1wJGGHX8" title="Remaining financial contractual commitment"&gt;292,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherCommitment_iI_c20250930_zVS6GHXac1Ke" style="text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;292,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0C_z1w4UppxP86b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zXa6OfihDjG8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact002005">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma (Phase 1b/2)</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact002007">January 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact002009">December
    2027</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      decimals="INF"
      id="Fact002011"
      unitRef="Integer">21</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact002013">December
    2026</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialPhaseMD1b2Member"
      decimals="0"
      id="Fact002015"
      unitRef="USD">0</us-gaap:OtherCommitment>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember"
      id="Fact002017">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer (Phase 1b)</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember"
      id="Fact002019">August 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember"
      id="Fact002021">December 2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember"
      decimals="INF"
      id="Fact002023"
      unitRef="Integer">37</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bMember"
      id="Fact002025">June 2026</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialPhase1bMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">0</us-gaap:OtherCommitment>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact002029">LB-100 combined with doxorubicin in advanced
    soft tissue sarcoma (Phase 1b)</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact002031">June 2023</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember"
      decimals="INF"
      id="Fact002033"
      unitRef="Integer">14</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact002035">December 2025</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialPhase1bTwoMember"
      decimals="0"
      id="Fact002037"
      unitRef="USD">292000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact002039"
      unitRef="USD">292000</us-gaap:OtherCommitment>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember"
      decimals="0"
      id="Fact002042"
      unitRef="USD">207004</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact002044"
      unitRef="USD">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact002046"
      unitRef="USD">78015</us-gaap:LitigationSettlementExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact002048"
      unitRef="USD">732532</us-gaap:DeferredCosts>
    <us-gaap:InventoryPartsAndComponentsNetOfReserves
      contextRef="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact002050"
      unitRef="USD">1144000</us-gaap:InventoryPartsAndComponentsNetOfReserves>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-11_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact002052"
      unitRef="USD">3095000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact002054"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact002056"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact002058"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact002060"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AmountRelatedToMilestonePayment
      contextRef="From2025-01-012025-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact002062"
      unitRef="USD">685107</LIXT:AmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact002064"
      unitRef="USD">292000</us-gaap:OtherCommitment>
    <LIXT:WorkOrderAgreementCosts
      contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002066"
      unitRef="USD">95000</LIXT:WorkOrderAgreementCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002068"
      unitRef="USD">4942</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002070"
      unitRef="USD">12610</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002072"
      unitRef="USD">16834</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002074"
      unitRef="USD">20838</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember"
      decimals="0"
      id="Fact002076"
      unitRef="USD">43597</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact002078"
      unitRef="USD">53000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-02-052021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002080"
      unitRef="USD">335000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002082"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002084"
      unitRef="USD">1603</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002086"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002088"
      unitRef="USD">10603</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002090"
      unitRef="USD">87823</us-gaap:DeferredCosts>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002092"
      unitRef="USD">153000</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact002094"
      unitRef="Pure">0.72</LIXT:ExpectedPaymentinServices>
    <LIXT:ExpectedPaymentThroughSoftware
      contextRef="From2023-06-222023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact002096"
      unitRef="Pure">0.28</LIXT:ExpectedPaymentThroughSoftware>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002098"
      unitRef="USD">3981</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002100"
      unitRef="USD">13475</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002102"
      unitRef="USD">11603</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002104"
      unitRef="USD">26207</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002106"
      unitRef="USD">61058</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact002108"
      unitRef="USD">91000</us-gaap:OtherCommitment>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002110"
      unitRef="USD">106380</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-08-272023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact002112"
      unitRef="Pure">0.47</LIXT:ExpectedPaymentinServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002114"
      unitRef="USD">4500</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002116"
      unitRef="USD">14900</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002118"
      unitRef="USD">13500</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002120"
      unitRef="USD">14900</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact002122"
      unitRef="USD">33691</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact002124"
      unitRef="USD">74000</us-gaap:OtherCommitment>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact002126"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact002128"
      unitRef="USD">25643</LIXT:RoyaltyPayable>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact002130"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact002132"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact002134"
      unitRef="USD">25643</LIXT:RoyaltyPayable>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-12-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact002136"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact002138"
      unitRef="USD">100000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact002140"
      unitRef="USD">1225000</us-gaap:PaymentsForRoyalties>
    <LIXT:RoyatiesPercentage
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact002142"
      unitRef="Pure">0.05</LIXT:RoyatiesPercentage>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-07-012025-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002144"
      unitRef="USD">7397</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-07-012024-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002146"
      unitRef="USD">7537</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002148"
      unitRef="USD">22191</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002150"
      unitRef="USD">68106</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002152"
      unitRef="USD">97835</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact002154"
      unitRef="USD">1765000</us-gaap:OtherCommitment>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact002156"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2025-07-012025-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact002158"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2025-01-012025-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact002160"
      unitRef="USD">12000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact002162"
      unitRef="USD">10000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ReimbursementExpense
      contextRef="From2025-07-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact002164"
      unitRef="USD">13600</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2024-07-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact002166"
      unitRef="USD">8000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2025-01-012025-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact002168"
      unitRef="USD">38400</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2024-01-012024-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact002170"
      unitRef="USD">35200</LIXT:ReimbursementExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002172"
      unitRef="EUR">391000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002174"
      unitRef="EUR">500000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002176"
      unitRef="EUR">100000</us-gaap:OtherCommitment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2025-07-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002178"
      unitRef="USD">0</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-07-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002180"
      unitRef="USD">76278</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002182"
      unitRef="USD">0</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-01-012024-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact002184"
      unitRef="USD">210362</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember624788609"
      decimals="0"
      id="Fact002186"
      unitRef="USD">695918</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2025-07-012025-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002188"
      unitRef="USD">7200</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-07-012024-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002190"
      unitRef="USD">9062</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2025-01-012025-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002192"
      unitRef="USD">42057</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-01-012024-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002194"
      unitRef="USD">18932</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002196"
      unitRef="USD">382579</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-09-30_custom_MRIGlobalMember"
      decimals="0"
      id="Fact002198"
      unitRef="USD">84000</us-gaap:OtherCommitment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact002200">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zkhik7tSdHfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_82C_z4eKQULVr7V8"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below or elsewhere in the notes to the consolidated financial statements, there were no material subsequent events
which affected, or could affect, the amounts or disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exercise
of Pre-Funded Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from October 1, 2025 through October 31, 2025, an additional &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpTiDTK6m0df" title="Pre-funded warrants exercisable"&gt;475,521&lt;/span&gt; pre-funded warrants exercisable at $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251031__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpwIKWT01vBa" title="Warrants exercisable price per share"&gt;0.00001&lt;/span&gt; per share
that were sold in the July 2, 2025 private placement were exercised, resulting in the issuance of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2r1Dj0AY0hj" title="Number of shares issued"&gt;475,521&lt;/span&gt; shares of common stock. As
of October 31, 2025, &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zamFPjpO4K8b" title="Pre-funded warrants remained unexercised"&gt;184,251&lt;/span&gt; pre-funded warrants remained unexercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SGN
Media Inc.&lt;/b&gt; On October 1, 2025, the Company entered into an agreement with SGN Media Inc (&#x201c;SGN&#x201d;) for marketing consulting
services for a term of one year. The agreement provides for a one-time payment of $&lt;span id="xdx_900_eus-gaap--ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_z4ptg0u3PL8e" title="Proceeds from sale of interest in subsidiary"&gt;20,000&lt;/span&gt; upon execution of the agreement and the reimbursement
of pre-approved expenses. &lt;span id="xdx_90E_eus-gaap--ManagementFeeDescription_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SGNMediaIncMember_zaLMiCnzWFQ6" title="Management fee description"&gt;Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LMC
Communications Inc.&lt;/b&gt; On October 1, 2025, the Company entered into an agreement with LMC Communications Inc (&#x201c;LMC&#x201d;) for
corporate communications services. The agreement is for a term of one year. The agreement provides for the payment of &lt;span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_uCAD_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zkBgxpfs3yO1" title="Payments for of common stock services"&gt;150,000&lt;/span&gt; Canadian
dollars (approximately $&lt;span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_zu6ykoOs976g" title="Payments for of common stock services"&gt;108,000&lt;/span&gt; as of September 30, 2025) upon execution, which can be paid by the issuance of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z4CLME4I6yKi" title="Number of shares issued, shares"&gt;30,000&lt;/span&gt; shares of the Company&#x2019;s
common stock. The Company has elected to pay &lt;span id="xdx_901_eus-gaap--SharesIssued_iI_c20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LMCCommunicationsIncMember_z7NCwSyB7Ir1" title="Number of shares issued, shares"&gt;30,000&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002202"
      unitRef="Shares">475521</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-10-31_custom_PlacementAgentsMember_us-gaap_SubsequentEventMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002204"
      unitRef="USDPShares">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-10-012025-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002206"
      unitRef="Shares">475521</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-10-31_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002208"
      unitRef="Shares">184251</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember"
      decimals="0"
      id="Fact002210"
      unitRef="USD">20000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ManagementFeeDescription
      contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_SGNMediaIncMember"
      id="Fact002212">Upon the completion of an acquisition and related financing, the Company is required to pay SGN a $20,000 per
month management fee and to further pay a monthly budget of $220,000 in the first month subsequent to an acquisition and $100,000 monthly
thereafter. The agreement is terminable by the Company upon 120 days written notice.</us-gaap:ManagementFeeDescription>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_custom_LMCCommunicationsIncMember"
      decimals="0"
      id="Fact002214"
      unitRef="CAD">150000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-01-012025-09-30_custom_LMCCommunicationsIncMember"
      decimals="0"
      id="Fact002216"
      unitRef="USD">108000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-012025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember"
      decimals="INF"
      id="Fact002218"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-10-01_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_LMCCommunicationsIncMember"
      decimals="INF"
      id="Fact002220"
      unitRef="Shares">30000</us-gaap:SharesIssued>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-09-30" id="Fact002221">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-09-30" id="Fact002222">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-09-30" id="Fact002223">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-09-30" id="Fact002224">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact002015"
          xlink:label="Fact002015"
          xlink:type="locator"/>
        <link:footnote id="Footnote002040" xlink:label="Footnote002040" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002015"
          xlink:to="Footnote002040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002027"
          xlink:label="Fact002027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002027"
          xlink:to="Footnote002040"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
